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Abstract
The clinical effectiveness of different surveillance strategies
to prevent colorectal cancer in people with intermediate-
grade colorectal adenomas: a retrospective cohort analysis,
and psychological and economic evaluations
Wendy Atkin,1* Amy Brenner,1 Jessica Martin,1 Katherine Wooldrage,1
Urvi Shah,1 Fiona Lucas,1 Paul Greliak,1 Kevin Pack,1 Ines Kralj-Hans,1
Ann Thomson,1 Sajith Perera,1 Jill Wood,1 Anne Miles,2 Jane Wardle,3
Benjamin Kearns,4 Paul Tappenden,4 Jonathan Myles,5 Andrew Veitch6
and Stephen W Duffy5
1Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer,
Imperial College London, London, UK
2Department of Psychological Sciences, Birkbeck, University of London, London, UK
3Cancer Research UK Health Behaviour Centre, University College London, London, UK
4School of Health and Related Research (ScHARR), Health Economics and Decision Science Section,
University of Sheffield, Sheffield, UK
5Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University
of London, London, UK
6New Cross Hospital, Wolverhampton, UK
*Corresponding author w.atkin@imperial.ac.uk
Background: The UK guideline recommends 3-yearly surveillance for patients with intermediate-risk (IR)
adenomas. No study has examined whether or not this group has heterogeneity in surveillance needs.
Objectives: To examine the effect of surveillance on colorectal cancer (CRC) incidence; assess
heterogeneity in risk; and identify the optimum frequency of surveillance, the psychological impact of
surveillance, and the cost-effectiveness of alternative follow-up strategies.
Design: Retrospective multicentre cohort study.
Setting: Routine endoscopy and pathology data from 17 UK hospitals (n = 11,944), and a screening data
set comprising three pooled cohorts (n = 2352), followed up using cancer registries.
Subjects: Patients with IR adenoma(s) (three or four small adenomas or one or two large adenomas).
Primary outcomes: Advanced adenoma (AA) and CRC detected at follow-up visits, and CRC incidence
after baseline and first follow-up.
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Methods: The effects of surveillance on long-term CRC incidence and of interval length on findings at
follow-up were examined using proportional hazards and logistic regression, adjusting for patient,
procedural and polyp characteristics. Lower-intermediate-risk (LIR) subgroups and higher-intermediate-risk
(HIR) subgroups were defined, based on predictors of CRC risk. A model-based cost–utility analysis
compared 13 surveillance strategies. Between-group analyses of variance were used to test for differences
in bowel cancer worry between screening outcome groups (n = 35,700). A limitation of using routine
hospital data is the potential for missed examinations and underestimation of the effect of interval
and surveillance.
Results: In the hospital data set, 168 CRCs occurred during 81,442 person-years (pys) of follow-up [206
per 100,000 pys, 95% confidence interval (CI) 177 to 240 pys]. One surveillance significantly lowered CRC
incidence, both overall [hazard ratio (HR) 0.51, 95% CI 0.34 to 0.77] and in the HIR subgroup (n = 9265;
HR 0.50, 95% CI 0.34 to 0.76). In the LIR subgroup (n = 2679) the benefit of surveillance was less clear
(HR 0.62, 95% CI 0.16 to 2.43). Additional surveillance lowered CRC risk in the HIR subgroup by a further
15% (HR 0.36, 95% CI 0.20 to 0.62). The odds of detecting AA and CRC at first follow-up (FUV1)
increased by 18% [odds ratio (OR) 1.18, 95% CI 1.12 to 1.24] and 32% (OR 1.32, 95% CI 1.20 to 1.46)
per year increase in interval, respectively, and the odds of advanced neoplasia at second follow-up
increased by 22% (OR 1.22, 95% CI 1.09 to 1.36), after adjustment. Detection rates of AA and CRC
remained below 10% and 1%, respectively, with intervals to 3 years. In the screening data set, 32 CRCs
occurred during 25,745 pys of follow-up (124 per 100,000 pys, 95% CI 88 to 176 pys). One follow-up
conferred a significant 73% reduction in CRC incidence (HR 0.27, 95% CI 0.10 to 0.71). Owing to the
small number of end points in this data set, no other outcome was significant. Although post-screening
bowel cancer worry was higher in people who were offered surveillance, worry was due to polyp detection
rather than surveillance. The economic evaluation, using data from the hospital data set, suggested that
3-yearly colonoscopic surveillance without an age cut-off would produce the greatest health gain.
Conclusions: A single surveillance benefited all IR patients by lowering their CRC risk. We identified a
higher-risk subgroup that benefited from further surveillance, and a lower-risk subgroup that may require
only one follow-up. A surveillance interval of 3 years seems suitable for most IR patients. These findings
should be validated in other studies to confirm whether or not one surveillance visit provides adequate
protection for the lower-risk subgroup of intermediate-risk patients.
Study registration: Current Controlled Trials ISRCTN15213649.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
This study examined the effects of the number of follow-up colonoscopies and the length of the intervalbetween follow-ups in people with three or four small adenomas (< 10 mm) or one or two adenomas,
at least one of which was large (≥ 10 mm). People with these types of adenoma (precancerous growths)
are deemed to be at ‘intermediate risk’ of getting bowel cancer. The aim of this study was to determine
the most appropriate frequency and number of follow-up colonoscopies to give this group of people in
order to detect large or advanced adenomas and prevent cancer, while also being cost-effective and
resource efficient. The study used data from 17 UK NHS hospitals and three bowel cancer screening
initiatives and trials. The risk of cancer and severe adenomas was assessed according to the number of
follow-ups, the interval between follow-ups, and the number, size and features of adenomas found at first
diagnosis. Our results suggest that follow-up reduces the risk of cancer and that an interval of 3–4 years
between follow-ups is suitable for the majority of intermediate-risk patients. However, some patients were
at lower risk than others, and may not gain anything from having more than one follow-up. A health
economist found that a 3-year interval was the most cost-effective follow-up strategy. Follow-up
examinations did not cause patients to feel worried, and it gave them reassurance that they did not
have cancer.
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Scientific summary
Background
Colonoscopy surveillance aims to reduce colorectal cancer (CRC) incidence and mortality by removing
adenomas before they become malignant and detecting cancer early. After polypectomy, CRC risk is
thought to depend on the quality of the examination as well as findings at baseline, particularly the
number, size and histological grade of removed adenomas, which are used to stratify patients into risk
groups with different surveillance recommendations. Current UK and US surveillance guidelines divide
patients with adenomas into three groups: low risk, intermediate (UK)/higher risk (US) and high risk.
Both guidelines recommend 3-yearly surveillance for the intermediate-/higher-risk group. However,
there remains uncertainty about the effect of surveillance on CRC risk and the optimum frequency of
surveillance in the intermediate-risk (IR) group, which constitutes nearly half of all patients with adenomas.
Objectives
The overall aim was to examine the optimum frequency of surveillance in people found to have
intermediate-grade colorectal adenomas. We aimed to examine the risks and benefits to the patient with
respect to prevention of CRC and the development of advanced adenomas (AAs); anxiety, morbidity and
mortality; costs and cost-effectiveness; and implications for the UK NHS.
Major objectives were to assess potential heterogeneity in CRC risk according to baseline patient, polyp and
procedural characteristics; to determine if there is a subgroup of IR patients who do not require surveillance,
or who require one surveillance examination but no further follow-up; and to examine whether the
recommended 3-year interval is too long, or could be safely extended in some patients. We also conducted
an economic evaluation to estimate the incremental cost-effectiveness of alternative adenoma follow-up
strategies, their impact on colonoscopy services and the total cost impact in England and Wales. In addition,
a psychological assessment examined the anxiety-inducing effects of colonoscopic surveillance.
Methods
We performed a retrospective, multicentre cohort study analysing data from two sources: a hospital data
set obtained from endoscopy and pathology databases from 17 UK NHS hospitals, and a screening data
set composed of three cohorts: the UK Flexible Sigmoidoscopy Screening Trial (UKFSST), the English Bowel
Cancer Screening Pilot (EP) and the Kaiser Permanente Colon Cancer Prevention Program (KP). Selected
hospitals had to have recorded endoscopy and pathology data electronically for at least 6 years. Eligible
patients had to have had a colonoscopy at baseline and intermediate-grade adenoma(s) detected. Patients
with medical conditions that increased their risk of CRC or with missing information that precluded
classification of adenoma surveillance risk or surveillance intervals were excluded.
Data relating to lower gastrointestinal endoscopic procedures were extracted from hospital endoscopy
databases. Pathology databases were searched for reports on colorectal lesions using Systematized
Nomenclature of Medicine (SNOMED) and Systematized Nomenclature of Pathology (SNOP) codes and
keywords. Corresponding endoscopy and pathology records were matched, patient identifiers removed,
and the anonymised data encrypted before removal from the hospital.
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A master database was created to store the endoscopy and pathology data in a standardised, structured
format. Many of the data required manual interpretation and coding, so a web-based coding application
was developed. Standard operating procedures (SOPs) were applied to promote uniformity of coding,
and coding accuracy and data interpretation were monitored regularly.
A ‘visit’ was defined as one or more examinations performed in close succession (usually within
11 months) to examine the whole colon and remove detected lesions. The baseline visit included the
examination at which adenomas were first diagnosed, and subsequent visits were defined as follow-up
visits. Surveillance intervals were timed from the latest most complete examination of one visit to the first
examination of the next visit. Patients were classified into adenoma surveillance risk groups using the
UK guideline:
l Low risk One or two small (< 10 mm) adenomas, no large (≥ 10 mm) adenomas.
l Intermediate risk Three or four small adenomas, none of which is large; or one or two adenomas,
at least one of which is large.
l High risk Five or more adenomas (any size); or three or more adenomas, at least one of which is large.
The primary outcomes were CRC incidence after baseline and first follow-up, and AA and CRC detected
at first and second follow-up visits (FUV1 and FUV2). An AA was defined as an adenoma of ≥ 10 mm,
or with villous or tubulovillous histology, or high-grade dysplasia (HGD). In some analyses, AAs and CRCs
that were seen at a prior visit were excluded, as they were considered a surrogate for polypectomy site
surveillance, which could confound the analyses. CRC was ascertained using pathological data recorded on
the study database and from national sources. The main exposures of interest were number of surveillance
visits and length of surveillance interval to first or second follow-up. Patient, procedural and polyp
characteristics were assessed as a priori risk factors and confounders.
Logistic regression was used to model the association of surveillance interval length and secondary risk
factors with findings at first and second follow-ups. Survival analysis was used to assess the effect of
surveillance on risk of CRC after baseline, and after first follow-up. All time-to-event data were censored
at first CRC diagnosis, death, emigration or end of follow-up. Time at risk started from the last most
complete colonoscopy in baseline or the first procedure in FUV1, and if CRC was diagnosed at a follow-up
visit then that follow-up visit was not included, as it did not offer any protection against CRC. ‘One minus
the Kaplan–Meier estimator of the survival function’ was used to illustrate the time to cancer diagnosis
and to estimate the cumulative risk of cancer with 95% confidence intervals (CIs) at 3, 5 and 10 years.
Independent predictors were identified in multivariable models, using backward stepwise selection with a
p-value of < 0.05 in the likelihood ratio test to determine the retention of variables in the final logistic and
Cox regression models.
In the psychological analysis, participants were men and women aged 55–64 years, at average risk of CRC,
invited for screening in the UKFSST (n = 35,891). Pre- and post-screening questionnaires were used to
assess negative and positive emotional consequences in participants with no polyps detected by flexible
sigmoidoscopy (FS), low-risk polyps removed at FS, high-risk polyps referred for colonoscopy or high-risk
polyps recommended for surveillance. Between-group analyses of variance (ANOVAs) were used to test for
differences between screening outcome groups.
The health-economic analysis used IR patients in the hospital data set. Thirteen alternative surveillance
strategies were evaluated, taking into account a range of alternative surveillance intervals and the
presence/absence of a cut-off for eligibility, based on patient age. A cost–utility analysis was undertaken,
whereby the primary health-economic outcome was defined in terms of the incremental cost per
quality-adjusted life-year (QALY) gained.
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Results
Hospital data set
There were 11,944 eligible IR patients, 55.5% of whom were male, and the median age was 66.7 years
[interquartile range (IQR) 58.4–74.0 years]; 4608 had at least one follow-up and 1635 had two or more.
A total of 168 CRCs developed during 81,442 person-years (pys) of observation time after baseline (206 per
100,000 pys, 95% CI 177 to 240 pys). A single follow-up visit was associated with a 49% lower CRC
incidence than no surveillance [hazard ratio (HR) 0.51, 95% CI 0.34 to 0.77], after adjusting for covariates.
Having two or more surveillance examinations conferred a further 19% reduction in CRC risk (HR 0.32,
95% CI 0.17 to 0.61). Lower-intermediate-risk (LIR) and higher-intermediate-risk (HIR) subgroups were
identified based on polyp and procedural risk factors for CRC identified in the Cox models. The HIR subgroup
included patients with any of the following baseline characteristics: an adenoma of ≥ 20mm or with HGD,
proximal polyps, no complete colonoscopy or poor bowel preparation. All other patients were assigned to
the LIR subgroup. The subgroups comprised 9265 HIR (77.6%) patients and 2679 LIR (22.4%) patients. CRC
risk was 69% lower in the LIR than in the HIR subgroup (HR 0.31, 95% CI 0.18 to 0.55; p < 0.0001). In the
HIR subgroup, one follow-up conferred a 50% reduction in risk (HR 0.50, 95% CI 0.34 to 0.76) and two or
more follow-ups a 64% reduction in risk (HR 0.36, 95% CI 0.20 to 0.62). In the LIR subgroup a single
follow-up conferred a 38% reduction in CRC risk. However, this result was non-significant; thus, the benefit
of surveillance in the LIR subgroup remained unclear (HR 0.62, 95% CI 0.16 to 2.43; p = 0.4700).
Of the 4608 patients who attended FUV1, 451 (9.8%) had AA and 52 (1.1%) had CRC detected. An 18%
increased odds of new AA and a 32% increased odds of CRC were seen per year increase in interval to
first follow-up [AA: odds ratio (OR) 1.18, 95% CI 1.12 to 1.24; CRC: OR 1.32, 95% CI 1.20 to 1.46].
Of the 1635 patients who attended the second follow-up, 146 (8.9%) had new AA and nine (0.6%)
had new CRC detected. At FUV2, a 22% increased odds of new advanced neoplasia (AN: AA or CRC)
was seen per year increase in interval (OR 1.22, 1.09 to 1.36); the association was significant only after
adjusting for confounding factors. At FUV1, there was a significant association between interval and
new AN in both the HIR (p < 0.0001) and LIR (p = 0.0433) subgroups. At FUV2, there was an association
between interval and new AN in the HIR subgroup (p = 0.0191), but not in the LIR subgroup (p = 0.4573).
Detection rates of new AA and CRC at follow-up remained at < 10% and < 1%, respectively, with an
interval of < 3 years in all IR subgroups except in patients with a poor examination.
Screening data set
In the pooled data set there were 2352 individuals: 67.8% were male, and the median age was 61.5 years
(IQR 58.0–65.0); 1828 had at least one follow-up and 1011 had two or more. A total of 32 CRCs
developed during 25,745 pys of observation time after baseline (124 per 100,000 pys, 95% CI 88 to
176 pys). One follow-up conferred a significant 73% reduction in the incidence of CRC (HR 0.27, 95% CI
0.10 to 0.71) after adjusting for risk factors identified in the hospital data set. Additional surveillance
did not appear to provide further protection. Participants were divided into HIR and LIR subgroups using
the definition derived from risk factors for CRC in the hospital data set. In the HIR subgroup, a single
surveillance visit conferred a 72% reduction in CRC risk (HR 0.28, 95% CI 0.09 to 0.92; p = 0.0508),
and in the LIR subgroup there was a non-significant reduction in risk (HR 0.25, 95% CI 0.05 to 1.30;
p = 0.2084).
In the 1828 (77.7%) screening participants who attended surveillance, AA and CRC were found at the first
follow-up in 4.2% and 0.7%, respectively. When models including the same set of predictors for findings
at first follow-up in the hospital data set were fitted to the screening data set, no association was found
between increasing interval to first follow-up and detection of AA or CRC (AA: OR 0.98, CI 0.86 to 1.12;
p = 0.72; CRC: OR 1.12, CI 0.84 to 1.48; p = 0.46). Similarly, no significant difference in risk of AA or CRC
at first follow-up was found between the LIR and HIR subgroups defined using long-term CRC risk in the
hospital data set.
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Bowel cancer worry differed by group (F3,31904 = 16.3; p < 0.001): there was more worry in the surveillance
group than in the no-polyps group, and no significant differences between the surveillance group and
the other two groups with polyps. Although general psychological distress differed by outcome group
(F3,32055 = 2.66; p < 0.05), the surveillance group reported less distress than the groups with no polyps or
lower-risk polyps. There were significant differences across the groups in reported emotional consequences
of screening (F3,31971 = 9.37; p < 0.001), with the surveillance group reporting higher positive consequences
of screening than all of the other groups. They also reported more reassurance than the lower-risk group,
although reassurance scores did not differ from the two remaining outcome groups.
Health-economic analysis.
Of the 13 surveillance options considered in the exploratory economic evaluation, 3-yearly ongoing
colonoscopic surveillance with no age limit produced the greatest expected health gain. The incremental
cost-effectiveness ratio (ICER) for this option (compared with an age cut-off of 75 years) was expected to be
< £3000 per QALY gained. The probabilistic sensitivity analysis indicated that, assuming a willingness-to-pay
threshold of £20,000 per QALY gained, the probability that this option would produce the greatest expected
net benefit was approximately 1.0. When compared marginally against the no-surveillance strategy, all
surveillance options either dominated or had an ICER that was < £1000 per QALY gained.
Conclusions
Our results from both the hospital and screening data sets provide strong evidence that a single follow-up
offers substantial benefit to all IR patients by lowering their future risk of CRC. The benefits of a second
surveillance were more modest. However, we identified a higher-risk subgroup that significantly benefited
from additional surveillance and, conversely, a lower-risk subgroup for whom additional surveillance may
not be necessary.
If CRC risk is considered high enough to warrant surveillance in a subgroup, our data suggest that it
should be done at 3 years, unless the prior examination is of poor quality, in which case an earlier
examination should be considered. Surveillance should not be delayed as rates of interval cancers increase.
The economic analysis confirmed that 3-yearly surveillance was the optimum strategy. Further gains might
be expected from an identified lower-risk subgroup for which a single surveillance visit might suffice.
The detection of polyps was associated with increased bowel cancer worry, but surveillance itself was
associated with improved psychological well-being.
Future studies are needed to further validate findings in this study and confirm whether or not some IR
patients may not need colonoscopic surveillance.
Study registration
This study is registered as ISRCTN15213649.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The call for proposal
This project was undertaken in response to a call for proposals by the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme in anticipation of an unsustainable
increase in requirements for surveillance colonoscopy with the impending introduction of the national
Bowel Cancer Screening Programme (BCSP) in 2006. There was real concern that an increase in adenoma
detection from the BCSP would diagnose many people as intermediate risk (IR), with a consequent impact
on endoscopy resources. Therefore, a call was issued to determine the optimum frequency of colonoscopic
follow-up in patients who were identified with intermediate-grade adenomas.
The current UK surveillance guideline was developed in 2002 and defines three risk groups (low,
intermediate and high risk) with different surveillance recommendations.1 From existing evidence it was
suggested that, for the low-risk group, colonoscopy surveillance might not be necessary, whereas for the
high-risk group surveillance was definitely indicated with an additional clearing examination 12 months
after initial diagnosis (but this group constitutes only around 10% of people with adenomas2). The IR
group, representing around 40% of patients with adenomas, was recommended to have a 3-yearly
surveillance colonoscopy. However, this recommendation was based on limited evidence to indicate the
optimum surveillance interval and the need for repeated surveillance.1
Available evidence suggested that it might be safe to stop surveillance in the IR group after one or two
negative examinations, depending on the age of the patient and the quality of the examination. Importantly,
it was also proposed that patients with intermediate adenomas (IAs) may vary in their risk of developing
colorectal cancer (CRC) and that there might be subgroups with different surveillance requirements.3 The
need to determine the optimum frequency of colonoscopic follow-up in IR patients was identified as a
priority by the Department of Health (DH).
Rationale
Colonoscopy is the most widely used procedure for investigating colonic symptoms, and for surveillance
of people at increased risk of CRC because of a personal or family history of CRC or adenomas. It is
widely accepted that most CRCs develop from adenomatous polyps,4–7 and that the detection and removal
(polypectomy) of these precursors through screening or surveillance reduces the risk of CRC.8–13 Adenomas
are very common and tend to recur. As such, the future risk of CRC after polypectomy is thought to depend
on findings during baseline colonoscopy, particularly the number, size and histological grade of removed
adenomas,3,14,15 as well as the completeness of examination and clearance of prevalent adenomas. This
evidence was used to stratify patients into risk groups, each with different colonoscopic surveillance
recommendations.1,16–18
Since Atkin et al.3 first suggested a variability in risk of CRC after adenoma removal in 1992, many
countries have developed adenoma surveillance guidelines, most of which are based on either the UK
or US guidelines. The indication for surveillance depends primarily on the presumed risk of recurrence of
advanced adenomas (AAs),15,19–23 and development of CRC, and also by age, comorbidity and patient
compliance. The current UK surveillance guideline was first commissioned and developed by the British
Society of Gastroenterology (BSG) in 2002 and has since been adopted by the National Institute for
Health and Care Excellence (NICE) and the European Union (EU) (Figure 1).24 Both UK and US guidelines
identify three risk groups, but the definitions and surveillance recommendations differ slightly.1,2 Both
guidelines identify a low-risk group, for which no surveillance or 5-yearly surveillance is recommended;
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1
an intermediate-(UK)/higher-risk (US) group, for which 3-yearly surveillance is recommended; and a
high-risk group, for which additional colonoscopy is recommended. In the UK, the guideline specifies a
single clearing colonoscopy at 12 months before continuing on 3-yearly surveillance.1,2,16,17,25
The fact that guidelines vary – particularly in defining the IR group and their surveillance recommendation18,26
– is indicative of the uncertainty about the optimum adenoma surveillance regime. After adenoma removal,
some patients have a risk of CRC similar to, or lower than, that of the general population,3,27,28 implying that
not all patients are at sufficient risk to warrant surveillance.3,14,27–31 The IR 3-yearly surveillance regime is based
on results of the National Polyp Study,20 which compared two follow-up colonoscopies with one follow-up
colonoscopy within 3 years and found no difference in the detection of adenomas with advanced pathology.
Two other studies32,33 also found the incidence of adenomas with advanced pathology to be similar
regardless of interval length. However, another trial found a non-significantly higher risk of CRC in patients
who were examined at 4 years than in those examined at 2 years.29,34
As colonoscopy is both costly and invasive, surveillance should be undertaken only in those who are at
increased risk and at the minimum frequency required to provide adequate protection against the
development of cancer.25 There is evidence of both over- and underutilisation of colonoscopy, and a
potential for more efficient allocation of endoscopy resources.35 The IR group comprises nearly 20% of
those subjects participating in the BCSP who undergo colonoscopy for a positive test,36 and nearly half of
adenoma patients,2 yet no study has yet systematically examined whether or not there is heterogeneity in
risk among patients who are currently offered 3-yearly surveillance. We sought to address the unanswered
questions surrounding the current IR group surveillance strategy, that is:
l What is the effect of interval length on detection rates of AA and CRC at follow-up examinations in
IR patients?
l Are there subgroups of IR patients who do not require surveillance, or who require only one follow-up?
Similarly, are there are subgroups that might benefit from shorter or longer surveillance intervals?
FIGURE 1 UK adenoma surveillance guidelines 2002. Reproduced from Surveillance guidelines after removal of
colorectal adenomatous polyps. Atkin WS, Saunders BP, Gut, vol. 51, pp. V6–9, 2002,1 with permission from
BMJ Publishing Group Ltd.
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l Does the risk of AA or CRC at first and second follow-ups vary by patient, procedural and polyp
characteristics, and surveillance interval length?
l Can we define factors that affect the risk of CRC after baseline in IR patients, for example number of
surveillance visits, patient/procedural/polyp characteristics?
Background to the design
As a randomised controlled trial (RCT) or prospective observational study would take many years to
complete, the use of pre-existing hospital patient data in a retrospective cohort study was the
recommended design. It was thought that this method would be quicker, cheaper and more convenient.
In addition, the use of such hospital patient data ensured that there would be sufficient variation in
adenoma surveillance intervals to enable comparison between them. This may not have been possible
with data collected prospectively because of the widespread adoption of UK surveillance guidelines.
Furthermore, longer patient follow-up times could also be obtained in this retrospective study design.
We also requested access to data from researchers of a number of screening studies on findings at
surveillance colonoscopy. Eight screening data sets were identified; however, only three provided adequate
data for our analyses (see Chapter 4, Screening data set, Background).
At the time there was no systematic call or recall of patients in adenoma surveillance, so the principal
investigator (PI) also wrote to the manufacturers of the patient management systems that were used to
manage patient data in hospitals in the UK NHS. The manufacturers were able to identify hospitals that
had used their software for a sufficiently long period of time. These hospitals were contacted and were
provided with a questionnaire to complete in order to determine their suitability for the study.
Aim and objectives
The overall aim was to examine the optimum frequency of surveillance in patients who were found to
have IR adenomas and assess the risks and benefits with respect to prevention of cancer/AA; anxiety,
morbidity and mortality; costs and cost-effectiveness; and implications for the NHS.
The primary objective was to assess whether or not there was substantial heterogeneity in the detection
of AA or CRC according to baseline characteristics and interval to first follow-up colonoscopy. The study
planned to determine if there was a subgroup of IR patients who do not require surveillance and whether
or not the size of this group is clinically significant. Finally, the study examined whether subgroups could
be identified for which the currently recommended 3-year interval is too long, or for which the interval can
be safely extended, or if there is a group that requires a second examination but no further follow-up.
An economic analysis aimed to estimate the incremental cost-effectiveness of alternative adenoma
follow-up strategies, including a policy of no follow-up for individuals who have intermediate-grade
adenomas. It also planned to estimate the impact of alternative adenoma follow-up strategies on
colonoscopy services, and the total cost impact of alternative adenoma follow-up strategies in England
and Wales.
A psychological impact analysis aimed to examine the anxiety-inducing effects of colonoscopic surveillance
or being informed that colonoscopy surveillance is required.
Study design and setting
This was a retrospective cohort study using data from two sources. A cohort of patients attending UK NHS
hospitals for diagnostic or surveillance endoscopy formed the largest data set – termed the ‘hospital data set’.
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3
Three smaller data sets were obtained from a research or screening setting, and involved average-risk
individuals undergoing screening: one from a UK screening trial, a second from a UK pilot screening
programme and a third from a US health surveillance programme – termed the ‘screening data sets’.
The core results were derived from the hospital data set, as there were difficulties in obtaining additional
screening data sets, and limited data completeness in the screening data sets that we were able to obtain.
A health-economics evaluation and psychological study were also conducted.
Structure of this report
The findings of the hospital and screening data sets are reported and discussed in Chapters 3 and 4,
respectively. The methods, which were largely the same for the two data sets, are described in Chapter 2,
with any additional methods unique to the screening data set described in Chapter 4. The health-economic
evaluation is reported in Chapter 5 and the psychological study is reported in Chapter 6. Finally, Chapter 7
presents a synthesis of results from the preceding chapters, as well as strengths/limitations and future work.
INTRODUCTION
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Chapter 2 Methods
Hospital selection
The hospital data set comprised routine gastrointestinal endoscopy and pathology data for patients having
diagnostic and surveillance procedures. Participating hospitals were required to have recorded endoscopy
and pathology data electronically for at least 6 years prior to the study start in 2006. After contacting
endoscopy and pathology database manufacturers, 28 NHS hospitals were identified as meeting these
criteria, and their participation in the study was requested. A number of hospitals were excluded because
of difficulties with data extraction and data quality issues (see Data collection from hospitals, below). In
total, 18 hospitals were included in the study. Two of these merged into the Imperial College Healthcare
Trust (Charing Cross and Hammersmith hospitals) and thus there were 17 hospital sites included; these are
listed in Table 1.
TABLE 1 Hospitals included in the study
Trust Hospital Study name Study code Collection dates
Brighton & Sussex University
Hospitals NHS Trust
Royal Sussex County
Hospital
Brighton BRI May 2001 to
April 2008
North Cumbria Acute
Hospitals Trust
Cumberland Infirmary Cumberland CI August 1998 to
September 2009
Imperial College Healthcare
NHS Trust
Charing Cross Hospital/
Hammersmith Hospital
Charing Cross/
Hammersmith
CX/HH October 1997 to
November 2007
Greater Glasgow and Clyde
NHS Trust
Glasgow Royal
Infirmary
Glasgow GRI May 1996 to
August 2009
University Hospitals of
Leicester NHS Trust
Leicester General
Hospital
Leicester LGH April 1998 to
March 2008
Royal Liverpool and
Broadgreen University
Hospitals Trust
Royal Liverpool
University Hospital
Liverpool RLUH January 2000 to
October 2009
Royal Wolverhampton
Hospitals NHS Trust
New Cross Hospital New Cross NC January 1993 to
November 2007
University Hospital of North
Tees Trust
University Hospital of
North Tees
North Tees NT June 1986 to
December 2006
Queen Elizabeth Hospital
NHS Trust
Queen Elizabeth
Hospital
Queen
Elizabeth
QEW March 1999 to
May 2006
Queen Mary’s Sidcup NHS
Trust
Queen Mary’s Hospital Queen Mary’s QMH October 1998 to
July 2009
Shrewsbury and Telford
Hospitals NHS Trust
Royal Shrewsbury
Hospital
Shrewsbury SH January 2002 to
September 2009
St George’s Healthcare NHS
Trust
St George’s Hospital St George’s SGH February 1992 to
July 2009
London North West
Healthcare NHS Trust
St Mark’s Hospital St Mark’s SMH January 1985 to
July 2007
continued
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Patient eligibility
Inclusion criteria
Patients with IR adenoma(s) and a baseline colonoscopy were eligible for inclusion in the study. Following
the UK guideline, IR patients were defined as those with three or four small adenomas (of < 10 mm) or
one or two adenomas, at least one of which was large (≥ 10 mm).
Exclusion criteria
Patients were excluded for having certain conditions if the condition increased their risk of CRC or could
have led to an abnormal pattern of surveillance. Some diagnoses resulted in exclusion regardless of when
they occurred, for example hereditary non-polyposis colorectal cancer (HNPCC), a genetic condition that
confers an increased risk of cancer throughout an individual’s lifetime. Other conditions resulted in
exclusion only if they were diagnosed at, or prior to, baseline, or, in other cases, patients were censored
after diagnosis of a particular condition rather than excluded altogether.
Patients were excluded if they had any of the following diagnoses at, or prior to, baseline:
l CRC or inflammatory bowel disease (IBD)
l resection/anastomosis
l volvulus.
Patients were excluded if they had the any of the following diagnoses at any time:
l family history of familial adenomatous polyposis (FAP)
l HNPCC
l Cowden syndrome
l juvenile or hamartomatous polyps.
Patients with polyposis could be excluded depending on polyposis type and time of diagnosis. Details of
time-dependent exclusions for polyposis and colitis can be found later in the report (see Appendix 5).
Patients were also excluded if they had no baseline colonoscopy, or had one or more procedures without a
date, or had more than 40 endoscopic procedures recorded.
TABLE 1 Hospitals included in the study (continued )
Trust Hospital Study name Study code Collection dates
Imperial College Healthcare
NHS Trust
St Mary’s Hospital St Mary’s ICMS December 1984 to
July 2010
Royal Surrey County Hospital
NHS Trust
Royal Surrey County
Hospital
Surrey SCH September 1997 to
May 2010
South Devon Healthcare
NHS Foundation Trust
Torbay District General
Hospital
Torbay TDG November 2000 to
August 2007
Yeovil District Hospital
Foundation Trust
Yeovil District Hospital Yeovil YDH February 1997 to
May 2008
METHODS
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Research governance
Data were collected from hospitals in England and Scotland. The following research governance approvals
were obtained to permit data collection and follow-up via external agencies:
l Approval was granted from the Royal Free Research Ethics Committee (REC) for the study throughout
the UK (REC reference 06/Q0501/45). The REC agreed that all sites should be exempt from site-specific
assessment. Further approval was granted for substantial amendments to allow changes to database
hosting arrangements and logistical arrangements for data collection and follow-up.
l Approval to access patient identifiable information without consent in England was granted from the
Patient Information Advisory Group (PIAG) [later the National Information Governance Board (NIGB) and
currently the Ethics and Confidentiality Committee at the Health Research Authority] in accordance with
Section 60 of the Health and Social Care Act 200137 (re-enacted by Section 251 of the NHS Act 200638).
Further approval was granted for substantial amendments to allow data to be extracted and anonymised,
and to link identifiable information obtained from multiple sources including hospital endoscopy and
pathology databases, the Hospital Episode Statistics (HES) database, and databases held by the Office for
National Statistics (ONS), National Health Service Information Centre (NHSIC) [subsequently the Health and
Social Care Information Centre (HSCIC)] and National Health Service Cancer Registries (NHSCR) [reference
PIAG 1–05(e)/2006]. This was necessary because of the retrospective nature of the study and the large
number of patients involved. Support was favourable based on the study’s System Level Security Policy
and compliance with Imperial College’s policy on data handling and storage, and a recommendation from
the Caldicott Guardian for the North West London Hospitals NHS Trust, who approved the arrangements
to ensure patient confidentiality and anonymity. In Scotland, similar approvals were obtained in 2013 from
the Community Health Index Advisory Group. Permission was granted to use the Community Health Index
(CHI) to enable the Information Services Division to clean the patient information within the study data
set, and to match identifiable information to data from the cancer and death registries.
l Research approval for the study was obtained from all relevant NHS care organisations for the study
sites, which were provided with the ethical approval documentation and the study protocol. As none of
the members of the study team had a contractual relationship with the NHS, honorary contracts/letters
of access were applied for and obtained for staff who were required to carry out work at the various
study sites, in agreement with the Research Governance Framework.
l Where necessary, applications were made to the custodians of external data sets to enable specific
researchers to access information controlled by external sources and to allow the study data set to be
linked to external data sets. In England, researcher status was approved and obtained from the ONS
and NHSIC for individual researchers, and applications to use individual records for medical research
were made to the NHSIC and the UK Association of Cancer Registries (UKACR). In Scotland, the Privacy
Advisory Committee (PAC) granted approval for patient record linkage with NHS National Services
Scotland (NSS) using CHI numbers, so that patients in Glasgow could be followed up to obtain details
of cancers and deaths (reference PAC Application 66/11).
To ensure that patient confidentiality was maintained throughout the study, no patient-identifiable
information – except date of birth – was stored on the study database. All patient identifiers were left
at the individual study sites in secure locations, and all information kept at the trial office was in a
pseudo-anonymised format. In addition, access to the Oracle database was controlled by username and
password security, as well as a firewall that restricted access to the database server to a limited number of
IP addresses. The majority of computers in the trial office were given access to the database, whereas
specific access to the data via the Oracle Application Express (APEX) version 3.2.1.00.10 (Oracle
Corporation, Redwood City, CA, USA) coding application was controlled via APEX’s built-in user
management facility.
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Data collection from hospitals
The data were extracted from hospital endoscopy and pathology databases by the study programmer.
A minority of databases had an interface that permitted bulk extraction of the data according to specific
criteria and in these cases data were extracted with assistance from hospital staff who were familiar with
the systems. However, for most endoscopy and pathology databases, the application interface was not
designed for bulk data extraction, so data extraction and processing was complex, with a number of
problems encountered, for example:
l When the maintenance and support of the endoscopy and pathology databases had been outsourced
to the database manufacturers, often only they could help with extracting the data or by writing
software enabling the study programmer to do so.
l Specialist support was required when data were held on legacy systems.
l Information technology (IT) staff at the hospitals sometimes had to restore archived data temporarily so
that they could be extracted.
l Most hospitals had replaced databases over the years, and therefore some data overlapped or were
duplicated (e.g. the same patient had records on more than one system).
l Sometimes several hospital visits were necessary to extract data from multiple databases, at the
convenience of the local IT experts.
l The data outputs from these databases were in a combination of structured and unstructured formats.
Structured data could be easily cleaned and converted into a standardised format for uploading.
Unstructured data (usually large text fields) needed bespoke programs written to extract, clean and
convert the data into a suitable format.
Owing to various technical difficulties with data extraction, inability to access databases, partial availability
of electronic data, unreliable Systematized Nomenclature of Medicine (SNOMED) coding and logistical
difficulties due to local staff availability, nine hospitals were excluded from the study (Table 2). From the
17 hospitals that were included in the study, data were extracted from 27 endoscopy and 29 pathology
systems. (A summary of data collection at each hospital can be seen in Appendix 1.)
Data extraction
Endoscopy data
Endoscopy databases were searched first in order to identify patients undergoing colonic examinations,
as the pathology databases contained a wide range of extracolonic samples. Before removal from the
hospital, the extracted data were split into patient identifiers and endoscopic data. Patient identifiers
included surname and forename(s), hospital number(s), NHS number, gender, postcode and date of birth.
Endoscopic data included date of procedure, type of procedure, indications, endoscopist name, endoscopist
comments, polyp information (such as size, shape, location, information on any biopsies taken), segment
reached, quality of bowel preparation, complications encountered, diagnosis and any other information.
The list of patient identifiers was cleaned to remove errors, inconsistencies and duplicates, and a unique
study number was assigned to every patient. Study numbers were made up of a three-letter code,
representing the hospital, followed by a six-digit number.
Pathology data
Pathology databases were searched for reports on colorectal lesions. The preferred search method used
in most hospitals was SNOMED (College of American Pathologists), which defined the site and type of
colonic lesions present. When this was not possible, Systematized Nomenclature of Pathology (SNOP)
(College of American Pathologists) codes (four-digit versions of SNOMED codes), keywords or SNOMED
International 3.0 codes (College of American Pathologists) were used (see Appendix 1 for details of the
methods used to collect pathology data at each centre). Initial validation checks were performed to ensure
that the pathology extract included the date of report, unique report number, type of procedure where
specimens were taken, number of specimens and histological details.
METHODS
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TABLE 2 Hospitals excluded from the study
Hospital
Reason for
exclusion Summary Details
Blackpool Victoria Software/data
collection issue
Incompatibility of old vs.
new software systems for
importing endoscopy data
Difficulties in bulk data
transfer from pathology
reports
Following the creation of extraction programs
and test runs, the statistics program was unable
to extract all of the necessary endoscopy data.
The main endoscopy reports could not be
extracted from the older EndoScribe data
imported into the newer ADAM system
The pathology system did not allow the
uploading of pathology reports in bulk
Bradford Royal
Infirmary
Software/data
collection issue
Old software systems
used to record data
Difficulties in bulk data
transfer
Pre-2005 SNOMED coding for pathology data
was unreliable
The Co-Path system proved to be problematic
and complex to extract multiple records – it
would have taken too long and would have
slowed down the system for the hospital
City Hospital,
Birmingham
Difficulties in
obtaining R&D
approval
Delays and limited
resources
The study encountered long delays in R&D
approval, owing to staff shortages in the R&D
department and time-consuming internal
procedures
George Eliot,
Nuneaton
Software/data
collection issue
Old software systems
used to record data
Difficulties in bulk data
transfer
The same difficulties with the Co-Path system as
encountered with Bradford Royal Infirmary
King George, Ilford Data collection
issue
Impractical to extract the
data
Difficulties in bulk data
transfer
The majority of older pathology data were
initially inaccessible because of software
licensing issues. When access was achieved, the
reports could be accessed only one at a time,
making it impractical to extract the data
Norfolk and Norwich
University Hospital
Technical issues
Missing data
Raw endoscopy and pathology data were
extracted between November 2009 and
August 2010 from the Micromed, EndoScribe
and Scribe databases and the pathology
database over several visits to the hospital,
and partly cleaned and anonymised. However,
on subsequent visits to complete the task the
data had been misplaced
Re-extraction would have been costly and
time-consuming
Pinderfields, Yorkshire Software/data
collection issue
Incomplete data The data provided by a new HICSS system
(Ascribe Ltd, now EMIS Group plc, Leeds, UK)
were lacking any endoscopy procedures other
than colonoscopy (e.g. sigmoidoscopy and rigid
sigmoidoscopy)
Queen Alexandra,
Portsmouth
Missing data Missing pathology data 2006–8
University Hospitals of
North Staffordshire
NHS Trust
Software/data
collection issue
Difficulties in bulk data
transfer
Not possible to do a bulk data extraction at this
hospital
HICSS, Hospital Integrated Clinical Support System; R&D, research and development.
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Linking endoscopy and pathology data
Patients identified from endoscopy records were matched to their pathology records using a combination
of hospital number, name and date of birth. Patient study numbers were then assigned to the matched
pathology records. Manual inspection of the data and preliminary analyses were performed at the hospital
to check that a sufficient number of pathology records were linked to a patient and that they occurred on,
or near, the date of an endoscopy. When there was cause for concern (e.g. very few endoscopies linked
to pathology reports; or endoscopies at which a biopsy was taken did not have an associated pathology
report; or a large number of pathology reports could not be linked to an endoscopy, suggesting that the
endoscopy extract did not retrieve all records), further investigations were undertaken and the data were
re-extracted from the endoscopy and pathology systems where necessary.
Pseudo-anonymising data
In order to maintain patient confidentiality in accordance with the EU Directive on Good Clinical Practice
(Directive 2005/28/EC), the Data Protection Act 199839 and the NHS Caldicott Principles, all patient
identifiers except date of birth were removed from the pathology and endoscopy data, and the
anonymised data were encrypted before being removed from the hospital.
A ‘patient-linking-file’ in Microsoft’s .xls or .xlsx format (Microsoft Corporation, Redmond, WA, USA),
storing each patient’s identifiable information and study number was created, encrypted, and left at each
hospital site. The raw endoscopy and pathology data and patient-linking-file were copied on to CDs and
stored in secure locations at the hospital under supervision of the local PI.
Development of the master database
A master database was created to store the data in a standardised, structured format. To facilitate the
statistical analysis, the data had to be classified into quantitative and qualitative variables, ensuring that
data from different hospitals were classified in the same way, as there was wide variation in the raw data
(e.g. field names were different; some data were coded or semi-coded, whereas other data were in
free-text fields; and data types varied). The PI, study researchers, statistician and study programmer defined
the data requirements for the study and designed the structure of the master database (see Appendix 2).
The master database was designed to store the following:
l the original source data (to safeguard against data loss during coding)
l fields to store structured data that had been automatically extracted, cleaned and standardised using
bespoke programs
l fields to store the structured data which were manually coded.
Reference data (sometimes referred to as look-up tables) were used to categorise and define permissible
values for data fields on the database. This method restricted the values to be recorded in a data field,
thereby preventing coding errors and also ensuring uniformity of data from different hospitals.
It was necessary to transform the variety of data received from different hospitals into a standardised data
set. As the volume of records was very large, it was necessary to code and categorise the data as much as
possible using automatic coding without compromising the integrity of the data. Programs were developed
to transform, clean and automatically code the data where possible. This involved several steps:
l identifying the fields containing information required for the study, taking into account varying field
names, data types and value representations
l extracting information from free-text fields using programming techniques such as ‘regular expressions’
and ‘fuzzy matching’, and translating them into the codes used on the master database
l translating values in the raw data into the codes used on the master database if the information was
already in a coded structured format
METHODS
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l identifying and consolidating overlapping data, and removing any redundancies (e.g. the same
endoscopy or pathology reports extracted from two different systems)
l identifying errors in the data and validating and correcting them (e.g. misspellings, different date
formats, accounting for false-positive matches)
l transforming polyp data to fit the structure of the polyp table in the master database. Some raw data
sets had structured data on polyps (i.e. each polyp was represented as a separate table record); for
other data sets, the study programmer had to separate the data into individual records.
After data transformation and cleaning, the raw data and structured data were uploaded to the master
database, ensuring that the data were linked correctly across tables. Exclusions of ineligible patients were
made automatically where possible, using programming techniques such as ‘regular expressions’ and
‘fuzzy matching’ to identify relevant keywords or phrases in the reports. Approximately 17% of patients
were excluded using automatic exclusions.
Manual data coding
The records of the remaining 83% patients who had not been auto-excluded were manually interpreted
and coded; this also involved checking the automatic coding on these records.
A web-based coding application with a graphical user interface was developed using APEX, allowing the
study researchers to read, interpret and code the information in the database efficiently. This was called
the Endoscopy and Pathology Reports Application (EPRA). The development of the EPRA evolved over time
as new data items were encountered at different hospitals, and as processes for coding and analysing the
data were developed. A change log of new features was maintained on the study database and updated
when a new version of the EPRA was released. (Details and screenshots of the EPRA are provided in
Appendix 3.)
Documents detailing standard operating procedures (SOPs) were produced to ensure standardised coding
methods between study researchers. SOPs covered all basic coding methods, rules for coding individual
fields within the database, and more complex processes used for tasks such as polyp numbering (see
below). All SOPs can be found in Appendix 4.
A specific study researcher was allocated a patient’s complete set of records to ensure that the study
researcher had access to all available information. The study researchers were responsible for:
l checking and correcting data that had been automatically coded
l checking that endoscopy and pathology records were properly linked
l coding the raw endoscopy and pathology data into structured data
l creating individual polyp records from the data provided in endoscopy reports. In some cases, the study
researchers found that polyps were described as groups rather than as individual polyps. This is
discussed further below
l raising queries on records that could not be fully coded due to incomplete or insufficient information
l creating a blank ‘pathology-based procedure report’ in cases for which the pathology record had no
linked procedure report. Clinical information available in the pathology report was used to deduce
details about the procedure from which the histological sample was obtained.
Coding accuracy and data interpretation were monitored to maintain consistency, using the
following methods:
l Study researchers systematically reviewed a blinded random sample of records that had been coded by
other study researchers.
l Regular meetings and continuous discussion/feedback were used to ensure uniformity of coding.
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Records that had not been coded because of incomplete or insufficient information were reviewed by the
study researchers, and further data were obtained from hospitals, where possible, in order to complete
the coding.
Polyp numbering
A polyp found at one endoscopy examination that was not removed or only partially removed could be
seen again at a later examination. To ensure that there was no double-counting of polyps, each polyp
was assigned a unique polyp number that could be used to link sightings of the same polyp at different
examinations. This process was called ‘polyp numbering’.
In approximately 17,000 patients, polyps were found on at least two occasions and were reviewed for
manual polyp numbering. All sightings of an individual polyp were assigned the same unique polyp
number. Each polyp was also assigned a match probability (to the nearest 10%), to indicate the degree of
certainty that two polyps were the same lesion. The polyp that appeared to have the greatest number of
matches with a high degree of certainty was chosen as a reference polyp, and all possible matches were
considered in relation to this polyp. Polyp numbering guidelines were used to match polyps accurately and
methodically, using all of the available information from the endoscopy and pathology reports. Particular
attention was given to the following factors, listed in order of importance. Sightings at different
examinations were considered more likely to be the same polyp if:
1. they occurred in the same segment of the colon, or in adjacent segments
2. there was an indication that the polyp at the earlier examination was not removed or was only
partially removed
3. the quality of bowel preparation at the first examination was poor, making it less likely that a lesion
would be removed
4. the lesions had similar grades of dysplasia
5. the lesions were the same histological type
6. the lesions had similar degrees of villousness.
Quality checks were carried out by the study researchers, who manually reviewed and checked a random
sample of records for which polyps had been numbered by other study researchers.
Polyps matched with an arbitrary probability of ≥ 70%, using the above criteria, were considered the same
lesion. More details on polyp numbering can be found in Appendix 6.
Polyp groups
Sometimes endoscopy reports described groups of polyps using terms such as ‘several’, ‘many’ and
‘multiple’, rather than individual polyps. During manual coding, specific fields were used to record this
information. Each group of polyps was recorded as a single record and populated with information such
as site, shape and histology, where this was common to all polyps within the group. Descriptions of the
size and number of polyps in the group (e.g. ‘tiny’, ‘multiple’) were recorded. Where information was
given for an individual polyp within the group, a polyp record was created and linked to the group record.
The whole group (and the individual polyps linked to it) was allocated a unique group number.
Patients with multiple polyps could have groups of polyps seen at more than one examination, and a
group of polyps seen at a later examination could include some or all of the polyps seen at a previous
examination. In order to link groups of polyps seen at more than one examination, a separate group
linking number was assigned to each group of polyps. This task was completed after all polyp groups had
been recorded for a patient. Groups of polyps seen at more than one examination were matched and a
probability was assigned, indicating the study researcher’s certainty that groups of polyps seen at separate
examinations were of the same group.
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The records for groups of polyps were then expanded into individual polyp records so that they could be
analysed. An estimate of the number of polyps in each group was deduced from a value coded for the
approximate number where available; otherwise the average of the minimum and maximum number of
polyps recorded by the endoscopist was used. Alternatively, a numeric value was estimated for each vague
number description (e.g. ‘some’, ‘several’, ‘few’), taking the average value for all groups in which both the
specific descriptor and a numeric value was reported; these values used to define the number of polyps in
the such groups are shown in Table 3.
Additional information on the number of individual polyps seen at previous or subsequent examinations
which were considered to be part of the same group was used to refine the estimate of the number of
polyps in that group (see Appendix 6).
Once a final estimate had been derived for the total number of polyps in each group at each examination,
a program was written to create individual polyp records. Where a polyp record was created based on the
presence of a polyp at a previous or subsequent examination, the program assigned the same polyp
number to the new polyp record, to show they were the same lesion.
Creating summary values for polyp characteristics
Most polyps were seen and removed at a single examination, and information about a polyp’s features
was available from a single endoscopy and pathology report. Alternatively, a polyp might be seen at more
than one examination with descriptive information contained in numerous endoscopy and pathology
reports. In both of these scenarios, a single polyp characteristic might be coded for in multiple data fields.
It was therefore necessary to create summary values for each lesion, taking into account information
provided in reports on polyp characteristics at individual examinations and across examinations. However,
the following issues had to be resolved first.
Missing polyp information
When information on a polyp characteristic was missing from the endoscopy report, it was sometimes
possible to obtain supplementary information from the pathology report, or from other examinations at
which the same polyp was detected.
Inconsistent polyp information
Polyp information reported in an endoscopy and pathology report for a specific examination could be
inconsistent. Similarly, information reported across multiple sightings of a single polyp could be
inconsistent. Sometimes it was clear from available information that an inconsistency was due to a coding
or transcriptional error in one or more hospital reports. Rules were identified to determine which data
items were likely to be errors; these records were manually reviewed and errors corrected where possible.
Inconsistencies that could not be explained by error were resolved using hierarchies of rules (see
Appendices 7 and 8).
TABLE 3 Estimated values assigned to descriptions of polyp numbers
Description Estimated no. of polyps
A few 3
Some 3
A number of 3
Several 3
Many 5
Multiple 5
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Vague polyp information
Wherever possible, information on polyp characteristics was recorded on the database exactly as reported
in endoscopy or pathology reports, and usually precise values were provided. However, in rare cases the
observations recorded in the endoscopy report about size and location could be vague; for example size
could be merely described as tiny or < 10 mm, and location could be described using a range of values;
this was particularly problematic when there were multiple lesions seen at an examination. These vague
descriptions of size, and ranges of values for size and location, were recorded in specific fields on the
database. Rules were defined to derive a summary value for size and location of each individual polyp at
an examination by combining all the available information. These rules are described in greater detail in
this section and in Appendices 7 and 8.
Summary values were determined for polyp size, histological features, location and shape, and were
derived separately for each visit. Summary values for polyp characteristics were derived using hierarchies of
rules. In general, three stages were involved:
1. data cleaning to identify, review and resolve any errors in the polyp data
2. assessment of polyp characteristics at a single examination
3. assessment of polyp characteristics across examinations within a visit, if a polyp had multiple sightings.
Size
Polyp size information was recorded in several fields on the database, as shown in Table 4.
Exact sizes (endoscopy or pathology size) were available for 65% of polyps (of all types, including adenomas)
but 8% of polyps had a numeric size with a minor discrepancy, or a size range (minimum and maximum
endoscopy size); both of these issues were resolved to give an accurate size. In only 6% of polyps was the
size estimated based on a qualitative size description (endoscopy size descriptor). This does not account for
other sightings of the same polyp, so the proportion without a precise, numerical size is likely to have been
even smaller than this. These proportions relate to all patients for whom we had data, rather than just IR
patients, as adenoma risk groups could not be discerned until summary values for size had been defined.
TABLE 4 Polyp size fields and derived values
Size field Variable namea Description Derived valuesa
Endoscopy size ENDO_SIZE Field used to record the exact size of a
polyp (in millimetres), when described
precisely in the endoscopy report
Derived endoscopy size
ENDO_SIZE, ENDO_SIZE_MIN and
ENDO_SIZE_MAX were combined
using a hierarchy of rules to give a
single derived endoscopy size for
each sighting of a polyp
Minimum
endoscopy size
ENDO_SIZE_MIN Field used to record the minimum size of a
polyp when a size range was described in
the endoscopy report (e.g. 8–10mm)
Maximum
endoscopy size
ENDO_SIZE_MAX Field used to record the maximum size of
a polyp when a size range was described
in the endoscopy report
Endoscopy size
descriptor
ENDO_SIZE_OTHER Field used to record the size of a polyp
when it was described in vague terms in
the endoscopy report (e.g. tiny, > 10mm,
< 5mm, etc.)
Derived endoscopy size descriptor
A numeric value was derived from
a description (see Table 5)
Pathology size PATH_SIZE Field used to record the exact size of a
polyp or biopsy specimen as described by
the pathologist in the pathology report
Derived pathology size
The precise size given in most
pathology reports is used
a These variable names are referred to in Appendices 7 and 8.
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The ‘endoscopy size descriptor field’ was used in cases for which a ‘vague’, qualitative or approximate size
description was given in the endoscopy report. A numerical value was derived for each size description by
analysing reports in which both qualitative size descriptions and a precise numerical size were given.
The median and interquartile range (IQR) were calculated for each numeric size field and cross-tabulated
against associated categories of the endoscopy size descriptor field, as shown in Table 5.
The endoscopy size and minimum and maximum endoscopy sizes were combined using a hierarchy of
rules to give a derived endoscopy size for each sighting of a polyp (see Appendices 7 and 8 for details).
The numerical values assigned to the endoscopy size descriptor field were used as the derived endoscopy
size descriptor. Most pathology reports provided a precise size, which was coded for each individual polyp
biopsied or resected at an examination – this was taken as the derived pathology size. Derived endoscopy
and pathology sizes were automatically assigned when possible. Study researchers manually reviewed
polyps for which derived endoscopy and pathology sizes could not be assigned automatically.
Finally, the three derived polyp sizes – derived endoscopy size, derived endoscopy size descriptor and
derived pathology size – were compared across examinations within a visit, and the largest of each derived
size was identified. The largest derived sizes were compared and the largest of these was used as the
summary polyp size. The only time the largest size was not used was if it was the derived endoscopy size
descriptor, and the derived endoscopy and derived pathology size was also available, which were
considered more accurate. Full details of these methods are provided in Appendices 7 and 8.
Histopathology
In all patients for whom data were collected, including low-, intermediate- and high-risk patients,
histological data were available for 66% of polyps (all types of polyps, including adenomas). In some cases
(34%), data on histological features of a polyp were missing because no biopsies were taken, a pathology
report could not be identified at the hospital, or the polyp in question was not retrieved at endoscopy or
not mentioned in the pathology report. This value does not account for other sightings of polyps – they
may have been removed at another examination – and we would expect some of these polyps to have
been insignificant and therefore not excised. Rules were applied to the data to resolve such issues and
derive polyp histology, where possible. First, if a polyp had any degree of villousness or dysplasia coded
then the polyp was assumed to be an adenoma. If the polyp was ≥ 10 mm in size and no histology was
recorded at any sighting of the polyp, the histology was set to ‘specimen not seen’ or ‘not able to
diagnose’. If the polyp without histology was ≥ 10 mm in size and the patient had at least one adenoma
recorded then the polyp was then assumed to be an adenoma.
TABLE 5 Assigning numerical values to endoscopy size descriptions
Endoscopy size
descriptor category
Endoscopy size (mm)
Derived
value size Rationale for derived value sizeMedian (IQR) n
Tiny 3 (2–3) 660 3mm Used the median
Small 3 (3–5) 1574 5mm Used the larger value of 5 mm to draw
a distinction between ‘Small’ and ‘Tiny’
< 5mm 3 (2–3) 35 3mm Used the median
5–9 mm n/a 0 7mm No examples so took the halfway point
< 10 8 (8–8) 3 8 mm Used the median of available examples
≥ 10mm 15 (13–15) 79 15mm Used the median
Large 20 (12–30) 2701 20 Used the median
n/a, not applicable.
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A polyp seen at more than one examination may not have been diagnosed as an adenoma until a later
sighting. As baseline started from first sighting of an adenoma, it was necessary to apply adenomatous
histology back to earlier sightings, provided that the sighting without histology occurred no more than
3 years prior to the adenoma diagnosis. Adenomatous histology was applied to earlier sightings of a polyp
only if the histology for the earlier sighting was unknown or recorded as hyperplastic, granulation tissue,
previous polypectomy site, normal mucosa, not possible to diagnose, or specimen not seen; this ensured
that histology of greater severity than an adenoma was not overwritten.
A single polyp seen at more than one examination could have different histological features recorded at
each sighting. To resolve these inconsistencies, histological types encountered in the study were split
into two groups: group 1 consisted of the outcomes of interest (CRCs and adenomas), along with all
histological types that could potentially occur in such lesions over time (Table 6); group 2 consisted of all
other histological types (data not presented). Group 1 histological types were listed from most to least
severe within the following groups – CRC, possible CRC, benign lesion, no polyp features/not possible
to diagnose – as shown in Table 6. When there was no clear-cut order in terms of malignant potential,
histological types were arbitrarily ordered by the specificity of the description. Initially, polyps with histology
from groups 1 and 2 recorded at different sightings were reviewed to check whether or not there was a
reporting or coding error. Then, for remaining polyps with histology from both groups, group 1 histology
took precedence for the purpose of this study, except when the group 1 histology was uncertain or
unimportant (e.g. ‘normal mucosa’, ‘granulation tissue’, ‘previous polypectomy site’, ‘not possible to
diagnose’ or ‘specimen not seen’), in which case the group 2 histology took precedence.
TABLE 6 Group 1 histology
Category POLYP_TYPE
CRC Cancer with remnant of sessile serrated lesion
Cancer with remnant of mixed/serrated adenoma
Cancer with remnant of mixed adenoma
Cancer with remnant of serrated adenoma
Cancer with remnant of adenoma
Cancer
Possible CRC Cancer or adenoma with HGD? (cancer in dispute)
Cancer with unknown primary
Possible cancer (suspicious features but may be non-adenomatous)
Benign lesion Sessile serrated lesion
Mixed polyp (adenomatous and metaplastic features)
Serrated adenoma
Adenoma/assumed adenoma
Unicryptal adenoma
Metaplastic/hyperplastic polyp
No polyp features/not possible to diagnose Previous polypectomy site
Granulation tissue
Normal mucosa
Not possible to diagnose
Specimen not seen
HGD, high-grade dysplasia.
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The histology of adenomas was further defined using their greatest degree of villousness and worst
dysplasia recorded within a visit.
Polyp location
The following rules were used to define a value for polyp location across all visits:
1. Where the segment was recorded at a surgical procedure, this took precedence over any segment
recorded at other types of procedure.
2. If there was no surgical procedure, the most frequently described segment was taken.
3. If no segment was mentioned more frequently than another, the most distal segment was taken.
4. In cases where a segment range was given, the following rules were applied:
l If only one range was described, the most proximal and distal segments were recorded on the
database as the true range (proximal defined as descending colon to terminal ileum; distal defined
as anus to sigmoid colon).
l If several site ranges were described, the smallest segment range was used as the true range,
provided that the difference in the position of the most proximal and distal segments in the range
was ≤ 2. Table 7 was used to allocate a position to each segment in order to calculate this difference.
If the segment range differed by more than two, the records were manually reviewed to reach
a decision.
Polyp shape
It was unclear if the most appropriate method for assigning the true shape of a polyp would be to use
an order of precedence, as with other polyp characteristics, or if the first description might be the most
accurate, as the shape of a polyp may have been altered once it was biopsied/resected. Shape values
included flat, sessile, pedunculated or subpedunculated. It was decided that the first recorded shape of a
lesion would be used.
TABLE 7 Position of the segments of the colon
Position Segment
1 Ileum
2 Caecum
3 Ascending colon
4 Hepatic flexure
5 Transverse colon
6 Splenic flexure
7 Descending colon
8 Sigmoid colon
9 Rectosigmoid
10 Rectum
11 Anus
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Procedure information
Procedure date and order
In most cases, the procedure date was simply the date of the endoscopy. However, if the endoscopy report
was not available, the pathology report was used to derive the examination date. Up to three dates might
be specified on the pathology report. The examination date was derived using the following order of
precedence:
1. date that the biopsy specimen was taken
2. date that the biopsy specimen was received at the laboratory
3. date of the pathologist’s report.
In the rare cases when it was not possible to derive a procedure date, the patient was excluded from the
study. Where procedures occurred on the same day, the reasons were specified and the examinations
were numbered to assign an order, otherwise it was specified why it was not possible to do so.
Procedure type
The master database contained two types of procedural report: endoscopy reports extracted directly from
endoscopy databases and pathology-based procedure reports generated using clinical and procedural
information from the pathology report. The latter were created by study researchers in cases when no
endoscopy report was available.
In cases where the procedure type was not reported or not specified (e.g. ‘endoscopy’), procedure type
was derived by applying a hierarchy of rules based on available information. For example, when a
procedure type was unknown, yet there was evidence that the transverse colon or beyond was reached,
the procedure type was probably a colonoscopy. When information such as bowel preparation and depth
of insertion was given, the procedure was probably a colonoscopy or flexible sigmoidoscopy (FS). Likewise,
if a lesion with a size of ≥ 10 mm was removed, or multiple adenomas were removed, the procedure was
also probably a colonoscopy or FS. Full details of rules for deriving procedure type are given in Appendix 7.
For some patients, it remained uncertain whether or not they had a baseline colonoscopy even after
procedure type was derived (i.e. derived procedure type was ‘colonoscopy or FS’ at baseline). As patients
had to have a baseline colonoscopy for inclusion in the study (a baseline colonoscopy was necessary to
accurately stratify patients into risk groups), procedures that were derived as ‘colonoscopy or FS’ were
reclassified as colonoscopies, based on adenoma risk group and type/timing of follow-up examinations.
For example, patients with a derived procedure type of ‘colonoscopy or FS’ at baseline who were classified
as IR or high risk (see Defining adenoma surveillance risk groups, below) were assumed to have had a
colonoscopy at some point during baseline, and so the derived procedure was relabelled as such (see
Appendix 7). Unlike baseline examinations, no derived procedure types were relabelled at follow-up
examinations. Instead, for each follow-up visit, the most complete whole-colon examination available was
defined using a hierarchy from ‘complete colonoscopy’ to ‘unknown procedure type’.
For patients without a baseline colonoscopy who had a colonoscopy at follow-up visit 1 (FUV1), the baseline
visit was shifted so that FUV1 became the baseline visit and the original baseline visit became a ‘prior’ visit.
To ensure that risk was not underestimated as a result of shifting baseline in this way, any adenomas found
at prior examinations (original baseline) were used to determine risk as well as those found during the
baseline visit.
Colonoscopy quality
Where there were several colonoscopies within a visit, the most complete examination and the best bowel
preparation achieved at any colonoscopy was taken as the highest quality examination achieved at that
visit. The quality and completeness of a colonoscopy was assessed, based on the segment of the colon
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reached, the most proximal polyp site, the quality of bowel cleansing prior to the examination and
whether or not the examination was marked as incomplete.
The quality of the colonoscopy was important for defining visits (see Defining baseline and surveillance
visits, below) as well as being a potential risk factor in the final data analysis.
Defining baseline and surveillance visits
For the purposes of this study, a ‘visit’ (baseline or follow-up) was defined as one or more examinations,
performed in close succession, with the aim of completing a full examination of the colon and removing all
detected lesions. This is based on the assumption that a single endoscopy is not always sufficient to
visualise the entire colon (e.g. owing to poor bowel preparation) or to remove large, numerous or
residual lesions.
Lesions found during the baseline visit were used to classify baseline risk of CRC and to stratify patients
into adenoma surveillance risk groups (see Defining adenoma surveillance risk groups, below). In addition,
certain diagnoses during baseline rendered the patient ineligible for the study, including CRC (see Patient
eligibility, above). Follow-up visits were then defined around the baseline visit, with the length of time
between visits being used to determine surveillance intervals.
Baseline visit
The baseline visit included the examination with the first adenoma sighting and any completion
examinations that occurred within the subsequent 11 months. For high-risk adenomas, surveillance
examinations are scheduled 1 year after the initial examination, in accordance with UK surveillance
guidelines, so 11 months was chosen as the most appropriate time frame to capture any completion
examinations into the baseline visit, without including high-risk follow-up examinations. After including all
examinations within 11 months, a small proportion of patients had additional procedures that occurred
shortly after the ‘latest’ baseline examination and thus needed to be included into the baseline visit.
Baseline was therefore extended a second time, to include any examinations within 6 months of the latest
baseline examination. Finally, in a handful of special scenarios, a third repeated extension was performed
to capture examinations within 6 or 9 months of the latest baseline examination (6 months if the latest
baseline examination was a colonoscopy and 9 months if it was a sigmoidoscopy). These rare cases
included scenarios for which:
l the latest baseline examination was incomplete
l quality of bowel preparation at the latest baseline examination was poor
l a large polyp (≥ 15 mm) was seen at the latest baseline examination
l the same polyp was seen at the latest baseline examination and the next examination, which occurred
within 6/9 months
l the latest baseline examination was followed directly by a surgical examination.
After the extension of baseline, the length of baseline was assessed; only 2% of patients with IR
adenomas had a baseline that exceeded 11 months in length.
Surveillance visits
A surveillance or follow-up visit was defined using similar rules for baseline. A follow-up visit comprised
the first examination after baseline (or after a follow-up visit) and any further examinations within the
subsequent 11 months. As with the baseline visit, the final examination in a follow-up visit was identified,
and the follow-up visit was extended as necessary, using the same criteria as for the extension of baseline.
This procedure was repeated until all examinations had been grouped into a follow-up visit. Visits
following a diagnosis of CRC, volvulus or resection/anastomosis were censored, as patient follow-up
would be affected by such diagnoses.
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Surveillance interval
Surveillance intervals were timed from the last most complete examination of one visit to the first
examination of the next visit, as defined in the NHS BCSP.40
Defining adenoma surveillance risk groups
Once the baseline visit and true polyp values were defined, patients could then be stratified into adenoma
surveillance risk groups. The risk groups were defined using the criteria for stratification of patients as low
risk, intermediate risk or high risk, as described in the current UK Guideline (adopted by NICE). These
definitions were applied based on all adenomas found within the baseline visit, and are given below. In
addition, patients who could not be classified into a specific adenoma risk group were grouped into
broader categories.
l Low risk One or two small (< 10 mm) adenomas [no large (≥ 10 mm) adenomas or adenomas of
unspecified size].
l Intermediate risk Three or four small adenomas (no large adenomas or adenomas of unspecified size)
or one or two adenomas, of which at least one is large.
l High risk Five or more adenomas (any or unknown size) or three or more adenomas, of which at least
one is large.
l Low/intermediate risk One adenoma of unknown size or two adenomas, of which none is large but
one or more has an unknown size.
l Intermediate/high risk Three or four adenomas, of which none is large but one or more has an
unknown size.
Patient follow-up
We matched our study patient data with records from external repositories of national patient data:
HSCIC, NHSCR Scotland and NSS in order to achieve the following:
l List clean patient records obtained from hospitals To correct patient information that had been entered
incorrectly into hospital databases.
l Identify duplicate records across hospitals Patients who had procedures at more than one hospital, and
would have been allocated a different study number for each hospital where their data were collected.
l Identify duplicate records in the same hospital Some patients were seen at the same hospital but, as a
result of variations in patient identifiers, they had not been identified as the same patient.
l Obtain cancers and deaths data Necessary to determine the incidence of CRC and the mortality status
of patients in the cohort. The HSCIC provided the cancers and mortality data for patients residing in
England or patients who resided in Scotland and had moved to England; the NHSCR provided the
cancers and mortality data on patients who resided in England but had now moved to Scotland
(the NHSCR and HSCIC work in partnership); and the NSS provided us cancers and mortality data
on patients who resided in Scotland.
List cleaning
The patient-linking-file that was left at each hospital by the study programmer inevitably contained some
patient identifiers that had been entered incorrectly into the hospital databases. It was therefore necessary
to use the HSCIC/NHSCR’s list cleaning and tracing service and NSS’s linking service to validate and link
the patient records to their database.
When the data sets were sent to HSCIC/NHSCR, no match was found for 5% of the patients. This revealed
a limitation of having missing information, in that there was a higher chance of the supplied information
matching more than one patient on the HSCIC database, resulting in rejection of a match. The study
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programmer worked closely with HSCIC to create bespoke matching algorithms that accounted for minor
differences in dates of birth, names and NHS numbers in order to get the correct match, and, in some
cases, additional data were collected from hospital to resolve the differences. Ultimately, matches were
found for 99.65% of all 253,798 patients by the HSCIC/NHSCR and NSS.
Duplicate patient records
The national data repositories provided a list of duplicate patients found across the cohort (including
patients from England/Wales and Scotland). When all of the duplicates had been identified, each set of
duplicate records on our master database were merged into one record and an audit log was kept to show
which records had been merged.
Cancer matching
Cancer and mortality (deaths) data for patients in our cohort were obtained from national patient data
repositories (HSCIC, NHSCR Scotland and NSS). These data had to be added to the master database,
taking into account the patient and cancer data already present, to ensure that there was no duplicated or
missing data. This process was termed ‘cancer matching’.
To identify duplicate records of cancers, a program was written to identify CRCs in the national
repositories’ data set and link them with the procedures and individual polyp records (including cancers) on
the master database. Data quality checks were carried out, and samples of records that had been linked
automatically were manually reviewed.
Cancers were linked to individual polyp records based on a hierarchy involving the cancer diagnosis date
from the external source, the date the polyp or cancer was identified in the hospital data, the location of
lesions, the polyp number, the time between the date of cancer diagnosis, and the date of the procedure
during which the lesion was identified. For cancers reported in hospital pathology reports but not in
national repositories, the hospital data were accepted as conclusive evidence of cancer, except when the
histology was recorded by the study researcher as ‘cancer in dispute’ or ‘cancer query’.
The histology for cancers recorded on the study database as ‘in situ’ cancers and ‘cancers in dispute’ was
compared with data from the national registries and automatically reclassified if necessary, using a
hierarchy of rules. For example, polyps mapped to an in situ cancer from external sources were reclassified
as ‘assume adenoma’ with high-grade dysplasia (HGD) if they were not already coded as such. Similarly,
polyps in the database not mapped to a cancer from external sources, but with a histology recorded as
‘cancer in dispute’, were reclassified as ‘assume adenoma’ with HGD. A full list of the rules is given in
Appendix 7 (see rule 13).
Values for the cancer diagnosis date, and site of the cancer, were assigned by comparing the data
recorded on the study database with data from the national registries and applying a hierarchy of rules to
arrive at the true value. For example, if the external cancer date preceded the mapped endoscopy date
then the external date was used. Likewise for site, if no site was given in the mapped endoscopy data
(or the site was non-specific), the site used in the external cancer data was used. A full list of the rules is
given in Appendix 7 (see rule 11).
Variables
Outcomes
The primary outcome measures were adenoma, AA and CRC detected at the first and second follow-up
visits, and CRC incidence after baseline, and after first follow-up. Previously seen lesions were excluded
from some analyses, as they were thought to be a proxy measure for patients undergoing polypectomy
site surveillance, and confounded the analysis. Outcomes that had not been seen at a previous visit were
termed ‘new’ outcomes (see Chapter 3, New and previously seen lesions at first follow-up).
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Advanced adenoma was defined as an adenoma of ≥ 10 mm, or with villous or tubulovillous histology, or
HGD. CRCs were ascertained using pathological data recorded on the study database and International
Statistical Classification of Diseases and Related Health Problems (ICD) codes in data from national
repositories. To determine which cancers from the national repositories were outcomes of interest, they
were grouped according to site and morphology (details are given in Appendix 7, rules 11 and 13). Only
cancers from national repositories that fell into the site groups ‘malignant lesions of the colon/rectum’
and certain ‘in situ neoplasm – colon’ were selected for the study. Specifically, outcomes included
adenocarcinomas of the colorectum and carcinomas with unspecified morphology located between the
rectum and caecum that were assumed to be adenocarcinomas. Cancers with unspecified morphology
located at sites related to the anus were likely to be squamous cell carcinomas and were therefore not
classed as outcomes unless they were linked to a rectal lesion, in which case they were assumed to be
adenocarcinomas. CRCs reported as a cause of death in national repositories were classed as outcomes if
the patient did not have cancer recorded in the cancer registry or hospital data.
Colorectal cancer sites were defined by the World Health Organization (WHO) ICD versions ICD-8, ICD-9
and ICD-10, and included site codes C18–C20 (www.who.int/classifications/icd/en/). Morphology of
colorectal neoplasia was coded with the Manual of Tumor Nomenclature and Coding codes,41 the WHO
International Classification of Diseases for Oncology (ICD-O) ICD-O-1 codes42 and ICD-O-2 codes.43
Exposures
The main exposures of interest were the length of the surveillance interval between baseline and first
follow-up, and between the first and second follow-ups. The surveillance interval was defined as the
period of time from the last most complete colonic examination at one visit to the first examination of
the next visit (as in the NHS BCSP).40 In order to define interval, a patient’s examinations were split into
baseline and follow-up visits (see Defining baseline and surveillance visits, above). Interval length was then
calculated and converted into a categorical variable with seven groups: > 18 months, 2, 3, 4, 5 and 6 years
(all ± 6 months) and ≥ 6.5 years. Patients with the shortest interval were used as a reference group to
compare with those who were exposed to a longer interval.
The other exposure of interest was the effect of adenoma surveillance on risk of CRC after baseline.
Patients who attended at least one follow-up visit at which cancer was not diagnosed were considered to
be exposed to surveillance.
Risk factors and potential confounders
Patient, procedural and polyp characteristics at baseline and follow-up were assessed as a priori risk
factors and confounders; these included age and gender, examination quality (based on completeness of
examination, quality of bowel preparation and difficulties encountered), calendar year of examination and
hospital attended, and the number, size, location and histology of polyps and adenomas, villousness
and dysplasia. All potential risk factors and confounders examined are listed and defined in Table 8.
Grouping of variables
All of the aforementioned risk factors were considered separately for the baseline visit and FUV1. In some
instances it was necessary to add an additional level to a variable; for example, at FUV1 some patients did
not have any adenomas or a colonoscopy, whereas at baseline every individual had an adenoma and a
colonoscopy. The quantitative variables interval length and calendar year were grouped into categorical
variables for some analyses and used in their continuous form in other circumstances. The remaining
quantitative variables (visit length, age, adenoma size, number of examinations, number of sightings of a
unique adenoma and numbers of specific polyp types) were grouped into categorical variables. Standard
categorisations were created for all categorical variables and these were used in the presentation of
univariable results. When appropriate, the process of selecting risk factors for inclusion in multivariable
models involved the investigation of the categorisation of some variables, and the final categorisation was
selected by evaluating the difference in effect between levels of the variable. When data were missing for
a particular variable, an ‘unknown’ category was created in order to avoid losing patients from the models,
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particularly those models adjusting for several confounders. Models were tested with, and without
including, the ‘unknown’ category to assess the difference it made.
Study size
Sample size requirements were based on the comparison of the rates of detection of AA or CRC at first
follow-up at two different intervals, using heterogeneity in practice with respect to follow-up intervals. It
was deemed plausible that 5% of subjects would have an intermediate- or high-risk lesion at first follow-up
at 4–6 years and 3% at 2–4 years.44,45 For 90% power to detect this rate in the sample at the 5%
TABLE 8 Potential risk factors and confounders
Factor Definition
Number of adenomas Total number of adenomas seen during a visit
Size of adenoma Size of the largest adenoma seen during visit
Villousness of adenoma Worst degree of villousness of an adenoma seen during visit
Dysplasia of adenoma Worst degree of dysplasia of an adenoma seen during visit
Distal or proximal adenomas Detection of distal or proximal adenoma(s) at a visit. Proximal defined as descending
colon to terminal ileum; distal defined as anus to sigmoid colon
Distal or proximal polyps Detection of distal or proximal polyp(s) of any type, including adenomas, at a visit.
Proximal defined as descending colon to terminal ileum; distal defined as anus to
sigmoid colon
Age, years Age of patient at time of visit
Gender Gender of patient
Length of visit Total length of a visit (in days, months or years)
Number of examinations Total number of examinations that make up a visit
Most complete examination Most complete procedure during visit (at baseline this was based on colonoscopy).
Completeness was determined from segment reached by scope or location of polyp(s).
A complete colonoscopy was one during which the scope reached, or polyps were
found in, the caecum or beyond. If no colonoscopy was performed during the visit then
the next most complete procedure type was used
Best bowel preparation at
colonoscopy
Best bowel preparation at a colonoscopy during a visit. If there was no colonoscopy
then this was classified as ‘no known colonoscopy’
Difficult examination Composite variable of examination quality. Ascertained from endoscopy report
information. Coded ‘yes’ if there was poor bowel preparation, the maximum segment
was not reached (i.e. caecum for colonoscopy, sigmoid colon for sigmoidoscopy) and
another indicator of poor examination quality was provided, such as patient discomfort,
looping, technical difficulty, equipment failure, etc.
Number of sightings of a
unique adenoma
The greatest number of times an adenoma was seen during a visit
Number of hyperplastic polyps Total number of hyperplastic polyps in a visit
Number of large hyperplastic
polyps
Total number of large (≥ 10mm) hyperplastic polyps in a visit
Number of polyps with
unknown histology
Total number of polyps for which there is no histology available
Calendar year Year during which the visit took place
Hospital Hospital at which the visit took place
Family history of cancer/CRC
reported
Patient has a family history of cancer or CRC indicated at an examination during or prior
to a visit
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significance level in a two-sided test, it was estimated that 4400 subjects with at least one follow-up
examination were required. For second or subsequent follow-up, the more relaxed criterion to estimate the
detection rate within 1% in either direction was applied. It was anticipated that 3% of subjects would have
intermediate- or high-risk lesions at second or subsequent follow-up. This required 1200 subjects with at
least two follow-up endoscopies.
Consideration was given to the fact that the sample size was required to provide relatively low coefficients
of variation of the test sensitivity (S) and λ2, the rate of progression to clinical CRC, so as to enable the
comparison of different intervals between follow-up with respect to rates of cancers that accrued. In order
to use these with confidence to predict effects of different follow-up policies, a high degree of precision in
estimation of S and λ2 was required. It was therefore stipulated that both have coefficients of variation of
no more than 30% [i.e. the standard error (SE) of each estimate has magnitude no larger than 30% of the
value of the estimate]. Closed-form estimation was not possible for these quantities and it was difficult
to predict the variability of the estimates. Work by Chen et al.46 and Wong et al.47 suggests that, with
around 30 events, coefficients of variation of ≤ 30% may be achieved if the rate of progression is small
(≤ 0.2 per annum). Stratification or the introduction of covariates would reduce the precision and therefore
the aim was to recruit a cohort with a total of 60 CRCs.
Stryker et al.48 found rates of progression in untreated adenomas suggestive of a λ2 of around 0.01 for
progression to CRC. Atkin et al.3 studied a wide case mix of treated polyps at entry (corresponding to the
situation in this project), and suggested a rate of around 2 per 1000 per year after colonoscopy overall and
around 4.5 per 1000 per year for the high-risk subgroup. Thus, in the literature at the time of the call for
proposal, the rate ranged from 2 to 10 per 1000 per year.
It was assumed that the underlying risk of CRC in the cohort would be considerably higher than the
population risk, but that the relative risk might be brought down by the protection of endoscopic
examination to between one and two times the population risk in males aged ≥ 50 years. This meant that
there would be between 2.5 and 5 end points per 1000 per year. In total, therefore, between 12,000 and
24,000 person-years (pys) of follow-up after endoscopy episodes would be required. Assuming an average
of 4 years’ observation, this required recruiting cohorts to a total of 6000 subjects. A failsafe strategy to
recruit 10,000 was proposed.
Statistical methods
The statistical analysis strategy was split into three main stages: analysis of (1) first follow-up findings in
relation to baseline findings; (2) second follow-up findings in relation to baseline and first follow-up
findings; and (3) incidence of CRC after baseline in relation to risk factors and exposure to surveillance.
The analysis of findings at follow-up aimed to ascertain whether or not there was substantial heterogeneity
of results at subsequent examination, in terms of detection rates of AA or CRC, according to risk factors
and confounders, and interval to follow-up colonoscopy. The analysis of the incidence of CRCs after
baseline aimed to determine the effect of surveillance on long-term CRC risk and to identify independent
risk factors for incident cancer. All tests were two-tailed with significance assigned at 5%. In all instances,
adjusted effect estimates from multivariable analyses should be considered superior to unadjusted effect
estimates reported in univariable analyses. Analyses were performed with Stata/IC version 13.1 (StataCorp
LP, College Station, TX, USA).
The distribution of baseline characteristics among patients with and without follow-up visits was compared
using chi-squared tests.
Follow-up visit 1 findings in relation to baseline findings
Initially, findings at FUV1 were investigated, considering any adenomas, AAs or CRCs, with a focus on AA
and CRC outcomes. The relationship between baseline risk factors and findings at FUV1 was modelled
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using univariable logistic regression to estimate unadjusted odds ratios (OR). The association between interval
length and baseline risk factors was evaluated using chi-squared tests. The relationship between interval from
baseline to FUV1 and outcomes at FUV1 was explored both with and without adjustment for baseline risk
factors using logistic regression models. Many risk factors for AA and CRC that were potential confounders
were known already, based on the substantial body of evidence in the literature.15,22,23 Owing to the large
number of potential confounders, backwards stepwise logistic regression models and likelihood ratio tests
(LRTs) were used to identify important confounders to be included in the models, with the significance level
for inclusion set at 5%. Interval, our main variable of interest, was constrained to be included in all models.
Models were also constructed to consider only ‘new’ outcomes, meaning that those lesions had not been
previously seen before FUV1. Separate models for all outcomes were constructed for interval considered as a
continuous variable and as a categorical variable. Effect modification of the association between interval and
new findings at FUV1 by age and gender were investigated by fitting models with interaction parameters
and performing a test for interaction; effect modification was investigated for only interval as a continuous
variable, as this enabled examination of potential trends, and it was unlikely to be of any practical use to
know whether or not the effect of interval was significantly different in a particular age group if there was no
trend in the effect.
Risk factors associated with an interval of < 2 years were identified using logistic regression, and a
backwards stepwise logistic regression model was used to identify independent predictors of an interval of
< 2 years. All p-values from models were calculated using LRTs.
Follow-up visit 2 findings in relation to baseline and follow-up visit 1 findings
A similar approach to the analysis of outcomes at FUV1 was adopted for outcomes at follow-up visit 2
(FUV2). The relationships between FUV1 risk factors and AA and CRC at FUV2, and between baseline risk
factors and AA and CRC at FUV2, were modelled using univariable logistic regression for each confounder
separately. Owing to the small number of CRCs detected at FUV2, AA and CRC were grouped together
and the outcome of interest was advanced neoplasia (AN). The relationship between interval from FUV1 to
FUV2 and detection of AN at FUV2 was explored both with and without adjustment for FUV1 risk factors,
baseline risk factors (including interval from baseline to FUV1) and cumulative baseline and FUV1 risk
factors using logistic regression models. Backwards stepwise logistic regression models and LRTs were used
to identify important confounders to be included in the models, with the significance level for inclusion set
at 5%. The chosen confounders from each of these models were then added to a stepwise model to
identify the most important factors. To compare the model fit of each of the constructed logistic regression
models, pseudo R-squared values and the Akaike information criterion (AIC) were calculated. As before,
our main variable of interest (interval to FUV2) was constrained to be included in all models. The complete
model selection process was performed separately for interval considered as a continuous variable and
as a categorical variable. All models considered only ‘new’ outcomes, that is lesions that had not been
previously seen before FUV2. Effect modification of the association between continuous interval and new
AN at FUV2 by age and gender was investigated by fitting models with interaction parameters and
performing a test for interaction.
Colorectal cancer incidence after baseline
In the analysis of CRC incidence after baseline, for patients matched to national sources the cut-off for
follow-up was either 31 December 2011 or 30 June 2012 (depending on the data source), and for
unmatched patients it was the date of the patient’s last recorded procedure. All time-to-event data were
censored at first CRC diagnosis, death, emigration or end of follow-up.
For the analysis of incidence following baseline, time at risk started from the latest most complete
colonoscopy in baseline, and for the analysis of incidence following FUV1, time at risk started on the date
of the first procedure in FUV1. If CRC was diagnosed at a follow-up visit, the follow-up visit was not
included as a visit, as it did not offer any protection against CRC. Incident CRC outcomes included ‘new’
CRCs only, that is cancers arising in lesions that had not been seen at baseline.
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‘One minus the Kaplan–Meier estimator of the survival function’ was used to illustrate the time to cancer
diagnosis and to estimate the cumulative risk of cancer with 95% confidence intervals (CIs) at 3, 5 and
10 years. The effects of surveillance and patient, procedural and polyp characteristics at baseline and
follow-up on long-term CRC incidence were examined using Cox proportional hazards models. Univariable
models were used to estimate unadjusted hazard ratios (HRs). Independent predictors of cancer incidence
were identified in a multivariable Cox proportional hazards model, using backward stepwise selection with
a p-value of < 0.05 in the LRT to determine the retention of variables in the final model. The number of
follow-up visits was included as a time-varying covariate and, as our main variable of interest, was constrained
to be included in all adjusted models. Effect modification of the association between surveillance and
long-term CRC risk by age and gender was investigated by fitting models with interaction parameters and
performing a test for interaction.
For the analysis of risk after baseline, only baseline risk factors were considered. For the analysis of risk
following FUV1, separate models were built, considering baseline factors only, FUV1 factors only and
cumulative factors only. The risk factors identified from these models were then considered together and
a final model selected. All p-values from models were calculated using LRTs.
The incidence of CRC was compared with that expected in the general population. Observed pys at risk
were calculated by gender and 5-year age group. Expected numbers of CRC cases were calculated by
multiplying the observed gender- and age-specific number of pys by the gender- and age-specific incidence
in the general population of England in 2007. The ratio of observed to expected cases was reported as a
standardised incidence ratio (SIR), and 95% CIs were computed assuming an exact Poisson distribution.
Sensitivity analyses and internal validation
We conducted several sensitivity analyses to investigate whether or not our methods were robust and did
not introduce bias into the results. To assess the methods we used to define baseline, follow-up visits
and interval, we restricted analyses of the effect of interval on the finding of new AA and CRC at FUV1
and the effect of surveillance on long-term CRC incidence after baseline: first, to patients with only one
colonoscopy in baseline, and, second, to patients who had at least one complete colonoscopy at FUV1.
To examine whether or not the definition of AA that was used had an impact on results, we performed
a sensitivity analysis for the outcome of new AA detection at FUV1 with a definition of AA that excluded
villous or tubulovillous histology, that is with AA defined as an adenoma with HGD or with a size
of ≥ 10 mm. Finally, we conducted sensitivity analyses of the effect of surveillance on long-term CRC
incidence when the cohort was restricted to patients who had at least 5 years and at least 7 years of time
in which hospital data had been collected; this was to examine the possible effect of misclassification of
attendance at follow-up visits on the estimated effect of surveillance.
To assess the predictive ability of the multivariable logistic models for the outcomes of new findings at
follow-up and the multivariable Cox regression models for the analysis of long-term cancer incidence,
we performed internal validation using k-fold cross-validation with k = 10.49 For each model, the linear
predictors were used to construct receiver operating characteristic (ROC) curves for each of the
10 validation sets, and the area under the ROC curve and its SE were calculated for each; the inverse
variance weighted mean ROC curve and area below the curve were then calculated from these.
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Chapter 3 Hospital data set: results and
discussion
Routine endoscopy and pathology records for 253,798 patients were assessed; 174,978 were excludedas no adenomas were reported: 45,716 were found to be ineligible as a result of colonic conditions,
2752 had no colonoscopy at baseline 92 had missing procedure dates and one had > 40 examinations,
leaving 30,259 eligible patients with a histologically confirmed adenoma at baseline. A total of 11,995
(40%) eligible patients were classified as having IR adenomas, of whom 51 IR patients were lost to follow-up
(could not be matched with national cancer registry data or embarked before the end of baseline), leaving
11,944 patients for the analysis (Figure 2).
IR patients
• Lost to follow-up, n = 51
Patients with lower gastrointestinal
endoscopy with or without pathology
(n = 253,798)
Excluded 
(N = 223,539)
• No adenomas, n = 174,978
• Colonic conditions (not mutually exclusive), n = 45,716
   • CRC at or prior to baseline, n = 16,081
   • Resection at, or prior, to baseline, n = 6798
   • IBD, Crohn’s disease, colitis, radiation proctitis/colitis,
      n = 30,555
   • Polyposis, juvenile polyps, hamartomatous polyps,
      n = 1744
   • HNPCC, family history of FAP, n = 264
   • Volvulus, n = 14
• No baseline colonoscopy, n = 2752
• Missing examination date(s), n = 92
• > 40 exams, n = 1
Eligible patients with IR adenomas
(n = 11,995)
Eligible patients with adenomas
(n = 30,259)
• Low: one or two adenomas, both small 
   (< 10 mm), n = 14,522
• Intermediate: three or four small adenomas,
   or one or two adenomas, at least one of 
   which is large (> 10 mm), n = 11,995
• High: > 5 small adenomas or > 3 adenomas,
   at least one of which is large, n = 2709
• Not classifiable, n = 1033
Whole cohort, n = 11,944
• Patients with > 1 follow-up, n = 4608
Data available for analysis
FIGURE 2 Participant flow diagram. Adapted from Atkin et al.50 © The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license. Reprinted with permission from Elsevier (The Lancet,
2017, http://dx.doi.org/10.1016/S1470-2045(17)30187-0).
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Baseline characteristics of all intermediate-risk patients and
those with follow-up
We examined demographic, procedural, adenoma and polyp characteristics at baseline, and date and
place of the baseline visit, for all 11,944 eligible IR patients. A total of 4608 (39%) patients had at least
one follow-up visit and all patients were followed using NHS data and national cancer registries and
deaths data (see Long-term cancer risk, below). We first assessed whether or not patients with and
without follow-up visits after baseline differed in order to determine the risk of selection bias in analysis of
findings at, and subsequent to, follow-up visits.
Table 9 describes demographic and procedural characteristics at baseline, and date of the baseline visit.
The median age of the whole cohort of IR patients was 66.7 years (IQR 58.4–74.0 years) and 55% were
male. Those who attended a follow-up were younger, on average, than those who did not (mean = 63.3
vs. 67.3 years; p < 0.001), but there was no difference by gender (p = 0.852). Most baseline examinations
occurred between 2000 and 2010 (84%), but patients attending follow-up had their baseline visits and,
consequently, their adenomas diagnosed significantly earlier than those without follow-up. The absolute
differences between hospitals in the proportion having follow-up were small, but because of large
numbers the results were significant (results not presented: p < 0.001).
More than half of patients had a 1-day baseline visit consisting of a single colonoscopy; however, 39% of
patients required two or three examinations during their baseline visit, and 12 patients had a long baseline
visit of ≥ 2 years, mainly to treat a large, recurring lesion (which was distally located in most cases).
Patients attending follow-up tended to have more baseline examinations and a longer duration of the
baseline visit, although absolute differences were small.
All patients had at least one baseline colonoscopy and 75% were reported to have had a complete
colonoscopy. In around 50% of patients, the ‘best’ bowel preparation at a baseline colonoscopy (some
individuals had more than one) was deemed to be satisfactory or better, and was described as poor in only
6% of cases; however, the quality of the bowel preparation was unknown for 45% of patients. In addition,
6% of patients were reported to have had a difficult examination at baseline: a composite measure of
examination quality that indicated an incomplete examination with poor preparation and additional
difficulties encountered. Patients who attended follow-up were more likely to have missing data on bowel
preparation (p < 0.001) and less likely to have had a complete colonoscopy (p < 0.001) at baseline than
those without follow-up.
TABLE 9 Baseline demographic and procedural characteristics according to follow-up attendance
Baseline factor
All IR patients
(N= 11,944)
Patients with
one or more
follow-up visits
(N= 4608)
Patients with
no follow-up
visits (N= 7336)
p-value
(chi-squared test)n % n % n %
Age (years) < 55 2122 17.77 1025 22.24 1097 14.95 < 0.001
≥ 55 and < 60 1321 11.06 622 13.50 699 9.53
≥ 60 and < 65 1858 15.56 788 17.10 1070 14.59
≥ 65 and < 70 2171 18.18 813 17.64 1358 18.51
≥ 70 and < 75 1786 14.95 714 15.49 1072 14.61
≥ 75 and < 80 1416 11.86 413 8.96 1003 13.67
≥ 80 1270 10.63 233 5.06 1037 14.14
HOSPITAL DATA SET: RESULTS AND DISCUSSION
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TABLE 9 Baseline demographic and procedural characteristics according to follow-up attendance (continued )
Baseline factor
All IR patients
(N= 11,944)
Patients with
one or more
follow-up visits
(N= 4608)
Patients with
no follow-up
visits (N= 7336)
p-value
(chi-squared test)n % n % n %
Gender Male 6625 55.47 2551 55.36 4074 55.53 0.852
Female 5319 44.53 2057 44.64 3262 44.47
Family history of
cancer
No 11,445 95.82 4368 94.79 7077 96.47 < 0.001
Yes 499 4.18 240 5.21 259 3.53
Year of baseline 1985–9 112 0.94 98 2.13 14 0.19 < 0.001
1990–4 327 2.74 241 5.23 86 1.17
1995–9 1430 11.97 1030 22.35 400 5.45
2000–4 4251 35.59 2317 50.28 1934 26.36
2005–10 5824 48.76 922 20.01 4902 66.82
Length of baseline
visit
1 day 6836 57.23 2496 54.17 4340 59.16 < 0.001
2–30 days 734 6.15 246 5.34 488 6.65
1–3 months 1643 13.76 664 14.41 979 13.35
3–6 months 1382 11.57 595 12.91 787 10.73
6–12 months 1177 9.85 508 11.02 669 9.12
1–2 years 160 1.34 91 1.97 69 0.94
2–3 years 8 0.07 5 0.11 3 0.04
3–4 years 4 0.03 3 0.07 1 0.01
Number of
examinations in
baseline visit
1 6826 57.15 2489 54.01 4337 59.12 < 0.001
2 3788 31.71 1518 32.94 2270 30.94
3 908 7.60 392 8.51 516 7.03
4+ 422 3.53 209 4.54 213 2.90
Most complete
colonoscopy
Complete 9016 75.49 2973 64.52 6043 82.37 < 0.001
Incomplete 1601 13.40 1157 25.11 444 6.05
Unknown 1327 11.11 478 10.37 849 11.57
Best bowel
preparation at
colonoscopy
Excellent 246 2.06 92 2.00 154 2.10 < 0.001
Good 3710 31.06 1309 28.41 2401 32.73
Satisfactory 1922 16.09 487 10.57 1435 19.56
Poor 671 5.62 194 4.21 477 6.50
Unknown 5395 45.17 2526 54.82 2869 39.11
Difficult
examinationa
No 11,229 94.01 4387 95.20 6842 93.27 < 0.001
Yes 715 5.99 221 4.80 494 6.73
a A difficult examination is an incomplete examination with poor bowel preparation and additional complicating factors.
Results for hospital not presented (p< 0.001).
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Table 10 describes the characteristics of the adenomas and polyps diagnosed during the baseline visit.
Patients defined as IR according to the UK Adenoma Surveillance guideline16 could not have had more
than four adenomas at baseline otherwise they would have been classified as high risk. Owing to the use
of adenoma size and number in the definition of IR, these characteristics were associated, and most
patients had one large adenoma as opposed to three or four small ones (66% vs. 9%). In 37% of
patients, the largest baseline adenoma was between 10 and 14 mm, whereas 34% had an adenoma of
> 20 mm in size. In addition, 17% of patients had a baseline adenoma with HGD, whereas 10% had an
adenoma with villous histology; 80% had an adenoma in the distal colon or rectum and 31% had a
proximal adenoma, whereas 14% had adenomas in both regions. In most patients, adenomas were seen
just once during baseline (74%); however, in some patients, a single adenoma was seen multiple times.
The distribution of adenoma characteristics was significantly different for those with and without follow-up,
but the absolute differences were small.
TABLE 10 Characteristics of adenomas and polyps (of any type) detected at baseline according to follow-up
attendance
Baseline factor
All IR patients
(N= 11,944)
Patients with
one or more
follow-up visits
(N= 4608)
Patients with no
follow-up visits
(N= 7336)
p-value
(chi-squared test)n % n % n %
Adenoma characteristics
Number 1 7842 65.66 3107 67.43 4735 64.54 < 0.001
2 3073 25.73 1151 24.98 1,922 26.20
3 748 6.26 240 5.21 508 6.92
4 281 2.35 110 2.39 171 2.33
Largest size (mm) < 10 1029 8.62 350 7.60 679 9.26 < 0.001
10–14 4417 36.98 1577 34.22 2840 38.71
15–19 2440 20.43 953 20.68 1487 20.27
≥ 20 4058 33.98 1728 37.50 2330 31.76
Worst histology Tubular 4742 39.70 1723 37.39 3019 41.15 < 0.001
Tubulovillous 5576 46.68 2136 46.35 3440 46.89
Villous 1142 9.56 459 9.96 683 9.31
Unknown 484 4.05 290 6.29 194 2.64
Worst dysplasia Low grade 9476 79.34 3427 74.37 6049 82.46 < 0.001
High grade 1994 16.69 850 18.45 1144 15.59
Unknown 474 3.97 331 7.18 143 1.95
Location Distal only 7831 65.56 3070 66.62 4761 64.90 < 0.001
Proximal only 1985 16.62 681 14.78 1304 17.78
Distal and
proximal
1665 13.94 601 13.04 1064 14.50
Unknown 463 3.88 256 5.56 207 2.82
Distal No 2448 20.50 937 20.33 1511 20.60 0.729
Yes 9496 79.50 3671 79.67 5825 79.40
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TABLE 10 Characteristics of adenomas and polyps (of any type) detected at baseline according to follow-up
attendance (continued )
Baseline factor
All IR patients
(N= 11,944)
Patients with
one or more
follow-up visits
(N= 4608)
Patients with no
follow-up visits
(N= 7336)
p-value
(chi-squared test)n % n % n %
Proximal No 8294 69.44 3326 72.18 4968 67.72 < 0.001
Yes 3650 30.56 1282 27.82 2368 32.28
Number of
sightings of a
single adenoma
1 8807 73.74 3311 71.85 5496 74.92 < 0.001
2 2548 21.33 1005 21.81 1543 21.03
3 390 3.27 182 3.95 208 2.84
4 108 0.90 63 1.37 45 0.61
5+ 91 0.76 47 1.02 44 0.60
Polyp characteristics (all types)
Number of
hyperplastic polyps
0 9874 82.67 3743 81.23 6131 83.57 0.005
1 1307 10.94 541 11.74 766 10.44
2 405 3.39 159 3.45 246 3.35
3 152 1.27 64 1.39 88 1.20
4 76 0.64 38 0.82 38 0.52
5+ 130 1.09 63 1.37 67 0.91
Number of large
hyperplastic polyps
0 11,761 98.47 4525 98.20 7236 98.64 0.232
1 168 1.41 75 1.63 93 1.27
2 10 0.08 6 0.13 4 0.05
3 3 0.03 1 0.02 2 0.03
4 1 0.01 1 0.02 0 0.00
5 1 0.01 0 0.00 1 0.01
Number of polyps
with unknown
histology
0 9322 78.05 3593 77.97 5729 78.09 0.004
1 1510 12.64 556 12.07 954 13.00
2 517 4.33 187 4.06 330 4.50
3 249 2.08 108 2.34 141 1.92
4 129 1.08 63 1.37 66 0.90
5+ 217 1.82 101 2.19 116 1.58
Distal polyp No 1980 16.58 739 16.04 1241 16.92 0.208
Yes 9964 83.42 3869 83.96 6095 83.08
Proximal polyp No 7369 61.70 2940 63.80 4429 60.37 < 0.001
Yes 4575 38.30 1668 36.20 2907 39.63
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Baseline polyp characteristics (including number, location and type) were considered as potential risk
factors for findings at follow-up. In addition to their IR adenoma(s), 17% had hyperplastic polyps and 2%
had large (≥ 10 mm) hyperplastic polyps found at baseline. In total, 83% of patients had a distal polyp,
38% had a proximal polyp and 25% had polyps in both regions. Polyp characteristics in those with and
without follow-up were generally similar; however, a greater proportion of patients without follow-up had
proximal polyps (p < 0.001).
Hospitals data set: patients attending follow-up visits
Table 11 describes the amount of follow-up in the hospital cohort. A total of 4608 patients had at least
one follow-up visit and 1635 had two. Only 555 patients had three or more follow-up visits, so analyses of
findings at follow-up were restricted to the first and second follow-up visits in which there were sufficient
numbers of outcomes (see Table 11).
Table 12 shows the intervals to visits in patients having follow-up. Almost 60% of patients returned for
their FUV1 earlier than the 3-year interval currently recommended for people with IR adenomas. The
interval between baseline and first follow-up was < 3 years in 59% of patients, 3–4 years in 31% of
patients and ≥ 5 years in 10% of patients. With regard to the interval between the first and second
follow-up visits, once again, most patients (47%) had an interval of < 3 years but a greater proportion
(41%) of patients had an interval of 3–4 years. Excluding the outliers with six or more follow-ups, the
proportion of patients with a short interval of < 18 months tended to decrease with increasing number of
follow-up visits.
TABLE 11 Number of follow-up visits in IR patients
Number of follow-up visits
Number of patients
Cumulative number of patients who
had at least 1, 2, 3 . . . x examinationsn %
1 2973 64.52 4608
2 1080 23.44 1635
3 354 7.68 555
4 135 2.93 201
5 45 0.98 66
6 14 0.30 21
7 2 0.04 7
8 2 0.04 5
9 2 0.04 3
10 1 0.02 1
Total 4608 100.00 4608
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First follow-up visit
Examinations and findings
Table 13 shows the proportion of patients found to have adenomas (all types), AA and CRC at FUV1
according to interval from baseline. Overall, 1605 (35%) patients had adenomas, 723 (16%) had AA and
84 (2%) had CRC detected at FUV1. The proportion of patients with adenomas was relatively constant across
different intervals and ranged from 34% to 40%, whereas the proportion of patients with AA showed
more variation, ranging from 14% to 26%, and the proportion with CRC ranged from 0.5% to 5%. The
proportion of patients with CRC detected at FUV1 tended to increase with increasing interval to FUV1.
Table 14 describes examinations undertaken during FUV1. For most patients, FUV1 comprised a single
examination (88%) and in 72% of patients the most complete examination was a complete colonoscopy.
Baseline risk factors for findings at first follow-up
Using univariable analyses, we investigated the crude associations of baseline demographic, procedural,
adenoma and polyp characteristics with findings at FUV1 in order to identify risk factors for adenomas,
AA and CRC and to assess potential confounders of the association between interval and outcomes.
Demographic and procedural characteristics
Table 15 details the crude effect of baseline demographic and procedural characteristics on the odds of
having adenomas (all types), AA or CRC found at FUV1.
Adenomas (all types)
Patients aged ≥ 55 years were more likely to have an adenoma found at FUV1 than those aged < 55 years;
however, no clear trend was seen after the age of 55 years. Women were 24% less likely to have an
adenoma detected (OR 0.76, 95% CI 0.67 to 0.86). Patients with a family history of cancer had a
non-significant 24% lower risk of adenoma (OR 0.76, 95% CI 0.57 to 1.01). The odds of detecting
adenomas at FUV1 were greater in those with later baseline visits (p = 0.0004).
TABLE 12 Number of follow-up visits and intervals to visits in IR patients
Follow-up
visit
number
Number of patients with varying interval lengthsa
Total< 18 months 2 yearsb 3 yearsb 4 yearsb 5 yearsb 6 yearsb ≥ 6.5 years
1 1760 (38.19) 976 (21.18) 1057 (22.94) 355 (7.70) 217 (4.71) 123 (2.67) 120 (2.60) 4608 (100)
2 397 (24.28) 376 (23.00) 518 (31.68) 152 (9.30) 131 (8.01) 31 (1.90) 30 (1.83) 1635 (100)
3 131 (23.60) 110 (19.82) 191 (34.41) 51 (9.19) 42 (7.57) 17 (3.06) 13 (2.34) 555 (100)
4 48 (23.88) 45 (22.39) 65 (32.34) 22 (10.95) 20 (9.95) 1 (0.50) 0 (0) 201 (100)
5 22 (33.33) 12 (18.18) 23 (34.85) 4 (6.06) 5 (7.58) 0 (0) 0 (0) 66 (100)
6 2 (9.52) 7 (33.33) 7 (33.33) 3 (14.29) 2 (9.52) 0 (0) 0 (0) 21 (100)
7 1 (14.29) 3 (42.86) 2 (28.57) 1 (14.29) 0 (0) 0 (0) 0 (0) 7 (100)
8 2 (40.00) 1 (20.00) 1 (20.00) 0 (0) 0 (0) 0 (0) 1 (20.00) 5 (100)
9 1 (33.33) 1 (33.33) 1 (33.33) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100)
10 0 (0) 1 (100.00) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
Total 2364 (33.29) 1532 (21.57) 1865 (26.26) 588 (8.28) 417 (5.87) 172 (2.42) 164 (2.31) 7102 (100)
a The interval to visit number 1 is the interval between baseline and first follow-up, the interval to visit number 2 is the
interval between FUV1 and FUV2, and so on.
b Interval ± 6 months.
Data within parentheses =%.
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TABLE 14 Examinations undertaken during FUV1
Examinations during FUV1
IR patients (N= 4608)
n %
Length of FUV1 1 day 4068 88.00
2–30 days 64 1.39
1–3 months 126 2.73
3–6 months 149 3.23
6–12 months 162 3.52
1–2 years 38 0.82
2–3 years 1 0.02
Number of examinations during FUV1 1 4060 88.00
2 394 8.55
3 101 2.19
4+ 53 1.15
Most complete examination during FUV1 Complete colonoscopy 3299 72.00
Colonoscopy of unknown completeness 259 6.00
Incomplete colonoscopy 404 8.77
Colonoscopy or FS 192 4.17
FS 326 7.07
Colonoscopy, FS or rigid sigmoidoscopy 103 2.24
Surgery 16 0.35
Unknown 9 0.20
TABLE 13 Adenomas, AAs and CRCs detected at FUV1, by interval between baseline and first follow-up
Interval baseline
to first follow-up
IR patients
Findings at FUV1
Adenoma AA CRC
Na % n % n % n %
< 18 months 1760 38.19 595 33.81 268 15.23 29 1.65
2 yearsb 976 21.18 349 35.76 165 16.91 25 2.56
3 yearsb 1057 22.94 360 34.06 151 14.29 6 0.57
4 yearsb 355 7.70 123 34.65 56 15.77 9 2.54
5 yearsb 217 4.71 85 39.17 34 15.67 4 1.84
6 yearsb 123 2.67 49 39.84 18 14.63 5 4.07
≥ 6.5 years 120 2.60 44 36.67 31 25.83 6 5.00
Total 4608 100.00 1605 34.83 723 15.69 84 1.82
a N= 4608 IR patients.
b Interval ± 6 months.
HOSPITAL DATA SET: RESULTS AND DISCUSSION
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Patients with a baseline visit of longer than 12 months or with four or more baseline examinations were
significantly more likely to have an adenoma detected. The association between the completeness of
colonoscopy and risk of detection of one or more adenomas was difficult to interpret when no evidence
was found of an association between adenoma detection and quality of bowel preparation. However,
having a difficult examination at baseline – a composite measure of different aspects of examination
quality including completeness and preparation – was associated with a significantly lower odds of having
an adenoma detected at FUV1 (OR 0.59, 95% CI 0.43 to 0.81).
Advanced adenomas
The odds of detecting AA at FUV1 significantly increased with increasing age (p < 0.0001). There was no
association with gender, or with year of the baseline visit.
There was a tendency for the AA detection rate to increase with increasing number of baseline
examinations or a longer duration of the baseline visit, with patients whose baseline visit was 12 months
or longer or who had four or more examinations having an almost threefold increased odds (OR 2.87,
95% CI 1.85 to 4.46, and OR 2.9, 95% CI 2.12 to 3.96, respectively). The odds of detecting AA were
57% greater among those with only an incomplete baseline colonoscopy (OR 1.57, 95% CI 1.22 to 2.02)
and 78% greater in patients with a colonoscopy of unknown completeness (OR 1.78, 95% CI 1.49 to
2.13). Bowel preparation quality was also predictive of having AA at FUV1.
Colorectal cancers
Only 84 CRCs were detected at FUV1; therefore, although significant associations with baseline risk
factors were seen, estimates were imprecise and CIs were wide. There was a strong relationship between
increasing age and CRC at FUV1, with a more than sixfold greater odds in patients aged ≥ 75 years (OR
6.81, 95% CI 2.99 to 15.50, for those aged 75–80 years and OR 7.51, 95% CI 3.08 to 18.34, for those
aged ≥ 80 years). No significant associations were found between gender, family history of cancer, year of
baseline, length of baseline or number of examinations in baseline.
There was strong evidence of an association between having an incomplete colonoscopy or poor bowel
preparation or a difficult examination at baseline and increased odds of detecting CRC at FUV1, with odds
increased by three- to fourfold.
Adenoma and polyp characteristics
Table 16 describes the crude relationship between characteristics of adenomas and polyps detected at
baseline and adenomas, AA and CRC at FUV1.
Adenomas (all types)
Associations between adenoma detection at FUV1 and the number, size, histology and dysplasia of
adenomas detected at baseline were all highly significant (p < 0.0001). Increasing number of adenomas,
villous histology and small size (< 10 mm), as opposed to larger size, were associated with a greater odds
of having adenomas at FUV1, whereas the association with dysplasia was difficult to interpret. Patients
with both a distal and proximal adenoma at baseline had a significant 59% increased odds of having an
adenoma detected at FUV1 (OR 1.59, 95% CI 1.33 to 1.90); however, this relationship was probably
confounded by the number of adenomas and, when considering proximal location separately, patients
with any proximal adenoma at baseline had a 40% greater odds of having an adenoma at FUV1 (OR 1.40,
95% CI 1.22 to 1.60). There was also evidence that patients who had multiple sightings of an individual
adenoma during baseline were more likely to have an adenoma detected at FUV1, with a large effect
size and highly significant p-value (p = 0.0001). Detection of a proximal polyp at baseline conferred a
significant 38% increased odds (OR 1.38, 95% CI 1.22 to 1.57).
HOSPITAL DATA SET: RESULTS AND DISCUSSION
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Advanced adenomas
There was strong evidence that detection of an adenoma of ≥ 20 mm, with villous or tubulovillous
histology or with HGD at baseline, was associated with an increased odds of AA at FUV1 – villous
histology had a particularly strong effect (OR 3.03, 95% CI 2.33 to 3.95). The number of adenomas was
significantly associated with detection of AA (p = 0.0068), but no clear trend was discernible. Multiple
sightings of an adenoma at different examinations during baseline was highly predictive and five or more
sightings conferred a more than sixfold increased odds (OR 6.37, 95% CI 3.56 to 11.39). Adenoma
location had no effect on the likelihood of having AA at FUV1. There was no relationship between AA and
any polyp-related variables.
Colorectal cancer
With only 84 CRCs detected at FUV1, CIs for associations between CRC and baseline adenoma and polyp
characteristics were wide; nevertheless, several significant associations were found. Villous histology and
HGD at baseline were significantly associated with increased odds of CRC at FUV1: patients with a villous
adenoma were four times more likely to have CRC at FUV1 than those with a tubular adenoma (OR 4.09,
95% CI 2.13 to 7.86), whereas HGD at baseline doubled the odds of CRC (OR 2.09, 95% CI 1.29 to 3.37).
Larger adenoma size appeared to confer an increased odds of CRC but, despite reaching statistical
significance (p = 0.0361), the imprecision of the measures of effect prevented firm conclusions from being
drawn. Multiple sightings of an adenoma during baseline was significantly associated with increased odds
of CRC (p = 0.0412) but adenoma location had no effect. No polyp characteristics were associated with
finding CRC at FUV1.
Baseline risk factors and interval
We explored the relationship between baseline risk factors and length of the interval between baseline and
FUV1 to assess whether or not any factors could be acting as confounders of the association between
findings at FUV1 and interval (Tables 17 and 18).
All factors were highly significantly associated with interval at the 1% level except for gender (p = 0.462),
family history of cancer (p = 0.067), a difficult examination (p = 0.150), large hyperplastic polyps (p = 0.645),
number of polyps with unknown histology (p = 0.586), distal adenomas (p = 0.353) and distal polyps
(p = 0.105). Results for non-significant factors are not presented here.
Patients of an older age, with an incomplete colonoscopy, poor bowel preparation, a large adenoma
(≥ 20 mm), an adenoma with villous histology or HGD, a proximal adenoma or polyp, or multiple sightings
of a unique adenoma at baseline tended to have a shorter interval. As all of these features were also
associated with increased odds of finding an adenoma, AA or CRC at FUV1, they could potentially be
confounding the association between findings at FUV1 and interval.
Effects of interval on findings at follow-up visit 1
Univariable analysis
The effect of interval on findings at the first follow-up was examined using univariable and multivariable
analyses. Tables 19–21 show the crude and adjusted associations between interval and adenomas
(advanced and non-advanced), AA and CRC at the first follow-up. The univariable analysis provided no
evidence of an association between adenomas and interval, with large p-values, small effect estimates
close to 1, and 95% CIs that included 1. Similarly, no relationship was observed between AA and interval.
For CRC, there was evidence of an association with interval: with interval modelled as a categorical
variable, there was evidence of a dose–response effect with a more than threefold increased odds of CRC
with an interval of 6.5 years or longer (OR 3.14, 95% CI 1.28 to 7.72), and with interval modelled as a
continuous variable, a 13% increased odds of CRC for every year increase in interval (OR 1.13, 95% CI
1.03 to 1.25).
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
43
TA
B
LE
17
B
as
el
in
e
d
em
o
g
ra
p
h
ic
an
d
p
ro
ce
d
u
ra
lc
h
ar
ac
te
ri
st
ic
s
as
so
ci
at
ed
w
it
h
le
n
g
th
o
f
in
te
rv
al
to
fi
rs
t
fo
llo
w
-u
p
B
as
el
in
e
ri
sk
fa
ct
o
r
C
at
eg
o
ry
In
te
rv
al
b
et
w
ee
n
b
as
el
in
e
an
d
fi
rs
t
fo
llo
w
-u
p
To
ta
l
p
-v
al
u
e
(c
h
is
q
u
ar
ed
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
To
ta
l
17
60
(3
8.
19
)
97
6
(2
1.
18
)
10
57
(2
2.
94
)
35
5
(7
.7
)
21
7
(4
.7
1)
12
3
(2
.6
7)
12
0
(2
.6
)
46
08
(1
00
)
n/
a
A
ge
(y
ea
rs
)
<
55
35
0
(3
4.
15
)
20
2
(1
9.
71
)
25
7
(2
5.
07
)
95
(9
.2
7)
56
(5
.4
6)
32
(3
.1
2)
33
(3
.2
2)
10
25
(1
00
)
<
0.
00
1
≥
55
an
d
<
60
21
1
(3
3.
92
)
11
7
(1
8.
81
)
16
4
(2
6.
37
)
56
(9
)
36
(5
.7
9)
15
(2
.4
1)
23
(3
.7
)
62
2
(1
00
)
≥
60
an
d
<
65
29
7
(3
7.
69
)
17
0
(2
1.
57
)
18
7
(2
3.
73
)
56
(7
.1
1)
40
(5
.0
8)
24
(3
.0
5)
14
(1
.7
8)
78
8
(1
00
)
≥
65
an
d
<
70
30
8
(3
7.
88
)
15
9
(1
9.
56
)
19
6
(2
4.
11
)
64
(7
.8
7)
39
(4
.8
)
25
(3
.0
8)
22
(2
.7
1)
81
3
(1
00
)
≥
70
an
d
<
75
30
6
(4
2.
86
)
16
5
(2
3.
11
)
14
5
(2
0.
31
)
41
(5
.7
4)
26
(3
.6
4)
13
(1
.8
2)
18
(2
.5
2)
71
4
(1
00
)
≥
75
an
d
<
80
18
5
(4
4.
79
)
94
(2
2.
76
)
74
(1
7.
92
)
27
(6
.5
4)
16
(3
.8
7)
10
(2
.4
2)
7
(1
.6
9)
41
3
(1
00
)
≥
80
10
3
(4
4.
21
)
69
(2
9.
61
)
34
(1
4.
59
)
16
(6
.8
7)
4
(1
.7
2)
4
(1
.7
2)
3
(1
.2
9)
23
3
(1
00
)
Y
ea
r
of
ba
se
lin
e
19
85
–
9
44
(4
4.
90
)
13
(1
3.
27
)
19
(1
9.
39
)
9
(9
.1
8)
6
(6
.1
2)
3
(3
.0
6)
4
(4
.0
8)
98
(1
00
)
<
0.
00
1
19
90
–
4
73
(3
0.
29
)
55
(2
2.
82
)
30
(1
2.
45
)
27
(1
1.
2)
15
(6
.2
2)
10
(4
.1
5)
31
(1
2.
86
)
24
1
(1
00
)
19
95
–
9
38
7
(3
7.
57
)
21
8
(2
1.
17
)
19
2
(1
8.
64
)
96
(9
.3
2)
41
(3
.9
8)
40
(3
.8
8)
56
(5
.4
4)
10
30
(1
00
)
20
00
–
4
71
4
(3
0.
82
)
48
4
(2
0.
89
)
67
3
(2
9.
05
)
19
4
(8
.3
7)
15
3
(6
.6
)
70
(3
.0
2)
29
(1
.2
5)
23
17
(1
00
)
20
05
–
10
54
2
(5
8.
79
)
20
6
(2
2.
34
)
14
3
(1
5.
51
)
29
(3
.1
5)
2
(0
.2
2)
0
(0
)
0
(0
)
92
2
(1
00
)
Le
ng
th
of
ba
se
lin
e
vi
si
t
1
da
y
93
6
(3
7.
5)
46
8
(1
8.
75
)
60
9
(2
4.
4)
20
5
(8
.2
1)
12
4
(4
.9
7)
73
(2
.9
2)
81
(3
.2
5)
24
96
(1
00
)
<
0.
00
1
2–
30
da
ys
11
2
(4
5.
53
)
47
(1
9.
11
)
51
(2
0.
73
)
14
(5
.6
9)
8
(3
.2
5)
5
(2
.0
3)
9
(3
.6
6)
24
6
(1
00
)
1–
3
m
on
th
s
28
5
(4
2.
92
)
11
3
(1
7.
02
)
15
6
(2
3.
49
)
40
(6
.0
2)
42
(6
.3
3)
18
(2
.7
1)
10
(1
.5
1)
66
4
(1
00
)
3–
6
m
on
th
s
25
1
(4
2.
18
)
13
6
(2
2.
86
)
12
4
(2
0.
84
)
43
(7
.2
3)
20
(3
.3
6)
14
(2
.3
5)
7
(1
.1
8)
59
5
(1
00
)
6–
12
m
on
th
s
15
5
(3
0.
51
)
17
4
(3
4.
25
)
94
(1
8.
5)
44
(8
.6
6)
18
(3
.5
4)
11
(2
.1
7)
12
(2
.3
6)
50
8
(1
00
)
≥
12
m
on
th
s
21
(2
1.
21
)
38
(3
8.
38
)
23
(2
3.
23
)
9
(9
.0
9)
5
(5
.0
5)
2
(2
.0
2)
1
(1
.0
1)
99
(1
00
)
HOSPITAL DATA SET: RESULTS AND DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
B
as
el
in
e
ri
sk
fa
ct
o
r
C
at
eg
o
ry
In
te
rv
al
b
et
w
ee
n
b
as
el
in
e
an
d
fi
rs
t
fo
llo
w
-u
p
To
ta
l
p
-v
al
u
e
(c
h
is
q
u
ar
ed
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
N
um
be
r
of
ba
se
lin
e
ex
am
in
at
io
ns
1
93
2
(3
7.
44
)
46
7
(1
8.
76
)
60
9
(2
4.
47
)
20
3
(8
.1
6)
12
4
(4
.9
8)
73
(2
.9
3)
81
(3
.2
5)
24
89
(1
00
)
<
0.
00
1
2
59
2
(3
9)
31
3
(2
0.
62
)
34
7
(2
2.
86
)
11
4
(7
.5
1)
79
(5
.2
)
41
(2
.7
)
32
(2
.1
1)
15
18
(1
00
)
3
16
7
(4
2.
6)
11
4
(2
9.
08
)
67
(1
7.
09
)
21
(5
.3
6)
9
(2
.3
)
7
(1
.7
9)
7
(1
.7
9)
39
2
(1
00
)
4+
69
(3
3.
01
)
82
(3
9.
23
)
34
(1
6.
27
)
17
(8
.1
3)
5
(2
.3
9)
2
(0
.9
6)
0
(0
)
20
9
(1
00
)
M
os
t
co
m
pl
et
e
co
lo
no
sc
op
y
C
om
pl
et
e
12
54
(4
2.
18
)
61
8
(2
0.
79
)
71
5
(2
4.
05
)
18
0
(6
.0
5)
11
8
(3
.9
7)
55
(1
.8
5)
33
(1
.1
1)
29
73
(1
00
)
<
0.
00
1
U
nk
no
w
n
31
8
(2
7.
48
)
23
7
(2
0.
48
)
25
7
(2
2.
21
)
14
8
(1
2.
79
)
76
(6
.5
7)
50
(4
.3
2)
71
(6
.1
4)
11
57
(1
00
)
In
co
m
pl
et
e
18
8
(3
9.
33
)
12
1
(2
5.
31
)
85
(1
7.
78
)
27
(5
.6
5)
23
(4
.8
1)
18
(3
.7
7)
16
(3
.3
5)
47
8
(1
00
)
Be
st
bo
w
el
pr
ep
ar
at
io
n
at
ba
se
lin
e
co
lo
no
sc
op
y
Ex
ce
lle
nt
/g
oo
d
55
1
(3
9.
33
)
29
2
(2
0.
84
)
31
7
(2
2.
63
)
12
2
(8
.7
1)
67
(4
.7
8)
43
(3
.0
7)
9
(0
.6
4)
14
01
(1
00
)
<
0.
00
1
Sa
tis
fa
ct
or
y
20
6
(4
2.
3)
11
4
(2
3.
41
)
10
5
(2
1.
56
)
26
(5
.3
4)
23
(4
.7
2)
9
(1
.8
5)
4
(0
.8
2)
48
7
(1
00
)
Po
or
85
(4
3.
81
)
52
(2
6.
8)
38
(1
9.
59
)
10
(5
.1
5)
6
(3
.0
9)
1
(0
.5
2)
2
(1
.0
3)
19
4
(1
00
)
U
nk
no
w
n
91
8
(3
6.
34
)
51
8
(2
0.
51
)
59
7
(2
3.
63
)
19
7
(7
.8
)
12
1
(4
.7
9)
70
(2
.7
7)
10
5
(4
.1
6)
25
26
(1
00
)
n/
a,
no
t
ap
pl
ic
ab
le
.
a
In
te
rv
al
±
6
m
on
th
s.
Re
su
lts
fo
r
ho
sp
ita
la
tt
en
de
d
no
t
pr
es
en
te
d
(p
<
0.
00
01
).
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
45
TA
B
LE
18
B
as
el
in
e
ad
en
o
m
a
an
d
p
o
ly
p
ch
ar
ac
te
ri
st
ic
s
as
so
ci
at
ed
w
it
h
le
n
g
th
o
f
in
te
rv
al
to
fi
rs
t
fo
llo
w
-u
p
B
as
el
in
e
ri
sk
fa
ct
o
r
C
at
eg
o
ry
In
te
rv
al
b
et
w
ee
n
b
as
el
in
e
an
d
fi
rs
t
fo
llo
w
-u
p
To
ta
l
p
-v
al
u
e
(c
h
is
q
u
ar
ed
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
To
ta
l
17
60
(3
8.
19
)
97
6
(2
1.
18
)
10
57
(2
2.
94
)
35
5
(7
.7
)
21
7
(4
.7
1)
12
3
(2
.6
7)
12
0
(2
.6
)
46
08
(1
00
)
n/
a
A
d
en
o
m
a
ch
ar
ac
te
ri
st
ic
s
N
um
be
r
1
11
58
(3
7.
27
)
66
3
(2
1.
34
)
69
8
(2
2.
47
)
25
1
(8
.0
8)
16
4
(5
.2
8)
84
(2
.7
)
89
(2
.8
6)
31
07
(1
00
)
0.
00
6
2
48
8
(4
2.
4)
24
1
(2
0.
94
)
25
6
(2
2.
24
)
70
(6
.0
8)
37
(3
.2
1)
33
(2
.8
7)
26
(2
.2
6)
11
51
(1
00
)
3
77
(3
2.
08
)
52
(2
1.
67
)
67
(2
7.
92
)
24
(1
0)
12
(5
)
4
(1
.6
7)
4
(1
.6
7)
24
0
(1
00
)
4
37
(3
3.
64
)
20
(1
8.
18
)
36
(3
2.
73
)
10
(9
.0
9)
4
(3
.6
4)
2
(1
.8
2)
1
(0
.9
1)
11
0
(1
00
)
La
rg
es
t
si
ze
(m
m
)
<
10
11
4
(3
2.
57
)
72
(2
0.
57
)
10
3
(2
9.
43
)
34
(9
.7
1)
16
(4
.5
7)
6
(1
.7
1)
5
(1
.4
3)
35
0
(1
00
)
<
0.
00
1
10
–
14
54
8
(3
4.
75
)
30
5
(1
9.
34
)
40
4
(2
5.
62
)
12
7
(8
.0
5)
90
(5
.7
1)
50
(3
.1
7)
53
(3
.3
6)
15
77
(1
00
)
15
–
19
34
8
(3
6.
52
)
19
1
(2
0.
04
)
22
3
(2
3.
4)
74
(7
.7
6)
57
(5
.9
8)
31
(3
.2
5)
29
(3
.0
4)
95
3
(1
00
)
≥
20
75
0
(4
3.
4)
40
8
(2
3.
61
)
32
7
(1
8.
92
)
12
0
(6
.9
4)
54
(3
.1
3)
36
(2
.0
8)
33
(1
.9
1)
17
28
(1
00
)
W
or
st
hi
st
ol
og
y
Tu
bu
la
r
62
1
(3
6.
04
)
35
0
(2
0.
31
)
45
1
(2
6.
18
)
13
2
(7
.6
6)
91
(5
.2
8)
39
(2
.2
6)
39
(2
.2
6)
17
23
(1
00
)
<
0.
00
1
Tu
bu
lo
vi
llo
us
82
8
(3
8.
76
)
45
2
(2
1.
16
)
47
7
(2
2.
33
)
17
1
(8
.0
1)
95
(4
.4
5)
59
(2
.7
6)
54
(2
.5
3)
21
36
(1
00
)
V
ill
ou
s
19
2
(4
1.
83
)
12
4
(2
7.
02
)
64
(1
3.
94
)
36
(7
.8
4)
15
(3
.2
7)
15
(3
.2
7)
13
(2
.8
3)
45
9
(1
00
)
U
nk
no
w
n
11
9
(4
1.
03
)
50
(1
7.
24
)
65
(2
2.
41
)
16
(5
.5
2)
16
(5
.5
2)
10
(3
.4
5)
14
(4
.8
3)
29
0
(1
00
)
W
or
st
dy
sp
la
si
a
Lo
w
gr
ad
e
12
52
(3
6.
53
)
71
7
(2
0.
92
)
84
2
(2
4.
57
)
26
9
(7
.8
5)
16
8
(4
.9
)
10
0
(2
.9
2)
79
(2
.3
1)
34
27
(1
00
)
<
0.
00
1
H
ig
h
gr
ad
e
39
4
(4
6.
35
)
19
2
(2
2.
59
)
16
1
(1
8.
94
)
46
(5
.4
1)
25
(2
.9
4)
14
(1
.6
5)
18
(2
.1
2)
85
0
(1
00
)
U
nk
no
w
n
11
4
(3
4.
44
)
67
(2
0.
24
)
54
(1
6.
31
)
40
(1
2.
08
)
24
(7
.2
5)
9
(2
.7
2)
23
(6
.9
5)
33
1
(1
00
)
Pr
ox
im
al
N
o
12
13
(3
6.
47
)
71
5
(2
1.
5)
76
6
(2
3.
03
)
27
1
(8
.1
5)
16
8
(5
.0
5)
95
(2
.8
6)
98
(2
.9
5)
33
26
(1
00
)
0.
00
1
Y
es
54
7
(4
2.
67
)
26
1
(2
0.
36
)
29
1
(2
2.
7)
84
(6
.5
5)
49
(3
.8
2)
28
(2
.1
8)
22
(1
.7
2)
12
82
(1
00
)
HOSPITAL DATA SET: RESULTS AND DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
B
as
el
in
e
ri
sk
fa
ct
o
r
C
at
eg
o
ry
In
te
rv
al
b
et
w
ee
n
b
as
el
in
e
an
d
fi
rs
t
fo
llo
w
-u
p
To
ta
l
p
-v
al
u
e
(c
h
is
q
u
ar
ed
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
N
um
be
r
of
si
gh
tin
gs
of
a
un
iq
ue
ad
en
om
a
1
12
16
(3
6.
73
)
65
2
(1
9.
69
)
80
7
(2
4.
37
)
26
7
(8
.0
6)
17
6
(5
.3
2)
94
(2
.8
4)
99
(2
.9
9)
33
11
(1
00
)
<
0.
00
1
2
42
8
(4
2.
59
)
22
2
(2
2.
09
)
21
1
(2
1)
68
(6
.7
7)
33
(3
.2
8)
24
(2
.3
9)
19
(1
.8
9)
10
05
(1
00
)
3
87
(4
7.
8)
50
(2
7.
47
)
22
(1
2.
09
)
11
(6
.0
4)
7
(3
.8
5)
3
(1
.6
5)
2
(1
.1
)
18
2
(1
00
)
4
19
(3
0.
16
)
31
(4
9.
21
)
8
(1
2.
7)
4
(6
.3
5)
0
(0
)
1
(1
.5
9)
0
(0
)
63
(1
00
)
5+
10
(2
1.
28
)
21
(4
4.
68
)
9
(1
9.
15
)
5
(1
0.
64
)
1
(2
.1
3)
1
(2
.1
3)
0
(0
)
47
(1
00
)
Po
ly
p
ch
ar
ac
te
ri
st
ic
s
N
um
be
r
of
hy
pe
rp
la
st
ic
po
ly
ps
0
14
31
(3
8.
23
)
78
2
(2
0.
89
)
86
9
(2
3.
22
)
28
3
(7
.5
6)
17
7
(4
.7
3)
93
(2
.4
8)
10
8
(2
.8
9)
37
43
(1
00
)
0.
01
0
1
19
2
(3
5.
49
)
11
8
(2
1.
81
)
13
9
(2
5.
69
)
39
(7
.2
1)
19
(3
.5
1)
23
(4
.2
5)
11
(2
.0
3)
54
1
(1
00
)
2
64
(4
0.
25
)
41
(2
5.
79
)
22
(1
3.
84
)
17
(1
0.
69
)
9
(5
.6
6)
5
(3
.1
4)
1
(0
.6
3)
15
9
(1
00
)
3
24
(3
7.
5)
19
(2
9.
69
)
9
(1
4.
06
)
4
(6
.2
5)
6
(9
.3
8)
2
(3
.1
3)
0
(0
)
64
(1
00
)
4
17
(4
4.
74
)
5
(1
3.
16
)
7
(1
8.
42
)
7
(1
8.
42
)
2
(5
.2
6)
0
(0
)
0
(0
)
38
(1
00
)
5+
32
(5
0.
79
)
11
(1
7.
46
)
11
(1
7.
46
)
5
(7
.9
4)
4
(6
.3
5)
0
(0
)
0
(0
)
63
(1
00
)
Lo
ca
tio
n
of
po
ly
ps
D
is
ta
lo
nl
y
10
06
(3
7.
04
)
59
1
(2
1.
76
)
61
6
(2
2.
68
)
21
5
(7
.9
2)
13
2
(4
.8
6)
79
(2
.9
1)
77
(2
.8
4)
27
16
(1
00
)
<
0.
00
1
Pr
ox
im
al
on
ly
22
6
(4
3.
88
)
93
(1
8.
06
)
11
9
(2
3.
11
)
37
(7
.1
8)
22
(4
.2
7)
12
(2
.3
3)
6
(1
.1
7)
51
5
(1
00
)
D
is
ta
la
nd
pr
ox
im
al
48
3
(4
1.
89
)
24
7
(2
1.
42
)
26
9
(2
3.
33
)
72
(6
.2
4)
40
(3
.4
7)
22
(1
.9
1)
20
(1
.7
3)
11
53
(1
00
)
U
nk
no
w
n
45
(2
0.
09
)
45
(2
0.
09
)
53
(2
3.
66
)
31
(1
3.
84
)
23
(1
0.
27
)
10
(4
.4
6)
17
(7
.5
9)
22
4
(1
00
)
Pr
ox
im
al
po
ly
p
N
o
10
51
(3
5.
75
)
63
6
(2
1.
63
)
66
9
(2
2.
76
)
24
6
(8
.3
7)
15
5
(5
.2
7)
89
(3
.0
3)
94
(3
.2
)
29
40
(1
00
)
<
0.
00
1
Y
es
70
9
(4
2.
51
)
34
0
(2
0.
38
)
38
8
(2
3.
26
)
10
9
(6
.5
3)
62
(3
.7
2)
34
(2
.0
4)
26
(1
.5
6)
16
68
(1
00
)
n/
a,
no
t
ap
pl
ic
ab
le
.
a
In
te
rv
al
±
6
m
on
th
s.
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
47
Multivariable analysis
To identify independent risk factors for having adenomas, AA or CRC at FUV1, and to adjust the effect
of interval for potential confounding factors, multivariable logistic regression was used. Interval was first
modelled as a categorical variable (model 1) and then as a continuous variable (model 2). Results of the
models for adenomas (all types), AA and CRC are shown in Tables 19–21, respectively.
Adenomas (all types)
Comparison of crude and adjusted estimates for the effect of interval on adenoma findings at FUV1
showed evidence of weak negative confounding, with the effect masked slightly by that of covariates.
After adjustment for covariates, the association between interval and detection of adenomas was
strengthened, but there was considerable overlap between the 95% CIs (with interval as a categorical
variable), most of which included 1, and statistical significance was reached only when interval was
modelled as a continuous variable. The latter model showed 6% greater odds of adenomas at FUV1 per
year increase in interval (OR 1.06, 95% CI 1.02 to 1.11; p = 0.0024).
A number of baseline characteristics were found to be independent risk factors for having an adenoma
detected at FUV1. These included older age, male gender, later year of baseline, no complete colonoscopy
and presence of multiple adenomas at baseline (all p < 0.001). Effect estimates for specific age categories
should be interpreted with caution owing to their imprecision. Other risk factors included the presence
of an adenoma of ≥ 20 mm or a proximal polyp, whereas odds were lower in patients with a difficult
baseline examination (composite variable for an incomplete examination with poor bowel preparation and
additional difficulties). Patients with a baseline visit of more than 1 day were significantly less likely to have
an adenoma detected at FUV1 (p < 0.001); however, there was considerable overlap between 95% CIs,
some of which included 1, which made interpretation difficult. Multiple sightings of an adenoma was a
strong risk factor for the detection of adenomas, and having the same adenoma seen five or more times
increased odds more than threefold (OR 3.13, 95% CI 1.53 to 6.39).
Models 1 and 2, which used interval as a categorical variable and continuous variable, respectively, were
very similar and selected the same variables. Crude and adjusted estimates of effect were similar for all
variables except length of baseline visit and most complete colonoscopy.
Advanced adenomas
There was little evidence of a relationship between interval and AA at FUV1, both before and after
adjusting for other factors; the test statistics were non-significant and all but one 95% CI included 1,
although there was a tendency towards increasing odds with increasing interval.
After adjusting for the effects of covariates, older age, no complete colonoscopy and the presence of an
adenoma of ≥ 20 mm at baseline were highly predictive of AA detection at FUV1 (all p < 0.001). Other
risk factors included the presence of a proximal polyp, an adenoma with villous or tubulovillous histology,
a large (≥ 10 mm) hyperplastic polyp or multiple adenomas at baseline. Multiple sightings of a unique
adenoma at baseline was a strong risk factor for AA at FUV1; a dose–response effect was demonstrated
and five or more sightings was associated with an almost fourfold greater odds of AA (OR 3.79, 95% CI
2.0 to 7.3). The two models, examining interval as a categorical and continuous variable, were very similar
and selected the same variables.
When comparing crude and adjusted estimates, the effects of age, adenoma size and histology, and number
of sightings of an adenoma were exaggerated before adjustment, suggesting positive confounding by
covariates in the models. There was also evidence of negative confounding, with no effect of proximal polyps,
and a smaller effect of completeness of colonoscopy, number of adenomas and large hyperplastic polyps
before adjustment for other factors. Number of hyperplastic polyps and presence of a large hyperplastic polyp
or a proximal polyp at baseline were significantly associated with AA only after adjustment.
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Colorectal cancer
A longer interval was significantly associated with increased odds of CRC detection at FUV1, both before
and after adjustment, regardless of whether interval was modelled as a continuous or categorical variable.
After adjustment for covariates there was 21% greater odds of finding CRC per year increase in interval
(OR 1.21, 95% CI 1.08 to 1.37; p = 0.0040). There was evidence of weak negative confounding as the
effect of interval became stronger after adjusting for other factors.
Independent baseline risk factors for CRC at FUV1 included older age, the detection of an adenoma with
villous or tubulovillous histology or with HGD, poor bowel preparation and a difficult examination (all p< 0.05),
the last of which was significant only in model 2, with interval as a continuous variable. There was evidence of
positive and negative confounding; the effects of histology, dysplasia and a difficult examination on CRC were
attenuated after adjustment, whereas the effect of bowel preparation was strengthened slightly.
Baseline risk factors for a short interval
Unexpectedly, little evidence of an association was found between interval and detection of adenomas or
AA at FUV1, even after adjusting for a number of covariates. As a large proportion of patients returned
sooner than expected for their first follow-up, crude and adjusted estimates of the effect of baseline
characteristics on interval length were calculated to allow a more detailed examination of baseline predictors
of a short interval. An arbitrary cut-off of 2 years from baseline was used to classify patients as having a
short interval, as this was the median interval length to FUV1 in the hospital cohort. A logistic regression
model was used and factors that were not significant in the model at the 95% level were not included in the
final model, and were therefore not adjusted for. Table 22 shows baseline risk factors for a short interval.
Age was significantly associated with a short interval (p < 0.0001), before and after adjustment for
confounding, with a tendency towards an increasing odds of a short interval with increasing age. After
adjustment, there was a 6% greater odds of a short interval per year increase in the calendar year of the
baseline visit (OR 1.06, 95% CI 1.04 to 1.08) and odds also increased for patients with multiple sightings
of a single adenoma (p < 0.0003). Conversely, patients without a complete colonoscopy at baseline were
significantly less likely to return early, possibly as a result of the experience of a difficult examination (OR
0.71, 95% CI 0.61 to 0.82). Patients with a longer baseline visit were less likely to have a short surveillance
interval; however, most 95% CIs included 1 so it was not possible to discern a real effect (p < 0.0001);
these results may be affected by adjustment for multiple sightings of an adenoma, as before adjustment
there was a positive association between length of baseline and a short interval. Having a large adenoma
(≥ 10 mm), an adenoma with HGD or a proximal polyp were also risk factors for a short interval.
The independent predictors of a short interval were also identified as risk factors for finding an adenoma,
AA or CRC at FUV1. However, adjustment for these factors made little difference to the effect estimates
for interval, and did not reveal an association between interval and adenoma (only associated when
interval was modelled as a continuous variable) or AA at FUV1. One possibility is that an unmeasured
confounder closely linked to a factor(s) associated with the outcome and exposure may have increased the
risk of a short interval and of having adenomas, AA or CRC at FUV1. This would cause an exaggerated
effect of a short interval on risk, resulting in a diminished effect of interval length overall. Multiple
sightings of a single adenoma at baseline was identified as a strong risk factor for a short interval and for
finding an adenoma or AA at FUV1, so it is possible that this factor was acting as a proxy measure for an
important, unmeasured confounder. This possibility is explored in detail in the next section.
New and previously seen lesions at first follow-up
As described in the previous section, we hypothesised that an unmeasured confounder was masking the
association between interval and the detection of adenoma, AA or CRC at FUV1. It was possible that a
proportion of individuals had a short interval because they were undergoing polypectomy site surveillance.
Such patients would have a large adenoma, probably seen multiple times during baseline for repeated
treatment, and possibly with advanced features such as HGD. Polypectomy site surveillance would be
carried out to check the site of a large lesion that might not have been completely removed at baseline,
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TABLE 22 Baseline characteristics associated with a short interval to first follow-up
Baseline predictors
Interval from baseline to first follow-up of ≤ 2 years
Unadjusted OR
(95% CI)
p-value
(LRT)
Adjusted OR
(95% CI)
p-value
(LRT)
Age (years) < 55 1.00 < 0.0001 1.00 < 0.0001
≥ 55 and < 60 1.04 (0.85 to 1.27) 1.02 (0.82 to 1.27)
≥ 60 and < 65 1.31 (1.09 to 1.58) 1.19 (0.97 to 1.46)
≥ 65 and < 70 1.18 (0.98 to 1.42) 1.11 (0.91 to 1.36)
≥ 70 and < 75 1.59 (1.31 to 1.93) 1.47 (1.20 to 1.82)
≥ 75 and < 80 1.66 (1.32 to 2.09) 1.45 (1.13 to 1.87)
≥ 80 2.32 (1.72 to 3.11) 1.94 (1.40 to 2.67)
Calendar year of baseline 1-year increase 1.06 (1.05 to 1.08) < 0.0001 1.06 (1.04 to 1.08) < 0.0001
Length of baseline visit 1 day 1.00 < 0.0001 1.00 < 0.0001
2–30 days 1.57 (1.21 to 2.05) 1.13 (0.82 to 1.57)
1–3 months 1.30 (1.10 to 1.55) 0.99 (0.79 to 1.23)
3–6 months 1.53 (1.28 to 1.84) 1.05 (0.84 to 1.31)
6–12 months 1.30 (1.07 to 1.57) 0.85 (0.67 to 1.08)
≥ 12 months 0.65 (0.43 to 0.98) 0.26 (0.15 to 0.45)
Most complete
colonoscopy
Complete 1.00 < 0.0001 1.00 < 0.0001
Incomplete/unknown 0.63 (0.55 to 0.71) 0.71 (0.61 to 0.82)
Largest adenoma (mm) < 10 1.00 < 0.0001 1.00 < 0.0001
10–14 1.09 (0.86 to 1.38) 1.29 (0.99 to 1.67)
15–19 1.22 (0.95 to 1.56) 1.44 (1.09 to 1.90)
≥ 20 1.78 (1.42 to 2.25) 1.80 (1.37 to 2.35)
Worst adenoma dysplasia Low grade 1.00 < 0.0001 1.00 < 0.0001
High grade 1.62 (1.39 to 1.89) 1.42 (1.20 to 1.68)
Number of sightings of a
unique adenoma
1 1.00 < 0.0001 1.00 0.0003
2 1.45 (1.26 to 1.67) 1.34 (1.09 to 1.64)
3 2.10 (1.53 to 2.87) 1.93 (1.33 to 2.80)
4 1.93 (1.15 to 3.24) 2.55 (1.38 to 4.72)
5+ 0.82 (0.46 to 1.47) 1.61 (0.77 to 3.34)
Proximal polyp No 1.00 < 0.0001 1.00 0.0005
Yes 1.31 (1.16 to 1.48) 1.29 (1.12 to 1.49)
Results for hospital attended not presented (p< 0.0001).
N= 4277.
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rather than to check for the occurrence of newly developed lesions or lesions missed at baseline (possibly
because of a poor-quality examination). The UK Adenoma Surveillance guideline16 assumes that all
detected lesions are removed at baseline before surveillance begins, and includes recommendations for the
treatment and surveillance of incompletely removed lesions. Such patients may require repeated treatment
over a number of examinations in order to achieve complete removal and are then expected to return for a
further examination(s) to check the polyp site.
We hypothesised that patients undergoing polypectomy site surveillance would be more likely not only to
return for follow-up sooner, but also to have a finding detected at FUV1 – the lesion under polypectomy
site surveillance. This could potentially confound the relationship between interval and detection of an
adenoma or AA at FUV1. Although difficult to recognise such cases from a retrospective series, it was
thought that lesions detected at FUV1 which were previously seen at baseline (i.e. the same lesion) were
more likely to have been found as a result of polypectomy site surveillance. The distribution of new and
previously seen outcomes by interval was examined to determine whether or not this was likely to be the case.
Tables 23–25 show a breakdown of IR patients by interval length and outcome status. Patients were
stratified into four groups: (1) those with no findings at FUV1; (2) those who have only a previously seen
finding; (3) those with both previously seen and new findings; and (4) those who have only a new finding.
The number of patients within each stratum was then assessed to determine whether or not it was
appropriate to exclude previously seen findings from the analyses.
After stratifying patients by interval and outcome status, increasing interval length was associated with
increased detection of new findings. Patients with a shorter interval had a greater proportion of previously
seen lesions detected than those with a longer interval. No such trend was seen among the ‘new and
previously seen’ findings group, although there were only a small number of patients in this group:
2% with adenomas, 1% with AA and < 1% with CRC.
Previously seen lesions detected at the first follow-up were most likely to represent lesions undergoing
polypectomy site surveillance when found in patients with a short interval between baseline and
follow-up. As interval length increased, it became less certain whether or not this was the case. Logistic
regression was performed using any findings (see Tables 19–21) and then using only new findings at FUV1
(Tables 26–30), having removed all previously seen findings.
All previously seen lesions were removed regardless of the interval length, rather than just those detected
in patients with a short interval to FUV1, in order to avoid the introduction of bias into the data set. If only
previously seen lesions in patients with short interval were removed from the analysis then this could
artificially increase the odds of an outcome among patients with a longer surveillance interval, which
would overestimate the effect of interval.
Effect of interval on new findings at first follow-up
After removal of previously seen lesions to adjust for the confounding effect of polypectomy site
surveillance, the association of interval with new findings at the first follow-up was examined using
univariable and multivariable analyses.
Univariable analysis
Table 26 shows the crude association between interval and new findings (adenomas, AA and CRC) at the
first follow-up – the effect of interval length was stronger than in the univariable analysis of all findings (new
and previously seen lesions) (compare Table 26 and Table 27). There was strong evidence of an association
between interval length and adenomas, AA and CRC at FUV1 (p < 0.0005), with an apparent dose–response
effect on all outcomes (see Table 26). When all findings (both new and previously seen) at FUV1 were
analysed, interval was associated with CRC only at FUV1. This suggests that, as predicted, lesions undergoing
polypectomy site surveillance were masking the association between interval and findings at FUV1. Although
CIs for new outcomes overlap somewhat, they rarely include 1, suggesting that there is a true association in
the population.
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
59
TA
B
LE
23
A
d
en
o
m
a
st
at
u
s
at
fi
rs
t
fo
llo
w
-u
p
b
y
in
te
rv
al
fr
o
m
b
as
el
in
e
to
fi
rs
t
fo
llo
w
-u
p
A
d
en
o
m
a
st
at
u
s
In
te
rv
al
fr
o
m
b
as
el
in
e
to
fi
rs
t
fo
llo
w
-u
p
,
n
(%
)
To
ta
l,
n
(%
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
N
on
e
11
65
(6
6.
19
)
62
7
(6
4.
24
)
69
7
(6
5.
94
)
23
2
(6
5.
35
)
13
2
(6
0.
83
)
74
(6
0.
16
)
76
(6
3.
33
)
30
03
(6
5.
17
)
Pr
ev
io
us
ly
se
en
on
ly
18
4
(1
0.
45
)
85
(8
.7
1)
45
(4
.2
6)
13
(3
.6
6)
4
(1
.8
4)
0
(0
)
3
(2
.5
0)
33
4
(7
.2
5)
N
ew
an
d
pr
ev
io
us
ly
se
en
48
(2
.7
3)
25
(2
.5
6)
15
(1
.4
2)
2
(0
.5
6)
2
(0
.9
2)
2
(1
.6
3)
0
(0
)
94
(2
.0
4)
N
ew
on
ly
36
3
(2
0.
63
)
23
9
(2
4.
49
)
30
0
(2
8.
38
)
10
8
(3
0.
42
)
79
(3
6.
41
)
47
(3
8.
21
)
41
(3
4.
17
)
11
77
(2
5.
54
)
To
ta
l
17
60
(1
00
)
97
6
(1
00
)
10
57
(1
00
)
35
5
(1
00
)
21
7
(1
00
)
12
3
(1
00
)
12
0
(1
00
)
46
08
(1
00
)
a
In
te
rv
al
±
6
m
on
th
s.
TA
B
LE
24
A
d
va
n
ce
d
ad
en
o
m
a
st
at
u
s
at
fi
rs
t
fo
llo
w
-u
p
b
y
in
te
rv
al
fr
o
m
b
as
el
in
e
to
fi
rs
t
fo
llo
w
-u
p
A
A
st
at
u
s
In
te
rv
al
fr
o
m
b
as
el
in
e
to
fi
rs
t
fo
llo
w
-u
p
,
n
(%
)
To
ta
l,
n
(%
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
N
on
e
14
92
(8
4.
77
)
81
1
(8
3.
09
)
90
6
(8
5.
71
)
29
9
(8
4.
23
)
18
3
(8
4.
33
)
10
5
(8
5.
37
)
89
(7
4.
17
)
38
85
(8
4.
31
)
Pr
ev
io
us
ly
se
en
on
ly
13
2
(7
.5
0)
75
(7
.6
8)
46
(4
.3
5)
11
(3
.1
0)
5
(2
.3
0)
0
(0
)
3
(2
.5
0)
27
2
(5
.9
0)
N
ew
an
d
pr
ev
io
us
ly
se
en
21
(1
.1
9)
9
(0
.9
2)
2
(0
.1
9)
1
(0
.2
8)
1
(0
.4
6)
2
(1
.6
3)
0
(0
)
36
(0
.7
8)
N
ew
on
ly
11
5
(6
.5
3)
81
(8
.3
0)
10
3
(9
.7
4)
44
(1
2.
39
)
28
(1
2.
9)
16
(1
3.
01
)
28
(2
3.
33
)
41
5
(9
.0
1)
To
ta
l
17
60
(1
00
)
97
6
(1
00
)
10
57
(1
00
)
35
5
(1
00
)
21
7
(1
00
)
12
3
(1
00
)
12
0
(1
00
)
46
08
(1
00
)
a
In
te
rv
al
±
6
m
on
th
s.
HOSPITAL DATA SET: RESULTS AND DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
TA
B
LE
25
C
o
lo
re
ct
al
ca
n
ce
r
st
at
u
s
at
fi
rs
t
fo
llo
w
-u
p
b
y
in
te
rv
al
fr
o
m
b
as
el
in
e
to
fi
rs
t
fo
llo
w
-u
p
C
R
C
st
at
u
s
In
te
rv
al
fr
o
m
b
as
el
in
e
to
fi
rs
t
fo
llo
w
-u
p
,
n
(%
)
To
ta
l,
n
(%
)
<
18
m
o
n
th
s
2
ye
ar
sa
3
ye
ar
sa
4
ye
ar
sa
5
ye
ar
sa
6
ye
ar
sa
≥
6.
5
ye
ar
s
N
on
e
17
31
(9
8.
35
)
95
1
(9
7.
44
)
10
51
(9
9.
43
)
34
6
(9
7.
46
)
21
3
(9
8.
16
)
11
8
(9
5.
93
)
11
4
(9
5.
00
)
45
24
(9
8.
18
)
Pr
ev
io
us
ly
se
en
on
ly
14
(0
.8
0)
16
(1
.6
4)
1
(0
.0
9)
0
(0
)
0
(0
)
1
(0
.8
1)
0
(0
)
32
(0
.6
9)
N
ew
an
d
pr
ev
io
us
ly
se
en
0
(0
)
0
(0
)
0
(0
)
0
(0
)
0
(0
)
1
(0
.8
1)
0
(0
)
1
(0
.0
2)
N
ew
on
ly
15
(0
.8
5)
9
(0
.9
2)
5
(0
.4
7)
9
(2
.5
4)
4
(1
.8
4)
3
(2
.4
4)
6
(5
)
51
(1
.1
1)
To
ta
l
17
60
(1
00
)
97
6
(1
00
)
10
57
(1
00
)
35
5
(1
00
)
21
7
(1
00
)
12
3
(1
00
)
12
0
(1
00
)
46
08
(1
00
)
a
In
te
rv
al
±
6
m
on
th
s.
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
61
Multivariable analysis
Logistic regression was used to identify independent risk factors for having new adenomas, AA or CRC at
FUV1, and to adjust the effect of interval for potential confounding factors. Interval was first modelled as a
categorical variable (model 1) and then as a continuous variable (model 2). Results of the models for new
adenomas (advanced and non-advanced), AA and CRC are shown in Tables 28–30, respectively.
Adenomas (all types)
After adjusting for the effects of covariates, the independent association between interval and new
adenomas at FUV1 remained highly significant (p < 0.0001), with 16% increased odds of having a new
adenoma per year increase in interval length (OR 1.16, 95% CI 1.11 to 1.21). The effect estimates were
TABLE 26 Crude association between interval to first follow-up and new findings at first follow-up
Interval from
baseline to
first follow-up
New findings at first follow-up
Adenoma AA CRC
Unadjusted OR
(95% CI)
p-value
(LRT)
Unadjusted OR
(95% CI)
p-value
(LRT)
Unadjusted OR
(95% CI)
p-value
(LRT)
< 18 months 1 < 0.0001 1 < 0.0001 1 0.0004
2 yearsa 1.22 (1.02 to 1.46) 1.21 (0.92 to 1.60) 1.08 (0.47 to 2.48)
3 yearsa 1.39 (1.17 to 1.65) 1.32 (1.01 to 1.72) 0.55 (0.20 to 1.53)
4 yearsa 1.47 (1.15 to 1.89) 1.73 (1.21 to 2.48) 3.03 (1.31 to 6.97)
5 yearsa 1.95 (1.45 to 2.63) 1.84 (1.20 to 2.83) 2.18 (0.72 to 6.64)
6 yearsa 2.17 (1.49 to 3.17) 2.05 (1.21 to 3.48) 3.91 (1.28 to 11.97)
≥ 6.5 years 1.70 (1.15 to 2.52) 3.63 (2.30 to 5.74) 6.12 (2.33 to 16.08)
Interval (per year
increase)
1.12 (1.08 to 1.16) < 0.0001 1.16 (1.11 to 1.22) < 0.0001 1.27 (1.16 to 1.40) < 0.0001
a Interval ± 6 months.
TABLE 27 Crude association between interval to first follow-up and any findings at first follow-up
Interval from
baseline to first
follow-up
Findings at FUV1
Adenoma AA CRC
Unadjusted OR
(95% CI)
p-value
(LRT)
Unadjusted OR
(95% CI)
p-value
(LRT)
Unadjusted OR
(95% CI)
p-value
(LRT)
< 18 months 1 0.5768 1 0.0830 1 0.0006
2 yearsa 1.09 (0.93 to 1.28) 1.13 (0.92 to 1.40) 1.57 (0.91 to 2.69)
3 yearsa 1.01 (0.86 to 1.19) 0.93 (0.75 to 1.15) 0.34 (0.14 to 0.82)
4 yearsa 1.04 (0.82 to 1.32) 1.04 (0.76 to 1.43) 1.55 (0.73 to 3.31)
5 yearsa 1.26 (0.94 to 1.68) 1.03 (0.70 to 1.53) 1.12 (0.39 to 3.22)
6 yearsa 1.30 (0.89 to 1.88) 0.95 (0.57 to 1.60) 2.53 (0.96 to 6.65)
≥ 6.5 years 1.13 (0.77 to 1.66) 1.94 (1.26 to 2.98) 3.14 (1.28 to 7.72)
Interval (per year
increase)
1.03 (0.99 to 1.07) 0.1117 1.04 (0.99 to 1.09) 0.1103 1.13 (1.03 to 1.25) 0.0232
a Interval ± 6 months.
N= 4608 IR patients.
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precise, and there was an apparent dose–response effect, providing strong evidence of an association.
There was also evidence of weak negative confounding as the effect was strengthened slightly
after adjustment.
Independent risk factors for new adenomas at FUV1 included older age, male gender, later date of
baseline, no complete colonoscopy, and the presence of hyperplastic polyps, proximal polyps or multiple
adenomas at baseline (all p < 0.004). A difficult examination or a baseline visit of longer than 1 day both
appeared to confer a lower chance of having a new adenoma; however, the association with length of
visit was irregular. The effect of number of sightings of an adenoma at baseline was somewhat difficult to
interpret, as two sightings conferred 22% greater odds, whereas three or more sightings were associated
with lower odds of having a new adenoma at FUV1.
Models 1 and 2, with interval as categorical and continuous, were very similar and used the same
covariates. All covariates were significant before and after adjustment, with little evidence of confounding.
After removal of previously seen findings, larger size of baseline adenoma was no longer predictive of
finding new adenomas at FUV1.
Advanced adenomas
There was strong evidence of a significant association between interval and new AA at FUV1: effect
estimates were precise and demonstrated a dose–response effect, with an 18% increased odds of new AA
at FUV1 per year increase in interval (OR 1.18, 95% CI 1.12 to 1.24; p < 0.0001). Adjustment for
covariates had little impact on the effect of interval.
Baseline risk factors for new AA at FUV1 included no complete colonoscopy (OR 1.69, 95% CI 1.34 to 2.11),
and the presence of an adenoma of ≥ 20mm (OR 1.30, 95% CI 1.06 to 1.60), a proximal polyp (OR 1.61,
95% CI 1.30 to 2.00) or a large hyperplastic polyp (OR 2.11, 95% CI 1.71 to 3.80). Older age also conferred
greater odds of new AA, although the association with increasing age was irregular.
Models 1 and 2 were quite similar. All risk factors were significantly associated with new AA before and
after adjustment except for largest adenoma, the effect of which was strengthened after adjustment.
After excluding previously seen lesions, histology, number of sightings of a single adenoma, and number
of adenomas or of hyperplastic polyps were no longer predictive of new AA at FUV1.
Colorectal cancer
After adjusting for the effects of covariates, the effect of interval length on new CRC at FUV1 was
strengthened, with a more than fivefold greater odds of CRC among those with an interval of ≥ 6 years,
and a 32% increase in odds per year increase in interval (OR 1.32, 95% CI 1.20 to 1.46). Owing to the
small number of new CRC outcomes, measures of effect for some strata of interval were imprecise;
however, the large effect sizes, tendency towards a dose–response effect and highly significant p-value
provide strong evidence of an association.
Older age and poor bowel preparation (p = 0.0005) were highly significant risk factors for new CRC at FUV1.
Although effect estimates were imprecise for individual categories, risk tended to increase with age and the
estimated increase in odds was sevenfold or greater for those aged ≥ 75 years and was fivefold greater for
poor bowel preparation. In model 2 (with interval as continuous), the absence of a complete colonoscopy
and the presence of proximal polyps at baseline were weakly associated with new CRC at FUV1.
There was some evidence of negative confounding as the effects of age, best bowel preparation and
proximal polyp were strengthened after adjusting for covariates. Histology and dysplasia of baseline
adenomas were no longer significantly associated with CRC at FUV1 after removal of previously seen
lesions from the analysis.
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Effect modification of the association between interval and new findings at
follow-up visit 1
We proposed that there might be an interaction between interval and age or gender. We investigated
interactions with interval to follow-up only as a continuous variable, as these results were more intuitive
and enabled the examination of potential trends.
There was no evidence of effect modification by age group or gender on new adenomas (Figure 3).
There was some evidence of effect modification for the finding of new AA at FUV1 (Figure 4). By age
group, the test for interaction was highly significant (p = 0.0100), although there was no clear trend in the
ORs. Increasing the interval had the greatest effect in the < 55 years age group but the decrease in effect
was not monotonic (Figure 4). To test for a trend in the ORs, an interaction was fitted between interval
and continuous age group; the p-value was 0.8987. Thus, the effect of interval differed between the
categorical age groups, but there was no trend in the effect with increasing age group. By gender, the
ORs suggested that increasing interval had a stronger effect in men than in women, but this difference
was not statistically significant (p = 0.0663). There was no evidence of effect modification on new CRC
(Figure 5).
Although we detected a significant interaction between interval and age group, we did not model the
interaction parameter in previously presented results, as it is likely to be impractical to offer different
surveillance strategies based on age or gender in a clinical setting.
Second follow-up visit
Characteristics and findings
Of the 4608 patients who attended FUV1, 1635 (36%) patients returned for FUV2 during our data
collection period and were not censored for cancer diagnosed at first follow-up.
Age (years)
< 55
> 55 to < 60
> 60 to < 65
> 65 to < 70
> 70 to < 75
> 75 to < 80
> 80
χ2 = 6.42; p = 0.38
6
1
Gender
Male
Female
χ2 = 1.34; p = 0.25
All patients
p < 0.001
1.25 (1.15 to 1.36)
1.09 (0.99 to 1.21)
1.13 (1.03 to 1.24)
1.18 (1.07 to 1.29)
1.15 (1.03 to 1.27)
1.14 (0.98 to 1.31)
1.03 (0.81 to 1.31)
OR for a 1-year increase in interval (95% CI)a
1.18 (1.12 to 1.25)
1.13 (1.06 to 1.20)
1.16 (1.11 to 1.21)
0.8 0.9 1 1.16 1.4
FIGURE 3 Effect of a 1-year increase in interval on the detection of new adenoma at FUV1 by age group and
gender. a, ORs adjusted for the other covariates included in model 2 in Table 28.
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Table 31 details the findings (new and previously seen) at FUV2 according to the interval between FUV1 and
FUV2. Adenomas were detected in 527 (32%) patients, AA in 232 (14%) patients and CRC in 17 (1%)
patients. The adenoma detection rate was high regardless of interval, varying from 30% to 43%, whereas
the proportion of patients with AA varied from 8% to 20%, and the proportion with CRC varied from none
to 3%. There was little evidence of a trend in findings with increasing interval for any of the outcomes.
Table 32 shows the examinations undertaken at FUV2. In 89% of patients, FUV2 comprised a single
procedure and was completed in 1 day. The most complete examination that we were able to glean from
Age (years)
< 60
> 60 to < 65
> 65 to < 70
> 70 to < 75
> 75 to < 80
> 80
χ2 = 8.78; p = 0.12
5
1
Gender
Male
Female
χ2 = 2.80; p = 0.0945
All patients
p < 0.0001
1.44 (1.18 to 1.76)
0.99 (0.58 to 1.71)
1.41 (1.14 to 1.75)
1.33 (1.08 to 1.63)
1.06 (0.74 to 1.51)
1.90 (1.30 to 2.77)
OR for a 1-year increase in interval (95% CI)a
1.43 (1.26 to 1.63)
1.21 (1.01 to 1.43)
1.32 (1.20 to 1.46)
0.5 0.75 1 1.32 2 3
FIGURE 5 Effect of a 1-year increase in interval on the detection of new CRC at FUV1 by age group and gender.
a, ORs adjusted for the other covariates included in model 2 in Table 30.
Age (years)
< 55
> 55 to < 60
> 60 to < 65
> 65 to < 70
> 70 to < 75
> 75 to < 80
> 80
χ2 = 16.81; p = 0.0100
6
1
Gender
Male
Female
χ2 = 3.37; p = 0.0663
All patients
p <  0.0001
1.33 (1.19 to 1.49)
0.95 (0.82 to 1.10)
1.15 (1.02 to 1.29)
1.28 (1.13 to 1.45)
1.18 (1.04 to 1.33)
1.16 (0.98 to 1.38)
1.09 (0.80 to 1.49)
OR for a 1-year increase in interval (95% CI)a
1.23 (1.15 to 1.32)
1.12 (1.04 to 1.21)
1.18 (1.12 to 1.24)
0.8 0.9 1 1.18 1.3 1.5
FIGURE 4 Effect of a 1-year increase in interval on the detection of new AA at FUV1 by age group and gender.
a, ORs adjusted for the other covariates included in model 2 in Table 29.
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TABLE 31 Adenomas, AAs and cancers found at FUV2 according to the interval between the first and second
follow-up visits
Interval FUV1 to FUV2
Number of
IR patients
(N= 1635)
Patients with findingsa at FUV2
Adenoma(s) AA(s) CRC(s)
n % (n/N) n % (n/N) n % (n/N)
< 18 months 397 144 36.27 79 19.90 4 1.01
2 yearsb 376 116 30.85 55 14.63 5 1.33
3 yearsb 518 153 29.54 63 12.16 3 0.58
4 yearsb 152 46 30.26 14 9.21 2 1.32
5 yearsb 131 44 33.59 11 8.40 2 1.53
6 yearsb 31 11 35.48 4 12.90 0 0
≥ 6.5 years 30 13 43.33 6 20.00 1 3.33
Total 1635 527 32.23 232 14.19 17 1.04
a Both new and previously seen lesions.
b Interval ± 6 months.
TABLE 32 Examinations undertaken during FUV2
Characteristic Category
IR patients (N= 1635)
n %
Number of examinations 1 1460 89.30
2 125 7.65
3 27 1.65
4+ 23 1.41
Length of FUV2 1 day 1461 89.36
2–30 days 14 0.86
1–3 months 36 2.20
3–6 months 44 2.69
6–12 months 61 3.73
1–2 years 16 0.98
3–4 years 3 0.18
Most complete examination at FUV2 Complete colonoscopy 1206 73.76
Colonoscopy not known to be complete 241 14.74
Colonoscopy or FS 47 2.87
FS 106 6.48
Colonoscopy, FS or rigid sigmoidoscopy 28 1.71
Surgery 6 0.37
Unknown procedure type 1 0.06
HOSPITAL DATA SET: RESULTS AND DISCUSSION
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information provided on procedure type and polyp location was a complete colonoscopy in 74% of cases,
and an incomplete colonoscopy in 15%. A further 5% are likely to have had a colonoscopy, as this is the
most common procedure to offer patients undergoing surveillance in the UK, but 6% had only a FS.
New and previously seen lesions at second follow-up
Tables 33–35 show the status of findings at FUV2 – whether or not a lesion had been seen at a previous
visit – stratified by the interval from FUV1 to FUV2. Similar to findings at FUV1, there was a trend towards
an increasing proportion of new findings in patients with a longer interval, and a greater proportion of
previously seen lesions in those with a shorter interval.
Based on these observations, all subsequent analyses of findings at FUV2 included only new findings, so as
to allow the association between interval to FUV2 and finding at FUV2 to be examined without any
confounding effects of polypectomy site surveillance, as was done in the analysis of new findings at FUV1.
TABLE 33 Adenoma status at second follow-up by interval from first to second follow-up
Adenoma
status
Interval to from first to second follow-up, n (%)
Total,
n (%)< 18 months 2 yearsa 3 yearsa 4 yearsa 5 yearsa 6 yearsa ≥ 6.5 years
None 253
(63.73)
260
(69.15)
365
(70.46)
106
(69.74)
87
(66.41)
20
(64.52)
17
(56.67)
1108
(67.77)
Previously seen
only
56
(14.11)
23
(6.12)
16
(3.09)
0 (0) 0 (0) 0 (0) 0 (0) 95
(5.81)
New and
previously seen
13
(3.27)
9
(2.39)
6
(1.16)
2
(1.32)
0 (0) 1
(3.23)
0 (0) 31
(1.90)
New only 75
(18.89)
84
(22.34)
131
(25.29)
44
(28.95)
44
(33.59)
10
(32.26)
13
(43.33)
401
(24.53)
Total 397
(100)
376
(100)
518
(100)
152
(100)
131
(100)
31
(100)
30
(100)
1635
(100)
a Interval ± 6 months.
TABLE 34 Advanced adenoma status at second follow-up by interval from first to second follow-up
AA status
Interval to from first to second follow-up, n (%)
Total,
n (%)< 18 months 2 yearsa 3 yearsa 4 yearsa 5 yearsa 6 yearsa ≥ 6.5 years
None 318
(80.10)
321
(85.37)
455
(87.84)
138
(90.79)
120
(91.6)
27
(87.10)
24
(80)
1403
(85.81)
Previously seen
only
51
(12.85)
23
(6.12)
12
(2.32)
0 (0) 0 (0) 0 (0) 0 (0) 86
(5.26)
New and
previously seen
4
(1.01)
5
(1.33)
5
(0.97)
0 (0) 0 (0) 1
(3.23)
0 (0) 15
(0.92)
New only 24
(6.05)
27
(7.18)
46
(8.88)
14
(9.21)
11
(8.40)
3
(9.68)
6 (20) 131
(8.01)
Total 397
(100)
376
(100)
518
(100)
152
(100)
131
(100)
31
(100)
30
(100)
1635
(100)
a Interval ± 6 months.
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The proportion of patients with new adenomas was high at both the first and second follow-ups,
regardless of interval length. The high detection rate of adenomas meant that this outcome was not
informative in terms of identifying an optimum surveillance strategy. For this reason, adenomas were not
considered as an end point in subsequent analyses for FUV2, and only AA or CRC were used as outcomes.
Follow-up visit 1 risk factors for new advanced adenomas and colorectal cancer
at follow-up visit 2
Univariable analyses were performed to assess the relationship between FUV1 characteristics and detection
of new AA and CRC at FUV2. Table 36 describes new AA and CRC incidence at FUV2 according to patient
characteristics and examinations at FUV1. Most patient or procedural characteristics were not significantly
predictive. There was weak evidence that suboptimal bowel preparation increased the odds of new AA
(p = 0.0178), but again 95% CIs included 1. There was some evidence of an association between new
CRC at FUV2 and a difficult examination at FUV1 (OR 5.99, 95% CI 1.22 to 29.35; p = 0.0636).
Table 37 describes new AA and new CRC incidence at FUV2 according to characteristics of adenomas and
polyps detected at FUV1. There was a tendency towards increasing odds of new AA at FUV2 with increasing
number and size of adenomas, severity of histology and proximal location of adenomas at FUV1, as well as
in the presence of proximal polyps or polyps of unknown histology. Odds of new AA tended to increase
with repeated sightings of an adenoma during FUV1 but the association was not significant (p = 0.0609).
No significant relationship was found between new CRC at FUV2 and characteristics of adenomas or polyps
seen at FUV1, a finding that was most likely due to the very small number of CRC outcomes at FUV2.
Baseline risk factors for new advanced adenomas and colorectal cancer at
the second follow-up visit
The crude association of baseline characteristics with new findings at FUV2 was investigated.
Table 38 describes crude associations of patient and procedural characteristics at baseline with new AA or
CRC at FUV2. Patients with an incomplete baseline colonoscopy had a twofold increased odds of AA at
FUV2 (OR 2.03, 95% CI 1.24 to 3.33). There was a tendency for increased odds of AA at FUV2 with
increasing interval length between baseline and FUV1, although effect estimates were imprecise and most
95% CIs included 1 (p = 0.0212). No other factors appeared to be associated with new AA at FUV2. There
was little evidence of an association between any patient or procedural characteristics at baseline and
detection of new CRC at FUV2, as estimates were extremely imprecise with wide CIs and non-significant
test statistics.
TABLE 35 Colorectal cancer status at second follow-up by interval from first to second follow-up
CRC status
Interval to from first to second follow-up, n (%)
Total,
n (%)< 18 months 2 yearsa 3 yearsa 4 yearsa 5 yearsa 6 yearsa ≥ 6.5 years
None 393
(98.99)
371
(98.67)
515
(99.42)
150
(98.68)
129
(98.47)
31
(100)
29
(96.67)
1618
(98.96)
Previously seen
only
2 (0.50) 1 (0.27) 2 (0.39) 1 (0.66) 2 (1.53) 0 (0) 0 (0) 8 (0.49)
New and
previously seen
2 (0.50) 4 (1.06) 1 (0.19) 1 (0.66) 0 (0) 0 (0) 1 (3.33) 9 (0.55)
Total 397
(100)
376
(100)
518
(100)
152
(100)
131
(100)
31
(100)
30
(100)
1635
(100)
a Interval ± 6 months.
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Table 39 describes the characteristics of polyps and adenomas detected at baseline, by whether patients
had new AA or CRC found at FUV2. There was no association between any baseline adenoma or polyp
characteristic and detection of new AA at FUV2. Similarly, no baseline polyp characteristic was a significant
predictor of new CRC at FUV2, although this was affected by the small number of CRCs found at FUV2.
Follow-up visit 1 risk factors and interval
The association between FUV1 risk factors and interval between FUV1 and FUV2 was examined to identify
potential confounders of the association between interval and new AA or CRC at FUV2 (see Appendix 9
for tables of results). Most FUV1 characteristics were significantly associated with interval at the 1% level.
A greater proportion of patients of an older age – or with a FS, poor bowel preparation, a difficult
examination at FUV1 or a long visit comprising multiple examinations – had a shorter interval. Additionally,
a greater proportion of patients with multiple adenomas, multiple sightings of a single adenoma, detection
of an adenoma of a larger size or with villous histology or severe dysplasia had a shorter interval.
Effect of interval on new findings at second follow-up
The effect of interval to second follow-up on new findings at FUV2 was examined using univariable and
multivariable analyses. As so few CRCs were found at FUV2, new AA and CRC were combined and new
AN was treated as the outcome measure instead.
Table 40 shows the association between interval from FUV1 to FUV2 and new AN at the second follow-up.
In the crude analysis, there was a tendency towards increasing odds of new AN with increasing interval to
FUV2; however, the relationship was not statistically significant (p = 0.2313) and most 95% CIs included 1.
When interval was modelled as a continuous variable, there was a borderline significant 11% increased
odds for every year increase in interval (OR 1.11, 95% CI 1.00 to 1.24; p = 0.0501).
Logistic regression was used to identify independent risk factors for having new AN at FUV2, and to adjust
the effect of interval for covariates. Interval was modelled as a categorical variable (model 1) and as a
continuous variable (model 2). Appendix 9 contains details of the models fitted. Baseline and FUV1 risk
factors were adjusted for in turn (models A and B) and in combination (model C), for interval as a
categorical and continuous variable. The cumulative effect of factors across baseline and FUV1 were also
adjusted for (model D), as well as a combination of individual and cumulative baseline and FUV1 factors
(model E), with interval as a categorical and continuous variable. When the fits of models A–E were
compared, with interval as categorical or continuous, model E was found to be the best in terms of its fit
to the data. Measures of fit used to assess the models were the AIC and the Bayesian information criterion
(BIC) (see Appendix 9 for additional results from other models and measures of fit).
After adjusting for covariates (model E, with interval as categorical and continuous), the effect of interval
was strengthened and the association with new AN at FUV2 became statistically significant, with evidence
of negative confounding. When interval was modelled as a categorical variable (model 1), there was an
increased odds of new AN with increasing interval length (p = 0.0164) and a 22% increased odds per year
increase in interval was seen when interval was modelled as a continuous variable (OR 1.22, 95% CI 1.09
to 1.36; p = 0.001); although some effect estimates were imprecise, the small p-values, large effect sizes
and tendency towards a dose–response relationship provided strong evidence of an association.
Other risk factors for AN at FUV2 included the detection of a ≥ 20 mm adenoma, proximal polyp or
multiple polyps with unknown histology at FUV1, or an incomplete colonoscopy or one or more polyps
with unknown histology at baseline. The detection of two or more adenomas across baseline and FUV1
(cumulative) was also associated with an increased odds of AN at FUV2 (p < 0.02). Models 1 and 2 were
very similar, with the same risk factors identified in each.
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Effect modification of the association between interval and new findings at
follow-up visit 2
A priori, we had proposed that there might be a difference in the effect of interval length on findings
by age or gender at FUV2 and, to investigate this, we fitted an interaction between continuous interval
and age group or gender for the outcome of new AN at FUV2. Results are presented in Figure 6; there
were no significant differences between age groups or between males and females in the effect of
increasing interval length.
Long-term cancer risk
A survival analysis was used to assess the incidence of CRC after both baseline (see Colorectal cancer risk
after baseline, below) and FUV1 (see Colorectal cancer risk after the first follow-up visit, below) to
determine the combined effects on future CRC risk of surveillance visits and baseline findings for the
former and surveillance visits and both baseline and first follow-up findings for the latter.
The entire IA cohort comprised 11,944 patients for the analysis of CRC incidence after baseline and
4517 patients with at least one follow-up – who remained free of CRC at FUV1 – for the analysis of CRC
incidence after FUV1.
The cohort was analysed using all observation time after baseline to assess whether or not surveillance had
a protective effect against CRC. If CRC was diagnosed at a follow-up visit, that follow-up visit was not
counted, as it could not have offered any protection against CRC.
Colorectal cancer risk after baseline
Overall, 168 CRCs developed during 81,442 pys of observation time after baseline (median 6.0 years,
IQR 3.8–9.2 years), giving an incidence rate of 206 (95% CI 177 to 240) per 100,000 pys at risk.
Age (years)
< 55
> 55 to < 60
> 60 to < 65
> 65 to < 70
> 65 to < 70
> 70 to < 75
> 80
χ2 = 6.81; p = 0.34
6
1
Gender
Male
Female
χ2 = 0.02; p = 0.88
All patients
p < 0.0001
1.35 (1.07 to 1.71)
1.03 (0.76 to 1.39)
1.08 (0.83 to 1.39)
1.07 (0.80 to 1.43)
1.37 (1.05 to 1.80)
1.33 (0.97 to 1.82)
1.67 (1.04 to 2.68)
OR for a 1-year increase in interval (95% CI)a
1.22 (1.06 to 1.42)
1.20 (1.02 to 1.42)
1.22 (1.09 to 1.36)
0.75 1 1.22 2 3
FIGURE 6 Effect of a 1-year increase in interval on the detection of new AN at FUV2 by age group and gender.
a, ORs adjusted for the other covariates included in model 2 in Table 40.
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Univariable analysis
The relationship between patient, procedural and polyp characteristics and long-term CRC incidence was
first investigated by determining incidence rates of CRC after baseline and crude HRs.
Table 41 shows CRC incidence stratified by baseline demographic and procedural characteristics. Older age
was a strong predictor of CRC (p < 0.0001), with a more than fourfold increased rate among those aged
75–80 years (HR 4.79, 95% CI 2.71 to 8.84). Patients whose best baseline colonoscopy was incomplete
were at an almost threefold increased risk (HR 2.78, 95% CI 1.94 to 3.98), and those with only poor
preparation at baseline had a more than twofold increased risk of CRC (HR 2.40, 95% CI 1.32 to 4.39),
although the overall effect of bowel preparation was not significant (p = 0.0597). Similarly, patients with a
difficult examination had twice the rate of CRC (HR 2.06, 95% CI 1.25 to 3.41). No association was found
between CRC and gender, family history of cancer, year of baseline, length of baseline, number of
examinations in the baseline visit or hospital attended (results for hospital not presented).
Table 42 shows CRC incidence stratified by adenoma or polyp characteristics at baseline. Detection of an
adenoma with HGD (HR 1.76, 95% CI 1.23–2.53) or a proximally located polyp (HR 1.53, 95% CI 1.13 to
2.08; p = 0.0066) or adenoma (HR 1.55, 95% CI 1.13 to 2.12; p = 0.0082) were significant predictors.
Tubulovillous or villous histology and unknown histology were significantly associated with increased CRC
risk. There was weak evidence that a large adenoma increased risk of CRC with a tendency towards
increasing risk of CRC with increasing size.
The unadjusted effect of surveillance on CRC incidence after baseline is presented in Table 43. Surveillance
was found to have a significant protective effect on future CRC risk, with a 46% reduction in risk with one
follow-up visit (HR 0.54, 95% CI 0.37 to 0.80) and a 61% reduction with two or more visits (HR 0.39,
95% CI 0.22 to 0.66), both in comparison with no follow-up visits.
Multivariable analysis
Cox proportional hazards regression modelling was used to examine the effect of surveillance on CRC risk,
controlling for the confounding effects of baseline factors.
Table 44 presents the results of the Cox regression using the full cohort and all available follow-up time
from the baseline visit. The model provided strong evidence of the beneficial effect of surveillance
(p = 0.0001), with a significant 49% lower CRC incidence with one follow-up visit compared with no
surveillance (HR 0.51, 95% CI 0.34 to 0.77). Having more than one surveillance examination offered
additional protection against CRC, with a 68% lower incidence after attendance at two or more follow-ups
(HR 0.32, 95% CI 0.17 to 0.61). As there was only a further 19% reduction in incidence associated
with two or more follow-ups, much of the protective effect appeared to be contributed by the initial
follow-up examination.
An increased rate of CRC was independently associated with older age, as well as with having an
incomplete colonoscopy or proximal polyps at baseline; both of the latter were estimated to confer an
almost twofold increase in risk (see Table 44; p < 0.0001). HGD and large adenoma size were also
independently predictive.
Colorectal cancer risk after the first follow-up visit
To assess the effect of additional surveillance on CRC risk after FUV1 accounting for findings at both
baseline and FUV1, an analysis was performed using 4517 patients who had at least one follow-up
visit and were free of CRC at their first follow-up. In these patients, 60 CRCs were diagnosed during
32,550 pys of follow-up time (184 per 100,000 pys); 38 CRCs were diagnosed after the occurrence of
just one follow-up and 22 after two or more.
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TABLE 41 Colorectal cancer incidence after baseline stratified by baseline demographic and procedural characteristics
Baseline factors
Number of
patients
(N= 11,944)
IR patients with long-term follow-up
CRC(s)
pys n= 168
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Age (years)
at baseline
< 55 2122 17,900.05 19 106.14 1 < 0.0001
≥ 55 and < 60 1321 10,475.16 10 95.46 0.95 (0.44 to 2.04)
≥ 60 and < 65 1858 13,308.84 20 150.28 1.53 (0.81 to 2.87)
≥ 65 and < 70 2171 14,190.37 39 274.83 2.95 (1.70 to 5.14)
≥ 70 and < 75 1786 11,579.17 27 233.18 2.54 (1.40 to 4.59)
≥ 75 and < 80 1416 8108.39 34 419.32 4.79 (2.71 to 8.48)
≥ 80 1270 5879.72 19 323.14 4.00 (2.09 to 7.66)
Gender Male 6625 44,061.76 95 215.61 1 0.4955
Female 5319 37,379.96 73 195.29 0.90 (0.66 to 1.22)
Family history
of cancer
No 11,445 77,544.37 160 206.33 1 0.9365
Yes 499 3897.34 8 205.27 0.97 (0.48 to 1.98)
Calendar year
of baseline
1985–94 439 6400.35 22 343.73 1 0.2389
1995–9 1430 15,648.51 43 274.79 0.85 (0.49 to 1.48)
2000–4 4251 33,510.37 64 190.99 0.66 (0.38 to 1.15)
2005–10 5824 25,882.49 39 150.68 0.57 (0.31 to 1.04)
Length of
baseline visit
1 day 6836 46,087.39 83 180.09 1 0.5751
2–30 days 734 4481.26 11 245.47 1.41 (0.75 to 2.64)
1–3 months 1643 11,217.87 26 231.77 1.32 (0.85 to 2.05)
3–6 months 1382 9815.99 24 244.50 1.37 (0.87 to 2.16)
6–12 months 1177 8560.31 21 245.32 1.35 (0.84 to 2.19)
≥ 12 months 172 1278.89 3 234.58 1.28 (0.41 to 4.06)
Number of
examinations
in baseline visit
1 6826 45,984.04 83 180.50 1 0.1909
2 3788 26,357.29 64 242.82 1.36 (0.98 to 1.88)
3 908 6200.41 12 193.54 1.09 (0.60 to 2.00)
4+ 422 2899.97 9 310.35 1.74 (0.87 to 3.46)
Completeness
of colonoscopy
Complete 9016 56,749.44 95 167.40 1 < 0.0001
Unknown 1601 15,605.39 29 185.83 0.97 (0.63 to 1.48)
Incomplete 1327 9086.89 44 484.21 2.78 (1.94 to 3.98)
Best bowel
preparation at
colonoscopy
Excellent/
good
3956 26,442.16 44 166.40 1 0.0597
Satisfactory 1922 10,317.55 22 213.23 1.39 (0.83 to 2.33)
Poor 671 3660.88 14 382.42 2.40 (1.32 to 4.39)
Unknown 5395 41,021.13 88 214.52 1.22 (0.85 to 1.75)
Difficult
examination
No 11,229 77,084.73 151 195.89 1 0.0101
Yes 715 4356.99 17 390.18 2.06 (1.25 to 3.41)
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TABLE 42 Colorectal cancer incidence after baseline stratified by baseline adenoma and polyp characteristics
Baseline factors
Number of
patients
(N= 11,944)
IR patients with long-term follow-up
CRC(s)
pys n= 168
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Adenoma characteristics
Number 1 7842 54,992.05 115 209.12 1 0.0816
2 3073 19,841.53 47 236.88 1.18 (0.84 to 1.65)
3 748 4701.77 5 106.34 0.53 (0.22 to 1.30)
4 281 1906.36 1 52.46 0.26 (0.04 to 1.85)
Largest size
(mm)
< 10 1029 6608.13 6 90.80 1 0.0760
10–14 4417 29,913.84 61 203.92 2.19 (0.95 to 5.07)
15–19 2440 16,965.60 33 194.51 2.07 (0.87 to 4.94)
≥ 20 4058 27,954.14 68 243.26 2.60 (1.13 to 6.00)
Worst
histology
Tubular 4742 32,214.79 48 149.00 1 0.0098
Tubulovillous 5576 37,064.54 83 223.93 1.51 (1.06 to 2.16)
Villous 1142 7611.79 18 236.48 1.59 (0.92 to 2.73)
Unknown 484 4550.59 19 417.53 2.44 (1.41 to 4.21)
Worst
dysplasia
Low grade 9476 63,137.92 111 175.81 1 0.0077
High grade 1994 12,964.32 40 308.54 1.76 (1.23 to 2.53)
Unknown 474 5339.47 17 318.38 1.51 (0.89 to 2.57)
Distal No 2448 16,295.31 37 227.06 1 0.4977
Yes 9496 65,146.41 131 201.09 0.88 (0.61 to 1.27)
Proximal No 8294 58,758.82 107 182.10 1 0.0082
Yes 3650 22,682.89 61 268.93 1.55 (1.13 to 2.12)
Number of
sightings of
a unique
adenoma
1 8807 60,393.43 118 195.39 1 0.4385
2 2548 16,965.28 38 223.99 1.17 (0.81 to 1.69)
3 390 2696.76 6 222.49 1.15 (0.51 to 2.61)
4 108 764.42 4 523.27 2.70 (1.00 to 7.31)
5+ 91 621.82 2 321.64 1.64 (0.41 to 6.65)
Polyp characteristics
Number of
hyperplastic
polyps
0 9874 67,518.89 143 211.79 1 0.7086
1 1307 8862.23 18 203.11 0.98 (0.60 to 1.60)
2 405 2656.32 3 112.94 0.55 (0.18 to 1.72)
3 152 1002.09 1 99.79 0.49 (0.07 to 3.53)
4 76 520.54 2 384.21 1.83 (0.45 to 7.40)
5+ 130 881.65 1 113.42 0.55 (0.08 to 3.92)
Any large
hyperplastic
polyps?
No 11,761 80,155.72 166 207.10 1 0.6897
Yes 183 1286.00 2 155.52 0.76 (0.19 to 3.07)
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Univariable analysis
We first examined the effect of factors found at FUV1 on CRC risk after FUV1 and then examined whether
or not any baseline factors could have affected risk.
Effect of follow-up visit 1 factors on future risk of colorectal cancer
Colorectal cancer incidence after FUV1 was stratified by demographic and procedural characteristics at
FUV1 (Table 45). Older age was strongly associated with increased CRC risk (p = 0.0067), as was having a
difficult examination (HR 3.98, 95% CI 2.02 to 7.88). There was some evidence of an association with
number of examinations at FUV1 (p = 0.0197), although the effect estimates were imprecise. No other
FUV1 risk factors were significant.
Colorectal cancer incidence after FUV1 was also stratified by characteristics of adenomas and polyps
detected at FUV1 (Table 46). The only feature that was significantly associated with increased CRC
incidence was the detection of a proximal polyp at FUV1 (HR 1.90, 95% CI 1.08 to 3.35). The detection of
an adenoma with tubulovillous (but not villous) histology was associated with a borderline significant
TABLE 42 Colorectal cancer incidence after baseline stratified by baseline adenoma and polyp characteristics (continued)
Baseline factors
Number of
patients
(N= 11,944)
IR patients with long-term follow-up
CRC(s)
pys n= 168
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Number of
polyps with
unknown
histology
0 9322 64,395.55 135 209.64 1 0.6239
1 1510 9781.43 15 153.35 0.75 (0.44 to 1.27)
2 517 3266.29 8 244.93 1.21 (0.59 to 2.46)
3 249 1650.11 5 303.01 1.45 (0.59 to 3.55)
4 129 849.83 3 353.01 1.68 (0.53 to 5.26)
5+ 217 1498.49 2 133.47 0.62 (0.15 to 2.50)
Distal polyp No 1980 13,188.16 32 242.64 1 0.3053
Yes 9964 68,253.55 136 199.26 0.81 (0.55 to 1.20)
Proximal polyp No 7369 52,583.80 93 176.86 1 0.0066
Yes 4575 28,857.92 75 259.89 1.53 (1.13 to 2.08)
TABLE 43 Colorectal cancer incidence after baseline stratified by the number of surveillance visits
Number of
follow-up visits
after baselinea
Number of
patients
(N= 11,944)
IR patients with long-term follow-up
CRC(s)
pys n= 168
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
0 7427 48,891.70 108 220.90 1 0.0002
1 2901 21,030.19 38 180.69 0.54 (0.37 to 0.80)
2+ 1616 11,519.83 22 190.97 0.39 (0.22 to 0.66)
a Number of follow-up visits was fitted as a time-dependent covariate.
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TABLE 44 Cox regression model of effect of surveillance on CRC incidence after baseline, adjusting for baseline
risk factorsa
Baseline risk factor Category Adjusted HR (95% CI) p-value (LRT)
Number of follow-up visits after baselineb 0 1 0.0001
1 0.51 (0.34 to 0.77)
2+ 0.32 (0.17 to 0.61)
Largest adenoma (mm) < 10 1 0.0177
10–19 2.93 (1.18 to 7.31)
≥ 20 3.16 (1.24 to 8.02)
Worst adenoma dysplasia Low grade 1 0.0107
High grade 1.66 (1.14 to 2.41)
Completeness of colonoscopy Complete 1 0.0002
Incomplete/unknown 1.92 (1.37 to 2.69)
Proximal polyps No 1 0.0002
Yes 1.91 (1.37 to 2.68)
Age (years) at baseline < 55 1 < 0.0001
≥ 55 and < 60 0.96 (0.42 to 2.17)
≥ 60 and < 65 1.42 (0.72 to 2.82)
≥ 65 and < 70 2.50 (1.37 to 4.58)
≥ 70 and < 75 2.47 (1.32 to 4.63)
≥ 75 and < 80 3.92 (2.13 to 7.22)
≥ 80 3.23 (1.64 to 6.38)
a A total of 11,470 patients were included in the model owing to the removal of 474 patients in whom information on
dysplasia were missing.
b Number of follow-up visits was fitted as a time-dependent covariate.
TABLE 45 Colorectal cancer incidence after FUV1 stratified by demographic and procedural characteristics of FUV1
First follow-up factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Age (years) at
first follow-up
< 55 722 6221.02 6 96.45 1 0.0067
≥ 55 and < 60 577 4714.19 6 127.28 1.39 (0.45 to 4.30)
≥ 60 and < 65 720 5486.11 5 91.14 1.04 (0.32 to 3.43)
≥ 65 and < 70 773 5746.65 14 243.62 2.93 (1.12 to 7.70)
≥ 70 and < 75 805 5312.84 15 282.33 3.66 (1.40 to 9.59)
≥ 75 and < 80 530 3193.95 8 250.47 3.45 (1.17 to 10.14)
≥ 80 390 1875.26 6 319.96 4.97 (1.56 to 15.84)
Gender Male 2493 17,845.15 32 179.32 1 0.7762
Female 2024 14,704.87 28 190.41 1.08 (0.65 to 1.79)
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TABLE 45 Colorectal cancer incidence after FUV1 stratified by demographic and procedural characteristics of FUV1
(continued )
First follow-up factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Family history
of cancer
No 4222 30,273.11 56 184.98 1 0.9207
Yes 295 2276.91 4 175.68 0.95 (0.34 to 2.62)
Year of first
follow-up
1985–94 159 2461 9 365.7 1 0.7501
1995–9 544 6206.05 13 209.47 0.69 (0.26 to 1.79)
2000–4 1601 13,311.8 21 157.75 0.63 (0.25 to 1.64)
2005–9 2213 10,571.17 17 160.81 0.83 (0.29 to 2.32)
Length of visit 1 day 4041 29,240.39 51 174.42 1 0.0512
2–30 days 54 314.53 0 0 n/a
1–3 months 99 669.45 0 0 n/a
3–6 months 137 943.26 5 530.08 3.21 (1.28 to 8.05)
6–12 months 152 1133.83 4 352.79 2.05 (0.74 to 5.68)
≥ 12 months 34 248.55 0 0 n/a
Number of
examinations
in visit
1 4033 29,184.02 51 174.75 1 0.0197
2 355 2477.71 5 201.8 1.16 (0.46 to 2.92)
3 87 576.87 4 693.39 4.27 (1.54 to 11.83)
4+ 42 311.41 0 0 n/a
Most complete
examination
Complete
colonoscopy
3258 22,886.03 36 157.3 1 0.1061
Colonoscopy
of unknown
completeness
250 2266.09 3 132.39 0.75 (0.23 to 2.45)
Incomplete
colonoscopy
390 3077.3 12 389.95 2.27 (1.18 to 4.38)
Colonoscopy
or FS
181 1519.34 2 131.64 0.71 (0.17 to 2.98)
FS 317 1896.99 3 158.15 1.04 (0.32 to 3.39)
Colonoscopy
or flexible or
rigid
sigmoidoscopy
100 774 2 258.4 1.49 (0.36 to 6.21)
Surgery 12 44.91 1 2226.86 17.27 (2.35 to 126.74)
Unknown 9 85.36 1 1171.46 6.26 (0.85 to 46.25)
Best bowel
preparation at
colonoscopy
Excellent/good 1274 9241.46 13 140.67 1 0.5331
Satisfactory 617 3758.6 4 106.42 0.82 (0.27 to 2.53)
Poor 240 1519.47 2 131.62 0.98 (0.22 to 4.33)
Unknown 1767 13,709.89 32 233.41 1.57 (0.82 to 3.00)
No known
colonoscopy
619 4320.61 9 208.3 1.40 (0.60 to 3.30)
Difficult
examination
No 4285 30,947.19 50 161.57 1 0.0007
Yes 232 1602.83 10 623.9 3.98 (2.02 to 7.88)
n/a, not applicable.
HOSPITAL DATA SET: RESULTS AND DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
TABLE 46 Colorectal cancer incidence after FUV1 stratified by adenoma and polyp characteristics of FUV1
First follow-up factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Adenoma characteristics
Number 0 2940 21,922.01 35 159.66 1 0.5336
1 1082 7450.29 18 241.6 1.61 (0.91 to 2.86)
2 315 2039.62 4 196.11 1.38 (0.49 to 3.89)
3 106 681.63 1 146.71 0.97 (0.13 to 7.08)
4 34 218.7 1 457.24 3.20 (0.44 to 23.44)
5+ 40 237.76 1 420.6 3.11 (0.42 to 22.80)
Largest size
(mm)
No
adenomas
2940 21,922.01 35 159.66 1 0.3690
< 10 1013 6804.36 13 191.05 1.29 (0.68 to 2.45)
10–14 213 1461.97 5 342 2.32 (0.91 to 5.94)
15–19 115 749.75 1 133.38 0.94 (0.13 to 6.87)
≥ 20 182 1188.45 4 336.57 2.26 (0.80 to 6.37)
Unknown 54 423.48 2 472.28 2.65 (0.63 to 11.11)
Worst histology No
adenomas
2940 21,922.01 35 159.66 1 0.0693
Tubular 946 6291.36 10 158.95 1.08 (0.53 to 2.19)
Tubulovillous 372 2452.04 10 407.82 2.83 (1.40 to 5.76)
Villous 122 839.62 1 119.1 0.78 (0.11 to 5.70)
Unknown 137 1044.98 4 382.78 2.39 (0.85 to 6.73)
Worst dysplasia No
adenomas
2940 21,922.01 35 159.66 1 0.3742
Low grade 1353 8802.29 20 227.21 1.57 (0.90 to 2.74)
High grade 101 669.8 2 298.6 2.05 (0.49 to 8.56)
Unknown 123 1155.92 3 259.53 1.46 (0.45 to 4.77)
Distal No
adenomas
2940 21,922.01 35 159.66 1 0.0607
No 718 4714.59 15 318.16 2.18 (1.18 to 4.00)
Yes 859 5913.42 10 169.11 1.13 (0.56 to 2.29)
Proximal No
adenomas
2940 21,922.01 35 159.66 1 0.1472
No 718 5111.38 10 195.64 1.29 (0.64 to 2.61)
Yes 859 5516.63 15 271.91 1.88 (1.02 to 3.45)
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increased risk of CRC after FUV1 (HR 2.83, 95% CI 1.40 to 5.76; overall p= 0.0693). Although non-significant,
there was a tendency towards an increased risk of CRC after FUV1 with the detection of multiple adenomas,
a large adenoma or an adenoma with HGD at FUV1. Imprecision of effect estimates precluded meaningful
interpretation for most factors.
TABLE 46 Colorectal cancer incidence after FUV1 stratified by adenoma and polyp characteristics of FUV1
(continued )
First follow-up factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Number of
sightings of a
single adenoma
No
adenomas
2940 21,922.01 35 159.66 1 0.4693
1 1381 9312.05 21 225.51 1.52 (0.88 to 2.62)
2 138 895.1 3 335.16 2.32 (0.71 to 7.58)
3 35 253.76 1 394.08 2.55 (0.35 to 18.65)
4 16 114.29 0 0 n/a
5+ 7 52.82 0 0 n/a
Polyp characteristics
Number of
hyperplastic
polyps
0 3743 27,365.8 51 186.36 1 0.6502
1 496 3364.3 5 148.62 0.85 (0.34 to 2.15)
2 160 1067.64 3 280.99 1.66 (0.52 to 5.35)
3 58 363.43 0 0 n/a
4 24 185.01 0 0 n/a
5+ 36 203.85 1 490.56 3.14 (0.43 to 22.86)
Any large
hyperplastic
polyps?
No 4477 32,294.35 60 185.79 n/a n/a
Yes 40 255.67 0 0
Number of
polyps with
unknown
histology
0 3742 27,017.94 47 173.96 1 0.8852
1 478 3395.46 9 265.06 1.48 (0.73 to 3.03)
2 142 1081.72 2 184.89 1.00 (0.24 to 4.13)
3 70 467.01 1 214.13 1.23 (0.17 to 8.93)
4 31 200.61 0 0 n/a
5+ 54 387.28 1 258.21 1.5 (0.21 to 10.85)
Distal polyp No polyps 2000 15,179.5 24 158.11 1 0.1295
No 848 5883.19 17 288.96 1.90 (1.02 to 3.55)
Yes 1669 11,487.33 19 165.4 1.11 (0.61 to 2.03)
Proximal polyp No polyps 2000 15,179.5 24 158.11 1 0.0042
No 1230 8816.78 12 136.1 0.90 (0.45 to 1.80)
Yes 1287 8553.74 24 280.58 1.90 (1.08 to 3.35)
n/a, not applicable.
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Effect of baseline factors on future risk of colorectal cancer
Few baseline factors were associated with CRC risk after FUV1 in univariable analyses (Table 47). There was
a tendency towards an increasing risk of CRC with increasing interval between baseline and FUV1; however,
the effect estimates were imprecise, with most 95% CIs crossing 1. Results also indicated an increased
risk of CRC in patients with unknown bowel preparation quality, no complete colonoscopy or a difficult
examination at baseline, but the associations were non-significant and most 95% CIs included 1.
Table 48 shows the CRC incidence after FUV1 stratified by characteristics of adenomas and polyps
detected at baseline. The only factor which reached statistical significance was the number of sightings of
a unique adenoma (p = 0.0494); risk tended to increase with increased viewings but interpretation was
TABLE 47 Colorectal cancer incidence after FUV1 stratified by baseline demographic and procedural characteristics
Baseline factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Family history
of cancer
No 4281 30,696.05 56 182.43 1 0.7605
Yes 236 1853.97 4 215.75 1.18 (0.43 to 3.24)
Calendar year
of baseline
visit
1985–94 330 4473.85 16 357.63 1 0.1929
1995–9 1004 9703.32 20 206.12 0.64 (0.31 to 1.32)
2000–4 2279 14,814.79 22 148.5 0.54 (0.26 to 1.15)
2005–10 904 3558.05 2 56.21 0.23 (0.05 to 1.10)
Length of visit 1 day 2455 18,050.92 30 166.2 1.00 0.9122
2–30 days 239 1667.52 4 239.88 1.47 (0.52 to 4.18)
1–3 months 651 4483.72 8 178.42 1.11 (0.51 to 2.43)
3–6 months 579 4163.45 9 216.17 1.33 (0.63 to 2.81)
6–12 months 497 3552.47 7 197.05 1.2 (0.53 to 2.73)
≥ 12 months 96 631.95 2 316.48 1.98 (0.47 to 8.3)
Number of
examinations
in visit
1 2448 17,977.1 30 166.88 1 0.3596
2 1487 10,618.22 22 207.19 1.25 (0.72 to 2.17)
3 381 2589.04 3 115.87 0.73 (0.22 to 2.41)
4+ 201 1365.66 5 366.12 2.24 (0.87 to 5.79)
Most
complete
colonoscopy
Complete 2926 19,853.68 32 161.18 1 0.5691
Unknown
completeness
1140 9260.95 19 205.16 1.16 (0.66 to 2.06)
Incomplete 451 3435.39 9 261.98 1.50 (0.71 to 3.15)
Best bowel
preparation at
colonoscopy
Excellent/
good
1371 9689.83 11 113.52 1 0.0560
Satisfactory 480 2695.92 2 74.19 0.73 (0.16 to 3.30)
Poor 184 1165.3 1 85.81 0.78 (0.10 to 6.07)
Unknown 2482 18,998.96 46 242.12 2.04 (1.06 to 3.95)
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TABLE 48 Colorectal cancer incidence after first follow-up stratified by baseline adenoma and polyp characteristics,
and interval between baseline and the first follow-up
Baseline factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Adenoma characteristics
Number 1 3040 22,527.05 45 199.76 1 0.4002
2 1129 7717.5 14 181.41 0.95 (0.52 to 1.73)
3 238 1494.08 0 0 n/a
4 110 811.39 1 123.24 0.63 (0.09 to 4.55)
Largest size
(mm)
< 10 2305.47 1 43.38 90.80 1 0.1103
10–14 11,142.76 17 152.57 203.92 3.41 (0.45 to 25.64)
15–19 6862.11 12 174.87 194.51 3.81 (0.49 to 29.32)
≥ 20 12,239.68 30 245.1 243.26 5.36 (0.73 to 39.36)
Worst histology Tubular 1700 12,040.66 17 141.19 1 0.4971
Tubulovillous 2096 14,676.49 27 183.97 1.31 (0.72 to 2.41)
Villous 440 3104.81 7 225.46 1.58 (0.65 to 3.80)
Unknown 281 2728.06 9 329.91 1.85 (0.79 to 4.30)
Worst dysplasia Low grade 3372 23,754.64 39 164.18 1 0.1088
High grade 822 5592.51 8 143.05 0.88 (0.41 to 1.89)
Unknown 323 3202.87 13 405.89 2.04 (1.05 to 3.94)
TABLE 47 Colorectal cancer incidence after FUV1 stratified by baseline demographic and procedural characteristics
(continued )
Baseline factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Difficult
examination
No 4308 31,127 55 176.70 1 0.1674
Yes 209 1423.02 5 351.37 2.03 (0.81 to 5.09)
Interval from
baseline to
first follow-up
< 18 months 1727 13,330.97 23 172.53 1 0.0089
2 yearsa 949 7105.08 11 154.82 0.93 (0.45 to 1.90)
3 yearsa 1051 6997.94 15 214.35 1.38 (0.72 to 2.66)
4 yearsa 345 2449.78 5 204.1 1.27 (0.48 to 3.36)
5 yearsa 213 1358.88 1 73.59 0.48 (0.07 to 3.59)
6 yearsa 118 660.13 5 757.43 5.15 (1.94 to 13.65)
≥ 6.5 years 114 647.25 0 0 n/a
n/a, not applicable.
a Interval ± 6 months.
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difficult because of a lack of precision. Although no other baseline adenoma or polyp risk factors reached
statistical significance and ORs were imprecise, there was a tendency towards an increased risk of CRC
after FUV1 with the detection of a large (≥ 10 mm) adenoma, an adenoma with tubulovillous or villous
histology, a proximal adenoma or polyp, or multiple polyps with unknown histology at baseline.
TABLE 48 Colorectal cancer incidence after first follow-up stratified by baseline adenoma and polyp characteristics,
and interval between baseline and the first follow-up (continued )
Baseline factors
Number of
patients
(N= 4517)
IR patients with long-term follow-up after first follow-up
CRC(s) after first follow-up
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Distal No 921 6512.4 11 168.91 1 0.7652
Yes 3596 26,037.62 49 188.19 1.10 (0.57 to 2.12)
Proximal No 3261 24,154.31 42 173.88 1.00 0.3847
Yes 1256 8395.71 18 214.40 1.28 (0.74 to 2.23)
Number of
sightings of
a unique
adenoma
1 3256 23,786.29 40 168.16 1 0.0494
2 981 6797.85 16 235.37 1.43 (0.80 to 2.55)
3 174 1255.55 0 0 n/a
4 61 399.74 2 500.33 3.19 (0.77 to 13.22)
5+ 45 310.58 2 643.95 3.70 (0.89 to 15.33)
Polyp characteristics
Number of
hyperplastic
polyps
0 3669 26,896.79 55 204.49 1 0.4610
1 529 3547.39 3 84.57 0.44 (0.14 to 1.40)
2 155 1039.77 0 0 n/a
3 64 429.76 1 232.69 1.22 (0.17 to 8.82)
4 37 227.95 0 0 n/a
5+ 63 408.36 1 244.88 1.30 (0.18 to 9.40)
Any large
hyperplastic
polyps?
No 4435 31,994.36 59 184.41 1 0.9814
Yes 82 555.66 1 179.97 1.02 (0.14 to 7.40)
Number of
polyps with
unknown
histology
0 3523 25,765.33 49 190.18 1 0.1700
1 544 3662.15 3 81.92 0.44 (0.14 to 1.41)
2 184 1230.67 4 325.03 1.78 (0.64 to 4.94)
3 106 755.28 2 264.8 1.40 (0.34 to 5.78)
4 61 400.04 2 499.95 2.81 (0.68 to 11.59)
5+ 99 736.56 0 0 n/a
Distal polyp No 727 5149.74 10 194.18 1 0.8231
Yes 3790 27,400.28 50 182.48 0.92 (0.47 to 1.82)
Proximal polyp No 2886 21,527.35 37 171.87 1 0.3835
Yes 1631 11,022.66 23 208.66 1.26 (0.75 to 2.13)
n/a, not applicable.
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Effect of surveillance on future risk of colorectal cancer
In a univariable analysis (Table 49), additional surveillance was estimated to reduce the risk of CRC after
FUV1 by 46% compared with no additional surveillance (HR 0.54, 95% CI 0.30 to 1.00); the p-value from
the LRT indicated significance (p = 0.0462), although the 95% CI included 1.
Multivariable analysis
In order to build a final multivariable model for the analysis of risk following FUV1, separate models were
first built considering baseline factors only, FUV1 factors only and cumulative factors only. The significant
risk factors identified from these models were then considered together and a final model was chosen.
Table 50 presents the results of the selected final Cox regression model of CRC incidence after the first
follow-up. There was a 41% reduction in CRC incidence with two or more follow-up visits compared with
TABLE 49 Colorectal cancer incidence after first follow-up stratified by the number of surveillance visits
Number of follow-up
visits after baseline
(including first follow-up)a
Number of
patients
(N= 4517)
IR patients with long-term follow-up
CRC(s)
pys n= 60
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
1 2901 21,030.19 38 180.69 1 0.0462
2+ 1616 11,519.83 22 190.97 0.54 (0.30 to 1.00)
a Number of follow-up visits was fitted as a time-dependent covariate.
TABLE 50 Cox regression model of the effect of additional surveillance on CRC incidence after FUV1, adjusting for
both individual and cumulative baseline and FUV1 factors
Risk factor Category Adjusted HR (95% CI) p-value (LRT)
Number of follow-up visits after baseline (including first follow-up)a 1 1 0.0923
2+ 0.59 (0.32 to 1.10)
Age (years) at first follow-up < 55 1 0.0151
55–59 1.35 (0.43 to 4.18)
60–64 1.01 (0.31 to 3.32)
65–69 2.77 (1.05 to 7.30)
70–74 3.42 (1.29 to 9.03)
75–79 2.98 (1.01 to 8.84)
≥ 80 4.66 (1.45 to 15.01)
Difficult examination at baseline or first follow-upb No 1 0.0066
Yes 2.67 (1.4 to 5.08)
Proximal polyps at first follow-up No polyps 1 0.0111
No 0.97 (0.48 to 1.96)
Yes 2.28 (1.28 to 4.07)
Largest adenoma at baseline, mm < 10 1 0.0418
10–19 3.96 (0.54 to 29.28)
≥ 20 5.89 (0.80 to 43.55)
a Number of follow-up visits was fitted as a time-dependent covariate.
b A difficult examination is a composite measure of poor examination quality, involving an incomplete examination with
poor bowel preparation and additional difficulties.
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only one follow-up, although this was not shown to be statistically significant (HR 0.59, 95% CI 0.32 to
1.10; p = 0.0923).
Independent risk factors for CRC after FUV1 included older age at FUV1, the presence of proximal polyps
at FUV1 or a difficult examination at either baseline or FUV1. There was weak evidence that a large
adenoma (≥ 10 mm) at baseline also increased CRC incidence after FUV1 [although the HRs suggested
a large effect, they had extremely wide CIs that included 1 and the LRT statistic was only borderline
significant (p = 0.0418)].
Effect modification of the association between surveillance and colorectal
cancer incidence
As for findings at follow-up, we hypothesised that there might be differences in the effect of surveillance
by age and gender. However, models with interactions terms included demonstrate no evidence of any
significant difference in the effect of surveillance by age or gender (Table 51).
Absolute risk of colorectal cancer in intermediate-risk patients
The absolute risk of CRC was assessed using cumulative incidence rates calculated using different
subsets of the cohort and varying periods of observation time, as presented in Table 52 and illustrated in
Figure 7. It should be noted that the results presented in this section for observation time partitioned by
the occurrence of surveillance may be contaminated, as some patients could have had surveillance that
we do not know about; this would artificially reduce the estimate of pre-surveillance risk and possibly
underestimate the effect of surveillance. Sensitivity analyses that assess the impact of this potential
misclassification can be found below (see Sensitivity analyses and internal validation).
TABLE 51 Effect of surveillance on CRC incidence by age group and gender
Characteristic
Number of
follow-up visits
after baselinea
New CRC after baseline New CRC after FUV1
HR (95% CI)b p-valuec HR (95% CI)b p-valuec
Age (years)d < 60 0 1 0.2116 n/a 0.8669
1 0.22 (0.06 to 0.77) 1
2+ 0.45 (0.17 to 1.20) 0.75 (0.22 to 2.55)
≥ 60 and < 75 0 1 n/a
1 0.69 (0.41 to 1.15) 1
2+ 0.25 (0.10 to 0.61) 0.52 (0.24 to 1.12)
≥ 75 0 1 n/a
1 0.38 (0.16 to 0.89) 1
2+ 0.36 (0.09 to 1.52) 0.56 (0.15 to 2.04)
Gender Male 0 1 0.1353 n/a 0.1285
1 0.45 (0.26 to 0.79) 1
2+ 0.18 (0.07 to 0.46) 0.40 (0.18 to 0.91)
Female 0 1 n/a
1 0.58 (0.32 to 1.05) 1
2+ 0.56 (0.26 to 1.21) 0.91 (0.41 to 2.05)
n/a, not applicable.
a Number of follow-up visits was fitted as a time-dependent covariate.
b HRs for the outcomes of new CRC after baseline and new CRC after FUV1 were adjusted for the other covariates
included in the models in Tables 44 and 50, respectively.
c The p-value for test for interaction between number of follow-up visits and the corresponding characteristic.
d Age at baseline for the analysis of new CRC after baseline and age at FUV1 for the analysis of new CRC after FUV1.
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TABLE 52 Colorectal cancer risk after baseline and first follow-up overall, and SIRs for CRC
Observation time
Number of
patients
Cumulative incidence at
Number of
observed
CRCs
Number of
expected
CRCs
SIRa
(95% CI)
3 years,
% (95% CI)
5 years,
% (95% CI)
10 years,
% (95% CI)
Observation time free
of surveillance in all IR
patients (censored at
first follow-up)
Total 11,944 0.5
(0.4 to 0.7)
1.1
(0.9 to 1.4)
2.9
(2.2 to 3.9)
108 102 1.06
(0.87 to 1.28)
All observation time
in all IR patients
Total 11,944 0.5
(0.3 to 0.6)
0.9
(0.7 to 1.1)
2.1
(1.7 to 2.5)
168 172 0.98
(0.84 to 1.14)
Observation time free
of further surveillance
after FUV1 in IR
patients with one or
more follow-up visits
(censored at second
follow-up)
Total 4517 0.4
(0.2 to 0.6)
0.8
(0.5 to 1.2)
2.3
(1.5 to 3.7)
38 44 0.87
(0.61 to 1.19)
All observation time
after FUV1 in IR
patients with one
follow-up visit
Total 4517 0.3
(0.2 to 0.5)
0.7
(0.5 to 1.0)
1.9
(1.4 to 2.6)
60 70 0.86
(0.65 to 1.10)
a Expected CRCs were calculated by multiplying the gender- and age-specific observed pys by the gender- and age-specific
incidence rates in the general population of England in 2007.
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FIGURE 7 Kaplan–Meier estimates of cumulative incidence. CRC incidence after baseline censoring at first
follow-up (a) and using all follow-up time (b); CRC incidence after the first follow-up censoring at the second
follow-up (c) and using all subsequent follow-up time (d). (continued )
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Cumulative incidence in the absence of surveillance was assessed by censoring the cohort at FUV1
(see Figure 7a). The cumulative incidence of CRC at 3, 5 and 10 years, respectively, was 0.5%, 1.1% and
2.9%, and CRC incidence was slightly, but non-significantly, higher than that of the general population.
Cumulative incidence in the whole cohort allowing for the effect of any surveillance was 0.5%, 0.9% and
2.1% at 3, 5 and 10 years, respectively (see Figure 7b). The cumulative incidence of CRC at 10 years was
reduced to 2.1%, and CRC incidence was the same as the general population level; these results must be
interpreted in the context of the fact that only 39% of the cohort were known to have had at least one
surveillance visit.
Cumulative incidence after a single surveillance was assessed by focusing on the cohort of IR patients who
attended follow-up and censoring at FUV2 to remove effects of additional surveillance (see Figure 7c).
Compared with pre-surveillance risk, the cumulative incidence of CRC at 10 years was lowered to 2.3%
after a single visit, and the CRC incidence was slightly lower than the general population, although not
significantly so.
Finally, we assessed absolute risk of CRC after one or more surveillance visits using all observation time
after the first follow-up in patients who attended one follow-up or more (see Figure 7d). Compared with
the analysis that censored the cohort at the second follow-up, by including the effect of additional
surveillance after the first follow-up, the cumulative incidence of CRC at 10 years was lowered to 1.9%,
and CRC incidence remained slightly lower than in the general population.
Lower- and higher-intermediate-risk subgroups
Lower- and higher-intermediate-risk subgroups after baseline
To assess whether or not heterogeneity exists within the IR group, and to see if all IR patients benefit from
surveillance after baseline, the cohort was divided into lower IR (LIR) and higher IR (HIR) subgroups. These
subgroups were defined using risk factors for CRC identified in the Cox regression model of CRC risk after
baseline (see Table 44); a HIR subgroup was defined to include patients with any of the following baseline
characteristics: an adenoma of ≥ 20 mm or with HGD, proximal polyps, no complete colonoscopy or poor
bowel preparation. All other patients were assigned to the LIR subgroup.
Older age was not used to define risk subgroups despite it being identified as a risk factor for CRC, as age
has practical implications for surveillance, with risks of complications increasing with age, and surveillance
often ceasing in patients aged ≥ 75 years. Bowel preparation quality was used despite it not being
predictive in the Cox model as it was a risk factor for finding CRC at FUV1 (see Table 30) and has a crucial
effect on examination quality. Although patients with an adenoma of ≥ 10 mm displayed similar risk to
those with an adenoma of ≥ 20 mm, only the latter size was used to define a higher-risk subgroup, as
almost all patients (91%) had a lesion of ≥ 10 mm; this led to their classification as IR and, thus, if
‘≥ 10 mm’ was used it would not be discriminant.
Based on this definition, the baseline subgroups comprised 2679 (22.4%) LIR and 9265 (77.6%) HIR
patients (Table 53). In the HIR subgroup, attendance at one or more follow-up visits was associated with a
significantly lower CRC risk than with no follow-up, with a 50% reduction for one follow-up (HR 0.50,
95% CI 0.34 to 0.76) and a 64% reduction for two or more (HR 0.36, 95% CI 0.20 to 0.62). Among
patients in the LIR subgroup, the benefit of surveillance was less clear and, because of the small number of
CRC end points, statistical significance was not reached and effect estimates were imprecise, although the
attendance at one or more follow-up visits was associated with a non-significant reduction in CRC risk
[38% reduction for one (HR 0.62, 95% CI 0.16 to 2.43); 71% reduction for two or more follow-ups
(HR 0.29, 95% CI 0.03 to 2.82)].
Table 54 shows the differences between patients in the HIR and LIR subgroups. Patients in the HIR
subgroup had significantly more follow-up visits than those in the LIR subgroup; however, the median
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TABLE 53 Colorectal cancer incidence and effect of surveillance after baseline in LIR and HIR subgroups
IR
subgroup
Number of
patients % pys
Patients
with
CRC (n)
Rate/100,000
pys (95% CI)
Effect of surveillance
Number of
follow-up
visits after
baselinea
Unadjusted HR
(95% CI)
p-value
(LRT)
LIR 2679 22.4 17,615 13 74 (43 to 127) 0 1 0.47
1 0.62 (0.16 to 2.43)
2+ 0.29 (0.03 to 2.82)
HIRb 9265 77.6 63,827 155 243 (208 to 284) 0 1 0.0001
1 0.50 (0.34 to 0.76)
2+ 0.36 (0.20 to 0.62)
a Number of follow-up visits was fitted as a time-dependent covariate.
b Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm or proximal polyps at
baseline; all remaining patients were classed as LIR.
TABLE 54 Number of follow-up visits, age and year of entry by risk subgroup
Factor
Number of
patients
LIR subgroup HIR subgroupa
p-value
(chi-squared test)n % n %
Total 11,944 2679 9265
Number of follow-up visits < 0.001
0 7427 1909 71.3 5518 59.6
1 2880 515 19.2 2365 25.5
2 1074 184 6.9 890 9.6
3+ 563 71 2.7 492 5.3
Age (years) at first adenoma detection < 0.001
< 55 2122 572 21.4 1550 16.7
≥ 55 and < 60 1321 311 11.6 1010 10.9
≥ 60 and < 65 1858 439 16.4 1419 15.3
≥ 65 and < 70 2171 473 17.7 1698 18.3
≥ 70 and < 75 1786 403 15.0 1383 14.9
≥ 75 and < 80 1416 260 9.7 1156 12.5
≥ 80 1270 221 8.2 1049 11.3
Year of baseline < 0.001
1985–94 439 71 2.7 368 4.0
1995–9 1430 283 10.6 1147 12.4
2000–4 4251 825 30.8 3426 37.0
2005–10 5824 1500 56.0 4324 46.7
a Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm or proximal polyps at
baseline; all remaining patients were classed as LIR.
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follow-up time was similar (6.1 years in the HIR subgroup vs. 5.7 years in the LIR subgroup). The HIR
subgroup was also older and had their baseline visit earlier on average; despite reaching statistical
significance, these differences were small.
Lower- and higher-intermediate-risk subgroups after the first follow-up visit
The HIR and LIR subgroups were redefined after FUV1 incorporating findings at both baseline and FUV1.
Specifically, the HIR subgroup was classified as patients with any of the following: an adenoma of
≥ 10 mm or with HGD, proximal polyps, no complete colonoscopy or poor bowel preparation at FUV1,
or an adenoma of ≥ 20 mm at baseline.
The risk subgroups after FUV1 comprised 1246 (27.6%) LIR patients and 3271 (72.4%) HIR patients (Table 55).
In the LIR subgroup, attendance for additional surveillance after FUV1 was associated with a non-significant
increased risk compared with only one follow-up visit (HR 1.20, 95% CI 0.14 to 10.31; p= 0.87), although the
effect estimate was very imprecise. By comparison, in the HIR subgroup attendance for additional surveillance
conferred a significant 53% reduction in CRC risk (HR 0.47, 95% CI 0.25 to 0.87; p= 0.0155).
Absolute risk of colorectal cancer in lower- and higher-intermediate-risk
subgroups
The absolute risk of CRC was assessed using cumulative incidence rates and SIRs, calculated using different
subsets of the cohort and varying periods of observation time, as presented in Table 56. The pre-surveillance
standardised CRC incidence in the LIR group was 60% below that of the general population, whereas the
HIR group had a 26% higher incidence. This large difference in cancer risk between subgroups was also
reflected in the 10-year cumulative incidence of CRC, which was 3.6% in the HIR subgroup compared with
1.0% in the LIR subgroup (Figure 8a).
Including the effect of any surveillance, the CRC incidence in the LIR group remained around 60% lower
than that of the general population, whereas the CRC incidence in the HIR subgroup was reduced to
a level 13% higher than the general population. The 10-year cumulative incidence of CRC in the HIR
subgroup was 2.4%, compared with 0.6% in the LIR subgroup (see Figure 8b).
We assessed the effect of just one follow-up visit on CRC risk by focusing on the cohort of IR patients who
attended follow-up and censoring at FUV2 to remove effects of additional surveillance (see Figure 8c); risk
groups were revised to incorporate findings at both baseline and FUV1. Compared with pre-surveillance
risk, the 10-year cumulative incidence of CRC after a single surveillance visit was lower, at 0.5% and 3.3%
in the LIR and HIR subgroups, respectively. In the low-risk subgroup, the standardised CRC incidence after
one follow-up visit was slightly lower than the pre-surveillance level at 68% below the general population
TABLE 55 Colorectal cancer incidence and effect of surveillance after FUV1 in LIR and HIR subgroups
IR
subgroup N % pys
Patients
with
CRC (n)
Rate/100,000
pys (95% CI)
Effect of surveillance
Number of
follow-up
visits after
baseline
(including first
follow-up)a
Unadjusted hazard
ratio (95% CI)
p-value
(LRT)
LIR 1246 27.6 9268 6 65 (29 to 144) 1 1 0.87
2+ 1.20 (0.14 to 10.31)
HIRb 3271 72.4 23,282 54 232 (118 to 303) 1 1 0.0155
2+ 0.47 (0.25 to 0.87)
a Number of follow-up visits was fitted as a time-dependent covariate.
b Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 10mm or proximal polyps at
first follow-up, or 20-mm+ adenoma at baseline; all remaining patients were classed as LIR.
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TABLE 56 Colorectal cancer risk after baseline and first follow-up in HIR and LIR subgroups, and SIRs for CRC
Observation
time
Number of
patients
Cumulative incidence at
Number of
observed
CRCs
Number of
expected
CRCs SIRa (95% CI)
3 years,
% (95% CI)
5 years,
% (95% CI)
10 years,
% (95% CI)
Observation time free of surveillance in all IR patients (censored at first follow-up)
Lower-risk
subgroup
2679 0.1 (0 to 0.4) 0.4 (0.2 to 1.0) 1.0 (0.4 to 2.4) 9 23 0.39 (0.18 to 0.75)
Higher-risk
subgroupb
9265 0.7 (0.5 to 0.9) 1.3 (1.0 to 1.7) 3.6 (2.6 to 4.8) 99 79 1.26 (1.02 to 1.53)
All observation time in all IR patients
Lower-risk
subgroup
2679 0.1 (0 to 0.4) 0.4 (0.2 to 0.8) 0.6 (0.3 to 1.2) 13 34 0.38 (0.20 to 0.65)
Higher-risk
subgroupb
9265 0.6 (0.4 to 0.7) 1.0 (0.8 to 1.3) 2.4 (2.0 to 2.9) 155 138 1.13 (0.96 to 1.32)
Observation time free of further surveillance after FUV1 in IR patients with one or more follow-up visits
(censored at second follow-up)
Lower-risk
subgroup
1246 0.2 (0 to 0.7) 0.3 (0.1 to 1.0) 0.5 (0.2 to 1.4) 4 13 0.32 (0.09 to 0.81)
Higher-risk
subgroupc
3271 0.4 (0.2 to 0.8) 1 (0.6 to 1.6) 3.3 (2.0 to 5.2) 34 31 1.09 (0.75 to 1.52)
All observation time after FUV1 in IR patients with one or more follow-up visits
Lower-risk
subgroup
1246 0.2 (0 to 0.7) 0.4 (0.1 to 0.9) 0.5 (0.2 to 1.1) 6 19 0.32 (0.12 to 0.70)
Higher-risk
subgroupc
3271 0.4 (0.2 to 0.7) 0.8 (0.5 to 1.2) 2.5 (1.8 to 3.5) 54 51 1.05 (0.79 to 1.37)
a Expected CRCs were calculated by multiplying the gender- and age-specific observed pys by the gender- and age-specific
incidence rates in the general population of England in 2007.
b Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm or proximal polyps
at baseline.
c Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 10mm or proximal polyps at
first follow-up, or adenoma ≥ 20mm at baseline.
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FIGURE 8 Kaplan–Meier estimates of cumulative incidence in HIR and LIR subgroups. CRC incidence after baseline
censoring at first follow-up (a) and using all follow-up time (b); CRC incidence after the first follow-up censoring at
the second follow-up (c) and using all subsequent follow-up time (d). HR represents the HIR subgroup, and LR
represents the LIR subgroup. (continued )
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FIGURE 8 Kaplan–Meier estimates of cumulative incidence in HIR and LIR subgroups. CRC incidence after baseline
censoring at first follow-up (a) and using all follow-up time (b); CRC incidence after the first follow-up censoring at
the second follow-up (c) and using all subsequent follow-up time (d). HR represents the HIR subgroup, and LR
represents the LIR subgroup.
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level. Similarly, for the HIR group, a single surveillance visit reduced the standardised, pre-surveillance CRC
incidence closer to that of the general population.
When the effect of additional surveillance after FUV1 was included, the 10-year cumulative incidence of
CRC in the HIR subgroup was 2.5% (see Figure 8d), compared with 3.3% when censoring at FUV2. The
standardised CRC incidence in the LIR subgroup remained unchanged – it was significantly lower than the
general population – whereas CRC incidence in the HIR group was further reduced to a level comparable
with that of the general population.
Findings at follow-up examinations in lower- and higher-intermediate-
risk subgroups
Lower- and higher-risk subgroups, derived from the Cox proportional hazards models for long-term CRC
risk (see Tables 44 and 50), were applied to findings at FUV1 and FUV2 to determine if the criteria used to
define the subgroups were discriminant in terms of risks of detecting AN at follow-up visits.
At FUV1, AN was detected in 6.2% of the LIR subgroup compared with 11.6% of the HIR subgroup
(see Table 57; OR 1.99, 95% CI 1.46 to 2.71; p < 0.0001); this suggests that risk factors for CRC after
baseline are also discriminant in terms of risk of AN at FUV1. At FUV2, new ANs was detected in 7.4%
and 10.0% of the LIR and HIR subgroups, respectively (OR 1.38, 95% CI 0.91 to 2.10; p = 0.1245); thus,
the risk groups were not discriminant for findings at FUV2, possibly owing to a lack of power because of
the small number of end points detected.
The effect of interval in the LIR and HIR subgroups was examined (Table 57). At FUV1, there was a highly
significant association between longer interval and new AN in the HIR subgroup (p < 0.0001); in the LIR
subgroup, the trend was only borderline significant, possibly because of a paucity of end points
(p = 0.0433). At FUV2, there was an association between interval and new AN in the HIR subgroup
(p = 0.0191), but not the LIR subgroup (p = 0.4573).
As interval had a strong effect on findings at both the first and second follow-ups in the HIR subgroup, the
effect of interval on findings at FUV1 was assessed in patients with HIR polyp factors only, HIR procedure
quality factors only, or both (Table 58). Interval had a significant effect in all subsets of the HIR group.
Although the test for trend was not as significant in patients who were classified as high risk based on
examination factors only, this is probably the result of the smaller size of this group.
Sensitivity analyses and internal validation
Owing to the complex nature of the hospital data set and the rules used to define baseline and follow-up
visits and interval, a number of sensitivity analyses were carried out to examine whether or not our
methods were robust and did not introduce bias into the study sample. Specifically, we restricted analyses
of the effect of interval on AA and CRC detection rates at FUV1, and the effect of surveillance on
long-term CRC risk after baseline to:
i. patients whose baseline visit comprised only a single colonoscopy – this verifies whether or not rules
used to define and extend the baseline visit were adequate or if they introduced bias into the
calculation of surveillance interval length
ii. patients with a complete colonoscopy at FUV1 – this assesses whether or not results were biased by
the inclusion of patients without a complete colonoscopy at FUV1 (arguably the lack of a complete
colonoscopy at FUV1 may mean that the surveillance visit was not as effective, as the whole colon
could not be examined).
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TABLE 57 Application of cancer risk subgroups to incidence of new AN at FUV1 and FUV2
Interval
to first
follow-up
FUV1 FUV2
Lower-risk subgroup Higher-risk subgroupa Lower-risk subgroup Higher-risk subgroupb
Number
with
FUV1
Number
of AN
(CRC) %
Number
with
FUV1
Number
of AN
(CRC) %
Number
with
FUV2
Number
of AN
(CRC) %
Number
with
FUV2
Number
of AN
(CRC) %
< 18 months 264 12 4.55 1496 134 (15) 8.96 43 1 (1) 2.33 354 28 (1) 7.91
2 yearsc 147 12 8.16 829 87 (9) 10.49 81 6 7.41 295 29 (4) 9.83
3 yearsc 227 9 3.96 830 101 (5) 12.17 164 15 9.15 354 37 (1) 10.45
4 yearsc 50 7 (1) 14.00 305 45 (8) 14.75 40 3 7.50 112 12 (1) 10.71
5 yearsc 53 3 5.66 164 30 (4) 18.29 59 3 5.08 72 8 11.11
6 yearsc 19 2 (1) 10.53 104 19 (3) 18.27 9 0 0 22 4 18.18
≥ 6.5 years 15 3 20.00 105 29 (6) 27.62 8 2 25.00 22 5 (1) 22.73
Total 775 48 (2) 6.19 3833 445 (50) 11.61 404 30 (1) 7.43 1231 123 (8) 9.99
pd= 0.0433 pd< 0.0001 pd= 0.4573 pd= 0.0191
OR for higher-intermediate
vs. LIR subgroup (95% CI),
p-value
1.99 (1.46 to 2.71), < 0.0001 1.38 (0.91 to 2.10), 0.1245
a Higher-risk subgroup= patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm
or proximal polyps at baseline.
b Higher-risk subgroup= patients with any of incomplete colonoscopy (including no known colonoscopy), poor bowel
preparation, HGD, adenoma ≥ 10mm or proximal polyps at FUV1 or adenoma ≥ 20mm at baseline.
c Interval ± 6 months.
d Note that ‘p’ is the p-value for a test for trend.
TABLE 58 Application of higher-intermediate cancer risk subgroups, broken down by risk factor, to incidence of
new AN at FUV1
Interval
FUV1
HIR subgroup
Polyp characteristics only Poor examination only
Poor examination and polyp
characteristics
Number
with
FUV1
Number
of AN
(CRC) %
Number
with
FUV1
Number
of AN
(CRC) %
Number
with
FUV1
Number
of AN
(CRC) %
< 18 months 926 71 (7) 7.7 204 21 (3) 10.3 366 42 (5) 11.5
2 yearsa 436 40 (3) 9.2 149 14 (2) 9.4 244 33 (4) 13.5
3 yearsa 465 59 (3) 12.7 177 17 9.6 188 25 (2) 13.3
4 yearsa 125 18 (2) 14.4 87 12 (3) 13.8 93 15 (3) 16.1
5 yearsa 61 9 (2) 14.8 52 10 (1) 19.2 51 11 (1) 21.6
6 yearsa 36 6 16.7 34 4 11.8 34 9 (3) 26.5
≥ 6.5 years 18 5 (1) 27.8 45 10 22.2 42 14 (5) 33.3
Total 2067 208 (18) 10.1 748 88 (9) 11.8 1018 149 (23) 14.6
pb< 0.0001 pb= 0.0137 pb < 0.0001
a Interval ± 6 months.
b Note that ‘p’ is the p-value for a test for trend.
HOSPITAL DATA SET: RESULTS AND DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
To check whether or not the definition of AA used had affected our results, a sensitivity analysis of the
effect of interval on AA detection rates at FUV1 was also performed, with the definition of AA changed
to a large (≥ 10 mm) adenoma or an adenoma with HGD (i.e. excluding villous or tubulovillous histology).
We also undertook sensitivity analyses to investigate the potential for misclassification of surveillance
attendance, and how this may have impacted on the apparent effect of surveillance on CRC risk after
baseline. Owing to a gap between the end of hospital data collection and patient follow-up with
cancer registries, around 50% of the hospital cohort had follow-up time after the end of data collection
during which they may have attended surveillance visits for which we were not able to collect reports.
We hypothesised that any such misclassification would be non-differential and would therefore result
in underestimation of the effect of surveillance. In addition, we may have potentially underestimated
pre-surveillance CRC risk after baseline owing to contamination of the no-surveillance group with patients
who had in fact attended one or more follow-ups. To investigate this, we restricted analyses of CRC risk
after baseline to patients with at least 5 years and at least 7 years of hospital data collection, among
whom any misclassification of surveillance attendance is extremely unlikely.
Patients with a single baseline colonoscopy
When the cohort was restricted to patients whose baseline visit comprised a single colonoscopy only (n= 2489),
the overall AA detection rate at FUV1 was 10.1%, compared with 9.8% in all patients who attended follow-up
(n= 4608). In addition, the effects of interval and baseline risk factors on the odds of detecting AA at FUV1
were similar to the effects observed in the main analysis (compare Table 59 and Table 29).
When the cohort was restricted to patients with a single colonoscopy at baseline, the CRC detection rate
at FUV1 was the same as in the main analysis, at 1.1%. The effect of interval on CRC detection at FUV1
differed somewhat in the sensitivity analysis; although some ORs differed to those estimated in the main
analysis, the trends observed were comparable (compare Table 60 and Table 30). The smaller number of
end points available in the sensitivity analysis meant that there was a greater degree of imprecision and
the results were less statistically significant than those of the main analysis.
In the sensitivity analysis of CRC risk after baseline restricted to patients with a single baseline colonoscopy
(n = 6500), 72 CRCs were diagnosed, compared with 168 CRCs in 11,944 patients in the main analysis.
The effect of a single surveillance visit remained the same, and the effect of two or more was similar;
however, because of the reduction in the number of end points, the ORs were less precise and the effect
of surveillance was only borderline significant (compare Table 61 and Table 44). Similar trends were seen
among baseline risk factors and CRC risk after baseline.
The similarity between these sensitivity analyses and the main analyses suggests that the methods used to
define and, in some cases, extend the baseline visit did not introduce bias into the data.
Patients with a complete colonoscopy at follow-up visit 1
Analyses of AA and CRC at FUV1 and CRC risk after baseline were repeated, this time restricting the cohort
to patients with a complete colonoscopy at FUV1. The detection rate of AA at FUV1 in the restricted cohort
(n= 3299) was 10.5%, which was marginally higher than the 9.8% detection rate in the full cohort. The effects
of interval and baseline risk factors on AA detection were similar to the effects observed in the main analysis,
apart from adenoma size, which was no longer statistically significant (compare Table 62 and Table 29).
When the analysis of CRC at FUV1 was carried out using only patients with a complete colonoscopy at
FUV1, the CRC detection rate was slightly lower, at 0.7%, compared with 1.1% in the main analysis.
The effect of surveillance interval was weaker and only borderline significant compared with the highly
significant effect obtained when all 4608 patients were analysed (compare Table 63 and Table 30).
In the analysis of CRC risk after baseline in patients with a complete colonoscopy at FUV1 (n = 10,685),
there were 144 CRCs diagnosed, which was only slightly less than the 168 CRCs in the full cohort.
Consequently, the effect of surveillance was almost identical in both analyses (compare Table 64 and
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Table 44). The effects of baseline risk factors on CRC risk were similar to the main analysis, except for the
effect of a large adenoma, which was slightly weaker and only borderline significant in the sensitivity analysis.
The fact that these sensitivity analyses and the main analyses demonstrated comparable effects of interval
and surveillance suggests that the inclusion of patients without a complete colonoscopy at FUV1 did not
bias the results in any way.
Redefining advanced adenoma
When the definition of AA was altered to include only adenomas of ≥ 10 mm or with HGD, 324 patients
had AA detected at FUV1 and the AA detection rate was 7.0%, compared with 415 and 9.8% when
villous or tubulovillous histology was included in the definition. The effect of interval was slightly stronger
when AA was redefined, with a trend of increasing odds of AA at FUV1 with increasing interval length as
observed in the main analysis (compare Tables 65 and 29). The associations between baseline risk factors
and AA at FUV1 were similar in both sets of analyses, except for adenoma size, which was only weakly
associated with AA at FUV1 using the restricted definition. These findings suggest that the inclusion of
villous or tubulovillous histology in the definition of AA is appropriate and did not bias our results for the
effect of interval on AA at FUV1.
Patients with specified minimum years of hospital data collected
To assess whether or not potential misclassification of surveillance attendance may have impacted on the
apparent effect of surveillance on CRC risk after baseline, sensitivity analyses were restricted to patients
TABLE 61 Cox regression model of effect of surveillance on CRC incidence after baseline, adjusting for baseline risk
factors, restricted to patients with only one colonoscopy at baseline
Baseline risk factor Category Adjusted HR (95% CI) p-value (LRT)
Number of follow-up visits after baselinea 0 1 0.0484
1 0.51 (0.27 to 0.96)
2+ 0.44 (0.18 to 1.08)
Largest adenoma (mm) < 10 1 0.0050
10–19 9.56 (1.3 to 70.3)
≥ 20 8.02 (1.05 to 61.41)
Worst adenoma dysplasia Low grade 1 0.0023
High grade 2.48 (1.44 to 4.26)
Completeness of colonoscopy Complete 1 0.0008
Incomplete/unknown 2.33 (1.44 to 3.79)
Proximal polyps No 1 0.0165
Yes 1.82 (1.13 to 2.95)
Age (years) at baseline < 55 1 0.0210
≥ 55 and < 60 1.11 (0.36 to 3.4)
≥ 60 and < 65 1.57 (0.6 to 4.09)
≥ 65 and < 70 2.35 (0.98 to 5.62)
≥ 70 and < 75 2.86 (1.17 to 7.01)
≥ 75 and < 80 3.84 (1.56 to 9.46)
≥ 80 3.37 (1.26 to 9.01)
a Number of follow-up visits was fitted as a time-dependent covariate.
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with at least 5 years (n = 4854) and at least 7 years (n = 3055) of hospital data. We were able to look only
at the effect of one or more surveillance visits compared with none because of the small numbers in the
LIR subgroup when restricting the analysis to patients with at least 7 years of hospital data.
Compared with the analysis using all patients (n = 11,944), the effect of surveillance was slightly stronger
when the cohort was restricted (Table 66). This underestimation of the effect of surveillance suggests
non-differential misclassification of surveillance attendance between patients with and without CRC,
with some contamination among patients classified as having no surveillance.
In the LIR and HIR subgroups, an underestimation of the effect of surveillance was also observed (see
Table 66). When the analysis was restricted to patients with at least 5 years of hospital data, the effect of
one or more surveillance visits was slightly underestimated in both risk subgroups. When the cohort was
restricted to patients with at least 7 years of hospital data, the effect of one or more surveillance visits was
only slightly stronger in the HIR subgroup but considerably so in the LIR subgroup, although the small
number of end points and imprecision in the latter group precluded interpretation. However, if we have
truly underestimated the effect substantially in our main analyses as a result of misclassification it may be
that surveillance is of considerable benefit in the LIR subgroup.
When pre-surveillance CRC risk was examined using sensitivity analyses restricted to patients with at least
5 years or at least 7 years of hospital data, there was evidence to suggest that pre-surveillance risk had
been underestimated in the main analyses (Table 67). Overall, patients with at least 7 years of follow-up
TABLE 64 Cox regression model of the effect of surveillance on CRC incidence after baseline, adjusting for baseline
risk factors and restricted to patients with a complete colonoscopy at the first follow-up
Baseline risk factor Category Adjusted HR (95% CI) p-value (LRT)
Number of follow-up visits after baselinea 0 1 0.0003
1 0.51 (0.32 to 0.81)
2+ 0.28 (0.12 to 0.64)
Largest adenoma (mm) < 10 1 0.0455
10–19 2.50 (1.00 to 6.27)
≥ 20 2.84 (1.11 to 7.26)
Worst adenoma dysplasia Low grade 1 0.0027
High grade 1.86 (1.26 to 2.76)
Completeness of colonoscopy Complete 1 < 0.0001
Incomplete/unknown 2.16 (1.51 to 3.08)
Proximal polyps No 1 0.0003
Yes 1.95 (1.37 to 2.77)
Age (years) at baseline < 55 1 < 0.0001
≥ 55 and < 60 0.92 (0.39 to 2.18)
≥ 60 and < 65 1.07 (0.50 to 2.28)
≥ 65 and < 70 2.41 (1.29 to 4.50)
≥ 70 and < 75 2.35 (1.23 to 4.51)
≥ 75 and < 80 3.37 (1.78 to 6.38)
≥ 80 2.93 (1.45 to 5.89)
a Number of follow-up visits was fitted as a time-dependent covariate.
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were at 54% higher risk of CRC than the general population, as opposed to the 6% higher risk
estimated previously.
The misclassification of surveillance attendance had a great effect on the SIR in the HIR group, the pre-
surveillance CRC risk of which became considerably greater than in the general population (see Table 67).
In the LIR subgroup the pre-surveillance CRC risk also appeared to have been underestimated, with the SIR
for LIR patients with at least 7 years of hospital data suggesting a 43% lower CRC incidence than in the
general population. Owing to the small number of end points the SIRs for the LIR subgroup were
imprecise, limiting interpretation.
Internal validation of models
To assess the performance of the multivariable logistic models for the outcomes of new findings at
follow-up and the multivariable Cox regression models for the analysis of long-term cancer incidence, we
performed internal validation using k-fold cross-validation with k = 10.
The 10-fold cross-validation results for the models for findings at FUV1 and FUV2 are presented in Figure 9
and Table 68. The presented results for new adenoma, AA and CRC at FUV1 and new AN at FUV2
correspond to models presented in Tables 28–30 and Table 40, respectively. For these models, the
weighted mean area under the ROC curve ranged from 64.5% to 87.5%, with greater variation seen for
the models for new CRC at FUV1 and new AN at FUV2. The predictions from the models for new CRC at
FUV1 performed the best at discriminating between patients with and without new findings, but all
models showed some ability to discriminate.
TABLE 66 Effect of surveillance on CRC risk after baseline among cohorts with differing number of hospital data
by HIR and LIR subgroups
Number of
surveillance
visits after
baselinea
Cohort
Full
With ≥ 5 years of hospital
data
With ≥ 7 years of hospital
data
Univariable HR
(95% CI)
p-value
(LRT)
Univariable HR
(95% CI)
p-value
(LRT)
Univariable HR
(95% CI)
p-value
(LRT)
Total
N= 11,944, cases= 168 N= 4854, cases= 108 N= 3055, cases= 83
0.0001 0.0003
0 1 1 1 0.0005
1+ 0.49 (0.34 to 0.70) 0.46 (0.30 to 0.70) 0.43 (0.27 to 0.69)
LIR subgroup
N= 2679, cases= 13 N= 936, cases= 7 N= 578, cases= 4
0.30 0.32
0 1 1 1 0.1228
1+ 0.51 (0.14 to 1.89) 0.45 (0.09 to 2.20) 0.18 (0.02 to 1.89)
HIR subgroup
N= 9265, cases= 155 N= 3918, cases= 101 N= 2477, cases= 79
< 0.0001 0.0002
0 1 1 1 0.0002
1+ 0.45 (0.31 to 0.66) 0.43 (0.28 to 0.67) 0.41 (0.25 to 0.67)
a Number of follow-up visits was fitted as a time-dependent covariate.
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FIGURE 9 Receiver operator characteristic curves for models of new findings at follow-up. ROC curves for each of
the 10 cross-validation sets (black) and the weighted mean of the 10 cross-validation ROC curves (green) for the
outcome of new adenoma at FUV1, with interval modelled as categorical (a) and as continuous (b); the outcome of
new AA at FUV1, with interval modelled as categorical (c) and as continuous (d); the outcome of new CRC at FUV1,
with interval modelled as categorical (e) and as continuous (f); and the outcome of new AN at FUV2, with interval
modelled as categorical (g) and as continuous (h). (continued )
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FIGURE 9 Receiver operator characteristic curves for models of new findings at follow-up. ROC curves for each of
the 10 cross-validation sets (black) and the weighted mean of the 10 cross-validation ROC curves (green) for the
outcome of new adenoma at FUV1, with interval modelled as categorical (a) and as continuous (b); the outcome of
new AA at FUV1, with interval modelled as categorical (c) and as continuous (d); the outcome of new CRC at FUV1,
with interval modelled as categorical (e) and as continuous (f); and the outcome of new AN at FUV2, with interval
modelled as categorical (g) and as continuous (h). (continued )
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The cross-validation results for the models for long-term CRC incidence are presented in Figure 10 and
Table 69. The results for incidence after baseline correspond to the model in Table 44 and results for
incidence after FUV1 correspond with the model in Table 50. The predictions from both models
demonstrated some ability to discriminate between patients who were and were not diagnosed with CRC,
with weighted mean areas under the ROC curve of 65–66%.
Discussion: hospital data set
Key findings
Does surveillance provide any benefit in terms of long-term cancer risk?
We found strong evidence that surveillance confers substantial benefit on IR patients by lowering their
future risk of CRC. Overall, the first surveillance visit appeared to offer most protection, and the benefit of
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FIGURE 9 Receiver operator characteristic curves for models of new findings at follow-up. ROC curves for each of
the 10 cross-validation sets (black) and the weighted mean of the 10 cross-validation ROC curves (green) for the
outcome of new adenoma at FUV1, with interval modelled as categorical (a) and as continuous (b); the outcome of
new AA at FUV1, with interval modelled as categorical (c) and as continuous (d); the outcome of new CRC at FUV1,
with interval modelled as categorical (e) and as continuous (f); and the outcome of new AN at FUV2, with interval
modelled as categorical (g) and as continuous (h).
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additional surveillance was not entirely clear. Having two or more surveillance visits was associated with an
increased reduction in CRC risk, but the effect in all IR patients was not significant.
Is there a group that does not require a follow-up examination or for which
a second follow-up examination might be omitted?
There appeared to be heterogeneity among IR patients in terms of long-term CRC risk and surveillance
needs. When patients were subdivided into HIR and LIR subgroups based on baseline polyp and procedural
predictors of CRC risk, the subgroups were discriminant in terms of future CRC risk. In the HIR subgroup,
one follow-up was associated with a strong protective effect against risk of CRC after baseline, and
additional surveillance provided significant further benefit compared with one follow-up alone. Before the
first surveillance visit, HIR patients were at 26% increased risk of CRC compared with general population;
after allowing for the effect of follow-up by including observation time after surveillance, the incidence
rate of CRC was reduced but was still 13% greater than in the general population, suggesting that
continued surveillance is beneficial for HIR patients.
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FIGURE 10 Receiver operator characteristic curves for models of long-term CRC incidence. ROC curves for each of
the 10 cross-validation sets (black) and the weighted mean of the 10 cross-validation ROC curves (green) for the
outcome of long-term CRC incidence after baseline (a) and after FUV1 (b).
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By comparison, the effect of surveillance in the LIR subgroup was less clear, although there was a trend
towards a reduction in CRC risk with a single follow-up, the results were not statistically significant. The
pre-surveillance (post-baseline) incidence rate of CRC was significantly lower than that of the general
population. When accounting for the effect of surveillance, there was a small reduction in the 10-year
cumulative incidence of CRC, and the LIR subgroup remained at lower risk than the general population.
Additional surveillance beyond one follow-up did not appear to provide any further reduction in risk in the
LIR subgroup.
Is a 3-year surveillance interval appropriate for intermediate-risk patients?
Findings from the hospital data set suggest that the current surveillance interval of 3 years is appropriate
for the majority of IR patients. At FUV1 the odds of detecting an AA or CRC increased significantly with
increasing interval length. CRC detection rates were < 1% before the interval extended beyond 3 years,
while AA detection rates were around 9% during this time. The proportion of patients with adenomas
remained relatively constant across intervals (30–40%), making adenomas an uninformative outcome for
specifying recommended follow-up intervals.
Based on these data we suggest that, in order to prevent delayed diagnosis of missed CRC or development
of new CRC, the first surveillance examination should be performed no later than 3 years after baseline.
In our data set, surveillance at 3 years would have been worthwhile, as there was an adequate yield of AA
but the detection rate of CRC was low. Our results do not suggest that surveillance needs to be done
earlier in most of this group of patients, as there was little increase in rates of AA in the first 3 years and a
low rate of CRC.
Similarly, at FUV2 we found no evidence to suggest that the current 3-year interval between the first
and second follow-ups is inappropriate. There was a significant increase in AN detection at FUV2 with
increasing interval length, and more than twice the odds of AN with an interval of > 3 years.
TABLE 69 Results of 10-fold cross-validation of models for long-term CRC incidence
Validation set
CRC incidence
After baseline After FUV1
Area under ROC curve Area under ROC curve
SE % SE %
1 61.8 8.3 53.6 15.2
2 62.2 6.5 78.3 6.9
3 62.5 9.0 47.5 16.4
4 60.5 6.4 60.9 10.4
5 69.2 7.0 52.2 13.0
6 66.2 7.1 65.8 18.5
7 62.4 7.4 60.4 12.1
8 61.1 8.8 78.0 9.2
9 66.6 7.3 66.6 8.3
10 76.3 7.0 43.3 12.1
Weighted mean 65.1 2.3 65.6 3.4
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Is there a group that needs a shorter interval to the first or second follow-up
examination, or for which follow-up could be postponed?
The LIR and HIR subgroups derived from models for long-term CRC risk (see Lower- and higher-
intermediate-risk subgroups, above) were discriminant when applied to findings at FUV1, but not FUV2.
The detection of AN at FUV1 increased with increasing interval length in both risk subgroups, but more
significantly so in the HIR subgroup. In the LIR subgroup, the AN detection rate was < 10% until the
interval exceeded 3 years, providing further evidence in favour of a 3-year interval. In the HIR subgroup,
the AN detection rate was 12% at 3 years, and a considerable proportion of CRCs occurred early;
however, CRC incidence was only 1% before 3 years, so any gains from a shorter interval are likely to be
small. An exception might be made for patients with incompletely removed lesions or a poor examination
at baselines in whom a repeat examination soon after baseline might be appropriate. An association
between increasing interval and AN at FUV2 was seen in the HIR subgroup but not the LIR subgroup,
possibly because of a lack of power in the latter. A 3-year interval to FUV2 appeared to be the most
appropriate for the HIR subgroup for the same reasons as for FUV1, but our data do not permit us to
deduce the interval to FUV2 in the LIR subgroup if surveillance is offered at all.
Risk factors
Older age, poor bowel preparation quality, incomplete colonoscopy, a large adenoma (≥ 20 mm) and
proximal polyps were identified as risk factors in a number of analyses of the hospital data set. Baseline
risk factors for AA at FUV1 were similar to those for CRC risk after baseline, providing evidence of the
validity of AA detection at follow-up as a short-term surrogate outcome for future risk of CRC. Risk factors
common to both analyses included older age, large adenoma size (≥ 20 mm), proximal polyps and
completeness of colonoscopy. HGD was associated with long-term CRC risk after baseline but not findings
at FUV1, whereas having a large hyperplastic polyp was a risk factor for AA at FUV1 but not for CRC after
baseline. Finding AA or CRC at FUV2, and future CRC risk after follow-up, were affected by both baseline
and FUV1 risk factors.
Some of these risk factors have been previously reported in the literature on multiple occasions;3,23,32,51
however, a lesser known risk factor is the presence of polyps in the proximal colon, which was associated
with a twofold increased risk of CRC in our cohort. An increased risk of AA at first surveillance in patients
with proximal adenomas at baseline has been noted by some authors,32,52 but, to our knowledge, no study
has identified this as a risk factor for CRC. The presence of proximal polyps may indicate a different
biological pathway, such as the serrated pathway, whereby patients may produce lesions with rapid
malignant transformation or be more likely to develop hard-to-find cancers in the proximal colon.53
Examination quality
Colonoscopy completeness and quality of bowel preparation were important predictors of CRC in our
cohort. Since the introduction of the national quality assessment tool in 2004 (UK National Endoscopy
Training Programme and the Global Endoscopy Rating Scale), there has been a substantial improvement in
colonoscopy quality, as assessed by ability to reach the caecum, and polyp detection rates, a measure of
meticulousness in examining the colonic mucosa.54,55 Furthermore, a study using data from the English
National Cancer Repository56 found a significant 27% decline in cancers diagnosed within 3 years of
colonoscopy between 2001 and 2008; such cancers are assumed to have arisen from missed or
incompletely removed lesions.
An incomplete colonoscopy might be due to a number of factors, from endoscopist performance to
patient characteristics such as older age or having prior abdominal or pelvic surgery.57,58 Risk factors for
poor bowel preparation quality include older age, overweight, diabetes and other comorbidities.59,60 In
those individuals for whom colonoscopy is difficult and therefore unsuccessful, it is probably inappropriate
to recommend repeated colonoscopic surveillance; alternative surveillance strategies need to be explored.
The NICE colonoscopy guidelines advise that a repeat examination is performed in cases of suboptimal
bowel preparation;24 however, paradoxically, this may result in reluctance on the part of an endoscopist to
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categorise bowel preparation quality as poor, particularly if the patient has been difficult to examine.
There is only weak evidence on how to salvage a procedure when bowel preparation is found to be
inadequate.61 However, the importance of achieving good bowel preparation cannot be overstated; a
systematic review62 found that adenoma detection rates were significantly higher in patients with adequate
or good-quality preparation compared with poor-quality preparation.
Strengths and limitations
A major strength of the hospital data set was the wide variation in surveillance interval length. Following
the adoption of national surveillance guidelines that prescribe set intervals,1,16,24 this feature is unlikely to
be seen in future data sets examining adenoma follow-up.
Another achievement of the investigation was the creation of a high-quality data set despite the numerous
difficulties encountered. The data used for the study were usually in a format that was not intended for
research purposes, and required extensive cleaning. Thorough data collection and meticulous data coding
enabled the ascertainment of detailed patient, procedural and polyp characteristics, the accuracy of which
was often corroborated through the use of more than one source of information, for example endoscopic
and pathological information, or multiple procedure reports. A major strength was that the raw source
data have been retained for verification of our cleaning processes.
Extensive data cleaning was used to resolve transcriptional errors in, or discrepancies between, reports.
Most data cleaning tasks were performed manually to ensure accuracy and avoid assumptions inherent to
automation. Any inconsistencies were carefully scrutinised before being corrected. To account for changes
in pathological classifications over the follow-up period, all lesions were classified using standardised,
up-to-date terminology from the EU guideline for quality assurance in CRC screening and diagnosis.63
Manual coding errors were minimised through comprehensive data consistency and validity checks, and
standardised coding procedures, ensuring data accuracy.
In terms of missing data, as a result of extensive work on recorded data, the number and size of adenomas at
baseline were complete, and only 4% of patients were missing data on histology or dysplasia. Completeness
of baseline colonoscopy was unknown in only 14% of patients, but quality of bowel preparation was missing
in 39% of patients and it is known that the reporting of the bowel preparation quality is subjective.64 The
‘unknown’ category was retained in analyses to avoid the introduction of bias, with the assumption that it
probably comprised a mixture of examinations with both suboptimal and good-quality bowel preparation.
Despite our rigorous coding and data cleaning methods, some measurement error and misclassification of
exposures and confounding factors is to be expected given the nature of the routine data used; however,
any misclassification should be non-differential and, thus, may have resulted in the underestimation of
the effect of surveillance and interval. The potential effect of misdetermination of intervals was dealt with
in the sensitivity analysis reported above (see Sensitivity analyses and internal validation). A number of
studies have highlighted the potential for polyp type, size, histology, dysplasia and number to be measured
inaccurately. Existing literature was used to estimate the potential effect of measurement error on our study
findings. In terms of measurement error of pathological attributes of adenomas, a number of sources are
available.65–69 These indicate excellent histopathological measurement of adenoma size, with interobserver
correlations among measures of the order of 0.98 and kappa values of the order of 0.85–0.90.66,67 This
would confer around a 2% bias in the estimates of logistic and Cox regression coefficients,70 and around
the same proportionate increase in size of 95% CIs – see Spiegelman et al.70 for mathematical details.
Endoscopic determination of size is likely to be more subject to error.66,68 Determination of grade of dysplasia
is generally observed to be good, with kappa values of the order of 0.6 and interobserve agreement as
high as 94%.65,67 Most studies find that determination of villous status (and further classification of villous
adenomas) is subject to a greater degree of measurement error, with kappa values of 0.40–0.60.65,67,69
However, in our sensitivity analyses, we found that this was not crucial to our results. Thus, it is likely that
measurement error of the pathological attributes of the adenomas, although not negligible, does not
significantly alter the interpretation of our results.
HOSPITAL DATA SET: RESULTS AND DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Another limitation of our study is that, although some patients were censored before the end of hospital
data collection, the majority had follow-up time after the end of data collection, during which they may
have attended surveillance visits. Patients who were aged ≥ 73 years at the end of data collection and who
had two or more follow-up visits, would not be affected in our analysis. Patients aged < 73 years with only
one or no surveillance visit, recorded at the end of data collection (≈50% of our cohort) could have an
underestimated number of surveillance visits resulting in the underestimation of the effect of surveillance
on CRC risk. This issue was addressed in sensitivity analyses restricted to patients with at least 5 years and
at least 7 years of hospital data; the sensitivity analyses suggested that, as expected, the effect of
surveillance may have been underestimated.
In addition, we may have underestimated pre-surveillance risk after baseline if some patients classified as
having no surveillance did, in fact, attend one or more follow-ups, which thus lowered their risk and
contaminated the ‘pre-surveillance’ group. This was of particular concern in the LIR subgroup, as their
pre-surveillance risk was very low compared with the general population (SIR = 0.39, 95% CI 0.18 to
0.75). When sensitivity analyses restricted to patients with at least 5 years or at least 7 years of hospital
data were undertaken, the results suggested that, although the pre-surveillance CRC risk may have been
underestimated as a result of misclassification of surveillance attendance, the LIR subgroup still appeared
to be at substantially lower risk than the general population; however, SIRs were imprecise because of the
small number of end points.
With regard to bias, we believe our methods to be relatively robust. National registries were consulted to
accurately trace almost all patients’ mortality and cancer status. Together with extensive interrogation
of follow-up data, this prevented loss to follow-up and limited the risk of selection bias and outcome
misclassification, ensuring the quality of the data set. Similarly, selection bias due to non-response was not
applicable because of the retrospective nature of the study – we extracted all available endoscopy and
pathology data on every adenoma patient who underwent an endoscopy between specific dates at all
study sites.
Exposed and unexposed groups (i.e. patients with and without follow-up, or with differing surveillance
intervals) were both drawn from the same hospital databases of patients presenting during similar time
periods, ensuring comparability. Potential selection bias could have resulted from the fact that those
who attended surveillance differed from those who did not in terms of patient, procedural and polyp
characteristics; however, the actual differences between patients with and without follow-up examinations
were generally small. The most notable differences were in age, completeness of colonoscopy, bowel
preparation and year of entry. Similarly, those with a short interval differed from those with a long interval.
As factors associated with attendance at one or more follow-up visits, or with a short interval, were also
risk factors for CRC after baseline and for AA and CRC at follow-up, then any selection bias should have
resulted in an underestimate of the effect of interval length or surveillance on CRC risk.
A complex set of rules was generated to group examinations into visits and intervals using the NHS BCSP
guideline.71 In general, most patients had a visit that consisted of a single colonoscopy, and the baseline
visit was extended beyond 11 months in only 2% of cases. With no clear surveillance recommendations or
reasons for the examination provided in the reports, this was the best available method. Some error in the
classification of interval length is to be expected; however, any misclassification is likely to be non-differential
and so should result in only-ran underestimate of the effect of interval. We undertook sensitivity analyses
using only those patients whose baseline visit comprised a single examination, or patients with a complete
colonoscopy at follow-up, and we found no noteworthy differences between these and our main analyses,
suggesting that the methods used to extend baseline and define visits and intervals were satisfactory and did
not introduce any form of bias into the data.
All a priori confounders – for example adenoma size, dysplasia and age – were adjusted for in
multivariable regression analyses in order to remove any potential confounding effects that may have
obscured the associations of interest. In general, there was no confounding or evidence of only weak
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confounding in most multivariable analyses. However, a particularly strong confounding factor was
identified when assessing the effect of interval on findings at follow-up. We found that patients at higher
risk of AN at follow-up were also more likely to have had a short interval, which appeared to be due to
recall for polypectomy site surveillance or continued treatment of a large lesion. This biased the effect
of interval, making a shorter interval appear risky and diminishing the effect of interval overall. This
confounding effect was adjusted for by removing all previously seen lesions from our analyses, as a prior
sighting was the best proxy measure that could be identified in the data available. Despite this, there is
some risk of residual confounding, which may have caused us to underestimate the effect of interval.
In cases for which only paper records were available (prior to the 1990s) a few early endoscopy
examination(s) may have been missed; however, as most baseline data fell between 2000 and 2010 (84%)
any missing data on prior examinations are likely to be negligible. We may have missed baseline or follow-up
examinations for patients who were treated at a hospital that was not included in the study. This was an
unavoidable problem inherent to the retrospective methods used, which could have resulted in the incorrect
classification of baseline, surveillance visits or risk groups. Owing to the wide geographic coverage of the
study, we believe that this is unlikely to affect many patients, if any. It should be noted that, although
follow-up examinations were assumed to be for surveillance, some may have been for symptomatic purposes.
Research using pseudo-anonymised data
A number of problems were encountered as a result of the use of pseudo-anonymised data in the hospital
data set. Our patient identifier lists, consisting of surname and forename(s), hospital number(s), NHS
number, gender, postcode and date of birth, were created from data held on endoscopy and pathology
systems. Inevitably, some of these patient identifiers were subject to data entry errors, such as spelling,
incorrect recording, spaces in the NHS numbers or transpositions errors, and not all of the patient
identifiers were available from the systems from which the data were extracted.
When carrying out patient follow-up, we found that a high percentage of our records could not be
matched by the HSCIC, as their algorithms were designed for cleaned data sets. Not having the patient
identifiers significantly limited our ability to correct the errors and complete the missing information.
Moreover, the HSCIC algorithms took very few fields into account in order to find a match which, in
around 7% of cases, resulted in either no match being found or multiple matches, which the HSCIC also
classifies as no match.
We worked closely with the HSCIC over several months to develop new algorithms to look at multiple
combinations of patient identifiers to find the match. Multiple checks were then done on the validity of
the matches in order to achieve a high match rate while avoiding compromising data integrity.
In around 2.5% of cases it was necessary to ask staff at individual hospitals to use the patient-identifiable
information they held (particularly the hospital number, which the HSCIC cannot use) to complete the
missing information on any cases that could not be matched with certainty after all of the algorithms had
been applied. The HSCIC then used the new information from the hospitals to re-match these cases. It was
very difficult to get the already overstretched hospital staff to do this work for us. Finally, where it was not
possible to find a match, the HSCIC performed manual ‘operator’ matches.
We also had to ensure that the individuals responsible for safeguarding the patient-linking-files at the
hospital were still contactable and that in the event that they moved, the information was passed to
another hospital staff member, who safeguarded the data.
The problem of following up patients to obtain information on cancers and deaths is an aspect of research
that would greatly benefit from an improved ability to use non-anonymised data, or from better access to
patient-identifiable information. For future follow-up, we would ideally like to hold all of the data collected,
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including patient identifiers, in one secure location, but current site-specific restrictions prevent the data from
being held centrally; each hospital trust has its own regulations and requires the data to be held within the
hospital environment. Currently, our latest cleaned data are held only by the HSCIC; if they were required to
un-flag our patients, it would take many months to collate, clean and match again. The re-matching of some
patients might not even be possible, as the original data collected were supplemented with information from
hospital databases, some of which were quite old and may no longer be available if the databases are
decommissioned. It is also possible that with tightening regulations, this process would not be permitted.
Carrying out detailed research using pseudo-anonymised data is extremely challenging and has not proved to
be the simple, time- and cost-saving exercise that may have been envisaged when the call for proposal using
retrospective data was originally made.
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Chapter 4 Screening data set: results and
discussion
Background
The study team had knowledge of several large data sets collected within screening studies and programmes,
which contained data on individuals who were under surveillance and were believed to have been followed
up. Seven screening data sets were originally identified for inclusion; however, four were excluded for
reasons given in Table 70, leaving only three which were deemed of sufficient size and quality for analysis:
the UK Flexible Sigmoidoscopy Screening Trial (UKFSST), the English Bowel Cancer Screening Pilot (EP) and
the Kaiser Permanente Colon Cancer Prevention Program (KP).
UK Flexible Sigmoidoscopy Screening Trial
The UKFSST aimed to examine the efficacy of a single FS screening in reducing CRC incidence and
mortality rates. The trial randomised 170,432 men and women aged between 55 and 64 years to either FS
screening or usual care, which at the time meant no CRC screening.10 A total of 40,674 participants was
screened by FS in 14 UK centres. Individuals undergoing FS screening who were found to have a large
(≥ 10 mm) lesion, three or more adenomas, villous or tubulovillous histology, severe dysplasia, malignant
disease or ≥ 20 hyperplastic polyps above the rectum were offered colonoscopy surveillance. The cohort
was followed up using records held by the ONS and cancer registries for incidence of CRC and deaths.
Follow-up data were available until 31 December 2012.
English Bowel Cancer Screening Pilot
This study was commissioned by the DH in 1999 to determine the feasibility of CRC screening using a
guaiac faecal occult blood test (gFOBT) in the UK. The pilot included two sites, one in Scotland and one in
England, and ran from 2000 to 2002.74 Men and women aged 50–69 years, registered with a NHS general
practitioner (GP), were invited to complete a gFOBT, and, by 2003, 189,319 subjects in England and
297,036 in Scotland had been invited for screening, with an uptake rate of around 60%. In the EP,
individuals who tested gFOBT positive were offered a meeting with a specialist screening practitioner at
one of three pilot centres, who assessed their fitness for colonoscopy. In total, 82% of referred participants
attended their colonoscopy. Pseudo-anonymised data on baseline and follow-up colonoscopies for those
TABLE 70 Screening data sets excluded from the study
Research data set Author Exclusion reason
Veteran Affairs Study Lieberman et al.
200072
Permission to access the data was not granted owing to concerns over
data security
Nottingham Trial of Faecal
Occult Blood Testing
Scholefield and
Moss 200273
Permission was denied for collection of data on follow-up examinations;
many of the data were available only in paper records and would have
been expensive and lengthy to retrieve
Scottish Bowel Cancer
Screening Pilot
Alexander 200374 Endoscopy and pathology data were not linked and would have had to
be linked manually. There were many repeat examinations with the
same information but varying dates, and over 1000 pathology reports
with no corresponding endoscopy report
Italian FS Screening Trial
(SCORE)
Segnan et al.
200275
In this one-off FS screening trial, 17,148 men and women were
invited and 9911 had FS screening in six centres. However, baseline
information and cancer registry information were obtained for only one
centre, which included only 194 subjects referred for colonoscopy
following screening. This data set was deemed too small for inclusion
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offered surveillance were available to 2012. Patient identifiers were sent directly to the ONS to obtain
cancer and mortality data; data were available until 30 June 2012.
Both the UKFSST and the EP had data available for the significant risk factors for AA and CRC that were
identified in the analysis of the hospital data set.
Kaiser Permanente Colon Cancer Prevention Program
The Northern California Kaiser Permanente Medical Care Program began its Colon Cancer Prevention
Program in 1994, with the aim of offering sigmoidoscopy screening to all members aged ≥ 50 years once
every 10 years.76,77 The KP data set with which we were provided comprised all participants with a baseline
sigmoidoscopy between January 1994 and December 1995 who then had a baseline colonoscopy within
6 months of sigmoidoscopy and at least 1 year of subsequent follow-up. Follow-up data on CRCs and
deaths were available up to 31 December 2006 or until the date the participant left the program, if earlier.
Methods
Rules used to derive variables for the hospital data set (see Chapter 2, Creating summary values for polyp
characteristics, Procedure information and Defining baseline and surveillance visits), including baseline and
follow-up visits, and polyp and procedural characteristics, were applied to the screening data set. The KP
data set did not contain information regarding quality of baseline colonoscopy; therefore, all subjects in
the KP cohort were assumed to have had a complete colonoscopy with good bowel preparation at
baseline. Analyses were performed with Stata/IC 13.1.
The baseline characteristics of IR subjects in the hospital and screening data sets, in the individual
screening cohorts, and in screening participants with and without follow-up, were compared. The
distribution of baseline characteristics among patients with and without follow-up visits in the screening
data set was compared using chi-squared tests.
In the analysis of long-term CRC risk after baseline, the cut-off for follow-up was the end date of follow-up
data availability in each of the individual screening cohorts. All time-to-event data were censored at first CRC
diagnosis, death, emigration, end of program participation (KP data set only) or end of follow-up. Time at risk
started from the latest most complete colonoscopy in baseline and, for the analysis of incidence following
FUV1, time at risk started on the date of the first procedure in FUV1. If CRC was diagnosed at a follow-up
visit, the follow-up visit was not included as a visit, as it did not offer any protection against CRC. ‘One minus
the Kaplan–Meier estimator of the survival function’ was used to illustrate the time to cancer diagnosis and to
estimate the cumulative risk of cancer with 95% CIs at 3, 5 and 10 years.
The effects of surveillance and baseline risk factors for CRC identified in the hospital data set on long-term
CRC incidence in the screening data set were examined. Univariable Cox proportional hazards models
were used to estimate unadjusted HRs. Independent predictors of cancer incidence identified in the
hospital data set were fitted to the screening data set using a multivariable Cox proportional hazards
model, with the number of follow-up visits included as a time-varying covariate.
Observed pys at risk were calculated by gender and 5-year age group. Expected numbers of CRC cases
were calculated by multiplying the observed gender- and age-specific number of pys by the gender- and
age-specific incidence in the general population of England in 2007. The ratio of observed to expected
cases was reported as a SIR, and 95% CIs were computed assuming an exact Poisson distribution.
Findings at FUV1 were investigated. The relationship between interval from baseline to FUV1 and new AA
and CRC at FUV1 was explored, both with and without adjustment for baseline risk factors identified in
the hospital data set. Logistic regression models were fitted to the pooled screening data set in order to
assess whether or not baseline risk factors identified in the hospital data set were predictive of advanced
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findings at first follow-up in screening populations. The predictive ability of these models for new AA and
CRC in the screening data set was assessed using receiver operating characteristic (ROC) curves.
Screening data set: comparison of results with the hospital
data set
Baseline characteristics of screening participants with intermediate-risk adenomas
In the pooled screening data set, there were 2352 subjects with IR adenomas: 796 in the UKFSST cohort,
407 in the EP cohort and 625 in the KP cohort. This compares with 11,944 in the hospital data set.
Table 71 compares the distribution of baseline demographic characteristics and risk factors for finding new
AA or new cancers at FUV1 identified from the hospital data set models in the different data sets and
cohorts. Participants in the pooled screening data set were younger: > 20% of patients in the hospital
cohort were aged > 75 years, compared with negligible numbers in all of the screening cohorts. Individuals
in the screening data set were also more likely to have had a better-quality baseline colonoscopy; this was
despite almost 80% of baseline examinations being done prior to 2000, compared with only 16% in the
hospital patients. Furthermore, the adenomas detected at baseline in the screening participants were less
likely to be large (≥ 20 mm) or have HGD.
The three screening cohorts also differed in several respects. There were differences in the age at which
screening was offered in the different cohorts: age 55–65 years in the UKFSST, age 50–69 years in the EP,
but a wider age range in the KP cohort. Thus, the UKSST participants tended to be younger than in the KP
and EP cohorts. The EP participants had their baseline between 2000 and 2010, whereas in the KP and
UKFSST cohorts almost all were between 1995 and 1999. Examination quality was slightly worse in the
UKFSST than in the EP or KP; however, data on examination quality were missing in the KP cohort, so all
participants were assumed to have had a complete colonoscopy with at least satisfactory bowel preparation
at baseline. Adenomas detected in the EP tended to be larger, and a much higher proportion had
tubulovillous histology (69.4% EP vs. 41.6% UKFSST and 31.2% KP) or HGD (20.4% EP vs. 12.7% UKFSST
and 4.3% KP).
Patients with and without surveillance
We examined the distribution of the baseline characteristics among screening participants with and
without surveillance after baseline to determine the risk of selection bias in analysis of findings at and
subsequent to follow-up visits (Table 72). Three-quarters of screening (1828) participants attended at least
one follow-up and the remaining 524 were followed using external cancer and deaths data only.
Those attending surveillance were younger, on average, than those who did not attend [mean 61.5 years
(SD 5.2) vs. mean 63.4 years (SD 7.1); p < 0.001), but there was no difference by gender or the quality of
baseline colonoscopy. Attenders were more likely to have a large adenoma (p = 0.0187), an adenoma with
tubulovillous histology (p < 0.0001) or an adenoma with HGD at baseline (p = 0.0070); however, the
proportions with proximal polyps or large (≥ 10 mm) hyperplastic polyps were similar.
Table 73 describes the number of follow-up visits in the screening and hospital data sets. Almost 80% of
screening participants had at least one follow-up examination, compared with < 40% of the hospital
patients, and 43% had at least two follow-ups, compared with only 14% of the hospital patients. The
amount of follow-up was relatively similar in the EP and UKFSST cohorts, whereas the KP cohort had a
greater proportion of participants without any follow-up (31% vs. 16–17%).
Long-term cancer risk
A survival analysis was undertaken to assess CRC incidence after baseline and after FUV1, to account for
length of follow-up time in each patient and allow investigation of the effect of surveillance on CRC risk.
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TABLE 71 Distribution of baseline demographic characteristics and risk factors for new AAs or CRC in the hospital data
set, stratified by the hospital data set, the pooled screening data set and the individual screening cohorts
Baseline risk factor
Cohort
Hospital
(N= 11,944)
Pooled
screening
(N= 2352) EP (N= 490)
UKFSST
(N= 952)
KPa
(N= 910)
n % n % n % n % n %
Age (years) at
start of baseline
< 55 2122 17.8 232 9.9 69 14.1 0 0 163 17.9
≥ 55 and < 60 1321 11.1 669 28.4 95 19.4 381 40.0 193 21.2
≥ 60 and < 65 1858 15.6 855 36.4 159 32.4 500 52.5 196 21.5
≥ 65 and < 70 2171 18.2 410 17.4 163 33.3 71 7.5 176 19.3
≥ 70 and < 75 1786 15.0 125 5.3 3 0.6 0 0 122 13.4
≥ 75 and < 80 1416 11.9 51 2.2 1 0.2 0 0 50 5.5
≥ 80 1270 10.6 10 0.4 0 0 0 0 10 1.1
Gender Male 6625 55.5 1595 67.8 327 66.7 655 68.8 613 67.4
Female 5319 44.5 757 32.2 163 33.3 297 31.2 297 32.6
Year of baseline 1980–94 439 3.7 0 0 0 0 0 0 0 0
1995–9 1430 12.0 1861 79.1 0 0 951 99.9 910 100
2000–4 4251 35.6 395 16.8 394 80.4 1 0.1 0 0
2005–10 5824 48.8 96 4.1 96 19.6 0 0 0 0
Most complete
colonoscopy
Complete 9016 75.5 2261 96.1 475 96.9 876 92.0 910 100
Incomplete/unknown 2928 24.5 91 3.9 15 3.1 76 8.0 0 0
Best bowel
preparation at
colonoscopy
Excellent/good/
satisfactory/unknown
11,273 94.4 2303 97.9 482 98.4 911 95.7 910 100
Poor 671 5.6 49 2.1 8 1.6 41 4.3 0 0
Largest
adenoma (mm)
< 10 1029 8.6 272 11.6 30 6.1 95 10.0 147 16.1
10–14 4417 37.0 1108 47.1 192 39.2 429 45.1 487 53.5
15–19 2440 20.4 512 21.8 144 29.4 210 22.1 158 17.4
≥ 20 4058 34.0 460 19.6 124 25.3 218 22.9 118 13.0
Worst adenoma
histology
Tubular 4742 39.7 1146 48.7 112 22.9 468 49.2 566 62.2
Tubulovillous 5576 46.7 1020 43.4 340 69.4 396 41.6 284 31.2
Villous 1142 9.6 153 6.5 30 6.1 63 6.6 60 6.6
Unknown 484 4.0 33 1.4 8 1.6 25 2.6 0 0
Worst adenoma
dysplasia
Low grade 9476 79.3 2071 88.1 389 79.4 811 85.2 871 95.7
High grade 1994 16.7 260 11.0 100 20.4 121 12.7 39 4.3
Unknown 474 4.0 21 0.9 1 0.2 20 2.1 0 0
Distal polyps No 1980 16.6 98 4.2 31 6.3 33 3.5 34 3.7
Yes 9964 83.4 2254 95.8 459 93.7 919 96.5 876 96.3
Proximal polyps No 7369 61.7 1682 71.5 348 71.0 709 74.5 625 68.7
Yes 4575 38.3 670 28.5 142 29.0 243 25.5 285 31.3
Largest
hyperplastic
polyp (mm)
< 10 or none 11,761 98.5 2284 97.1 484 98.8 913 95.9 887 97.5
≥ 10 183 1.5 68 2.9 6 1.2 39 4.1 23 2.5
a No information was available on the quality of examinations in the KP cohort; all patients in this cohort were assumed to
have had at least one complete colonoscopy with satisfactory or better bowel preparation during baseline.
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TABLE 72 Distribution of baseline risk factors in pooled screening data set with and without surveillance visits
Baseline risk factor
Participants with
one or more
surveillance visits
(N= 1828)
Participants with
no surveillance
visits (N= 524)
p-value
(chi-squared test)n % n %
Age (years) at start of
baseline
< 55 56 10.7 176 9.6 < 0.0001
≥ 55 and < 60 119 22.7 550 30.1
≥ 60 and < 65 163 31.1 692 37.9
≥ 65 and < 70 97 18.5 313 17.1
≥ 70 and < 75 52 9.9 73 4.0
≥ 75 and < 80 27 5.2 24 1.3
≥ 80 10 1.9 0 0
Gender Male 1232 67.4 363 69.3 0.4171
Female 596 32.6 161 30.7
Most complete
colonoscopy
Complete 1760 96.3 501 95.6 0.4836
Incomplete/unknown 68 3.7 23 4.4
Best bowel preparation
at colonoscopy
Excellent/good/satisfactory/
unknown
1788 97.8 515 98.3 0.5061
Poor 40 2.2 9 1.7
Largest adenoma (mm) < 10 201 11.0 71 13.5 0.0187
10–14 841 46.0 267 51.0
15–19 415 22.7 97 18.5
≥ 20 371 20.3 89 17.0
Worst adenoma
histology
Tubular 843 46.1 303 57.8 < 0.0001
Tubulovillous 843 46.1 177 33.8
Villous 116 6.4 37 7.1
Unknown 26 1.4 7 1.3
Worst adenoma
dysplasia
Low grade 1590 87.0 481 91.8 0.0070
High grade 222 12.1 38 7.2
Unknown 16 0.9 5 1.0
Distal polyps No 70 3.8 28 5.3 0.1262
Yes 1758 96.2 496 94.7
Proximal polyps No 1311 71.7 371 70.8 0.6821
Yes 517 28.3 153 29.2
Largest hyperplastic
polyp (mm)
< 10 or none 1778 97.3 506 96.6 0.3993
≥ 10 50 2.7 18 3.4
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TABLE 73 Distribution of the number of follow-up visits in the hospital data set, the pooled screening data set and
in the individual screening cohorts
Number of
follow-up visits
Data set Cohort
Hospital
(N= 11,944)
Pooled screening
(N= 2352) EP (N= 490)
UKFSST
(N= 952)
KP
(N= 910)
n % n % n % n % n %
None 7336 61.4 524 22.3 83 16.9 156 16.4 285 31.3
1 2973 24.9 817 34.7 158 32.2 262 27.5 397 43.6
2 1080 9.0 723 30.7 189 38.6 338 35.5 196 21.5
3 354 3.0 235 10.0 52 10.6 153 16.1 30 3.3
4 135 1.1 42 1.8 6 1.2 34 3.6 2 0.2
5 45 0.4 10 0.4 2 0.4 8 0.8 0 0
6–10 21 0.2 1 0.04 0 0 1 0.1 0 0
TABLE 74 Long-term incidence of CRC following baseline by cohort
Cohort
Follow-up time,
years: median (IQR) pys
Number
with CRC
Rate (per 100,000 pys)
(95% CI)
Adjusted HR
(95% CI)a
p-value
(LRT)
Hospital 6.0 (3.8–9.2) 81,441.7 168 206.3 (177.3 to 240.0) 1 0.0693
Screening 11.2 (9.0–14.2) 25,745.0 32 124.3 (87.9 to 175.8) 0.69 (0.46 to 1.04)
EP 9.6 (7.3–10.6) 4264.4 8 187.6 (93.8 to 375.1) n/a n/a
UKFSST 14.5 (13.8–15.1) 12,777.5 17 133.0 (82.7 to 214.0)
KP 10.9 (8.4–11.4) 8703.1 7 80.4 (38.3 to 168.7)
n/a, not applicable.
a Adjusted for age and number of follow-up visits.
The median follow-up time was greater in the screening data set than in the hospital data set (11.2 years
vs. 6.0 years). Among 2352 screening participants, 32 CRCs developed during 25,745 pys, with an overall
incidence rate of 124.3 per 100,000 pys (95% CI 87.9 to 175.8 pys); this compares with a rate of 206.3
per 100,000 in the hospital data set (Table 74). When formally compared, there was a borderline
significant, 31% lower risk of CRC in the screening data set, after adjusting for age and number of
follow-up visits (p = 0.0693). Among the screening cohorts, the EP had the highest CRC incidence,
which was not dissimilar to the hospital data set, followed by the UKFSST cohort; the KP cohort had a
considerably lower incidence rate of CRC. The Kaplan–Meier curves in Figure 11 illustrate how the risks
differ in the screening and hospital data sets (see Figure 11a) and also demonstrate how risks differ
between screening data set cohorts; notably, cancers were diagnosed in the EP cohort earlier than in the
UKFSST and KP cohorts (see Figure 11b).
Table 75 shows the crude effects of surveillance and baseline factors on incidence of CRC after baseline in
the pooled screening data set. A single surveillance examination was associated with a significant 72%
lower risk of CRC (HR 0.28, 95% CI 0.10 to 0.72).
As no procedural or polyp characteristics were predictive of CRC in the screening data set, risk factors
identified in the hospital data set (including older age, incomplete colonoscopy, poor bowel preparation,
large adenoma size, HGD, villous histology, proximal polyps and large hyperplastic polyp) were applied to
the screening data set. These factors showed a tendency towards an increased risk of CRC, although the
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results were not significant and CIs for the HRs were wide and included 1 (probably because of the small
number of CRC outcomes in the screening data set).
Cox proportional hazards regression was used to examine the effect of surveillance on CRC risk, controlling
for potential confounding factors, with number of follow-up visits modelled as a time-varying covariate
(Table 76). As no polyp or procedure factors were predictive of CRC in univariable analyses (see Table 75),
the model was fitted using the set of risk factors for CRC identified from the hospital data set (see Table 44).
The screening data set results provided further evidence of the benefit of surveillance in IR patients, with
one follow-up visit conferring a significant 73% reduction in the rate of CRC (HR 0.27, 95% CI 0.10 to
0.71), after adjusting for covariates (adjusted effect estimates were similar to the crude estimates,
suggesting little confounding).
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FIGURE 11 Kaplan–Meier estimate of cumulative incidence by data set (a) and screening cohorts (b). Effect of
surveillance on CRC risk in the screening data set.
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TABLE 75 Incidence of CRC after baseline in the pooled screening data set, according to baseline risk factors and
number of follow-up visits
Risk factor pys
Number
with CRC
Rate (per
100,000 pys)
Unadjusted HR
(95% CI)
p-value
(LRT)
Number of follow-up
visits after baselinea
0 11,198.7 18 160.7 1 0.0154
1 8848.4 6 67.8 0.28 (0.10 to 0.72)
2+ 5697.9 8 140.4 0.36 (0.13 to 0.97)
Age (years) at baseline < 55 2240.8 1 44.6 1 0.2889
≥ 55 and < 60 8009.6 7 87.4 1.44 (0.17 to 11.95)
≥ 60 and < 65 9965.0 14 140.5 2.35 (0.30 to 18.21)
≥ 65 and < 70 3907.5 8 204.7 4.14 (0.52 to 33.19)
≥ 70 and < 75 1129.9 2 177.0 2.76 (0.25 to 30.41)
≥ 75 and < 80 433.5 0 0
≥ 80 58.8 0 0
Gender Male 17,223.9 20 116.1 1 0.6062
Female 8521.1 12 140.8 1.21 (0.59 to 2.47)
Most complete
colonoscopy
Complete 24,605.5 31 126.0 1 0.5845
Incomplete/
unknown
1139.5 1 87.8 0.60 (0.08 to 4.41)
Best bowel
preparation at
colonoscopy
Excellent/good/
satisfactory/
unknown
25,164.0 32 127.2 n/a n/a
Poor 581.0 0 0
Largest baseline
adenoma, mm
< 10 2870.4 3 104.5 1 0.5979
10–19 17,721.7 20 112.9 1.05 (0.31 to 3.54)
≥ 20 5152.9 9 174.7 1.57 (0.43 to 5.82)
Worst adenoma
histology
Tubular 12,508.8 13 103.9 1 0.0747
Tubulovillous 11,113.1 13 117.0 1.15 (0.53 to 2.47)
Villous 1714.5 6 350.0 3.39 (1.29 to 8.93)
Unknown 408.7 0 0 n/a
Worst adenoma
dysplasia
Low grade 22,540.5 25 110.9 1 0.1029
High grade 2926.3 7 239.2 2.12 (0.92 to 4.91)
Unknown 278.2 0 0 n/a
Distal polyps No 1050.3 0 0 n/a n/a
Yes 24,694.7 32 129.6
Proximal polyps No 18,554.9 21 113.2 1 0.3958
Yes 7190.1 11 153.0 1.38 (0.67 to 2.86)
Largest hyperplastic
polyp (mm)
< 10 or none 25,010.4 31 123.9 1 0.9370
≥ 10 734.6 1 136.1 1.08 (0.15 to 7.95)
n/a, not applicable.
a Number of follow-up visits was fitted as a time-dependent covariate.
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None of the baseline risk factors for CRC identified in the hospital data set were significantly predictive of
CRC in the screening cohort, before or after adjustment for covariates. The ORs suggested that older age,
proximal polyps, a large adenoma, or an adenoma with HGD increased the risk of CRC; however, 95% CIs
were wide, precluding interpretation.
Lower- and higher-intermediate-risk subgroups
The screening data set was divided into LIR and HIR subgroups using the definition derived from risk
factors for CRC after baseline identified in the Cox regression model of CRC risk in the hospital data set
(see Chapter 3, Lower- and higher-intermediate-risk subgroups, and Table 44). The HIR subgroup was
defined to include participants with any of the following baseline characteristics: an adenoma of ≥ 20 mm
or with HGD, proximal polyps, no complete colonoscopy or poor bowel preparation. All other participants
were assigned to the LIR subgroup.
Table 77 compares the proportion of participants and CRC incidence in the LIR and HIR subgroups by data
set, with the HIR subgroup stratified by polyp and procedural risk factors. In the screening data set, the
HIR and LIR subgroups comprised 51% and 49% of participants, respectively. By contrast, in the hospital
cohort the LIR subgroup comprised only 22%.
In the screening data set, incidence of CRC after baseline was 36% lower in the LIR subgroup than in
the HIR subgroup but the risk subgroups were not significantly different (HR 0.64, 95% CI 0.31 to 1.32;
p = 0.22); by comparison, in the hospital data set the LIR subgroup was at significantly lower risk (HR 0.31,
95% CI 0.18 to 0.55; p < 0.0001). As results may have been affected by differences in age between the
TABLE 76 Cox regression model of the effect of surveillance on long-term CRC incidence in the pooled screening
data set, adjusted for baseline risk factors identified in the hospital data seta
Baseline risk factorsb Category Adjusted HR (95% CI) p-value (LRT)
Number of follow-up visits after baselinec 0 1.00 0.0123
1 0.27 (0.10 to 0.71)
2+ 0.33 (0.12 to 0.90)
Largest adenoma (mm) < 10 1.00 0.6826
10–19 1.11 (0.32 to 3.85)
≥ 20 1.57 (0.40 to 6.15)
Worst adenoma dysplasia Low grade 1.00 0.0900
High grade 2.26 (0.94 to 5.43)
Completeness of colonoscopy Complete 1.00 0.4519
Incomplete/unknown 0.50 (0.07 to 3.74)
Proximal polyp No 1.00 0.3793
Yes 1.41 (0.67 to 2.97)
Age (years) < 55 1.00 0.3299
≥ 55 and < 60 1.67 (0.20 to 13.88)
≥ 60 and < 65 2.64 (0.34 to 20.53)
≥ 65 and < 70 4.41 (0.55 to 35.41)
≥ 70 2.44 (0.22 to 27.00)
a A total of 2331 patients were included in the model as a result of the removal of 21 participants who were missing
information on dysplasia.
b The baseline risk factors included in this model were those identified as significant in the hospital cohort, with the
exception that hospital has been excluded.
c Number of follow-up visits was fitted as a time-dependent covariate.
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hospital and screening data sets, analyses were repeated, restricting the analysis to participants aged
55–69 years. This had little effect on the screening data set, but CRC incidence was reduced in the high-
risk subgroup of the hospital data set, from a rate of 242.8 to 204.7 per 100,000 pys. As a consequence,
differences between the higher- and lower-risk subgroups in the hospital and screening data sets became
similar (HR 0.51, 95% CI 0.24 to 1.06, and HR 0.59, 95% CI 0.28 to 1.28, respectively). These results
suggest that people in the lower-risk group are at approximately 40–50% lower risk than those in the
higher-risk group.
With regard to specific higher-risk polyp factors, approximately 50% of subjects in both the screening and
hospital data sets were classified as HIR because of polyp characteristics alone (HGD, adenoma of ≥ 20 mm
or proximal polyps at baseline). Among these subjects, the incidence rate of CRC after baseline was 201.7
and 163.6 per 100,000 pys in the hospital and screening data sets, respectively. When the HIR subgroup
was restricted to participants/patients aged 55–69 years and those with only polyp risk factors, the rate of
CRC became more similar in the hospital and screening data sets (150.1 vs. 180.6 per 100,000 pys).
The main difference between data sets, apart from age, was the proportion with a poor examination.
In the screening data set only 2.7% of all participants were classified as HIR based solely on examination
factors (an incomplete colonoscopy or poor bowel preparation), compared with 11.6% of the hospital data
set. Similarly, the proportion of participants in the screening data set who were classified as HIR owing to
both polyp and procedural factors was smaller than in the hospital data set (2.8% vs. 16.7%). Among these
subjects, the incidence rate of CRC after baseline was 124.1 and 357.6 per 100,000 pys in the screening
and hospital data sets, respectively. Restricting the analysis by age had little impact on these rates.
Effect of surveillance in the lower- and higher-intermediate-risk subgroups
The effect of surveillance in the LIR and HIR subgroups was examined, stratifying the HIR subgroup by risk
factor, and restricting the analyses by age (Table 78). In the screening data set, there was a 72% lower risk of
CRC with one follow-up visit than with no follow-up in the HIR subgroup, although the effect of surveillance
was only borderline significant (HR 0.28, 95% CI 0.09 to 0.92; overall p = 0.0508). Attendance at additional
follow-ups (two or more) did not appear to provide any further benefit. When the HIR subgroup was
restricted to participants with HIR polyp characteristics only, the effect of surveillance was very similar to the
effect in the HIR subgroup overall. Surveillance also had a comparable effect in the LIR subgroup, although
the effect estimates were imprecise and the association was non-significant (HR 0.25, 95% CI 0.05 to 1.30,
for one follow-up visit; overall p = 0.2084), probably as a result of the smaller number of CRC end points in
the LIR subgroup.
By contrast, in the hospital data set a single follow-up visit appeared to provide less of a reduction in risk in
the HIR subgroup, although the effect was considerable and highly significant (for one follow-up visit HR
0.50, 95% CI 0.34 to 0.76) and additional surveillance was associated with a further 14% reduction in
risk. Similarly, the effect of surveillance in the LIR subgroup was also smaller than in the screening data set,
but interpretation was still limited by imprecision and lack of power (p = 0.4741; HR 0.63, 95% CI 0.16 to
2.43, for one follow-up visit).
When the screening data set was restricted to participants aged 55–69 years, a single follow-up appeared
to have a greater effect in the LIR subgroup, but, again, the effect estimates were imprecise and results
were non-significant (HR 0.15, 95% CI 0.02 to 1.41). In the hospital data set restricted by age, it was
difficult to make inferences regarding the effect of surveillance in patients with HIR polyp characteristics
only or in the LIR subgroup owing to imprecision.
Absolute risk of colorectal cancer in the screening data set
The cumulative incidence of CRC after baseline, and after the first follow-up, was examined in the
screening data set, and risk of CRC was compared with that of the general population (Table 79). A total
of 1816 participants with at least one follow-up, and who remained free of CRC at FUV1, were used for
the analysis of CRC incidence after FUV1. If CRC was diagnosed at a follow-up visit, the follow-up visit was
not included as a visit, as it did not offer any protection against CRC.
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TABLE 78 Effect of surveillance by data set in LIR and HIR subgroups
Cohort n %
Effect of surveillance
Number of
follow-up visits
after baselinea
Unadjusted HR
(95% CI)
p-value
(LRT)
Hospital
(N = 11,944)
Higher-risk subgroupb 9265 77.6 0 1 0.0001
1 0.50 (0.34 to 0.76)
2+ 0.36 (0.20 to 0.62)
Lower-risk subgroup 2679 22.4 0 1 0.4741
1 0.62 (0.16 to 2.43)
2+ 0.29 (0.03 to 2.82)
Higher-risk subgroup classifications
Polyp factors onlyc 5874 49.2 0 1 0.0078
1 0.79 (0.46 to 1.36)
2+ 0.26 (0.10 to 0.66)
Poor examination
onlyd
1391 11.6 0 1 0.3943
1 0.51 (0.18 to 1.41)
2+ 0.82 (0.25 to 2.67)
Polyp factors and
poor examinatione
2000 16.7 0 1 0.0001
1 0.21 (0.09 to 0.49)
2+ 0.28 (0.11 to 0.67)
Screening
(N = 2352)
Higher-risk subgroupb 1200 51.0 0 1 0.0508
1 0.28 (0.09 to 0.92)
2+ 0.30 (0.09 to 1.01)
Lower-risk subgroup 1152 49.0 0 1 0.2084
1 0.25 (0.05 to 1.30)
2+ 0.46 (0.09 to 2.46)
Higher-risk subgroup classifications
Polyp factors onlyc 1071 45.5 0 1 0.0647
1 0.30 (0.09 to 0.98)
2+ 0.30 (0.09 to 1.02)
Restricted to age 55–69 years
Hospital
(N = 5350)
Higher-risk subgroupb 4127 77.1 0 1 0.1186
1 0.58 (0.30 to 1.10)
2+ 0.48 (0.21 to 1.07)
Lower-risk subgroup 1223 22.9 0 1 0.914
1+ 0.92 (0.19 to 4.39)
Higher-risk subgroup classifications
Polyp factors onlyc 2725 50.9 0 1 0.1769
1 1.22 (0.49 to 3.01)
2+ 0.36 (0.08 to 1.57)
continued
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TABLE 78 Effect of surveillance by data set in LIR and HIR subgroups (continued )
Cohort n %
Effect of surveillance
Number of
follow-up visits
after baselinea
Unadjusted HR
(95% CI)
p-value
(LRT)
Screening
(N = 1934)
Higher-risk subgroupb 1017 52.6 0 1 0.0743
1 0.29 (0.09 to 0.97)
2+ 0.32 (0.09 to 1.12)
Lower-risk subgroup 917 47.4 0 1 0.1571
1 0.15 (0.02 to 1.41)
2+ 0.53 (0.08 to 3.28)
Higher-risk subgroup classifications
Polyp factors onlyc 893 46.2 0 1 0.0943
1 0.31 (0.09 to 1.05)
2+ 0.32 (0.09 to 1.12)
a Number of follow-up visits was fitted as a time-dependent covariate.
b Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm or proximal polyps
at baseline.
c Patients who at baseline have any of HGD, adenoma ≥ 20mm or proximal polyps, but do not have incomplete
colonoscopy or poor bowel preparation.
d Patients who at baseline have either incomplete colonoscopy or poor bowel preparation, but do not have any of HGD,
adenoma ≥ 20mm or proximal polyps.
e Patients who at baseline have either incomplete colonoscopy or poor bowel preparation, and also have any of HGD,
adenoma ≥ 20mm or proximal polyps.
TABLE 79 Colorectal cancer risk after baseline in the absence of surveillance by data set, overall and in HIR and LIR
subgroups, and SIRs for CRCa
Cohort
Number of
patients pys
CRC
Cumulative incidence, %
(95% CI) at: Number of
observed
cases
Number of
expected
cases
SIRb
(95% CI)3 years 5 years 10 years
Hospital Total 11,944 48,891.7 0.5 (0.4
to 0.7)
1.1 (0.9
to 1.4)
2.9 (2.2
to 3.9)
108 102 1.06 (0.87
to 1.28)
Lower-risk
subgroup
2679 12,021.0 0.1 (0.03
to 0.4)
0.4 (0.2
to 1.0)
1.0 (0.4
to 2.4)
9 23 0.39 (0.18
to 0.75)
Higher-risk
subgroupc
9265 36,870.7 0.7 (0.5
to 0.9)
1.3 (1.0
to 1.7)
3.6 (2.6
to 4.8)
99 79 1.26 (1.02
to 1.53)
Screening Total 2352 11,198.7 0.3 (0.1
to 0.7)
0.6 (0.3
to 1.2)
1.9 (1.0
to 3.5)
18 20 0.90 (0.53
to 1.42)
Lower-risk
subgroup
1152 5890.9 0.2 (0.05
to 0.8)
0.5 (0.2
to 1.3)
1.1 (0.4
to 2.6)
7 10 0.67 (0.27
to 1.38)
Higher-risk
subgroupc
1200 5307.8 0.4 (0.1
to 1.1)
0.8 (0.3
to 2.0)
2.7 (1.2
to 6.3)
11 10 1.15 (0.57
to 2.06)
a All observation time free of surveillance in all subjects was included in this analysis (data were censored at FUV1 in
subjects with at least one follow-up visit).
b Expected CRCs were calculated by multiplying the gender- and age-specific observed pys by the gender- and age-specific
incidence rates in the general population of England in 2007.
c Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm or proximal polyps
at baseline.
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Absolute risk of CRC in the screening and hospital data sets, in the absence of surveillance, was assessed
by censoring at FUV1 (see Table 79). In the screening data set, the cumulative incidence of CRC at 10 years
was 1.9% overall, and 1.1% and 2.7%, respectively, in LIR and HIR subgroups. In the hospital data set,
equivalent rates were 2.9%, 1.0% and 3.6%, respectively, so slightly higher than in the screening data set.
Age- and gender-standardised incidence rates in the absence of surveillance were 0.90, 0.67 and 1.15,
overall and in the HIR, and LIR groups, respectively, in the screening data set. Equivalent figures for the
hospital data set were 1.06, 0.39 and 1.26, respectively. Thus, there were small differences between the LIRs
in the screening and hospital data sets.
Using all observation time, risk of CRC was determined allowing for the effect of surveillance in those
who attended (Table 80); comparisons between the hospital and screening data sets must be interpreted
with caution because of the greater number of follow-up visits in the screening data set. Compared with
pre-surveillance risk, the cumulative incidence of CRC at 10 years was reduced to 0.9%, and incidence
was significantly lower in the screening data set than in the general population (SIR = 0.61, 95% CI 0.41
to 0.85). The 10-year cumulative incidence of CRC in the LIR subgroup was 0.8%, compared with 1.1%
in the HIR subgroup. Incidence in the LIR subgroup was reduced to around 50% of that of the general
population level, and was 26% lower in the HIR subgroup, although not significantly so (the 95% CI
included 1). In comparison with the screening data set, CRC risk in the HIR subgroup of the hospital data
set remained above the general population level despite allowing for the effect of surveillance (with the
caveat that less surveillance occurred in the hospital data set), whereas risk in the LIR subgroup was slightly
lower than that of the screening data set.
Patients attending follow-up visits
In the screening data set, 1828 participants attended one or more follow-up visits. The effect of interval,
and baseline factors on the detection of AA or CRC at FUV1 was examined using univariable and
multivariable analyses.
The number of follow-ups and intervals to successive follow-ups were examined (Table 81). Overall, the
proportion with an interval between 3 and 4 years remained relatively constant, varying between 45% and
60% to different follow-ups, and showing no trend with increasing follow-up visit number.
TABLE 80 Colorectal cancer risk after baseline including all follow-up, overall and in HIR and LIR subgroups in the
pooled screening data set, and SIRs for CRC
Cohort N pys
CRC
Cumulative incidence, %
(95% CI), at Number of
observed
cases
Number of
expected
cases
SIRa
(95% CI)3 years 5 years 10 years
Hospital Total 11,944 81,441.7 0.5 (0.3
to 0.6)
0.9 (0.7
to 1.1)
2.1 (1.7
to 2.5)
168 172 0.98 (0.84
to 1.14)
Lower-risk
subgroup
2679 17,614.8 0.1 (0 to
0.4)
0.4 (0.2
to 0.8)
0.6 (0.3
to 1.2)
13 34 0.38 (0.20
to 0.65)
Higher-risk
subgroupb
9265 63,826.9 0.6 (0.4
to 0.7)
1.0 (0.8
to 1.3)
2.4 (2.0
to 2.9)
155 138 1.13 (0.96
to 1.32)
Screening Total 2352 25,745.0 0.2 (0.09
to 0.5)
0.6 (0.3
to 1.0)
0.9 (0.6
to 1.5)
32 53 0.61 (0.41
to 0.85)
Lower-risk
subgroup
1152 12,555.0 0.2 (0.04
to 0.7)
0.4 (0.1
to 1.0)
0.8 (0.4
to 1.5)
12 26 0.47 (0.24
to 0.81)
Higher-risk
subgroupb
1200 13,190.0 0.3 (0.08
to 0.8)
0.8 (0.4
to 1.5)
1.1 (0.6
to 2.0)
20 27 0.74 (0.45
to 1.14)
a Expected CRCs were calculated by multiplying the gender- and age-specific observed pys by the gender- and age-specific
incidence rates in the general population of England in 2007.
b Patients with any of incomplete colonoscopy, poor bowel preparation, HGD, adenoma ≥ 20mm or proximal polyps
at baseline.
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The interval to first follow-up varied considerably between the individual screening cohorts (Table 82).
The KP cohort tended to have a longer interval, with most participants (29.9%) returning at 5 years. By
contrast, most UKFSST and EP participants had an interval of 3–4 years (59% and 54%), and a greater
proportion returned in < 18 months than in the KP cohort.
Findings at the first follow-up
In the analysis of findings at follow-up in the hospital data set, we found that the association between
interval and findings was being masked by the effect of polypectomy site surveillance. Patients undergoing
polypectomy site surveillance were more likely to have the same lesion seen again at FUV1 and were also
more likely to return sooner for their first follow-up. To adjust for this confounding effect, all findings at
FUV1 that had been previously seen were removed from the analysis in the hospital data set. We examined
findings at FUV1 in the screening data set stratified by whether or not they had been seen previously. No
previously seen cancers were detected at FUV1 so we restricted analysis to AA to determine whether or
TABLE 81 Number of follow-up visits and intervals to visits for the pooled screening data set
Follow-up
visit no.
Number (%) of patients with varying interval lengthsa
< 18
months 2 yearsb 3 yearsb 4 yearsb 5 yearsb 6 yearsb
≥ 6.5
years Total
1 304 (16.63) 132
(7.22)
530
(28.99)
367
(20.08)
276
(15.10)
90
(4.92)
129 (7.06) 1828
(100)
2 64 (6.34) 93 (9.22) 375
(37.17)
231
(22.89)
149
(14.77)
64
(6.34)
33 (3.27) 1009
(100)
3 32 (11.15) 25 (8.71) 130
(45.30)
37 (12.89) 41 (14.29) 17
(5.92)
5 (1.74) 287 (100)
4 7 (13.46) 10
(19.23)
19 (36.54) 6 (11.54) 6 (11.54) 2 (3.85) 2 (3.85) 52 (100)
5 2 (18.18) 1 (9.09) 3 (27.27) 2 (18.18) 3 (27.27) 0 (0) 0 (0) 11 (100)
6 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 21 (100)
a The interval to visit number 1 is the interval between baseline and first follow-up, the interval to visit number 2 is the
interval between FUV1 and FUV2, and so on.
b Interval ± 6 months.
TABLE 82 Distribution of interval between baseline and first follow-up in the pooled screening data set and
individual screening cohorts
Interval baseline to first follow-up
Pooled screening
data set (N= 1828)
Cohort
EP (N= 407) UKFSST (N= 796) KP (N= 625)
n % n % n % n %
< 18 months 304 16.6 80 19.7 217 27.3 7 1.1
2 yearsa 132 7.2 41 10.1 60 7.5 31 5.0
3 yearsa 530 29.0 145 35.6 267 33.5 118 18.9
4 yearsa 367 20.1 75 18.4 208 26.1 84 13.4
5 yearsa 276 15.1 51 12.5 38 4.8 187 29.9
6 yearsa 90 4.9 8 2.0 3 0.4 79 12.6
≥ 6.5 years 129 7.1 7 1.7 3 0.4 119 19.0
a Interval ± 6 months.
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not patients with a short interval were more likely to have a previously seen lesion (Table 83). Very few
participants had only a previously seen AA detected at FUV1 (0.7%), but the proportion of patients with a
previously seen AA was greater among those with a shorter interval. Consequently, all analyses of findings
at FUV1 in the screening data set considered only new outcomes.
The detection of new AA and CRC at FUV1 in the hospital and screening data sets, and individual
screening cohorts, was compared (Table 84). A new AA was detected at FUV1 in only 4.2% compared
with 9.8% in the screening and hospital data sets, respectively (p < 0.0001). The proportion with new CRC
was slightly lower in the screening data set than in the hospital data set (0.7% vs. 1.1%; p = 0.0852).
The incidence of new AA and CRC at FUV1 was examined in the LIR and HIR subgroups, as defined using
risk factors for long-term CRC identified in the hospital data set (Table 85). In the hospital data set, the
odds of both new AA and CRC were significantly lower in the LIR subgroup compared with the HIR
subgroup. Results were similar when the analysis was restricted by age. Thus, in the hospital data set the
risk factors identified for longer-term CRC after baseline were predictive of findings at first follow-up. In
the screening data set, however, the risk factors for long-term CRC risk were not predictive, either overall
or in the age-restricted group.
Effect of interval on findings at follow-up
Table 86 shows the crude effect of interval to FUV1 in the screening data set on the detection of new
AA or CRC at FUV1. No associations were found, and the proportion with new AA remained relatively
constant with intervals of < 18 months to 6 years, ranging from 3.3% to 4.7%. Very few CRCs were
TABLE 83 Advanced adenoma status at first follow-up by interval from baseline to first follow-up in the pooled
screening data set
AA status
Interval from baseline to first follow-up, n (%)
Total,
n (%)< 18 months 2 yearsa 3 yearsa 4 yearsa 5 yearsa 6 yearsa ≥ 6.5 years
None 287 (94.4) 123 (93.2) 503 (94.9) 351 (95.6) 262 (94.9) 87 (96.7) 126 (97.7) 1739 (95.1)
Previously seen
only
3 (1.0) 3 (2.3) 4 (0.7) 2 (0.5) 1 (0.4) 0 (0) 0 (0) 13 (0.7)
Previously seen
and new
1 (0.3) 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 2 (0.1)
New only 13 (4.3) 6 (4.5) 22 (4.2) 14 (3.8) 13 (4.7) 3 (3.3) 3 (2.3) 74 (4.0)
Total 304 (100) 132 (100) 530 (100) 367 (100) 276 (100) 90 (100) 129 (100) 1828 (100)
a Interval ± 6 months.
TABLE 84 New advanced findings at FUV1 in the hospital data set, pooled screening data set and the individual
screening cohorts
New findings at
first follow-up
Data set
p-value
(chi-squared test)
Cohort
Hospital
(N= 4608)
Pooled screening
(N= 1828)
EP
(N= 407)
UKFSST
(N= 796)
KP
(N= 625)
n % n % n % n % n %
AA 451 9.8 76 4.2 < 0.0001 26 6.4 37 4.6 13 2.1
CRC 52 1.1 12 0.7 0.0852 4 1.0 3 0.4 5 0.8
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detected and they were irregularly distributed, varying from 0.3% to 1.1% across intervals of between
2 and 6 years.
We also investigated the crude associations of baseline characteristics with findings at FUV1 in order to
identify risk factors for new AA and CRC and to assess potential confounders of the association between
interval and outcomes in the screening data set (Table 87). Detection of a large adenoma at baseline
was significantly associated with increased odds of AA at FUV1 (p = 0.0278); although estimates were
imprecise, a ≥ 20 mm adenoma was associated with an almost threefold increase (OR 2.83, 95% CI 1.07
to 7.52). No other risk factor was significant for either AA or CRC, although there was a tendency towards
greater odds of AA with an incomplete colonoscopy, poor bowel preparation, an adenoma with villous
histology, or a large hyperplastic polyp, and increased odds of CRC with older age, female gender, an
incomplete colonoscopy or the detection of an adenoma with HGD at baseline. The number of outcomes
in these analyses was too small to enable meaningful associations to be assessed.
Logistic regression was performed using the same set of predictors identified in the models of findings
at FUV1 in the hospital data set in order to compare the estimated coefficients from the screening and
hospital models (Table 88). The same variables were used, as almost nothing was predictive in the screening
data set. The hospital model for AA included continuous interval, proximal polyps, age, completeness of
colonoscopy, largest adenoma size (< 20 mm, ≥ 20 mm) and large hyperplastic polyps (see Table 29).
The model for new CRC included the same factors except for adenoma size and large hyperplastic polyps
(see Table 30), and also included quality of bowel preparation. Owing to the narrower range of ages in
the screening data set, 24 subjects aged > 75 years were removed from the model, as no events occurred.
Among the subjects included in the model for new CRC, no cancer occurred in those whose best
colonoscopy bowel preparation was poor; thus, this predictor was not included in the model, as it would
predict the outcome perfectly. There was no effect of interval on the odds of new AA or CRC, after
adjusting for covariates, and none of the independent risk factors for findings at FUV1 identified in the
hospital data set was predictive of findings at FUV1 in the screening data set.
The ROC curves for the above models were plotted. For new AA, the area under the curve was 0.60
(95% CI 0.53 to 0.67); thus, the variables in the model were somewhat predictive of new AA at first
follow-up in the screening data set (Figure 12). For new CRC, the area under the curve was 0.71
(95% CI 0.56 to 0.86), which demonstrated that interval length, examination quality and older age
were fair predictors of CRC at first follow-up in the screening data set (Figure 13).
Discussion: screening data set
Key findings
Is a 3-year interval appropriate? Is there a group that needs a shorter interval
to the first or second follow-up examination, or for which follow-up could
be postponed?
In the screening data set, there was no association between interval and AA or CRC detection at FUV1,
before or after adjustment for covariates, possibly due to the lack of variation in interval length. Thus
evidence from the screening data set was uninformative in terms of appropriateness of the 3-year interval
for IR patients.
In screening programmes, interval length tends to be prescribed, so any variation in interval length in our
screening data set tended to be between, rather than within, cohorts; for example, the KP cohort tended
to have a longer interval, of around 5 years, and also had a considerably lower rate of CRC, whereas in the
EP and UKFSST cohorts a shorter interval of around 3 years was more common and there were higher
rates of CRC, thus cancelling out any potential effects of interval when the cohorts were pooled. Similarly,
HIR and LIR subgroups derived from the hospital data set were not discriminant when applied to findings
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TABLE 88 Logistic regression of new advanced findings at FUV1 and interval to first follow-up in the pooled
screening cohort, adjusted for baseline factors identified in the hospital cohort
Risk factora
New findings at FUV1
AA CRC
Adjusted OR
(95% CI)
p-value
(LRT)
Adjusted OR
(95% CI)
p-value
(LRT)
Interval from baseline to
first follow-up
1-year increase 0.98 (0.86 to 1.12) 0.8192 1.12 (0.84 to 1.48) 0.4635
Proximal polyps at baseline No 1 0.9978 1 0.8482
Yes 1.00 (0.60 to 1.68) 0.88 (0.23 to 3.30)
Age (years) at start of
baseline
< 60 1 0.644 1 0.1581
≥ 60 and < 65 1.20 (0.72 to 2.01) 2.14 (0.39 to 11.83)
≥ 65 and < 70 0.91 (0.45 to 1.85) 4.64 (0.84 to 25.53)
≥ 70 0.58 (0.13 to 2.48) 7.23 (0.98 to 53.52)
Completeness of baseline
colonoscopy
Complete 1 0.6132 1 0.3779
Incomplete/unknown 1.32 (0.46 to 3.80) 2.95 (0.36 to 24.19)
Largest baseline adenoma
(mm)
< 20 1 0.0173 n/a
≥ 20 1.90 (1.14 to 3.18)
Large hyperplastic polyp at
baseline
No 1 0.0819 n/a
Yes 2.63 (0.98 to 7.01)
n/a, not applicable.
a The baseline risk factors included in these models were those identified as significant in the corresponding models for
new AA and new CRC at first follow-up in the hospital cohort, with the exception that hospital has been excluded from
both models and best bowel preparation has been excluded from the model for CRC as no events occurred in patients
with poor preparation.
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FIGURE 12 Receiver operating characteristic curve from logistic regression model of the application to the screening
data set of the hospital data set risk factors for new AA at the first follow-up. Area under ROC curve= 0.6013.
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at FUV1 in the screening data set. We were therefore unable to validate our findings regarding the
optimum interval inferred from the hospital data set using the screening data set.
When the risk subgroups were applied to findings at first follow-up in the screening data set there were
slightly lower odds of new AA in the LIR subgroup, but higher odds of new CRC, further reflecting the fact
that the screening data set did not validate the hospital data set in terms of findings at follow-up.
Does surveillance provide any benefit in terms of long-term cancer risk? Is there
a group that does not require a follow-up examination or for which a second
follow-up examination might be omitted?
Results from the screening data set validated findings of a protective effect of a single surveillance visit in
the hospital data set, with a significant 73% lower risk of CRC observed after one follow-up. Additional
surveillance did not appear to provide any further protection, possibly because the screening participants
were already at lower risk as a consequence of their younger age and better-quality examinations.
Although pre-surveillance CRC incidence in the screening data set was not significantly different from that
of the general population, when observation time after surveillance was included in survival analyses the
CRC incidence became significantly lower than the general population rate, providing further evidence that
surveillance is effective in reducing cancer risk.
When the risk subgroups defined using CRC risk factors derived from the hospital data set were applied to
the screening data set, the subgroups did not differ significantly. The absence of a significant difference
between the risk subgroups in the screening data set may be a result of the small number of outcomes,
and this lack of power prohibited conclusions regarding the effect of surveillance in the LIR subgroup from
being drawn; although there was a trend towards a reduction in CRC risk with a single follow-up in the
LIR subgroup, the results were not statistically significant. In the HIR subgroup a single surveillance had a
strong protective effect, as in the whole screening cohort, and additional surveillance did not seem to offer
further protection.
To account for differences in age between the hospital and screening cohorts, some analyses were
restricted to patients aged 55–69 years. This did not have an impact on the risk of CRC in the HIR
subgroup compared with the LIR subgroup in the screening data set, which remained non-significantly
different, nor did it change the effect of surveillance in the risk subgroups. Restriction by age, however, did
cause the rate of CRC in the LIR subgroup to become very similar between the hospital and screening data
sets, which was surprising, as the overall rate of CRC was higher in the hospital data set. Furthermore, in
patients aged 55–69 years who were defined as HIR only because of polyp risk factors, the rate of CRC
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FIGURE 13 Receiver operating characteristic curve from logistic regression model of the application to the screening
data set of the hospital data set risk factors for new CRC at the first follow-up. Area under ROC curve= 0.7117.
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was similar in both the hospital and screening data sets, suggesting that the polyp risk factors for CRC
identified from the hospital data set are discriminant and relevant when applied to a screening population.
Risk factors
No baseline procedural or patient characteristics were independent predictors of AA or CRC at follow-up
or of long-term CRC risk in the screening data set. Consequently, models were built using risk factors
identified in the hospital data set.
Strengths and limitations
A major limitation of the screening data set was the lack of variation in interval length, which meant that
no effect of interval was observed and no conclusions could be drawn from the screening data set
regarding the optimum surveillance interval for patients with IR adenomas. Another limitation was the
small number of CRC end points in the screening data set, which meant that the LIR and HIR subgroups
were not significantly different in terms of CRC risk and were not discriminant in terms of findings at
follow-up.
Although the data were mostly complete, assumptions had to be made for the KP cohort about
examination quality owing to a lack of such data. This may have resulted in misclassification of bowel
preparation and completeness of colonoscopy, but, as all patients were assumed to have both satisfactory
preparation and a complete examination, any misclassification should be non-differential.
A strength of the screening data set was that follow-up time was substantially longer than in the hospital
data set, which is preferable for survival analysis, although the number of cancers diagnosed was small.
Additionally, despite the limitations and major differences in patient characteristics between the screening
and hospital data sets, the screening data set validated our finding from the hospital data set of the
protective effect of surveillance in IR patients. Additionally, results from the screening data set supported
hospital data set results, which indicated that most protection comes from the first follow-up and that the
LIR subgroup may not require surveillance.
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Chapter 5 Health-economic evaluation of
alternative surveillance strategies for patients in
whom intermediate-grade adenomas have
been detected
Introduction
This chapter details the methods and results of a model-based health-economic evaluation of alternative
strategies for the surveillance of individuals in whom intermediate-grade adenomas have been detected.
The chapter is set out in the following sections:
l Economic analysis scope sets out the scope of the health-economic analysis.
l Conceptual and implemented model structure details the conceptual logic and structure of the
health-economic model.
l Evidence used to inform the model parameters details the evidence used to inform the model’s
input parameters.
l Model evaluation methods details the model evaluation methods.
l Model verification and validation methods details the methods used to ensure the credibility of the
health-economic model.
l Health-economic results presents the results of the analysis.
The discussion and conclusions of the analysis then follow at the end of the chapter.
Economic analysis scope
The main research question addressed by the economic evaluation is ‘what is the optimal strategy for the
surveillance of individuals in whom intermediate-grade adenomas have been detected?’. The scope of the
health-economic analysis is summarised in Table 89.
The population included in the health-economic analysis relates to individuals in whom intermediate-grade
adenomatous polyps have been detected. Thirteen alternative surveillance strategies were evaluated using
the model; these options were formulated through discussion among the research team, taking into
account a range of alternative surveillance intervals and the presence/absence of a cut-off for eligibility
based on patient age. The options evaluated are 3-yearly, 5-yearly and 10-yearly colonoscopic surveillance
with/without a maximum age cut-off of age 75 years (options S1–6), once-only colonoscopic surveillance
with/without a maximum age cut-off age of 75 years (options S7–12) and no surveillance following the
baseline visit (option S13). The economic evaluation takes the form of a cost–utility analysis whereby
the primary health-economic outcome is defined in terms of the incremental cost per quality-adjusted
life-year (QALY) gained. Costs and health outcomes are evaluated from the perspective of the NHS and
Personal Social Services (PSS) over the patients’ remaining lifetime. In line with current recommendations,78
all costs and health outcomes are discounted at a rate of 3.5% per year. All costs were valued at
2012–13 prices.
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Conceptual and implemented model structure
Conceptual model
Figures 14 and 15 present problem-orientated conceptual models79 of the natural history of CRC and
pathways for adenoma surveillance, respectively. These conceptual models form the basis of the
implemented health-economic model described below (see Implemented health-economic model structure
and assumptions).
It is widely accepted that the majority of CRCs follow the adenoma–carcinoma sequence whereby
malignant neoplasia develops from pre-existing pre-malignant adenomatous polyps within the bowel
(see Figure 14). There is indirect evidence to suggest that a smaller proportion of cancers may arise de
novo, although there has historically been both controversy and uncertainty surrounding these competing
theories of disease natural history.80 The development CRC is associated with a reduction in health-related
quality of life (HRQoL) and survival.
On detection of the initial adenomatous polyp(s) at the baseline visit (see Figure 15), either as a consequence
of follow-up of a positive colorectal screening test or through opportunistic examination, the identified
adenoma(s) would be removed, most likely via polypectomy (although surgery may be required in a small
proportion of cases). Patients would subsequently be considered adenoma free, although it is possible that
other lesions (adenomas and/or cancer) had been previously missed at the baseline visit. While undergoing
adenoma surveillance, patients would no longer be invited to attend CRC screening. Patients may
subsequently develop further adenomatous polyps and CRC. Depending on the surveillance schedule
adopted, further colonoscopic examination and intervention may interrupt this natural history process.
TABLE 89 Economic analysis scope
Population Patients in whom intermediate-grade adenomas have been detected
Interventions and comparators S1. 3-yearly colonoscopy, maximum surveillance age= 75 years
S2. 5-yearly colonoscopy, maximum surveillance age= 75 years
S3. 10-yearly colonoscopy, maximum surveillance age= 75 years
S4. 3-yearly colonoscopy, no maximum surveillance age
S5. 5-yearly colonoscopy, no maximum surveillance age
S6. 10-yearly colonoscopy, no maximum surveillance age
S7. Once-only colonoscopy 3 years post baseline, maximum surveillance age= 75 years
S8. Once-only colonoscopy 5 years post baseline, maximum surveillance age= 75 years
S9. Once-only colonoscopy 10 years post baseline, maximum surveillance age = 75 years
S10. Once-only colonoscopy 3 years post baseline, no maximum surveillance age
S11. Once-only colonoscopy 5 years post baseline, no maximum surveillance age
S12. Once-only colonoscopy 10 years post baseline, no maximum surveillance age
S13. No colonoscopy
Outcome Incremental cost per QALY gained
Time horizon Patients’ remaining lifetime
Perspective NHS and PSS
Discount rate 3.5% per year
Price year 2012–13
PSS, Personal Social Services; QALY, quality-adjusted life-year.
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Subsequent adenomas identified at colonoscopic surveillance would be removed, thereby reducing the risk
of CRC.10 Given the imperfect test sensitivity of colonoscopy,81–83 a proportion of adenomas present in the
bowel may be missed. The identification of preclinical (undiagnosed) CRC at colonoscopy surveillance would
lead to the patient being referred for further investigations and treatment; again, a proportion of previously
undetected cancers may be missed as a result of imperfect test sensitivity. Colonoscopy is associated with a
number of relatively infrequent complications including lower gastrointestinal bleeding and perforation.
Bleeding is most likely to be managed conservatively, necessitating an overnight stay in hospital. Perforation
may be managed conservatively or in some cases may require more immediate surgical intervention.84 In a
small proportion of cases, bowel perforation may be fatal. The diagnosis and subsequent treatment of CRC
may lead to improvements in survival and HRQoL; the management of the disease and the outlook for
patients is strongly influenced by stage at diagnosis.
Implemented health-economic model structure and assumptions
The health-economic model was implemented as a next-event patient-level simulation using SIMUL8®
software (SIMUL8 Corporation, Boston, MA, USA). Figures 16 and 17 present the implemented simulation
model structure and logic. The model comprises five mutually exclusive health states: (1) no adenomas;
(2) adenomas; (3) preclinical CRC; (4) diagnosed CRC; and (5) dead. The structure of the health-economic
model was defined in line with that of the multistate model (MSM) analysis (see Baseline model of natural
history progression and colonoscopy test characteristics, below), which, in turn, was defined according to the
patients’ true underlying histology and colonoscopy test characteristics. Differential prognoses by adenoma
type and cancer stage are not captured within the model. Health states are defined according to the index
lesion (i.e. the most AA or cancer present within the patient’s bowel). Disease natural history is assumed to
follow the adenoma–carcinoma sequence, as illustrated in Figure 14. The model does not allow for the
development of de novo cancers without patients first developing one or more prior adenomas.
The model simulates the experience of patients from the identification and removal of the index adenoma(s)
at the baseline visit through to the development of further adenomas and CRC, and the impact of alternative
colonoscopic surveillance options on this natural history process, as described above (see Conceptual model).
Patients enter the model following the detection and removal of intermediate-grade adenomatous polyps at
their baseline colonoscopy visit. Patient-level characteristics (age, life expectancy, time to disease progression,
time to next surveillance colonoscopy) are then sampled and assigned to each patient. Four competing
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Development of adenoma(s)
Malignant onset
Diagnosis of clinical cancer
Death due to CRC
Normal epithelium
(no adenomas, no cancer)
Adenomatous polyp(s)
Preclinical CRC
Clinical CRC
Dead
FIGURE 14 Colorectal cancer conceptual disease logic model.
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events are simulated: (1) death as a result of other causes; (2) progression to next most advanced health
state; (3) attendance at next scheduled surveillance colonoscopy (provided the patient is still eligible); and
(4) death as a result of undiagnosed/diagnosed CRC. The next event is determined according to the
minimum of patient-specific time-to-event outcomes for these four competing events.
Patients progress through the natural history component of the model until they (1) die from other causes,
(2) die as a consequence of undiagnosed/diagnosed CRC or (3) attend their next scheduled surveillance
colonoscopy. At surveillance colonoscopy, patients without significant colorectal histology are assumed to
receive negative colonoscopic findings and remain in the ‘no adenomas’ state. For patients with previously
undetected adenomas, their adenomas may be identified by colonoscopy and subsequently removed via
polypectomy; these patients subsequently transit back to the ‘no adenomas’ state. In a proportion of
patients, adenomas present in the patient’s bowel may be missed at any colonoscopy visit. For patients
with previously undetected CRC, the tumour may be identified by colonoscopy, after which the patient
would go on to receive further investigation and treatment. In a proportion of these patients, the presence
of preclinical cancer will be missed by colonoscopy. The probability of detecting lesions is determined by
the test sensitivities estimated using the MSM (see Baseline model of natural history progression and
colonoscopy test characteristics, below). Patients with undiagnosed CRC may present symptomatically at
any point in time; these patients are assumed to progress immediately to the clinical cancer state.
Health utilities are defined according to the presence/absence of cancer without differentiation according
to cancer stage. The model assumes that neither the prior detection of adenomas nor the incidence of
complications following colonoscopy impacts on HRQoL; this is consistent with previous economic models
of CRC screening.85–87 In addition, the base-case analysis of the model assumes that different health
utilities are applied at the point of development of CRC. It is possible, however, that a patient’s HRQoL
would be affected by the diagnosis of clinical cancer rather than the development of preclinical disease.
These assumptions are tested in the sensitivity analyses (see Probabilistic scenario analysis, below). The total
QALY gain associated with each surveillance strategy is determined by the resulting incidence of CRC and
the overall amount of time spent alive with/without cancer.
The model includes the costs associated with colonoscopy, lifetime costs associated with the diagnosis
and management of CRC, and the costs of managing complications of colonoscopy. Costs are accrued
as patients undergo colonoscopy and at the point of diagnosis of CRC. Cost profiles for the simulated
population differ according to the surveillance option under consideration and its impact on the incidence
and timing of cancer diagnosis.
The visual logic code underpinning the simulation is provided in Appendix 10.
The model makes the following key assumptions:
l Natural history disease progression follows the adenoma–carcinoma sequence. The model does not
allow for the development of de novo cancers.
Surveillance COL
(plus event router)
Preclinical CRC
0 
Clinical CRC
0
Dead
0
Model exit point
100,000
Adenoma
0
No adenomas
0
Model entry
100,000
FIGURE16 Implemented simulation model. COL, colonoscopy.
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l Disease states are defined according to the presence/absence of adenomas and cancer and whether or
not cancer is clinically diagnosed.
l At any point in time, patients may have more than one lesion within their bowel (multiple adenomas
or synchronous adenomas and cancer); health-state occupancy and colonoscopy test sensitivity are
defined according to the index lesion (the most AA/cancer).
l With the exception of CRC survival, progression rates through the natural history model are constant
with respect to time.
l The sensitivity of colonoscopy is imperfect and differs for adenomas and cancers.
l The specificity of colonoscopy is perfect; false-positive test results are not considered within the model.
l Patients are sufficiently fit to undergo colonoscopy (in reality, a small proportion of patients may
undergo alternative diagnostic tests).
l Compliance with scheduled investigations is perfect.
l Adenoma recurrence rates are independent of the number and characteristics of previous
adenomas removed.
l Surveillance colonoscopy is associated with risks of perforations and gastrointestinal bleeds.
l Bowel perforation may be fatal.
l The survival of patients with undiagnosed CRC is half that of patients with diagnosed CRC. This
assumption is necessary, as it is not possible to observe this rate and the MSM censored patients for
the event of death.
l Surveillance colonoscopy does not have an impact on the stage distribution of patients with
diagnosed CRC.
l Patients undergoing surveillance colonoscopy will not be eligible to participate in general population
CRC screening programmes.
l The presence of preclinical cancer impacts on survival and HRQoL.
l The presence of diagnosed cancer impacts on survival and HRQoL.
Evidence used to inform the model parameters
Summary of evidence used to inform the model parameters
Table 90 summarises the evidence sources used to inform the parameter values assumed within the
health-economic model. These are described in further detail below.
Table 91 summarises the parameter values applied directly within the model.
Patient characteristics
The model takes account of two initial patient characteristics: age and gender. These variables influence
life expectancy and HRQoL for patients without cancer. Patient age and gender were based on the
statistical analysis of the hospital data presented in Chapter 3 (see Baseline characteristics of all
intermediate risk patients and those with follow-up). Within the model, patients aged < 50 years were
assumed to be distributed equally within the age interval 30–49 years. Age and gender distributions
were held fixed within the simulation; uncertainty surrounding these data was not considered.
Baseline model of natural history progression and colonoscopy
test characteristics
The baseline natural history progression rates and colonoscopy test characteristics were derived through
the development of a multistate model-based analysis of hospital data detailed in Chapter 3 (see First
follow-up visit). Data were available on first colonoscopy after baseline for 4608 subjects. Data for each
subject consisted of the time since baseline examination and the state allocated to the subject: normal,
adenoma or presymptomatic cancer (the presymptomatic nature was not certain but the assumption had
to be made for estimation to be possible). If a subject had a colonoscopy between (N – 1) and N years then
their time to colonoscopy was approximated by (N – 1/2) years. The total number of subjects who had a
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TABLE 90 Evidence used to inform the model parameters
Model parameter group Source
Age distribution for patients with detected adenomas Statistical analysis of hospital dataa
Gender distribution for patients with detected adenomas Statistical analysis of hospital dataa
Baseline transition rates between no adenoma(s), adenoma(s), preclinical
CRC and clinical CRC
MSM of hospital datab
Colonoscopy test characteristics (sensitivity and specificities for adenomas
and cancer)
MSM of hospital datab
Health utility general population Ara and Brazier 201088
Health utility CRC Djalalov et al. 201489
Age- and gender-specific other cause mortality ONS interim life tables 2010–1290
CRC survival National Bowel Cancer Audit Annual Report
201391
Probability of bleed due to colonoscopy EP
Probability of perforation due to colonoscopy EP
Probability of death following perforation Gatto et al. 200392
Cost CRC (lifetime) Whyte et al. 201286
Cost surveillance colonoscopy NHS Reference Costs 2012–1393
Cost management of bleeding NHS Reference Costs 2012–1393
Cost management of perforation NHS Reference Costs 2012–1393
a See Chapter 3, Baseline characteristics of all intermediate risk patients and those with follow-up.
b See Baseline model of natural history progression and colonoscopy test characteristics, above.
TABLE 91 Model parameters and distributions
Parameter Distribution Mean
Parameter
1 2 3
Sojourn no adenoma to
adenoma (years)
MSM posterior 9.64 9.64 7.25 11.97
Sojourn adenoma to
preclinical cancer (years)
MSM posterior 23.48 23.48 10.95 43.97
Sojourn preclinical to clinical
cancer (years)
MSM posterior 2.15 2.15 0.46 7.46
Relative survival preclinical vs.
clinical
Beta 0.50 7.00 7.00 –
Transition probability clinical
cancer to dead
Weibull (MVN) – 1.08 4.67 –
Specificity adenomas/cancer Fixed 1.00 1.00 – –
Sensitivity adenomas MSM posterior 0.77 0.77 0.70 0.83
Sensitivity cancer MSM posterior 0.88 0.88 0.50 0.99
Probability complication Beta 0.01 26.00 3664.00 –
Probability complication is
perforation
Beta 0.08 2.00 24.00 –
Probability death | perforation Beta 0.05 4.00 73.00 –
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colonoscopy between (N – 1) and N years after baseline, and the number of these observed to have
presymptomatic cancer, or adenomas, for each N, are given in Table 92.
The structure of the MSM is shown in Figure 18.
The multistate model comprises four natural history states:
l O state (no adenomas or cancer)
l A adenoma
l C presymptomatic cancer
l S symptomatic cancer.
Subjects who are truly in state O have no adenoma or cancer.
Subjects who are truly in state A have an adenoma that is correctly observed at a screen with probability
Sa; they are otherwise observed to be in state O.
Subjects who are truly in state C have cancer but are asymptomatic, and at a screen are detected to have
cancer with probability Sc; they are otherwise observed to be in state O.
Thus, a subject may be observed to be in state O but may truly be in one of states O, A or C. The model
assumes that subjects undergo the transitions O→ A, A→ C and C→ S as time-homogeneous Poisson
processes with rates λ0, λ1 and λ2, respectively.
TABLE 91 Model parameters and distributions (continued )
Parameter Distribution Mean
Parameter
1 2 3
HRQoL no cancer MVN 0.81 0.81 – –
HRQoL preclinical cancer Beta 0.73 358.98 132.77 –
HRQoL clinical cancer Beta 0.73 358.98 132.77 –
Cost surveillance COL Normal £514.38 £514.38 £16.80 –
Cost cancer (lifetime) Normal £20,212.59 £20,212.59 £3031.89 –
Cost perforation Normal £4170.95 £4170.95 £464.59 –
Cost bleed Normal £192.41 £192.41 £29.47 –
Distribution key
Distribution
Parameter
1 2 3
Posterior Mean 2.5th percentile 97.5th percentile
MVN Mean Covariance not shown
Beta Alpha Beta n/a
Normal Mean SE n/a
Weibull Alpha Beta n/a
COL, colonoscopy; MVN, multivariate normal; n/a, not applicable.
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Let the probability that a subject is observed to be in state X at time t after their clearance be p(X^ ; t), let
the probability that a subject is truly in state X at time t after clearance be p(X; t) and let the probability
that a subject is truly in state V at time t after clearance given that they were truly in state U at clearance
be given by p(U, V; t). Finally, let the probability that a subject observed to be in state O at clearance is
truly in state X at that time be given by p0(X).
Subjects are given a screen at clearance and entered into the study only if they are observed to be in
state O. The probability of a subject being observed in state C at a time t after clearance is given by:
p(C^;t) = Scp(C;t) = Scfp0(O)p(O,C;t) + p0(A)p(A,C;t) + p0(C)p(C,C;t)g, (1)
TABLE 92 Summary data used in the multistate model
Years to colonoscopy Cancers Adenomas Total colonoscopies
1 4 72 384
2 17 482 1936
3 5 230 813
4 6 270 881
5 8 84 233
6 3 72 188
7 3 29 84
8 1 13 33
9 2 9 28
10 1 2 11
11 1 2 5
12 0 1 1
13 0 0 1
14 0 1 3
15 1 3 4
16 0 1 1
18 0 0 1
20 0 0 1
Normal
O
Adenoma
Aλ0 λ1 λ2
Presymptomatic
cancer
C
Adenoma
found with
probability
Sa
Cancer found
with
probability
Sc
Symptomatic
cancer
S
FIGURE 18 Structure of the multistate model.
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which can be shown to be equal to:
Sc
(Sa−mc) λ0λ1
(λ2− λ1)
e− λ0t − e − λ1t
λ1 − λ0
−
e− λ0t − e− λ2t
λ2− λ0
+
(1− Sc)λ1(e− λ1t − e− λ2t )
(λ2− λ1)
+mce − λ2t
 
,

(2)
where:
mc ≅
λ0− λ1
λ2
(1− Sc). (3)
Similarly, the probability of a subject being observed in state A at a time t after clearance is given by:
p(A^;t) = SAp(A;t) = Safp0(O)p(O,A;t) + p0(A)p(A,A;t)g, (4)
which can be shown to be equal to:
Sa
(Sa−mc) λ0(e−λ0t − e−λ1t )
(λ1− λ0)
+ (1− Sa)e−λ1t
 
. (5)
We wish to estimate x = (Sa,Sc,λ0,λ1,λ2). Under the Bayesian paradigm, inference can be performed by
obtaining the posterior distribution:
Pr(xjD)∝Pr(Djx)Pr(x), (6)
where D is the data obtained, and Pr(x) is the prior distribution on x. We use a non-informative proper
prior for Pr(x).
Pr(x) = U(Sa;0,1)U(Sc;0,1)U(λ0;0,10)U(λ1;0,10)U(λ2;0,10), (7)
where U(;c,d) is a uniform distribution over the real interval (c,d). The likelihood, Pr(D|x), is given by:
Pr(Djx) =∏
N
i=1
p(bVl, ti), (8)
where subject i is observed to be in state Vl, at time ti after clearance.
This inference can be performed using the program STAN which obtains samples from an approximation
to the posteriors density p(x) by the method of Hamiltonian Monte Carlo. We used four chains of 1000
samples, taking 500 samples in each chain as ‘burn-in’ and using the remaining 500, and checking
convergence through examination of the Gelman and Rubin diagnostic. Sample medians of each
component of were taken as the estimates of the parameters and sample 2.5% and 97.5% quantiles were
used to obtain their credible intervals. Within the health-economic analysis, the Convergence Diagnostic
and Output Analysis samples, which are the correlated parameter samples from the joint posterior
distribution from the model, were used directly. Table 93 presents the posterior median and 95% credible
intervals for the estimated MSM parameters.
Other-cause mortality
Other-cause mortality rates were modelled using 2012 interim life expectancy tables published by the
ONS.90 Remaining life expectancy conditional on individual patient age and gender was modelled using
non-parametric distributions.
Survival of patients with colorectal cancer
The MSM (see Baseline model of natural history progression and colonoscopy test characteristics, above)
did not include data on other-cause mortality or deaths due to CRC; within the statistical analysis these
data were effectively treated as censored. As such, evidence from other sources was required to inform the
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survival duration for patients with preclinical CRC and for patients with diagnosed CRC. As noted above in
Implemented health-economic model structure and assumptions, the survival of patients with CRC was not
split by stage within the model. A number of options exist from which estimates of survival for patients
with CRC could be estimated: these include RCTs, cancer registries, model-based syntheses and clinical
audits. Registry data are not ideal, as these typically report relative survival rates relative to an age-matched
population over a finite time period. Without a baseline survival estimate for patients without cancer these
are difficult to interpret, and the appropriateness of extrapolating relative survival rates beyond the
specified period (typically 1, 3 or 5 years) may be questionable. RCT evidence may provide an alternative
source of evidence of survival estimates; however, such data tend to be upwardly biased because of a lack
of representativeness of the sample, for example owing to younger age, performance status and other
potential confounders. In addition, most CRC trials report outcomes for specific treatments and patient
groups at a specific point in the treatment pathway rather than reporting survival outcomes from diagnosis
for the CRC population as a whole.
In light of these problems, the health-economic model instead utilises reported survival data collected as
part of the 2013 National Bowel Cancer Audit Programme (NBOCAP).91 Absolute overall survival estimates
were available for 2 years from the NBOCAP. The key assumption resulting from the use of these data is
that the stage of patients within the audit is representative of the stage of patients progressing to CRC
within the modelled population.
The available survival data were digitised using Engauge® 4.7 software (Engauge Digitizer Open Source
Project, Torrance, CA, USA). The digitised data were used to reproduce the underlying patient-level
time-to-event data using methods reported by Guyot et al.94 within the software package R 0.98.977
(RStudio) (Table 94). Given the high event rates reported within the audit report, the analysis assumes
zero censoring.
Regression methods were used to fit a range of alternative candidate parametric survivor functions to the
replicated patient-level time-to-event data. The candidate survivor functions included exponential, Weibull,
Gompertz, log-normal and log-logistic models. Model discrimination was undertaken by examining
log-hazard plots and through examination of the AIC and the BIC statistics for each model. The plausibility
TABLE 93 Summary results of the MSM
Parameter Posterior median 95% credible interval
λ0 0.104 0.084 to 0.132
λ1 0.045 0.024 to 0.083
λ2 0.687 0.146 to 1.854
Sa 0.776 0.719 to 0.824
Sc 0.917 0.65 to 0.985
TABLE 94 Reproduced Kaplan–Meier estimates based on the 2013 NBOCAP data91
Time (years) Number censored Number who died Number at risk S(t) S(ti)
0 0 0 50,130 – 1
0.25 0 5013 45,117 0.90 0.90
0.50 0 2005 43,112 0.96 0.86
1.00 0 4011 39,101 0.91 0.78
1.50 0 3007 36,094 0.92 0.72
2.00 0 2507 33,587 0.93 0.67
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of the extrapolated portion of each curve was examined through comparison with other less recent but
more complete audit data reported for the Wessex region.95 Figure 19 presents the empirical Kaplan–Meier
estimate together with the fitted exponential, Weibull, Gompertz, log-normal and log-logistic survivor
functions. Table 95 presents the AIC and BIC statistics for each model.
As shown in Figure 19, within the observable period, all five of the candidate survivor functions appear to
provide a reasonable fit to the observed data; this is also reflected in the similarity of the AIC and BIC
statistics for each survival model. Unsurprisingly, as the log-logistic and log-normal are statistically similar
models, they produce very similar estimates. These two models appear implausible, however, as both
suggest that around 15% of patients will still be alive at 30 years post diagnosis. These models were
ruled out on this basis. The extrapolated portions of the remaining exponential Gompertz and Weibull
survivor functions appear to be broadly similar. The Weibull model was selected for inclusion in the
health-economic model because of its lower AIC and BIC values. The mean survival for the modelled
Weibull survivor function is estimated to be approximately 4.54 years. Uncertainty surrounding the
correlated parameters of the Weibull survivor function was sampled from a multivariate normal (MVN)
distribution using the estimated variance–covariance matrix for the model.
It is important to note that the survival of patients with undiagnosed CRC is not directly observable and
could not be indirectly estimated using the MSM. Instead, this estimate was based on an assumption.
Within the model, the survival of patients with undiagnosed CRC was assumed to be half of that for
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FIGURE 19 Empirical and modelled survivor functions for overall survival.
TABLE 95 The AIC and BIC values for fitted parametric survival models
Parametric model AIC BIC
Exponential 97,202.41 97,211.23
Weibull 97,107.04 97,124.69
Gompertz 97,193.89 97,211.53
Log-normal 96,978.51 96,996.15
Log-logistic 96,105.23 96,122.87
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patients with diagnosed CRC (this assumption was varied within the simple sensitivity analysis – see
Probabilistic scenario analysis, below).
Health-related quality of life
The definition of HRQoL states within the model was guided by the states included in the MSM
(see Baseline model of natural history progression and colonoscopy test characteristics, above).
The MSM defines histology according to the presence/absence of adenomas and the clinical status
of any CRC present (either diagnosed or not).
A systematic review was planned to inform the HRQoL parameters within the health-economic model.
Systematic searches for studies, utilising the Health Utilities Index, the Short Form questionnaire-6
Dimensions and the European Quality of Life-5 Dimensions questionnaires, were undertaken based on a
previously published CRC search strategy96 across 15 electronic databases:
l MEDLINE and MEDLINE in Process & Other Non-Indexed citations (via Ovid)
l EMBASE (via Ovid)
l Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost)
l BIOSIS previews (via WoK)
l Science Citation Index (via Web of Science)
l Cochrane Database of Systematic Reviews (Cochrane)
l Cochrane Central Register of Controlled Trials (Cochrane)
l Database of Abstracts of Reviews of Effects (Cochrane)
l NHS Health Economic Evaluation Database (Cochrane)
l HTA Database (Cochrane)
l EconLit (via Ovid)
l Web of Science (via WoK)
l Conference Proceedings index (Web of Science via WoK)
l ProQuest Dissertations and Theses (ProQuest)
l Tufts (Cost-effectiveness Analysis Registry).
However, once the searches were complete and the sifting process was under way, the authors were
alerted to the publication of another systematic review of preference-based HRQoL values in 2014,
by Djalalov et al.89 This study89 had also adopted the same broad search strategy as our review (see
Appendix 11). Consequently, our systematic review was aborted and estimates from Djalalov et al.89 were
instead used to inform estimates of quality of life for patients with CRC within the health-economic model.
The model assumes an overall value of 0.73 for CRC. Uncertainty surrounding this estimate was modelled
using a beta distribution assuming a SE of 0.03. For patients without CRC, a health-utility value of
HRQoL 0.81 was estimated based on general population utilities reported by Ara and Brazier,88 and the
distribution according to the age and gender weights in the intermediate-grade adenomas data set.
Uncertainty surrounding this parameter was estimated using a MVN distribution.
Probability of complications associated with colonoscopy
The probability of experiencing complications of colonoscopy was taken from the first round of the English
Bowel Screening Pilot (Table 96).
Within the prevalence round of the screening pilot, two perforations were reported in 3690 colonoscopies;
a probability of perforation due to colonoscopy of 0.0005 was assumed in the model. Similarly, a further
24 non-fatal events involving bleeding and/or abdominal pain were reported; a probability of bleeding of
0.006 was assumed in the model. The probability of death following perforation was taken from a study
by Gatto et al.92 (4 of 77 perforations, probability = 5.19%). Uncertainty surrounding these parameters was
characterised using beta distributions.
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Costs associated with surveillance and the diagnosis and management of
colorectal cancer
The model includes the costs of colonoscopy, the costs of managing complications of colonoscopy and the
lifetime costs associated with the diagnosis and management of CRC (Table 97). The costs of colonoscopy
and associated complications were taken from NHS Reference Costs 2012–13.93 Estimates of the lifetime
costs of diagnosis and management of CRC were taken from a previous modelling study reported by
Whyte et al.86 and adjusted according to the stage distribution reported in the 2011 report of the NBOCAP.97
Standard errors surrounding the reference cost estimates were estimated using the IQRs and number of
data submissions. The SE for the lifetime cost of CRC diagnosis and management was assumed to be 15%
of the mean. Uncertainty surrounding cost parameters was characterised using normal distributions.
Model evaluation methods
Model stability testing
Given that the model adopts a simulation approach, it is necessary to determine how many patient runs
are sufficient to produce stable results. Strategy-specific life-years gained (LYGs), QALYs and total costs
were evaluated using simulation cohort sizes ranging from 1000 patients to 1 million patients for three
alternative surveillance options (3-yearly surveillance, no age cut-off; 5-yearly surveillance, no age cut-off;
and 10-yearly surveillance, no age cut-off).
Figures 20–22 present the per cent deviation in total LYGs, total QALYs and total costs for each cohort size
relative to a baseline size of 1 million patients.
The stability test analyses presented in Figures 20–22 indicate that the total LYGs, total QALYs and total
costs are very stable for sample sizes of ≥ 50,000 patients (< 1% deviation from a baseline of 1 million
patients). In order to ensure stability in the model results, a total sample size of 300,000 patients was
conservatively selected for all probabilistic analyses.
TABLE 96 Probabilities of complications and death due to colonoscopy
Complication Number of events Total number of colonoscopies performed
Perforations 2 3690
Other (considered as bleeding) 24
Total 26
TABLE 97 Costs (£) assumed within the health-economic model
Cost parameter Mean SE Source
Colonoscopy 514.38 16.80 NHS Reference Costs 2012–13,93 day case FZ15Z, diagnostic
colonoscopy, ≥ 19 years
Management of perforation 1896.65 211.26 NHS Reference Costs 2012–13,93 elective inpatient WA12D,
complications of procedures with critical care score 0
Management of bleed 192.41 29.47 NHS Reference Costs 2012–13,93 elective inpatient (excess
bed-day) gastrointestinal bleed, without interventions,
with critical care score 0–4
Lifetime cost of CRC diagnosis
and management
20,212.59 3031.89 Whyte et al. 201286
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Probabilistic model evaluation and uncertainty analysis
The model was evaluated probabilistically over 1000 Monte Carlo samples, each of which comprised
300,000 individually sampled patients. Absolute estimates of the total cost and health gains associated with
each surveillance strategy were based on the expectation of the mean. The incremental cost-effectiveness of
alternative surveillance strategies was evaluated using standard cost-effectiveness decision rules,98 whereby
each option was compared with its next best alternative. Options that were dominated or extendedly
dominated were ruled out of the analysis. Uncertainty surrounding the incremental costs and health
outcomes was represented using cost-effectiveness planes and cost-effectiveness acceptability curves
(CEACs); these present the probability that each option produces the greatest net benefit at a given
willingness-to-pay (WTP) threshold.
It is important to note that some of the model parameters are subject to considerable uncertainty. In
particular, the expected survival duration and health utility for patients with undiagnosed preclinical cancer
are unobservable; these parameters have been populated using assumptions. Within the base-case
analysis, the health utility for patients with preclinical cancer is assumed to be equal to that of patients
with clinically diagnosed disease, whereas their expected survival is assumed to be equal to half of that for
diagnosed patients. In order to examine the importance of this uncertainty on the model results, five
alternative probabilistic scenarios were evaluated:
l Probabilistic scenario analysis 1 – preclinical cancer utility = clinical cancer utility, preclinical
survival = 0.33 × clinical survival.
l Probabilistic scenario analysis 2 – preclinical cancer utility = clinical cancer utility, preclinical
survival = 0.67 × clinical survival.
l Probabilistic scenario analysis 3 – preclinical cancer utility = general population utility, preclinical
survival = 0.33 × clinical survival.
l Probabilistic scenario analysis 4 – preclinical cancer utility = general population utility, preclinical
survival = 0.50 × clinical survival.
l Probabilistic scenario analysis 5 – preclinical cancer utility = general population utility, preclinical
survival = 0.67 × clinical survival.
In addition to the probabilistic analysis, simple one-way sensitivity analyses were undertaken to examine
the impact of individual parameters on the results of the economic analysis (Table 98); these analyses were
undertaken using point estimates of parameters rather than using the probabilistic model.
TABLE 98 Simple sensitivity analyses undertaken
Scenario number Description
1 Base case using point estimates of parameters
2 Test sensitivity for adenomas increased by 5 percentage points
3 Test sensitivity for adenomas decreased by 5 percentage points
4 Test sensitivity for cancer increased by 5 percentage points
5 Test sensitivity for cancer decreased by 5 percentage points
6 Test sensitivity for adenomas and cancer increased by 5 percentage points
7 Test sensitivity for adenomas and cancer decreased by 5 percentage points
8 Survival of patients with preclinical CRC +25%
9 Survival of patients with preclinical CRC –25%
10 All cost estimates +25%
11 All cost estimates –25%
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Value of information analysis
Alongside the cost-effectiveness analysis, value of information (VOI) methods were used to estimate the
monetary value of eliminating existing uncertainty through undertaking further research. VOI analysis can
be used to assess the value of additional information on all parameters [global expected value of perfect
information (EVPI)] or on specific parameter groups or individual parameters [expected value of partial perfect
information (EVPPI)], thereby enabling the prioritisation of further research through pursuing research projects,
the additional information of which is expected to yield the greatest pay-off in terms of expected net benefit.
Uncertainty in model parameters indicates that there is a possibility of selecting a suboptimal strategy, and
hence the VOI is high in situations where the additional information gained from further research would lead
to a switch away from the strategy adopted given current information. Similarly, if further research on a
specific parameter would not lead to a switch in adoption decisions, there is no value in conducting such
research. VOI analysis can therefore be considered as a useful tool in placing a ceiling on the monetary value
of further research, whereas EVPPI can be used to provide a basis for informing the design of clinical trials and
other studies. Within the analysis, the global EVPI (i.e. the monetary value of eliminating all uncertainty in the
model parameters) was estimated using standard methods.99 The EVPPI for all individual parameters was
estimated using non-linear regression methods reported by Strong and Oakley100
Model verification and validation methods
A number of efforts were made to ensure the credibility of the health-economic analysis and the
underlying model on which this was based; these methods were based on the taxonomy of model errors
and other threats to model credibility recently published by Tappenden and Chilcott.101
l The characterisation of the natural history of CRC was guided by previous models of the
adenoma–carcinoma sequence and the feasibility of the multistate modelling given available hospital
data (see Chapter 3, First follow-up visit).
l The model is based on formal conceptual modelling:79 this helps to draw out key assumptions,
abstractions and simplifications in the final model.
l All model inputs were double-checked against the original input material.
l The model was developed and evaluated in line with the current NICE reference for economic evaluations.78
l Black-box testing was undertaken to ensure that the model was behaving as intended. This included
automated and manual checking check by two researchers (PT and BK) to ensure that both the
developed conceptual models are sufficient to meet the objectives of the evaluation and credibility was
not lost during the translation from the conceptual to the mathematical model.
l Grey-box validation was undertaken to examine whether or not intermediate outcomes recorded within
the model (e.g. number of deaths due to various causes, number of patients with symptomatic/
surveillance-detected cancers) met predetermined expectations.
l White- and grey-box validation were undertaken by checking the integrity of the model programming,
running tests with isolated parts of the code by two researchers (PT and BK), and analysing simulated
patient pathways for credibility.
l Additional validation checks were undertaken including checking that any logical relationships between
model inputs (such as correlations or monotonic relationships) were preserved and sampled input
values did not violate boundary constraints (such as sampling negative survival times), and assessing the
performance of the model under extreme input values.
l Any errors or omissions that were identified as a result of the validation checks were rectified, and the
validations checks were repeated, leading to a process of iterative model improvement.
l The model and associated economic analysis were peer reviewed by methodological experts.
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Health-economic results
Base-case analysis
Central estimates of cost-effectiveness: base-case analysis (probabilistic, utility
preclinical cancer = utility clinical cancer, survival preclinical cancer = survival
clinical cancer × 0.50)
Table 99 presents the central estimates of cost-effectiveness based on the probabilistic version of the
model. The analysis indicates that more frequent surveillance is associated with greater health gains
(irrespective of whether or not an age cut-off is applied). Of the 13 options included in the analysis, option
S4 (3-yearly ongoing surveillance with no age cut-off) is expected to be the most effective. Options that
include once-only surveillance or no surveillance are expected to be dominated by more effective and less
expensive options. Option S6 (10-yearly ongoing surveillance with no age cut-off) is expected to be ruled
out as a result of extended dominance; this means that greater health gains could be achieved by funding
a combination of other non-dominated options. The incremental cost-effectiveness ratios (ICERs) for the
remaining non-dominated options are all very low (< £3000 per QALY gained). The ICER for the most
effective option, option S4 (3-yearly ongoing surveillance with no maximum age cut-off), compared with
the next most effective option (option S1: 3-yearly ongoing surveillance up to age 75 years) is expected to
be approximately £2748 per QALY gained.
It should be noted that when compared marginally against the no-surveillance strategy (option S13), all
surveillance options either dominate or have an ICER that is < £1000 per QALY gained.
Table 100 presents a breakdown of the model results in terms of QALYs gained pre and post cancer
diagnosis, cost components and number of additional surveillance colonoscopies for individuals identified
as having intermediate-grade adenomas.
TABLE 99 Base-case analysis, central estimates of cost-effectiveness (probabilistic, utility preclinical cancer= utility
clinical cancer, survival preclinical cancer = survival clinical cancer × 0.50)
Option QALYs Costs (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
S4: 3-yearly ongoing, no maximum age 9.66 3706 0.12 336 2748.10
S1: 3-yearly ongoing, maximum age 75 years 9.54 3370 0.07 152 2079.73
S5: 5-yearly ongoing, no maximum age 9.47 3218 0.08 113 1355.74
S2: 5-yearly ongoing, maximum age 75 years 9.38 3105 0.21 87 422.78
S6: 10-yearly ongoing, no maximum age 9.20 3039 – – Ext dom
S11: Once only at 5 years, no maximum age 9.18 3128 – – Dominated
S3: 10-yearly ongoing, maximum age 75 years 9.18 3018 – – –
S8: Once only at 5 years, maximum age 75 years 9.17 3106 – – Dominated
S10: Once only at 3 years, no maximum age 9.14 3235 – – Dominated
S12: Once only at 10 years, no maximum age 9.14 3040 – – Dominated
S9: Once only at 10 years, maximum age 75 years 9.13 3031 – – Dominated
S7: Once only at 3 years, maximum age 75 years 9.13 3196 – – Dominated
S13: No surveillance 8.95 3083 – – Dominated
Ext dom, extended dominance.
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The results presented in Table 100 indicate that the differences in the costs of additional surveillance
colonoscopies between the options are small, ranging from £515 (baseline colonoscopy only) to £2274
per patient. Although option S4 is associated with the greatest number of additional surveillance
colonoscopies, and hence the greatest cost of surveillance, this option is also associated with the greatest
reduction in cancer costs and produces the greatest QALY gains.
Probabilistic sensitivity analysis (base case)
Figure 23 presents an absolute cost-effectiveness plane for the 13 options included in the economic analysis.
The plane indicates that the costs and QALYs are broadly similar between all 13 surveillance options.
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FIGURE 23 Cost-effectiveness plane (absolute costs and QALYs).
TABLE 100 Breakdown of base-case model results
Option
Non-cancer
QALYs
Cancer
QALYs
Surveillance
costs (£)
Complication
costs (£)
Cancer
costs (£)
Number of surveillance
colonoscopies
S1 9.29 0.25 1542 7 1822 2.79
S2 9.09 0.29 1075 4 2027 1.55
S3 8.84 0.33 755 2 2262 0.71
S4 9.45 0.21 2274 12 1421 5.24
S5 9.20 0.26 1443 6 1769 2.82
S6 8.87 0.33 847 2 2191 1.08
S7 8.79 0.34 855 2 2340 0.73
S8 8.83 0.34 815 2 2290 0.69
S9 8.79 0.34 718 1 2312 0.56
S10 8.80 0.34 935 3 2298 0.90
S11 8.84 0.33 876 2 2250 0.83
S12 8.80 0.34 743 2 2296 0.62
S13 8.57 0.38 515 0 2569 0.00
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Figure 24 presents CEACs for each of the 13 options. Assuming a WTP threshold of £20,000 per QALY
gained, the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the
greatest net benefit is approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained, the
probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the greatest net
benefit is also approximately 1.0.
Expected value of perfect information analysis
The per-patient global EVPI was calculated; assuming thresholds of £20,000 per QALY gained and £30,000
per QALY gained, the global EVPI is expected to be zero. As the global EVPI is expected to be zero, the partial
EVPPIs for individual parameters are also zero. This suggests that, given the model structure and the data used
to inform it, undertaking further research to eliminate current levels of uncertainty would not change the
adoption decision; hence, the value of undertaking further research is zero.
Probabilistic scenario analysis
Scenario analysis 1 (probabilistic, utility preclinical cancer = utility clinical
cancer, survival preclinical cancer = survival clinical cancer × 0.33)
A separate probabilistic analysis was undertaken assuming that the relative survival of patients with
preclinical CRC is equal to one-third of the survival for patients with clinically diagnosed CRC, and
assuming that the utility of patients with preclinical CRC is equal to that of patients with diagnosed CRC.
Table 101 presents the central estimates of cost-effectiveness for this scenario.
The results of scenario analysis 1 are similar to those presented in the base-case analysis. Options that
include once-only surveillance or no surveillance are expected to be ruled out because of dominance.
Option S6 (10-yearly ongoing surveillance with no age cut-off) is expected to be ruled out because of
extended dominance (greater health gains could be achieved by funding a combination of other
non-dominated options). The ICERs for the remaining non-dominated options are all very low (< £3000
per QALY gained). The ICER for the most effective option, option S4 (3-yearly ongoing surveillance with
no maximum age cut-off), compared with the next most effective option (option S1: 3-yearly ongoing
surveillance up to age 75 years) is expected to be approximately £2111 per QALY gained.
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FIGURE 24 Base-case analysis, CEACs (probabilistic, utility preclinical cancer= utility clinical cancer, survival
preclinical cancer = survival clinical cancer × 0.50).
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Figure 25 presents CEACs for each of the 13 options. Assuming a WTP threshold of £20,000 per QALY
gained, the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the
greatest net benefit is approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained, the
probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the greatest net
benefit is also approximately 1.0.
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FIGURE 25 Scenario analysis 1, CEACs (probabilistic, utility preclinical cancer = utility clinical cancer, survival
preclinical cancer = survival clinical cancer × 0.33).
TABLE 101 Scenario analysis 1, central estimates of cost-effectiveness (probabilistic, utility preclinical cancer= utility
clinical cancer, survival preclinical cancer = survival clinical cancer × 0.33)
Option QALYs Costs (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
S4: 3-yearly ongoing, no maximum age 14.22 5137 0.30 627 2111
S1: 3-yearly ongoing, maximum age 75 years 13.92 4511 0.15 192 1302
S5: 5-yearly ongoing, no maximum age 13.78 4319 0.21 224 1057
S2: 5-yearly ongoing, maximum age 75 years 13.56 4094 0.47 182 385
S6: 10-yearly ongoing, no maximum age 13.16 3956 – – Ext dom
S3: 10-yearly ongoing, maximum age 75 years 13.09 3912 – – –
S11: Once only at 5 years, no maximum age 12.96 4069 – – Dominated
S8: Once only at 5 years, maximum age 75 years 12.95 4042 – – Dominated
S12: Once only at 10 years, no maximum age 12.94 3944 – – Dominated
S9: Once only at 10 years, maximum age 75 years 12.93 3930 – – Dominated
S10: Once only at 3 years, no maximum age 12.87 4180 – – Dominated
S7: Once only at 3 years, maximum age 75 years 12.85 4135 – – Dominated
S13: No surveillance 12.51 3971 – – Dominated
Ext dom, extended dominance.
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The per-patient global EVPI was calculated for this scenario; assuming thresholds of £20,000 per QALY
gained and £30,000 per QALY gained, the global EVPI is expected to be zero. As the global EVPI is
expected to be zero, the partial EVPPIs for individual parameters are also zero.
Scenario analysis 2 (probabilistic, utility preclinical cancer = utility clinical cancer,
survival preclinical cancer = survival clinical cancer × 0.67)
A separate probabilistic analysis was undertaken assuming that the relative survival of patients with
preclinical CRC is equal to two-thirds of the survival for patients with clinically diagnosed CRC, and
assuming that the utility of patients with preclinical CRC is equal to that of patients with diagnosed CRC.
Table 102 presents the central estimates of cost-effectiveness for this scenario.
The results for scenario analysis 2 are similar to those presented in the base-case analysis. Options that
include once-only surveillance or no surveillance are expected to be ruled out because of dominance.
Option S3 (1-yearly ongoing surveillance with no age cut-off) is also expected to be dominated. The ICERs
for the remaining non-dominated options are all very low (< £2000 per QALY gained). The ICER for the
most effective option, option S4 (3-yearly ongoing surveillance with no maximum age cut-off), compared
with the next most effective option (option S1: 3-yearly ongoing surveillance up to age 75 years) is
expected to be approximately £1574 per QALY gained.
Figure 26 presents CEACs for each of the 13 options. Assuming a WTP threshold of £20,000 per QALY
gained, the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the
greatest net benefit is approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained,
the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the greatest
net benefit is also approximately 1.0.
The per-patient global EVPI was calculated for this scenario; assuming thresholds of £20,000 per QALY
gained and £30,000 per QALY gained, the global EVPI is expected to be zero. As the global EVPI is
expected to be zero, the partial EVPPIs for individual parameters are also zero.
TABLE 102 Scenario analysis 2, central estimates of cost-effectiveness (probabilistic, utility preclinical cancer= utility
clinical cancer, survival preclinical cancer = survival clinical cancer × 0.67)
Option QALYs Costs (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
S4: 3-yearly ongoing, no maximum age 14.27 5575 0.25 392 1574
S1: 3-yearly ongoing, maximum age 75 years 14.02 5183 0.16 251 1551
S5: 5-yearly ongoing, no maximum age 13.86 4932 0.18 69 385
S2: 5-yearly ongoing, maximum age 75 years 13.68 4864 0.38 80 209
S6: 10-yearly ongoing, no maximum age 13.30 4783 – – –
S3: 10-yearly ongoing, maximum age 75 years 13.24 4790 – – Dominated
S11: Once only 5 years, no maximum age 13.12 4985 – – Dominated
S8: Once only 5 years, maximum age 75 years 13.11 4973 – – Dominated
S12: Once only 10 years, no maximum age 13.10 4857 – – Dominated
S9: Once only 10 years, maximum age 75 years 13.09 4848 – – Dominated
S10: Once only 3 years, no maximum age 13.04 5123 – – Dominated
S7: Once only 3 years, maximum age 75 years 13.02 5095 – – Dominated
S13: No surveillance 12.70 5018 – – Dominated
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Scenario analysis 3 (probabilistic, utility preclinical cancer = utility general population,
survival preclinical cancer = survival clinical cancer × 0.33)
A separate probabilistic analysis was undertaken assuming that the relative survival of patients with
preclinical CRC is equal to one-third of the survival for patients with clinically diagnosed CRC, and
assuming that the utility of patients with preclinical CRC is equal to that of the general population.
Table 103 presents the central estimates of cost-effectiveness for this scenario.
TABLE 103 Scenario analysis 3, central estimates of cost-effectiveness (probabilistic, utility preclinical cancer= utility
general population, survival preclinical cancer = survival clinical cancer × 0.33)
Option QALYs Costs (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
S4: 3-yearly ongoing, no maximum age 14.23 5137 0.29 £627 2152
S1: 3-yearly ongoing, maximum age 75 years 13.93 4511 0.15 £192 1280
S5: 5-yearly ongoing, no maximum age 13.78 4319 0.21 £224 1078
S2: 5-yearly ongoing, maximum age 75 years 13.58 4094 0.47 £182 386
S6: 10-yearly ongoing, no maximum age 13.18 3956 – – Ext dom
S3: 10-yearly ongoing, maximum age 75 years 13.11 3912 – – –
S11: Once only 5 years, no maximum age 12.98 4069 – – Dominated
S8: Once only 5 years, maximum age 75 years 12.96 4042 – – Dominated
S12: Once only 10 years, no maximum age 12.96 3944 – – Dominated
S9: Once only 10 years, maximum age 75 years 12.95 3930 – – Dominated
S10: Once only 3 years, no maximum age 12.89 4180 – – Dominated
S7: Once only 3 years, maximum age 75 years 12.87 4135 – – Dominated
S13: No surveillance 12.53 3971 – – Dominated
Ext dom, extended dominance.
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FIGURE 26 Scenario analysis 2, CEACs (probabilistic, utility preclinical cancer = utility clinical cancer, survival
preclinical cancer = survival clinical cancer × 0.67).
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Options that include once-only surveillance or no surveillance are expected to be ruled out because of
dominance. Option S6 (10-yearly ongoing surveillance with no age cut-off) is expected to be ruled out
because of extended dominance. The ICERs for the remaining non-dominated options are all very
low (< £3000 per QALY gained). The ICER for the most effective option, option S4 (3-yearly ongoing
surveillance with no maximum age cut-off), compared with the next most effective option (option S1:
3-yearly ongoing surveillance up to age 75 years) is expected to be approximately £2152 per QALY gained.
Figure 27 presents CEACs for each of the 13 options. Assuming a WTP threshold of £20,000 per QALY
gained, the probability that 3-yearly ongoing surveillance with no age cut-off will produce the greatest
net benefit is approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained, the probability
that 3-yearly ongoing surveillance with no age cut-off will produce the greatest net benefit is also
approximately 1.0.
The per-patient global EVPI was calculated for this scenario; assuming thresholds of £20,000 per QALY
gained and £30,000 per QALY gained, the global EVPI is expected to be zero. As the global EVPI is
expected to be zero, the partial EVPPIs for individual parameters are also zero.
Scenario analysis 4 (probabilistic, utility preclinical cancer = utility general
population, survival preclinical cancer = survival clinical cancer × 0.50)
A separate probabilistic analysis was undertaken assuming that the relative survival of patients with
preclinical CRC is equal to half of the survival for patients with clinically diagnosed CRC, and assuming that
the utility of patients with preclinical CRC is equal to that of the general population. Table 104 presents
the central estimates of cost-effectiveness for this scenario.
The results for this scenario are similar to those presented in the base-case analysis. Options that include
once-only surveillance or no surveillance are expected to be ruled out because of dominance. The ICERs for
the remaining non-dominated options are all very low (< £2000 per QALY gained). The ICER for the most
effective option, option S4 (3-yearly ongoing surveillance with no maximum age cut-off), compared with
the next most effective option (option S1: 3-yearly ongoing surveillance up to age 75 years) is expected to
be approximately £1872 per QALY gained.
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FIGURE 27 Scenario analysis 3, CEACs (probabilistic, utility preclinical cancer = utility general population, survival
preclinical cancer = survival clinical cancer × 0.33).
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
189
Figure 28 presents CEACs for each of the 13 options. Assuming a WTP threshold of £20,000 per QALY
gained, the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the
greatest net benefit is approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained,
the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the greatest
net benefit is also approximately 1.0.
The per-patient global EVPI was calculated for this scenario; assuming thresholds of £20,000 per QALY
gained and £30,000 per QALY gained, the global EVPI is expected to be zero. As the global EVPI is
expected to be zero, the partial EVPPIs for individual parameters are also zero.
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FIGURE 28 Scenario analysis 4, CEACs (probabilistic, utility preclinical cancer = utility general population, survival
preclinical cancer = survival clinical cancer × 0.50).
TABLE 104 Scenario analysis 4, central estimates of cost-effectiveness (probabilistic, utility preclinical cancer= utility
general population, survival preclinical cancer = survival clinical cancer × 0.50)
Option QALYs Costs (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
S4: 3-yearly ongoing, no maximum age 14.26 5409 0.26 491 1872
S1: 3-yearly ongoing, maximum age 75 years 14.00 4918 0.16 225 1420
S5: 5-yearly ongoing, no maximum age 13.84 4693 0.19 135 725
S2: 5-yearly ongoing, maximum age 75 years 13.65 4558 0.39 107 275
S6: 10-yearly ongoing, no maximum age 13.26 4451 0.07 15 224
S3: 10-yearly ongoing, maximum age 75 years 13.20 4436 – – –
S11: Once only 5 years, no maximum age 13.08 4614 – – Dominated
S8: Once only 5 years, maximum age 75 years 13.06 4595 – – Dominated
S12: Once only 10 years, no maximum age 13.06 4486 – – Dominated
S9: Once only 10 years, maximum age 75 years 13.05 4476 – – Dominated
S10: Once only 3 years, no maximum age 12.99 4739 – – Dominated
S7: Once only 3 years, maximum age 75 years 12.98 4704 – – Dominated
S13: No surveillance 12.65 4589 – – Dominated
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Scenario analysis 5 (probabilistic, utility preclinical cancer = utility general
population, survival preclinical cancer = survival clinical cancer × 0.67)
A separate probabilistic analysis was undertaken assuming that the relative survival of patients with
preclinical CRC is equal to two-thirds of the survival for patients with clinically diagnosed CRC, and
assuming that the utility of patients with preclinical CRC is equal to that of the general population.
Table 105 presents the central estimates of cost-effectiveness for this scenario.
Options that include once-only surveillance or no surveillance are expected to be ruled out because of
dominance. The ICERs for the remaining non-dominated options are all very low (< £2000 per QALY
gained). The ICER for the most effective option, option S4 (3-yearly ongoing surveillance with no maximum
age cut-off), compared with the next most effective option, option S1 (3-yearly ongoing surveillance up to
age 75 years) is expected to be approximately £1627 per QALY gained.
Figure 29 presents CEACs for each of the 13 options. Assuming a WTP threshold of £20,000 per QALY
gained, the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the
greatest net benefit is approximately 1.0. Assuming a WTP threshold of £30,000 per QALY gained,
the probability that 3-yearly ongoing surveillance with no age cut-off is expected to produce the greatest
net benefit is also approximately 1.0.
The per-patient global EVPI was calculated for this scenario; assuming thresholds of £20,000 per QALY
gained and £30,000 per QALY gained, the global EVPI is expected to be zero. As the global EVPI is
expected to be zero, the partial EVPPIs for individual parameters are also zero.
Simple sensitivity analysis
Table 106 presents the results of the simple sensitivity analysis of the base-case model.
The simple sensitivity analysis consistently suggests that option S4 (3-yearly ongoing surveillance with no
maximum age cut-off) is expected to produce the greatest number of QALYs. The ICER for this option is
< £6000 per QALY gained across all scenarios. It is also noteworthy that none of the deterministic ICERs
for any of the surveillance options exceeds £5000 per QALY gained.
TABLE 105 Scenario analysis 5, central estimates of cost-effectiveness (probabilistic, utility preclinical cancer= utility
general population, survival preclinical cancer = survival clinical cancer × 0.67)
Option QALYs Costs (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
S4: 3-yearly ongoing, no maximum age 14.28 5575 0.24 392 1627
S1: 3-yearly ongoing, maximum age 75 years 14.04 5183 0.17 251 1514
S5: 5-yearly ongoing, no maximum age 13.87 4932 0.17 69 399
S2: 5-yearly ongoing, maximum age 75 years 13.70 4864 0.38 80 209
S6: 10-yearly ongoing, no maximum age 13.32 4783 – – –
S3: 10-yearly ongoing, maximum age 75 years 13.26 4790 – – Dominated
S11: Once only 5 years, no maximum age 13.14 4985 – – Dominated
S8: Once only 5 years, maximum age 75 years 13.13 4973 – – Dominated
S12: Once only 10 years, no maximum age 13.12 4857 – – Dominated
S9: Once only 10 years, maximum age 75 years 13.11 4848 – – Dominated
S10: Once only 3 years, no maximum age 13.06 5123 – – Dominated
S7: Once only 3 years, maximum age 75 years 13.05 5095 – – Dominated
S13: No surveillance 12.72 5018 – – Dominated
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Impact on NHS expenditure
Given that the alternative surveillance options considered within the health-economic analysis include
different intervals and age cut-offs, together with expected changes to the NHS BCSP that may alter the
specific populations eligible for screening and the screening modality used, estimating the expected impact
of the alternative surveillance options on the NHS budget is difficult. Based on data from the NHS BCSP
reported by Kearns et al.,102 the positivity rate for the initial FOBT screen during the period 2008–11 is
estimated to be 2.21%. According to this same source, 909,839 usable kits were returned in 2011, which
implies a total of 20,097 individuals testing positive and requiring further investigation. Assuming that
17% of these patients are classed as having IR adenomas,36 this would suggest an incident population of
around 3417 patients each year. However, the lifetime incremental cost of the alternative surveillance
options relative to a policy of no adenoma surveillance is small (–£59 to £1166); hence, it is likely that the
overall impact of alternative adenomas surveillance options on NHS expenditures each year will also be
relatively small, and may even produce small cost-savings depending on which option is pursued.
Attributing the entire lifetime incremental cost for option S4 (3-yearly ongoing surveillance with no
maximum age) against a policy of no adenoma surveillance to the estimated incident IR population
suggests a maximum budget impact of around £4M over the lifetime of 3417 incident patients.
Discussion
Summary of cost-effectiveness findings
This chapter has presented the methods and results of a health-economic simulation model used to assess
the cost-effectiveness of 13 surveillance options for patients with intermediate-grade adenomatous polyps.
The model results suggest that 3-yearly ongoing colonoscopic surveillance without an age cut-off is
expected to produce the greatest health gain. The ICER for this option (compared against the same strategy
with an age cut-off of 75 years) is expected to be approximately £2748 per QALY gained. The probabilistic
sensitivity analysis indicates that, assuming a WTP threshold of £20,000 per QALY gained, the probability
that this option produces the greatest expected net benefit is approximately 1.0.
When compared marginally against the no-surveillance strategy, all surveillance options either dominate or
have an ICER which is < £1000 per QALY gained.
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FIGURE 29 Scenario analysis 5, CEACs (probabilistic, utility preclinical cancer = utility general population, survival
preclinical cancer = survival clinical cancer × 0.67).
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Several alternative probabilistic scenario analyses were undertaken to explore uncertainty surrounding
unobservable parameters relating to the survival and HRQoL impacts of preclinical cancer. However, the
results were similar to the base-case findings; hence, the economic conclusions of the analysis are not
strongly influenced by these assumptions. The simple one-way sensitivity analyses also support the
base-case results. Given the favourable cost-effectiveness profile of 3-yearly ongoing surveillance and
the limited decision uncertainty, the global EVPI and individual parameter EVPPIs estimated by the model
are approximately zero.
Limitations and uncertainties
The interpretation of the findings of the economic analysis presented here requires some consideration of
limitations of the model, as well as the uncertainties within the current evidence base. These are discussed
below.
Assumptions regarding the natural history of colorectal cancer
The model assumes that all cancers arise from prior adenomas. However, there is indirect evidence to
suggest that a proportion of CRCs arise de novo rather than as a consequence of the adenoma–carcinoma
sequence. This theory of disease natural history was not considered within the MSM and hence could
not be incorporated into the health-economic analysis, and its impact on the cost-effectiveness of the
alternative surveillance options is unclear. Furthermore, given better data, it may have been possible to
produce a more accurate representation of the natural history process, for example by capturing different
malignant potential of different types and numbers of adenomas present in the bowel, perhaps including
the use of frailty models to distinguish between those adenomas which will develop into cancer and those
which will not. It is also noteworthy that the MSM includes states for preclinical and clinical cancer but
does not differentiate by cancer stage; the model is ‘blunt’ in the sense that surveillance may result in a
shift in stage distribution at diagnosis and thus lead to different estimates of diagnosis and treatment
costs; this potential effect is not reflected within the model.
Assumptions regarding adenoma surveillance programmes
The model includes only the possibility of premalignant adenoma detection through surveillance;
in reality adenomas may be detected in a small number of patients through symptomatic or opportunistic
presentation. Furthermore, the model does not include the possibility of participation in national screening
programmes following discharge of a planned adenoma surveillance programme. In addition, all patients
are assumed to attend their scheduled surveillance visits and all are assumed to be sufficiently fit to
undergo colonoscopy. These assumptions may be somewhat optimistic and, as a consequence, the model
may overestimate the clinical benefits and cost-effectiveness of surveillance programmes in comparison
with what may be expected to be seen in usual clinical practice.
Prognosis of patients with preclinical/clinical colorectal cancer
The model uses survival data derived from the NBOCAP to inform parameters relating to the expected
survival of patients with CRC. These data were required as the MSM censored patients for death. The
NBOCAP data are subject, however, to considerable censoring; hence, there is uncertainty surrounding
their long-term extrapolation. Although the sensitivity analysis suggests that this does not strongly
influence the model results, further data in the future may enable a more accurate evaluation of
alternative adenoma surveillance strategies.
Surveillance options considered
The model evaluation includes two types of surveillance option: (1) ongoing surveillance with a fixed
interval between scheduled visits; and (2) once-only surveillance. These options were agreed by the project
team prior to implementation of the health-economic model. The model is capable, however, of
considering more complex surveillance strategies, for example schedules with different time intervals or
schedules that take into account previous histological findings or numbers of attendances. It may be
possible that an alternative surveillance option, which has not been defined for inclusion in this analysis,
could produce greater expected health gains than those estimated within this analysis.
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It is also important to recognise that surveillance options which include more frequent ongoing visits will
put greater stress on endoscopy services. Although 3-yearly ongoing surveillance appears to be the most
effective strategy, and such health gains are expected to be achieved at a cost which may be acceptable to
NHS policy-makers, it may be preferable to pursue less effective strategies that also offer a favourable
cost-effectiveness profile.
Conclusions
Of the 13 surveillance options considered, 3-yearly ongoing colonoscopic surveillance without an age
cut-off is expected to produce the greatest health gain. The ICER for this option (compared with the same
strategy with an age cut-off of 75 years) is expected to be < £3000 per QALY gained.
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
195

Chapter 6 Psychological study: examination of
anxiety levels
Introduction
Existing studies of the psychological effects of CRC screening have shown few adverse effects of faecal
occult blood testing,103 FS104 or colonoscopy105 among the screened population as a whole. However,
there has been little research looking at the psychological impact of entering a surveillance programme
after screening.
Surveillance may have a positive psychological effect by giving patients a sense of ongoing care, along with
reassurance that they do not have bowel cancer. However, colonoscopy is widely seen as an uncomfortable
and embarrassing procedure,106 and regular screening might be a reminder of cancer risks.
In the IA study, we were asked to investigate the psychological impact of surveillance using retrospective
data only. We therefore undertook additional analyses of the UKFSST data to answer this question.
Methods
Sample
Participants were men and women aged 55–64 years, at average risk of CRC, invited for screening in 12 of
the 14 study centres in the UKFSST.107 Exclusion criteria for the trial were:
l inability to provide consent
l personal history of CRC, adenomas, or IBD
l strong family history of CRC (two or more close relatives affected)
l severe or terminal disease with a life expectancy of < 5 years
l presence of a temporary health problem that would prevent the patient from having FS
l sigmoidoscopy or colonoscopy within the previous 3 years.
Patients eligible for inclusion in the trial were sent a letter by their GP, with an information leaflet on CRC
and FS screening, and were asked whether or not they would accept the offer of screening if invited.
Respondents who replied saying that they were interested in screening were randomly allocated to
screening or to usual care.107 Data from the pilot and the first study centre were excluded from the
analyses because different post-screening questionnaires had been used.
In the UKFSST, individuals with one to two small tubular adenomas were considered ‘lower risk’ and were
not offered colonoscopy after their polyps were removed at FS, whereas those with more numerous
tubular adenomas or AA were offered colonoscopy. The majority of these individuals were offered
surveillance colonoscopy in accordance with a prescribed protocol, similar to the British Society of
Gastroenterology guidelines for the management of ‘higher risk’ cases.1 Outcomes data were available for
35,891 individuals. Of these:
l 26,573 had no polyps detected
l 7401 had lower-risk polyps, removed at FS
l 183 had higher-risk polyps, were referred to colonoscopy and then discharged
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l 1543 had higher-risk polyps, were referred to colonoscopy and then recommended for ongoing
colonoscopic surveillance
l 62 were considered higher risk but colonoscopy was not performed for a variety of reasons (e.g. they
were too ill or did not want to undergo the procedure); a further six were referred straight to surgery
and 123 were diagnosed with cancer – these 191 were excluded, leaving a total sample of 35,700.
Participants were sent a detailed questionnaire 3–6 months after screening, by which time they had
been told whether or not they needed surveillance. The response rate to this questionnaire was 90%
(Figure 30). Completion of the post-screening questionnaire was higher among women, older people
and people with lower levels of socioeconomic deprivation.
A subsample (n = 6389) had also completed a detailed questionnaire 6 months prior to screening
attendance, making it possible to compare pre- and post-screening results in this group. However, the
subsample contained only 20 individuals who were discharged following colonoscopy, so these 20 patients
were excluded from longitudinal analyses.
Measures
Demographic variables including date of birth, gender and postcode were supplied by GP practices.
Socioeconomic deprivation was indexed by converting postcode into Townsend Index scores108 (an
established indicator of area-based socioeconomic deprivation in England) for all centres except Glasgow.
Primary outcome variables
l Bowel cancer worry was assessed before and after screening using the question: ‘How worried are you
about getting bowel cancer?’ Response options were on a four-point Likert scale: ‘not worried at all’,
‘a bit worried’, ‘quite worried’ and ‘very worried’.
l Psychological distress was measured post screening using the 12-item version of the General Health
Questionnaire (GHQ-12).109 This assesses how people have felt in the preceding 3 months, with a
four-item response scale: ‘better/more than usual’, ‘same as usual’, ‘less than usual’ and ‘much less
Randomised
to screening
(n = 50,963)
No polyps
(n = 26,573)
Attended
screening
(n = 35,981)
Did not attend
screening
(n = 15,072)
Completed
post-screening
questionnaire
(n = 24,293)
Completed
post-screening
questionnaire
(n = 6763)
Completed
post-screening
questionnaire
(n = 123)
Completed
post-screening
questionnaire
(n = 1376)
Cancer diagnosed
(n = 123)
Colonoscopy
not performed
(n = 62)
Surgery only
(n = 6)
Lower-risk polyps
(n = 7401)
Higher-risk polyps,
discharged after
colonoscopy
(n = 183)
Higher-risk polyps,
surveillance after
colonoscopy
(n = 1543)
Excluded
from study
(n = 191)
FIGURE 30 Trial profile.
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than usual’. Responses were scored 0–3 and summed to produce a scale from 0 to 36, with higher
scores indicating greater distress.
l Positive emotional consequences of screening were assessed post screening using three items from the
positive emotional subscale of the Psychological Consequences of screening Questionnaire (PCQ).110
These were: ‘Do you think that your experience of having the Flexi-Scope test has . . .’ : ‘made you feel
more hopeful about the future?’; ‘made you feel less anxious about bowel cancer?’; ‘given you a
greater sense of wellbeing?’. Response options were on a four-point Likert scale (‘not at all’; ‘a little
bit’; ‘quite a bit’; and ‘a great deal’) and were summed to produce a score from 3 to 12, with higher
scores indicating more positive consequences. Cronbach’s alpha for the emotional items was 0.81,
which is similar to the value of 0.89 reported for the full 10-item scale (containing positive and
negative emotional items).
Secondary outcome variables
l Reassurance was assessed post screening using a single item on reassurance from the PCQ: ‘Do you
think that your experience of having the Flexi-Scope test has given you a sense of reassurance that you
do not have bowel cancer?’ Response options were on a four-point Likert scale: ‘not at all’, ‘a little bit’,
‘quite a bit’ and ‘a great deal’.
l Generalised anxiety was measured before and after screening using the six-item version of the
Spielberger State–Trait Anxiety Inventory.111 This asks people to consider how they are feeling ‘right
now’ and includes items such as ‘I feel calm’ or ‘I am tense’. Responses were added giving a score of
between 6 and 24, with higher scores indicating higher levels of anxiety.
l Bowel symptoms were assessed before and after screening using the stem question: ‘Because we are
studying bowel screening, we would like to know how often people get these bowel symptoms. In the
last three months have you . . .’ : ‘been constipated’; ‘had haemorrhoids (piles)’; ‘had diarrhoea’; ‘been
troubled with wind’; ‘had pains in the abdomen (gut)’; ‘had bowel incontinence’; ‘noticed blood in your
stools’. Response options were: ‘no’, ‘occasionally’ or ‘frequently’. People were classified as having ‘one or
more’ bowel symptoms (if they replied ‘occasionally’ or ‘frequently’ to any of the questions) or ‘none’.
l GP attendance was measured before and after screening using the question: ‘About how many times
have you been to see your GP in the last 3 months?’ Response options were ‘have not been’, ‘once’,
‘twice’, ‘three or more times’.
Statistical analysis
Between-group analyses of variance (ANOVAs) were used to test for differences between screening outcome
groups. Contrasts were used to examine whether or not the surveillance group differed from the three other
outcome groups. Changes over time (pre- to post-screening) were assessed using repeated-measures ANOVA
with time as a within-subjects variable and screening outcome group as a between-subjects variable.
Results
Demographic variables
Outcome groups differed significantly by age and gender. The groups with lower-risk polyps and higher-
risk polyps assigned to surveillance were slightly older than the group with no polyps (average age – no
polyps, 60.3 years; lower-risk polyps, 60.5 years; higher-risk polyps, discharged, 60.5 years; higher-risk
polyps, surveillance, 60.7 years). All three groups with polyps had a higher proportion of men (no polyps:
46% men; lower risk: 62%; higher risk, discharged: 62%; higher risk, surveillance: 68%). Socioeconomic
deprivation was not associated with the presence or absence of polyps. Age and gender were entered into
all analyses as independent variables, but results are reported only when age or gender moderated the
psychological impact associated with different screening outcomes.
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Post-screening scores
Primary outcome variables
Bowel cancer worry differed across the four groups (F3,31904 = 16.3; p < 0.001) but planned contrasts
showed higher worry in the surveillance group than in the no-polyps group, and no significant differences
between the surveillance group and the other two groups with polyps. Although general psychological
distress (GHQ) differed by outcome group (F3,32055 = 2.66; p < 0.05), the surveillance group reported lower
distress than the groups with no polyps or lower-risk polyps (Table 107).
There were significant differences across the groups in reported emotional consequences of screening
(F3,31971 = 9.37; p < 0.001), with the surveillance group reporting higher positive consequences of screening
than all the other groups (see Table 107). They also reported higher reassurance than the lower-risk group,
although reassurance scores did not differ from the two remaining outcome groups. There was a
significant age-by-group interaction (F3,32054 = 3.38; p < 0.05), with no age differences in reassurance
among people with no polyps or lower-risk polyps, but greater reassurance among those aged > 60 years
who were assigned to surveillance (F1,1349 = 6.78; p < 0.01) (see Table 107).
Secondary outcome variables
Anxiety differed across outcome groups (F3,31667 = 7.22; p < 0.001), with people assigned to surveillance
reporting significantly lower post-screening anxiety than the groups with no or lower-risk polyps (see
Table 107). There were also group differences in bowel symptoms (F3,288869 = 5.73; p < 0.001) and GP visits
TABLE 107 Post-screening measures of psychological impact by screening outcome
Variables
No polyps
(n= 24,293)
Lower-risk
polyps, no
colonoscopy
(n= 6763)
Higher-risk
polyps,
discharged
after
colonoscopy
(n= 123)
Higher-risk
polyps,
surveillance
after
colonoscopy
(n= 1376)
Primary outcome
Bowel cancer worry 1–4 (higher scores indicate
greater worry)
1.91 (0.01)* 1.99 (0.01) 1.90 (0.08) 1.96 (0.02)
Psychological distress 0–36 (higher scores
indicate greater distress:
a score of 24 = cut-off for
psychiatric illness)
8.91
(0.03)**
8.87 (0.05)* 8.83 (0.36) 8.58 (0.11)
Positive emotional
consequences of
screening
3–12 (higher scores
indicate greater positive
consequences)
8.16
(0.02)***
8.10
(0.03)***
8.01 (0.24)* 8.53 (0.07)
Reassurance do not
have bowel cancer
1–4 (higher scores indicate
greater reassurance)
3.53 (0.01) 3.45 (0.01)* 3.48 (0.07) 3.50 (0.02)
Secondary outcome
Generalised anxiety 6–24 (higher scores
indicate greater anxiety)
9.85
(0.03)***
9.96
(0.05)***
9.52 (0.37) 9.35 (0.12)
Bowel symptoms 0–7 (higher scores indicate
a greater number of
symptoms)
1.54
(0.01)***
1.56 (0.02)** 1.71 (0.14) 1.70 (0.04)
GP visits 1–4 (higher scores indicate
more frequent GP visits)
1.97 (0.01) 1.94 (0.01) 2.20 (0.10)** 1.94 (0.03)
Figures are number (SE).
Asterisks denote that the group differs significantly from the group assigned to surveillance: *p< 0.05; **p< 0.01;
***p< 0.001.
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(F3,30601 = 3.60; p < 0.05), with the surveillance group reporting more bowel symptoms post screening than
the groups with no or lower-risk polyps. However, they reported fewer GP visits than the group discharged
following colonoscopy, and did not differ on this measure from the groups with no or lower-risk polyps.
Pre- and post-screening measures
In order to check whether or not post-screening group differences simply reflected pre-screening group
differences, and to see whether or not factors such as worry increased or decreased following screening,
we examined longitudinal changes in a subsample. As noted above, these analyses excluded the group
discharged following colonoscopy because the sample size was too small.
There were no differences between outcome groups on pre-screening bowel cancer worry, generalised
anxiety, number of bowel symptoms reported or frequency of GP visits. Bowel cancer worry declined over
time (F1,6440 = 45.9; p < 0.001), with a significant interaction between change in worry over time and
outcome group (F2,6440 = 4.11; p < 0.05). However, reductions in worry in the surveillance group were
greater than in the lower-risk group, although the difference was not significant (F1,1743 = 3.34; p < 0.10)
and no difference was observed between the surveillance and the no-polyps group (Table 108).
There was a significant reduction in anxiety over time (F1,6377 = 41.6; p < 0.001) and also a significant
interaction with group (F2,6377 = 4.29; p < 0.05), with the surveillance group showing a greater reduction
in anxiety than both the lower-risk group (F1,1724 = 8.03; p < 0.01) and the no-polyps group (F1,4926 = 5.53;
p < 0.05) (see Table 108).
TABLE 108 Measures of psychological impact by screening outcome, on subsample who completed pre- and
post-screening questionnaires
Outcome No polyps (n= 24,293)
Lower-risk polyps, no
colonoscopy (n= 6763)
Higher-risk polyps, surveillance
after colonoscopy (n= 1376)
Bowel cancer worry (1–4, higher scores indicate greater worry)
Pre 2 0.00 (0.01) 2 0.05 (0.02) 2 0.06 (0.05)
Post 1 0.86 (0.01) 1 0.98 (0.02) 1 0.88 (0.05)
Change 0 0.14 0 0.07 0 0.18
Generalised anxiety (6–24, higher scores indicate greater anxiety)
Pre 10 0.10 (0.05) 10 0.09 (0.10) 10 0.49 (0.23)
Post 9 0.63 (0.06) 9 0.80 (0.10) 9 0.41 (0.25)
Change 0 0.47* 0 0.29** 1 0.08
Bowel symptoms (0–7, higher scores indicate a greater number of symptoms)
Pre 2 0.11 (0.02) 2 0.01 (0.04) 2 0.14 (0.10)
Post 1 0.60 (0.02) 1 0.53 (0.04) 1 0.82 (0.09)
Change 0 0.51* 0 0.48 0 0.32
GP visits (1–4, higher scores indicate more frequent GP visits)
Pre 1 0.97 (0.02) 1 0.96 (0.03) 2 0.02 (0.07)
Post 1 0.90 (0.02) 1 0.83 (0.03) 1 0.98 (0.07)
Change 0 0.07 0 0.13 0 0.04
Figures are number (SE).
Asterisks denote that the group differs significantly from the group assigned to surveillance: *p< 0.05; **p < 0.01.
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Although the number of reported bowel symptoms decreased following screening (F1,5662 = 181.2;
p < 0.001), the interaction between change over time and screening outcome group was not significant.
Pairwise comparisons indicated smaller reductions in symptoms in the surveillance group than in the
no-polyps group (F1,4367 = 4.38; p < 0.05) but the former was similar to that observed in the lower-risk
group. Self-reported frequency of GP visits decreased significantly over time (F1,5998 = 8.80; p < 0.01) but
the interaction between change over time and outcome group was not significant (see Table 108).
Discussion
Following screening, we found that bowel cancer worry was higher in patients undergoing surveillance
than in those who had no polyps detected, but did not differ from the level observed in the group found
to have lower-risk polyps, suggesting that bowel cancer worry was related to the detection of growths in
the bowel rather than to colonoscopic surveillance itself. In addition, the decline in bowel cancer worry
in the surveillance group over time was equivalent to that observed in the group who had no polyps
found and did not undergo surveillance, supporting the idea that surveillance did not make people worry
about bowel cancer. On other measures, there was evidence of beneficial psychological outcomes in the
surveillance group, who reported lower general distress and more positive consequences of screening, and
had greater reductions in anxiety than both the no-polyps group and the lower-risk group. This suggests
that the positive consequences of screening may extend beyond the removal of polyps and are perceived
as greater among people assigned to colonoscopic surveillance. People assigned to surveillance were also
more reassured that they did not have bowel cancer than the lower-risk group (who had polyps detected
but no colonoscopy) and levels of reassurance were similar to those observed among people with no
polyps found, indicating that a programme of surveillance following the detection of polyps offers as much
reassurance as having no polyps detected in the first place.
No differences were observed between the group assigned to colonoscopic surveillance and people
discharged following colonoscopy in post-screening bowel cancer worry, psychological distress, reassurance
that they did not have bowel cancer, anxiety or number of bowel symptoms. However, the group discharged
following colonoscopy reported fewer positive consequences of screening and a greater frequency of GP
visits than the surveillance group. That said, relatively few people were discharged following colonoscopy so
comparisons may have been underpowered to detect small differences.
Limitations of the study include the lower response rates among men, younger people and people from
areas with higher socioeconomic deprivation, and we cannot rule out the possibility that these groups might
experience a higher proportion of adverse consequences following screening. However, with the exception
of the group discharged following colonoscopy, completion rates were similar across the three outcome
groups, so it seems unlikely that this would have affected the pattern of results observed in the present
study. The lower response rate in the group who were discharged following colonoscopy is more
problematic, and might have contributed to the failure to find differences between them and the group
assigned to surveillance.
Information on the demographic characteristics of the sample was limited to age, gender and
socioeconomic deprivation, leaving open the possibility that the screening outcome groups may have
differed in other ways that could have influenced their responses. For example, differences between the
screening outcome groups in dispositional optimism or depression may have led to greater endorsement of
positive or negative items, respectively. But, if this were the case, differences between the screening
outcome groups on pre-screening bowel cancer worry and anxiety should have been apparent, and no
such differences were observed. In addition, the pattern of findings varied across measures, suggesting
that global response biases are an unlikely explanation for the effects observed.
No measures of general quality of life were taken, so it is unclear whether or not surveillance colonoscopy
might have a more general impact. However, both screening- and cancer-specific concerns were assessed,
and previous research has tended to show stronger effects when specific rather than general measures of
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psychological impact are used.112 It therefore seems unlikely that adverse psychological effects associated
with surveillance colonoscopy went undetected, although effects on social or physical aspects of life may
have done.
Additional limitations of this study include its focus on people who had taken up the offer of an invitation
to be screened and who may therefore have more positive views on medical testing than other members
of the general population. Consequently, the results may not be generalisable to a higher-risk group who
are explicitly recommended to have screening, and among whom attitudes towards medical surveillance
and testing may be less positive. In addition, we assessed only the relatively short-term psychological
impact of screening and therefore do not know whether or not the observed positive consequences persist
over time.
A further limitation was the use of single-item measures for a number of the outcome variables, which
are less reliable than multiple-item scales and may have reduced the likelihood of detecting significant
differences. Although the large sample size compensates for this limitation to some extent, future research
could use improved measures of reassurance and use of health care to verify the findings observed here.
The results of the current study are broadly reassuring and show that referral for colonoscopic surveillance
is not associated with adverse psychological consequences. Although post-screening bowel cancer worry
and bowel symptoms were higher in people assigned to surveillance, they declined over time and were
equivalent to levels observed in the other two groups found to have polyps. This suggests they were a
result of polyp detection rather than surveillance per se. Overall, surveillance itself appeared to be
associated with improved psychological well-being.
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Chapter 7 Synthesis
Current UK guidelines recommend 3-yearly surveillance for patients classified as being at IR based oncharacteristics of adenomas that were found at baseline colonoscopy. The IR group represents 17%
of people testing positive in the NHS BCSP,36 and around 40% of patients with adenomas in the hospital
data set in this study, with consequent demand on colonoscopy resources, yet the heterogeneity of the
group in terms of cancer risk and surveillance requirements has not been investigated. We therefore
sought to examine the effect of surveillance interval length on detection rates of AA and CRC in patients
attending follow-up after removal of IR adenomas, and of surveillance colonoscopy on CRC risk after
baseline. We investigated whether or not there exist subgroups of patients who might not benefit from
surveillance, or in whom a single surveillance examination might suffice, and also assessed whether or not
the interval to surveillance should be shortened or could be safely extended in certain patients.
Hospital and screening data sets
To investigate these questions we used two main sources of data. The first, the hospital data set,
represented a symptomatic population; being the largest data set (n = 11,944), this formed the core of our
study. The second, smaller, screening data set comprised an asymptomatic screening population (n = 2352)
from three individual screening studies. There were several differences between the hospital and screening
data sets. Patients in the hospital data set were older, and examinations were generally more recent
(2005–10), and, as a result, the average follow-up time for CRC risk was shorter than for the screening
data (6.0 years vs. 11.0 years). The hospital cohort had more adenomas that were large (≥ 20 mm) or had
HGD, more reports of poor-quality examinations, and lower follow-up attendance (40% hospital data set
vs. 80% screening data set; 14% vs. 43% with two or more follow-ups). Because the hospital data set
was larger, this data set was used to identify risk factors at baseline and FUV1 for future CRC risk and for
findings at FUV1 and FUV2, and thereby to identify HIR and LIR subgroups.
In the hospital data set, 20% of baseline examinations and 50% of follow-up procedures took place after
2004. Since then when examination quality has probably improved, as demonstrated by the declining
proportion of patients with an incomplete colonoscopy in our data over time; however, there was no
evidence to suggest that bowel preparation quality had improved. Examination quality was better in the
screening data set than in the hospital data set (96% with complete colonoscopy vs. 76%). We have
shown that this difference partly explains the larger size of the LIR subgroup and lower rate of CRC in the
screening data set, and may also account for the lower detection rates of AA and CRC at FUV1.
Main findings
Is a 3-year interval appropriate? Is there a group that needs a shorter interval
to the first or second follow-up examination, or in which follow-up could
be postponed?
Our results from the hospital data set suggest that the current surveillance interval of 3 years is suitable
for the majority of IR patients, as detection rates of CRC were < 1% before the interval extended beyond
3 years, and detection rates of AA were around 9% during this time, making the examination at 3 years
worthwhile. The data do not indicate that surveillance needs to be done earlier in this group of patients,
as in the first 3 years there was little increase in rates of AA and a low rate of CRC, so any gains from a
shorter interval are likely to be very small.
In the hospital data set, at FUV1 the odds of detecting AA or CRC increased significantly with increasing
with interval length. In contrast, in the screening data set there was no association between interval and
findings at FUV1, before or after adjustment for covariates, possibly due to the lack of variation in interval
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length within cohorts, as in a screening programme, recommended surveillance intervals are usually fixed.
Also, the KP cohort tended to have a longer interval and a lower rate of CRC, whereas in the EP and
UKFSST cohorts a shorter interval was more common and there were higher rates of CRC, thus cancelling
out any potential effects of interval when the cohorts were pooled. We were therefore unable to validate
our findings regarding the optimum interval inferred from the hospital data set using the screening
data set.
Does surveillance provide any benefit in terms of long-term cancer risk? Is there
a group who do not require a follow-up examination or in whom a second
follow-up examination might be omitted?
We found strong evidence that a single surveillance visit conferred substantial benefit to IR patients by
lowering their future risk of CRC, in both the hospital and screening data sets. In the hospital data set, one
follow-up conferred a significant 49% reduced risk of CRC after baseline, and results from the screening
data set validated this finding, with a significant 73% lower risk of CRC observed after one follow-up.
The first surveillance visit appeared to offer most of the protection, and the benefit of additional surveillance
was less clear. In the hospital data set, having two or more follow-up visits was associated with an additional
reduction in CRC risk, whereas in the screening data set additional surveillance did not appear to provide
any further protection, possibly because the screening participants were already at lower risk as a
consequence of their younger age and better-quality examinations.
There did appear to be heterogeneity among IR patients in terms of long-term CRC risk and surveillance
needs. The LIR and HIR subgroups (based on polyp and procedural predictors of CRC risk) were discriminant
in terms of future CRC risk in both the hospital and screening data sets, although the difference was not
statistically significant in the screening data set. In both data sets, in the HIR subgroup a single surveillance
visit was associated with a strong protective effect against risk of CRC, and additional surveillance appeared
to provide further benefit.
By contrast, in both data sets, in the LIR subgroup the first surveillance visit was associated with a small,
non-significant reduction in risk, and additional surveillance did not appear to provide any further
protection. In addition, the pre-surveillance (post-baseline) standardised incidence rate of CRC in the LIR
subgroup was lower than that of the general population, significantly so in the hospital data set.
We conclude that those in the HIR subgroup are likely to benefit from additional surveillance after the first
follow-up, but, for the LIR group, additional surveillance, or potentially any surveillance, may be unnecessary.
The HIR subgroup is at higher risk of CRC than the general population, and continued surveillance appears
to reduce this risk close to the population level. The small number of CRC end points in the LIR subgroup in
both data sets prevented us from concluding whether or not this group would benefit from surveillance.
Indeed, as the LIR subgroup were already at lower risk than the general population, the question remains as
to what level of surveillance should they be offered in the future.
Economic evaluation
A health-economic simulation model, which assessed the cost-effectiveness of 13 surveillance options for
patients with intermediate-grade adenomas, suggested that 3-yearly ongoing colonoscopic surveillance
without an age cut-off would produce the greatest health gain. The ICER for this option (compared
against the same strategy with an age cut-off of 75 years) was expected to be approximately £2748 per
QALY gained. Although 3-yearly ongoing surveillance appears to be the most effective strategy and health
gains are expected to be achieved at a cost which may be acceptable to NHS policy-makers, it may be
preferable to pursue less effective strategies that also offer a favourable cost-effectiveness profile. As such,
the potential to safely stop surveillance in the LIR subgroup remains an important and pertinent finding
that warrants further investigation.
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Psychological study
The results of the psychological study demonstrated that referral for colonoscopic surveillance is not
associated with adverse psychological consequences. Although post-screening bowel cancer worry and
bowel symptoms were higher in people assigned to surveillance, they declined over time and were
equivalent to levels observed in the other two groups found to have polyps. This suggests that they were
a result of polyp detection rather than surveillance per se. Overall, surveillance itself appeared to be
associated with improved psychological well-being and, consequently, were colonoscopic surveillance to
be stopped in a subset of IR patients it may be necessary to consider offering an alternative intervention,
such as a faecal immunochemical test, to patients in order to provide reassurance.
Factors affecting surveillance
Examination quality
Colonoscopy completeness and quality of bowel preparation were important predictors of CRC in our
cohort. There has been a substantial improvement in endoscopy quality in the past 10 years; however,
there needs to be clear guidance on how to manage patients who are found to have adenomas
warranting surveillance and who have suboptimal examinations. Although colonoscopy guidelines advise
that a repeat examination is performed in such cases,24 for those individuals in whom colonoscopy is
difficult and therefore unsuccessful it is probably inappropriate to recommend repeated colonoscopic
surveillance; alternative whole-bowel investigations should be offered instead.
Missed and incompletely resected lesions
Important lesions found at surveillance colonoscopy are thought to be a mixture of missed lesions,
incompletely excised baseline lesions and newly developing lesions.17,113 A systematic review of six studies,114
including 465 patients, found an adenoma miss rate of up to 7% for adenomas of ≥ 10mm, 18% for
adenomas of 6–9mm and 35% for small (≤ 5mm) adenomas, with an overall miss rate of one in five polyps;
flat and sessile serrated lesions were especially likely to be missed.115,116 The potential for lesions missed at
baseline to develop into post-colonoscopy CRCs,117,118 and the possibility that missed baseline lesions may
cause underestimation of risk and improper surveillance recommendations – the Will Rogers phenomenon119 –
should be taken into account when considering how soon to perform surveillance after baseline. For this
reason, if a patient is deemed to be at sufficient risk to warrant surveillance, the first surveillance should not
be delayed.
Compliance
Another factor to consider when determining appropriate intervals is the effect on patient adherence to
surveillance. In light of this, we might ask whether surveillance should be performed soon after baseline or
not, and what are the possible reasons for carrying out surveillance sooner. Compliance with surveillance
colonoscopy is not extensively studied, although the limited studies available suggest that compliance
rates in studies of post-polypectomy surveillance range from 66% to 85%.8,33,120–122 We were not able to
examine compliance in our study, which recorded only if a person attended follow-up and not if they were
scheduled to do so.
Compliance with surveillance may be improved by inviting patients to return sooner. In the US National
Polyp Study,8 compliance was slightly higher in patients whose first examination was at 1 year than in
those first examined at 3 years (83% vs. 78%), providing some evidence that a shorter interval may be
beneficial in terms of improving adherence. A randomised trial in England found that patients with a 2- or
5-year surveillance interval had compliance rates of 86% and 74%, respectively, although non-attenders
were pursued using postal reminders and a letter to GPs, which may have improved attendance in both
groups.33 A larger proportion of patients in the 5-year interval group were lost to follow-up due to death
or because they reached 75 years of age, making them ineligible for surveillance; thus, it is difficult to
discern the effect of interval on compliance in this study. However, this study does show that if surveillance
is to be stopped at age 75 years then surveillance for patients aged > 70 years at initial adenoma detection
should not have their surveillance examinations delayed if they are fit and at high enough risk.
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Strengths and limitations
A major strength of this study was the wide variation in surveillance interval length, which is a unique
feature of the hospital data set. Another achievement, in terms of the hospital data set, was the creation
of a high-quality data set despite the numerous difficulties encountered, which demonstrates that,
although problematic, it is possible to use data from routine secondary care sources and obtain reliable
results, as evidenced by validation of our results in the screening data set.
Apart from data on examination quality in both the hospital and screening data sets, there were very few
missing data and this, together with the use of extensive data cleaning, reduced the risk of bias arising
from measurement error or misclassification. Owing to the nature of the routine data that made up the
hospital data set, some measurement error and misclassification is inevitable; however, this would most
likely have been non-differential and thus would have resulted in the underestimation of the effect of
surveillance and interval length. Furthermore, follow-up was complete for almost all patients, limiting the
potential for selection bias, and the study had wide geographic coverage, which improves external validity.
Sensitivity analyses described in Chapter 3 (see Sensitivity analyses and internal validation) provided
evidence of the relative robustness of the methods used to define visits and intervals, to extend baseline
and to define the outcome of AA. The results of these analyses did not differ substantially from the main
analyses and thus suggested that the applied methods did not introduce bias.
A limitation of our study is that in the hospital data set, although some patients were censored before the
end of hospital data collection, the majority had follow-up time after the end of data collection in which
they may have attended surveillance visits. Sensitivity analyses restricted to patients with at least 5 years
of follow-up indicate that the effect of surveillance on CRC risk and absolute pre-surveillance risk in the
cohort is likely to have been underestimated as a consequence of contamination of the no-surveillance
group. This could be remedied through the collection of additional hospital data in the future.
One limitation of the economic analysis is that the model assumed that all cancers arise from prior
adenomas when there is indirect evidence to suggest that a proportion of CRCs arise de novo rather than
as a consequence of the adenoma–carcinoma sequence. Furthermore, given better data, frailty models –
to distinguish between those adenomas that will develop into cancer and those that will not – may have
produced a more accurate representation of the natural history process. Additionally, the MSM did not
differentiate by cancer stage, which may result in different estimates of diagnosis and treatment costs.
The model also assumed adenoma detection through surveillance, but, in reality, adenomas may also be
detected through symptomatic or opportunistic presentation. Furthermore, the model may overestimate
the clinical benefits and cost-effectiveness of surveillance programmes in comparison with usual clinical
practice as all patients were assumed to attend their scheduled surveillance visits and be sufficiently fit to
undergo colonoscopy. Finally, the model assessed only ongoing surveillance with a fixed interval or
once-only surveillance; however, it may be possible that alternative surveillance options that were not
defined for inclusion in this analysis could produce greater expected health gains than those estimated
within this analysis.
Implications for health care
Although policy changes cannot be recommended, we believe that the findings of this study provide
high-quality evidence which will allow policy-makers to review current surveillance guidelines for individuals
with intermediate-grade adenomas. The results suggest that, although the current 3-year interval is
appropriate for most, patients with certain baseline characteristics may not benefit from additional
surveillance beyond the first follow-up, offering the potential to alleviate pressure on endoscopy services.
In terms of the implications that this research may have for health care, the difficulties encountered during
the study indicate that improved reporting techniques and standardisation across hospital endoscopy and
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pathology systems would enable the more effective use of such data for research purposes in the future.
We feel that this is an important point, as hospital endoscopy and pathology data contain invaluable
information that should be recorded bearing future research in mind.
Recommendations for future research
Future studies are needed to validate whether or not the long-term CRC risk factors identified in this study
are predictors of findings at surveillance, as suggested by results from our hospital data set. Research is
also needed to further examine whether or not surveillance is of equal benefit to all IR patients, and
whether or not one surveillance visit provides adequate protection for some.
A number of outstanding research questions can be investigated using this high-quality data set; such
investigations should be relatively straightforward, as all data are coded and analysable. Future research
could investigate the optimum surveillance strategies for low- and high-risk groups, both of which are
present in large numbers within the original study cohort. Specifically, we plan to use the data set to
determine the optimum frequency of surveillance in patients with high-risk adenomas and the necessity for
the 1-year post-baseline colonoscopy currently recommended, and to verify whether or not the low-risk
group is of low enough risk of CRC to justify offering no surveillance. Research into the effect of
hyperplastic polyps and other serrated lesions on the risk of AN will also be possible using this rich data
set, and we will examine the modifying effect of hyperplastic and serrated polyps on future risk of CRC in
patients with low-, intermediate- or high-risk adenomas and identify appropriate surveillance intervals.
We will also investigate the feasibility of collecting information on follow-up examinations for the last
5 years, during which time we followed the hospital cohort using national sources but did not have the
resources to collect further data.
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Chapter 8 Conclusions
Our results provide strong evidence that a single surveillance visit confers substantial benefit to IRpatients by lowering their future risk of CRC. IR patients showed heterogeneity in terms of their
surveillance needs; in the hospital data set a HIR subgroup benefited from additional surveillance after the
first follow-up examination, but in the LIR subgroup additional surveillance may be unnecessary, as patients
in this subgroup were at a substantial 60% lower risk than the general population, even before their first
surveillance visit.
The screening data set results validated findings from the survival analysis in the hospital cohort, providing
further evidence of the benefit of surveillance in IR patients. Risk subgroups derived from risk factors for
longer-term CRC in the hospital data set were discriminant in terms of CRC risk in the screening data set,
but did not discriminate between individuals with and without findings at the first follow-up, probably
because individuals in the screening data sets were at lower risk and had fewer outcomes.
Referral for colonoscopic surveillance was not associated with adverse psychological consequences. Rather,
bowel cancer worry was seemingly related to the detection of growths in the bowel rather than to
colonoscopic surveillance itself. Overall, surveillance itself appeared to be associated with improved
psychological well-being.
Although 3-yearly ongoing surveillance appears to be the most effective strategy, and such health gains
are expected to be achieved at a cost which may be acceptable to NHS policy-makers, it may be preferable
to pursue less effective strategies that also offer a favourable cost-effectiveness profile.
Future studies should be undertaken to further validate the findings of this study, and confirm whether or
not surveillance is truly of benefit to all IR patients, and whether or not one surveillance visit provides
adequate protection for some.
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Appendix 1 Hospital data collection from
endoscopy and pathology databases
Data were bulk extracted from hospital endoscopy and pathology databases. This document contains asummary of systems from which data were extracted and the methods used.
Endoscopy and pathology data extraction summary
The following is a summary of the data extracted from each hospital’s endoscopy and pathology
databases, with an explanation of the information recorded in each field.
Endoscopy systems in use at the hospital:
Extraction Dates:
Extraction Dates:
Methods used to extract the pathology data:
Missing pathology manually collected later:
Extraction issues on endoscopy systems:
Extraction issues on pathology systems:
Pathology systems in use at the hospital:
Endoscopy systems that
were in use at the hospital 
between certain time periods.
For the recent systems, the 
end date will be the last time 
data were collected by us from 
those systems so they may 
still be in use
Pathology systems that
were in use at the hospital 
between certain time periods.
For the recent systems the 
end date will be the last time 
data were collected by us from 
those systems so they may 
still be in use
Issues encountered
when extracting 
the data
Study researchers manually
collected any pathology data that were
missing and these are the dates
within which the data were collected
Methods used to extract
the pathology data
Period within which 
the pathology data 
were extracted
Issues encountered
when extracting 
the data
Period within which
the endoscopy data 
were extracted
Royal Sussex County Hospital, Brighton and Sussex University Hospitals
NHS Trust
Endoscopy systems in use at the hospital: Unisoft (2001–Apr 2008)
Extraction dates: May 2001–Apr 2008
Extraction issues on endoscopy systems: The hospital staff had to set up Unisoft’s GI auditors’ kit in order to
extract the data
GI, gastrointestinal.
Pathology systems in use at the hospital: Radius (1986–2005)
WinPath (2005–Apr 2008)
Extraction dates: Jan 2000–Apr 2008
Methods used to extract the pathology data: SNOMED codes Version 2
Missing pathology manually collected later: May 2001–Apr 2008
Extraction issues on pathology systems: The WinPath system went live in May 2005 so previous data were
extracted from legacy systems. From other investigations we think the
legacy system might be Radius, based on seeing Radius in use at other
hospitals
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Charing Cross Hospital and Hammersmith Hospital, Imperial College
Healthcare NHS Trust
Endoscopy systems in use at the hospital: EndoScribe (Sept 1997–Nov 2007) migrated and extracted via Scorpio
Extraction dates: Sep 1997–Nov 2007
Extraction issues on endoscopy systems: The data from EndoScribe had been migrated to Scorpio so the data
were extracted via Scorpio
Pathology systems in use at the hospital: Osiris (Jan 1992–Apr 2002)
WinPath (1990–2004)
Co-Path (2004–Apr 2011)
Extraction dates: Feb 1990–Jul 2010
Methods used to extract the pathology
data:
Osiris – SNOP codes (four-digit versions of SNOMED codes)
Co-Path – search terms used: adenocarcinoma, adenoma, anastomosis,
angiodysplasia, anus, benign tumour, bowel, cancer, carcinoid, colitis,
colon, Crohn’s disease, diverticular disease, diverticulosis, FAP,
haemorrhoids, hemicolon, IBD, malignant, melaena, melanosis coli, piles,
polyp, polyposis, polyps, proctitis, prolapse, rectum, stricture, suspected
IBD, tumour, volvulus
WinPath – this was an old archive database in Microsoft Access®
(Microsoft Corporation, Redmond, WA, USA) format. We extracted the
relevant pathology from this
Missing pathology manually collected
later:
Jan 1993–Apr 2011
Extraction issues on pathology systems: Osiris and WinPath were used in parallel between 1992 and 2002, so
any overlapping records were merged
Other extraction issues: Hammersmith and Charing Cross hospitals had overlapping data so they
were combined as one centre
St Mary’s Hospital, Imperial College Healthcare NHS Trust
Endoscopy systems in use at the hospital: Micromed (1980–2007)
Scorpio (2007–Aug 2010)
Extraction dates: Dec 1984–Aug 2010
Extraction issues on endoscopy systems: Scorpio data were extracted after 6 p.m. to ensure that it did not slow
the system down. Extracts for colonoscopy and FS were done separately
and broken down into years
There was only one computer with Micromed on it, which was located in
the endoscopy reception and could be used only after hours, as there
were concerns that there was no back-up of the data for the system. Our
team had to work within these restricted time constraints to extract the
data
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Pathology systems in use at the hospital: Telepath (1988–Nov 2010)
Extraction dates: 1990–Jul 2010
Methods used to extract the pathology
data:
Missing pathology manually collected
later:
1987–Nov 2010
Extraction issues on pathology systems: Used Telepath SIFT search for SNOP CODES (four-digit versions of
SNOMED codes)
Cumberland Infirmary, North Cumbria University Hospitals NHS Trust
Endoscopy systems in use at the hospital: EndoScribe (1998–Sep 2009)
Extraction dates: Jul 1998–Sep 2009
Extraction issues on endoscopy systems: Two searches were performed on EndoScribe, one for colonoscopy
and one for sigmoidoscopy. Both searches extracted the same fields.
Test runs were carried out to determine which fields contained useful
information and 20,000 records were extracted
Pathology systems in use at the hospital: Telepath (1988–Dec 2009)
Extraction dates: Jul 1998–Sep 2009
Methods used to extract the pathology
data:
Used Telepath SIFT search for SNOP CODES (4-digit versions of SNOMED
codes)
Missing pathology manually collected
later:
Oct 1994–Dec 2009
Extraction issues on pathology systems: The study programmer was trained by iSoft, which manufactures
Telepath
Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde
Endoscopy systems in use at the hospital: EndoScribe (1995–2005)
GIScribe (2003–2007)
Unisoft (2007–Sep 2009)
Extraction dates: Apr 1996–Sep 2009
Extraction issues on endoscopy systems: EndoScribe and GIScribe were used concurrently for approximately a
2-year period (2002–2005), so during this period data could appear on
either system. A return visit was necessary to retrieve missing data from
EndoScribe that was assumed to be on GIScribe
Pathology systems in use at the hospital: Telepath (1987–Nov 2011)
Extraction dates: Jan 1996–Sep 2009
Methods used to extract the pathology
data:
Used Telepath SIFT search for SNOP CODES (4-digit versions of SNOMED
codes)
Missing pathology manually collected
later:
Aug 1992–Nov 2011
Extraction issues on pathology systems: The study programme was trained by iSoft, which manufactures Telepath
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Leicester General Hospital, University Hospitals of Leicester NHS Trust
Endoscopy systems in use at the hospital: Unisoft (1998–present)
Extraction dates: 1988–Apr 2008
Extraction issues on endoscopy systems: Unisoft created a bespoke query for the study programmer to extract the
data from the endoscopy database. This was installed at the hospital
using the Unisoft GI Auditor’s Kit
Pathology systems in use at the hospital: iLaboratory (iLab) (previously called APEX), supported by iSOFT
(1988–Dec 2009)
Extraction dates: 1988–Apr 2008
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
May 1997–Dec 2009
Extraction issues on pathology systems: Data were extracted in the form of CSV files, one for each year from
1997 to 2007. The format of the CSV files was difficult to work with,
as each line of the report was on a new row, so the study programmer
wrote a program to format and extract the data
CSV, comma-separated values.
New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust
Endoscopy systems in use at the hospital: Micromed (1992–2007)
Extraction dates: 1993–2007
Extraction issues on endoscopy systems: The system was used consistently from only 1993 onwards. Instructions
for extracting data were obtained from the designer of the database,
Medical Systems
Pathology systems in use at the hospital: Radius (1988–1999)
APEX (2000–Apr 2010)
Extraction dates: 1993–Nov 2007
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
Jan 1986–Apr 2010
Extraction issues on pathology systems: APEX data were extracted in December 2007, but we were unable to
extract free-text information and had to wait until the data were
migrated to the Technidata system. Data were re-extracted from
Technidata in May 2010 to complete the missing information. Technidata
were still undergoing data cleaning so we recollected the data in
April 2011, as some of the previously corrected records were corrupt
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University Hospital of North Tees, North Tees and Hartlepool NHS
Foundation Trust
Endoscopy systems in use at the hospital: Micromed (1986–2006)
Unisoft (2006–2008)
Extraction dates: 1986–2006
Extraction issues on endoscopy systems: Instructions for extracting data from MicroMed were provided by the
company that designed the system
Pathology systems in use at the hospital: Clynisis and Pathlan LIMS (Jan 1997–Dec 2001)
QuadraMed OmniLab LIMS (Mar 2004–Oct 2009)
Extraction dates: 2004–2007
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
Dec 1996–Oct 2009
Extraction issues on pathology systems: The histology system moved from Hartlepool to North Tees in January
2002 and OmniLab was not used until March 2004. Between these
dates, they used a William Woodard system at North Tees, but the
system was no longer operational so data could not be bulk extracted
from it. In August 2010 we recontacted the hospital and found that they
had data on OmniLab from 2002 onwards. The data between 2002 and
March 2004 were then manually collected by the study researchers. We
were unable to match any of the Pathlan data to the endoscopy data.
This centre had a large number of endoscopy reports with missing
pathology, so the additional information was collected as part of the
missing pathology data collection by the study researchers
Queen Elizabeth Hospital, South London Healthcare NHS Trust
Endoscopy systems in use at the hospital: EndoScribe (1999–Jun 2006)
ADAM (2006–present): not used
Extraction dates: 1999–Jun 2006
Extraction issues on endoscopy systems: On the ADAM system, the body of the report with the details was not
exported by default so a decision was made not to use these data. Data
from EndoScribe were extracted using a global search for the word ‘polyp’
Pathology systems in use at the hospital: HBO (2000–2006)
Clinysis (2006–Apr 2011)
Extraction dates: 2000–2006
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
Nov 1999–Apr 2011
Extraction issues on pathology systems: Clinysis was the system in use at the time of data collection. We tried to
extract the data using SNOMED codes but the extracted data were limited
and not usable. It was therefore decided that only data from HBO would be
used. Clinysis was used for the missing pathology data collection
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Queen Mary’s Hospital, South London Healthcare NHS Trust
Endoscopy systems in use at the hospital: Micromed (1985–Jan 2006)
Unisoft (2003–Jul 2009)
Extraction dates: Oct 1988–Jul 2009
Extraction issues on endoscopy systems: It was necessary to restore the old Micromed database from a back-up
tape. The systems were used in parallel between 2003 and 2006,
so duplicate records were merged
Pathology systems in use at the hospital: Data prior to APEX had been migrated to APEX (1988–1994) APEX
(1994–Jan 2011)
Extraction dates: Jul 1987–Dec 2009
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
May 1988–Jan 2011
Extraction issues on pathology systems: An iSoft consultant was hired to extract data from the APEX system
Royal Liverpool University Hospital, Royal Liverpool and Broadgreen
University Hospitals NHS Trust
Endoscopy systems in use at the hospital: Bespoke system (1991–2006)
Unisoft (2006–Oct 2009)
Extraction dates: Jan 2000–Oct 2009
Extraction issues on endoscopy systems: Hospital staff set up the system to extract the data
Pathology systems in use at the hospital: Telepath (1996–Nov 2010)
Extraction dates: Jan 2000–Oct 2009
Methods used to extract the pathology
data:
SNOMED codes Version 2
Missing pathology manually collected
later:
May 1991–Nov 2010
Extraction issues on pathology systems: Hospital staff helped the study programmer to extract the data
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Royal Surrey County Hospital, Royal Surrey County Hospital NHS
Foundation Trust
Endoscopy systems in use at the hospital: Micromed (1997–May 2010)
Extraction dates: Sep 1997–May 2010
Extraction issues on endoscopy systems: Micromed was used from 1988 but the records up to 1996 were lost.
Searches produced errors that caused the system to crash. Data
extraction had to be performed by hospital staff in batches, each batch
consisting of all the records for a 6-month period
Pathology systems in use at the hospital: Bespoke System (1991–2001) that existed on Telepath
Telepath (2002–Sep 2009)
Clinisys WinPath (Oct 2009–Nov 2010)
Extraction dates: 1997–Sep 2009
Methods used to extract the pathology
data:
Combination of branched searches and using wildcards to search on
words such as adenoma’, ‘polyp’, ‘tumour’, colorectal sites, plus
SNOMED codes version 2
Missing pathology manually collected
later:
Jun 1996–Nov 2010
Extraction issues on pathology systems: Data were only bulk extracted from the Telepath system at Royal Surrey,
which had some years for which the data were not SNOMED coded. We
therefore had to conduct separate searches on SNOMED codes, branded
searches, and wild card searches
St George’s Hospital, St George’s Healthcare NHS Trust
Endoscopy systems in use at the hospital: Micromed (1992–Jul 2009)
Extraction dates: Feb 1992–Jul 2009
Extraction issues on endoscopy systems: Instructions for extracting data were obtained from the designer of the
database, Medical Systems
Pathology systems in use at the hospital: Other electronic system (1988–1993)
iLaboratory (iLab) (previously called APEX), supported by iSOFT
(1994–Jul 2009)
Extraction dates: Aug 1997–Dec 2009
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
Feb 1992–July 2009
Extraction issues on pathology systems: In July 2009, the body of the pathology report could not be extracted.
An iSoft consultant was hired to extract the data for us in January 2010
to complete the missing information
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Royal Shrewsbury Hospital, Shrewsbury and Telford Hospital NHS Trust
Endoscopy systems in use at the hospital: EndoScribe (2001–2009)
Extraction dates: Nov 2001–Sep 2009
Extraction issues on endoscopy systems: The study programmer was familiar with the system
Pathology systems in use at the hospital: Telepath (1992–2010)
Extraction dates: 2000–Sept 2009
Methods used to extract the pathology
data:
SNOP CODES (four-digit versions of SNOMED codes)
Missing pathology manually collected
later:
Jan 2002–Sep 2009
Extraction issues on pathology systems: The study programmer required training from iSoft to extract the data
from Telepath. Pathology records were collected only as far back as the
endoscopy data were documented
St Mark’s Hospital, North West London Hospitals NHS Trust
Endoscopy systems in use at the hospital: Metabase (1972–2003)
Endosoft (2004–present)
Extraction dates: 1972–Jul 2007
Extraction issues on endoscopy systems: Following data extraction from Metabase, the computer on which
Metabase was stored stopped working and is no longer accessible.
Luckily the data that we required had been extracted before the
computer stopped working
Pathology systems in use at the hospital: Cerner Classic and City Road (1989–Oct 2002)
Cerner LIMS (Oct 2002–May 2011)
Extraction dates: Aug 1987–31 Oct 2006
Methods used to extract the pathology
data:
SNOMED codes version 2
Missing pathology manually collected
later:
Nov 1986–May 2011
Extraction issues on pathology systems: The records from the different systems were merged
Torbay Hospital, South Devon Healthcare NHS Foundation Trust
Endoscopy systems in use at the hospital: EndoScribe (2000–2007)
Scorpio (2007–present)
Extraction dates: Oct 2000–Aug 2007
Extraction issues on endoscopy systems: Hospital staff helped with the extraction of data
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Pathology systems in use at the hospital: EDS (1998–2009)
WinPath (2010–Oct 2010)
Extraction dates: Jun 1999–Feb 2008
Methods used to extract the pathology
data:
Search on the words ‘polyp’ and ‘adenoma’
Missing pathology manually collected
later:
Jan 1998–Oct 2010
Extraction issues on pathology systems: Initially the search on the word ‘polyp’ did not pick up all relevant
reports, so the study programmer revisited the hospital to extract reports
using the search terms ‘polyp’ and ‘adenoma’
Yeovil District Hospital, Yeovil District Hospital NHS Foundation Trust
Endoscopy systems in use at the hospital: EndoScribe (1997–2008)
Extraction dates: Feb 1997–May 2008
Extraction issues on endoscopy systems: Some technical issues encountered with special characters in the files
making the data transformation process difficult
Pathology systems in use at the hospital: PathoSys (1997–Sep 2010)
Extraction dates: Jan 1998–Dec 2007
Methods used to extract the pathology
data:
Hospital used a combination of search by SNOMED version 3.5, which
included anything coded as a colorectal polyp of any type, with any
associated M codes that would include carcinoma
Missing pathology manually collected
later:
Feb 1997–Sep 2010
Extraction issues on pathology systems: The pathology search was difficult as it was carried out over several
months and involved a number of manipulations, first as a text file and
then in Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA).
One out of the four pathology files extracted did not have hospital
numbers, so the matching was done using name and date of birth
Systematized Nomenclature of Medicine codes version 2
The following is a comprehensive list of SNOMED version 2 codes that were sent to hospital pathology
departments in order to extract the data.
Yeovil District Hospital did not use SNOMED version 2, so the hospital staff used the SNOMED version 2
codes that we supplied and searched for the corresponding SNOMED version 3.5 codes.
Some hospitals searched for SNOP codes, which are the first four digits of the SNOMED version 2 codes
that we supplied, without the initial T or M.
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Codes for lesion site
Code Description
T-68010 Rectal mucous membrane
T-68002 Perineal flexure of rectum
T-68001 Sacral flexure of rectum
T-68000 Rectum, NOS
T-67995 Descending colon and sigmoid colon, CS
T-67995 Left hemicolon
T-67995 Left colon
T-67990 Sigmoido-sigmoidocolic, CS
T-67990 Sigmoid colon and sigmoid colon, CS
T-67980 Colo-sigmoidocolic, CS
T-67980 Colon and sigmoid colon, CS
T-67970 Caeco-sigmoidocolic, CS
T-67970 Caecum and sigmoid colon, CS
T-67965 Caecum and ascending colon, CS
T-67965 Right hemicolon
T-67965 Right colon
T-67960 Colo-caecal, CS
T-67960 Colon and caecum, CS
T-67950 Colon and skin, CS
T-67940 Caecum and abdominal wall, CS
T-67930 Sigmoid colon and abdominal wall, CS
T-67920 Colo-rectal, CS
T-67920 Colon and rectum, CS
T-67910 Colon and abdominal wall, CS
T-67900 Colo-colic, CS
T-67900 Colon and colon, CS
T-67860 Pericolic tissue
T-67850 Phrenicocolic ligament
T-67840 Mesentery of sigmoid colon
T-67830 Mesentery of descending colon
T-67820 Transverse mesocolon
T-67810 Mesentery of ascending colon
T-67800 Mesocolon, NOS
T-67800 Mesentery of colon, NOS
T-67700 Sigmoid colon
T-67600 Descending colon
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Code Description
T-67500 Splenic flexure of colon
T-67500 Left colic flexure
T-67400 Transverse colon
T-67300 Hepatic flexure of colon
T-67300 Right colic flexure
T-67200 Ascending colon
T-67120 Frenulum of ileocaecal valve
T-67110 Ileocaecal ostium
T-67100 Caecum
T-67090 Colonic serosa
T-67080 Colonic subserosa
T-67073 Tenia libera
T-67072 Tenia omentalis
T-67071 Tenia mesocolica
T-67070 Tenia coli
T-67060 Appendix epiploica
T-67050 Colonic solitary lymphoid nodule
T-67045 Haustra of colon
T-67045 Colonic haustra
T-67042 Colonic muscularis propria, circular layer
T-67041 Colonic muscularis propria, longitudinal layer
T-67040 Colonic muscularis propria
T-67030 Colonic submucosa
T-67020 Colonic crypt of Lieberkühn
T-67016 Colonic lamina propria
T-67015 Colonic epithelium
T-67012 Colonic gland, NOS
T-67011 Lamina muscularis of colonic mucous membrane
T-67010 Colonic mucous membrane
T-67000 Colon, NOS
T-67000 Large bowel, NOS
T-67000 Large intestine
CS, combined site; NOS, not otherwise specified.
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Codes for lesion type
Code Description
M-74008 Dysplasia, severe
M-74007 Dysplasia, moderate
M-74006 Dysplasia, mild
M-74005 Dysplasia, atypical
M-74003 Severe dysplasia (morphological abnormality)
M-74002 Moderate dysplasia (morphological abnormality)
M-74001 Mild dysplasia (morphological abnormality)
M-74000 Dysplasia (morphological abnormality)
M-72041 Tubulovillous adenoma
M-72042 Hyperplastic polyp (morphological abnormality)
M-72040 Polypoid hyperplasia (morphological abnormality)
M-76800 Polyp
M-76801 Polyp, sessile
M-76802 Polyp, pedunculated
M-76803 Polyp, atypical
M-76804 Polyp, ulcerated
M-76805 Polyp, inflamed
M-76806 Polyp, vascular
M-76807 Polyp, hyalinised
M-76808 Polyp, myxoid
M-76809 Polyp, multiple
M-76810 Polyp, fibroepithelial
M-76820 Inflammatory polyp
M-7680A Inflammatory polyp [dup] (morphological abnormality)
M-82633 Adenocarcinoma in tubulovillous adenoma (morphological abnormality)
M-82632 Adenocarcinoma in situ in tubulovillous adenoma (morphological abnormality)
M-82630 Tubulovillous adenoma (morphological abnormality)
M-82623 Villous adenocarcinoma (morphological abnormality)
M-82613 Adenocarcinoma in villous adenoma (morphological abnormality)
M-82612 Adenocarcinoma in situ in villous adenoma (morphological abnormality)
M-82611 Villous adenoma, NOS
M-82610 Villous adenoma (morphological abnormality)
M-82603 Papillary adenocarcinoma (morphological abnormality)
M-82600 Papillary adenoma (morphological abnormality)
M-82553 Adenocarcinoma with mixed subtypes (morphological abnormality)
M-82453 Adenocarcinoid tumour (morphological abnormality)
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Code Description
M-82451 Tubular carcinoid (morphological abnormality)
M-82443 Composite carcinoid (morphological abnormality)
M-82433 Goblet cell carcinoid (morphological abnormality)
M-82423 Enterochromaffin-like cell tumour, malignant (morphological abnormality)
M-82421 Enterochromaffin-like cell carcinoid (morphological abnormality)
M-82413 Enterochromaffin cell carcinoid (morphological abnormality)
M-82411 Carcinoid tumour, argentaffin, NOS
M-82403 Carcinoid tumour (except of appendix, M-82401) (morphological abnormality)
M-82401 Carcinoid tumour of uncertain malignant potential (morphological abnormality)
M-82313 Carcinoma simplex (morphological abnormality)
M-82303 Solid carcinoma (morphological abnormality)
M-82302 Ductal carcinoma in situ, solid type (morphological abnormality)
M-82213 Adenocarcinoma in multiple adenomatous polyps (morphological abnormality)
M-82210 Multiple adenomatous polyps (morphological abnormality)
M-82203 Adenocarcinoma in adenomatous polyposis coli (morphological abnormality)
M-82200 Adenomatous polyposis coli (morphological abnormality)
M-82153 Adenocarcinoma of anal glands (morphological abnormality)
M-82143 Parietal cell carcinoma (morphological abnormality)
M-82130 Serrated adenoma (morphological abnormality)
M-82120 Flat adenoma (morphological abnormality)
M-82113 Tubular adenocarcinoma (morphological abnormality)
M-82110 Tubular adenoma (morphological abnormality)
M-82103 Adenocarcinoma in adenomatous polyp (morphological abnormality)
M-82102 Adenocarcinoma in situ in adenomatous polyp (morphological abnormality)
M-82100 Adenomatous polyp (morphological abnormality)
M-814FF Adenoma AND/OR adenocarcinoma (morphological abnormality)
M-81490 Canalicular adenoma (morphological abnormality)
M-81482 Glandular intraepithelial neoplasia, grade III (morphological abnormality)
M-81473 Basal cell adenocarcinoma (morphological abnormality)
M-81470 Basal cell adenoma (morphological abnormality)
M-81460 Monomorphic adenoma (morphological abnormality)
M-81453 Carcinoma, diffuse type (morphological abnormality)
M-81443 Adenocarcinoma, intestinal type (morphological abnormality)
M-81433 Superficial spreading adenocarcinoma (morphological abnormality)
M-81423 Linitis plastica (morphological abnormality)
M-81413 Scirrhous adenocarcinoma (morphological abnormality)
M-81406 Adenocarcinoma, metastatic (morphological abnormality)
M-81403 Adenocarcinoma, no subtype (morphological abnormality)
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Code Description
M-81402 Adenocarcinoma in situ (morphological abnormality)
M-81401 Atypical adenoma (morphological abnormality)
M-81400 Adenoma, no subtype (morphological abnormality)
M-80103 Carcinoma, no subtype (morphological abnormality)
M-88500 Lipoma, no ICD-O subtype (morphological abnormality)
M-88501 Atypical lipoma (morphological abnormality)
M-95903 Malignant lymphoma, no ICD-O subtype (morphological abnormality)
M-95906 Malignant lymphoma, metastatic (morphological abnormality)
M-84800 Mucinous adenoma (morphological abnormality)
M-84803 Mucinous adenocarcinoma (morphological abnormality)
M-84903 Signet ring cell carcinoma (morphological abnormality)
M-80203 Carcinoma, undifferentiated (morphological abnormality)
M-80413 Small cell carcinoma (morphological abnormality)
M-76880 Lymphoid polyp (morphological abnormality)
M-75630 Hamartomatous polyp (morphological abnormality)
M-75640 Juvenile polyp (morphological abnormality)
M-44440 Granulomatous polyp, a polyp showing granulomatous inflammation (morphological abnormality)
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Appendix 2 Study database, entity relationship
diagram and data dictionary
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Patients
Patients loaded to the IA database.
Columns
Name Type Optional Default Comments
STUDY_NUMBER VARCHAR2(10) PRIMARY KEY, unique identifier assigned
to each patient, starts with hospital code
GENDER VARCHAR2(1) Y Gender of patient
DOB DATE Y Date of birth of patient
EXCLUDED NUMBER(1) Y 0 If set to 1 this patient has been excluded
from the study
HOSPITAL VARCHAR2(4) Y Hospital the patient attended.
REFERENCE DATA:XHOSPITALS
ANALYSED NUMBER(1) Y 0 Set by study researchers – if set to 1 it
means the record has been fully analysed
and coded
ASSIGNED_TO VARCHAR2(10) Y The study researcher responsible for
coding this record. REFERENCE DATA:
CODERS (not listed in this document)
COMMENTS CLOB Y Study researchers’ comments
EXCLUSION_REASON NUMBER(2) Y Reason patient has been excluded.
REFERENCE DATA:XEXCLUSION
PROVISIONAL_EXCLUSION NUMBER(1) Y 0 Set to 1 if patient matches provisional
exclusion criteria – no polyps, only one
endoscopy examination, or no linked or
unlinked pathology
ANALYSED_TIME DATE Y Time when the record was analysed –
set by trigger PATIENT_ANALYSE_TIME
REVIEW NUMBER(1) Y Redundant field – set to 1 if patient is
being reviewed, set to 2 once review
finished
EXCLUDED_BY VARCHAR2(1) Y A= Automatically excluded by program;
C= Coder Excluded
EXCLUDE_TIME DATE Y Time when the record was excluded,
set by trigger PATIENT_EXCLUDE_TIME
ALL_VIEW NUMBER(1) Y 0 If set to 1, any study researcher can view
this patient’s record in the EPR
application
OLD_ASSIGNED_TO VARCHAR2(100) Y Redundant field – stores the name of the
study researcher who originally coded or
queried the record, if the record is now
assigned to a new study researcher
REVIEW_PN NUMBER(1) Y Redundant field – used to carry out
quality checks on polyp numbering
DEVELOPER_NOTES VARCHAR2(500) Y Used by the developer to record notes
specific to the record
MASTER_STUDYNUMBER VARCHAR2(10) Y The master study number of the patient
after the patient record had been
merged with other records
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Name Type Optional Default Comments
DUPLICATE_MERGED_ON DATE Y Date when a duplicate record was
merged – only recorded for duplicate
patients
REASON_MERGED VARCHAR2(2000) Y Reason why a record was merged
CHECKED_DUPLICATE VARCHAR2(1) Y Redundant field – used by study
researchers to indicate that they had
checked a merged record
MERGE_CODER_COMMENTS VARCHAR2(4000) Y Comments recorded by study researchers
for merged patients
FINAL_MASTER VARCHAR2(20) Y The final study number of the patient
after the patient record had been
merged with duplicate records across all
centres
Primary key
Name Columns
PATIENT_PK STUDY_NUMBER
Foreign keys
Name Columns Referencing table Columns
PATIENT_EXCLUSION_REASON EXCLUSION_REASON XEXCLUSION EXCLUSION_ID
PATIENT_FK_CODER ASSIGNED_TO CODERS USERNAME
PATIENT_FK_HOSPITAL HOSPITAL XHOSPITALS HOSPITAL_ID
Indexes
Name Columns Type
PATIENT_ANAYLSEDTIME ANALYSED_TIME Normal
PATIENT_ASSIGNEDTO ASSIGNED_TO Normal
PATIENT_PK STUDY_NUMBER Unique
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Patient conditions
Coded information to show whether a patient had a cancer or resection at first examination.
Columns
Name Type Optional Default Comments
PATIENT_CONDITIONS_ID NUMBER(10) Unique ID for the PATIENT_CONDITIONS
table. This table stores information on
conditions and other features about a
patient
STUDY_NUMBER VARCHAR2(10) Unique study number for a patient
PATIENT_CONDITIONS_TYPE_ID NUMBER(3) Code for the patient condition
Primary key
Name Columns
PATIENT_CONDITIONS_PK PATIENT_CONDITIONS_ID
Unique keys
Name Columns
PATIENT_CONDITIONS_UNIQUE STUDY_NUMBER,PATIENT_CONDITIONS_TYPE_ID
Foreign keys
Name Columns Referencing table Columns
PATIENT_CONDITIONS_FK_SN STUDY_NUMBER PATIENT STUDY_NUMBER
Indexes
Name Columns Type
PATIENT_CONDITIONS_PK PATIENT_CONDITIONS_ID Unique
PATIENT_CONDITIONS_UNIQUE STUDY_NUMBER,PATIENT_CONDITIONS_TYPE_ID Unique
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Endoscopy
Endoscopy examinations undertaken by patient.
Columns
Name Type Optional Default Comments
ENDO_ID VARCHAR2(13) PRIMARY KEY, unique identifier
assigned to each endoscopy record,
Trigger – NEW_ENDO_ID, start with E
(normal) or EP (phantom endoscopy),
incorporates hospital code
STUDY_NUMBER VARCHAR2(10) Study number of the patient to whom
the endoscopy examination belongs
PROCEDURE_DATE DATE Y Date of procedure
INDICATIONS VARCHAR2(1000) Y Raw textual data – indications for
examination
SEGMENT_REACHED_OLD VARCHAR2(1000) Y Raw textual data – segment of the
colon reached
COMPLICATIONS VARCHAR2(4000) Y Raw textual data – complications
encountered during examination
BOWEL_PREP_OLD VARCHAR2(1000) Y Raw textual data – bowel preparation
details
BIOPSY_TEXT VARCHAR2(4000) Y Raw textual data – biopsies taken at
examination
DIAGNOSIS VARCHAR2(1000) Y Raw textual data – diagnosis at
examination
DIAGNOSIS_REPORT VARCHAR2(4000) Y Raw textual data – main report text for
examination
ADDITIONAL_DETAILS VARCHAR2(4000) Y Raw textual data – additional
endoscopy report details
FURTHER_MANAGMENT VARCHAR2(4000) Y Raw textual data – further
management details
DUPLICATE NUMBER(1) Y 0 Redundant field – set to 1 if a possible
duplicate record
LINKED NUMBER(1) Y Redundant field – set to 1 if
examination is linked to a pathology
report
ENDOSCOPIST VARCHAR2(100) Y Raw textual data – name of
endoscopist who performed
examination
ENDOSCOPIST_COMMENTS VARCHAR2(4000) Y Raw textual data – any additional
comments from endoscopist
PROCEDURE_TYPE_OLD VARCHAR2(4000) Y Raw textual data – procedure type
PHANTOM_PATH_ID VARCHAR2(20) Y The path_id of the pathology record in
cases where no procedure report was
available. A blank endoscopy report
was created and linked to the
pathology record
BOWEL_PREP NUMBER(1) Y Coded bowel preparation value
REFERENCE DATA:XBOWEL_PREP
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Name Type Optional Default Comments
PROCEDURE_TYPE NUMBER(2) Y Coded field – procedure type
REFERENCE DATA:XPROCEDURE
DISTANCE_REACHED NUMBER(3) Y Coded field – distance reached by
endoscope (in cm)
SEGMENT_REACHED NUMBER(2) Y Coded field – segment reached by
endoscopy
REFERENCE DATA:XBOWEL_SEGMENT
RESECTION NUMBER(1) Y 0 Coded field – set to 1 if the patient has
a resection noted
CODED NUMBER(1) Y 0 Coded field – set to 1 by study
researcher when they had completed
coding and analysing the endoscopy
record
BIOPSY_NON_POLYP NUMBER(1) Y Coded field set by study researcher to
indicate that a non-polyp biopsy was
taken at the examination
RESECTION_OLD VARCHAR2(4000) Y Raw textual data – information on
resection
COMMENTS VARCHAR2(4000) Y Study researcher’s comments
QUERY_TIME DATE Y Redundant field – time when a query
was set, updated by the trigger
ENDO_QUERY_TIME
REQUERY NUMBER(1) Y 0 Redundant field – set to 1 if study
researcher has come back to query and
still cannot resolve it
REVIEW_NOTES VARCHAR2(4000) Y Redundant field – old review notes field
EXAM_NUMBER VARCHAR2(3) Y Coded field – order of examinations
on the same day. Only same-day
examinations are numbered, and field
used only if patient has no
examinations without a date
EXAM_NUMBER_UNKNOWN VARCHAR2(3) Y Coded field – reason why study
researcher was unable to allocate a
ranking for the examination. If this is
recorded, it may invalidate the ranking
on EXAM_RANKING for this patient
REFERENCE DATA:
EXAM_NUMBER_UNKNOWN
REASON_EXAM_SAME_DAY VARCHAR2(3) Y Coded field – reason why examination
happened on the same day as another
examination
REFERENCE DATA:
REASON_EXAM_SAME_DAY
EXAM_RANKING VARCHAR2(3) Y Coded field – ranking of all
examinations for the patient. Used
where the patient has at least one
examination without a date. This field
overrides EXAM_NUMBER
OPERATION_TYPE VARCHAR2(2) Y Coded field – used for surgery to record
operation type
REFERENCE DATA:OPERATION_TYPE
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Name Type Optional Default Comments
RESECTION_SPECIMEN_LENGTH VARCHAR2(200) Y Coded field – specimen length at
resection (mm)
PATH_MISS_10MM NUMBER(1) Y Redundant coded field – pathology
missing query suboption: ‘> 10mm’.
Most queries were resolved and
unresolved queries were recorded in
the table NFEATURE
PATH_MISS_SENTLAB NUMBER(1) Y Redundant coded field – pathology
missing query suboption: ‘sent to lab’.
Most queries were resolved and
unresolved queries were recorded in
the table NFEATURE
PATH_MISS_BIOPSYTEXT NUMBER(1) Y Redundant coded field – pathology
missing query suboption: ‘in biopsy
text’. Most queries were resolved and
unresolved queries were recorded in
the table NFEATURE
PATH_MISS_CANCERINDICATED NUMBER(1) Y Redundant coded field – pathology
missing query suboption: ‘cancer has
been indicated’. Most queries were
resolved and unresolved queries were
recorded in the table NFEATURE
GEN_SUPREPORTMISS NUMBER(1) Y Redundant coded field – general query
suboption: ‘supplementary report
missing’. Most queries were resolved
and unresolved queries were recorded
in the table NFEATURE
GEN_POSSCANCER NUMBER(1) Y Redundant coded field – general query
suboption: ‘possible cancer’. Most
queries were resolved and unresolved
queries were recorded in the table
NFEATURE
GEN_WHENCANCER NUMBER(1) Y Redundant coded field – general query
suboption: ‘when was cancer?’ Most
queries were resolved and unresolved
queries were recorded in the table
NFEATURE
GEN_WHENRESECT NUMBER(1) Y Redundant coded field – general query
suboption: ‘when was resection?’ Most
queries were resolved and unresolved
queries were recorded in the table
NFEATURE
GEN_POLYPNUM NUMBER(1) Y Redundant coded field – general query
suboption: ‘polyp numbers’. Most
queries were resolved and unresolved
queries were recorded in the table
NFEATURE
GEN_TERMUNSURE NUMBER(1) Y Redundant coded field – general query
suboption, unsure of terminology. Most
queries were resolved and unresolved
queries are recorded on table
NFEATURE
APPCODE_TRUNC NUMBER(1) Y Redundant coded field – application
coding error query suboption for
truncated pathology report. Most
queries were resolved and unresolved
queries are recorded on table
NFEATURE
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Name Type Optional Default Comments
APPCODE_BLANKPATH NUMBER(1) Y Redundant coded field – application
coding error query suboption for blank
pathology report. Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
DISCUSS_HNPCC NUMBER(1) Y Redundant coded field – Discuss query
suboption, hereditary non-polyposis
CRC (HNPCC)? Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
DISCUSS_COLITIS NUMBER(1) Y Redundant coded field – discuss query
suboption, colitis? Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
DISCUSS_HOWCODE NUMBER(1) Y Redundant coded field – discuss query
suboption, how to code? Most queries
were resolved and unresolved queries
are recorded on table NFEATURE
EXL_CANCER1ST NUMBER(1) Y Redundant coded field – exclusion
query suboption, cancer first
examination. Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
EXL_RESECTION1ST NUMBER(1) Y Redundant coded field – exclusion
query suboption, resection first
examination. Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
EXL_HNPCC NUMBER(1) Y Redundant coded field – exclusion
query suboption, HNPCC. Most queries
were resolved and unresolved queries
are recorded on table NFEATURE
EXL_POLYPOSIS NUMBER(1) Y Redundant coded field – exclusion
query suboption, polyposis. Most
queries were resolved and unresolved
queries are recorded on table
NFEATURE
EXL_COLITIS NUMBER(1) Y Redundant coded field – exclusion
query suboption, colitis. Most queries
were resolved and unresolved queries
are recorded on table NFEATURE
EXAM_ORDER NUMBER(3) Y Coded field – chronological ranking
of examinations. Lowest number
corresponds to earliest examination
NOTES VARCHAR2(4000) Y Study researcher or study programmer’s
notes related to this record
APPCODE_IRRELEVANT NUMBER(1) Y Redundant coded field – application
coding error query suboption used for
irrelevant endoscopy. Most queries
were resolved and unresolved queries
are recorded on table NFEATURE
APPCODE_DUPLICATE NUMBER(1) Y Redundant coded field – application
coding error query suboption used for
duplicate endoscopy. Most queries
were resolved and unresolved queries
are recorded on table NFEATURE
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Name Type Optional Default Comments
APPCODE_TRUNC_ENDOSCOPY NUMBER(1) Y Redundant coded field – application
coding error query suboption – used for
truncated report. Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
APPCODE_BLANK_ENDO NUMBER(1) Y Redundant coded field – application
coding error query suboption – used for
blank endoscopy. Most queries were
resolved and unresolved queries are
recorded on table NFEATURE
POLYP_MATCHING_QUERY VARCHAR2(1) Y Coded field – used for marking cases
where the endoscopy and pathology
information does not link the polyps
clearly
OLD_STUDY_NUMBER VARCHAR2(10) Y Used for merging records. This is the
original study number associated with
this endoscopy. It may be the same as
field STUDY_NUMBER if the record has
not been merged to another master
record
SOURCE_HOSPITAL VARCHAR2(10) Y Hospital where the data were extracted
from. It may be different to the hospital
of the master study number if cross
centre merging was done
Primary key
Name Columns
ENDOSCOPY_PK ENDO_ID
Foreign keys
Name Columns Referencing table Columns
ENDOSCOPY_BOWEL_PREP BOWEL_PREP XBOWEL_PREP PREP_ID
ENDOSCOPY_FK STUDY_NUMBER PATIENT STUDY_NUMBER
ENDOSCOPY_FK_QUERY QUERY XQUERY QUERY_ID
ENDOSCOPY_PROCEDURE PROCEDURE_TYPE XPROCEDURE PROCEDURE_ID
ENDOSCOPY_SEGMENT_REACHED SEGMENT_REACHED XBOWEL_SEGMENT SEGMENT_ID
Indexes
Name Columns Type
ENDOSCOPY_PK ENDO_ID Unique
ENDOSCOPY_QUERYTIME QUERY_TIME Normal
ENDOSCOPY_STUDYNUMBER STUDY_NUMBER Normal
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Diagnosis
Coded diagnosis information for each endoscopy report.
Columns
Name Type Optional Default Comments
DIAGNOSIS_ID NUMBER(10) PRIMARY KEY, unique identifier assigned
to each indication sub-type
ENDO_ID VARCHAR2(13) Endoscopy ID of report this diagnosis
value is linked to
DIAGNOSIS_TYPE_ID NUMBER(3) Diagnosis type, REFERENCE DATA:
XDIAGNOSIS_TYPES
Primary key
Name Columns
DIAGNOSIS_PK DIAGNOSIS_ID
Unique keys
Name Columns
DIAGNOSIS_UNIQUE ENDO_ID,DIAGNOSIS_TYPE_ID
Foreign keys
Name Columns Referencing table Columns
DIAGNOSIS_FK_ENDO ENDO_ID ENDOSCOPY ENDO_ID
DIAGNOSIS_FK_XDIAGTYPE DIAGNOSIS_TYPE_ID XDIAGNOSIS_TYPES DIAGNOSIS_TYPE_ID
Indexes
Name Columns Type
DIAGNOSIS_ID_ENDOID ENDO_ID Normal
DIAGNOSIS_PK DIAGNOSIS_ID Unique
DIAGNOSIS_UNIQUE ENDO_ID,DIAGNOSIS_TYPE_ID Unique
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Diagnosis types
Coded diagnosis subtypes for each endoscopy report (e.g. colitis and polyposis subtypes).
Columns
Name Type Optional Default Comments
ID NUMBER(10) PRIMARY KEY, unique identifier assigned
to each diagnosis subtype
DIAGNOSIS_TYPE_ID NUMBER(3) Y Diagnosis type for which this subtype
had been defined, REFERENCE DATA:
XDIAGNOSIS_TYPES
ENDO_ID VARCHAR2(13) Y Endoscopy ID of report to which this
diagnosis value is linked
DIAGNOSIS_SUB_TYPE_ID NUMBER(3) Y Diagnosis sub-type, REFERENCE DATA:
XDIAGNOSIS_SUB_TYPES
Primary key
Name Columns
DIAGNOSIS_SUB_TYPE_PK ID
Unique keys
Name Columns
DIAGNOSIS_SUB_TYPE_UNIQUE DIAGNOSIS_TYPE_ID,ENDO_ID,DIAGNOSIS_SUB_TYPE_ID
Foreign keys
Name Columns
Referencing
table Columns
DIAGNOSIS_SUB_TYPE_FK_ENDO ENDO_ID,DIAGNOSIS_TYPE_ID DIAGNOSIS ENDO_ID,DIAGNOSIS_TYPE_ID
Indexes
Name Columns Type
DIAGNOSIS_SUB_TYPE_PK ID Unique
DIAGNOSIS_SUB_TYPE_UNIQUE DIAGNOSIS_TYPE_ID,ENDO_ID,DIAGNOSIS_SUB_TYPE_ID Unique
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Indications
Coded indication information for each endoscopy report.
Columns
Name Type Optional Default Comments
INDICATION_ID NUMBER(10) PRIMARY KEY, unique identifier assigned
to each indication
ENDO_ID VARCHAR2(13) Endoscopy ID of report to which this
indication value is linked
INDICATION_TYPE_ID NUMBER(3) Indication Type. REFERENCE DATA:
XINDICATION_TYPES
Primary key
Name Columns
INDICATIONS_PK INDICATION_ID
Unique keys
Name Columns
INDICATIONS_UNIQUE ENDO_ID,INDICATION_TYPE_ID
Foreign keys
Name Columns Referencing table Columns
INDICATIONS_FK_ENDO ENDO_ID ENDOSCOPY ENDO_ID
INDICATIONS_FK_XINDTYPE INDICATION_TYPE_ID XINDICATION_TYPES INDICATION_TYPE_ID
Indexes
Name Columns Type
INDICATIONS_ID_ENDOID ENDO_ID Normal
INDICATIONS_PK INDICATION_ID Unique
INDICATIONS_UNIQUE ENDO_ID,INDICATION_TYPE_ID Unique
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Indication SUB_TYPES
Coded indication information for each endoscopy report.
Columns
Name Type Optional Default Comments
INDICATION_ID NUMBER(10) PRIMARY KEY, unique identifier assigned
to each indication
ENDO_ID VARCHAR2(13) Endoscopy ID of report to which this
indication value is linked
INDICATION_TYPE_ID NUMBER(3) Indication Type. REFERENCE DATA:
XINDICATION_TYPES
Primary key
Name Columns
INDICATIONS_PK INDICATION_ID
Unique keys
Name Columns
INDICATIONS_UNIQUE ENDO_ID,INDICATION_TYPE_ID
Foreign keys
Name Columns Referencing table Columns
INDICATIONS_FK_ENDO ENDO_ID ENDOSCOPY ENDO_ID
INDICATIONS_FK_XINDTYPE INDICATION_TYPE_ID XINDICATION_TYPES INDICATION_TYPE_ID
Indexes
Name Columns Type
INDICATIONS_ID_ENDOID ENDO_ID Normal
INDICATIONS_PK INDICATION_ID Unique
INDICATIONS_UNIQUE ENDO_ID,INDICATION_TYPE_ID Unique
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NFEATURE
Coded features for each endoscopy report – used to record queries, errors, medical conditions, and so on.
Columns
Name Type Optional Default Comments
NFEATURE_ID NUMBER(10) PRIMARY KEY, unique identifier assigned
to each notable feature
ENDO_ID VARCHAR2(13) Endoscopy ID of report that this notable
feature is linked to
NFEATURE_TYPE_ID NUMBER(3) Notable feature type, REFERENCE DATA:
XNFEATURE_TYPES
Primary key
Name Columns
NFEATURE_PK NFEATURE_ID
Unique keys
Name Columns
NFEATURE_UNIQUE ENDO_ID,NFEATURE_TYPE_ID
Foreign keys
Name Columns Referencing table Columns
NFEATURE_FK_ENDO ENDO_ID ENDOSCOPY ENDO_ID
Indexes
Name Columns Type
NFEATURE_ID_ENDOID ENDO_ID Normal
NFEATURE_PK NFEATURE_ID Unique
NFEATURE_UNIQUE ENDO_ID,NFEATURE_TYPE_ID Unique
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TABLE: PATHOLOGY
Columns
Name Type Optional Default Comments
PATH_ID VARCHAR2(20) PRIMARY KEY, unique pathology report ID
STUDY_NUMBER VARCHAR2(10) Y Study number of patient this pathology
report belongs to (can be blank if no
endoscopy examination from that patient)
PATHOLOGIST VARCHAR2(1000) Y Raw textual data – name of pathologist
who carried out report
REPORT CLOB Y Raw textual data – main body of
pathology report
ADDITIONAL_REPORT CLOB Y Raw textual data – additional pathology
report information
MICROSCOPIC_DESCRIPTION CLOB Y Raw textual data – microscopic
description of biopsy specimen
CLINICAL_HISTORY CLOB Y Raw textual data – clinical history of
patient this specimen came from
SPECIMEN CLOB Y Raw textual data – description of biopsy
specimen (often called macroscopic
report)
CONCLUSION CLOB Y Raw textual data – conclusion of report
SPECIMEN_TYPE VARCHAR2(4000) Y Raw textual data – type of specimen
(e.g. polyp biopsy)
COMMENTS VARCHAR2(4000) Y Raw textual data – pathologist comments
LOCATION VARCHAR2(4000) Y Raw textual data – location the specimen
came from (often name of hospital ward
or department)
COLLECTION_DATE DATE Y Coded field – collection date of biopsy
specimen
RECEIVE_DATE DATE Y Coded field – date biopsy specimen
received at laboratory (may be different
from collection data of specimen)
REPORT_DATE DATE Y Coded field – date report written by
pathologist
REQUESTED_DATE DATE Y Coded field – date pathology was
requested
NAME_MATCHED NUMBER(1) Y 0 Coded field – set to 1 if the pathology
report was matched by name (and DOB)
to an endoscopy patient (and not by
hospital number which is more accurate)
DUPLICATE NUMBER(1) Y Coded field – set to 1 if possible duplicate
pathology report
EXCLUDED NUMBER(1) Y 0 Coded field – reason pathology report has
been excluded, REFERENCE DATA:
XPATH_EXCLUSION
HOSPITAL VARCHAR2(4) Coded field – hospital this report belongs
to, REFERENCE DATA:XHOSPITALS
MATCHING_ERROR NUMBER(1) Y Redundant field – set to 1 if possible error
made when matching this pathology
report to a endoscopy report
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Name Type Optional Default Comments
ENDO_ID VARCHAR2(13) Y Linked field – endoscopy ID of endoscopy
report this pathology report is linked to
(report of biopsy taken from that
endoscopy examination)
QUERY NUMBER(2) Y Coded field – query study researcher had
regarding pathology report, RFERENCE
DATA:XPATH_QUERY (used with unlinked
path report)
NORMAL_MUCOSA NUMBER(1) Y Coded field – set to 1 if all pathology
report states is normal mucosa found –
used with unlinked path reports
MAN_COLLECTED_PATH NUMBER Y Record collected manually by coders by
visiting hospitals. REFERENCE DATA:
MAN_COLLECTED_PATH
NOTES VARCHAR2(4000) Y Study researcher or study programmer’s
notes related to the pathology
PATHOLOGY_SOURCE VARCHAR2(255) Y Recorded for some reports to show where
the pathology data were extracted from
OLD_STUDY_NUMBER VARCHAR2(10) Y Study number associated with this
pathology report prior to merging. If it is
not the same as STUDY_NUMBER then it
was not merged or was the master record
Primary key
Name Columns
PATHOLOGY_PK PATH_ID
Foreign keys
Name Columns Referencing table Columns
PATHOLOGY_CON_EXCLUDE EXCLUDED XPATH_EXCLUSION EXCLUSION_ID
PATHOLOGY_CON_HOSPITAL HOSPITAL XHOSPITALS HOSPITAL_ID
PATHOLOGY_CON_QUERY QUERY XPATH_QUERY QUERY_ID
PATHOLOGY_ENDOFK ENDO_ID ENDOSCOPY ENDO_ID
PATHOLOGY_FK_PAT STUDY_NUMBER PATIENT STUDY_NUMBER
Indexes
Name Columns Type
PATHOLOGY_ID_ENDOID ENDO_ID Normal
PATHOLOGY_PK PATH_ID Unique
PATHOLOGY_SN STUDY_NUMBER Normal
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POLYP
Columns
Name Type Optional Default Comments
POLYP_ID VARCHAR2(20) PRIMARY KEY, unique identifier
assigned to each polyp record.
A trigger created value, starts with
P (normal) or PP (Phantom polyp)
also has code for hospital embedded
Trigger – POLYP_T1
STUDY_NUMBER VARCHAR2(10) Study number of patient to whom
this polyp belongs
ENDO_ID VARCHAR2(13) Linked field – endoscopy ID of
report to which this polyp is linked
ENDO_SEGMENT_OLD VARCHAR2(1000) Y Raw textual data – location of the
polyp within the colon as per
the endoscopy report
ENDO_SHAPE_OLD VARCHAR2(50) Y Raw textual data – shape of the
polyp as per the endoscopy report
HOSPITAL VARCHAR2(4) Y Hospital of patient
REFERENCE DATA: XHOSPITALS
ENDO_DISTANCE NUMBER(3) Y Coded field – distance polyp found
into bowel (cm)
ENDO_SIZE NUMBER(4,1) Y Coded field – size of polyp (mm)
ASSUME_ENDO_SIZE NUMBER(4,1) Y Coded field – override the
ENDO_SIZE by this size. The study
researcher believes this is the most
appropriate size
ENDO_SIZE_OTHER NUMBER(2) Y Coded field – other size of polyp
(described in words rather than an
actual size)
REFERENCE DATA:XPOLYP_SIZE
ASSUME_ENDO_SIZE_OTHER NUMBER(2) Y Coded field – override the
ENDO_SIZE_OTHER by this size.
The study researcher believes this is
the most appropriate size
ENDO_SIZE_MIN NUMBER(4,1) Y Coded field – minimum size of
polyp (mm)
ENDO_SIZE_MAX NUMBER(4,1) Y Coded field – maximum size of
polyp (mm)
ENDO_SHAPE NUMBER(2) Y Coded field – shape of polyp from
the endoscopy report
REFERENCE DATA:XPOLYP_SHAPE
ENDO_SEGMENT NUMBER(2) Y Coded field – location of the polyp
within the colon as per the
endoscopy report
REFERENCE DATA:
XBOWEL_SEGMENT
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Name Type Optional Default Comments
ENDO_SEGMENT_TO NUMBER(2) Y Coded field – location of the polyp
within the colon. Only used when a
site range is given rather than a
specific site and the range is
recorded on fields ENDO_SEGMENT
and ENDO_SEGMENT_TO
REFERENCE DATA:
XBOWEL_SEGMENT
CLINICAL_HISTOLOGY VARCHAR2(3) Y Coded field – clinical histology for a
polyp
REFERENCE DATA:
CLINICAL_HISTOLOGY
ENDO_QUANTITY_OTHER NUMBER(2) Y Coded field – recorded when a
group of polyps is recorded as an
individual polyp row when the exact
number of polyps is unknown. This
is a description value of the quantity
of polyps in the group
REFERENCE DATA:
XPOLYP_NUMBERS
MIN_QTY NUMBER Y Coded field – minimum quantity of
polyps. Only used when the polyp
record represented a group of
polyps
MAX_QTY NUMBER Y Coded field – maximum quantity of
polyps. Only used when the polyp
record represented a group of
polyps
APPROX_QTY NUMBER Y Coded field – recorded where a
group of polyps is recorded as an
individual polyp row when the
approximate number of polyps is
unknown
PHANTOM_PATH_ID VARCHAR2(20) Y Linked field – the pathology report
linked to this polyp where the polyp
was created from a pathology
report that has no corresponding
endoscopy report
REMOVAL_METHOD NUMBER(2) Y Coded field – method of polyp
removal
REFERENCE DATA:
XEXCISION_METHOD
EXCISION_COMPLETE NUMBER(1) Y Coded field – whether or not the
polyp was completely excise
REFERENCE DATA:
EXCISION_COMPLETE
PIECEMEAL_BIOPSY NUMBER(1) Y Coded field – set to 1 if polyp was
biopsied in a piecemeal fashion
MAX_BIOPSY_SIZE NUMBER(3) Y Coded field – maximum size given
of biopsy by pathologist (mm)
PATH_SIZE NUMBER(4,1) Y Coded field – size of polyp (mm)
from pathology report
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Name Type Optional Default Comments
ASSUME_PATH_SIZE NUMBER(4,1) Y Coded field – override the
PATH_SIZE by this size. The study
researcher believes this is the most
appropriate size
PATH_SHAPE NUMBER(2) Y Coded field – shape of polyp from
the pathology report
REFERENCE DATA:XPOLYP_SHAPE
PATH_HISTOLOGY NUMBER(3) Y Coded field – polyp type or
classification
REFERENCE DATA:
XPOLYP_HISTOLOGY
ASSUME_PATH_HISTOLOGY NUMBER(3) Y Coded field – used to correct
histology on the individual polyp
rows where the study researcher
believed that the pathology
information was erroneous or
incorrect
PATH_DYSPLASIA NUMBER(2) Y Coded field – dysplasia of polyp
REFERENCE DATA:XDYSPLASIA
PATH_COMMENTS VARCHAR2
(4000)
Y Redundant field – comments about
polyp from pathology report
PATH_ADENOMA_TYPE NUMBER(2) Y Coded field – morphology of
adenomatous tissues
REFERENCE DATA:
XADENOMA_TYPE
FATE_OF_BIOPSY NUMBER(2) Y Coded field – fate of polyp biopsy
REFERENCE DATA:XBIOPSY_FATE
EXCISION_EXTENT NUMBER(1) Y Coded field – extent of polyp
excision
REFERENCE DATA:
XEXCISION_EXTENT
FRAGMENT_NO NUMBER(3) Y Coded field – number of relevant
fragments of adenoma or polyp
found at pathology
SERRATION VARCHAR2(2) Y Coded field – if the polyp had
serration features
ENDO_PATH_MAPPING VARCHAR2(3) Y Coded field – field used to record
the rule used for matching
pathology to polyp where it was not
apparent
PATH_MULTI_ENDO_LINK VARCHAR2(16) Y Coded field – used to link an
individual polyp to a group of polyps
recorded at the same examination
(i.e. the group will be recorded as an
individual polyp row and will have a
value in the ENDO_QUANTITY_OTHER
field). Shows that the polyp is part of a
group
MULTIPLE_POLYP_GROUP NUMBER(5) Y Coded field – used to classify group
of polyps and individual polyps
within the group seen at the same
examination
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Name Type Optional Default Comments
MULTIPLE_GROUP_LINKING NUMBER(5) Y Coded field – used to allocate a
unique group number for a set
of polyps seen across many
examinations
REFERENCE DATA:
MULTIPLE_GROUP_LINKING
MULTIPLEGROUP_MATCHPROB NUMBER(5) Y Coded field – certainty that polyp
has been matched correctly –
recorded as a percentage
REFERENCE DATA:
POLYP_MATCH_PROB
POLYP_NUMBERED VARCHAR2(1) Y Coded field -Y or N flag showing
whether polyp has been numbered
or not. REFERENCE DATA:
POLYP_NUMBERED
POLYP_NUMBER NUMBER(3) Y Coded field – all occurrences of the
individual polyps seen at different
examinations were assigned the
same number
MATCH_PROBABILITY NUMBER(3) Y Coded field – certainty that polyp
has been matched correctly –
recorded as a percentage
REFERENCE DATA:
POLYP_MATCH_PROB
DERIVED_POLYP_NUMBER NUMBER(20) Y Derived field – each polyp allocated
a unique number. If the polyp was
sighted again that it was given the
same DERIVED_POLYP_NUMBER
DERIVED_ENDO_RANGE VARCHAR2(2000) Y Derived field – the study
programmer wrote a program to
automatically derive an endoscopy
size from the different size values
given at endoscopy where possible
DERIVED_ENDO_RANGE_GROUP VARCHAR2(2000) Y Derived field – method used to
derive DERIVED_ENDO_RANGE
DERIVED_ENDO_SIZE VARCHAR2(100) Y Derived field – the study
programmer wrote a program to
automatically derive an endoscopy
size from the different size values
given at endoscopy after the size
values had been reviewed by the
study researchers and corrections
had been made
DERIVED_ENDO_SIZE_SOURCE VARCHAR2(400) Y Derived field – method used to
derive DERIVED_ENDO_SIZE
DERIVED_ENDO_SIZE_OTHER NUMBER(2) Y Derived field – derived from the
fields ASSUME_ENDO_SIZE_OTHER
and ENDO_SIZE_OTHER with
ASSUME_ENDO_SIZE_OTHER
always taking precedence over
ENDO_SIZE_OTHER
DERIVED_ENDOSIZE_OTHER_SOURCE VARCHAR2(4000) Y Derived field – which field the size
was taken from (i.e. ASSUME_ENDO_
SIZE_OTHER or ENDO_SIZE_OTHER)
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Name Type Optional Default Comments
DERIVED_PATH_SIZE NUMBER(4,1) Y Derived field – derived from the
fields ASSUME_PATH_SIZE and
PATH_SIZE (ASSUME_PATH_SIZE
took precedence)
DERIVED_PATH_SIZE_SOURCE VARCHAR2(4000) Y Coded field – field from which the
size DERIVED_PATH_SIZE was
derived
Primary key
Name Columns
POLYP_PK POLYP_ID
Foreign keys
Name Columns Referencing table Columns
POLYP_BIOPSY REMOVAL_METHOD XEXCISION_METHOD METHOD_ID
POLYP_DYSPLASIA PATH_DYSPLASIA XDYSPLASIA DYSPLASIA_ID
POLYP_ENDO_SHAPE ENDO_SHAPE XPOLYP_SHAPE POLYPSHAPE_ID
POLYP_ENDO_SIZE_OTHER ENDO_SIZE_OTHER XPOLYP_SIZE POLYPSIZE_ID
POLYP_FK_ADENOMATYPE PATH_ADENOMA_TYPE XADENOMA_TYPE ADENOMA_TYPE_ID
POLYP_FK_BIOPSYFATE FATE_OF_BIOPSY XBIOPSY_FATE BIOPSY_FATE_ID
POLYP_FK_ENDO ENDO_ID ENDOSCOPY ENDO_ID
POLYP_FK_EXCISIONEXTENT EXCISION_EXTENT XEXCISION_EXTENT EXCISION_ID
POLYP_FK_HOSPITAL HOSPITAL XHOSPITALS HOSPITAL_ID
POLYP_FK_PATEINT STUDY_NUMBER PATIENT STUDY_NUMBER
POLYP_HISTOLOGY PATH_HISTOLOGY XPOLYP_HISTOLOGY POLYPTYPE_ID
POLYP_PATH_SHAPE PATH_SHAPE XPOLYP_SHAPE POLYPSHAPE_ID
POLYP_QUANTITY_OTHER ENDO_QUANTITY_OTHER XPOLYP_NUMBERS POLYPNUMBERS_ID
POLYP_SEGMENT ENDO_SEGMENT XBOWEL_SEGMENT SEGMENT_ID
Indexes
Name Columns Type
MP_POLYP_GROUP MULTIPLE_POLYP_GROUP,1 Normal
MP_POLYP_GROUP_LINKING MULTIPLE_GROUP_LINKING,1 Normal
POLYP_ID_ENDOID ENDO_ID Normal
POLYP_ID_STUDYNUMBER STUDY_NUMBER Normal
POLYP_PK POLYP_ID Unique
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DERIVED_MP_POLYPS
A copy of the POLYP table for all multiple polyp patients who had at least one endo quantity row.
The endo quantity rows have been multiplied out on this table.
Columns
Name Type Optional Default Comments
POLYP_ID VARCHAR2(20) PRIMARY KEY, unique identifier
assigned to each polyp record.
A trigger created value, starts with
P (normal) or PP (Phantom polyp)
also has code for hospital
embedded. Trigger – POLYP_T1
STUDY_NUMBER VARCHAR2(10) Study number of patient to whom
this polyp belongs
ENDO_ID VARCHAR2(13) Linked field – endoscopy ID of
report to which this polyp is linked
ENDO_SEGMENT_OLD VARCHAR2(1000) Y Raw textual data – location of the
polyp within the colon as per the
endoscopy report
ENDO_SHAPE_OLD VARCHAR2(50) Y Raw textual data – shape of the
polyp as per the endoscopy report
HOSPITAL VARCHAR2(4) Y Hospital of patient
REFERENCE DATA: XHOSPITALS
ENDO_DISTANCE NUMBER(3) Y Coded field – distance polyp found
into bowel (cm)
ENDO_SIZE NUMBER(4,1) Y Coded field – size of polyp (mm)
ASSUME_ENDO_SIZE NUMBER(4,1) Y Coded field – override the
ENDO_SIZE by this size. The study
researcher believes this is the most
appropriate size
ENDO_SIZE_OTHER NUMBER(2) Y Coded field – other size of polyp
(described in words rather than an
actual size)
REFERENCE DATA:XPOLYP_SIZE
ASSUME_ENDO_SIZE_OTHER NUMBER(2) Y Coded field – override the
ENDO_SIZE_OTHER by this size.
The study researcher believes this is
the most appropriate size
ENDO_SIZE_MIN NUMBER(4,1) Y Coded field – minimum size of
polyp (mm)
ENDO_SIZE_MAX NUMBER(4,1) Y Coded field – maximum size of
polyp (mm)
ENDO_SHAPE NUMBER(2) Y Coded field – shape of polyp from
the endoscopy report
REFERENCE DATA:XPOLYP_SHAPE
ENDO_SEGMENT NUMBER(2) Y Coded field – location of the polyp
within the colon as per the
endoscopy report
REFERENCE DATA:
XBOWEL_SEGMENT
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Name Type Optional Default Comments
ENDO_SEGMENT_TO NUMBER(2) Y Coded field – location of the polyp
within the colon. Only used when a
site range is given rather than a
specific site and the range is
recorded on fields ENDO_SEGMENT
and ENDO_SEGMENT_TO
REFERENCE DATA:
XBOWEL_SEGMENT
CLINICAL_HISTOLOGY VARCHAR2(3) Y Coded field – clinical histology for a
polyp
REFERENCE DATA:
CLINICAL_HISTOLOGY
ENDO_QUANTITY_OTHER NUMBER(2) Y Coded field – recorded where a
group of polyps is recorded as an
individual polyp row where the
exact number of polyps is unknown.
This is a description value of the
quantity of polyps in the group
REFERENCE DATA:
XPOLYP_NUMBERS
MIN_QTY NUMBER Y Coded field – minimum quantity of
polyps. Only used when the polyp
record represented a group of
polyps
MAX_QTY NUMBER Y Coded field – maximum quantity of
polyps. Only used when the polyp
record represented a group of
polyps
APPROX_QTY NUMBER Y Coded field – recorded where a
group of polyps is recorded as an
individual polyp row where the
approximate number of polyps is
unknown
PHANTOM_PATH_ID VARCHAR2(20) Y Linked field – the pathology report
linked to this polyp where the polyp
was created from a pathology
report that has no corresponding
endoscopy report
REMOVAL_METHOD NUMBER(2) Y Coded field – method of polyp
removal
REFERENCE DATA:
XEXCISION_METHOD
EXCISION_COMPLETE NUMBER(1) Y Coded field – whether or not the
polyp was completely excise
REFERENCE DATA:
EXCISION_COMPLETE
PIECEMEAL_BIOPSY NUMBER(1) Y Coded field – set to 1 if polyp was
biopsied in a piecemeal fashion
MAX_BIOPSY_SIZE NUMBER(3) Y Coded field – maximum size given
of biopsy by pathologist (mm)
ENDO_COMMENTS VARCHAR2(4000) Y Redundant field – study researcher
comments about polyps from
endoscopy examination
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PATH_SIZE NUMBER(4,1) Y Coded field – size of polyp (mm)
from pathology report
ASSUME_PATH_SIZE NUMBER(4,1) Y Coded field – override the
PATH_SIZE by this size. The study
researcher believes this is the most
appropriate size
PATH_SHAPE NUMBER(2) Y Coded field – shape of polyp from
the pathology report
REFERENCE DATA:XPOLYP_SHAPE
PATH_HISTOLOGY NUMBER(3) Y Coded field – polyp type or
classification
REFERENCE DATA:
XPOLYP_HISTOLOGY
ASSUME_PATH_HISTOLOGY NUMBER(3) Y Coded field – used to correct
histology on the individual polyp
rows where the study researcher
believed that the pathology
information was erroneous or
incorrect
PATH_DYSPLASIA NUMBER(2) Y Coded field – dysplasia of polyp
REFERENCE DATA:XDYSPLASIA
PATH_COMMENTS VARCHAR2(4000) Y Redundant field – comments about
polyp from pathology report
PATH_ADENOMA_TYPE NUMBER(2) Y Coded field – morphology of
adenomatous tissues
REFERENCE DATA:
XADENOMA_TYPE
FATE_OF_BIOPSY NUMBER(2) Y Coded field – fate of polyp biopsy
REFERENCE DATA:XBIOPSY_FATE
EXCISION_EXTENT NUMBER(1) Y Coded field – extent of polyp
excision
REFERENCE DATA:
XEXCISION_EXTENT
FRAGMENT_NO NUMBER(3) Y Coded field – number of relevant
fragments of adenoma or polyp
found at pathology
SERRATION VARCHAR2(2) Y Coded field – if the polyp had
serration features
ENDO_PATH_MAPPING VARCHAR2(3) Y Coded field – field used to record
the rule used for matching
pathology to polyp when it was not
apparent
PATH_MULTI_ENDO_LINK VARCHAR2(16) Y Coded field – used to link an
individual polyp to a group of polyps
recorded at the same examination
(i.e. the group will be recorded
as an individual polyp row and
will have a value in the
ENDO_QUANTITY_OTHER field).
Shows that the polyp is part of a
group
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Name Type Optional Default Comments
MULTIPLE_POLYP_GROUP NUMBER(5) Y Coded field – used to classify group
of polyps and individual polyps
within the group seen at the same
examination
MULTIPLE_GROUP_LINKING NUMBER(5) Y Coded field – used to allocate a
unique group number for a set
of polyps seen across many
examinations
REFERENCE DATA:
MULTIPLE_GROUP_LINKING
MULTIPLEGROUP_MATCHPROB NUMBER(5) Y Coded field – certainty that polyp
has been matched correctly –
recorded as a percentage
REFERENCE DATA:
POLYP_MATCH_PROB
POLYP_NUMBERED VARCHAR2(1) Y Coded field – Y or N flag showing
whether polyp has been numbered
or not
REFERENCE DATA:
POLYP_NUMBERED
POLYP_NUMBER NUMBER(3) Y Coded field – all occurrences of the
individual polyps seen at different
examinations were assigned the
same number
NUMBERED_TIME DATE Y Should not be used to find the date
when the polyp was numbered.
Gets updated if a polyp has a
number when the polyp is updated
on any screen
MATCH_PROBABILITY NUMBER(3) Y Coded field – certainty that polyp
has been matched correctly –
recorded as a percentage
REFERENCE DATA:
POLYP_MATCH_PROB
DERIVED_POLYP_NUMBER NUMBER(20) Y Derived field – each polyp allocated
a unique number. If the polyp was
sighted again it was given the same
DERIVED_POLYP_NUMBER
DERIVED_ENDO_RANGE VARCHAR2(2000) Y Derived field – the study
programmer wrote a program to
automatically derive an endoscopy
size from the different size values
given at endoscopy where possible
DERIVED_ENDO_RANGE_GROUP VARCHAR2(2000) Y Derived field – method used to
derive DERIVED_ENDO_RANGE
DERIVED_ENDO_SIZE VARCHAR2(100) Y Derived field – the study
programmer wrote a program to
automatically derive an endoscopy
size from the different size values
given at endoscopy after the size
values had been reviewed by the
study researchers and corrections
had been made
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Name Type Optional Default Comments
DERIVED_ENDO_SIZE_SOURCE VARCHAR2(400) Y Derived field – method used to
derive DERIVED_ENDO_SIZE
DERIVED_ENDO_SIZE_OTHER NUMBER(2) Y Derived field – derived from the
fields ASSUME_ENDO_SIZE_OTHER
and ENDO_SIZE_OTHER with
ASSUME_ENDO_SIZE_OTHER always
taking precedence over
ENDO_SIZE_OTHER
DERIVED_ENDOSIZE_OTHER_SOURCE VARCHAR2(4000) Y Derived field – which field the
size was taken from (i.e.
ASSUME_ENDO_SIZE_OTHER
or ENDO_SIZE_OTHER)
DERIVED_PATH_SIZE NUMBER(4,1) Y Derived field – derived from the
fields ASSUME_PATH_SIZE and
PATH_SIZE (ASSUME_PATH_SIZE
took precedence)
DERIVED_PATH_SIZE_SOURCE VARCHAR2(4000) Y Coded field – field from which the
size DERIVED_PATH_SIZE was derived
NEW_POLYP NUMBER Y A unique number allocated to every
new polyp created when an endo
quantity row (multiple polyp row)
was separated out into individual
polyps. Shows which polyps were
automatically generated
NEW_POLYP_STATUS VARCHAR2(30) Y Allocated automatically when an
endo quantity row (multiple polyp
row) was separated out into
individual polyps. This value was
used to indicate whether the row
was created based on an existing
polyp or new polyp
Primary key
Name Columns
DERIVED_MP_POLYPS_PK POLYP_ID
Foreign keys
Name Columns Referencing table Columns
DERIVED_MP_POLYPS_FK ENDO_ID ENDOSCOPY ENDO_ID
Indexes
Name Columns Type
DERIVED_MP_POLYPS_ID_ENDOID ENDO_ID Normal
DERIVED_MP_POLYPS_PK POLYP_ID Unique
DERIVED_MP_POLYPS_STUDYNUMBER STUDY_NUMBER Normal
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
267
DERIVED_MP_SUMMARY
A table derived using a program to summarise the values of variables used in estimating the number of
polyps within an endo quantity row.
Columns
Name Type Optional Default Comments
STUDY_NUMBER VARCHAR2(10) Study number of the patient
POLYP_ID VARCHAR2(20) Polyp ID of an endo quantity row (group
of polyps)
POLYP_GROUP NUMBER(5) Y Coded field – used to classify group of
polyps and individual polyps within the
group seen at the same examination
GROUP_LINKING NUMBER(5) Y Coded field – used to allocate a unique
group number for a set of polyps seen
across many examinations
REFERENCE DATA:
MULTIPLE_GROUP_LINKING
TOTALPOLYPS VARCHAR2(4000) Y Derived field – the total number of
unique polyps seen for the endo quantity
row across all examinations. It was
derived by taking into account number
of multilinked polyps, the number of
unique polyps with the same
MULTIPLE_GROUP_LINKING seen at
other examinations and deducting any
polyps with the same
MULTIPLE_GROUP_LINKING that had
been excised prior to the procedure date
of the endo quantity row
SAMEEXAMPOLYPS VARCHAR2(4000) Y Derived field – the total number of
multilinked polyps at the same
examination for the endo quantity row
POLYPCOUNTEXAM VARCHAR2(4000) Y Derived field – this was the total number
of polyps observed at the same
examination as the endo quantity row
POLYPCOUNTGROUP VARCHAR2(4000) Y Derived field –this was the total number
of polyps seen at the same examination
where the MULTIPLE_POLYP_GROUP or
MULTIPLE_GROUP_LINKING of the endo
quantity row matched the individual and
multilinked polyps
POLYPCOUNTGROUP_OTHERS VARCHAR2(4000) Y Derived field – this was the total
number of multilinked polyps seen
at the same examination where the
MULTIPLE_POLYP_GROUP and
MULTIPLE_GROUP_LINKING of the endo
quantity row and polyps match
ESTIMATED_QUANTITY NUMBER Y Derived field – ENDO_QUANTITY_OTHER
field translated into actual values. The
following quantities were assigned to
each option: few – 3, some – 3, num of
– 3, several – 3, many – 5, multiple – 5
MIN_QTY NUMBER Y Coded field – minimum quantity of
polyps in the group recorded by the
study researcher
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Name Type Optional Default Comments
MAX_QTY NUMBER Y Coded field – maximum quantity of
polyps in the group recorded by the
study researcher
APPROX_QTY NUMBER Y Coded field – approximate quantity of
polyps recorded by the study researcher
EXCISION_EXTENT NUMBER(1) Y Coded field – extent of polyp excision
REFERENCE DATA:XEXCISION_EXTENT
MAX_ROWS VARCHAR2(4000) Y Derived field – this was the total number
of polyps that should be multilinked to
the ENDO QUANTITY ROW. The total
included the existing multi linked rows
and any other rows that made up the
group of the endo quantity row. A
number of rules were used to derive this
MAX_ROWS_DATASOURCE VARCHAR2(4000) Y Derived field – records the name of the
field used to obtain the MAX_ROWS for
this endo quantity row
ROWSADD VARCHAR2(4000) Y Derived field – total number of polyps
that would be added when the endo
quantity row was multiplied out, and
included the number of new polyps
that are created from existing polyps
observed at other examinations, and also
completely new polyps that were not
observed but guesstimated based on the
information available
ROWSADD_OVERRIDE VARCHAR2(4000) Y Derived field – only applied for cases where
there were more than one endo quantity
rows at the same examination with the
same MULTIPLE_GROUP_LINKING.
If the MAX_ROWS was taken from
TOTAL_POLYPS for the more than one
endo quantity rows with the same
MULTIPLE_GROUP_LINKING at the same
examination, then it was important to
ensure that a ratio was used to divide the
TOTAL_POLYPS among those endo
quantity rows after deducting any
multilinked polyps. The program
calculated the TOTAL_POLYPS minus
POLYPCOUNTGROUP and then divided
that based on ESTIMATED_QUANTITY
Primary key
Name Columns
POLYPID_PK POLYP_ID
Unique keys
Name Columns
DERIVED_MP_SUMMARY_UNIQUE STUDY_NUMBER,POLYP_ID
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Foreign keys
Name Columns Referencing table Columns
DERIVED_MP_SUMMARY_FK POLYP_ID POLYP POLYP_ID
Indexes
Name Columns Type
DERIVED_MP_SUMMARY_UNIQUE STUDY_NUMBER,POLYP_ID Unique
POLYPID_PK POLYP_ID Unique
ALLCANCERS_OTHERSOURCES
Cancers from external sources and their mapping to the endoscopy and polyp tables.
Columns
Name Type Optional Default Comments
OURCANCERID VARCHAR2(200) Our unique ID for each cancer
STUDY_NUMBER VARCHAR2(10) Y Unique study number
TABLERECORDID NUMBER Y ID of the cancer from the
source table
DATA_SOURCE VARCHAR2(200) Y Data source to say which table
the data come from
LOAD_DATE DATE Y When data were loaded
EVENT_TYPE VARCHAR2(30) Y Event type as supplied by the
HSCIC/NHSCR
LAT_DOB_DATE DATE Y Latest date of birth as supplied
by the HSCIC/NHSCR
LAT_GENDER VARCHAR2(10) Y Latest gender as supplied by the
HSCIC/NHSCR
EVENT_DATE DATE Y Cancer diagnosis date as
supplied by the HSCIC/NHSCR
DEATH_REG_NO_CASITE VARCHAR2(100) Y Cancer site as supplied by the
HSCIC/NHSCR
SITEICD9 VARCHAR2(100) Y Cancer site as supplied by NSS
SITEICD10 VARCHAR2(100) Y Cancer site as supplied by the
NSS
MORPHOLOGYTYPE VARCHAR2(100) Y Cancer morphology code
supplied by the HSCIC/NHSCR
TYPEICDO VARCHAR2(100) Y Cancer morphology code
supplied by the NSS
TYPEICDO2 VARCHAR2(100) Y Cancer morphology code
supplied by the NSS
TYPEICDO3 VARCHAR2(100) Y Cancer morphology code
supplied by the NSS
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Name Type Optional Default Comments
LAST_UPLOADED DATE Y When we received the data
BASELINE_DETAILS VARCHAR2(4000) Y Baseline placement of the
examination using baseline
dates supplied by statistician
ON_IA_BASELINE VARCHAR2(1) Y Whether the cancer is part of
the adenoma cohort
NEAREST_ENDO_ID VARCHAR2(500) Y Derived automatched ENDO_ID
nearest to the cancer
NEAREST_POLYP_ID VARCHAR2(500) Y Derived automatched POLYP_ID
nearest to the cancer within the
endoscopy corresponding to
the NEAREST_ENDO_ID
PROXIM_NEAREST_POLYP_ID VARCHAR2(4000) Y Derived proximity of the
NEAREST_POLYP_ID using our
bowel segment
DERIVED_COLORECTAL_BYSITE VARCHAR2(4000) Y Derived classification of cancer
groups
NEAREST_CANCER_ENDO_ID VARCHAR2(500) Y Derived automatched ENDO_ID
when cancer was rematched
using different rules for the
second time
NEAREST_CANCER_POLYP_ID VARCHAR2(500) Y Derived automatched POLYP_ID
when cancer was rematched
using different rules for the
second time
SOURCE_NEAREST_CANCER_ENDO_ID VARCHAR2(2000) Y Derived reason on why cancer
was rematched second time to
an endoscopy
PROXIM_NEAREST_CAN_POLYP_ID VARCHAR2(4000) Y Derived proximity of the
NEAREST_CANCER_POLYP_ID
using our bowel segment
DERIVED_PROXIMITY NUMBER(3) Y Derived proximity of cancer
calculated using our bowel
segment
CODER_ENDO_ID VARCHAR2(4000) Y Study researcher manually
reviewed record and mapped
cancer to this ENDO_ID
CODER_POLYP_ID VARCHAR2(4000) Y Study researcher manually
reviewed record and mapped
cancer to this POLYP_ID
CANCER_MATCHING NUMBER(3) Y Study researcher manually
reviewed the record and
classified their findings into one
of these categories
CANCERSITE_DESC VARCHAR2(4000) Y Used for the EPR screens to
display the cancer site description
for the study researcher
MORPHOLOGY_DESC VARCHAR2(4000) Y Used for the EPR screens to
display the cancer type
description or the study
researcher
DERIVED_ENDO_ID VARCHAR2(50) Y Derived from NEAREST_ENDO_ID;
NEAREST_CANCER_ENDO_ID
AND CODER_ENDO_ID
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Name Type Optional Default Comments
DERIVED_POLYP_ID VARCHAR2(50) Y Derived from
NEAREST_POLYP_ID;
NEAREST_CANCER_POLYP_ID
AND CODER_POLYP_ID
DERIVED_METHOD VARCHAR2(500) Y Methods use to obtain the
DERIVED_ENDO__ID AND
DERIVED_POLYP_ID
DERIVED_EXCLUDE_CANCER VARCHAR2(5) Y Derived field – cancers were
excluded based on the study
researcher’s cancer matching
classification, such as duplicate
or not CRC
DEVELOPER_NOTES VARCHAR2(4000) Y Additional information about
the data added by the study
programmer
SITE_CODING_SYSTEM VARCHAR2(15) Y Derived field – ICD coding
system for the derived cancer site
TYPE_CODING_SYSTEM VARCHAR2(15) Y Derived field – ICD coding system
for the derived morphology code
DERIVED_SITEGROUPING VARCHAR2(4000) Y Derived field – the cancer site
grouping
DERIVED_MORPHGROUPING VARCHAR2(4000) Y The morphology code grouping
DERIVED_SITE_MORPH_DECISION VARCHAR2(4000) Y Derived field – cancer outcome
derived using combinations of
cancer site and morphology
groupings for the HSCIC/NSS/
NHSCR cancer
DERIVED_FINAL_POLYP_ID VARCHAR2(50) Y Derived field – this is the final
mapping of our polyp to the
HSCIC/NSS/NHSCR cancer for
the IA study derived using
various rules. It is populated
only when the cancer is an
outcome and not excluded
DERIVED_FINAL_POLYP_SOURCE VARCHAR2(500) Y Derived field – provides the rule
or method used to get the
DERIVED_FINAL_POLYP_ID
DERIVED_TRUE_CANCERDATE_SOURCE VARCHAR2(2000) Y Derived field – cancer date that
should be used for analysis –
HSCIC/NSS/NHSCR one or our
mapped polyp data
DERIVED_TRUE_SITE_SOURCE VARCHAR2(2000) Y Derived field – cancer site that
should be used for analysis –
HSCIC/NSS/NHSCR one or our
mapped polyp data
DERIVED_TRUE_MORPHOLOGY_SOURCE VARCHAR2(2000) Y Derived field – cancer
morphology that should be
used for analysis – HSCIC/NSS/
NHSCR one or our mapped
polyp data
DERIVED_FINAL_ENDO_ID VARCHAR2(50) Y Derived field – this is the final
mapping of our endoscopy to
the HSCIC/NSS/NHSCR cancer
for the IA study derived using
various rules. Its only populated
where the cancer is an outcome
and not excluded
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
272
Name Type Optional Default Comments
DERIVED_FINAL_ENDO_ID_SOURCE VARCHAR2(500) Y Derived field – provides the rule
or method used to get the
DERIVED_FINAL_ENDO_ID
DERIVED_FINAL_OUTCOME VARCHAR2(500) Y Derived field – cancer outcome
derived using combinations of
cancer site and morphology
groupings and our polyp data
DERIVED_FINAL_OUTCOME_SOURCE VARCHAR2(500) Y Derived field – where the final
outcome was derived from –
HSCIC/NSS/NHSCR one or our
mapped polyp data
DERIVED_DEATHS_OUTCOME VARCHAR2(500) Y Derived field – populated where
the cancer is ascertained from a
death report and information
about the cancer classification
DERIVED_DEATHS_OUTCOME_REASON VARCHAR2(500) Y Derived field – populated where
the cancer is ascertained from a
death report and the reason
why this death was included as
a cancer outcome
DERIVED_SITE_CODE VARCHAR2(20) Y Derived field – final cancer site
code for this cancer derived
from DEATH_REG_NO_CASITE;
SITEICD10 AND SITEICD9
DERIVED_MORPHOLOGY_CODE VARCHAR2(20) Y Derived field – final morphology
code for this cancer derived
from: MORPHOLOGYTYPE;
TYPEICDO3; TYPEICDO2; and
TYPEICDO
Primary key
Name Columns
OURCANCERID_PK OURCANCERID
Unique keys
Name Columns
ALLCANCERS_OTHERSOURCES_UNIQUE STUDY_NUMBER,OURCANCERID
Indexes
Name Columns Type
ALLCANCERS_OTHERSOURCES_UNIQUE STUDY_NUMBER,OURCANCERID Unique
OURCANCERID_PK OURCANCERID Unique
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DATA_CLEANING_GROUPS
The reference table describing the detailed action for all incidents (data-cleaning tasks assigned to
study researchers) after the manual coding had been done. The actual records reviewed are on table
REVIEW_DATA_CLEANING.
Columns
Name Type Optional Default Comments
INCIDENT VARCHAR2(50) The incident number of the task being
reviewed
REVIEW_GROUP VARCHAR2(50) The review group is a group within the
same incident with slightly different
criteria for review
ACTION VARCHAR2(4000) Y Action describing what needs to be
reviewed
DEVELOPER_COMMENT CLOB Y Study programmer comments
Primary key
Name Columns
DATA_CLEANING_GROUPS_PK INCIDENT,REVIEW_GROUP
Indexes
Name Columns Type
DATA_CLEANING_GROUPS_PK INCIDENT,REVIEW_GROUP Unique
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REVIEW_DATA_CLEANING
Records reviewed by study researchers on the EPR application in relation to specific data cleaning tasks.
The task was known as the incident. The details of the task can be obtained by linking this table to
table DATA_CLEANING_GROUPS.
Columns
Name Type Optional Default Comments
CLEANING_ID VARCHAR2(100) Unique ID for the cleaning task
TABLE_NAME VARCHAR2(50) The table containing the unique identifier
of the record being reviewed
STUDY_NUMBER VARCHAR2(10) The patient unique study number
UNIQUE_COLUMN_NAME VARCHAR2(50) The column within the table contained in
TABLE_NAME which has the unique
identifier of the record being reviewed
UNIQUE_RECORD_ID VARCHAR2(50) The unique identifier of the record being
reviewed within table contained in
TABLE_NAME and column contained in
UNIQUE_COLUMN_NAME
INCIDENT VARCHAR2(50) Y The incident number (task number). This can
be linked to the DATA_CLEANING_GROUPS
table to get full description of task
REVIEW_GROUP VARCHAR2(50) Y Relates to the REVIEW_GROUP on the
DATA_CLEANING_GROUPS
CLEANING_DESC VARCHAR2(4000) Y Additional cleaning instructions specific to
this record
CHECK_COMPLETE VARCHAR2(1) Y Y means that the record has been reviewed
for this task. Blank or N means not reviewed
REVIEW_METHOD VARCHAR2(30) Some records are reviewed via spreadsheets
and uploaded by the database manager and
others are reviewed via the screens – APEX
REVIEW_COMMENTS VARCHAR2(4000) Y Other comments from the study
programmer
APP_USER_LAST_UPD_USER VARCHAR2(60) Y Study researcher who reviewed the record
APP_USER_LAST_UPD_DATE DATE Y Date when the record was the record was
reviewed by the study researcher
RESTR_APP_USER VARCHAR2(20) Y Temporary access given to this study
researcher for review. The patient record
would be assigned to a different study
researcher
POLYP_ID VARCHAR2(20) Y The polyp ID is provided where the review
is specific to a polyp
PATH_ID VARCHAR2(20) Y Pathology ID when the record being
reviewed is linked to pathology
PHANTOM_PATH_ID VARCHAR2(20) Y Pathology ID when the record being
reviewed is linked to pathology and where
no endoscopy report was available
CLEANINGNOTES VARCHAR2(4000) Y Study researcher’s notes
CANCER_ID VARCHAR2(400) Y Recorded for some cases where a cancer
record was being reviewed
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Primary key
Name Columns
REVIEW_DATA_CLEANING_PK CLEANING_ID
Foreign keys
Name Columns Referencing table Columns
REVIEW_DATA_CLEANING_FK_SN STUDY_NUMBER PATIENT STUDY_NUMBER
REVIEW_DATA_CLEANING_REF INCIDENT,REVIEW_GROUP DATA_CLEANING_GROUPS INCIDENT,REVIEW_GROUP
Indexes
Name Columns Type
REVIEW_DATA_CLEANING_PK CLEANING_ID Unique
Reference data
Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
CANCER_MATCHING 1 Matched correctly
CANCER_MATCHING 2 Not matched correctly
CANCER_MATCHING 3 Not matched correctly –
missing polyp
CANCER_MATCHING 4 Not matched correctly –
missing examination
CANCER_MATCHING 5 New polyp created
CANCER_MATCHING 6 Not a CRC
CANCER_MATCHING 7 Looks like NHSIC/NHSCR have
a duplicate cancer
CANCER_MATCHING 8 Matched by coder
CANCER_MATCHING 9 Coder confirmed cancer is prior
to first examination recorded
on database
CANCER_MATCHING 10 Coder confirmed cancer is after
last examination recorded on
the database
CANCER_MATCHING 11 HSCIC/NHSCR should have
classified this as a CRC
CANCER_MATCHING 12 No indication of cancer on our
records
CANCER_MATCHING 13 Exclude this case as segment
appears incorrect. (Only use
when data source is deaths)
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
CANCER_MATCHING 14 This is an in situ that cannot be
mapped to our polyp
CLINICAL_HISTOLOGY 1 Adenoma
CLINICAL_HISTOLOGY 2 Metaplastic/hyperplastic
CLINICAL_HISTOLOGY 3 Serrated adenoma
CLINICAL_HISTOLOGY 4 Leiomyoma
CLINICAL_HISTOLOGY 5 Inflammatory
CLINICAL_HISTOLOGY 6 Normal mucosa
CLINICAL_HISTOLOGY 8 Carcinoid/neuroendocrine
tumour
CLINICAL_HISTOLOGY 10 Juvenile polyp
CLINICAL_HISTOLOGY 11 Mucosal prolapse
CLINICAL_HISTOLOGY 14 Ulcer
CLINICAL_HISTOLOGY 15 Inflammation
CLINICAL_HISTOLOGY 16 Melanosis coli
CLINICAL_HISTOLOGY 17 Submucosal haematoma
CLINICAL_HISTOLOGY 19 Angiodysplasia
CLINICAL_HISTOLOGY 20 Ischaemia
CLINICAL_HISTOLOGY 21 Xanthoma
CLINICAL_HISTOLOGY 22 Oedema
CLINICAL_HISTOLOGY 23 Regenerative polyp
CLINICAL_HISTOLOGY 24 Hamartomatous polyp
CLINICAL_HISTOLOGY 25 Haemangioma
CLINICAL_HISTOLOGY 26 Non-Hodgkin’s lymphoma
CLINICAL_HISTOLOGY 27 Fibroepithelial polyp
CLINICAL_HISTOLOGY 28 Crohn’s disease
CLINICAL_HISTOLOGY 29 Neurofibromatosis
CLINICAL_HISTOLOGY 30 Colitis
CLINICAL_HISTOLOGY 31 Lipoma
CLINICAL_HISTOLOGY 32 Pseudolipomatus
CLINICAL_HISTOLOGY 33 Spirochaetosis
CLINICAL_HISTOLOGY 34 Granulation tissue
CLINICAL_HISTOLOGY 35 Gastric heterotopia
CLINICAL_HISTOLOGY 36 Cap polyp
CLINICAL_HISTOLOGY 37 Lymphoid polyp
CLINICAL_HISTOLOGY 39 Previous polypectomy site
CLINICAL_HISTOLOGY 40 Ganglioneuromatosis
CLINICAL_HISTOLOGY 41 Amyloid
CLINICAL_HISTOLOGY 43 Congestion
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
CLINICAL_HISTOLOGY 44 Lymphangiectasia
CLINICAL_HISTOLOGY 45 Proctitis
CLINICAL_HISTOLOGY 50 Cancer
CLINICAL_HISTOLOGY 51 Cancer + adenoma
CLINICAL_HISTOLOGY 52 Cancer in dispute
CLINICAL_HISTOLOGY 53 Mixed adenoma/metastases
CLINICAL_HISTOLOGY 56 Unicryptal adenoma
CLINICAL_HISTOLOGY 57 Metastases – another site
CLINICAL_HISTOLOGY 58 Cancer + serrated adenoma
CLINICAL_HISTOLOGY 59 Cancer +mixed adenoma
CLINICAL_HISTOLOGY 60 METS/tumour – infiltrating
CLINICAL_HISTOLOGY 61 Squamous cell carcinoma
CLINICAL_HISTOLOGY 62 Cancer query
CLINICAL_HISTOLOGY 63 Gastrointestinal stromal tumour
CLINICAL_HISTOLOGY 64 Sarcoma
CLINICAL_HISTOLOGY 65 Unknown primary
CLINICAL_HISTOLOGY 66 Anaplastic/undifferentiated
carcinoma
CLINICAL_HISTOLOGY 67 Basaloid /cloacogenic cancer
CLINICAL_HISTOLOGY 68 Sessile serrated lesion
CLINICAL_HISTOLOGY 69 Cancer + sessile serrated lesion
CLINICAL_HISTOLOGY 70 Granular cell tumour
CLINICAL_HISTOLOGY 71 Melanoma
CLINICAL_HISTOLOGY 72 Anal wart
CLINICAL_HISTOLOGY 90 Not possible to diagnose
CLINICAL_HISTOLOGY 91 Specimen not seen
ENDO_PATH_MAPPING 1 Rule 1 – histology size rule
ENDO_PATH_MAPPING 2 Rule 2 – hyperplastic distal
≤ 5mm rule
ENDO_PATH_MAPPING 3 Rule 3 – excision method rule
ENDO_PATH_MAPPING 4 Rule 4 – specimen labels rule
ENDO_PATH_MAPPING 5 Rule 5 – other sighting
EXAM_NUMBER_UNKNOWN 1 Could not rank
EXAM_NUMBER_UNKNOWN 2 Examination is blank
EXCISION_COMPLETE 1 Complete
EXCISION_COMPLETE 2 Incomplete
EXCISION_COMPLETE 3 Uncertain
MAN_COLLECTED_PATH 0 No
MAN_COLLECTED_PATH 1 Main pathology
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
MAN_COLLECTED_PATH 2 Other pathology
MULTIPLE_GROUP_LINKING 1 GROUP1
MULTIPLE_GROUP_LINKING 2 GROUP2
MULTIPLE_GROUP_LINKING 3 GROUP3
MULTIPLE_GROUP_LINKING 4 GROUP4
MULTIPLE_GROUP_LINKING 5 GROUP5
MULTIPLE_GROUP_LINKING 6 GROUP6
MULTIPLE_GROUP_LINKING 7 GROUP7
MULTIPLE_GROUP_LINKING 8 GROUP8
MULTIPLE_GROUP_LINKING 9 GROUP9
MULTIPLE_GROUP_LINKING 10 GROUP10
MULTIPLE_GROUP_LINKING 11 GROUP11
MULTIPLE_GROUP_LINKING 12 GROUP12
MULTIPLE_GROUP_LINKING 13 GROUP13
MULTIPLE_GROUP_LINKING 14 GROUP14
MULTIPLE_GROUP_LINKING 15 GROUP15
MULTIPLE_GROUP_LINKING 16 GROUP16
MULTIPLE_GROUP_LINKING 17 GROUP17
MULTIPLE_GROUP_LINKING 18 GROUP18
MULTIPLE_GROUP_LINKING 19 GROUP19
MULTIPLE_GROUP_LINKING 20 GROUP20
MULTIPLE_GROUP_LINKING 21 GROUP21
MULTIPLE_GROUP_LINKING 22 GROUP22
MULTIPLE_GROUP_LINKING 23 GROUP23
MULTIPLE_GROUP_LINKING 24 GROUP24
MULTIPLE_GROUP_LINKING 25 GROUP25
MULTIPLE_POLYP_GROUP 1 GROUP1
MULTIPLE_POLYP_GROUP 2 GROUP2
MULTIPLE_POLYP_GROUP 3 GROUP3
MULTIPLE_POLYP_GROUP 4 GROUP4
MULTIPLE_POLYP_GROUP 5 GROUP5
MULTIPLE_POLYP_GROUP 6 GROUP6
MULTIPLE_POLYP_GROUP 7 GROUP7
MULTIPLE_POLYP_GROUP 8 GROUP8
MULTIPLE_POLYP_GROUP 9 GROUP9
MULTIPLE_POLYP_GROUP 10 GROUP10
MULTIPLE_POLYP_GROUP 11 GROUP11
MULTIPLE_POLYP_GROUP 12 GROUP12
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
MULTIPLE_POLYP_GROUP 13 GROUP13
MULTIPLE_POLYP_GROUP 14 GROUP14
MULTIPLE_POLYP_GROUP 15 GROUP15
MULTIPLE_POLYP_GROUP 16 GROUP16
MULTIPLE_POLYP_GROUP 17 GROUP17
MULTIPLE_POLYP_GROUP 18 GROUP18
MULTIPLE_POLYP_GROUP 19 GROUP19
MULTIPLE_POLYP_GROUP 20 GROUP20
MULTIPLE_POLYP_GROUP 21 GROUP21
MULTIPLE_POLYP_GROUP 22 GROUP22
MULTIPLE_POLYP_GROUP 23 GROUP23
MULTIPLE_POLYP_GROUP 24 GROUP24
MULTIPLE_POLYP_GROUP 25 GROUP25
MULTIPLE_POLYP_GROUP 26 GROUP26
OPERATION_TYPE 1 Right hemicolectomy
OPERATION_TYPE 2 Left hemicolectomy
OPERATION_TYPE 3 Transanal resection
OPERATION_TYPE 4 Transanal excision
OPERATION_TYPE 5 Anterior resection
OPERATION_TYPE 6 Sigmoid resection
OPERATION_TYPE 7 Sigmoid colectomy
OPERATION_TYPE 8 Extended right hemicolectomy
OPERATION_TYPE 9 Extended left hemicolectomy
OPERATION_TYPE 10 Subtotal colectomy
OPERATION_TYPE 11 Abdominoperineal resection
OPERATION_TYPE 12 Transverse colectomy
OPERATION_TYPE 13 High anterior resection
OPERATION_TYPE 14 Low anterior resection
OPERATION_TYPE 15 Total colectomy
OPERATION_TYPE 16 Laparotomy with colostomy
OPERATION_TYPE 17 Hartmann’s procedure
OPERATION_TYPE 18 Laparotomy
OPERATION_TYPE 19 Laparoscopic anterior resection
OPERATION_TYPE 20 Proctocolectomy
OPERATION_TYPE 21 TME
OPERATION_TYPE 22 TEMS
OPERATION_TYPE 23 Laparoscopic subtotal
colectomy
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Definition (populated only if
further explanation of field is
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OPERATION_TYPE 24 Laparoscopy assisted right
hemicolectomy
OPERATION_TYPE 25 Ileorectal anastomosis
OPERATION_TYPE 26 Laparoscopic assisted resection
of sigmoid colon
OPERATION_TYPE 27 Right hemicolectomy and
laparotomy
OPERATION_TYPE 28 Ileosigmoid bypass
OPERATION_TYPE 29 Panproctocolectomy
OPERATION_TYPE 30 Laparoscopy-assisted left
hemicolectomy
OPERATION_TYPE 31 Subtotal proctocolorectomy
OPERATION_TYPE 32 Subtotal proctocolectomy
OPERATION_TYPE 33 Proctosigmoidectomy
OPERATION_TYPE 34 Resection – other
OPERATION_TYPE 35 Non-resection surgery
OPERATION_TYPE 36 Completion colectomy
OPERATION_TYPE 37 Double resection
OPERATION_TYPE 38 Proctectomy
OPERATION_TYPE 39 Not surgery
OPERATION_TYPE 40 Transverse colectomy
OPERATION_TYPE 41 Laparoscopic caecectomy
OPERATION_TYPE 42 Local excision
OPERATION_TYPE 43 Extended transverse colectomy
OPERATION_TYPE 44 Colectomy
OPERATION_TYPE 45 Transverse colon resection
OPERATION_TYPE 46 Ileocolic anastomosis
OPERATION_TYPE 47 Stapled excision of polyp
OPERATION_TYPE 48 Colostomy
OPERATION_TYPE 49 Partial colectomy
OPERATION_TYPE 50 Posterior mesorectal resection
OPERATION_TYPE 51 Rectosigmoid resection
OPERATION_TYPE 52 Anterior resection and right
hemicolectomy
OPERATION_TYPE 53 Right hemicolectomy and
sigmoid resection
OPERATION_TYPE 54 Left hemicolectomy and AP
resection
POLYP_MATCH_PROB 10 10%
POLYP_MATCH_PROB 20 20%
POLYP_MATCH_PROB 30 30%
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
POLYP_MATCH_PROB 40 40%
POLYP_MATCH_PROB 50 50%
POLYP_MATCH_PROB 60 60%
POLYP_MATCH_PROB 70 70%
POLYP_MATCH_PROB 80 80%
POLYP_MATCH_PROB 90 90%
POLYP_MATCH_PROB 100 100%
POLYP_NUMBERED N N
POLYP_NUMBERED Y Y
REASON_EXAM_SAME_DAY 1 Emergency surgery
REASON_EXAM_SAME_DAY 2 First procedure abandoned
REASON_EXAM_SAME_DAY 3 First procedure incomplete
REASON_EXAM_SAME_DAY 4 This examination may not
belong to this patient
REASON_EXAM_SAME_DAY 5 Follow-on examination
REASON_EXAM_SAME_DAY 6 From same procedure
REASON_EXAM_SAME_DAY 7 Unknown
REVIEW_METHOD APEX Reviewed by coders via APEX
REVIEW_METHOD SPREAD Reviewed on spreadsheet
REVIEW_NUMBERED N N
REVIEW_NUMBERED Y Y
SERRATION 1 Confirmed
SERRATION 2 Possible
XADENOMA_TYPE 1 Tubular The pathologist describes the
morphology of the adenomatous
tissue as tubular
XADENOMA_TYPE 3 Tub-vill The pathologist describes the
morphology of the adenomatous
tissue as tubulovillous
XADENOMA_TYPE 2 Villous The pathologist describes the
morphology of the adenomatous
tissue as villous
XBIOPSY_FATE 1 Retrieved To be used when the polyp has
been collected by the endoscopist
from the colon after excision, and
not left inside the colon. This may
or may not have been sent to
pathology
XBIOPSY_FATE 2 Burnt off Method of removal that destroys
the polyp in situ
XBIOPSY_FATE 4 Unknown To be used when the coder is
unsure what has happened to
the polyp post excision/biopsy
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Definition (populated only if
further explanation of field is
required)
XBIOPSY_FATE 5 Not retrieved The specimen was lost after
removal either inside the patient
or outside the patient on
collection. A specimen/biopsy
may still have been sent to
pathology
XBOWEL_PREP 1 Poor
XBOWEL_PREP 2 Satisfactory
XBOWEL_PREP 3 Good
XBOWEL_PREP 4 Excellent
XBOWEL_SEGMENT 33 Anus An
XBOWEL_SEGMENT 5 Splenic flexure SF
XBOWEL_SEGMENT 6 Transverse colon TC
XBOWEL_SEGMENT 25 Transverse colon (distal) TC(d)
XBOWEL_SEGMENT 26 Transverse colon (mid) TC(m)
XBOWEL_SEGMENT 27 Transverse colon (proximal) TC(p)
XBOWEL_SEGMENT 7 Hepatic flexure HF
XBOWEL_SEGMENT 8 Ascending colon AC
XBOWEL_SEGMENT 29 Ascending colon (distal) AC(d)
XBOWEL_SEGMENT 36 Ascending colon (mid) AC(m)
XBOWEL_SEGMENT 28 Ascending colon (proximal) AC(p)
XBOWEL_SEGMENT 9 Caecum CM
XBOWEL_SEGMENT 1 Rectum RM
XBOWEL_SEGMENT 37 Rectum (distal) RM(d)
XBOWEL_SEGMENT 38 Rectum (mid) RM(m)
XBOWEL_SEGMENT 39 Rectum (proximal) RM(p)
XBOWEL_SEGMENT 34 Ileocaecal valve ICV
XBOWEL_SEGMENT 10 Terminal Ileum TI
XBOWEL_SEGMENT 2 Rectosigmoid RS
XBOWEL_SEGMENT 3 Sigmoid colon SC
XBOWEL_SEGMENT 24 Sigmoid colon (distal) SC(d)
XBOWEL_SEGMENT 40 Sigmoid colon (mid) SC(m)
XBOWEL_SEGMENT 23 Sigmoid colon (proximal) SC(p)
XBOWEL_SEGMENT 4 Descending colon DC
XBOWEL_SEGMENT 22 Descending colon (distal) DC(d)
XBOWEL_SEGMENT 41 Descending colon (mid) DC(m)
XBOWEL_SEGMENT 21 Descending colon (proximal) DC(p)
XBOWEL_SEGMENT 11 Anastomosis Anas
XBOWEL_SEGMENT 31 Colostomy Colos
XBOWEL_SEGMENT 32 Neoterminal ileum TI Neo
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XBOWEL_SEGMENT 35 Ileal pouch Il Po
XBOWEL_SEGMENT 42 Pre pouch ileum Il Pre-Po
XDIAGNOSIS_SUB_TYPES_COLITIS 1 Confirmed colitis Confirmed colitis
XDIAGNOSIS_SUB_TYPES_COLITIS 2 Ulcerative colitis Chronic form of IBD
characterised by ulceration of
the colon and rectum
XDIAGNOSIS_SUB_TYPES_COLITIS 3 Microscopic colitis Refers to both collagenous
colitis and lymphocytic colitis,
characterised by increase in
inflammatory cells
XDIAGNOSIS_SUB_TYPES_COLITIS 4 Lymphocytic colitis Subtype of microscopic colitis,
characterised by chronic
non-bloody watery diarrhoea
and an accumulation of
lymphocytes in the colonic
mucosa and lamina propria
XDIAGNOSIS_SUB_TYPES_COLITIS 5 Collagenous colitis Subtype of microscopic colitis,
characterised by chronic watery
diarrhoea, rectal bleeding and
deposition of collagen in the
lamina propria
XDIAGNOSIS_SUB_TYPES_COLITIS 6 Healed colitis Redundant code – not available
on the screen
XDIAGNOSIS_SUB_TYPES_COLITIS 7 History of colitis Redundant code – not available
on the screen
XDIAGNOSIS_SUB_TYPES_COLITIS 8 Ischaemic colitis Inflammation and injury of the
colon as a result of inadequate
blood supply
XDIAGNOSIS_SUB_TYPES_COLITIS 9 Diversion colitis Inflammation in a
non-functioning colonic pouch
occurring as a complication of
ileostomy or colostomy, often
within the year following the
surgery
XDIAGNOSIS_SUB_TYPES_COLITIS 10 Infective colitis Inflammation of the colon
caused by bacterial or viral
infection, commonly due to
Clostridium difficile
XDIAGNOSIS_SUB_TYPES_COLITIS 11 Chemical colitis Inflammation of the colon
caused by the introduction of
harsh chemicals by an enema or
other procedure
XDIAGNOSIS_SUB_TYPES_COLITIS 12 Pseudomembranous colitis Subtype of infectious colitis,
characterised by the formation
of pseudomembranes
XDIAGNOSIS_SUB_TYPES_COLITIS 13 Drug-induced colitis Inflammation of the colon as a
result of treatment with various
types of drug, (e.g. NSAIDs,
anticoagulants, SSRIs)
XDIAGNOSIS_SUB_TYPES_COLITIS 14 Radiation colitis Inflammation and damage of the
colon as a result of exposure to
X-rays or radiation; commonly
occurs after radiation therapy for
cancer
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Definition (populated only if
further explanation of field is
required)
XDIAGNOSIS_SUB_TYPES_COLITIS 15 Reactive colitis Redundant code – not available
on the screen
XDIAGNOSIS_SUB_TYPES_COLITIS 16 Procedural/enema related Inflammation of the colon as a
result of the endoscopic
procedure
XDIAGNOSIS_SUB_TYPES_COLITIS 17 Possible colitis Possible colitis [of a certain
type(s)]
XDIAGNOSIS_SUB_TYPES_COLITIS 18 Antibiotic-associated colitis Inflammation of the colon as a
result of antimicrobial therapy
XDIAGNOSIS_SUB_TYPES_COLITIS 19 Indeterminate colitis Colitis that has features of both
Crohn’s disease and ulcerative
colitis
XDIAGNOSIS_SUB_TYPES_COLITIS 20 Atypical colitis Colitis that does not conform to
criteria for accepted types of
colitis
XDIAGNOSIS_SUB_TYPES_COLITIS 21 Other colitis 1 Other colitis 1 spare
XDIAGNOSIS_SUB_TYPES_COLITIS 22 Other colitis 2 Other colitis 2 spare
XDIAGNOSIS_SUB_TYPES_COLITIS 23 Ulcerative proctitis Ulcerative proctitis is the least
severe form of IBD
XDIAGNOSIS_SUB_TYPES_COLITIS 25 Radiation proctitis – autocoded
XDIAGNOSIS_SUB_TYPES_COLITIS 99 Rule out colitis Rule out colitis
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 1 Confirmed polyposis Confirmed polyposis
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 2 FAP Presence of multiple adenomas
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 3 Juvenile polyposis Presence of juvenile polyps
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 4 PJ polyposis Presence of Peutz–Jeghers type
(hamartomatous) of polyps; PJS
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 5 Hyperplastic polyposis Presence of multiple hyperplastic
polyps
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 6 Possible Possible polyposis [of a certain
type(s)]
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 7 Serrated polyposis Presence of multiple serrated
polyps
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 8 Lymphoid polyposis Presence of multiple lymphoid
polyps
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 9 Cap polyposis Presence of multiple cap polyps
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 10 Other polyposis 1 Other polyposis – spare 1
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 11 Other polyposis 2 Other polyposis – spare 2
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 12 MAP MYH-associated polyposis:
mutations in the MUTYH gene
cause an autosomal recessive
form of FAP (also called
MUTYH-associated polyposis).
Polyps caused by mutated MYH
do not appear until adulthood
and are less numerous than
those found in patients with
APC gene mutations
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XDIAGNOSIS_SUB_TYPES_POLYPOSIS 99 Rule out polyposis Rule out polyposis
XDIAGNOSIS_TYPES 1 Polyps Endoscopist has found polyps in
the bowel during the examination
XDIAGNOSIS_TYPES 2 Diverticular disease Endoscopist has observed
uncomplicated diverticula in the
colon (diverticulosis) or inflamed
diverticular (diverticulitis)
XDIAGNOSIS_TYPES 3 Haemorrhoids Endoscopist has observed
haemorrhoids/piles
XDIAGNOSIS_TYPES 4 Colitis The endoscopist has specified
the presence of colitis from the
observations made during the
examination
XDIAGNOSIS_TYPES 5 Cancer Malignant neoplasm
XDIAGNOSIS_TYPES 6 Crohn’s disease The endoscopist strongly
suspects the patient has Crohn’s
disease or is known to already
have Crohn’s disease
XDIAGNOSIS_TYPES 7 Proctitis Endoscopist has observed
Inflammation of the lining of the
rectum and anus. Telangiectasia
is a similar condition involving
the blood vessels and can be
classified under proctitis
XDIAGNOSIS_TYPES 8 Piles See haemorrhoids
XDIAGNOSIS_TYPES 9 Anastomosis Endoscopist has mentioned the
anastomosis which is the surgical
reconnection of two parts of the
colon post resection
XDIAGNOSIS_TYPES 10 Benign tumour Endoscopist has observed an
abnormal growth/neoplasm that
they feel lacks the malignant
qualities of cancer
XDIAGNOSIS_TYPES 11 Volvulus Endoscopist has observed a life
threatening bowel obstruction
where the bowel twists on itself
XDIAGNOSIS_TYPES 12 Angiodysplasia Endoscopist has observed areas of
vascular malformation in the gut
and can be a common cause of
unexplained bleeding in the colon
XDIAGNOSIS_TYPES 13 Melaena Black, ‘tarry’ faeces that are
associated with gastrointestinal
haemorrhage. There are some
inconsistencies in the coding of
this field
XDIAGNOSIS_TYPES 14 Incomplete examination Any description that suggests
the examination was not fully
compete due to physical or
technical difficulties, (e.g.:
l incomplete examination
l inadequate examination
l limited examination
l intubation unsuccessful)
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Definition (populated only if
further explanation of field is
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XDIAGNOSIS_TYPES 15 Suspected IBD Endoscopist has seen features
that are suspicious of/indicating
IBD
XDIAGNOSIS_TYPES 16 IBD IBD – a group of conditions
affecting the colon and small
intestine, including Crohn’s
disease and ulcerative colitis
XDIAGNOSIS_TYPES 17 Ulcers/ulceration An inflammatory and often
suppurating lesion on the skin or
an internal mucous surface
resulting in necrosis of tissue
XDIAGNOSIS_TYPES 18 Colonic obstruction Obstruction of the colon,
preventing the normal transit of
the products of digestion
There are some inconsistencies
in the coding of this field
XDIAGNOSIS_TYPES 19 Fissure A crack or tear in the tissue
There are some inconsistencies
in the coding of this field
XDIAGNOSIS_TYPES 20 Strictures An abnormal narrowing of the
colon. The stricture may be due
for example to scar tissue or to a
tumour. Stricture refers to both
the process of narrowing and
the narrowed part itself
There are some inconsistencies
in the coding of this field
XDIAGNOSIS_TYPES 21 FAP – redundant do not use FAP. Redundant code – see
incident 350
XDIAGNOSIS_TYPES 22 Polyposis A hereditary disease in which
numerous polyps erupt in a part
of the body, especially on the
lining of the colon and rectum,
and often become malignant
XDIAGNOSIS_TYPES 23 Prolapse The falling down or slipping of a
body part from its usual position
or relations
There are some inconsistencies
in the coding of this field
XDIAGNOSIS_TYPES 24 Non-exclusion colitis Colitis that does not fit within
the exclusion criteria
XDIAGNOSIS_TYPES 25 Possible Crohn’s disease The possible presence of Crohn’s
disease in the colon
XDIAGNOSIS_TYPES 43 Radiation and proctitis found Words radiation and proctitis
found
XDIAGNOSIS_TYPES 44 Radiation and ulcers found Words radiation and ulcers
found
XDYSPLASIA 1 Mild The pathologist describes mild
dysplasia/atypia
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XDYSPLASIA 2 Moderate The pathologist describes
moderate or focally moderate
dysplasia/atypia
XDYSPLASIA 3 Low grade The pathologist describes
low-grade dysplasia/atypia. This
is synonymous with either mild
or moderate dysplasia. Use only
when specified
XDYSPLASIA 4 High grade The pathologist describes HGD/
atypia. This is synonymous with
severe dysplasia. Use only when
specified
XDYSPLASIA 5 Severe The pathologist describes severe
or focally dysplasia/atypia
XDYSPLASIA 6 Intramucosal cancer The pathologist describes
presence of intramucosal cancer
XDYSPLASIA 7 Intramucosal cancer in dispute Intramucosal cancer in dispute
XEXCISION_EXTENT 1 Excised Endoscopist believes he has
removed the polyp from the
colon
XEXCISION_EXTENT 2 Partially excised Endoscopist has specified that
they have only removed part of
the polyp
XEXCISION_EXTENT 3 Not excised Endoscopist has not excised the
polyp. They may still have
biopsied the polyp for pathology
XEXCISION_METHOD 1 Cold biopsy Also Cold Bx/B’x. Insert if
specified by endoscopist or
pathologist
XEXCISION_METHOD 2 Hot biopsy Also Hot Bx/B’x. Insert if
specified by endoscopist or
pathologist
XEXCISION_METHOD 3 Snare A wire loop device designed to
slip over a polyp and, on closure,
result in removal of the polyp
XEXCISION_METHOD 4 Cold snare Insert if specified by endoscopist
or pathologist
XEXCISION_METHOD 5 Hot snare Insert if specified by endoscopist
or pathologist
XEXCISION_METHOD 7 EMR Endoscopic mucosal resection.
Insert if specified by endoscopist
or pathologist
XEXCISION_METHOD 9 Unknown Used when you know removal
or biopsy has taken place but
the method is unspecified
XEXCISION_METHOD 10 APC Argon plasma coagulation
XEXCLUSION 1 Crohn’s disease Chronic inflammatory disease
that can affect any part of the
intestinal tract
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XEXCLUSION 2 Ulcerative colitis Chronic digestive disease
characterised by inflammation
of the colon that includes
characteristic ulcers, or open sores
XEXCLUSION 3 Colitis Chronic digestive disease
characterised by inflammation of
the colon
XEXCLUSION 4 FAP Inherited condition in which
numerous polyps form mainly in
the epithelium of the large
intestine
XEXCLUSION 5 Family Hx FAP History of family members who
have suffered with FAP
XEXCLUSION 6 Polyposis Colon has a very large number
of polyps lining a large
proportion of the colons surface
XEXCLUSION 7 P-J polyposis Hereditary intestinal polyposis
syndrome characterised by the
development of benign
hamartomatous polyps in the
gastrointestinal tract
XEXCLUSION 8 Cancer first examination Malignant findings in the colon
that have been confirmed by
pathological assessment linked
to the first endoscopic
examination for that patient in
our records
XEXCLUSION 9 Resection first examination Partial or complete removal of
the colon occurring before first
endoscopic examination for that
patient in our records
XEXCLUSION 10 IBD IBD
XEXCLUSION 21 HNPCC Familial predisposition indicates
elevated risk for polyp and/or
bowel cancer development by
genetic influence
XEXCLUSION 97 No bowel examinations
recorded
Excluded as none of the
endoscopies are a bowel
examination for this patient
XEXCLUSION 98 Other – see developer notes Excluded as records without
endoscopies – see developer’s
notes
XEXCLUSION 99 Other – see comments Other condition not listed here
that may exclude patient from
study
XHOSPITALS BRI Brighton Hospital
XHOSPITALS CI Cumberland Infirmary
XHOSPITALS CX Charing Cross Hospital
XHOSPITALS GRI Glasgow Royal Infirmary
XHOSPITALS ICMS St Mary’s – Imperial Trust
XHOSPITALS LGH Leicester General Hospital
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Definition (populated only if
further explanation of field is
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XHOSPITALS NC New Cross
XHOSPITALS NT North Tees
XHOSPITALS QEW Queen Elizabeth Hospital
XHOSPITALS QMH Queen Mary’s Hospital
XHOSPITALS RLUH Liverpool University Hospital
XHOSPITALS SCH Royal Surrey County Hospital
XHOSPITALS SGH St George’s
XHOSPITALS SH Shrewsbury Hospital
XHOSPITALS SMH St Mark’s Hospital
XHOSPITALS TDG Torbay District General Hospital
XHOSPITALS YDH Yeovil District Hospital
XINDICATION_TYPES 1 Polyps The patient has had previous
polyps
XINDICATION_TYPES 2 Diverticular disease Presence of uncomplicated
diverticula in the colon
(diverticulosis) or inflamed
diverticular (diverticulitis)
XINDICATION_TYPES 3 Haemorrhoids Swelling and inflammation of
the veins in the rectum and
anus. This is the same as piles
XINDICATION_TYPES 4 Colitis The endoscopist has specified
the presence of colitis prior
to the procedure. Colitis is a
chronic digestive disease
characterised by inflammation of
the colon. Inflammation alone
does not warrant a classification
of colitis
XINDICATION_TYPES 5 Carcinoma The patient has had a carcinoma
prior to the examination in
question
XINDICATION_TYPES 6 Cancer The patient has had a cancer
prior to the examination in
question
XINDICATION_TYPES 7 Crohn’s disease Chronic inflammatory disease
which can affect any part of the
gastrointestinal tract
(It is a member of the colitis
family but is defined separately
here for clarity)
XINDICATION_TYPES 8 Anaemia Deficiency of haemoglobin in the
blood
XINDICATION_TYPES 9 Diarrhoea Frequent loose or liquid bowel
movements
XINDICATION_TYPES 10 Abdominal pain Generalised pain in the
abdominal region. LIF and RIF
pain can also be classified as
abdominal pain
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XINDICATION_TYPES 11 Rectal bleeding Bleeding appearing to come
from the rectum
XINDICATION_TYPES 12 Abnormal barium enema Abnormal findings on a barium
enema prior to examination in
question
XINDICATION_TYPES 13 Abnormal CT Abnormal findings on a CT scan
prior to examination in question
XINDICATION_TYPES 14 Abnormal sigmoidoscopy Abnormal findings on a
sigmoidoscopy prior to
examination in question
XINDICATION_TYPES 15 Family history of CRC Patient has relatives who have
had CRC
There are some inconsistencies
in the coding of this field
XINDICATION_TYPES 16 Hereditary non-polyposis CRC An inherited condition with
which there is a very high
chance of getting CRC
XINDICATION_TYPES 17 Change in bowel habit The patient is experiencing a
change in the frequency of
bowel movements compared
with normal
XINDICATION_TYPES 18 Polyposis A condition through which a
person suffers with a large
number of polyps coating a large
surface area throughout the colon
XINDICATION_TYPES 19 Constipation Hard faeces that are difficult to
expel, often accompanied by a
reduction in the frequency of
bowel movements
XINDICATION_TYPES 20 Rectal_Mass Palpable mass in the area of the
rectum
XINDICATION_TYPES 21 Abdominal mass Palpable mass in the area of the
abdomen
XINDICATION_TYPES 22 Weight loss Uncharacteristic loss of body mass
XINDICATION_TYPES 23 Positive faecal occult blood test Also FOBT or FOB. Positive result in
screening test for ‘unseen’ blood
XINDICATION_TYPES 24 Rectal pain Pain in the rectum
XINDICATION_TYPES 25 Query polyps To test for the presence of
polyps/suspect presence of polyps
XINDICATION_TYPES 26 Query colitis To test for the presence of
colitis/suspect possible colitis
XINDICATION_TYPES 27 Query Crohn’s disease To test for the presence of
Crohn’s disease/suspect possible
Crohn’s disease
XINDICATION_TYPES 28 Mucus discharge Mucus that passes out of the
rectum from a source in the
bowel
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XINDICATION_TYPES 29 Bowel Cancer Screening
Programme
The patient is having an
endoscopy examination as part of
the national Bowel Cancer
Screening Programme. Could also
be written as BCSP
Please note that not all records
coded with this indication as part
of the national Bowel Cancer
Screening Programme
XINDICATION_TYPES 30 Volvulus Life-threatening bowel
obstruction where the bowel
twists on itself
XINDICATION_TYPES 31 Incontinence Involuntary leakage of faeces
There are some inconsistencies
in the coding of this field
XINDICATION_TYPES 32 Melena Black, ‘tarry’ faeces, which are
associated with gastrointestinal
haemorrhage
There are some inconsistencies
in the coding of this field
XINDICATION_TYPES 33 Tenesmus Feeling of the need to evacuate
the bowels, with little or no stool
passed
There are some inconsistencies
in the coding of this field
XINDICATION_TYPES 34 Query cancer To test for the presence of
cancer
XINDICATION_TYPES 35 Family History of Cancer A history of cancer within the
family, indicating a hereditary
risk
There are some inconsistencies
in the coding of this field
XINDICATION_TYPES 36 IBD Inflammatory bowel disease –
a group of conditions affecting
the colon and small intestine,
including; Crohn’s disease and
ulcerative colitis
XINDICATION_TYPES 37 Ulcers/ulceration An inflammatory and often
suppurating lesion on the skin or
an internal mucous surface
resulting in necrosis of tissue
XINDICATION_TYPES 38 Colonic obstruction Obstruction of the colon,
preventing the normal transit of
the products of digestion
There are some inconsistencies
in the coding of this field
XINDICATION_TYPES 39 Fissure A crack or tear in the tissue
There are some inconsistencies
in the coding of this field
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XINDICATION_TYPES 40 Query polyposis To test for the presence of
polyposis
XINDICATION_TYPES 41 Family Hx of FAP Family history of FAP
XINDICATION_TYPES 42 Cowden syndrome A rare inherited disorder
characterised by multiple
tumour-like growths called
hamartomas and an increased
risk of developing CRC
XINDICATION_TYPES 43 Radiation and proctitis found Words radiation and proctitis
found
XINDICATION_TYPES 44 Radiation and ulcers found Words radiation and ulcers found
XNFEATURE_TYPES 1 Pathology – blank
XNFEATURE_TYPES 2 Pathology – truncated
XNFEATURE_TYPES 3 Endoscopy – irrelevant
XNFEATURE_TYPES 4 Endoscopy – duplicate
XNFEATURE_TYPES 5 Endoscopy – truncated
XNFEATURE_TYPES 6 Endoscopy – blank
XNFEATURE_TYPES 7 Condition – possible cancer
first examination
XNFEATURE_TYPES 8 Condition – possible resection
first examination
XNFEATURE_TYPES 9 Condition – possible HNPCC
XNFEATURE_TYPES 10 Condition – possible polyposis
XNFEATURE_TYPES 11 Condition – possible IBD
XNFEATURE_TYPES 12 General – supplementary report
missing
XNFEATURE_TYPES 13 General – possible cancer
XNFEATURE_TYPES 14 General – when cancer
XNFEATURE_TYPES 15 General – when resection
XNFEATURE_TYPES 16 General – polyp numbers
XNFEATURE_TYPES 17 General – unsure terminology
XNFEATURE_TYPES 18 Pathology linking
XNFEATURE_TYPES 19 Pathology missing – sent to
laboratory/await pathology
stated
XNFEATURE_TYPES 20 Pathology missing – large polyp
of ≥ 10mm
XNFEATURE_TYPES 21 Pathology missing – biopsy
indicator
XNFEATURE_TYPES 22 Pathology missing – cancer/
tumour indicated
XNFEATURE_TYPES 23 Polyp matching
XNFEATURE_TYPES 24 Refer back to
XNFEATURE_TYPES 25 Discuss – IBD
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XNFEATURE_TYPES 26 Discuss – how best to code
XNFEATURE_TYPES 27 Discuss – HNPCC
XNFEATURE_TYPES 28 Pathology – unclear specimen
origin
XPATH_EXCLUSION 0 –
XPATH_EXCLUSION 1 General
XPATH_EXCLUSION 2 Not relevant pathology
XPATH_EXCLUSION 3 Duplicate
XPATH_QUERY 1 Blank pathology
XPATH_QUERY 2 Truncated pathology report
XPATH_QUERY 3 Unclear specimen origin
XPATH_QUERY 4 Possible link
XPATIENT_CONDITIONS_TYPES 8 Cancer first examination
XPATIENT_CONDITIONS_TYPES 9 Resection first examination
XPOLYP_HISTOLOGY 1 Adenoma Pathologist specifies adenoma/
adenomatous polyp. Benign
dysplastic colonic tumour. Can
progress to become malignant
XPOLYP_HISTOLOGY 2 Metaplastic/hyperplastic Benign non-dysplastic polyps
with lengthening and cystic
dilation of mucosal glands.
Hyperplastic and metaplastic are
synonymous with each other
XPOLYP_HISTOLOGY 3 Serrated adenoma Benign dysplastic colonic
tumour, which has a serrated
appearance under the
microscope
XPOLYP_HISTOLOGY 4 Leiomyoma Benign neoplasm of smooth
muscle
XPOLYP_HISTOLOGY 5 Inflammatory Inflammatory polyp
XPOLYP_HISTOLOGY 6 Normal mucosa Specimen shows no signs of a
polyp and levels of dysplasia/
atypia are within normal limits
XPOLYP_HISTOLOGY 8 Carcinoid/neuroendocrine
tumour
Tumour originating from the
neuroendocrine system
XPOLYP_HISTOLOGY 10 Juvenile polyp Rare form of large bowel polyp
XPOLYP_HISTOLOGY 11 Mucosal prolapse Slippage of mucosa
XPOLYP_HISTOLOGY 14 Ulcer A break in the lining of the
digestive tract that fails to heal
naturally
XPOLYP_HISTOLOGY 15 Inflammation Generalised inflammation of
mucosa
XPOLYP_HISTOLOGY 16 Melanosis coli Pigmentation of the wall of the
colon, not associated with any
disease pathway
XPOLYP_HISTOLOGY 17 Submucosal haematoma Result of bleeding outside of the
blood vessels
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XPOLYP_HISTOLOGY 19 Angiodysplasia Vascular malformation in the gut
which can often cause bleeding
into the colon
XPOLYP_HISTOLOGY 20 Ischaemia Restriction of blood supply
XPOLYP_HISTOLOGY 21 Xanthoma Fatty deposits under the skin or
mucosa causing yellow bumps
XPOLYP_HISTOLOGY 22 Oedema Swelling due to accumulation of
fluids
XPOLYP_HISTOLOGY 23 Regenerative polyp Hyperplastic polyp of the gastric
mucosa
XPOLYP_HISTOLOGY 24 Hamartomatous polyp Benign mucosal polyps usually
found in the jejunum and ileum
(small bowel)
XPOLYP_HISTOLOGY 25 Haemangioma Benign noncancerous tumour
composed of rapidly proliferating
blood vessels
XPOLYP_HISTOLOGY 26 Non-Hodgkin’s lymphoma NHL: A diverse group of blood
cancers that include any kind of
lymphoma except Hodgkin’s
lymphomas
XPOLYP_HISTOLOGY 27 Fibroepithelial polyp Benign cutaneous lesion/skin tag
XPOLYP_HISTOLOGY 28 Crohn’s disease An autoimmune inflammatory
disease that can affect any part
of the gastrointestinal tract. If
you notice Crohn’s disease, this
person should be excluded from
the study using the query section
XPOLYP_HISTOLOGY 29 Neurofibromatosis Genetically inherited disease in
which nerve fibres grow tumours
XPOLYP_HISTOLOGY 30 Colitis Chronic bowel disease
characterised by inflammation of
the colon. Only to be used if
colitis is specified, there is a
separate option for generalised
inflammation. If you notice colitis
then this person should be
excluded from the study using
the query section
XPOLYP_HISTOLOGY 31 Lipoma Benign tumour composed of
fatty tissue
XPOLYP_HISTOLOGY 32 Pseudolipomatus Artifactual microscopic change in
tissues that resembles fatty
infiltration
XPOLYP_HISTOLOGY 33 Spirochaetosis A type of bacterial infection of
the colon
XPOLYP_HISTOLOGY 34 Granulation tissue Tissue that replaces fibrin clots
during the healing of tissue
XPOLYP_HISTOLOGY 35 Gastric heterotopia Normal gastric mucosa seen
elsewhere in the body
XPOLYP_HISTOLOGY 36 Cap polyp Inflammatory polyp with a ‘cap’
of debris or granulation tissue
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XPOLYP_HISTOLOGY 37 Lymphoid polyp Benign polyps occurring when
lymphoid follicles are present in
the colon
XPOLYP_HISTOLOGY 39 Previous polypectomy site Appears to be tissue from the
site where a previous polyp was
removed
XPOLYP_HISTOLOGY 40 Ganglioneuromatosis Tumours arising from the
nervous system
XPOLYP_HISTOLOGY 41 Amyloid Insoluble fibrous protein
aggregates
XPOLYP_HISTOLOGY 43 Congestion Mucosal cells appear congested
XPOLYP_HISTOLOGY 44 Lymphangiectasia Intestinal disease characterised
by lymphatic dilatation
XPOLYP_HISTOLOGY 45 Proctitis Inflammation of the lining of the
anus and rectum
XPOLYP_HISTOLOGY 50 Cancer Malignant neoplasm/moderately
differentiated adenoncarcinoma/
carcinoma. If you notice cancer
and it is the patient’s first dated
endoscopy record then this
person should be excluded from
the study using the query section
XPOLYP_HISTOLOGY 51 CA+ adenoma Moderately differentiated
carcinoma/cancer/malignant cell
types, seen to be arising from an
adenoma
XPOLYP_HISTOLOGY 52 CA in dispute Cancer is suspected/pathologist
is suspicious of malignancy or
there is a difference of option on
the diagnosis
XPOLYP_HISTOLOGY 53 Mixed adenomas/metastases Polyp displaying characteristics of
an adenoma and those of a
metaplastic polyp. This is rare
XPOLYP_HISTOLOGY 55 CA+mixed/serrated adenoma Moderately differentiated
carcinoma/cancer/malignant cell
types, seen to be arising from a
serrated adenoma
XPOLYP_HISTOLOGY 56 Unicryptal adenoma Very early beginning of
adenoma growth
XPOLYP_HISTOLOGY 57 Metastases – another site Malignant material found in the
colon that is not from a primary
bowel cancer and originates
elsewhere in the body
XPOLYP_HISTOLOGY 58 CA+ serrated adenoma Carcinoma/cancer/malignant/
invasive cell types, seen to be
arising from a serrated polyp or
adenoma
XPOLYP_HISTOLOGY 59 CA+mixed adenoma Carcinoma/cancer/malignant/
invasive cell types, seen to be
arising from a mixed polyp or
adenoma
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XPOLYP_HISTOLOGY 60 METS/tumour – infiltrating Malignant material that is
infiltrating into the colon from
a tumour outside the colon
(if unsure use ‘Mets from
another site’)
XPOLYP_HISTOLOGY 61 Squamous cell carcinoma Skin cancer normally found in
the anus, but may be reported
as rectal. Code as squamous cell
carcinoma
XPOLYP_HISTOLOGY 62 Cancer query If a pathologist mention or
suspects but is not able to
confirm a diagnosis of cancer/
malignancy
XPOLYP_HISTOLOGY 63 GIST Gastrointestinal stromal tumour
XPOLYP_HISTOLOGY 64 Sarcoma Cancerous tumour of soft tissue
XPOLYP_HISTOLOGY 65 Unknown primary Confirmed malignancy of an
unclear or unknown primary
XPOLYP_HISTOLOGY 66 Anaplastic/undifferentiated
carcinoma
A rare type of cancer often
diagnosed at advanced stage,
usually found in the small
intestine
XPOLYP_HISTOLOGY 67 Basaloid /cloacogenic cancer Sometimes listed as a subclass of
squamous cell cancers. They
develop in the transitional zone,
also called the cloaca. These
cancers look slightly different
under the microscope, but they
behave and are treated like
other squamous cell carcinomas
of the anal canal
XPOLYP_HISTOLOGY 68 Sessile serrated lesion A serrated polyp not of the
traditional serrated adenoma
type. Usually, but not always,
without dysplasia
XPOLYP_HISTOLOGY 69 CA+ sessile serrated lesion Cancer arising in a polyp of the
sessile serrated lesion type
XPOLYP_HISTOLOGY 70 Granular cell tumour Usually benign, circumscribed,
tumour-like lesion of soft tissue,
particularly of the tongue,
composed of large cells with
prominent granular cytoplasm
XPOLYP_HISTOLOGY 71 Melanoma Anorectal melanoma is
melanoma affecting the anus
and/or rectum. Melanoma is a
cancer that develops from cells
called melanocytes
XPOLYP_HISTOLOGY 72 Anal wart A growth, also known as
condyloma, found at the
anus/rectal opening caused by
HPV. Some HPV strains have
been associated with increased
risk of anal cancer
XPOLYP_HISTOLOGY 90 Not possible to diagnose The polyp sample is too small or
too damaged on removal to
reliably diagnose the specimen
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XPOLYP_HISTOLOGY 91 Specimen not seen No evidence of a specimen in
the pot received at pathology
XPOLYP_NUMBERS 1 Few
XPOLYP_NUMBERS 2 Some
XPOLYP_NUMBERS 3 Num of
XPOLYP_NUMBERS 4 Several
XPOLYP_NUMBERS 5 Many
XPOLYP_NUMBERS 6 Multiple
XPOLYP_SHAPE 10 Pedunc The polyp observed was on a
stalk
XPOLYP_SHAPE 20 Sessile Polyp with no stalk
XPOLYP_SHAPE 30 Flat Polyp that is flat on the surface
of the bowel
XPOLYP_SHAPE 40 Pseudo A mass that has the appearance
of a polyp but is not
XPOLYP_SHAPE 50 Sub ped Avoid using this option
XPOLYP_SIZE 1 Tiny
XPOLYP_SIZE 2 Small
XPOLYP_SIZE 3 < 5mm
XPOLYP_SIZE 4 5–9mm
XPOLYP_SIZE 5 > 10mm
XPOLYP_SIZE 6 Large
XPOLYP_SIZE 7 < 10mm
XPROCEDURE 1 Colonoscopy The endoscopic examination
of the whole of the large colon
and the distal part of the small
bowel with a camera on a tube
passed through the anus
XPROCEDURE 2 FS The endoscopic examination
of the large intestine from the
rectum to the distal sigmoid
using a flexible scope
XPROCEDURE 3 Proctoscopy Short ridged metal tube is
inserted into the rectum, anal
cavity or sigmoid to enable direct
visualisation of the area
XPROCEDURE 4 Rigid sigmoidoscopy The endoscopic examination of
the large intestine from the
rectum to the distal sigmoid
using a rigid scope
XPROCEDURE 5 Sigmoidoscopy Examination of the large colon
up until the sigmoid colon
XPROCEDURE 6 Surgical
XPROCEDURE 7 Endoscopy Endoscopy
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Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XQUERY 1 General To be used for any other query,
particularly if you feel it warrants
discussion with other members
of the team. When using a
general query, you should
describe the nature of the query
in the comments box below the
query field
XQUERY 2 Pathology linking To be used when a pathology
report appears to be linked
incorrectly to an endoscopy
record
XQUERY 3 Application coding error To be used when indicating that
options or drop-down menus
will be changed at a later date
by the database administrator
and you will return at a later
date to finish coding
XQUERY 4 Polyp matching To be used when coder is unable
to match pathological
information to the polyps in the
list due to lack of detail or clarity
XQUERY 5 Exclude To be used when a patient’s
endoscopy or pathology report
indicates the presence of study
exclusion criteria. For details on
the exclusion criteria see the
‘Exclusion SOP’
XQUERY 6 Pathology missing To be used when there has
clearly been a biopsy/excision
that is awaiting histology and
does not appear to have a linked
pathology report
XQUERY 7 Refer back to To be used when coder wants to
come back to a record at a later
time
XQUERY 8 Discuss To be used when a endoscopy
record should be discussed in a
coder’s meeting
XQUERY_POLYP_NUM 1 Other To be used for any other query,
particularly if you feel it warrants
discussion with other members
of the team. When using a
general query, you should
describe the nature of the query
in the comments box below the
query field
XQUERY_POLYP_NUM 2 Resolved When the query has been
resolved
XQUERY_POLYP_NUM 3 Multiple quantity – other rows When patient has unspecified
number of polyps
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
299
Reference data domain Code Description
Definition (populated only if
further explanation of field is
required)
XQUERY_POLYP_NUM 4 Multiple polyps/polyposis/
HNPCC
Multiple polyps/polyposis/HNPCC
XQUERY_POLYP_NUM 5 Lack of information Lack of information
XQUERY_POLYP_NUM 6 Polyp matching query Polyp matching query
APC, argon plasma coagulation; Bx/B’x’, biopsy; CA, cancer; CT, computerised tomography; EMR, endoscopic mucosal
resection; GIST, gastrointestinal stromal tumour; HPV, human papillomavirus; Hx; history; LIF, left iliac fossa; MAP,
MYH-associated polyposis; METS, metastases; NHL, non-Hodgkin’s lymphoma; NSAID, non-steroidal anti-inflammatory
drug; PJS, Peutz–Jeghers syndrome; RIF, right iliac fossa; SSRI, selective serotonin reuptake inhibitor; TEMS, transanal
endoscopic microsurgery; TME, total mesorectal excision.
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Appendix 3 Endoscopy and Pathology Report
Application
APEX Coding Application  
Patient List screen 
 
This screen shows a list of those patient records that still need to be coded. Records were 
anonymised with patients only identified by a unique study number. Patients were 
selected by clicking on their individual study number or by typing the study number into 
the search bar. This screen included a function that allowed the user to filter, sort, and 
highlight records. The ‘flashback’ feature also allowed the user to return to the data as it 
existed at a previous point in time. On the right-hand side of the screen was a ‘Patient 
Lists’ navigation panel, which allowed study researchers to access records that they had 
already analysed or categorised. It also showed the last record analysed.  
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Patient Details screen 
 
This screen showed a list of all endoscopy records, polyps found, and all pathology records 
linked to the patient. From here, the study researcher could access each endoscopy record by 
clicking on the individual endoscopy ID number; the same was true for polyp and pathology 
records. The polyp numbering screen could also be accessed from this page to enable the 
study researcher to complete polyp numbering if necessary. The Patient Details screen 
allowed the study researcher to manually link pathology reports that needed to be linked to 
the endoscopy records listed. Some pathology reports collected did not have a corresponding 
endoscopy report. It may be that some endoscopy reports were not captured during data 
extraction or some pathology reports may have been related to appointments outside the 
endoscopy department. A large proportion of unlinked pathology reports were due to surgical 
procedures. In these cases, ‘phantom endoscopies’ were created by the study researchers 
which allowed them to record pathological findings and any details of the procedure 
mentioned in the pathology report. The creation of a phantom endoscopy record was achieved 
by clicking on the unlinked pathology ID which opened an unlinked pathology screen. 
 
Originally, study researchers could manually exclude patients on this screen if the patient 
met certain exclusion criteria. At a later date it was decided that Manual Exclusion ought to 
be renamed Patient Status and that any exclusion from the study ought to occur at the analysis 
stage. Data cleaning tasks were shown at the bottom of this screen. 
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Endoscopy Overview screen 
 
This screen showed the endoscopy record and a list of polyps found at the exam. The 
endoscopy record contained details of the type of exam, extent of exam, any potential 
limitations, and observations that occurred. The polyp list contained details of the endoscopic 
and pathological appearance of anything regarded as a polyp or cancer at endoscopy. Any 
queries relating to this endoscopy record or the linked pathology report could be recorded 
here using a drop-down menu and any comments could be recorded in the comments field. 
This field was ultimately replaced by a Notable Features field. 
 
From this screen study researchers could navigate to five other screens which enabled further 
details to be added to the Endoscopy Overview screen and the polyp list.  
 
Endoscopy Indications Details screen 
 
This screen showed a list of clinical indications for endoscopy. Additional indications were 
added here if they were mentioned elsewhere in the report. 
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This screen showed the main body of text from the endoscopy report and a list of diagnoses 
for the patient. Additional diagnoses were added here if they were mentioned anywhere in the 
report. 
 
Endoscopy Polyp Coding screen 
 
This screen was accessed from the Endoscopy Overview screen by clicking on the ‘Add/edit 
polyp’ button above the polyp list. It showed the polyp list in a form which could be edited 
using a series of drop-down menus. The endoscopy report was also on this screen for the 
study researchers’ reference. 
Endoscopy Diagnosis Details screen 
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This screen was accessed from the Endoscopy Overview screen by selecting the ‘Edit Polyp 
Pathology’ button below the polyp list. It showed the polyp list in a form which could be 
edited using a series of drop-down menus. The pathology report was also on this screen for 
the study researchers’ reference. 
 
Notable Features screen 
 
 
This screen was accessed by selecting the Edit Notable Features button. It included the 
endoscopy report fields and a drop-down menu for selecting notable features, such as a 
reference to a possible patient condition or if pathology was thought to be missing 
Pathology Polyp Coding screen 
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Polyp Numbering screen 
 
This screen was accessed from the patient details screen. It displayed the polyp row(s) for 
each exam, with exams shown in date order. The study researcher was able to review all 
polyp details in order to match any polyps thought to be of the same origin and apply a 
percentage certainty to each match. Although not depicted in the above screenshot, the view 
also included the endoscopy and pathology reports for the selected polyp. 
 
Pathology Linking screen 
On this screen, the study researchers could examine the pathologies available and, taking into 
account the procedure and pathology dates, select the endoscopy report which should be 
linked to each pathology report, using pull-down menus. The endoscopy and pathology 
reports were available underneath the linking table for the study researchers’ reference. 
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Unlinked Pathology screen 
 
This screen showed the full pathology report and was used to create a phantom endoscopy 
record. Any reasons for exclusion or comments could be recorded here, e.g. if the pathology 
was from an examination that was not relevant to the study, if the pathology record was a 
duplicate of one already coded, or the pathology report was blank. The study researchers 
could either go straight through to the Phantom Polyp Coding screen by clicking on the Edit 
Phantom Polyps button or to the Unlinked Endo Coding screen by clicking on the Edit 
Phantom Endoscopy button 
 
NB: Phantom endoscopies were later renamed pathology-based procedure reports 
Unlinked Pathology Endo Coding screen 
 
This screen allowed the study researchers to record any information from the pathology 
report that would be present on the Endoscopy Overview screen. If the report detailed a 
surgical specimen, it also provided the opportunity to record what kind of surgical procedure 
was carried out. There were two buttons to record indications and diagnoses as seen on the 
Endoscopy Overview screen. Exclusion information, which later became notable features, 
could be entered here using the Edit Notable Features button. The Phantom Polyp Coding 
screen was accessible using the Code Phantom Polyps button. 
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Phantom Polyp Coding screen 
 
This screen was used to add polyp rows and to record information regarding polyps or 
cancers seen in the unlinked pathology report. 
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Exam Numbering screen 
 
This screen was accessed by selecting the Exam Numbering button (which only appeared 
when exam numbering was required) on the Patient Details screen. This was when the patient 
was seen to have either more than one procedure on the same day or no procedure date 
recorded. The study researcher examined the endoscopy reports and attempted to number the 
procedures in date order using any evidence mentioned in the reports. 
 
Data Coding Review screen
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This screen was reached by selecting the Review tab at the top of the main page. A process 
was put in place to review the quality and consistency of the manually coded data. This 
review process was also used to monitor new study researchers who were still in their 
training and probation period. A random sample of linked records was taken and marked for 
review, enabling all the study researchers to view these records. A patient’s study number 
was selected on the Review screen to view their reports. Comments could be made by adding 
a row in the Endoscopy Review screen as shown below. 
 
 
 
All study researchers worked through the selected records looking for errors and commented 
on their findings. Once complete, the comments were compiled and any problems 
encountered could be addressed.  
 
There is a Review SOP for this process. One of the study researchers had access to a form in 
the Endoscopy and Pathology Report Application which allowed her to set up reviews. It 
could be used to review specific study researchers or all researchers, but only for a single 
hospital’s records at one time. There was a feature to extract a random sample of records 
coded for a specified number of days ago. For more specific reviews, a custom statement had 
to be written by the study programmer. 
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Appendix 4 Standard Operating Procedures
This appendix consists of all SOPs and related documents, as listed below.
l Intermediate Adenoma Coding Application SOP.
l Coding Reference Document.
l Exclusion SOP.
l Checking Coder Excluded Records SOP.
l Coders Reference Document – Phantom Reports.
l Phantom Endoscopy SOP.
l Review SOP.
l Polyposis and Colitis Reclassification Review SOP.
l Examination Numbering and Multiple Row Review SOP.
l Summary of Changes to Coding Documents (Aug 2009).
l Summary of Changes to Coding Documents (Sep 2009).
l Summary of Changes to Coding Documents (Oct 2009).
l Missing Pathology Collection SOP.
l Visit Checklist.
l Missing Pathology Coding SOP.
l Polyp Matching Re-queries – Coding Rules.
l Polyp Numbering SOP.
l March 2012 – SOP Updates and Amendments.
l Cancer Reclassification Review SOP.
l ONS Encryption SOP.
 
Intermediate Adenoma Coding Application SOP 
(Ann Thomson, Jill Waddingham 3/12/2012) 
Contents 
1. Database Overview  
2. How to Code Records  
3. The Patient Details Screen  
4. Checklist 1: Endoscopy Overview Screen  
5. Checklist 2: Add/Edit Polyp Screen  
6. Manual Pathology Linking  
7. Checklist 3: Edit Polyp Pathology Screen  
8. How to Query Records  
9. How to Exclude a Patient  
10. Top Tips!  
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1. Database Overview 
There are 5 tabs at the top of the coding application when you come to the first screen; these allow access to 
all the areas of the database. Below is a guide to what is in each section. These sections are: 
1. Coding  
2. Hospital Overview 
3. Bugs & Suggestions 
4. Help 
5. Review 
 
 
 
• Patient List screen: 
This screen shows a list of patients that still need to be coded. Patients have been anonymised and are 
identified only by a unique study number. Each patient can be selected by clicking on the individual 
study number or by typing the study number you want to recall into the search bar. On this screen there 
is a function that allows the user to filter, sort and highlight records. The flashback feature also allows 
the user to return to the data as it existed at a previous point in time. On the right hand side of the screen 
is a helpful ‘Patient Lists’ navigation panel, which allows coders to access records that they have already 
analysed or categorised. It also shows the last record analysed.  
• Patient Details screen: 
This screen shows a list of all endoscopy records, polyps found and all pathology records that are linked 
to the patient. From here you can enter each individual endoscopy record by clicking on the individual 
endoscopy ID number; the same is true for each polyp and pathology record. The polyp numbering 
screen can also be accessed from this page to enable the coder to complete polyp numbering if 
necessary. This is the screen that you can use to exclude patients that meet the exclusion criteria. Data 
cleaning tasks will be shown at the bottom of this screen. 
 
• Endoscopy Overview screen: 
This screen shows the endoscopy record and a list of polyps found at that endoscopy. The endoscopy 
record contains details of the type of exam, extent of the exam and any potential limitations and 
observations that occurred at endoscopy. The polyp list contains details on the endoscopic and 
pathological appearance of the polyp. From this screen you can navigate to four other screens which 
enable further details to be added to the Endoscopy Overview screen and polyp list. 
• Endoscopy Indications Details screen: 
This screen shows a list of clinical indications that precluded endoscopy. Additional indications 
can be added from here if they are present elsewhere on the report. 
• Endoscopy Diagnosis Details screen: 
This screen shows a list of diagnoses for the patient. Additional diagnoses can be added from 
here if they are present elsewhere on the report. 
• Endoscopy Polyp Coding screen: 
This screen is accessed from the Endoscopy Overview screen by clicking on the ‘Add/edit polyp’ 
button above the Polyp List and it shows the polyp list in a form which can be edited using a 
series of drop down menus. The endoscopy report is summarised above for the coder’s reference. 
• Pathology Polyp Coding screen: 
This screen is accessed from the Endoscopy Overview screen by clicking on the ‘Edit Polyp 
Pathology’ button below the polyp list and it shows the polyp list in a form which can be edited 
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using a series of drop down menus. The pathology report is summarised above for the coder’s 
reference. 
• Polyp Numbering Screen: 
This screen is accessed from the patient details screen. It displays the polyp row(s) for each exam, with 
exams shown in date order. The coder is able to review all polyp details in order to match any polyps 
thought to be the same and apply a percentage certainty to each match. 
 
 
 
This screen shows a drop down menu which enables the selection of the centre of interest and on the 
right hand side the navigation panel is also present which enables the coder to look at the records they 
have already analysed or select those that have been flagged for query. This screen also shows a pie 
chart detailing the coding progress. 
 
 
This screen enables the user to note down any problems or suggestions found so that they can be viewed 
and monitored by database administrators. 
 
 
This screen enables the user to view any reference documents which have been written to help the 
coding process. 
 
 
This section is for coders to review sections of the coding to check for systematic errors and make 
comments for correction. 
 
 
The default list dropdown lets you choose which patient list (e.g All Patients, Query Patients) you would 
prefer the application to switch back to when you press Analyse, Cancel or Apply Changes in the main 
Patient page.  
Each time you login the default value is set back to the coding list (the first page you come to when you 
login). 
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 2. How to code records 
3. The Patient Details Screen 
4
6
17
19
21
3
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3. The Patient Details Screen 
This screen summarises patient information and is where the coding process begins. It lists all the endoscopy 
records, pathology records and polyps that relate to an individual patient.  
 
 
The Patient Status box in this screen allows the coder to exclude a patient 
based on the details provided in the endoscopy and pathology reports listed. 
Come back to this box when you have finished coding. 
This screen also displays: 
• A list of total polyps found in that patient at all the endoscopy 
exams (Polyp List) 
• A list of pathology records which are related to the findings at the 
endoscopy exams listed (Pathology List) 
• A list of other pathology records related to the patient but unrelated 
to the endoscopy exams listed (Pathology Unlinked).  
• Link to the polyp numbering screen, if appropriate. 
• Data cleaning task(s), if appropriate 
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 4. Checklist 1: Endoscopy Overview Screen 
 
 Check that any information from the ‘Diagnosis Report’ and ‘Endoscopist Comments/Additional 
Details’ boxs (if present) (see purple arrows) have been correctly entered into the following fields: 
Procedure Type – Type of endoscopic procedure used to investigate the colon 
Segment Reached – the segment of the large bowel which was reached by the endoscope 
Distance Reached – the distance reached by the endoscope in cm.  
Bowel Prep – quality of bowel cleansing prior to the exam 
 
 Check that any indications in the ‘Indications Summary’ box (green arrow) have been coded in the far 
right hand box labelled ‘Indications’ (see red arrow) 
If indications need to be added/amended:  
 
 
 
 
 Check that any Diagnoses in the ‘Diagnosis Summary’ box (black arrow) have been coded by looking at 
the right hand column under ‘Diagnosis’ (see blue arrow) 
If diagnoses need to be added/amended:  
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Scenarios you may encounter whilst in this screen 
Scenario Possible Solutions 
Contradictory 
information between 
fields 
 
When the diagnosis report shows evidence that contradicts an entered field, coders 
must always go with the report. 
E.g. Bowel prep marked as ‘Excellent’ in the field but report notes poor bowel 
prep; change field to ‘Poor’. 
 
Contradictory 
Information in the 
Diagnosis Report 
 
In some cases the Diagnosis Report contains two contradictory statements about 
the Bowel Preparation. This may be due to automatically generated sentences at 
the top of the report. Coders should use the latter sentence or any free text 
description in the additional details field to code bowel prep. If in doubt flag 
records up for group discussion. 
 
Growth/polyp/tumour 
does not appear on 
polyp list 
 
Any polyps mentioned in the endoscopy report that do not appear in the polyp list 
below will need to be added manually by coders. The endoscopy may also 
mention tumours, polypoidal growths or lesions – these must also be added as 
polyps. However, this does not include: strictures, Angiodysplasia or ulcers. These 
can be added to the diagnosis field instead. 
To add a polyp manually: 
 
 
 
 
Don’t forget to go through the coding process as usual once it has been added. 
 
Possible polyps not 
listed in polyp list 
 
If an endoscopist sees a polyp but cannot find it again (i.e. it was not visible on 
retraction) – Add a polyp row using the method above 
 
If an endoscopist sees a possible polyp or is in any way unsure about the polyps 
presence and there is no linked pathology – DO NOT add a polyp row 
 
Pathology report 
attached to an 
endoscopy with no 
polyp 
 
In this case, check the pathology for polyps. If polyps are identified in the 
pathology coders must add each polyp manually following the instructions in the 
scenario above. Remember to carefully check that the pathology is correctly 
linked to the endoscopy in question by looking at the date of pathology and 
endoscopy and any previous exams on the patient’s records. 
 
 
Blank Diagnosis 
Report 
 
In some cases the Diagnosis Report will be missing, in which case, fill in any 
information available and move onto the next stage. 
 
 
 
Indication/Diagnosis 
not present on drop 
down menu 
Double check the indication does not suggest something that warrants exclusion. 
If you cannot find a description on the list that adequately describes the indication, 
it should be left blank. 
  
Family History as an 
Indication 
Coders should only us the Indication options ‘Family History of Colorectal 
Cancer’ and ‘Family History of Cancer’ when specified. When the Endoscopist 
only states ‘Family History’ no indication should be coded. 
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5. Checklist 2: Add/Edit Polyp Screen 
  
 Check that any polyp information from the ‘Diagnosis Report’ (purple arrow) has been entered correctly 
into the following fields: 
Size-mm – This refers to the size of the polyp in mm 
Size Other – This can be used when as specific size of a polyp is not stated  
Max Size – This refers to the maximum size of a polyp if there are a number of polyps and only the        
largest polyp’s size is stated or there is a size range 
Min Size – This refers to the minimum size of a polyp if there is a size range stated rather than a 
specific size 
Shape – This refers to the shape of the polyp in the bowel 
Segment – This refers to the segment of the large bowel the polyp was found in  
Segment to – This is used if there is a range of segments. The most proximal segment in which a 
polyp is added here and the most distal in the ‘Segment’ field 
Dist-cm – This refers to the distance at which the scope was inserted when the polyp was found  
Exc Method – This refers to the method used to biopsy or excise the polyp  
Exc Extent – This refers to whether or not the polyp was excised or not. If biopsied, this should be 
left blank as the excision cannot be assumed. 
Biopsy Fate – This refers to what happened to the polyp after biopsy/excision 
Piece – This refers to whether a lesion has been removed piecemeal or not.  
Quantity – Used when polyps are present and a specific number is not stated  
No Info – This refers to whether or not a polyp mentioned has any information given about it 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
318
Scenarios you may encounter whilst in this screen 
Scenario Possible Solutions 
Size of polyp not 
specified 
In the event that there is no indication of polyp size stated in the report, the box must 
be left blank (remove any zeros) 
 
If there is a range of sizes or a maximum size, these should be added as an alternative 
if a specific size is not available. 
 
 
Excision/ biopsy 
method not 
specified 
 
• It is worth checking the ‘Biopsy Text’ field which may contain further 
information on method. 
• If not, the coder must select ‘Unknown Method’ in the excision method menu. 
Try not to leave this blank, unless there was no excision. 
 
 
 
Blank Diagnosis 
Report 
In some cases the Diagnosis Report will be missing, in which case, fill in any 
information available and move onto the next stage. 
 
 
Pathology appears 
to be missing 
• The text in the report suggests the polyp has been excised or biopsied but a 
pathology report has not been linked to the endoscopist.  
• Only flag records with polyps as ‘Pathology Missing’ 
 
There are two ways to deal with this problem: 
1) Refer to the patient overview screen and look at the list of unlinked pathology 
reports. Check the contents and the dates to check any of these reports should 
be attached to the endoscopy record. If they do, you can manually link the 
records together – see manual pathology linking below 
2) If the unlinked pathologies do not appear to match the endoscopy, this record 
can be queried as ‘Pathology missing’. For information on how to query see 
the query page of this document page 15. 
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6. Manual Pathology Linking 
Coders can manually link pathology records to endoscopy records in the list if they feel they are certain they 
should be linked. This can be done in the Patient screen. To link pathology, select the ‘Link Pathology’ 
button (Purple arrow) 
This will take you through to the ‘Pathology Linking’ screen. Here you can select from the list on 
endoscopies (Red arrow) that you think should be linked to each of the pathology records listed in the table 
at the top of the screen. When you do this, consider the date of the report on both the endoscopy and 
pathology reports carefully. 
When you have finished linking, go back into the endoscopy record and match the histology as normal. 
If any information indicates that the unlinked pathology belongs to another, missing endoscopy report, then 
coders must NOT link the data, even if the data relates to the same polyp. Instead, coders should create a 
phantom endoscopy (see Phantom SOP and Coders reference document – phantoms). 
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7. Checklist 3: Edit Polyp Pathology Screen  
 
 Use a combination of the information from the sections in the pathology report (red arrow) to match up 
each polyp with the pathological description and fill in as many details as possible about the polyp into 
the following fields: 
 
Dysplasia – This refers to the level of dysplasia/atypia exhibited by the polyp  
Adenoma Type – This refers to the extent of the tubular or villous features exhibited by any 
adenomas 
Histology – This refers to the type of lesion as seen under the microscope 
Size-mm – This refers to the size of the specimen that the pathologist has received for analysis. 
Coders should always record the maximum diameter stated in mm. In cases where it is difficult to 
match the size to the polyp then follow the guidelines for ‘polyp matching’ outlined below and in 
cases where it is simply not possible to assign the correct size to the corresponding polyp then leave 
it blank. 
Exc Comp – Refers to the completion of excision as concluded by the pathologist 
Piece - This refers to whether a lesion has been removed piecemeal or not. 
Multi Link – This is used to link polyps created at pathology with relate to ‘multiple’ polyps added 
at endoscopy 
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Scenarios you may encounter whilst in this screen 
Scenario Possible Solutions 
Cannot match 
polyp with 
pathology 
details 
 
• If the polyps are of a similar size and from the same segment, the coder should choose 
to allocate the worst pathology to the largest polyp (only if both of the polyps are 
under 10mm in size) 
• Similarly, if 2 polyps have been identified at endoscopy but only one pathology is 
provided and it is unclear which polyp this relates to, then, provided that the polyps 
are of similar size and were found in the same section of the bowel, the coder can 
assume that the pathology relates to the larger polyp. This rule only applies when 
both/all polyps involved are less than 10mm (see below). 
• If there are two polyps of similar size in different locations that you cannot match. 
Use the segment range fields in the add/edit polyp screen to adapt each polyp so it 
covers the sections of both polyps and then apply the histology details. The same can 
be done with size if absolutely necessary as long as both polyps are above 10mm or 
below 10mm. This can be done using the min and max size fields in the add/edit 
polyp screen.  
 
 
 
If you still have a problem matching the polyps, record this endoscopy record as a query 
in the endoscopy overview screen. The query for this case would be: ‘Polyp Matching’. 
For information on how to query see the query page of this document (pg 10). 
 
Individual 
pathologies 
provided for 
Multiple 
Polyps 
• Pathology reports sometimes give individual diagnoses for ‘multiple polyps’. In this 
case, manually add a row for each polyp pathology mentioned, leaving the row for 
‘multiple polyps’ blank. 
e.g. 2 adenomas and 2 metaplastic OR 6 metaplastic OR one adenoma (add an extra 
polyp row for each of these) 
 
• To indicate that these polyps relate to the row labelled ‘multiple’ by selecting the 
polyp ID of the ‘Multiple’ row in Multi Link field. 
 
• If a single collective diagnosis is given at pathology for ‘multiple polyps’, then code 
accordingly in the ‘multiple polyp’ row. 
e.g. the polyps in the sigmoid are all Metaplastic. 
 
• When there are ‘multiple’ adenomas and an individual dysplasia grade is not allocated 
the following rules apply: 
o A number of adenomas ranging from mild to moderate  code as ‘low grade’ 
o A number of adenomas ranging from moderate to severe  code as a general 
query and mark it as “dysplasia range problem” in the comments field. 
 
Description 
could be one of 
two mutually 
exclusive 
options on 
drop down 
 
When a pathology report describes the histology of a polyp always choose the worst 
diagnosis.  
e.g. ‘Tubular adenoma with moderate to severe dysplasia’ – this would be 
recorded as a tubular adenoma with severe dysplasia.  
 
e.g. ‘either a mildly dysplastic adenoma or a metastatic polyp’ – this would be 
recorded as an adenoma. 
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No definite 
diagnosis 
• If the pathologist has reported a probable histology, the coder should assume that this 
is a diagnosis. For example a ‘Probable Adenoma’ or a ‘Probable Metaplastic’ would 
be coded as Adenoma and Metaplastic. 
 
• If the sample is too small or damaged to be diagnosed then this should be marked 
under the histology field as ‘Not possible to diagnose’. 
 
Excision 
cannot be 
assessed 
This should be marked under the complete excision field as ‘Uncertain’ 
 
 
Endoscopy and 
Pathology give 
conflicting 
information 
There will be occasions where the endoscopy report states something that is then 
contradicted by the pathology report. In this case we always give preference to endoscopy 
information.  
            e.g. Endoscopy refers to a polyp as ‘sessile’ but the pathology report refers to it  
as ‘pedunculated’. In this case we would code the polyp as sessile. 
                
 
8. How to Query a Record 
 
In the event of a query, do not code the record but instead go to the ‘Endoscopy Overview’ page and use the 
‘Query’ drop-down menu (red arrow) to categorise the query. This will then open a ‘Query Options’ check 
list in the bottom right corner of the screen from which you may select the reason for the query (Black 
arrow). If there is no corresponding tick box category or you wish to further clarify or comment on the 
reason for the query then use the comments box to describe it. Once you have queried a record, you can 
click to ‘Apply Changes’ (Blue arrow), return to the previous screen using the breadcrumbs and remember 
to not code the record as this makes it easier to pick out when returning to in the future. 
These are the query categories with their associated tick box options explained. You will be given the 
following options to choose from: 
Application Coding 
Error –  
 
To be used when indicating that options or drop-down menus will be changed at a 
later date by the database administrator and you will return at a later date to finish 
coding.  
• Blank pathology – when a pathology is attached but has no text 
• Truncated path report – when the text is clearly cut off before the end of the 
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pathology report 
• Irrelevant endoscopy – when endoscopy report is from an unrelated region i.e.  
gynaecological exam, upper GI exam 
• Duplicate endoscopy – when there are two of the same endoscopy report 
• Truncated endoscopy – when the text is clearly cut off before the end of the 
endoscopy report 
• Blank endoscopy - when endoscopy has no text 
Discuss –  
 
To be used when coders wish to discuss the record with other members of the team. 
• IBD - use when you are uncertain whether exclusion for colitis/crohn’s  is 
required due to terminology or ambiguous wording 
• How best to code - use when you have been unable to record data 
effectively or feel the need to discuss with the other coders how best to 
proceed. 
• HNPCC - use when HNPCC is suspected 
 
Exclude – 
 
To be used when a patient’s endoscopy or pathology report may indicate something 
worthy of exclusion but requires further clarification. If you wish to exclude 
something based on the procedures set out for exclusion, use the Patient Status box 
when you return to the main patient details screen. 
• Cancer first exam - use when you have query excluded because a cancer 
was seen on first endoscopy/confirmed by pathology 
• Resection first exam - use when you have query excluded because in the 
first procedure, terminology indicates that the patient has had surgery 
shortening the bowel  
• HNPCC - use when you have query excluded because HNPCC family 
cancer syndrome has been indicated in any report 
• Polyposis - use when the colon has a very large number of polyps (20+) 
lining a large proportion of the colons surface. It may be acceptable to 
exclude for less than 20 polyps if there is a number of exams with multiple 
polyps and information indicating family history of polyps 
• Colitis - use when you have query excluded because colitis or any of the 
inflammatory bowel diseases  have been indicated at endoscopy or 
pathology in any report 
General –  
 
To be used for any queries other than those already listed. These may include : 
• Sup Report Missing – when an report indicates that there should be a 
further exam and there is no such record shown* 
• Possible Cancer – when the endoscopist is uncertain if he sees a cancer or 
not, and there is no pathology or other reports to confirm or deny cancer 
• When Cancer – when it is not possible to identify when a cancer occurred 
(usually when it has been referred to in the indications)**  
• When Resection - when it is not possible to identify when a resection 
occurred (usually when it has been referred to in the indications)**  
• Polyp Numbers – when it is not clear how many polyp rows should be 
added  
• Unsure Terminology – when terminology is used that cannot be defined 
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using the Glossary of Terms or Google. 
 
*  be sure to check that the date of the intended, missing report does fall outside of 
the dates for which we have collected data for each hospital (see the Dataset Date 
Range document) 
** if a previous cancer/resection is referred to in the indications for the 1st exam, 
then this should be excluded for ‘Cancer at 1st Exam’/’Resection at 1st Exam’ 
 
Pathology linking - 
 
Pathology linking queries are to be used when the coder is unsure if a pathology 
report should be linked to an endoscopy. 
 
Pathology Missing –  
 
To be used when there has clearly been a biopsy/excision of a polyp that is 
awaiting histology and does not appear to have a linked pathology report. If you are 
unsure you can use the following criteria: 
1. The endoscopy report specifically refers to sending the polyp sample to 
pathology/histology/labs 
2. Polyps that have been biopsied or if there is biopsy text relating to the 
section of the bowel that polyps were found. 
3. Polyps ≥10mm or Tumours/Cancers, even they haven’t been biopsied 
(unless the exam specifically states that they have not been removed or 
biopsied for some reason) 
Only exams with polyps should be marked as pathology missing.  
• Sent to lab/await pathology stated - Use when it says “Sent to labs” or 
“Await pathology/histology” in any of the text fields 
• Large polyp of >=10mm - use when polyp size of >= 10mm or described 
as large.  
• Biopsy Indicator - use when there is some indication of pathology 
requested in the biopsy text box 
• Cancer/tumour indicated - use when a cancer is seen or suspected. 
Clarification of the presence of cancer is important for the study 
 
Polyp Matching –  To be used when coder is unable to match pathological information to the polyps in 
the list due to lack of detail or clarity. 
 
Refer Back To -  To be used for personal reference when you need to come back to a record.  
 
Once all queries have been followed up through additional data collection, if you do not feel you can resolve 
them then tick the re-query box (Green arrow). This will send the record to a new list where they can be 
reviewed at a later date. 
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9. How to Exclude a Patient 
The exclusion SOP sets out the criteria for exclusion of patients, this should be carefully observed. Excluded 
patients do not need to be coded but any records for these patients that have already been coded can be left 
and do not need to be deleted. If you find a patient to be worthy of exclusion you should do this immediately  
in the patient details screen. Using the Patient Status box on the right hand side of the screen you can select 
exclude (Red arrow) and then use the drop down menu to select an Exclusion Reason (Blue arrow). If you 
select ‘Other’ do not forget to put your reasons in the comments box at the top of the screen and Apply 
Changes.  
 
10. Top Tips! 
 Try coding the pathology of a polyp faster by using the keyboard instead of your mouse. Simply use 
the letters of the category you wish to select to avoid going through the whole list, then press tab to 
go onto the next column. For example to code a moderately dysplastic tubular adenoma with a 
specimen size of 2mm, start in the dysplasia box and type; M M TAB T TAB A TAB 2. 
 
 The keyboard can also be used to navigate through all of the polyp coding screens using the Alt key 
plus the letter that is in brackets on each of the submit buttons. E.g. to add/edit a polyp you can click 
on the add/edit polyp button or use the keyboard and press ‘Alt+a’ 
 
 
 
 Navigation back to previous screens should be done using breadcrumbs, links or tabs. Avoid using 
the internet browser navigation buttons. 
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 In some cases the endoscopist will mention polyps in their summary that have already been referred 
to in the report. Coders must be aware of this, taking care not to add the same polyp twice, and if 
unsure, flag up reports for group discussion. 
 
 Anal Cancer and Colorectal Cancer are distinct. Anal cancer occurs via a completely separate and 
unrelated pathways so do not treat anal cancers and colorectal cancer. If in doubt, query the record 
for discussion.  
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Coding Reference Document 
(3/12/2012) 
Contents 
 
1. Patient Details screen menus 
 
2.  Endoscopy overview screen menus 
3.  Endoscopy indications screen menus 
4. Endoscopy diagnosis screen menus 
 
5. Add/Edit polyp screen menus 
 
6. Edit polyp pathology screen menus 
7.  Unlinked Pathology  
 
8. Unlinked Pathology Endo Coding  
 
9.  Phantom Polyp Coding  
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1. Patient Details Screen (patient status box): 
 
For further details on exclusions – see Exclusion SOP 
Field Name Option Definition 
Excluded  
 
Tick box option. Select if you wish to exclude a patient, then 
choose a reason from the list below. 
Exclusion 
Reason 
Cancer 1st Exam It is indicated there has been a cancer prior to the earliest dated 
exam or the pathologist diagnoses a Cancer (Adenocarcinoma) 
during the first exam on record. 
Cancers arising from adenomas or disputed cancers should 
NOT be excluded. 
Colitis The endoscopist or pathologist notes a history/previous 
diagnosis of colitis or the pathologist confirms colitis at any of 
the exams.  
Crohn’s Disease The endoscopist or pathologist notes a history/previous 
diagnosis of crohn’s or the pathologist confirms crohn’s at any 
of the exams. 
FAP The endoscopist reports or the pathologist identifies Familial 
Adenomatous Polyposis.  
Family Hx FAP The exam indicates that close family members of the patient 
have had FAP or there is a genetic indication (see SOP for 
details). 
HNPCC The exam reports/identifies the patient as having Hereditary 
non-polyposis colorectal cancer, or, a family history or genetic 
predisposition for HNPCC. 
IBD The endoscopist notes a history/previous diagnosis of IBD or the 
pathologist confirms IBD at any of the exams. 
Other – See Comments There is a reason to exclude the patient that does not fit with any 
of the reasons on the list. The reason should be detailed in the 
comments box on the patients details screen and should be 
justified using the Exclusion SOP. 
P-J Polyposis The exam indicates presence of Peutz-Jeghers polyposis. 
Polyposis The exam indicates presence of another type of polyposis.  
Resection 1st Exam The exam indicates there has been a resection prior to the first 
dated exam on the list. 
Ulcerative Colitis The endoscopist notes a history/previous diagnosis of Ulcerative 
Colitis, or, the pathologist confirms Ulcerative Colitis at any of 
the exams. 
 
2. Endoscopy Overview Screen: 
 
Field Name Option Definition 
Procedure 
Type 
Colonoscopy The endoscopic examination of the whole of the large colon and the 
distal part of the small bowel with a  camera on a tube passed through 
the anus. 
Flexible 
Sigmoidoscopy 
The endoscopic examination of the large intestine from the rectum to 
the distal descending, using a flexible scope. 
Proctoscopy Short ridged metal tube is inserted into the rectum, anal cavity or 
sigmoid to enable direct visualisation of the area. 
Rigid The endoscopic examination of the large intestine from the rectum to 
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Sigmoidoscopy the distal sigmoid, using a rigid scope.
Sigmoidoscopy Examination of the large colon up to the distal descending. 
Segment 
Reached 
 
 
 
 
 
 
 
Note: Complete or 
Total Colonoscopy 
can be assumed to 
have reached the 
Cecum. A complete 
or total ileo-
colonoscopy can be 
assumed to have 
reached the 
Terminal ileum.  
Bowel Prep Excellent          
       These should just be inserted as stated in the report Good 
Poor 
Satisfactory 
Distance 
Reached 
 This is a number field. Type in the distance reached by the endoscope 
from the anus if it is specified by the endoscopist. 
Query Application Coding 
Error 
 
 
 
To be used when indicating that options or drop-down menus will be 
changed at a later date by the database administrator and you will 
return at a later date to finish coding.  
 
Coders can further categorise this query by selecting one or more of 
the following: 
 
• Blank pathology – when a pathology is attached but has no text 
• Truncated path report – when the text is clearly cut off before the 
end of the pathology report 
• Irrelevant endoscopy – when endoscopy report is from an 
unrelated region i.e. gynaecological exam, upper GI exam 
• Duplicate endoscopy – when there are two of the same endoscopy 
report 
• Truncated endoscopy – when the text is clearly cut off before the 
end of the endoscopy report 
• Blank endoscopy - when endoscopy has no text 
 
Discuss To be used when coders wish to discuss the record with other members 
of the team. 
 
Coders can further categorise this query by selecting one or more of 
the following: 
 
• Colitis – when the query is regarding Colitis
• How to code – when unclear about how to code any part of the 
record 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
330
• HNPCC – when the query is regarding HNPCC 
Exclude To be used when a patient’s endoscopy or pathology report indicates, 
but does not confirm the presence of study exclusion criteria. For 
details on the exclusion criteria see the ‘Exclusion SOP’. 
 
Coders can further categorise this query by selecting one or more of 
the following: 
 
• Cancer 1st exam  
• Resection 1st exam 
• HNPCC                         When it is unclear if you should exclude 
for... 
• Polyposis  
• Colitis   
General To be used for any other query, particularly if you feel it warrants 
discussion with other members of the team. When using a general 
query, you should describe the nature of the query in the comments box 
below the query field.  
 
Coders can further categorise this query by selecting one or more of 
the following: 
 
• Sup Report Missing – when an report indicates that there should 
be a further exam and there is no such record shown* 
• Possible Cancer – when the endoscopist is uncertain if he sees a 
cancer or not, and there is no pathology or other reports to 
confirm or deny cancer 
• When Cancer – when it is not possible to identify when a cancer 
occurred (usually when it has been referred to in the indications)**  
• When Resection - when it is not possible to identify when a 
resection occurred (usually when it has been referred to in the 
indications)**  
• Polyp Numbers – when it is not clear how many polyp rows should 
be added  
• Unsure Terminology – when terminology is used that cannot be 
defined using the Glossary of Terms or Google. 
 
*  be sure to check that the date of the intended, missing report does 
fall outside of the dates for which we have collected data for each 
hospital (see the Dataset Date Range document) 
** if a previous cancer/resection is referred to in the indications for the 
1st exam, then this should be excluded for ‘Cancer at 1st 
Exam’/’Resection at 1st Exam’ 
Pathology Linking To be used when a pathology report appears to be linked/unlinked 
incorrectly to an endoscopy record, but it is not certain.  
 
If the pathology is clearly linked/unlinked incorrectly, it can be 
manually linked/unlinked using the Link Pathology button on the 
patient details screen. Once the linking has been corrected there is no 
need to query the record. 
Pathology Missing To be used when there has clearly been a biopsy/excision that is 
awaiting histology and does not appear to have a linked pathology 
report. If you are unsure you can use any of the following criteria: 
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4. The endoscopy report specifically refers to sending a sample of 
a polyp to pathology/histology/labs 
5. The endoscopy report specifically refers to awaiting histology 
for a polyp 
6. Large polyps (10mm+) with no pathology that have been 
biopsied 
7. Cancer is indicated 
8. The biopsy text relates to a  polyp segment or refers to a 
polypectomy 
 
Coders can further categorise their queries by selecting one or more of  
the following: 
 
• Sent Labs/Hist Req – when the report specifically refers to sending 
a sample of a polyp to pathology/histology/labs 
• Biopsy Indicator – when the Biopsy Text field refers to a biopsy 
from the same segment as a polyp or a polypectomy 
• 10mm+ - when one or more polyps are 10mm or above 
• Cancer Indicated – when a polyp is referred to as highly 
suspicious/tumour/cancer 
 
In all these cases the pathology is NOT missing if the endoscopist 
states that the polyps in question have not been biopsied.  
 
Note: Polyps that have not been excised may have been biopsied. If 
unsure – query the record as Pathology Missing. 
Polyp Matching To be used when coder is unable to match pathological information to 
the polyps in the list due to lack of detail or clarity.  
 Refer Back To To be used for personal reference when you need to come back to a 
record. 
Comments  This is a free text field. This should be used to enter any comments that 
relate to the record or the query. 
 
 
3. Endoscopy Indications Screen: 
 
Field Name Option Definition 
Indication Abdominal Mass Swelling or mass in the abdomen. 
Abdominal Pain Generalised pain in the abdominal region. LIF and RIF 
pain can also be classified as abdominal pain. 
Abnormal Barium Enema Abnormal findings on a Barium Enema prior to exam in 
question (sometimes referred to as an ‘equivocal 
BA/Barium Enema’). 
Abnormal CT Abnormal findings on a CT scan prior to exam in question. 
Abnormal Sigmoidoscopy Abnormal findings on a Sigmoidoscopy prior to exam in 
question. 
Anaemia  Deficiency of haemoglobin in the blood. 
Bowel Cancer Screening 
Programme 
The patient is having an endoscopy examination as part of 
the national Bowel Cancer Screening Programme (BCSP). 
Cancer The patient has had a colorectal cancer prior to the exam 
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 in question. 
Carcinoma 
 
The patient has had a carcinoma prior to the exam in 
question.  
Change in Bowel Habits 
 
The patient is experiencing a change in the frequency of 
bowel movements compared to normal. 
Colitis The endoscopist has specified the presence of colitis prior 
to the procedure. Colitis is a chronic digestive disease 
characterized by inflammation of the colon. Inflammation 
alone does not warrant a classification of colitis. 
(It is a member of the IBD family but is defined separately 
here for clarity) 
Colonic Obstruction Presence of a blockage in the large bowel prior to the 
exam. 
Constipation Hard faeces that are difficult to expel, often accompanied 
by a reduction in the frequency of bowel movements. 
Crohn’s  Chronic inflammatory disease which can affect any part of 
the gastrointestinal tract. 
 (It is a member of the IBD family but is defined 
separately here for clarity) 
Diarrhoea Frequent loose or liquid bowel movements. 
Diverticular Disease Presence of uncomplicated diverticula in the colon 
(Diverticulosis) or inflamed diverticular (Diverticulitis). 
Family History of Cancer* Patient has relatives who have or have had cancer 
(unknown type). 
Family History of 
Colorectal Cancer* 
Patient has relatives who have had colorectal cancer. 
Fissure Natural crack or tear in skin tissue, which can cause 
bleeding. Present in the past or prior to the exam. 
Haemorrhoids Swelling and inflammation of the veins in the rectum and 
anus. This is the same as piles. 
Hereditary Non-Polyposis 
Colorectal Cancer 
An inherited condition where there is a very high chance 
of getting colorectal cancer. 
IBD Inflammatory Bowel Disease. This encompasses a number 
of conditions such as colitis and Crohn’s disease. Use only 
if the endoscopist says ‘IBD’. If they specify colitis or 
Crohn’s then use these options.  
Incontinence Involuntary leakage of faeces. 
Melena/Melana Stools stained black by a dark blood pigment. 
Mucus Discharge Mucous that passes out of the rectum from a source in the 
bowel. 
Polyposis A condition where a person suffers with a large number of 
polyps coating a large surface area throughout the colon. 
Polyps The patient has had known previous polyps.  
Positive Faecal Occult 
Blood Test 
Also FOBT or FOB. Positive result in screening test for 
‘unseen’ blood. 
Query Cancer It has been indicated that the reason for the exam is that 
the patient is suspected to have colorectal cancer. 
Query Colitis 
 
It has been indicated that the reason for the exam is that 
the patient is suspected to have colitis. This may be 
indicated as ?IBD, in which case both query colitis and 
query Crohn’s should be added to the indications.  
Query Crohns It has been indicated that the reason for the exam is that 
the patient is suspected to have Crohns. This may be 
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indicated as ?IBD, in which case both query colitis and 
query Crohns should be added to the indications. 
Query polyps It has been indicated that the reason for the exam is that 
the patient is suspected to have polyps. This is usually 
depicted by ‘polyps seen on barium enema/CT’.  
Rectal Bleeding Bleeding appearing to come from the rectum. 
Rectal Pain Pain in the rectum. 
Rectal Mass Palpable mass in the area of the rectum. 
Tenesmus Feeling or urge to defecate but without needing to pass 
stool. 
Ulcers Known presence of ulcers prior to the exam or presence of 
ulcers in the past. 
Volvulus Life threatening bowel obstruction where the bowel twists 
on itself. 
Weight Loss Uncharacteristic loss of body mass. 
 
 
*Coders should only us the Indication options ‘Family History of Colorectal Cancer’ and ‘Family 
History of Cancer’ when specified. When the Endoscopist only states ‘Family History’ no indication 
should be coded. 
 
 
4. Endoscopy Diagnosis Screen: 
 
Field Name Option Definition 
Diagnosis Anastomosis Endoscopist has observed an Anastomosis which is the 
surgical reconnection of two parts of the colon post 
resection.  
Angiodysplasia/Telangectasia Endoscopist has observed areas of vascular 
malformation in the gut. Can be a common cause of 
unexplained bleeding in the colon. Sometimes referred 
to as AVMs/AVCMs.  
Benign Tumour Endoscopist has observed an abnormal 
growth/neoplasm that they feel lacks the malignant 
qualities of cancer. 
Cancer Malignant neoplasm. 
Colitis The endoscopist has specified the presence of colitis 
from the observations made during the exam.  
Colonic Obstruction Endoscopist comes across an obstruction of unspecified 
nature in the colon upon examination – this does not 
include cancers or large polyps. 
Crohn’s The endoscopist strongly suspects the patient has 
crohn’s disease or is known to already have crohn’s 
disese. 
Diverticular disease Endoscopist has observed uncomplicated diverticula in 
the colon (Diverticulosis) or inflamed diverticular 
(Diverticulitis). 
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FAP The endoscopist or the pathologist suspect the presence 
of Familial Adenomatous Polyposis due to the number 
of polyps in the colon. 
Fissure Endoscopist visualised a fissue during the course of the 
exam, this is a natural crack or tear in skin tissue. Can 
cause bleeding.  
Haemorrhoids Endoscopist has observed Haemorrhoids/piles. 
IBD Inflammatory Bowel Disease. This encompasses a 
number of conditions such as colitis and Crohn’s 
disease. Use only if the endoscopist says ‘IBD’. If they 
specify colitis or Crohn’s then use these options. 
Incomplete exam A record should be coded as Incomplete Exam when the 
max segment is not reached AND a reason is given 
(other than ‘planned limited procedure’ or ‘pathology 
encountered’).  
Possible reasons include; 
 Looping (of the bowel or scope) 
 Patient consent withdrawn 
 Unsuccessful intubation 
 A technical problem 
 Poor Bowel Prep 
 An abandoned procedure 
 Patient intolerance/discomfort  
Melena/Melana  Stools stained black by a dark blood pigment. 
Piles See haemorrhoids 
Polyposis Endoscopist suspects the presence of polyposis due to 
the number of polyps observed in the bowel. 
Polyps Endoscopist has found polyps in the bowel during the 
exam. 
Proctitis Endoscopist has observed Inflammation of the lining of 
the rectum and anus.  
Prolapse Endoscopist has observed a part of the bowel 
prolapsing (falling or slipping out of place). Or the 
endoscopist has observed mucosal prolapse.  
Suspected IBD Endoscopist has reason to suspect Colitis or Crohns 
disease and has taken biopsies to confirm but the 
pathology is not present. (Apthous Ulcers can also be 
recognised as Suspected IBD) 
 
Note: Remember to check if pathology confirms or 
refutes a suspicion of IBD. If it is explicitly ruled out, 
remove ‘Suspected IBD’ from the Diagnosis. If it is 
confirmed, refer to page 3 – Exclusion Reasons. 
Strictures Endoscopist visualises a stricture during the exam. This 
is an abnormal narrowing of a bodily passage. This can 
be due to cancer, diverticulosis or inflammation. 
Ulcers Endoscopist visualises ulcers in the colon. 
Volvulus Endoscopist has observed a life threatening bowel 
obstruction where the bowel twists on itself. 
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5. Add/Edit Polyp Screen: 
 
Field Name Option Definition 
Size-mm  This is a number field. The size of the polyp stated by the 
endoscopist should be noted here. Convert to mm if 
necessary. Only to be used if an exact number is specified. 
Size Other 5-9mm Polyp is between 5 and 9mm. Exact size is not specified. 
<10mm The polyp is smaller than 10mm/sub centimetre. Exact size is 
not specified. 
<5mm The polyp is smaller than 5mm. Exact size is not specified. 
>10mm The polyp is larger than 10mm. Exact size is not specified. 
Large The polyp(s) are described as large. Exact size is not 
specified. 
Small The polyp(s) are described as small. Exact size is not 
specified. 
Tiny The polyp(s) are described as tiny. Exact size is not specified. 
Max Size  This is a number field. If multiple polyps are noted and 
maximum size is given, this can be entered here. This field 
can also be used to add a size where a size range is given to a 
single polyp. 
Min Size  This is a number field. This field can also be used to add a 
size where a size range is given to a single polyp. 
Shape Pedunculated The polyp observed was on a stalk. 
Sessile Polyp with no stalk. 
Flat Polyp that is flat on the surface of the bowel. 
Pseudo Polyp  A mass that has the appearance of a polyp but is not. 
Sub Pendunc Avoid using this option. 
Segment The segment of the 
colon in which a polyp 
is found.  
 
(If a range of segments 
is stated the most distal 
is entered here) 
 
 
 
 
Note: Right colon can 
be assumed to be 
Ascending colon unless 
otherwise specified in 
pathology. Proximal 
colon cannot. 
 
 
Segment to If a range of segments is 
stated the most proximal 
is entered here. 
 
See diagram above. 
Dist-cm 
 
 This is a number field. Sometimes the distance in which the 
polyp was found from the anus is stated. This should be 
entered in cm. 
Exc Method APC The endoscopist or pathologist specifies the primary use of 
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Argon Plasma Coagulation.  
Cold Biopsy Also Cold Bx/B’x. Insert if specified by endoscopist or 
pathologist. 
Hot Biopsy Also Hot Bx/B’x. Insert if specified by endoscopist or 
pathologist. 
Snare A wire loop device designed to slip over a polyp and, upon 
closure, result in removal of the polyp. 
Cold Snare Insert if specified by endoscopist or pathologist. 
Hot Snare Insert if specified by endoscopist or pathologist. 
EMR Endoscopic mucosal resection. Insert if specified by 
endoscopist or pathologist. 
Unknown Method Used when you know removal or biopsy has taken place but 
the method is unspecified or they used the term 
‘diathermised’. 
Exc Extent  Excised Endoscopist has specified that they have removed the polyp. 
Partially Excised Endoscopist has specified that they have only removed part of 
the polyp. Use this option when it is stated in the diagnosis 
report. 
Not Excised Endoscopist has specified that they have not removed the 
polyp. They may still have biopsied the polyp for pathology. 
Biopsy Fate Retrieved The polyp has been collected by the endoscopist from the 
colon after excision, and not left inside the colon. (This may 
or may not have been sent to pathology.) Only use when 
specifically stated by the endoscopist. 
Burnt Off Method of removal that destroys the polyp in situ. 
Not Retrieved  The specimen was lost after removal either inside the patient 
or outside the patient upon collection. A specimen/biopsy 
may still have been sent to pathology. 
Piece Yes The polyp has been removed piecemeal 
No The polyp has not been removed piecemeal. If this is the case, 
this can be left blank if preferred. 
Quantity  A number of The endoscopist describes the presence of “A number of” 
polyps. Exact number not specified. 
Few The endoscopist describes the presence of “A few” polyps. 
Exact number not specified. 
Many The endoscopist describes the presence of “Many” polyps. 
Exact number not specified. 
Multiple The endoscopist describes the presence of “Multiple” polyps. 
Exact number not specified. 
Several The endoscopist describes the presence of “Several” polyps. 
Exact number not specified. 
Some The endoscopist describes the presence of “Some” polyps. 
The exact number not specified. 
No Info Yes There is a polyp mentioned but there is no information that 
can be entered into the polyp row. 
 
6. Edit Polyp Pathology Screen 
 
Field Name Option Definition 
Dysplasia High Grade The pathologist describes high grade dysplasia/atypia. 
This is synonymous with severe dysplasia. Use only when 
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specified. 
IM Cancer The pathologist describes presence of Intra-mucosal 
cancer. 
IM Cancer in dispute The pathologist cannot confidently confirm IM cancer. 
Low Grade The pathologist describes low grade dysplasia/atypia. This 
is synonymous with either mild or moderate dysplasia.  
If the pathologist describes ‘mild to moderate’ or ‘mild 
and moderate’ dysplasia, use this option. 
Mild The pathologist describes Mild dysplasia/atypia.  
Moderate The pathologist describes Moderate or focally moderate 
dysplasia/atypia.  
Severe The pathologist describes Severe or focally severe 
dysplasia/atypia 
Adenoma Type Tubular The pathologist describes the morphology of the 
Adenomatous tissue as tubular. 
Tubulovillous The pathologist describes the morphology of the 
Adenomatous tissue as tubulovillous. A polyp with both 
tubular and villous morphology is considered 
tubulovillous.  
Villous The pathologist describes the morphology of the 
Adenomatous tissue as villous. 
Not to be confused with villiform mucosa. 
Histology Adenoma Pathologist specifies adenoma / Adenomatous polyp. 
Benign dysplastic colonic tumour. Can progress to become 
malignant. 
Amyloid Insoluble fibrous protein aggregates.  
Angiodysplasia Vascular malformation in the gut which can often cause 
bleeding into the colon. 
Ca+adenoma Carcinoma / cancer / malignant / invasive cell types, seen 
to be arising from an adenoma or when a cancer diagnosis 
also includes adenomatous material. 
Ca+mixed Carcinoma / cancer / malignant / invasive cell types, seen 
to be arising from a mixed polyp or adenoma 
Ca+serrated  Carcinoma / cancer / malignant / invasive cell types, seen 
to be arising from a serrated polyp or adenoma 
Ca in dispute If a pathologist cannot confidently confirm cancer / 
malignancy / level of invasion in an adenoma or cannot 
decide between an adenoma or cancer. 
Cancer query If a pathologist mention or suspects but is not able to 
confirm a diagnosis of cancer / malignancy 
Cancer Malignant neoplasm / adenocarcinoma / carcinoma/ 
malignancy / invasion  
Note – if Cancer is diagnosed at the 1st exam – see  page 3 
– Exclusion Reasons 
Cap polyp  Inflammatory polyp with a ‘cap’ of debris or granulation 
tissue. 
Carcinoid/neuroendocrine 
tumour 
Tumour originating from the neuroendocrine system. 
Colitis Chronic bowel disease characterised by inflammation of 
the colon. Only to be used if colitis is specified, there is a 
separate option for generalised inflammation.  
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Note – if Crohns is diagnosed – see  page 3 – Exclusion 
Reasons 
Congestion Mucosal cells appear congested. 
Crohn’s disease An autoimmune inflammatory disease that can affect any 
part of the gastrointestinal tract  
Note – if Crohns is diagnosed – see  page 3 – Exclusion 
Reasons 
Fibroepithelial polyp Benign cutaneous lesion / skin tag. ‘Polypiod fibrous 
nodules’ can also be coded as this. 
Ganglioneuromatosis Tumours arising from the nervous system. 
Gastric heterotopia Normal gastric mucosa seen elsewhere in the body. 
GIST Gastro Intestinal Stromal Tumour 
Granulation tissue Tissue that replaces fibrin clots during the healing of 
tissue. 
Haemangioma Benign noncancerous tumour composed of rapidly 
proliferating blood vessels. 
Hamartomatous polyp Benign mucosal polyps usually found in the jejunum and 
ileum (small bowel). 
Inflammation Generalised inflammation of mucosa. 
Inflammatory  Inflammatory polyp. 
Ischaemia Restriction of blood supply. 
Juvenile polyp Rare form of large bowel polyp. AKA retention polyp. 
Leiomyoma Benign neoplasm of smooth muscle. 
Lipoma Benign tumour composed of fatty tissue. 
Lymphangiectasia Intestinal disease characterised by lymphatic dilation. 
Lymphoid polyp Benign polyps occurring where lymphoid follicles are 
present in the colon. 
Melanosis coli Pigmentation of the wall of the colon, not associated with 
any disease pathway. 
Metaplastic/Hyperplastic Benign non-dysplastic polyps with lengthening and cystic 
dilation of mucosal glands. Hyperplastic and Metaplastic 
are synonymous with each other. 
 
“Hyperplastic areas” may also be coded this way. 
Metastases from another 
site 
Malignant material that is not from a primary bowel 
cancer and originates from a cancer somewhere else in 
the body. 
Mets/tumour infiltrating Malignant material that is infiltrating into the colon from 
a tumour outside the colon (if unsure use ‘Mets from 
another site’) 
Mixed 
adenoma/metaplastic 
Polyp displaying characteristics of an adenoma and those 
of a metaplastic polyp. This is rare. 
Mucosal prolapse Slippage of mucosa. 
Neurofibromatosis Genetically inherited disease where nerve fibres grow 
tumours. 
Non-Hodgkins Lymphoma (NHL) A diverse group of blood cancers that include any 
kind of lymphoma except Hodgkin’s lymphomas.  
Normal mucosa Specimen shows no signs of a polyp and levels of 
dysplasia/atypia are within normal limits. 
Not possible to diagnose The polyp sample is too small or too damaged on removal 
to reliably diagnose the specimen. 
Oedema Swelling due to accumulation of fluids. 
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Previous polypectomy site  Appears to be tissue from the site where a previous polyp 
was removed. 
Proctitis Inflammation of the lining of the anus and rectum. 
Pseudolipomatus Artifactual microscopic change in tissues that resembles 
fatty infiltration. 
Regenerative polyp Hyperplastic polyp of the gastric mucosa. 
Sarcoma Cancerous tumour of soft tissue 
Serrated adenoma Benign dysplastic colonic tumour which has a serrated 
appearance under the microscope. 
Specimen not seen No evidence of a specimen in the pot received at 
pathology. 
Spirochaetosis  A type of bacterial infection of the colon. 
Squamous cell carcinoma Skin Cancer normally found in the anus, but may be 
reported as rectal. Code as squamous cell carcinoma. 
Submucosal haematoma Result of bleeding outside of the blood vessels.  
Ulcer A break in the lining of the digestive tract that fails to heal 
naturally. 
Unicryptal adenoma Very early beginning of adenoma growth. 
Xanthoma Fatty deposits under the skin or mucosa causing yellow 
bumps. 
Size-mm  This is a number field. The size of the sample received for 
histological examination should be written here. Coders 
should always record the maximum diameter stated. 
Exc Complete Complete Pathologist has specified that the polyp appears 
completely excised. 
Incomplete Pathologist has specified that the polyp appears to be 
incompletely excised. 
Uncertain The pathologist is unsure about the completeness of 
excision or the extent of excision cannot be accessed. 
Piece  Yes The pathologist has indicated the polyp appears to have 
undergone piecemeal removal. 
No This does not need to be used and can be left blank. 
Multi Link  This drop down menu will give a list of the polyp ID’s 
found at the exam. These can be selected if two rows are 
linked (see SOP for more details on when to link polyps). 
 
7. Unlinked Pathology Page: 
 
Field Name Option Definition 
Excluded General Use this option for any general queries about the report. 
Not Relevant Path 
 
Use this option when a report describes a biopsy from any site 
other than the Large Bowel. 
Duplicate Use this option when the pathology report is a duplicate and 
needs to be deleted. 
Query Blank Pathology Use this option when the pathology report is blank. 
Possible Link Use this option when the details of the pathology (in terms of 
date, polyp numbers and segments) indicate that it may belong 
to an endoscopy report in the Patient Page. 
Truncated Pathology 
Report 
Use this option when the pathology report is truncated. 
Unclear Specimen Use this option when it is unclear if the specimen is from the 
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Origin large bowel or not.
Normal 
Mucosa 
 This is a tick box option. Use this option when the report does 
not describe any polyp attributes. 
Note: A phantom report must still be created even if there is 
no endoscopic information to fill in. 
 
 
8.  Unlinked Pathology Endo Coding Page: 
 
Field Name Option Definition 
Procedure 
Type 
Colonoscopy The endoscopic examination of the whole of the large colon and the 
distal part of the small bowel with a camera on a tube passed through 
the anus. 
Flexible 
Sigmoidoscopy 
The endoscopic examination of the large intestine from the rectum to 
the distal descending, using a flexible scope. 
Proctoscopy Short ridged metal tube is inserted into the rectum, anal cavity or 
sigmoid to enable direct visualisation of the area. 
Rigid 
Sigmoidoscopy 
The endoscopic examination of the large intestine from the rectum to 
the distal sigmoid, using a rigid scope. 
Sigmoidoscopy Examination of the large colon up to the distal descending. 
Bowel Prep Excellent  
Good 
Poor 
Satisfactory  
        
       These should just be inserted as stated in the report 
Segment 
Reached 
 
 
 
 
 
 
 
Note: Complete or 
Total Colonoscopy 
can be assumed to 
have reached the 
Cecum. A complete 
or total ileo-
colonoscopy can be 
assumed to have 
reached the 
Terminal ileum.  
Distance 
Reached (cm) 
 This is a text field. Type in the distance (in cm’s) reached by the 
endoscope from the anus if it is specified. 
Query Application Coding 
Error 
To be used when indicating that options or drop-down menus will be 
changed at a later date by the database administrator and you will 
return at a later date to finish coding.  
Discuss To be used when coders wish to discuss the record with other members 
of the team. 
Exclude To be used when a patient’s endoscopy or pathology report indicates, 
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but does not confirm the presence of study exclusion criteria. For 
details on the exclusion criteria see the ‘Exclusion SOP’.  
General To be used for any other query, particularly if you feel it warrants 
discussion with other members of the team. When using a general 
query, you should describe the nature of the query in the comments box 
below the query field.  
Pathology Linking To be used when a pathology report appears to be linked/unlinked 
incorrectly to an endoscopy record, but it is not certain.  
 
Note: If the pathology is clearly linked/unlinked incorrectly, it can be 
manually linked/unlinked using the Link Pathology button on the 
patient details screen. Once the linking has been corrected there is no 
need to query the record. 
Pathology Missing This option is not relevant, do not use. 
Polyp Matching This option is not relevant, do not use.  
 Refer Back To To be used for personal reference when you need to come back to a 
record. 
Comments  This is a free text field. This should be used to enter any comments that 
relate to the record or the query. 
 
For Indications and Diagnosis Screen please see sections; 3 & 4 
 
9.  Phantom Polyp Coding: 
 
Field Name Option Definition 
E Size  This is a number field. The size of the polyp stated by the 
endoscopist should be noted here. Convert to mm if 
necessary. Only to be used if an exact number is specified. 
Size Other 5-9mm Polyp is between 5 and 9mm. Exact size is not specified. 
<10mm The polyp is smaller than 10mm/sub centimetre. Exact size is 
not specified. 
<5mm The polyp is smaller than 5mm. Exact size is not specified. 
>10mm The polyp is larger than 10mm. Exact size is not specified. 
Large The polyp(s) are described as large. Exact size is not 
specified. 
Small The polyp(s) are described as small. Exact size is not 
specified. 
Tiny The polyp(s) are described as tiny. Exact size is not specified. 
Shape Pedunculated The polyp observed was on a stalk. 
Sessile Polyp with no stalk. 
Flat Polyp that is flat on the surface of the bowel. 
Pseudo Polyp  A mass that has the appearance of a polyp but is not. 
Sub Pendunc Avoid using this option. 
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Segment The segment of the colon 
in which a polyp is found.  
 
(If a range of segments is 
stated the most distal is 
entered here) 
 
 
 
 
Note: Right colon can be 
assumed to be Ascending 
colon unless otherwise 
specified in pathology. 
Proximal colon cannot. 
  
Segment to If a range of segments is 
stated the most proximal is 
entered here. 
 
See diagram above. 
Dist-cm 
 
 This is a number field. Sometimes the distance in which the 
polyp was found from the anus is stated. This should be 
entered in cm. 
Exc Method APC The endoscopist or pathologist specifies the primary use of 
Argon Plasma Coagulation.  
Cold Biopsy Also Cold Bx/B’x. Insert if specified by endoscopist or 
pathologist. 
Hot Biopsy Also Hot Bx/B’x. Insert if specified by endoscopist or 
pathologist. 
Snare A wire loop device designed to slip over a polyp and, upon 
closure, result in removal of the polyp. 
Cold Snare Insert if specified by endoscopist or pathologist. 
Hot Snare Insert if specified by endoscopist or pathologist. 
EMR Endoscopic mucosal resection. Insert if specified by 
endoscopist or pathologist. 
Unknown Method Used when you know removal or biopsy has taken place but 
the method is unspecified or they used the term 
‘diathermised’. 
Piece Yes The polyp has been removed piecemeal 
No The polyp has not been removed piecemeal. If this is the case, 
this can be left blank if preferred. 
P Size  This is a number field. The size of the sample (in mm) 
received for histological examination should be written here. 
Coders should always record the maximum diameter stated. 
Dysplasia High Grade The pathologist describes high grade dysplasia/atypia. This is 
synonymous with severe dysplasia. Use only when specified. 
IM Cancer The pathologist describes presence of Intra-mucosal cancer.  
IM Cancer in dispute The pathologist cannot confidently confirm IM cancer. 
Low Grade The pathologist describes low grade dysplasia/atypia. This is 
synonymous with either mild or moderate dysplasia.  
If the pathologist describes ‘mild to moderate’ or ‘mild and 
moderate’ dysplasia, use this option. 
Mild The pathologist describes Mild dysplasia/atypia.  
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Moderate The pathologist describes Moderate or focally moderate 
dysplasia/atypia.  
Severe The pathologist describes Severe or focally severe 
dysplasia/atypia 
Adenoma 
Type 
Tubular The pathologist describes the morphology of the 
Adenomatous tissue as tubular. 
Tubulovillous The pathologist describes the morphology of the 
Adenomatous tissue as tubulovillous. A polyp with both 
tubular and villous morphology is considered tubulovillous.  
Villous The pathologist describes the morphology of the 
Adenomatous tissue as villous. 
Not to be confused with villiform mucosa. 
Histology Adenoma Pathologist specifies adenoma / Adenomatous polyp. Benign 
dysplastic colonic tumour. Can progress to become malignant. 
Amyloid Insoluble fibrous protein aggregates.  
Angiodysplasia Vascular malformation in the gut which can often cause 
bleeding into the colon. 
Ca+adenoma Carcinoma / cancer / malignant / invasive cell types, seen to 
be arising from an adenoma or when a cancer diagnosis also 
includes adenomatous material. 
Ca+mixed Carcinoma / cancer / malignant / invasive cell types, seen to 
be arising from a mixed polyp or adenoma 
Ca+serrated  Carcinoma / cancer / malignant / invasive cell types, seen to 
be arising from a serrated polyp or adenoma 
Ca in dispute If a pathologist cannot confidently confirm cancer / 
malignancy / level of invasion in an adenoma or cannot 
decide between an adenoma or cancer. 
Cancer query If a pathologist mention or suspects but is not able to confirm 
a diagnosis of cancer / malignancy 
Cancer Malignant neoplasm / adenocarcinoma / carcinoma/ 
malignancy / invasion  
Note – if Cancer is diagnosed at the 1st exam – see  page 3 – 
Exclusion Reasons 
Cap polyp  Inflammatory polyp with a ‘cap’ of debris or granulation 
tissue. 
Carcinoid tumour Tumour originating from the neuroendocrine system. 
Colitis Chronic bowel disease characterised by inflammation of the 
colon. Only to be used if colitis is specified, there is a separate 
option for generalised inflammation.  
Note – if Crohns is diagnosed – see  page 3 – Exclusion 
Reasons 
Congestion Mucosal cells appear congested. 
Crohn’s disease An autoimmune inflammatory disease that can affect any part 
of the gastrointestinal tract  
Note – if Crohns is diagnosed – see  page 3 – Exclusion 
Reasons 
Fibroepithelial polyp Benign cutaneous lesion / skin tag. ‘Polypiod fibrous nodules’ 
can also be coded as this. 
Ganglioneuromatosis Tumours arising from the nervous system. 
Gastric heterotopia Normal gastric mucosa seen elsewhere in the body. 
GIST Gastro Intestinal Stromal Tumour 
Granulation tissue Tissue that replaces fibrin clots during the healing of tissue. 
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Haemangioma Benign noncancerous tumour composed of rapidly 
proliferating blood vessels. 
Hamartomatous polyp Benign mucosal polyps usually found in the jejunum and 
ileum (small bowel). 
Inflammation Generalised inflammation of mucosa. 
Inflammatory  Inflammatory polyp. 
Ischaemia Restriction of blood supply. 
Juvenile polyp Rare form of large bowel polyp. AKA retention polyp. 
Leiomyoma Benign neoplasm of smooth muscle. 
Lipoma Benign tumour composed of fatty tissue. 
Lymphangiectasia Intestinal disease characterised by lymphatic dilation. 
Lymphoid polyp Benign polyps occurring where lymphoid follicles are present 
in the colon. 
Melanosis coli Pigmentation of the wall of the colon, not associated with any 
disease pathway. 
Metaplastic/Hyperplastic Benign non-dysplastic polyps with lengthening and cystic 
dilation of mucosal glands. Hyperplastic and Metaplastic are 
synonymous with each other. 
 
“Hyperplastic areas” may also be coded this way. 
Metastases from another 
site 
Malignant material that is not from a primary bowel cancer 
and originates from a cancer somewhere else in the body. 
Mets/tumour infiltrating Malignant material that is infiltrating into the colon from a 
tumour outside the colon (if unsure use ‘Mets from another 
site’) 
Mixed 
adenoma/metaplastic 
Polyp displaying characteristics of an adenoma and those of a 
metaplastic polyp. This is rare. 
Mucosal prolapsed Slippage of mucosa. 
Neurofibromatosis Genetically inherited disease where nerve fibres grow 
tumours. 
Non-Hodgkins 
Lymphoma 
(NHL) A diverse group of blood cancers that include any kind 
of lymphoma except Hodgkin’s lymphomas.  
Normal mucosa Specimen shows no signs of a polyp and levels of 
dysplasia/atypia are within normal limits. 
Not possible to diagnose The polyp sample is too small or too damaged on removal to 
reliably diagnose the specimen. 
Oedema Swelling due to accumulation of fluids. 
Previous polypectomy 
site  
Appears to be tissue from the site where a previous polyp was 
removed. 
Proctitis Inflammation of the lining of the anus and rectum. 
Pseudolipomatus Artifactual microscopic change in tissues that resembles fatty 
infiltration. 
Regenerative polyp Hyperplastic polyp of the gastric mucosa. 
Sarcoma Cancerous tumour of soft tissue 
Serrated adenoma Benign dysplastic colonic tumour which has a serrated 
appearance under the microscope. 
Specimen not seen No evidence of a specimen in the pot received at pathology. 
Spirochaetosis  A type of bacterial infection of the colon. 
Squamous cell 
carcinoma 
Skin Cancer normally found in the anus, but may be reported 
as rectal. Code as squamous cell carcinoma. 
Submucosal haematoma Result of bleeding outside of the blood vessels.  
Ulcer A break in the lining of the digestive tract that fails to heal 
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naturally. 
Unicryptal adenoma Very early beginning of adenoma growth. 
Xanthoma Fatty deposits under the skin or mucosa causing yellow 
bumps. 
Exc Complete Complete Pathologist has specified that the polyp appears completely 
excised. 
Incomplete Pathologist has specified that the polyp appears to be 
incompletely excised. 
Uncertain The pathologist is unsure about the completeness of excision 
or the extent of excision cannot be accessed. 
 
Updated with new histology terms that were added for cancer review. These included cancer types - GIST, 
Sarcoma, squamous cell carcinoma. A 'cancer query' added to compliment 'cancer in dispute'. 'Mets/tumour 
infiltrating' added to compliment 'mets from another site'. 
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Exclusion SOP 
(Sajith Perera 3/12/2012) 
Exclusion if found at ANY EXAM 
If the following conditions are presented as either a diagnosis or an indication in any of the patient’s 
endoscopy or pathology records then that patient is excluded. 
Criteria: Definition: Mention of the following terms 
in any of the fields may 
indicate the presence of the 
exclusion criteria: 
Hereditary Non-
Polyposis Colorectal 
Cancer OR Family 
History of HNPCC 
 
 
“Familial predisposition indicates elevated 
risk for polyp and/or bowel cancer 
development by genetic influence” 
 
HNPCC 
Lynch Syndrome 
MSH1/2 mutation 
MLH1/2 mutation 
HNPCC Pedigree 
HMSH2 
Colitis (any type) 
 
 
 
“Colitis is a chronic digestive disease 
characterised by inflammation of the colon” 
Only exclude if it is specified as being 
present by the endoscopist or strongly 
suspected by the pathologist after looking at 
the histology. 
Colitis is a chronic disease, if a patient has 
‘healed colitis’ it is only non-active. 
Therefore still exclude. 
Diverticular colitis is NOT an exclusion 
criteria as this is Diverticulitis. 
Some (short-term) colitis should NOT be 
excluded for. Non-exclusion colitis types 
are: 
 Diversion colitis 
 Infective colitis ( such as that caused 
by Clostridium difficile or another 
infectious agent)  
 Pseudomembranous colitis 
 Reactive colitis 
 Procedural/enema related colitis 
Ulcerative colitis 
Microscopic colitis 
Lymphocytic colitis 
Collagenous colitis  
Healed colitis 
History of Colitis 
Ischemic Colitis 
Ulcerative proctitis 
Indeterminate colitis 
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Exclusion if found at FIRST EXAM 
The following conditions will exclude the patient if they are identified within the first endoscopy exam 
(chronologically) for that patient. The conditions can be identified either within the diagnosis or indication 
 Drug-induced colitis 
 Antibiotic-associated colitis 
 Radiation colitis 
 Chemical colitis 
 Ischemic colitis 
Crohn’s Disease “Chronic inflammatory disease which can 
affect any part of the intestinal tract” 
Healed crohn’s 
History of crohn’s 
Inflammatory Bowel 
Disease (IBD) 
 
“An umbrella term that encompasses 
conditions such as Crohn’s and colitis” 
DO NOT GET CONFUSED WITH IBS 
(irritable bowel syndrome) 
Chronic Inflammation  
Ulcerative Proctitis 
Polyposis (any type) “Colon has a very large number of polyps 
(20+) lining a large proportion of the colons 
surface. It may be acceptable to exclude for 
less than 20 polyps if there is a number of 
exams with multiple polyps and information 
indicating family history of polyps ”- rule no 
longer used as of March 2012. 
 
NB - March 2012, polyposis patients 
reviewed. 
Only those with reports where the 
endoscopist or pathologist explicitly states 
presence of polyposis will be coded as 
polyposis. Numbers of polyps will be used 
to classify polyposis patients at analysis. 
Familial Adenomatous 
Polyposis (FAP) 
Multiple Adenomatous 
Polyposis (MAP) 
Juvenile Polyposis 
Adenomatous Polyposis Coli 
(APC) 
Peutz-Jegher’s syndrome 
Hyperplastic polyposis 
Serrated polyposis 
Lymphoid polyposis 
Cap polyposis 
Polyposis 
MYH 
Family History of FAP 
 
 
“History of family members who have 
suffered with FAP” 
FH FAP 
FH Familial Adenomatous 
Polyposis 
FAPC 
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fields for this exam. If the conditions are found on any other endoscopy exams (not the patient’s first exam) 
then the patient is not excluded and is coded as normal.  
 
Criteria: Definition: Mention of the following terms 
in any of the fields may 
indicate the presence of the 
exclusion criteria: 
Stoma “Surgically created opening of the colon 
through the abdominal wall” 
Reversal 
Colostomy bag 
Resection “Partial or complete removal of the colon” Hartman’s procedure OR HAR 
Neo-terminal ileum 
Ileostomy 
Colostomy 
Pouch (however not pouch of 
douglas) 
Pouchitis 
Pouchoscopy 
Rectal Stump 
Suture 
AP Resection (abdominal 
perineal) OR APR 
Colectomy / Hemicolectomy 
Rectal Sponge 
Anastomosis “The connection of two parts of the bowel 
post-resection” 
 
Cancer  “Malignant findings in the colon that have 
been confirmed by pathological assessment 
or the patient has had cancer prior to the 
first examination listed as is undertaking 
cancer follow-up” 
Cancers that is seen but 
unconfirmed/suspected at first exam but 
confirmed at a second procedure should 
also be excluded. 
Adenocarcinoma 
Moderately differentiated 
adenocarcinoma 
Carcinoma 
Malignant tumour 
Signet cell carcinoma 
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Cancers in dispute that are not resolved 
should NOT be excluded. 
Any other cancers that exist outside the 
bowel should NOT be excluded 
Cancers occurring within an adenoma 
(Ca+adenoma) should NOT be excluded. 
 
 
The patient can be excluded by using a custom perl program (exclude.pl) that will automatically go through 
all the patient endoscopy records in a dataset and exclude the relevant patients. 
 
Provisional Exclusion 
 
• Patient has no polyps plus no linked pathology 
• Patient may have multiple endoscopy records 
• Done automatically 
• Only used if we can reliably tell if polyps were found during an endoscopy exam. 
o Endoscribe date, this classification is not used because of this reason. 
 
 
A custom Perl program (exclude.pl) carries out these types of exclusions automatically. 
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Checking Coder Excluded Records SOP 
(Amy Brenner 3/29/2011) 
 
Coder Excluded Records 
A number of patients were excluded based on exclusion criteria.  As a result, in some cases these patient 
records were not fully coded. Due to developments, they need to be properly coded in the same way as all 
other records. There are a number of issues that coders should be aware of when going through coder 
excluded records. 
 
Identifying Coder Excluded Records 
After selecting a hospital you should change the settings to ‘Coder Excluded Patients’. 
 
The exclusion criteria are: 
• Resection 1st exam 
• Cancer 1st exam  
• Colitis 
• Crohns 
• IBD 
• HNPCC/family history of HNPCC 
• Family history of FAP 
• Polyposis 
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Checklist 
When checking coder excluded records you should confirm the following: 
1) Are all the endoscopy reports coded? 
2) Has all the endoscopy and pathology information been entered?  
Sometimes information may have been left out despite the report having been coded. You will need 
to go into both the endoscopy and pathology screens for each individual report to check this. 
 
3) Have phantom endoscopy reports been created for all unlinked pathology reports? 
4) Should the patient be excluded? 
It is important to ensure that the patient has been excluded correctly. Please take note that a number 
of records have been excluded as ‘Cancer 1st exam’, however the patient only had ‘ca + adenoma’ at 
their first exam, not cancer.  Bear this in mind and be sure to uncheck the exclusion box if the patient 
has been inappropriately excluded.  Analyse the record if there are no queries. 
 
5) Once all reports are fully coded, the patient should be marked as ‘Checked Excluded’.  
This will result in the patient being moved from ‘Coder Excluded’ in the Patient List to ‘Checked 
(Coder Excluded)’. The ‘Checked Excluded’ button is shown below. 
 
Creating New Queries 
In some cases, checking coder excluded records will result in the creation of new queries. A query should be 
used if the patient cannot be confidently coded, however unnecessary queries should be avoided as it is 
unlikely that they will be resolved.  
A new missing pathology query should only be created if: 
 Cancer is suspected 
 Histology requested/sent to labs 
 Biopsy text indicator 
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NB – You should only begin checking coder excluded patients at centres for which missing pathology 
has already been uploaded. Any queries should be marked as a re-query. 
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Exclusion Reference Document 
 Definition: Mention of the following terms 
in any of the fields may indicate 
the presence of the exclusion 
criteria  
Exclusion if found at ANY EXAM 
 
Hereditary Non-
Polyposis Colorectal 
Cancer OR Family 
History of HNPCC 
“Familial predisposition indicates elevated 
risk for polyp and/or bowel cancer 
development by genetic influence” 
 
HNPCC 
Lynch Syndrome 
MSH1/2 mutation 
MLH1/2 mutation 
HNPCC Pedigree 
Colitis (any type) 
 
 
 
“Colitis is a chronic digestive disease 
characterised by inflammation of the colon” 
 
Only exclude if it is specified as being 
present by the endoscopist or strongly 
suspected by the pathologist after looking at 
the histology. 
 
Colitis is a chronic disease, if a patient has 
‘healed colitis’ it is only non-active. 
Therefore still exclude. 
 
Diverticular colitis is NOT an exclusion 
criteria as this is Diverticulitis. 
 
Some (short-term) colitis should not be 
excluded for. Non-exclusion colitis types 
are: 
 Diversion colitis 
 Infectious colitis ( such as that 
caused by Clostridium difficile or 
another infectious agent)  
 Pseudomembranous colitis 
 Reactive colitis 
 Procedural colitis 
 Drug-induced colitis 
 Antibiotic-associated colitis 
 Radiation colitis 
 Chemical colitis 
 Ischemic colitis 
Ulcerative colitis 
Microscopic colitis 
Lymphocytic colitis 
Collagenous colitis  
Healed colitis 
History of colitis 
Ulcerative Proctitis 
Indeterminate colitis 
Crohn’s Disease 
 
“Chronic inflammatory disease which can 
affect any part of the intestinal tract” 
Healed crohn’s 
History of crohn’s 
Inflammatory Bowel 
Disease (IBD) 
 
 
“An umbrella term that encompasses 
conditions such as Crohn’s and colitis” 
 
DO NOT GET CONFUSED WITH IBS 
(irritable bowel syndrome) 
Chronic Inflammation 
Ulcerative Proctitis 
Polyposis (any type) “Colon has a very large number of polyps 
(20+) lining a large proportion of the colons 
surface. It may be acceptable to exclude for 
less than 20 polyps if there is a number of 
Familial Adenomatous Polyposis 
(FAP) 
Multiple Adenomatous Polyposis 
(MAP) 
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Exclusion if found at FIRST EXAM 
 
Stoma “Surgically created opening of the colon 
through the abdominal wall” 
Reversal 
Colostomy bag 
Resection “Partial or complete removal of the colon” Hartman’s procedure OR HAR 
Neo-terminal ileum 
Ileostomy 
Colostomy 
Pouch (however not pouch of 
douglas) 
Pouchitis 
Pouchoscopy 
Rectal Stump 
AP Resection (abdominal perineal) 
OR APR 
Colectomy / Hemicolectomy 
Rectal Sponge 
Anastomosis 
 
“The connection of two parts of the bowel 
post-resection” 
 
Cancer  “Malignant findings in the colon that have 
been confirmed by pathological assessment 
or the patient has had cancer prior to the first 
examination listed as is undertaking cancer 
follow-up” 
 
Cancers that is seen but 
unconfirmed/suspected at first exam but 
confirmed at a second procedure should also 
be excluded. 
 
Cancers in dispute that are not resolved 
should NOT be excluded. 
 
Any other cancers that exist outside the 
bowel should NOT be excluded 
 
Cancers occurring within an adenoma 
(Ca+adenoma) should NOT be excluded. 
Adenocarcinoma 
Moderately differentiated 
adenocarcinoma 
Carcinoma 
Malignant tumour 
Signet cell carcinoma 
exams with multiple polyps and information 
indicating family history of polyps ”- rule no 
longer used as of March 2012. 
 
NB - March 2012, polyposis patients 
reviewed. 
Only those with reports where the 
endoscopist or pathologist explicitly states 
presence of polyposis will be coded as 
polyposis. Numbers of polyps will be used 
to classify polyposis patients at analysis. 
Juvenile Polyposis 
Adenomatous Polyposis Coli 
(APC) 
Peutz-Jegher’s syndrome 
Hyperplastic polyposis 
Serrated polyposis 
Lymphoid polyposis 
Cap polyposis 
Polyposis 
MYH 
Family History of FAP 
 
 
 
“History of family members who have 
suffered with FAP” 
FH FAP 
FH Familial Adenomatous 
Polyposis 
FAPC 
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Coders Reference Document – Phantom Reports 
(Ann Thomson 3/12/2012) 
 
1. Patient Page: 
 
Field Name Option Definition 
Excluded General Use this option for any general queries about the report. 
Not Relevant Path Use this option when a report describes a biopsy from any site 
other than the Large Bowel. 
Duplicate Use this option when the a number of the same reports have 
been uploaded 
Query Blank Pathology Use this option when the pathology report is blank. 
Possible Link Use this option when the details of the pathology (in terms of 
date, polyp numbers and segments) indicate that it may belong 
to an endoscopy report in the Patient Page. 
Truncated Pathology 
Report 
Use this option when the pathology report is truncated. 
Unclear Specimen 
Origin 
Use this option when it is unclear if the specimen is from the 
large bowel or not. 
Normal 
Mucosa 
 This is a tick box option. Use this option when the report does 
not describe any polyp attributes. 
Note: A phantom report must still be created even if there is no 
endoscopic information to fill in. 
 
 
2. Unlinked Pathology Endo Coding Page: 
 
Field Name Option Definition 
Procedure 
Type 
Colonoscopy The endoscopic examination of the whole of the large colon and the 
distal part of the small bowel with a camera on a tube passed through 
the anus. 
Flexible 
Sigmoidoscopy 
The endoscopic examination of the large intestine from the rectum to 
the distal descending, using a flexible scope. 
Proctoscopy Short ridged metal tube is inserted into the rectum, anal cavity or 
sigmoid to enable direct visualisation of the area. 
Rigid 
Sigmoidoscopy 
The endoscopic examination of the large intestine from the rectum to 
the distal sigmoid, using a rigid scope. 
Sigmoidoscopy Examination of the large colon up to the distal descending. 
Bowel Prep Excellent  
Good 
Poor 
Satisfactory  
        
       These should just be inserted as stated in the report 
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Segment 
Reached  
 
 
 
 
 
Note: Complete or 
Total Colonoscopy 
can be assumed to 
have reached the 
Cecum. A complete 
or total ileo-
colonoscopy can be 
assumed to have 
reached the 
Terminal ileum.  
Distance 
Reached (cm) 
 This is a text field. Type in the distance (in cm’s) reached by the 
endoscope from the anus if it is specified. 
Query Application Coding 
Error 
To be used when indicating that options or drop-down menus will be 
changed at a later date by the database administrator and you will 
return at a later date to finish coding.  
Discuss To be used when coders wish to discuss the record with other members 
of the team. 
Exclude To be used when a patient’s endoscopy or pathology report indicates, 
but does not confirm the presence of study exclusion criteria. For 
details on the exclusion criteria see the ‘Exclusion SOP’.  
General To be used for any other query, particularly if you feel it warrants 
discussion with other members of the team. When using a general 
query, you should describe the nature of the query in the comments box 
below the query field.  
Pathology Linking To be used when a pathology report appears to be linked/unlinked 
incorrectly to an endoscopy record, but it is not certain.  
 
Note: If the pathology is clearly linked/unlinked incorrectly, it can be 
manually linked/unlinked using the Link Pathology button on the 
patient details screen. Once the linking has been corrected there is no 
need to query the record. 
Pathology Missing This option is not relevant, do not use. 
Polyp Matching This option is not relevant, do not use.  
 Refer Back To To be used for personal reference when you need to come back to a 
record. 
Comments  This is a free text field. This should be used to enter any comments that 
relate to the record or the query. 
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For Indications and Diagnosis Screen please see sections; 3 & 4 of Main Coders Reference Document 
 
3. Phantom Polyp Coding: 
 
Field Name Option Definition 
E Size  This is a number field. The size of the polyp stated by the 
endoscopist should be noted here. Convert to mm if 
necessary. Only to be used if an exact number is specified. 
Size Other 5-9mm Polyp is between 5 and 9mm. Exact size is not specified. 
<10mm The polyp is smaller than 10mm/sub centimetre. Exact size is 
not specified. 
<5mm The polyp is smaller than 5mm. Exact size is not specified. 
>10mm The polyp is larger than 10mm. Exact size is not specified. 
Large The polyp(s) are described as large. Exact size is not 
specified. 
Small The polyp(s) are described as small. Exact size is not 
specified. 
Tiny The polyp(s) are described as tiny. Exact size is not specified. 
Shape Pedunculated The polyp observed was on a stalk. 
Sessile Polyp with no stalk. 
Flat Polyp that is flat on the surface of the bowel. 
Pseudo Polyp  A mass that has the appearance of a polyp but is not. 
Sub Pendunc Avoid using this option. 
Segment The segment of the colon in 
which a polyp is found.  
 
(If a range of segments is 
stated the most distal is 
entered here) 
 
 
 
 
Note: Right colon can be 
assumed to be Ascending 
colon unless otherwise 
specified in pathology. 
Proximal colon cannot. 
  
Segment to If a range of segments is 
stated the most proximal is 
entered here. 
 
See diagram above. 
Dist-cm 
 
 This is a number field. Sometimes the distance in which the 
polyp was found from the anus is stated. This should be 
entered in cm. 
Exc Method APC The endoscopist or pathologist specifies the primary use of 
Argon Plasma Coagulation.  
Cold Biopsy Also Cold Bx/B’x. Insert if specified by endoscopist or 
pathologist. 
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Hot Biopsy Also Hot Bx/B’x. Insert if specified by endoscopist or 
pathologist. 
Snare A wire loop device designed to slip over a polyp and, upon 
closure, result in removal of the polyp. 
Cold Snare Insert if specified by endoscopist or pathologist. 
Hot Snare Insert if specified by endoscopist or pathologist. 
EMR Endoscopic mucosal resection. Insert if specified by 
endoscopist or pathologist. 
Unknown Method Used when you know removal or biopsy has taken place but 
the method is unspecified or they used the term 
‘diathermised’. 
Piece Yes The polyp has been removed piecemeal 
No The polyp has not been removed piecemeal. If this is the 
case, this can be left blank if preferred. 
P Size  This is a number field. The size of the sample (in mm) 
received for histological examination should be written here. 
Coders should always record the maximum diameter stated. 
Dysplasia High Grade The pathologist describes high grade dysplasia/atypia. This is 
synonymous with severe dysplasia. Use only when specified. 
IM Cancer The pathologist describes presence of Intra-mucosal cancer.  
IM Cancer in dispute The pathologist cannot confidently confirm IM cancer. 
Low Grade The pathologist describes low grade dysplasia/atypia. This is 
synonymous with either mild or moderate dysplasia.  
If the pathologist describes ‘mild to moderate’ or ‘mild and 
moderate’ dysplasia, use this option. 
Mild The pathologist describes Mild dysplasia/atypia.  
Moderate The pathologist describes Moderate or focally moderate 
dysplasia/atypia.  
Severe The pathologist describes Severe or focally severe 
dysplasia/atypia 
Adenoma 
Type 
Tubular The pathologist describes the morphology of the 
Adenomatous tissue as tubular. 
Tubulovillous The pathologist describes the morphology of the 
Adenomatous tissue as tubulovillous. A polyp with both 
tubular and villous morphology is considered tubulovillous.  
Villous The pathologist describes the morphology of the 
Adenomatous tissue as villous. 
Not to be confused with villiform mucosa. 
Histology Adenoma Pathologist specifies adenoma / Adenomatous polyp. Benign 
dysplastic colonic tumour. Can progress to become 
malignant. 
Amyloid Insoluble fibrous protein aggregates.  
Angiodysplasia Vascular malformation in the gut which can often cause 
bleeding into the colon. 
Ca+adenoma Carcinoma / cancer / malignant / invasive cell types, seen to 
be arising from an adenoma or when a cancer diagnosis also 
includes adenomatous material. 
Ca+mixed Carcinoma / cancer / malignant / invasive cell types, seen to 
be arising from a mixed polyp or adenoma 
Ca+serrated  Carcinoma / cancer / malignant / invasive cell types, seen to 
be arising from a serrated polyp or adenoma 
Ca in dispute If a pathologist cannot confidently confirm cancer / 
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malignancy / level of invasion in an adenoma or cannot 
decide between an adenoma or cancer. 
Cancer query If a pathologist mention or suspects but is not able to confirm 
a diagnosis of cancer / malignancy 
Cancer Malignant neoplasm / adenocarcinoma / carcinoma/ 
malignancy / invasion  
Note – if Cancer is diagnosed at the 1st exam – see  page 3 – 
Exclusion Reasons 
Cap polyp  Inflammatory polyp with a ‘cap’ of debris or granulation 
tissue. 
Carcinoid/neuroendocrine 
tumour 
Tumour originating from the neuroendocrine system. 
Colitis Chronic bowel disease characterised by inflammation of the 
colon. Only to be used if colitis is specified, there is a 
separate option for generalised inflammation.  
Note – if Crohns is diagnosed – see  page 3 – Exclusion 
Reasons 
Congestion Mucosal cells appear congested. 
Crohn’s disease An autoimmune inflammatory disease that can affect any part 
of the gastrointestinal tract  
Note – if Crohns is diagnosed – see  page 3 – Exclusion 
Reasons 
Fibroepithelial polyp Benign cutaneous lesion / skin tag. ‘Polypiod fibrous 
nodules’ can also be coded as this. 
Ganglioneuromatosis Tumours arising from the nervous system. 
Gastric heterotopia Normal gastric mucosa seen elsewhere in the body. 
GIST Gastro Intestinal Stromal Tumour 
Granulation tissue Tissue that replaces fibrin clots during the healing of tissue. 
Haemangioma Benign noncancerous tumour composed of rapidly 
proliferating blood vessels. 
Hamartomatous polyp Benign mucosal polyps usually found in the jejunum and 
ileum (small bowel). 
Inflammation Generalised inflammation of mucosa. 
Inflammatory  Inflammatory polyp. 
Ischaemia Restriction of blood supply. 
Juvenile polyp Rare form of large bowel polyp. AKA retention polyp. 
Leiomyoma Benign neoplasm of smooth muscle. 
Lipoma Benign tumour composed of fatty tissue. 
Lymphangiectasia Intestinal disease characterised by lymphatic dilation. 
Lymphoid polyp Benign polyps occurring where lymphoid follicles are present 
in the colon. 
Melanosis coli Pigmentation of the wall of the colon, not associated with any 
disease pathway. 
Metaplastic/Hyperplastic Benign non-dysplastic polyps with lengthening and cystic 
dilation of mucosal glands. Hyperplastic and Metaplastic are 
synonymous with each other. 
 
“Hyperplastic areas” may also be coded this way. 
Metastases from another 
site 
Malignant material that is not from a primary bowel cancer 
and originates from a cancer somewhere else in the body. 
Mets/tumour infiltrating Malignant material that is infiltrating into the colon from a 
tumour outside the colon (if unsure use ‘Mets from another 
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site’) 
Mixed 
adenoma/metaplastic 
Polyp displaying characteristics of an adenoma and those of a 
metaplastic polyp. This is rare. 
Mucosal prolapsed Slippage of mucosa. 
Neurofibromatosis Genetically inherited disease where nerve fibres grow 
tumours. 
Non-Hodgkins 
Lymphoma 
(NHL) A diverse group of blood cancers that include any 
kind of lymphoma except Hodgkin’s lymphomas.  
Normal mucosa Specimen shows no signs of a polyp and levels of 
dysplasia/atypia are within normal limits. 
Not possible to diagnose The polyp sample is too small or too damaged on removal to 
reliably diagnose the specimen. 
Oedema Swelling due to accumulation of fluids. 
Previous polypectomy site  Appears to be tissue from the site where a previous polyp was 
removed. 
Proctitis Inflammation of the lining of the anus and rectum. 
Pseudolipomatus Artifactual microscopic change in tissues that resembles fatty 
infiltration. 
Regenerative polyp Hyperplastic polyp of the gastric mucosa. 
Sarcoma Cancerous tumour of soft tissue 
Serrated adenoma Benign dysplastic colonic tumour which has a serrated 
appearance under the microscope. 
Specimen not seen No evidence of a specimen in the pot received at pathology. 
Spirochaetosis  A type of bacterial infection of the colon. 
Squamous cell carcinoma Skin Cancer normally found in the anus, but may be reported 
as rectal. Code as squamous cell carcinoma. 
Submucosal haematoma Result of bleeding outside of the blood vessels.  
Ulcer A break in the lining of the digestive tract that fails to heal 
naturally. 
Unicryptal adenoma Very early beginning of adenoma growth. 
Xanthoma Fatty deposits under the skin or mucosa causing yellow 
bumps. 
Exc 
Complete 
Complete Pathologist has specified that the polyp appears completely 
excised. 
Incomplete Pathologist has specified that the polyp appears to be 
incompletely excised. 
Uncertain The pathologist is unsure about the completeness of excision 
or the extent of excision cannot be accessed. 
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Phantom Endoscopy SOP 
(Ann Thomson 8/9/2010) 
Overview 
  
Unlinked Pathology 
Shows a list of patients 
with unlinked pathology. 
In most cases these 
patients will have already 
been analysed 
Unlinked Path 
Query 
Shows all the Unlinked 
Pathology Patients that 
you have queried 
Phantom Endoscopy 
Present 
Shows a list of patients for 
whom you have created 
phantom endoscopies. A 
patient will only appear here 
once you have created 
phantom endoscopies for all 
of the unlinked pathology. If 
you leave any unlinked 
pathologies un-queried, un-
excluded and without a 
phantom endoscopy, it will 
remain in the Unlinked 
Pathology list 
Note  
Patients may appear more than once across different lists.  For example, if you query a patient and create 
phantom endoscopies for all the available unlinked pathology, the patient will appear in both the Unlinked 
Pathology Query list and the Phantom Endoscopy Present list 
Unlinked Path 
Exclude 
Shows all the Unlinked 
Pathology Patients for 
which you have 
excluded unlinked 
pathology reports 
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Flow Chart 
 
 
 
 
 
 
   
  
  
 
   
 
 
 
 
 
Create 
Code Phantom Polyps 
Add Row 
Save Save 
Save 
Submit 
Apply Changes 
Apply Changes 
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Patient Screen 
 
! After adding phantom reports for all of the Pathology List Unlinked records be sure to check if any 
resections or cancers coded have occurred at first exam.  
! Make sure that the unlinked pathology is not supposed to be linked to any of the present endoscopy 
exams. Link the reports if both of the following criteria are predominantly fulfilled; 
 The collection dates from the Pathology List Unlinked correspond to the procedure date from the 
Endoscopy List (uncoded or coded), (see red arrows)* 
 Endoscopy fields – Polyp Segment, Size and Shape –correspond with the Segment, Size and 
Shape in Pathology.  
If uncertain go into the unlinked pathology report and select ‘Possible Link’ from the Query drop 
down option. 
 
* The dates can sometimes be up to 2 weeks apart. To be safe – if the dates are within a month of each other, 
always check for other indicators that the reports should be linked.  
 
To Link Reports 
 
 
 
Once you have submitted, go into the report via the endoscopy exam and code as normal. For more 
information on Polyp Linking see the Coding Application SOP (page 11). 
 
 
Note: If you have linked an unlinked report, a phantom report does not need to be created. 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
364
Unlinked Pathology Screen 
 
Possible Issues in this screen 
 
Issue Ways of Identifying the Issue Solution 
Pathology is 
from outside of 
the Large 
Bowel 
 
Use the information from the all the 
fields on the screen to check that the 
report refers to a biopsy from the large 
bowel, if uncertain see issue below 
If the report only refers to a biopsy from outside of the
large bowel then select Not Relevant Pathology from 
the Excluded drop down option and save* 
 
Uncertain 
Biopsy Origin 
 
The report does not specify location but 
it may have come from the large bowel 
(if it contains ‘tubular’ or ‘villous’  
adenoma’s or metaplastic/hyperplastic 
polyps then code as if from general 
bowel, segment unknown) 
Select Uncertain Biopsy Origin from the Query drop 
down option and save* 
The Report is 
Blank 
All of the fields will be completely 
empty  
Select Blank Pathology from the Query drop down 
option and save 
Truncated Text  If the report is truncated it will often 
stop abruptly in the middle of a 
sentence. It may sometimes be clear 
Code any relevant information available. Select 
Truncated Report from the Query drop down option 
and save 
Report 
Describes 
Normal 
Mucosa 
 Tick the ‘normal mucosa’ box then create a phantom 
endoscopy but leave it blank (do not add a polyp row)
 
 
* Remember to check the whole report as sometimes biopsies from the large bowel are included in reports 
for biopsies from the duodenum, in this case, code the information from the large bowel biopsies and ignore 
the biopsies from elsewhere. 
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Checklist 1: Unlinked Pathology Endo Coding Screen 
 
 Fill in any relevant information from the Report, Comments, Microscopic Description, Specimen, 
Clinical History, Specimen Type and Conclusion text boxes into the following fields: 
Procedure Type – Type of procedure used to investigate the colon 
Segment Reached – the segment of the large bowel which was reached by the endoscope 
Distance Reached – the distance reached by the endoscope in cm.  
Bowel Prep – quality of bowel cleansing prior to the exam 
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Checklist 2: Unlinked Pathology Endo Coding Screen 
 
 Check that any indications in the report have been coded in the far right hand box labelled ‘Indications’  
If indications need to be added/amended:  
 
 
 
 
 Check that any Diagnoses in the report have been coded by looking at the right hand column under 
‘Diagnosis’ 
If diagnoses need to be added/amended:  
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Checklist 3: Phantom Polyp Coding Screen 
 
How to add a Polyp Row 
 
 
 
The polyp row will show both endoscopy fields and pathology fields, separated by colour.  
 
 
 
Note that Polyp rows should only be added if the histology is for a cancer, polyp, adenoma or mentions 
dysplasia. Any other histology should just have a blank phantom endoscopy created without a polyp row. 
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Review SOP 
(Ann Thomson) 
 
1. How to set up a review 
  
 
1. Select the Review Tab 
at the top of the screen 
2. Select Set Review Patients  
4. Select the following; 
a) A hospital 
b) An individual coder OR all coders 
c) The number of days 
d) The number of records to be reviewed 
3. If a review is already set, check 
that all the coders have finished with 
the current review, then select Reset 
Review 
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2. Review Application  
 
In the Review tab of the coding application you will find a list of records to be reviewed. 
Once you have selected the record you will be able to view all the pathology, endoscopy and polyp details in 
the Patient Details screen.  
You can see if a patient has been excluded. If they have been excluded, check that the exclusion reason is 
valid.  
Note; if a patient is excluded, the coder may not have coded all available information. As long as the 
exclusion reason is valid, this is acceptable. 
1. View a patient from the list 
by selecting a Study Number 
Any comments you make will appear here 
2. View an endoscopy record by 
selecting an Endo ID 
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In the Endoscopy Overview screen you can view the endoscopy report and all coded information from 
endoscopy. 
 Things to check in this screen;  
 Has the record been queried?  If so, is the query appropriate? 
 Has all the appropriate endoscopy and pathology polyp information been added? 
 Have all the appropriate Indications and Diagnosis been entered? 
 Has the Bowel Prep been entered correctly? 
 
* Every record that has been reviewed needs a comment. Select ADD ROW and add any relevant 
comments, making sure that the coder will understand what needs to be amended. If the record is completely 
correct then write ‘ok’. 
 
3. Categorising the Errors 
 
Using the document Review Errors – Definitions and Examples (Appendix A) reviewers are able to 
categorise any errors found into Minor, Moderate and Major Errors. This may not be necessary for every 
review. 
 
 
 
 
 
 
 
3. Select Add Row and enter comments*
4. Select Submit to exit the 
record and go back to the Patient 
Details screen 
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Appendix A 
Review Errors –Definitions and Examples 
Minor Errors   
(Should be no more than 5/40 per review) 
These are errors which inevitably occur in the data due to human error; this cannot be avoided, but should 
be kept to a minimum. 
  
 Missed Specimen Sizes – individually this is minor (less than 3 per review) 
 Missed polyp Distance 
 Missing/Incorrect Excision Extent/Retrieval information – individually this is minor (less than 3 per 
review) 
 Indication/Diagnosis Missed – where the information buried in the text of additional fields, or is 
unclear/not obvious  
 Individual (1 per review) Keyboard/Mouse errors – where the coder has hit the wrong button 
accidentally. This will be hard to identify, however, in some instances it is obvious, i.e. when 
Metaplastic has been coded as Metastases from another Site. 
Moderate Errors  
(Should be no more than 3/40 per review)  
These are errors due to carelessness and inaccuracy. They will occur, but must be flagged and corrected. 
Once they have been pointed out, the coder should try and ensure they do not repeat the same type of error. 
 
 Indication/Diagnosis Missed – where the information is within the main report field or is clear and 
obvious 
 Missing/Incorrect polyp Segment coded 
  Consistent (1 or more per review) Keyboard/Mouse errors 
 Missing/Incorrect Excision Extent/Retrieval information – consistently (3 or more per review) 
 Incorrect Polyp Matching – where pathology has been assigned to the wrong polyp row - when it is 
not definitively clear, (in cases where it is very unclear see Interpretation Issues)  
 Missed Specimen Sizes – consistently (3 or more per review) 
 Incorrect/Missing histopathology assigned to a polyp row – when the information is unclear 
Major Errors  
(Should be no more than 1/40 per review) 
These are errors due to inattention, misinterpretation and misunderstanding. Once they have been discussed 
and re-explained, they should not occur again. 
 
 Missed Lesions(no polyp row added when required) – either at Endoscopy or Pathology 
 Incorrect/Missing histopathology assigned to a polyp row – when the information is evidently clear 
 Exam not excluded when required 
 Exam not queried when required 
 Pathology assigned to the wrong polyp row - when it is evidently clear 
Interpretation Issues 
 
There will also be some errors which are hard to interpret. For example, the histology of an adenoma may be 
ambiguously described, where one coder might interpret the information differently from another. Unless 
there are rules or a protocol for these instances, we cannot necessarily identify these as genuine errors. They 
should be counted as Interpretation Issues and be discussed with the coder to ensure the issue is not one of 
miss-understanding.  
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Polyposis and Colitis Reclassification Review SOP 
(Amy Brenner 5/14/2012) 
Contents 
 
• Incident 196 – Polyposis Review  
• Incident 197 – Colitis Review  
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
373
Incident 196 – Polyposis Review  
It was decided that a new method should be used to code polyposis. Firstly, polyposis should ONLY be 
coded as a diagnosis if the presence of polyposis is explicitly stated by the endoscopist or pathologist. 
Secondly, polyposis should be reclassified into more specific definitions. Consequently, a new section has 
been developed for coding a diagnosis of polyposis so that the coders can select sub-options for this 
diagnosis type. The following new polyposis sub-type options have been added: 
• Confirmed Polyposis – Definite polyposis  
• Rule out Polyposis – Endoscopist/pathologist suggests that polyposis should be ruled out 
• FAP - Presence of multiple adenomas 
• Juvenile Polyposis - Presence of juvenile polyps 
• PJ Polyposis - Presence of PJ-type (hamartomatous) polyps. Peutz-Jeghers syndrome (PJS) 
• Hyperplastic Polyposis - Presence of multiple hyperplastic polyps 
• Possible polyposis - Possible polyposis (of a certain type(s)) 
• Serrated polyposis - Presence of multiple serrated polyps 
• Lymphoid polyposis - Presence of multiple lymphoid polyps 
• Cap polyposis - Presence of multiple cap polyps 
• Other Polyposis 1 - Spare1 
• Other Polyposis 2 - Spare2 
 
The indications field has also been updated to allow coders to add a specific subtype. All subtype options 
aside from ‘confirmed’, ‘rule out’ and ‘possible’ have been included.  
If the endoscopist/pathologist clearly states that a patient has polyposis then the coder should add a row for 
‘Polyposis’ in the diagnosis field and click save. As soon as this happens the relevant sub-options will 
appear. The drop-down menu ‘Polyposis Status’ enables the coder to add either ‘Confirmed polyposis’ or 
‘Rule our polyposis’ (blue arrow), while a ‘Possible polyposis’ tick box allows the coder to show that 
polyposis is uncertain (green arrow). The other tick boxes let the coder to define what type(s) of polyposis 
was diagnosed or indicated. There are 2 spare checkboxes - Other Polyposis 1 and Other Polyposis 2. These 
will be used if the database administrator is not available. Coders will decide what the checkbox will be and 
the database administrator should be informed and will change the name when possible.  
Records not selected for review within incident 196 group A and B (either excluded for Family Hx FAP, 
FAP or P-J Polyposis or Polyposis) were put in groups C and D respectively to be reviewed. 
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 On the Diagnosis section above a ‘Save’ button was created. This will do exactly as the ‘Submit’ button 
does but the user will remain on this screen instead of going back to the Endoscopy screen.  
Please note: 
 If polyposis has been added as a diagnosis based on the previous rule using polyp numbers, then 
polyposis should be removed as well as any polyposis exclusions.  
 
 The sub-options must be saved using the ‘Update polyposis details’ button (red arrow). If you use the 
main ‘Save’ or ‘Submit’ buttons against the Diagnosis it will not save the sub-options (see notes in 
red as reminders). If you select ‘Polyposis’ in the Diagnosis and click delete, it will automatically 
delete all the sub-options.  
 
 The diagnosis ‘FAP’ should not be used anymore. Polyposis should be added as a diagnosis and then 
the sub-type ‘FAP’ should be selected. The ‘FAP’ diagnosis will be removed once cleaning is 
complete. 
 
 If polyposis is diagnosed at multiple exams, the coder should only review and add ‘confirmed’ and 
the polyposis subtype for the first exam encountered where a subtype of the condition is confirmed. 
This will then be used as a marker for the patient. If the polyposis is not confirmed and only 
‘possible’ or no subtype is mentioned then coders will still review and code all records until a 
specific subtype is confirmed. 
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Incident 197 – Colitis Review 
It was decided that colitis should be reclassified into more specific definitions. Similarly, a section has been 
developed for coding a diagnosis of colitis so that the coders can select sub-options for this diagnosis type. 
The following new colitis sub-type options have been added: 
• Confirmed Colitis - Inflammation of the colon 
• Rule out Colitis – Endoscopist/pathologist suggests that colitis should be ruled out 
• Ulcerative Colitis - Chronic form of IBD characterized by ulceration of the colon and rectum 
• Ulcerative Proctitis – Ulcerative colitis confined to the rectum 
• Microscopic Colitis - Refers to both collagenous colitis and lymphocytic colitis, characterized by 
increase in inflammatory cells 
• Lymphocytic Colitis - Subtype of microscopic colitis, characterized by chronic non-bloody watery 
diarrhea and an accumulation of lymphocytes in the colonic mucosa and lamina propria 
• Collagenous Colitis - Subtype of microscopic colitis, characterized by chronic watery diarrhea, rectal 
bleeding and deposition of collagen in the lamina propria 
• Ischemic Colitis - Inflammation and injury of the colon as a result of inadequate blood supply 
• Diversion Colitis - Inflammation in a nonfunctioning colonic pouch occuring as a complication of 
ileostomy or colostomy, often within the year following the surgery 
• Infective Colitis - Inflammation of the colon caused by bacterial or viral infection, commonly due to 
Clostridium difficile 
• Chemical Colitis - Inflammation of the colon caused by the introduction of harsh chemicals by an 
enema or other procedure 
• Pseudomembranous Colitis - Subtype of infectious colitis, characterized by the formation of 
pseudomembranes 
• Drug-Induced Colitis - Inflammation of the colon as a result of treatment with various types of drug 
e.g. NSAIDs, anticoagulants, SSRIs 
• Radiation Colitis - Inflammation and damage of the colon as a result of exposue to x-rays or 
radiation, commonly occurs after radiation therapy for cancer 
• Procedural/Enema related - Inflammation of the colon as a result of the endoscopic procedure 
• Possible Colitis - Possible colitis (of a certain type(s)) 
• Other Colitis 1 
• Other Colitis 2 
The indications field has also been updated to allow coders to add a specific subtype. All subtype options 
aside from ‘confirmed’, ‘rule out’ and ‘possible’ have been included.  
If a patient has colitis then the coder should add a row for ‘Colitis’ in the diagnosis field and click save. As 
soon as this happens the relevant sub-options will appear. The drop-down menu ‘Colitis Status’ enables the 
coder to add either ‘Confirmed colitis or ‘Rule out colitis (blue arrow). The tick boxes allow the coder to 
define what type(s) of colitis was diagnosed or indicated. 
There are 2 spare checkboxes - Other Colitis 1 and Other Colitis 2. These will be used if the database 
administrator is not available. Coders will decide what the checkbox will be and the database administrator 
should be informed and will change the name when possible.  
NB: The sub-options must be saved using the ‘Update colitis details’ button (red arrow). If you use the main 
‘Save’ or ‘Submit’ buttons against the Diagnosis it will not save the sub-options (see notes in red as 
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reminders). If you select ‘colitis in the Diagnosis and click delete, it will automatically delete all the sub-
options. 
 
       
 
A new option called ‘Possible Crohns’ has also been added to the Diagnosis drop down to cover all possible 
eventualities for IBD. Suspected IBD will be used as an umbrella term for cases in which IBD cannot be 
confirmed. 
 
NB - If colitis is diagnosed at multiple exams, the coder should only review and add ‘confirmed’ and the 
colitis subtype for the first exam encountered where a subtype of the condition is confirmed. This will then 
be used as a marker for the patient. If colitis is not confirmed and only ‘possible’ or no subtype is mentioned 
then coders will still review and code all records until a specific subtype is confirmed. 
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RULES FOR BOTH POLYPOSIS AND COLITIS: 
 
1) In some cases colitis/polyposis may be confirmed but the subtype may be unclear (a number of 
possibilities might be suggested). The coded should make sure the patient has two or more 
appropriate diagnosis subtypes coded and they should also have BOTH 'confirmed' and 'possible’ 
checked. 
 
2) If coders select one or more subtypes then the coder MUST also select either 'confirmed', 'rule out' or 
'possible'. 
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Exam Numbering and Multiple Row Review SOP 
(Amy Brenner) 
Contents 
 
• Incident 154 – Exam Numbering 
• Incident 138 – Multiple Rows  
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Incident 154 – Exam Numbering 
In two instances exam numbering is needed to clarify the order in which exams took place: 
• Group A - Ranking endoscopies without a date (use’ exam ranking’ field) 
• Group B - Ranking multiple exams on the same date (use ‘exam number’ field) 
 
 
On the patient details page an ‘Exam Numbering button’ is displayed above un-coded and coded 
endoscopies. These buttons will only appear where the patient is part of Incident 154. 
 
When you click the exam numbering button it takes you to the exam numbering screen. This screen will 
display all the procedures for the patient with the additional fields ‘exam number’, ‘exam ranking’, ‘exam 
number/rank unknown’ and ‘reason exam same day’.  
The ‘reason exam on the same day’ is a drop down menu and includes these options: 
 Emergency Surgery  
 1st Procedure Abandoned 
 1st Procedure Incomplete 
 This exam may not belong to this patient 
 Follow-on exam 
 Same procedure 
The ‘exam number/rank unknown’ is a drop down menu with one option of ‘Could not rank’, which should 
be used when you are unable to number/rank an exam.  
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 The exams are broken down by derived procedure date so that you can clearly see exams that happened on 
the same day. The derived procedure date displays the endoscopy procedure date. When that is not available 
it derives the date from the various dates recorded against pathology, such as collection date, report date, 
received date etc. These individual dates can still be seen in the related pathology report. 
When you click on an endoscopy, that record will be highlighted and the endoscopy, pathology and polyp 
details for the selected record will be displayed below. This information should be used to determine the 
order in which the exams took place. 
 
 
 
NB - When ranking exams with no date use the ‘Exam ranking’ field, whilst exams on the same day should 
be numbered using the ‘Exam number’ field. 
 For Group A (exam with no date) ALL of the exams should be ranked using the ‘Exam ranking’ 
field. 
 For Group B (multiple exams on same date) only the exams with the same date should be numbered 
using the ‘Exam number’ field. 
 For Group B, in cases where it is not possible to ascertain the order of all exams the coder should try 
to give an indication of where an exam with no date goes by ranking whichever exams you can. 
 No exams should be given the same number. 
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 The ‘reason exam on the same day’ field should be applied to the subsequent exam EXCEPT for the 
reason ‘This exam may not belong to this patient’ which should be applied to the exam that appears 
to be incorrect. 
 For exams that cannot be numbered the ‘exam number unknown’ field should be applied. 
 
If exams on the same day are found to be duplicates that have been missed previously, coders should mark 
the appropriate record with an application coding error – duplicate endoscopy query and tick the re-query 
box. 
Once all exams have been numbered click the ‘Submit’ button to save this information and then mark the 
incident as complete on the patient details screen.  
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Incident 138 – Multiple Polyp Rows 
 
Previously it was not possible to code specific quantities or clinical histology (seen at endoscopy) details for 
multiple rows (polyp rows with the ‘quantity other’ field coded). All records with multiple rows are being 
reviewed to insure that no important information has been overlooked. There are 2 groups here as shown 
below: 
• Group A - No multi-linked polyps 
• Group B - Multi-linked polyps 
 
 
 
 
On the patient details screen in the data cleaning section, columns called ‘polyp id’ and ‘endo id’ will appear 
against all ‘Data Cleaning – Endoscopies’ tasks and will be populated with a polyp_id/endo_id that coders 
may use to directly access certain screens. If you click on the endo_id, it takes you to the endoscopy. If you 
click on the polyp_id, it takes you to the polyp details screen.  
To review multiple row details coders should go to the polyp details screen where endoscopy, pathology and 
other polyp rows will be shown above and below the multiple row polyp information. The details of any 
multi-linked polyps will also be shown (group B).  
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 Coders should browse the endoscopy and pathology details for anything that may provide information for 
the following fields: 
• clinical histology – histology described at endoscopy i.e. ‘appears to have multiple adenomas’ 
• approximate quantity – the approximate number of polyps 
• maximum quantity – the maximum possible number of polyps 
• minimum quantity – the minimum possible number of polyps 
• no. fragments – the number of relevant fragments of adenoma or polyp seen at pathology 
 If any of this information is available it should be coded into the new fields provided in the polyp details 
screen (see red arrows). 
What information to look for: 
 Information from previous and subsequent exams may be used if appropriate 
e.g. previous exam states ‘ 3 polyps not excised’, current exam says ‘multiple polyps’ at endoscopy 
then goes on to describe 3 polyps at pathology, assume that the ‘approximate number’ of polyps is 3. 
 
 If present at pathology, biopsy sample indicators can be used for ‘approx quantity’  
e.g. ‘’….presence of several tubular adenomas with low grade dysplasia (A16, A17, A18, A20)’’ = 4 
       ‘’… multiple hyperplastic polyps in the rectum (A1, A2 and A5)’’ = 3 
 
 If pathology describes individual polyps count them and use this as the ‘minimum number’ 
 
 
Dealing with fragments: 
If pathology describes a specific number of tissue fragments... 
 
 and all of them are found to be adenomas or polyps, give the original fragment number in the ‘no. 
fragments’ field 
 
 and a particular number of them are found to be adenomas or polyps, give this number in the ‘no. 
fragments’ field 
 
 and it only specifies that some/a number of/a few etc. are found to be adenomas or polyps, assume 
that at least 2 fragments must be normal mucosa. Subtract 2 from the original fragment number and 
put this in the ‘no. fragments’ field 
NB - Multiple rows coded in unlinked pathologies do NOT have a ‘multi-link’ field so any related polyps 
will not be displayed as multi-linked polyps. Thus these should not be included in the ‘approx. quantity’. 
Any changes should be saved using the ‘Apply changes’ button, then the incident should be marked as 
completed on the patient screen. 
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Summary of Changes to Coding Documents 
(Aug 2009) 
 
Listed below is a summary of each of the major documents the coders use and the changes that have been 
made since the last published (major) version. Please make yourselves aware of these changes in the SOP. 
 
List of changes to SOP: 
 
Summary of change Section Page 
Added a section about what to do if the endoscopist 
describes “possible polyps” 
 
Endoscopy overview 
scenarios 
7 
Updated screen shot 
Changed the field ‘piecemeal’ to ‘piece’ 
Added a description of the new ‘No Info’ field 
 
Checklist 2 8 
Updated screen shot 
Changed the field ‘piecemeal’ to ‘piece’ 
Added a description of the new ‘Multi Link’ field 
 
Checklist 3 10 
In the second scenario down, more information has been 
added about use of the Multi Link menu and what to do 
when you have an unspecified number of polyps with a 
range of dysplasia levels 
 
Edit polyp pathology 
scenarios 
11 
Updated screen shot 
Explanation of the ‘Requery’ option 
 
How to query a record 13 & 14 
Explanation about Anal cancer added  Top Tips 14 
 
List of changes to Coders reference document: 
Summary of change Section Page 
Change of name to ‘Coders reference document’ this 
was due to the fact I have now incorporated all fields 
with an explanation of how to use them. This is no longer 
just drop down menus 
 
Title Page  
Added definitions of distal, mid and proximal to the 
segment reached field information 
 
Added ‘distance reached’ and ‘comments’ fields with 
information on how to fill these in 
 
Endoscopy overview screen 3 & 4 
Definitions and appropriate use of: 
Colonic obstruction 
Endoscopy indications screen 5 & 6 
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
387
Family history of cancer 
Fissure 
IBD 
Ulcers have been added to the list 
 
Definitions and appropriate use of: 
Colonic obstruction 
FAP 
Fissure 
IBD 
Polyposis 
Suspected IBD 
Strictures 
Ulcers have been added to the list 
 
Endoscopy diagnosis screen 7 & 8 
Added ‘size (mm)’, ‘Piece’ and ‘no info’ fields with 
information on how to fill these in 
 
Added definitions of distal, mid and proximal to the 
segment reached field information 
 
 
Add/Edit polyp screen 9 & 10 
Added definition of ‘metastases from another site’ to the 
histology drop down menu. 
 
Added ‘size (mm)’, ‘Piece’ and ‘Multi Link’ fields with 
information on how to fill these in 
 
 
Edit polyp pathology screen 12 
 
List of changes to Exclusion SOP: 
 
Summary of change Section Page 
2 additional terms were added to aid the identification of 
possible HNPCC 
 
Inflammatory Bowel disease (IBD) and its definition was 
added to the exclusion criteria 
Exclusion if found at ANY 
EXAM 
1 
Additional term added to aid the identification of 
possible resection 
 
Definition of cancer was extended and clarified in 
further detail. 
Exclusion if found at FIRST 
EXAM 
2 
Cancers that do not originate from the colon should 
NOT be excluded at first exam 
Exclusion if found at FIRST 
EXAM 
2 
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Summary of Changes to Coding Documents 
(Sept 2009) 
 
Listed below is a summary of each of the major documents the coders use and the changes that have been 
made since the last published (major) version. Please make yourselves aware of these changes in the SOP. 
 
List of changes to SOP: 
 
Summary of change Section Page 
Updated. 
 
Contents 2 
Included the exclude function in the description of the 
patient details screen. 
 
Database Overview 3 
Updated the screen shot and description of the screens 
content to include the exclude function. 
 
Patient Details Screen 5 
Added clarification criteria to the pathology missing 
query. 
 
How to Query a Record 13 
Re-defined when to use query exclude vs. excluding 
patient. 
 
How to Query a Record 13 
Added a new section to explain the exclusion process for 
a patient using the patient status box. 
How to Exclude a Patient 14 
 
List of changes to Coders reference document: 
 
Summary of change Section Page 
I have added this new section which explains the data 
entry features for the patient status box which allows 
coders to exclude patients. 
 
Patient Details Screen 
(patient status box) 
3 
In the section referring to segment I have clarified when 
you can make the assumption that the endoscopist is 
talking about the ascending colon. 
 
Add/Edit Polyp Screen 10 
In the section referring to excision method I have 
clarified when to code this as APC. 
 
Add/Edit Polyp Screen 10 
In the section referring to size of polyp and max size of 
polyp I have clarified which to use when you get an exact 
size and a size range for a polyp and which numbers to 
insert.  
 
Add/Edit Polyp Screen 10 
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In the section about queries I have added some helpful 
criteria to help you decided if it should be flagged up as 
pathology missing – e.g. if it is a large polyp etc. 
Endoscopy Overview Screen 4-5 
 
List of changes to Exclusion SOP: 
 
Summary of change Section Page 
Clarified when and when not to exclude different types 
of cancers: 
 Cancers elsewhere in the body 
 Ca+adenomas 
 
Exclusion if found at FIRST 
EXAM 
2 
Clarified when to exclude due to colitis and the 
differences between where you see it at endoscopy and 
pathology 
 
Exclusion if found at ANY 
EXAM 
1 
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Summary of Changes to Coding Documents 
(Oct 2009) 
 
Listed below is a summary of each of the major documents the coders use and the changes that have been 
made since the last published (major) version. Please make yourselves aware of these changes in the SOP. 
 
List of changes to SOP: 
 
Summary of change Section Page 
NONE.   
 
 
List of changes to Coders reference document: 
 
Summary of change Section Page 
Clarification of the Segment reached option. Complete/ 
Total ileo-colonoscopy and colonoscopy can assume to 
have reached terminal ileum and cecum respectively. 
 
Endoscopy Overview Screen 4 
It has been clarified under ‘Query Crohn’s’ and ‘Query 
Colitis’ that both should be added when ?IBD is listed in 
the indications summary. 
 
Endoscopy Indications 
Screen 
7 
Clarified the guidance for when to enter suspected IBD 
to the diagnosis or not. 
Endoscopy Diagnosis Screen 9 
 
List of changes to Exclusion SOP: 
 
Summary of change Section Page 
NONE.   
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Missing Pathology Collection SOP 
(Ann Thomson, 8/26/2010) 
Introduction 
When returning to hospitals to collect missing data, the following queries are used as criteria as to 
which records to search for. These queries will generate some false negatives, i.e. records where 
pathology was, in fact, not missing, but never existed. 
 
Missing Pathology Queries - ALL 
Endoscopy exams are queried as ‘Missing Pathology’ by a coder when there has clearly been a 
biopsy/excision of a polyp that is awaiting histology and does not appear to have a linked pathology 
report. Coders use following criteria to identify missing pathology: 
1. The endoscopy report specifically refers to sending the polyp sample to pathology/histology/labs 
2. Polyps that have been biopsied or if there is biopsy text relating to the section of the bowel that polyps 
were found. 
3. Polyps ≥10mm or Tumours/Cancers, even they haven’t been biopsied (unless the exam specifically 
states that they have not been removed or biopsied for some reason) 
Missing Pathology can be further categorised using one or more of the following fields; 
• Sent to lab/await pathology stated  
• Large polyp of >=10mm 
• Biopsy Indicator  
• Cancer/tumour indicated  
 
Application Coding Error Queries - ALL 
Coders use this option to indicate the following; 
• Blank pathology fields - when a pathology report has fields that contain no information 
• Truncated report - when either endoscopy or pathology reports seem to cut off mid sentence 
Coders also sometimes use this option when indicating that fields or drop-down menus will be changed at 
a later date by the database administrator and you will return at a later date to finish coding.  
General Queries – Supplemental Report Missing, When Cancer, When Resection 
There are a number of different categories of general query, when collecting missing data we are only 
concerned with three categories;  
• Supplemental endoscopy report(s) missing –when there is an indication that the patient has 
been referred for endoscopy in the near future e.g. when flexi-sig indicates that endoscopy would 
be appropriate or when procedure has been abandoned and a follow up colonoscopy is mentioned. 
• When cancer? –when it is not possible to work out when a mentioned cancer arose 
• When resection? –when an anastomosis or any of the terminology indicating resection e.g. neo-
terminal ileum is suddenly used 
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For Instructions on how to produce a list of missing pathology study numbers go to G:\IA\Missing 
Pathology – Setting up a Missing Pathology Access Database 
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Linking the Data  
Why do we need to link the data? 
 
The data is pseudo anonymised. In other words, the study numbers (which coders can see in the database) 
are created specifically for the Intermediate Adenoma study. These study numbers are linked to real patient 
and hospital information on a CD.  
To search for records on a pathology system you will need to use patient information. This means that the 
list of study numbers with missing pathology must be linked with the corresponding study numbers on the 
CD containing patient information.  
The CD 
 
IMPORTANT: The CD contains confidential patient information and must NOT be lost, destroyed or 
taken outside of the hospital. 
 
The CD is kept at the hospital and is password protected. Before you visit the hospital you must check the 
Data CD Storage document (SharePoint →Hospitals) and contact the person responsible for the CD. 
Organise for the CD to be available for collection the morning that you are due to visit the hospital, you will 
also need to return the CD at the end of the day. Make sure that you have the password for the CD on your 
visit. 
Note: There are 2 CD’s at each hospital, they are duplicates, it does not matter which CD you choose to 
collect. 
The Data CD Cover 
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CD Process Summary 
Formatting Data  
 
Once you have opened the Patient Linking file, you will be able to view an excel spreadsheet. This data 
needs to be in the same format as it is in the access database. Use the checklist below.  
 
 
 
 The field names are on Row 1 of the spreadsheet (in some cases there may be rows above the field 
names, delete these) 
 The field names are in the right order (as above) 
 The field names are named correctly (as above), for example Date of Birth will need to be changed 
to DOB 
Once you have formatted the spreadsheet, save and close it. 
Linking Data Summary  
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Follow these steps in order 
  
1. Select Options 
2. Select Enable Content 
3. Select OK 
4. Select External data 
5. Select Excel 
6. Browse for 
the Patient 
Linking file 
that you 
saved to your 
desktop 
7. Select Append 
into Patient table 
8. Select OK 
9. Over the next 2 screens – select 
Next, Next, Finish 
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Adding the Report to the Database 
The Database 
 
Now that you have created a list of patient’s with missing pathology  that is linked to patient information, 
Access will automatically create a database for you to enter the reports into.  
Before you open the database, it is helpful  to mark the duplicate patients in the system. These are patients 
that have more than one query. Follow the steps in the Missing_Pathology table below to mark the 
duplicates. 
 
 
 
1. Right Click on the 
STUDY_NUMBER field 
and select ‘Sort A – Z’ 
2. Scroll through the 
study numbers and 
search for duplicates 
3. Using the drop 
down menu in the 
Missing_Reason 
field mark the 
duplicated records 
as Duplicate. 
Remember to leave 
the first row for each
duplicated patient 
blank 
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You are now ready to copy and paste records into the database Select the Pathology Missing Form in the 
patient table and the screen (see below) will appear. 
 
! Remember that you have ordered the patients and marked the duplicates. Before you do anything in 
the database you should re-order the patients by name. To do this right click on the field ‘Surname’ 
and select ‘Sort A-Z’.  
 
 
 Patient Information  
The patient demographics for each endoscopy missing a pathology report will be displayed in these 
fields. You can use this information to search the hospital system for the patient’s records. 
 
 Endoscopy and Query Information  
These fields display information about the endoscopy report that has been queried as having a 
missing pathology, including the type of query and date of the procedure.  
 
 Pathology Report 
Copy and paste the appropriate pathology report into this field. Check the following; 
 
 The pathology collection/report date corresponds with the date of the procedure (i.e. they are 
roughly within one month of each other)  
Pathology 
Missing tab 
Pathology 
reports that are 
already on the 
database 
Copy the 
report into 
this field 
Patient 
Information 
Endoscopy 
and Query 
Information  
The date of the procedure 
which is missing a 
pathology report 
Enter any other 
reports you find 
for the patient 
here 
Use drop down to 
enter a reason if you
cannot find/enter the
report Next/Previous pathology 
missing record 
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 We do not already have the report (see the Pathology Reports We Already Have field) 
 The report is of a specimen from the Large Bowel (if in doubt and there are no other 
appropriate reports, then copy the report in anyway) 
 The report is from within the range of dates that we are collecting reports for. The only time 
we are interested in pathology outside of these dates is when it helps to solve a general query 
such as ‘when cancer’ or ‘suspected ibd’. In these cases if you find relevant information, do 
not copy the report but answer the query in the pathology box. 
 Missing Reason  
If you cannot find any appropriate report for this queried endoscopy, use the following options on 
this drop down field to give a reason; 
 
 No Patient on system – the patient could not be found on the system 
 No  Pathology Reports on System – the patient was found but there was no available pathology 
 Pathology Available but not for that date – other pathology from the large bowel was found 
 Irrelevant Pathology – the only available report is for a specimen from a site other than the 
large bowel 
 Already Have all Available Path – we already have all the relevant reports 
 Already Have Path For This Query – we already have the specific pathology 
 Duplicate – we have already coded all of this patients data in a previous record 
 Non-Colorectal Cancer Solves Query – use when non-relevant path solves query, write in notes 
box. 
 Relevant Path Falls Outside of Catchment Dates – as above, write in notes box (but do not 
copy report) 
 Other – see notes comment. 
  
 Other Reports 
A patient will most likely have more than one report. These ‘other reports’ may be useful and you 
should copy them into this field. Do this even when you have been unable to find the pathology that 
was originally queried as missing. Check that; 
 
 We do not already have the report (see the Pathology Reports We Already Have field) 
 The report is of a specimen from the Large Bowel (if in doubt and there are no other 
appropriate reports, then copy the report in anyway) 
 
In some cases there will be multiple ‘other reports’. You can add all of these to the Other Report 
field. Between each report you should leave a space and enter the text – ‘NEW REPORT’. 
 
Issues you might encounter 
 You may find that a ‘when cancer’ or ‘when resection’ query cannot be solved by any pathologies 
within the catchment years, but that a report outside of these dates provides a date at which cancer 
was confirmed or negated. In this case you should type in the relevant information (date of report, 
what was found i.e. cancer/no cancer, if it was removed) in the comments box.  You may simply 
write “no exams in or out of the catchment years show a diagnosis of cancer”. 
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 When one patient has more than one query, they will appear more than once in the database. To 
avoid extra, unnecessary work, you should copy and paste all the pathology for one patient into one 
record. Subsequent records for that patient can then be left blank. You should mark these subsequent 
records as ‘Duplicate’ in the missing reason drop down. It is possible to automatically mark duplicate 
patient records (see page 6), so that when you come across them it is obvious. REMEMBER – you 
must pay attention to the type of query in each duplicate record, the pathology report needed to solve 
a ‘when cancer’ or ‘when resection’ query may fall outside of the catchment years 
 You may come across pathology for normal mucosa. Provided you are sure that this pathology is 
from the large bowel copy and paste it into the database as normal. 
 If the sample is clearly from another hospital write in CAPS at the top of the report ‘FROM 
ANOTHER HOSP’. 
 
End of Visit Checklist 
It is VERY important that you complete the following checklist before leaving the hospital; 
 Run the Delete Patient Data query in the database. ONLY do this when you have completed your 
visit and processed all the missing pathology queries.  A window will pop up to ensure you want to 
delete the patient information. 
 
 Copy the database file to the usb drive (if pass worded this is same as laptop) 
 Delete the Patient Linking File from your desktop 
 Delete ANY files with patient information on them 
 If you have been using the laptop be sure to delete any files with patient information on 
 Once you have deleted these files, make sure that you clear the recycling bin 
 Return the CD to the person you originally retrieved it from and ensure that they will put it into the 
same place as before (you may wish to do this before the end of the visit, after you have linked the 
data) 
 Delete/Destroy your note of the CD password 
 
 
 
 
Delete Patient Data 
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Passwords 
 
CD  You will be given this before you make a 
visit. Keep the password safe and destroy it 
at the end of your visit. You may want to 
store the password on your phone as this 
will be harder to lose 
SafeStick   
Laptop   
Zip-File   
Access Database   
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Visit Checklist 
 
Things to check before confirming the visit: 
 Access – you will need access to the hospital server and the pathology system 
 
 Some centres will have past pathology systems. Check if the data we require (i.e. data from 
the catchment years for the original data extract*) is all on one system. If it is not, check that 
you can gain access to the current AND older system(s) 
 
 Check with the hospital staff which version of Microsoft Office is used – 2000, 2003 or 2007. 
If it is 2000, inform Ann asap. 
 
Before you go on each hospital visit please check the following lists to ensure that you have 
everything you need: 
 Memory Stick, containing; 
o Access database (specific to the hospital you are visiting)    
 Missing Pathology SOP 
 Contact details of the person you will be meeting 
 Map of the hospital or instructions on how to find Pathology   
 Mobile phone 
 Catchment years for original data extract 
 CD Password 
 Arranged to have a user name and login for the hospital server 
 Honorary Contract 
 Lap Top  
CD Drive for the Lap Top 
* Catchment years for the original data extract; the data that was originally collected from the hospital will have a from 
and to date e.g. data for Brighton hospital ranges from 2001 – 2008 (inclusive). This is important to note, as we do not 
want to collect pathology from outside of these dates. Ask Ann for these dates. 
E
SSE
N
T
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Missing Pathology Coding SOP 
(Amy Brenner, 8/15/2011) 
Coding Missing Pathology Reports 
A number of new pathology reports were collected during hospital visits that were undertaken to 
resolve coding queries (missing pathology, exclude, application coding error and general queries). 
As a result, some patient records have new, previously missing pathology reports that need to be 
coded. The following method should be used when dealing with these records.  
 
Identifying Records with New Pathology 
Patients with new pathology reports will be flagged with a ‘Y’ in the Manual Path column as shown 
below. 
 
For each centre, the following queries should be checked in order to find new pathology reports: 
• Pathology Missing 
• Application Coding Error 
• Exclude (except for Brighton) 
• General (Possible Cancer, When Cancer, When Resection, Supplemental Report 
Missing)  
• It is probably easier to go over all General queries rather than try and find specific 
ones.  
In cases where new pathology was automatically collected from hospital databases as opposed to 
being manually collected, you can identify the records with new pathology by looking at the ‘Upload 
Details’ on the centre screen, which will show NPH (see red arrow).  
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Using New Pathology to Solve Queries 
The majority of the queries listed above will be solved by the new pathology so pay attention to the 
specific query type.  Bear the query in mind when reading the new pathology report and aim to solve 
it. However, in some cases there will be no new pathology... 
When a report is queried as pathology missing but no relevant pathology was retrieved: 
1) Re-query the report as pathology missing if: 
 The polyp was sent to labs 
 The endoscopist mentions awaiting histology 
 There are relevant details in the biopsy indicator box 
 Cancer/resection is indicated after the first exam (if these are indicated at first exam then 
exclude the patient) 
 
2) Clear the query and code as normal if: 
 The reason for the original query was the polyp was 10mm + 
 You are unclear why the record was queried in the first place 
Irrelevant or Duplicated Linked Pathology 
In some cases multiple or inappropriate pathology reports may be attached to an endoscopy report.  
Reasons for this: 
 When an ‘Application Coding Error – Truncated Pathology’ query has been applied to 
the record the old and new pathology will be linked.  
 When a ‘Pathology Missing’ query has been accidentally applied to a record (due to 
human error – these will be rare).  
 When another type of examination took place on the same date, i.e. upper GI exam 
 When the same report has been uploaded twice. 
How to deal with linked duplicates or irrelevant pathology reports: 
 In these cases coders can mark the inappropriate pathology reports that need to be deleted 
from the database.  
 To do this the coder should access the pathology report by going into the pathology 
record directly from the patient screen. 
 Then, using the ‘Excluded’ drop-down menu the coder can mark the record as either a 
duplicate, irrelevant pathology or general (see red arrow). 
 NB - Any polyp rows must be deleted before leaving the pathology screen. 
 If not already linked, the coder must then link the appropriate pathology report to the 
endoscopy report. 
 The coder can then code the patient information and polyp details normally from the 
appropriate pathology report. 
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There is a location field in the linked pathology reports so that you can see the source of the data in 
order to make it easier to identify irrelevant pathology. 
 
In cases where data was automatically collected from hospital databases the pathology data source is 
shown at the bottom of the pathology screen. This may be useful as you may find the same pathology 
from different sources. 
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New Unlinked Pathology & ‘Other’ Reports 
Some of the new pathology will be in the form of unlinked pathology reports, which will either 
require a phantom endoscopy to be created or may need to be linked manually depending on their 
contents and collection/ received date (see Phantom SOP for more detail). 
Some of the unlinked pathology reports will not contain any relevant pathology. These will be 
classed as ‘other’ reports, and should be marked as ‘Excluded’ – ‘Irrelevant pathology’. 
Alternatively some unlinked pathology reports may be duplicates and should be marked as 
‘Excluded’ – ‘Duplicate’. 
When an unlinked pathology report has biopsies that are NOT; 
 Polyps (Inflammatory, Juvenile, Fibro-epithelial, etc. – see Phantom SOP for more detail) 
 Adenomas 
 Cancer 
 
Create a blank phantom endoscopy, tick the normal mucosa box, save and exit the report. 
 
! Remember to take note of any new cancers/resections that are added to a patient’s record 
through the new pathology report(s). Be sure to check if this creates the need to exclude a 
patient based on the order of the exams. 
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Polyp Matching Re-queries – Coding Rules 
  (16th August 2012) 
1) Size - Assign the worst histology to the largest polyp. 
 
2) In general, hyperplastic polyp pathology should be assigned to the most distal lesion but 
ONLY if this lesion is 5mm or less in size. 
 
3) Excision extent – if size is not available, assume that polyps which were snared are larger 
than those that were hot biopsied.  
 
4) When the rules above cannot be used then it can be assumed that specimen labels i.e. 1-10/A-
E, go from the most proximal to most distal site. 
 
5) If none of the above rules can be applied then use size and segment ranges to code pathology. 
 
NB - All polyp matching re-queries will be assigned a ‘polyp matching best guess’ label on the 
appropriate endoscopy record so they can be identified at analysis and the polyp matching re-query 
will be removed. 
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Polyp Numbering SOP 
(Amy Brenner, 6/1/2011) 
 
Polyp Numbering 
 
Introduction 
Sometimes a polyp found at one endoscopy may be seen again at a later endoscopy. This is because 
the polyp was not removed or was only partially removed, i.e. de-bulked or biopsied. Alternatively, 
some residual polyp may have been left intact accidentally or there may have been re-growth after 
the polyp was thought to have been completely excised.  
 
A number of patients (c.20000) were identified as requiring manual polyp numbering. These are 
patients who have two or more exams with polyps found on at least two occasions.  The polyps 
found in these patients need to be numbered in order to ensure that the same polyp is not counted as a 
number of different polyps.  
 
 
Polyp Numbering Records 
After selecting a hospital you should change the settings to ‘Polyp Numbering Patients’. 
 
Once in a patient record you need to select the ‘Polyp Numbering’ button located above the Polyp 
List, which will take you to the polyp numbering screen. 
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Polyp Numbering Screen 
The polyp numbering screen contains an individual row for each polyp found at every exam, with 
various details given (as show below). It also shows endoscopy and pathology details for the polyp 
row that is selected, as well as a polyp numbering query field. 
 
The polyps can be numbered by using the Polyp No. drop-down menu (blue arrow). Polyps that need 
matching (i.e. the same polyp seen at different exams) should be given the same polyp number. 
The polyp row that is selected is highlighted in yellow. The endoscopy and pathology details and 
summary of each exam can be seen below the polyp table by clicking on the relevant Polyp ID 
(green arrow). If one or more polyps have been numbered, then the coder should click Save (red 
arrow) before selecting a new polyp row in order to prevent this information from being lost. 
NB – Only polyps that match need to be assigned a polyp number. All other polyps will be 
assigned a unique number automatically. 
 
Once all matching polyps have been numbered then the coder must set all polyps to numbered (pink 
arrow).  The record can then be submitted using the Submit button (purple arrow), which will save 
the polyp numbering details and return the coder to the patient screen. Finally, click ‘Apply 
Changes’ to leave the record.  The record will then move into the Polyp Numbering Completed 
category in the Patient List, or to the Polyp Numbering Query category if a polyp numbering query 
has been created. 
The Polyp Numbered field (brown arrow) enables coders to differentiate between non-matching, 
checked polyps and newly added polyps. When first entering the polyp numbering screen the 
Numbered field is blank. The polyp being numbered will be set ‘Y’ if you click on ‘Save’. Before 
you leave the record you ‘set all polyps to numbered’ so that it is clear you have looked at all the 
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polyps. You can also manually set a polyp to ‘Y’ or ‘N’. If you return to the record at a later date any 
newly added polyps will show Polyp Numbered ‘N’. 
Polyp Match Probability 
 
 
The Match Probability drop-down menu (black arrow) is used to indicate the percentage certainty 
that polyps match. It is important to match as many polyps with as high a probability as possible for 
analytical purposes. 
A single polyp should be used as a point of reference from which all other possible matches are 
based. This shall be termed the ‘reference polyp’. The coder should select a polyp that can be 
matched to the greatest number of polyps with the most certainty. The reference polyp should always 
be given 100% Match Probability. All possible matching polyps should then be given a match 
probability in relation to the reference polyp. 
For example, say a patient has 5 examinations with a rectal polyp found at each. The first exam takes  
place in 1999, whilst the other 4 all occur in 2002 in close proximity. You are certain that the rectal 
polyps found at the 4 later exams are a definite match, as it is a large polyp that is undergoing de-
bulking. It seems likely that the first polyp is also a match but the histology varies slightly and the 
timescale raises some doubt. The reference polyp should be the second polyp found as you can then 
set the Match Probability of the subsequent 3 polyps to 100% and set that of the first polyp to 70%. 
If you were to use the first polyp as the reference polyp then the 4 later polyps would all be given a 
lower Match probability of 70% despite them being a clear match with each other, making the polyp 
matching less accurate. 
 
• 100% - absolutely certain polyps match 
• 50% - equally likely to be the same polyps or different polyps 
• 20% - unlikely to be the same polyps but a small possibility 
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
411
Polyp Summary, Endoscopy and Pathology Fields  
In order to match polyps appropriately the coder should use all the information provided in the Polyp 
Summary, Endoscopy Details and Pathology Report for each polyp, being sure to follow the polyp 
numbering guidelines. 
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Polyp Numbering Guidelines 
In order to match polyps you should pay particular attention to the following factors, which are listed  
in order of importance: 
 segment 
 length of time passed between exams 
 indication that polyp was not removed or was partially removed i.e. debulking, 
discomfort 
 excision extent/excision complete 
 bowel prep 
 method of excision 
 size 
 dysplasia 
 adenoma type 
 histology 
You will have to take all these factors into account and use your judgement to decide whether or not 
any polyps need to be matched.  
With regards to segment, the segment matching guide below can be used, where one should consider 
matching polyps found in the same segment group or the group either side, if other factors listed 
above indicate that polyps may match. For example a polyp in group 2 could be matched with a 
polyp in group 1, 2 or 3. 
Segment Matching Guide 
Segme
nt 
Group 
Numbe
r 
1 2 3 4 5 6 7 
Segme
nt 
Name 
Anus Sigmoid Colon 
Descendin
g Colon 
Transvers
e Colon 
Hepatic 
Flexure 
Ileoceca
l Valve 
Anastomos
is 
 
Rectum 
Sigmoid 
Colon 
(Distal) 
Descendin
g Colon 
(Distal) 
Transvers
e Colon 
(Distal) 
Ascendin
g Colon 
(Distal) 
Termin
al Ileum 
Rectum 
(Distal) 
Sigmoid 
Colon 
(Mid) 
Descendin
g Colon 
(Mid) 
Transvers
e Colon 
(Mid) 
Ascendin
g Colon 
(Mid) 
Pre 
Pouch 
Ileum 
Rectum 
(Mid) 
Sigmoid 
Colon 
(Proxima
l) 
Descendin
g Colon 
(Proximal
) 
Transvers
e Colon 
(Proximal
) 
Ascendin
g Colon 
(Proxima
l) 
Ileal 
Pouch Colostomy 
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Rectum 
(Proximal) Splenic 
Flexure Caecum 
Neo-
Termin
al Ileum Rectosigmoid 
Polyp Numbering Query  
If it is unclear whether or not two or more polyps should be matched then the coder can query the 
record using the Polyp numbering query field. The drop-down Query box should be used to select 
the General option and then the coder should write the reason for querying the record in the 
comments box. If the query is later resolved then the query option should be changed to Resolved. 
The record can be re-queried if the issue cannot be resolved. 
 
Situations when you may want to create a query... 
 Exam(s) with no date 
 Polyposis (too many polyps) 
 Polyp matching query on record 
 Exams with numerous polyp rows with quantities – ‘multiple row’ 
 When the case is too complicated to match polyps 
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Other Cases to be Aware of... 
• Quantity Field and Multi-link 
Coders should look out for polyps with information in the Quantity field (black arrow). This 
may indicate that some of the polyps found at this exam are multi-linked. Any multi-linked 
polyps can be identified by the ‘Path Multi Endo Link’ row on the polyp numbering page 
(blue arrow). 
 
 
 
In complex cases where numerous quantity rows appear, a polyp numbering ‘Multiple Row’ 
query can be applied if it is not possible to confidently match them.  
 
When appropriate an individual polyp(s) should be matched to a polyp row with a quantity, 
e.g. 
Exam 1                                                                                  Polyp Number 
Several 2mm Rectal Polyps Not Excised                                  1               
Exam 2 
2mm Polyp in the Rectum Excised                                            1               
2mm Polyp in the Rectum Excised                                            1               
2mm Polyp in the Rectum Excised                                            1               
 
An individual polyp row can also be matched to a multiple polyp row in cases where a large 
polyp is later referred to as a carpet/cluster of polyps etc. 
 
Finally, in some cases it may be necessary to link two or more multiple rows together, 
however multilinked rows should not be matched as they are already linked to the polyp 
group in question. 
 
• Non-polyp Histology and ‘Not Possible to Diagnose’ 
Some records will have histology such as normal mucosa, mucosal prolapse or inflammation. 
In general, these ‘polyps’ should NOT be matched. However, in some cases it may be 
necessary to match such ‘polyps’.  
 For example, if in subsequent examinations it seems likely that the polyp was 
misdiagnosed then this should be matched, i.e. the first biopsy was inadequate and relevant 
histology is found later.  
 Polyps with irrelevant histology should also be matched if a specimen is clearly stated as 
being a biopsy from a previous polypectomy/excision site. 
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As a rule, only polyps, adenomas or cancers should be matched. Any other histology should 
be dealt with as discussed above.  
 
Extra consideration may be needed for polyp rows with the histology ‘not possible to 
diagnose’. In this case the coder should again use their initiative to determine whether or not 
this should be matched. 
 
• Multiple Exams on Same Date 
Be aware that some exams may have the same date, resulting in polyps that were in fact 
found at separate exams being listed under the same exam date. This can be identified on the 
polyp numbering page by looking at the Endo ID.  
 
 
 
• Matching Polyps Found at Same Exam 
In some cases polyps found at the same exam may need to be matched. For example, a 
number of polyps seen may be re-growths/remnants of previous single large polyp or tumour. 
 
• Metaplastic Polyps 
When small (<5mm) metaplastic polyps are seen at a number of exams it is fair to assume 
that these are different polyps that are new or were previously missed, unless the report 
contains information to indicate otherwise. 
Coders should also be aware that in some cases it may be appropriate to match serrated 
adenomas and metaplastic polyps as a result of common misdiagnosis. 
 
• Which polyp? 
Cases may arise where it is possible to match a number of polyps at one exam to a polyp(s) at 
another exam, and no particular polyp row contains information to make it any more likely a 
match than the others.  
Choose a polyp and match it. The match probability should not be affected by the fact that 
you are unsure about which polyp to match. It should be based solely on the probability of the 
polyps being the same. 
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March 2012 – SOP Updates and Amendments 
 
1. Coders Reference Document 
 
Cancer Review: 
New histology terms were added for the cancer review/cleaning task (reviewing ca+adenoma, 
cancers, mets from another site).  
 New cancer types added - GIST, Sarcoma, squamous cell carcinoma 
 'Cancer query' added to compliment 'cancer in dispute' 
 'Mets/tumour infiltrating' added to compliment 'metastasis from another site' 
 ‘Ca+mixed/serrated’ separated into ‘ca+mixed’ and ca+serrated’ 
 ‘Carcinoid tumour’ changed to ‘carcinoid/neuroendocrine tumour’ 
 ‘IM cancer in dispute’ added to compliment ‘IM Cancer’ which is now being used to 
reclassify cancers coded previously. 
 
General: 
Application coding error options updated to include new options (truncated endoscopy, truncated 
pathology, blank endoscopy, blank pathology, duplicate endoscopy, irrelevant endoscopy). 
2. Coders Reference Document – Phantoms 
 
Cancer Review: 
New histology terms were added for the cancer review/cleaning task (reviewing ca+adenoma, 
cancers, mets from another site).  
 New cancer types added - GIST, Sarcoma, squamous cell carcinoma 
 'Cancer query' added to compliment 'cancer in dispute' 
 'Mets/tumour infiltrating' added to compliment 'metastasis from another site' 
 ‘Ca+mixed/serrated’ separated into ‘ca+mixed’ and ca+serrated’ 
 ‘Carcinoid tumour’ changed to ‘carcinoid/neuroendocrine tumour’ 
 
3. Coding Application SOP 
 
Patient details screen – information edited to describe details of access to polyp numbering screen 
and data cleaning tasks. 
 
Query – Application coding error options updated to include new options (truncated endoscopy, 
truncated pathology, blank endoscopy, blank pathology, duplicate endoscopy, irrelevant endoscopy). 
Re-query – defined new use (i.e. once query followed up with data collection but cannot be solved) 
4. Exclusion SOP Reference Document 
Colitis – non-exclusion types listed. 
Polyposis – new terms added. New coding rule mentioned (i.e. patients will only be classified as 
having polyposis if the endoscopist or pathologist explicitly states that they have the disease. 
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Numbers of polyps will no longer be used by coders. Instead polyp numbers will be used to classify 
patients as having polyposis at analysis). 
5. Exclusion SOP 
Colitis – non-exclusion types listed. 
Polyposis – new terms added. New coding rule mentioned (i.e. patients will only be classified as 
having polyposis if the endoscopist or pathologist explicitly states that they have the disease. 
Numbers of polyps will no longer be used by coders. Instead polyp numbers will be used to classify 
patients as having polyposis at analysis). 
6. Missing Pathology Coding SOP 
None 
7. Missing Pathology Collection SOP 
None 
8. Phantom SOP 
Minor amendments 
9. Polyp Numbering SOP 
Minor amendments 
10. Review SOP 
None 
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Cancer Reclassification Review SOP 
  (Amy Brenner, 5/14/2012) 
 
Incident 195 – Cancer Review 
It was decided that all cancers in the database needed to reviewed and reclassified into more specific 
categories. More detailed pathology coding options have been added to the database to enable this. 
There are 4 different groups to be reviewed. 
Ca+adenoma (Group A) - Firstly all records with ‘ca+adenoma’ coded in a polyp row are to be 
reviewed and, if necessary, recoded to fit the new cancer definitions taken from the EU 2010 
guidelines.  A number of new histology options have been added for this, including ‘Ca + mixed 
adenoma’ and ‘Ca + serrated adenoma’, as well as dysplasia options of ‘IM cancer in dispute’.   
  
 
Cancer in dispute (Group B) – Records coded as ‘ca in dispute’ are being reviewed to allow them 
to be reclassified into a further category of ‘query cancer’ so that it is possible to differentiate 
between a suspicion of cancer and an inability to determine the precise level of invasion in cancerous  
tissue i.e. high grade dysplasia in an adenoma or invasive cancer in an adenoma. 
Metastases (Group C) – Records which have been coded at ‘metastases – another site’ are being 
reviewed so that they can be reclassified into a further category of ‘mets/tumour – infiltrating’ so that 
it is possible to differentiate between a cancer that has grown into the bowel from a nearby site and 
cancer that has developed in the bowel through metastasis from a non-adjacent organ. 
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Cancer (Group D - G) – Any cancers that are NOT adenocarcinomas have been identified so they 
can be reclassified as more specific types of cancer i.e. squamous cell carcinoma, sarcoma, GIST, 
lymphoma. A word search was used to extract relevant records for this review and new terms were 
added to the histology drop-down menu to allow such records to be recoded. 
A number of new histology options were added to the histology drop-down menu, whilst some of the 
current options definitions were amended, as shown below. New options are shown in blue, old 
options in red and options with new definitions are in black.  
HISTOLOGY DESCRIPTION 
Ca+adenoma Carcinoma / cancer / malignant / invasive cell types, seen to be 
arising from an adenoma or when a cancer diagnosis also includes 
adenomatous material.  
Ca+mixed  
(Ca+mixed/serrated adeno) 
Carcinoma / cancer / malignant / invasive cell types, seen to be 
arising from a mixed polyp or adenoma 
Ca+serrated  
(Ca+mixed/serrated adeno) 
Carcinoma / cancer / malignant / invasive cell types, seen to be 
arising from a serrated polyp or adenoma 
Cancer Query  If a pathologist mention or suspects but is not able to confirm a 
diagnosis of cancer / malignancy  
Ca in dispute If a pathologist cannot confidently confirm cancer / malignancy / 
level of invasion in an adenoma or cannot decide between an 
adenoma or cancer. 
Cancer Malignant neoplasm / adenocarcinoma / carcinoma/ malignancy / 
invasion 
Carcinoid/Neuroendocrine 
tumour 
(Carcinoid tumour) 
Tumour originating from the neuroendocrine system. 
Metastases - another site  
 
Malignant material found in the colon that is not from a primary 
bowel cancer and originates elsewhere in the body. 
Mets/tumour - infiltrating  
 
Malignant material that is infiltrating into the colon from a tumour 
outside the colon (if unsure use ‘Mets from another site’) 
Unknown Primary Malignant material found in the colon that has an unclear or 
unknown primary 
Non-Hodgkin’s Lymphoma (NHL) A diverse group of blood cancers that include any kind of 
lymphoma except Hodgkin’s lymphomas.  
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Squamous Cell Carcinoma Skin Cancer normally found in the anus, but may be reported as 
rectal. Code as squamous cell carcinoma. 
G.I.S.T                   Gastro Intestinal Stromal Tumour 
Sarcoma  Cancerous tumour of soft tissue 
Basaloid/cloacogenic cancer Subclass of squamous cell cancers that develop in the transitional 
zone, also called the cloaca. These cancers look slightly different 
under the microscope but they behave and are treated like other 
squamous cell carcinomas of the anal canal. 
Anaplastic/undifferentiated 
cancer 
A rare type of cancer often diagnosed at advanced stage, usually 
found in the small intestine 
 
To review an incident, access the appropriate record from the patient screen and go over the 
pathology report to determine whether or not the polyp row needs to be recoded in line with these 
new definitions. The cancer staging diagram below can be used as a guide for when to classify 
histology as severe dysplasia, IM cancer or ca + adenoma. 
Cancer Staging Diagram: 
 
NB: -   Connective tissue = lamina propria 
 Thin muscle layer = muscularis mucosa 
 Thick muscle layer = muscularis propria 
 
Green = Severe Dysplasia (involving the epithelium) 
Yellow = IM Cancer (invading the lamina propria and/or muscularis mucosa) 
Red = Cancer (penetration of the muscularis mucosa and invasion of the submucosa) 
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Please note: 
 The ‘Ca + mixed/serrated adenoma’ option will be removed once coders have reclassified 
these – NO records should have ‘Ca + mixed/serrated adenoma’ once reviewed. 
 If a supplementary report is present this information should take precedence over the original 
pathology report. 
 Ca in situ = high grade dysplasia + adenoma, NOT cancer 
 Mention of AIN3 indicates squamous cell carcinoma 
 Mention of Dukes staging indicates invasive carcinoma 
 When cancers are described as arising from a dysplastic area, only the dysplasia type and 
cancer should be coded, NOT Ca + adenoma. 
 Sometimes a polyp is resected at endoscopy then the patient has a colectomy and no residual 
malignancy/cancer is found (sometimes there may be some lymph nodes but no trace of the 
polyp).  A Dukes stage may still be given in the report despite no further cancer being 
present. Be careful not to code as a cancer, and if there is any residual adenoma then just code 
as adenoma. Ensure it is 100% numbering matched to the cancer. 
 
Example: 
 
‘An irregular polypoid lesion 2 cms diameter. Sections show the lesion to be a tubulovillous 
adenomatous polyp showing severe dysplastic change.  In addition, in one area near the tip there is 
a focus of traumatic ulceration/haemorrhage, presumably related to the previous biopsies.  In this 
area there is evidence of  
intramucosal carcinoma with small fragments of malignant looking epithelium, some of which 
appear buried in the muscularis mucosae. Some small islands of epithelium are also seen in a nearby 
mucosal vessel, but it is unclear whether this represents true invasion or simply traumatic artefact. 
There is no evidence of invasion of the central connective tissue core of the polyp or of the vessels in 
the core. The base of the lesion is well seen and it appears completely excised. The focus of 
intramucosal malignant change being well clear of the base by 1 cm +. There is no evidence of 
amyloid in this specimen.’ 
 
In the above example the polyp was coded as a ca + adenoma under the old rules but should now be 
coded as IM cancer, Ca in dispute. 
 
Once the record has been reviewed use the ‘Submit and Return to Patient’ button to take you back to 
the patient screen where you should ensure that any cancer exclusion has been applied correctly and 
mark the incident as checked.  
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ONS Encryption SOP 
 
Prior to the visit; 
 Contact the person in charge of the Data CD (find their contact details in ‘Data CD Storage’ 
spreadsheet on SharePoint).  
 Arrange a time and place to meet with them and collect the CD.  
 Inform them that you will only need the data for a few hours and then you will need to 
hand it back to them. 
 Be aware that the CD may have some missing data (usually missing NHS numbers). 
 Find out the name and contact details of someone who can help to fill in the missing NHS 
numbers (usually PAS manager or information systems staff) using the information we 
already have (Name, DOB, Hospital Number). 
 Ensure that you have a fully charged lap top with the encryption software and a CD drive. 
 Ensure that you have the Data CD password (ask Ann). 
 Ensure that you know the encryption password (ask Ann). 
 Print off and take all the relevant R&D approvals for the hospital (on SharePoint). 
 Print off and take your honorary contract and research passport (on SharePoint). 
 
Encryption; 
1. Insert the CD into the lap top 
2. Locate the patient data spreadsheet (often called ‘patient linking data’) 
3. Export/Unzip onto the desktop 
4. Open 
5. Key in the password 
6. Format the fields as below; 
 
 If there are any missing fields make sure there is still a column and header for the field 
but leave it blank. 
 If there are any extra fields, add them as columns to the right of address and make a note 
of them. 
 If there are missing NHS numbers you will need to contact the PAS manager/information 
systems 
 
7. Save the spreadsheet to your desktop under the file name ‘Intermediate Adenoma Study – 
‘insert hospital name’ – ONS’. 
Study_Number Hospital_Number Surname Forename DOB NHS Gender Postcode Address 
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8. Right click on the logo of the spreadsheet and select the option to encrypt the data with the 
SafeGuard PrivateCrypto (Sophos) software and key in the password. 
9. Save the encrypted version to a memory stick. 
10. Delete ALL other versions of the data (except the original on the CD) ensuring that the 
recycling bin is also cleared. 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
424
Appendix 5 Colitis and polyposis exclusion
criteria
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Appendix 6 Polyp numbering
Polyp numbering
Sometimes a polyp that was found at one endoscopy was seen again at a later endoscopy. This was
because the polyp was not removed or was only partially removed (i.e. de-bulked or biopsied).
Alternatively, some residual polyp may have been left intact accidentally or there may have been regrowth
after the polyp was thought to have been completely excised.
It was necessary to link these polyps to ensure that the same polyp was not counted as separate polyps.
This process was called ‘polyp numbering’.
Numbering individual polyps
The study programmer added the POLYP_NUMBER and MATCH_PROBABILITY fields to the POLYP table
and added a new screen to the Endoscopy and Pathology Report (EPR) application. Approximately 17,000
patients required manual polyp numbering. These were patients who had two or more examinations with
polyps found on at least two occasions.
The study researchers reviewed these patients and all occurrences of the individual polyps seen at different
examinations (including individual polyps within multiple polyp groups) were assigned the same number
in the POLYP_NUMBER field and a percentage was assigned in the MATCH_PROBABILITY field to indicate
the certainty that polyps were the same unique lesion. A single polyp was used as a reference from which
all other possible matches were then based. All information provided in the endoscopy and pathology
reports was used to identify unique polyps across all examinations. Polyp numbering guidelines were used
to match the polyps accurately and methodically, with particular attention given to the following factors,
listed in order of importance:
1. segment (proximity)
2. indication that polyp was not removed or was partially removed (i.e. de-bulking, discomfort)
3. excision extent/excision complete
4. bowel preparation
5. method of excision
6. size
7. dysplasia
8. adenoma type
9. histology.
It was necessary to allocate a polyp number only if the polyp was seen multiple times. This was a complex
process and the study researcher took into account all the polyp fields, information from the endoscopy
and pathology reports and used their own judgement to decide whether it was in fact the same polyp or a
different one. Manual quality checks were done by the study researchers, who reviewed and checked a
random sample of records that had been polyp numbered by other study researchers. Automatic checks
were also done to identify cases with the same POLYP_NUMBER which had large difference such as
sizes, segments of the polyps and so on and such records were manually reviewed and corrected
where necessary.
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A new field called DERIVED_POLYP_NUMBER was created in the polyp table. As described previously,
POLYP_NUMBER was assigned only if the polyp was seen across other examinations. In order to analyse
the data and derive other fields, it was necessary to allocate a unique number to each polyp. After manual
polyp numbering was completed, analysis on the MATCH_PROBABILITY was conducted by the statistician.
It was decided that only polyps with a MATCH_PROBABILITY of ≥ 70% would be considered the same
lesion. The study programmer wrote a program to assign a DERIVED_POLYP_NUMBER which was a unique
number for every polyp across all examinations. If the polyp had a POLYP_NUMBER assigned to it then all
occurrences of that polyp were assigned the same DERIVED_POLYP_NUMBER if the MATCH_PROBABILITY
was ≥ 70%. The DERIVED_POLYP_NUMBER and POLYP_NUMBER did not always match. However, if
polyps had the same POLYP_NUMBER and MATCH_PROBABILITY was ≥ 70% they would all have the
same DERIVED_POLYP_NUMBER.
Polyp groups
Coding multiple polyps
To simplify the concept of ‘multiple polyps’ the following definitions have been used to describe the
different types of polyp rows recorded by the study researchers in the POLYP table, based on how they
were observed.
l Endo quantity row An individual polyp row was created in the POLYP table and used to record a group
of polyps. The ENDO_QUANTITY_OTHER was set to values such as ‘many’, ‘several’, ‘multiple’, as
described in the endoscopy or pathology report.
l Multilinked polyp An individual polyp row was created in the POLYP table but the polyp was also
part of a group of polyps (i.e. it belonged to an ‘endo quantity row’). The PATH_MULTI_ENDO_LINK
would match the POLYP_ID of the ‘endo quantity row’, showing that they are part of a larger group
defined in the ‘endo quantity row’.
l Individual polyps Polyps that were not part of the group. In some cases, polyps could be recorded as
an individual polyp at a particular examination, but may have been seen as part of a group at a
previous or subsequent examination.
During the manual coding phase of the study, the study programmer created fields ENDO_QUANTITY_OTHER,
PATH_MULTI_ENDO_LINK, MULTIPLE_POLYP_GROUP and MULTIPLE_POLYP_GROUP_LINKING in the POLYP
table so that the study researchers could record this information. A group of polyps was recorded as an
individual polyp row called an ‘endo quantity row’ and populated with information common to all polyps
within that group such as segment, shape, histology, and so on, and the ENDO_QUANTITY_OTHER field was
used to record the descriptive quantity of polyps in that group such as ‘tiny’, ‘multiple’, etc. Additional
individual polyp rows were created for any polyps within the group for which additional information was
available, and the POLYP_ID of the ‘endo quantity row’ was selected in the PATH_MULTI_ENDO_LINK field for
these polyps to link them to the ‘endo quantity row’. The whole group (i.e. the ‘endo quantity row’), and the
individual polyps linked to it, were allocated the same unique MULTIPLE_POLYP_GROUP. This method was
used to record groups of polyps seen at the same examination.
For example, if the endoscopy description said ‘In the distal sigmoid colon multiple sessile polyps were
found. The largest was 2 mm; 2 of these were excised and 1 was retrieved’ then one ‘endo quantity row’
would be created as shown in the record highlighted in red (Figure 31), and the ENDO_QUANTITY_OTHER
would be set to ‘multiple’. Multilinked polyps would be created as per the records highlighted in
green (see Figure 31) below. The records in green would be linked to the record in red and their
PATH_MULTI_ENDO_LINK would match the POLYP_ID of the record in red. All the records in the group
would be allocated the same MULTIPLE_POLYP_GROUP, in this case ‘Group 2’.
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
430
FIGURE 31 Coding multiple row polyps.
When all of the groups of polyps had been recorded for a patient, the study researchers reviewed all of
the groups of polyps and individual polyps that may have been observed within a group at the same
or other examinations, and linked them all using the MULTIPLE_POLYP_GROUP_LINKING field.
The MULTIPLE_GROUP_LINKING field was labelled as ‘Multiple Group No.’ on the EPR application.
It was used to allocate a unique group number for a set of polyps seen across many examinations.
The MULTIPLE_POLYP_GROUP where the polyp group or individual polyp was first seen was used to
populate the MULTIPLE_GROUP_LINKING for all observations of the polyp at different examinations.
The study researcher selected a designated group that was a MULTIPLE_POLYP_GROUP starting with
‘Group1’, identified all occurrences of the polyps within that group and allocated the same
MULTIPLE_GROUP_LINKING to them. The study researcher then moved on to the next ‘endo quantity row’
for which no MULTIPLE_GROUP_LINKING had been assigned, and this became the next designated group.
The following rules were used to assign the designated group to the MULTIPLE_GROUP_LINKING field for
the following polyp rows:
l All polyp rows where PATH_MULTI_ENDO_LINK matched the POLYP_ID of the ‘endo quantity row’ and
where the MULTIPLE_POLYP_GROUP matched the designated group.
l All polyp rows (groups and individual polyps) where the polyps appeared to be the same as the polyps
for which the MULTIPLE_GROUP_LINKING had already been assigned and matched the designated
group. The match probability was also recorded on the MULTIPLEGROUP_MATCHPROB field to show
how certain the study researcher was that it was the same MULTIPLE_GROUP_LINKING.
l All ‘endo quantity rows’ that appeared to be the same as the polyps for which the
MULTIPLE_GROUP_LINKING had already been assigned and all multilinked polyps rows where
PATH_MULTI_ENDO_LINK matched the POLYP_ID of the associated ‘endo quantity row’.
The following example shows how the study programmer allocated the MULTIPLE_POLYP_GROUP and
MULTIPLE_POLYP_GROUP_LINKING. The study researcher allocated a unique group number to each set of
polyps seen at a particular examination. The following is a screenshot from the EPR application, which
shows how the MULTIPLE_POLYP_GROUP was assigned.
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FIGURE 32 Screenshot showing multiple groups and group linking.
For example, two groups were identified for the examination 11-SEP-2006:
l Polyp P-GRI142761 is the polyp with quantity ‘few’ and it is also multilinked to polyp P-GRI142762 so
they were both assigned ‘GROUP1’.
l Polyp P-GRI92177 is the polyp with quantity ‘multiple’ and it is also multilinked to polyp P-GRI142763
so they were both assigned ‘GROUP2’.
For examination 12-DEC-2006 one group was identified:
l Polyp P-GRI142764 is the polyp with quantity ‘some’ and therefore assigned ‘GROUP3’.
Once all the polyps have been created and the MULTIPLE_POLYP_GROUP had been allocated, the
MULTIPLE_GROUP_LINKING was done as follows:
l Starting with MULTIPLE_POLYP_GROUP ‘Group1’ (designated group), the ‘endo quantity row’ and
the polyps multi-linked to it were assigned ‘Group1’ on the MULTIPLE_GROUP_LINKING field.
This included polyps P-GRI142761 and P-GRI142762. Any polyps that appeared to be the same
as the polyps in group P-GRI142761 or polyp P-GRI142762 were also assigned ‘Group1’ in the
MULTIPLE_GROUP_LINKING field (i.e. polyp P-GRI42764).
l Moving to the next designated group ‘Group2’, polyp P-GRI92177 was the polyp with quantity
‘multiple’ and it is also multi-linked to polyp P-GRI142763, so they were both assigned ‘GROUP2’ in
the MULTIPLE_GROUP_LINKING field. Polyps P-GRI92181, P-GRI6481 and P-GRI12964 all appeared to
be the same polyps are the ones already in MULTIPLE_GROUP_LINKING ‘Group 2’, so they were
assigned as ‘GROUP2’ in the MULTIPLE_GROUP_LINKING field.
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Multiplying out the endo quantity rows
The process of estimating the number of polyps within an ‘endo quantity row’ and separating them out
into individual polyps is known as ‘multiplying out the endo quantity row’. The method to calculate this
took into account all of the different scenarios in which a polyp is observed across many examinations.
A summary table called ‘DERIVED_MP_SUMMARY’ was generated, which contained the POLYP_ID,
STUDY_NUMBER, MULTIPLE_POLYP_GROUP, MULTIPLE_GROUP_LINKING of each ‘endo_quantity_row’
and the following fields (some were derived):
1. APPROX_QTY Approximate quantity of polyps recorded by the study researcher.
2. MIN_QTY Minimum quantity of polyps in the group recorded by the study researcher.
3. MAX_QTY Maximum quantity of polyps in the group recorded by the study researcher.
4. TOTAL_POLYPS The total number of unique polyps seen for the ‘endo quantity row’ across all
examinations. It was derived by taking into account number of multi-linked polyps, the number of
unique polyps with the same MULTIPLE_GROUP_LINKING seen at other examinations, and deducting
any polyps with the same MULTIPLE_GROUP_LINKING that had been excised prior to the procedure
date of the ‘endo quantity row’.
5. SAMEEXAMPOLYPS The total number of multi-linked polyps at the same examination for
the ‘endo_quantity_row’.
6. ESTIMATED_QUANTITY The ‘ENDO_QUANTITY_OTHER’ field contained categories like few, some,
several and so on. It was necessary to translate these categories into values for analysis. The statistician
conducted an analysis by comparing all of the records for which the ‘ENDO_QUANTITY_OTHER’,
‘MIN_QTY’ and ‘MAX_QTY’ fields had been recorded. The results of the analysis were discussed by
study researchers in order to arrive at an ESTIMATED_QUANTITY for each option. This provided an
indication of the number of records in the group especially when there was no other indication of
quantity. The following quantities were assigned to each option.
TABLE 109 Values assigned to ENDO_QUANTITY_OTHER
ENDO_QUANTITY_OTHER ESTIMATED_QUANTITY
Few 3
Some 3
Number of 3
Several 3
Many 5
Multiple 5
l Use the largest of TOTAL_POLYPS, SAME_EXAM_POLYPS and MAX_QTY if MAX_QTY > 0.
l Use the largest of MIN_QTY, ESTIMATED_QUANTITY, SAME_EXAM_POLYPS and TOTAL_POLYPS if
MIN_QTY > 0 and if APPROX_QTY and MAX_QTY are blank.
l Use the largest of, ESTIMATED_QUANTITY, SAME_EXAM_POLYPS and TOTAL_POLYPS if the
TOTAL_POLYPS > 0 or SAME_EXAM_POLYPS > 0.
1. MAX_ROWS_DATASOURCE This was used to record the field assigned to the MAX_ROWS based on
the above rules.
2. ROWSADD This was a derived field and was the total number of polyps that would be added to the
‘endo quantity row’, and included the number of new polyps that are created from polyps observed at
other examinations and also completely new polyps that were not observed but estimated based on the
information available.
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The following rules were used to calculate the ROWSADD field:
l Sometimes the ‘endo quantity row’ was marked as partially excised i.e. EXCISION_EXTENT = 2. In this
scenario, the study researchers thought that there may have been more polyps than the ones
multilinked to the ENDO QUANTITY ROW, so the study programmer took a conservative estimate and
added one row in such cases:
¢ If the MAXROWS = SAMEEXAMPOLYPS so ROWSADD = 0
¢ If the MAXROWS = SAMEEXAMPOLYPS and EXCISION_EXTENT <> 2 then ROWSADD = 0
l If the POLYPCOUNTGROUP_OTHERS > 0 and the MAX_ROWS_DATASOURCE = ’TOTAL_POLYPS’ then
ROWSADD =MAXROWS – (SAMEEXAMPOLYPS + POLYPCOUNTGROUP_OTHERS). This ensured that
that any polyps that already existed within that examination were excluded as the ‘TOTAL_POLYPS’
included them. Otherwise, the ROWSADD =MAXROWS – (SAMEEXAMPOLYPS), as all of the other
fields included the SAMEEXAMPOLYPS in their total.
l ROWSADD_OVERRIDE This override was applied only for cases for which there were more than one
‘endo quantity rows’ at the same examination with the same MULTIPLE_GROUP_LINKING. If the
MAX_ROWS_DATASOURCE = ’TOTAL_POLYPS’ for the more than one ‘endo quantity rows’ with the
same MULTIPLE_GROUP_LINKING at the same examination then it was important to ensure that
a ratio was used to divide the TOTAL_POLYPS among those ‘endo quantity rows’ after deducting any
multilinked polyps. The program calculated the ‘TOTAL_POLYPS’ minus POLYPCOUNTGROUP and then
divided that based on ESTIMATED_QUANTITY.
Creating the DERIVED_MP_POLYPS table
The process of separating out the ‘endo quantity rows’ was based on estimates so it was decided that a
new table called DERIVED_MP_POLYPS would be used for this without changing any of the data on the
POLYP table. The table DERIVED_MP_POLYPS was created, which contained a copy of the POLYP table for
all patients who had at least one ‘endo quantity row’. For patients with ‘endo quantity rows’, this table
was used as the master data set for polyp information. The following rules were applied for this migration
of data:
l The MULTIPLE_GROUP_LINKING was set to null if the group match probability was < 70%.
l If PROCEDURE_DATE was blank then it was populated from the endoscopy or pathology table.
l The following fields recorded on the ‘endo quantity row’ were copied to the multilinked polyps in sets
unless the fields on the multilinked polyp already had some data in at least one of the values in the set.
¢ EXCISION_EXTENT = 1
¢ PATH_HISTOLOGY, PATH_DYSPLASIA, PATH_ADENOMA_TYPE,
SERRATION, ASSUME_PATH_HISTOLOGY
¢ FATE_OF_BIOPSY and REMOVAL_METHOD
¢ ENDO_SHAPE, ENDO_SHAPE_OLD and PATH_SHAPE
¢ ENDO_SEGMENT, ENDO_SEGMENT_TO, ENDO_SEGMENT_OLD and ENDO_DISTANCE
¢ ENDO_SIZE, ENDO_SIZE_OTHER, ASSUME_ENDO_SIZE and ASSUME_ENDO_SIZE_OTHER
¢ PATH_SIZE and ASSUME_PATH_SIZE
¢ ENDO_SIZE_MAX and ENDO_SIZE_MIN
¢ CLINICAL_HISTOLOGY
¢ EXCISION_COMPLETE
¢ HOSPITAL
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Creating new polyp rows from existing polyp rows
An ‘endo quantity row’ contained groups of polyps but some of the polyps may have been recorded as
individual or multilinked polyps at prior or subsequent examinations. It was important to ensure that any
new polyps created from existing polyps were also assigned the same DERIVED_POLYP_NUMBER and
MULTIPLE_GROUP_LINKING to ensure that they were linked.
The new polyps were also multilinked to the ‘endo_quantity_row’. A new field called NEW_POLYP_STATUS
was also created and assigned the value ‘EXISTING POLYP’ to indicate that the row was created based on
an existing polyp.
Any existing polyps at previous or subsequent examinations that met the following criteria were used to
create the new polyps:
l The MULTIPLE_GROUP_LINKING of the ‘endo quantity row’ matched the MULTIPLE_GROUP_LINKING
of the existing polyp at prior or subsequent examination.
l The existing polyp did not have the same ENDO_ID as the ‘endo quantity row’.
l If the existing polyp has EXCISION_EXTENT = 1 or EXCISION_COMPLETE = 1 and if the polyp was seen
at an examination prior to the examination of the ‘endo quantity row’ then it was not used. However,
the EXCISION information was not always reported properly. Therefore, if the polyp was seen again
later then it was used.
l If there was an existing polyp with the same DERIVED_POLYP_NUMBER as another polyp recorded on
the same examination as the ‘endo_quantity_row’ then it was not used.
l Sometimes the existing polyp was a new polyp created at a prior examination when the ‘endo quantity
row’ of that examination was separated into rows. In such a case it was assumed then it was the same
polyp seen again (unless excised previously) and it was allocated the same DERIVED_POLYP_NUMBER.
This ensured that the numbers of polyps were not overestimated.
If the polyp was created from an existing polyp then only the DERIVED_POLYP_NUMBER and
MULTIPLE_GROUP_LINKING were used from the existing POLYP to create the new polyp. It would have
been incorrect to copy all of the information from the existing polyps, as the polyp data could change over
the course of the examinations. It was deemed more appropriate to use the information from ‘endo
quantity row’ as the information recorded against it was applied to all polyps in the group. It was also
agreed that when the statistician would derive the true values for polyps across all examinations and the
data on actual observed polyps would take precedence over the new polyps created.
The following fields are copied from the ‘endo quantity row’ as they were common to all polyps in the
group: MULTIPLE_POLYP_GROUP, STUDY_NUMBER, ENDO_ID, PROCEDURE_DATE, CLINICAL_HISTOLOGY,
PATH_HISTOLOGY, PATH_DYSPLASIA, PATH_ADENOMA_TYPE, SERRATION, ASSUME_PATH_HISTOLOGY,
FATE_OF_BIOPSY, REMOVAL_METHOD, ENDO_SHAPE, ENDO_SHAPE_OLD, PATH_SHAPE,
ENDO_SEGMENT_TO, ENDO_SEGMENT_OLD, ENDO_DISTANCE, ENDO_SEGMENT, EXCISION_COMPLETE,
HOSPITAL, ENDO_SIZE, ENDO_SIZE_OTHER, ASSUME_ENDO_SIZE, ASSUME_ENDO_SIZE_OTHER,
PATH_SIZE, ENDO_SIZE_MAX, ENDO_SIZE_MIN. The EXCISION_EXTENT was copied only if it was set to 1.
The POLYP_ID of the ‘endo quantity row’ was copied to the PATH_MULTI_ENDO_LINK of the new polyp.
The ‘POLYP_ID’ was generated from the POLYP_ID of the ‘endo quantity row’ and by appending ‘-V’
followed by a unique number for the new polyp. This showed that it was multiplied out from the ‘endo
quantity row’.
Creating new polyp rows
The number of rows created from existing polyps was deducted from ROWSADD or ROWSADD_OVERRIDE
to calculate the number of completely new polyps to be added. Based on this, new polyps were created
where necessary.
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A new unique DERIVED_POLYP_NUMBER was generated for every new polyp created. The following fields
are copied from the ENDO QUANTITY ROW: MULTIPLE_POLYP_GROUP, MULTIPLE_GROUP_LINKING,
MULTIPLEGROUP_MATCHPROB, STUDY_NUMBER, ENDO_ID, PROCEDURE_DATE, CLINICAL_HISTOLOGY,
PATH_HISTOLOGY, PATH_DYSPLASIA, PATH_ADENOMA_TYPE, SERRATION, ASSUME_PATH_HISTOLOGY,
FATE_OF_BIOPSY, REMOVAL_METHOD, ENDO_SHAPE, ENDO_SHAPE_OLD, PATH_SHAPE,
ENDO_SEGMENT_TO, ENDO_SEGMENT_OLD, ENDO_DISTANCE, ENDO_SEGMENT, EXCISION_COMPLETE,
HOSPITAL, ENDO_SIZE, ENDO_SIZE_OTHER, ASSUME_ENDO_SIZE, ASSUME_ENDO_SIZE_OTHER,
PATH_SIZE, ENDO_SIZE_MAX, ENDO_SIZE_MIN. The EXCISION_EXTENT was only copied if it is set to 1.
The POLYP_ID of the ‘endo quantity row’ was copied to the PATH_MULTI_ENDO_LINK of the new polyp.
The polyp ID was created from the POLYP_ID of the ENDO QUANTITY ROW by appending ‘-V’ followed by a
unique number for the new polyps. This showed that it was multiplied out from the ENDO QUANTITY ROW.
When the fields such as TOTAL_POLYPS were derived, the figure was based on observed polyps. However,
it did not take into account any new polyps created at every examination, based on our estimates and
calculations. Factoring this into the algorithm would have made it very complex and it was very likely the
number of polyps would have been overestimated. It was decided that the estimates would be based on
actual polyps observed and would not include any new polyp rows created as a result of multiplying
out rows.
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Appendix 7 Rules applied for data analysis
Rules defined before data were received by statistician
Multiple polyp group numbering and multiplication out of rows
Sometimes, an endoscopist referred to the polyps seen at an examination in a vague manner, meaning
that it was unclear precisely how many polyps were seen. All details available for a group of polyps were
coded within a single ‘Multiple polyp row’ to deal with this issue. Coders would set the polyp field ‘endo
quantity other’ to a value such as multiple, some or few, depending on the report, so that the single polyp
row could represent a group of polyps. Such polyp groups were termed ‘endo quantity rows’. Additional
fields were used to indicate the number of polyps that the endo quantity row represented, where such
information was available; this included minimum, maximum and approximate number of polyps. In
addition to a multiple polyp row, an individual may have had other lesions. Furthermore, in some cases it
was possible to glean more in-depth polyp details from the pathology, some of which related to individual
polyps within the multiple polyp row. A polyp row would be added to record these specific polyp details
and then that row would be ‘multilinked’ to the endo quantity row to demonstrate that it was part of the
group of polyps described at endoscopy.
All polyps found at an examination with a multiple polyp row were termed ‘multiple row groups’. Within a
multiple row group there may be:
l Endo quantity rows Polyps with endo quantity other value (i.e. many, several, multiple).
l Multilinked polyps Polyp rows containing further details on specific polyps of the endo quantity row
which are linked to the endo quantity row by the polyp_id of the endo quantity row (i.e. polyps at the
same examination).
l Individual linked polyps Polyps within the endo quantity rows that are seen at other examinations.
They will be within the same linking group (MULTIPLE_GROUP_LINKING) as explained later.
l Individual polyps Polyps that are never part of the group.
When the initial polyp numbering was done, coders used the polyp numbering field to associate groups
of polyps to other groups, as well as to individual polyps. It was therefore difficult to identify whether
or not individual polyps within groups found at different examinations were the same. As a result,
two fields were created: MULTIPLE_POLYP_GROUP (Multiple Polyp Group at the same examination) was
used to allocate a unique group number to each set of polyps seen at a particular examination, and
MULTIPLE_GROUP_LINKING (Multiple Group No – across all examinations) was used to allocate a unique
group number for a set of polyps seen across many examinations.
Some automatic coding was performed. A unique group number was allocated to each set of polyps seen
at a particular examination for the MULTIPLE_POLYP_GROUP field. For the MULTIPLE_GROUP_LINKING, a
unique group number was allocated for a set of polyps seen across many examinations and in most cases
it was associated with the multiple polyp group where the polyp set was seen first time. The program
iterated through each MULTIPLE_POLYP_GROUP starting with GROUP1 and grouped all polyps within that
set which had been seen at any examination and allocated the MULTIPLE_GROUP_LINKING number.
The following rules were used to associate individual polyps to groups.
Any polyps:
l that were ‘multilinked’ to the group
l with the same polyp number to the first group they were seen
l with the same polyp number as another multiple row that had linked polyps.
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The polyp number was reset for all polyps that were part of a multiple polyp group and the data clerks
then had to identify individual polyps that were part of the same MULTIPLE_GROUP_LINKING group across
all examinations, and allocate the same polyp number to them.
Within a ‘Multiple row group’ there may be:
l Endo quantity rows (e.g. many, several, multiple).
l Multilinked polyps – polyp rows containing further details on specific polyps of the ‘endo quantity row’
which are linked by the polyp_id (i.e. polyps at the same examination).
l Individual linked polyps – polyps within the ‘endo quantity rows’ that are seen at other examinations.
l Individual polyps – polyps that are never part of the group.
It was decided that in order to analyse these records, each endo quantity row had to be ‘multiplied out’
into single polyp rows, and the data available and some rules were used to calculate the number of polyp
rows to be added. If the group of polyps was linked to groups that had been seen previously and not fully
excised then a method was used to ensure that the same polyp number was allocated to those polyps to
show the reoccurrence. The information recorded on the endo quantity row (such as segment, histology,
size, etc.) was also copied over to the new polyps as it applied to all the polyps in the group.
A variable called ‘total polyps’, which was the number of unique polyps seen for the endo quantity
rows across all examinations was calculated using multilinked polyps, individual linked polyps and
derived_polyp_number. The variable ‘same examination polyps’ field was calculated to provide the total
number of multilinked polyps present at the same examination.
First, the following estimated quantities were assigned based on the endo quantity other field:
ENDO_QUANTITY_OTHER ESTIMATED_QUANTITY
Few 3
Some 3
Number of 3
Several 3
Many 5
Multiple 5
The following hierarchy was then used to calculate the maximum number of polyps ‘max rows’ that made
up the multiple rows.
Use:
1. the largest of total polyps, same examination polyps and approximate quantity only if approximate
quantity > 0
2. the largest of total polyps, same examination polyps and ‘average of minimum quantity and maximum
quantity‘ only if minimum quantity > 0 and maximum quantity > 0
3. the largest of total polyps, same examination polyps and maximum quantity if maximum quantity > 0
4. the largest of minimum quantity, estimated quantity, same examination polyps and total polyps if
minimum quantity > 0 and if approximate quantity and maximum quantity are blank
5. the largest of estimated quantity, same examination polyps and total polyps if the total polyps > 0 or
same examination polyps > 0
6. the maximum of estimated quantity.
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The ‘max rows’ were then used to assess how many new rows should be created. The following rules
were used:
1. If max rows = same examination polyps and excision extent is ‘partially excised’ then add one new
polyp row.
2. If max rows = same examination polyps and excision extent is not ‘partially excised’ then no rows to add.
3. Otherwise new polyp rows = (max rows – same examination polyps).
Derived examination date created
Endoscopy and pathology reports sometimes had different types of date associated with them. In addition,
where the endoscopy report was missing, a pathology based procedure report was created and the date
of procedure was based on the pathology report. In order to define a true ‘examination date’ for every
procedure, these dates were put into the following order of precedence, from most to least important.
Date:
1. of procedure
2. of collection of biopsy specimen
3. on which biopsy specimen was received at laboratory
4. on which report was written by pathologist.
Derived examination numbers created
When it was unclear what order a patient’s examinations occurred in, manual examination numbering was
done by coders. This was necessary for patients with one or more missing examination dates or with two or
more procedures on the same date. Following manual examination numbering, a ‘derived_exam_number’
was then created to order all remaining examinations, accounting for any examination numbering that was
assigned by coders. It was necessary to understand the order in which examinations occurred in to be able
to group them into visits and accurately assign risk groups.
Derived polyp segments created
Sometimes the segment recorded across sightings of the same unique polyp varied. For example, at one
examination the polyp may be described as a sigmoid lesion, whereas at another it may be in the
rectum. In order to define a true polyp segment, two derived polyp segment fields were created. The
‘derived_polyp_segment’ field contained either the segment the polyp was found in or, if a range of segments
was given, the most distal segment. If a range of segments was recorded, ‘derived_polyp_segment_to’
contained the most proximal segment.
Derived polyp numbering created
Sometimes a polyp that was found at one endoscopy was seen again at a later endoscopy. This was
because the polyp was not removed or was only partially removed (i.e. de-bulked or biopsied).
Alternatively, some residual polyp may have been left intact or there may have been re-growth after
presumed complete excision. A number of patients required manual polyp numbering in order to ensure
that a unique polyp was not counted more than once. A ‘match probability’ was used to indicate the
degree of certainty that matched polyps were the same unique lesion. A single polyp was used as a
reference from which all other possible matches were then based. All information provided in the
endoscopy and pathology reports was used to identify unique polyps that needed to be matched. Polyp
numbering guidelines were used to match polyps accurately and methodically, with particular attention
given to the following factors, listed in order of importance:
1. segment (proximity)
2. length of time passed between examinations
3. indication that polyp was not removed or was partially removed (i.e. de-bulking, discomfort)
4. excision extent/excision complete
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5. bowel preparation
6. method of excision
7. size
8. dysplasia
9. adenoma type
10. histology.
After manual polyp numbering was completed, a cut-off of 70% was chosen following a review of the
data, meaning that, for each patient, polyps numbered the same with a match probability of ≥ 70% were
considered to be the same lesion. All other polyps in that patient were then assigned a unique number
that was stored in the ‘derived polyp number’ field.
Three derived polyp size fields created
On the study database, size was recorded using a number of fields in order to accommodate the different
types of information relating to polyp size that were supplied in endoscopy and pathology reports.
The following endoscopy and pathology sizes were recorded on the database: assume_endo_size,
endo_size, endo_size_min, endo_size_max, endo_size_other, assume_endo_size_other, path_size and
assume_path_size. In addition to these, eight new fields were created on the polyp table to record
derived polyp sizes that were based on the original size fields. There were three main derived size fields:
derived_endo_size, derived_endo_size_other and derived_path_size, which were used to define true polyp
size [see Rules applied after data compilation, below (rule 14: True values for polyps found during and
prior to baseline, part A – true values]. All of the derived fields are described below:
l derived_endo_size – derived from the fields assume_endo_size, endo_size, endo_size_min,
endo_size_max and derived_endo_range (assume_endo_size took precedence over endo_size)
l derived_endo_size_source – shows which field the size was taken from
l derived_endo_size_other – derived from the fields assume_endo_size_other and endo_size_other
(assume_endo_size_other took precedence)
l derived_endosize_other_source – shows which field the size was taken from
l derived_path_size – derived from the fields assume_path_size and path_size (assume_path_size
took precedence)
l derived_path_size_source – shows which field the size was taken from
l derived_endo_range – complex field to deal with polyp groups, see rules below.
The rules used to define these derived sizes were numerous and complex, particularly for
derived_endo_size.
Endoscopy sizes
The derived_endo_size was assigned using an algorithm that took into consideration assume_endo_size,
endo_size, endo_size_min and endo_size_maximum. It was particularly difficult to define the use of
endo_size_max and endo_size_min in the algorithm.
For all cases where endo_size_max was the only size recorded, it was suggested that no size should be
assigned, as this field was thought to be too unreliable. It was problematic to assign a derived_endo_size
to polyps that only had an endo_size_max and no other size because when an endoscopist used
endo_size_max it was often to describe the sizes of a group of polyps. Thus, endo_size_max may have
truly applied to only one of the polyps in a group, resulting in an inaccurate true polyp size being assigned
to other lesions in the group, if it were used. This would then lead to such polyps being classified as higher
risk than they really were. If endo_size_max was ≤ 5 mm then it was assumed to be the correct size, as the
size was only small. In cases for which there was only one polyp, it was also assumed that the polyp’s size
was endo_size_maximum.
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Alternatively, in some cases, a polyp had already been assigned endo_size_max as an actual endo_size; if a
patient had endo_size_max applied to a group of polyps and an individual polyp at that examination had
an actual endo_size identical to the endo_size_max, and the polyps were all in the same segment or
segment range or had no segment, then it was assumed that an individual polyp had already been
assigned the maximum size and thus the other polyps in the group were deemed to be of an ‘unknown’
size. This was done automatically (see derived endo range). Coders reviewed the remaining cases for which
a group of polyps had only endo_size_max in order to determine which polyp was the largest in the
group. Others in the group were then be deemed to be of an ‘unknown’ size.
Some polyps had only endo_size_min and endo_size_max available to assign derived_endo_size. These polyps
were also problematic, as it was not appropriate to assign a true polyp size by calculating an average of the
two sizes, particularly in cases for which the endo_size_min and endo_size_max differed considerably. As with
endo_size_max, the endo_size_min and endo_size_max fields tended to be used to when a group of polyps
was seen at endoscopy. There were two particular scenarios: scenario A occurred when an endoscopy report
provided specific size (and site) details for individual polyps; however, a size range was used by coders so that
pathology could be assigned to a polyp, as the pathology report did not give sufficient detail to determine
to which polyp the histology belonged. Scenario B arose when the endoscopy report gave only broad details
of size (and site) for a group of polyps, so a size range had to be used because no individual polyp details
were given, for example 10 polyps of between 5 and 25 mm. Polyps that fell into each scenario had to be
reviewed manually to try and assign more specific sizes, wherever possible.
For scenario A
l When endoscopy reports gave the actual size (and site) of individual polyps, the specific size and site
details were put into to the actual_endo_size (and segment) field.
In order to assign histology to specific polyps, rules were devised and it was proposed that an additional
field called ‘endo path mapping’ was added. Using this new field, the specific rule used to assign the
histology could be set for any polyps that were assumed to be related to a specific histological description
within the pathology report.
Pathology was assigned to a specific polyp using the following criteria:
1. Histology most likely to be associated with a large polyp was assigned to the largest lesion. Specifically,
the largest polyp was villous, severely dysplastic, tubulovillous and, finally, mild/moderately dysplastic
(in order of histological features most predictive of largest size).
2. In general, hyperplastic polyp pathology was assigned to the most distal lesion but only if this lesion
was < 5 mm.
3. Excision extent – polyps that were snared were assumed to be larger than those that were hot biopsied.
4. When the rules above could not be used then it was assumed that specimen labels (i.e. 1–10/A-E, went
from the most proximal to most distal site).
For scenario B
l When the endoscopy report only gave a range of sizes and segments for a group of polyps, coders
tried to assign one lesion the smallest size and one the largest, using the same rules for assuming
histology.
l In cases for which there were only two polyps, this resolved size for both polyps. In cases for which there
were more than two polyps, coders tried to determine an assumed size for other polyps in the group.
l If it was not possible to assign the smallest and largest size, then coders tried to assign one lesion the
largest size.
l If it was impossible to assume specific size for any polyps then size ranges were left. The sizes of polyps
that were not assigned an assumed endo size were deemed ‘unknown’.
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Specifically, the following records were reviewed:
l endo_size_min is < 10 mm, endo_size_max is ≥ 10 mm AND sizes differ by ≥ 3 mm
l endo_size_min is ≥ 10 mm, endo_size_max is ≥ 15 mm AND sizes differ by ≥ 5 mm
l endo_size_min is ≤ 5 mm, endo_size_max is 6–9 mm AND sizes differ by ≥ 2 mm
l endo_size_min is > 5 mm, endo_size_max is ≤ 9 mm AND sizes differ by ≥ 3 mm.
For cases that were not reviewed, an average was assigned to all polyps for which endo_size_min and
endo_size_max did not differ considerably, whereas ‘unknown’ was assigned to all polyps in the review
that were not assigned an assumed size. An average was also assigned to any cases with just one polyp
with endo_size_min and endo_size_max.
Derived endo range
The derived_endo_range field was used to automatically derive sizes for polyp groups (polyps found at
the same examination) made up of polyps with an endo_size_min or endo_size_max and another polyp(s)
with the same endo_size or assume_endo_size as the endo_size_max of the other polyps in the group,
all of which had the same segment. The segments and sizes had to match in order to assign the
derived_endo_range, as otherwise one could not be sure that all of the polyps were part of the same
group. It was not possible to calculate a derived_endo_range for polyps with both endo_size_min and
endo_size_max, or in cases where the segments of the polyps in the group were different. Cleaning
incident 404 was created to review such records manually, and, once reviewed, the derived_endo_range
was set to blank. The rules used for derived_endo_range were as follows.
1. Group A1: Polyp with an endo_size_max of ≤ 5 mm and no endo_size_min. The derived_endo_range
was set to endo_size_max.
2. Group A2: Polyp with an endo_size_min of ≤ 5 mm and no endo_size_max. The derived_endo_range
was set to endo_size_min.
3. Group X1: Polyp with an endo_size_min and endo_size_max that both matched the assume_endo_size
or endo_size of polyps at the same endoscopy with the same segment. Such polyps were allocated their
assume_endo_size or endo_size and the other polyps with that range were allocated ‘unknown size’ as
the derived_endo_range.
4. Group Y1: Polyp with an endo_size_max that matched the assume_endo_size or endo_size of another
polyp at the same examination, but the segments did not match. The record was reviewed manually.
The derived_endo_range was set to assume_endo_size or endo_size for the polyp that had this
information and ‘unknown’ for the other polyps at the endoscopy with the same endo_size_max and
no assume_endo_size or endo_size and any segment.
5. Groups B, C and D set the derived_endo_range to endo_size for the main polyp and ‘unknown’ for the
rest of the group when there was only endo_size_max (not endo_size_min) and it matched the
endo_size of the main polyp in the group.
¢ B was applied for groups when just endo_segment for all polyps in the set.
¢ C was applied for groups when endo_segment and endo_segment_to were recorded for all polyps
in the set.
¢ D was applied for groups when neither endo_segment and endo_segment_to were recorded for all
polyps in the set.
6. Groups E, F and G set the derived_endo_range to endo_size for the main polyp and ‘unknown’ for the
rest of the group when there was only endo_size_min (not endo_size_max) and it matched the
endo_size of the main polyp in the group.
¢ E was applied for groups when just endo_segment was recorded.
¢ F was applied for groups when endo_segment and endo_segment_to were recorded.
¢ G was applied for groups when neither endo_segment and endo_segment_to were recorded.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
442
7. Groups H, I and J set the derived_endo_range to assume_endo_size for the main polyp and ‘unknown’
for the rest of the group when there was only endo_size_max (not endo_size_min) and it matched the
assume_endo_size of the main polyp in the group.
¢ H was applied for groups when just endo_segment was recorded.
¢ I was applied for groups when endo_segment and endo_segment_to were recorded.
¢ J is applied for groups when both endo_segment and endo_segment_to are blank for all polyps in
the set.
8. Groups K, L and M set the derived_endo_range to assume_endo_size for the main polyp and
‘unknown’ for the rest of the group when there was only endo_size_min (not endo_size_max) and it
matched the assume_endo_size of the main polyp in the group.
¢ K was applied for groups when just endo_segment was recorded.
¢ L was applied for groups when endo_segment and endo_segment_to were recorded.
¢ M was applied for groups when neither endo_segment and endo_segment_to were recorded.
9. The derived_endo_range was set to blank if the group had been reviewed as part of incident 404.
Size discrepancies
Although work on polyp size was being undertaken, cases were identified that had large discrepancies
between the sizes recorded in different fields, at the same examination and at different examinations (for a
unique polyp). Although most discrepancies seemed to be due to different measuring techniques used by
endoscopists and pathologists, some reports had a coding or transcription error/typo and one of the sizes
could be amended. As 10 mm is an important cut-off point at which a polyp becomes classified as high
risk, for discrepancies at the same examination there was a manual review of cases for:
l endo_size 10–20 mm and path_size ≥ 40 mm
l endo_size < 10 mm and path_size ≥ 20 mm
l endo_size_other = tiny, small, < 5 mm, 5–9 mm, ≤ 10 mm and pathology size ≥ 20 mm.
At different examinations the following were reviewed (polyps matched with a probability of ≥ 70%):
l endo_size < 10 mm at any examination and path_size ≥ 30 mm at any subsequent examination
l endo_size < 10 mm at any examination and endo_size ≥ 30 mm at any subsequent examination
l endo_size 10–20 mm at any examination and path_size ≥ 40 mm at any subsequent examination
l endo_size 10–20 mm at any examination and endo_size ≥ 40 mm at any subsequent examination
l endo_size_other = tiny, small, < 5 mm, 5–9 mm, ≤ 10 mm at any examination and endo_size or
path_size ≥ 30 mm at any subsequent examination.
Two new fields were added to the database to accommodate the review: ‘assumed endo size’ and
‘assumed path size’. The correct ‘assumed’ size was coded in the appropriate field, which took precedence
over endo_size or path_size. When doing the review, in order to identify and resolve the size errors,
particular attention was paid to the excision method (i.e. was the method most viable for the removal of a
large polyp or a small polyp) and the follow-up and patient’s history in general.
Additionally, for certain centres it seemed that endoscopy size was always recorded using the term ‘max
endo size’, so these cases were identified and reviewed in order for the size to be correctly assigned to the
endoscopy size field instead.
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Derived endoscopy size
Once the derived_endo_range was generated and size discrepancies were reviewed and corrected where
necessary, rules were applied to obtain the derived_endo_size. The first set of rules were applied to
any polyps that were not a quantity row (i.e. endo_quantity_other has a value) or a multilinked polyp
(i.e. path_multi_endo_link has been set).
1. Assume_endo_size took precedence over all endoscopy sizes, as this was field used to indicate any
corrected sizes that should be used.
2. Endo_size took precedence over all endoscopy sizes except assume endo size, as this was deemed to
be the next most accurate size available.
3. The automated derived_endo_range took precedence over all endoscopy sizes except
assume_endo_size and endo_size, as this field took account of issues surrounding endo_size_min and
endo_size_max and the way in which they were used to describe groups of polyps.
4. If there was only one polyp at an examination with endo_size_max and no other size then
derived_endo_size must use this value.
5. If there was only one polyp at an examination with endo_size_min and no other size then
derived_endo_size must use this value.
6. If there was only one polyp at an examination with just endo_size_min and endo_size_max then the
average of endo_size_min and endo_size_max was used, as it was clear that this applied to only the
one polyp and not to a group.
7. A polyp with only endo_size_min, and endo_size_max which was not reviewed, was applied an
average of endo_size_min endo_size_min.
8. A polyp that was reviewed and did not have endo_size and assume_endo_size was set as Unknown.
9. For a polyp that was reviewed and did not yet have derived_endo_size, which had no endo_size_min
and endo_size_max ≤ 5, the derived_endo_size was set to the endo_size_max.
10. For a polyp which was reviewed and did not yet have derived_endo_size, which had no
endo_size_max and endo_size_min ≤ 5, the derived_endo_size was set to the endo_size_min.
11. A polyp that did not yet have a derived endo size and was not in IA Cohort was not allocated a size.
This was because, in order to classify derived_endo_size for such cases, all patients would have to be
reviewed under incident 404E and 404F, not just those in the IA cohort.
Slightly different rules were applied to patients with multiple polyps (patients with a ‘quantity other’ or
multilinking, when an individual polyp row represents more than one polyp). A mp_set (multiple polyp set)
was defined as a group of polyps at the same examination, which was made up of a polyp with a quantity
row (i.e. endo_quantity_other has a value) and another group of polyps that were multilinked to it
(i.e. path_multi_endo_link of these polyps is equal to the polyp_id of the quantity row). The following
additional rules were also applied to this group.
1. Allocated the endo_size_min as derived_endo_size if the polyp was not a quantity row or a multilinked
polyp. The derived_endo_size was a not yet set and the endo_size_max was null. The endo_size_min
did not match any endo_size, assume_endo_size or endo_size_min of another polyp at the same
endoscopy.
2. Allocated the endo_size_max as derived_endo_size if the polyp was not a quantity row or a multilinked
polyp. The derived_endo_size as a not yet set and the endo_size_min was null. The endo_size_max
did not match any endo_size, assume_endo_size or endo_size_max of another polyp at the same
endoscopy.
3. Allocated the average of endo_size_min and endo_size_max as derived_endo_size if the polyp was not
a quantity row or a multilinked polyp. The derived_endo_size was not yet set and there were no other
polyps at the same endoscopy.
4. Allocated the average of endo_size_min and endo_size_max as derived_endo_size to all polyps when
size was ≤ 5 except for any polyps that already had a minimum/maximum allocated. Records with
unknown size were overwritten when this applied (derived_endo_range remained as unknown so it is
clear when this was done).
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
444
5. Derived_endo_size was set to endo_size_min when there was only endo_size_min and it was ≤ 5.
This size was allocated to all polyps in the group unless they already had a derived value. Records with
unknown size were overwritten when this applied (derived_endo_range remained as unknown so it is
clear when this was done).
6. Derived_endo_size was set to enod_size_max where there was only endo_size_max and it was ≤ 5.
This size was allocated to all polyps in the group unless they already had a derived value. Records with
unknown size were overwritten when this applied (derived_endo_range remained as unknown so it is
clear when this was done).
7. An average of endo_size_min and endo_size_max was allocated to all polyps that were still without
derived_endo_size, irrespective of the magnitude of these sizes, except for any polyps that already had
a minimum/maximum allocated. It did not overwrite records with ‘unknown’ when this applied.
Derived endoscopy size other
Derived_endo_size_other was derived from the fields’ assume_endo_size_other and endo_size_other with
assume_endo_size_other always taking precedence over endo_size_other, as this field was used to code
corrected ‘assumed’ sizes. Derived_endosize_other_source shows the field from which the size was taken.
Derived pathology size
Derived_path_size was derived from the fields’ assume_path_size and path_size with assume_path_size
always taking precedence over path_size, as this field was used to code corrected ‘assumed’ sizes.
Derived_path_size_source shows the field from which the size was taken.
Data compilation in Stata
Dropped patients without endoscopies
Patients who did not have any endoscopies present on the study database were removed before analysis, as
there was no way to ensure that the patient had a colonoscopy. As such, their baseline risk could not have been
calculated with much accuracy, as there was no way to guarantee that their entire colon had been examined.
Additionally, important clinical information may have been missing, for example genetic predisposition to CRC or
FAP. Such patients would originally have had some form of endoscopic procedure on the database otherwise
their pathology report(s) would not have been extracted from the hospital; however, this was then removed at a
later date, most likely because it was for an upper gastrointestinal procedure.
Dropped auto-excluded patients
Some patients were auto-excluded prior to manual coding based on words found within their endoscopy
or pathology reports, such as cancer, FAP or HNPCC. These patients were dropped from the analysis,
as they had not been coded.
Rules applied after data compilation
1. Numeric endoscopy size other.
2. Derived procedure type.
3. Derived pathology histology.
4. Relabel as adenomas based on villousness/dysplasia.
5. Choose patients with one or more adenomas found.
6. Exclude any patients with missing examination dates.
7. Relabel any ≥ 10-mm polyps without histology as assume adenoma.
8. Apply baseline rules: define prior, baseline, follow-up.
9. Extend baseline.
10. Redefine baseline for patients without baseline colonoscopy.
11. Cancer matching rules.
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12. Apply exclusions for conditions.
13. Adding in situ cancers and recoding histology in relation to cancer/in situ cancer.
14. True values for polyps found during, and prior to, baseline.
15. True values to be applied across all sightings of polyps.
16. Baseline risk groups.
17. Relabel procedure types of baseline endoscopies.
18. Indicate that patients do not have confirmed baseline colonoscopy.
19. Follow-up visit numbering.
20. True values for polyps found during follow-up visits.
21. Start/end date collecting records at each centre.
22. Cancer and AA end points.
23. Procedure types at follow-up visits.
24. Visit date and visit intervals.
25. Censoring of examinations after patient diagnosed with certain conditions.
26. Deaths information.
27. Tracing information.
28. Map previously seen cancers from external sources.
For each rule, a lay description is provided followed by the statistician’s technical description.
Rule 1: numeric endoscopy size other
On the study database, size was recorded using a number of fields to accommodate the different types of
information relating to polyp size that were supplied in endoscopy and pathology reports. The following
endoscopy and pathology sizes were recorded on the database: assume endo size, endo size, endo size
min, endo size max, endo size other, assume endo size other, path size, assume path size.
The ‘endoscopy size descriptor field’ was used in cases for which a ‘vague’, qualitative or approximate size
description was given in the endoscopy report. A numerical value was derived for each size description by
analysing reports for which both qualitative size descriptions and a precise numerical size was given.
The median and IQR was calculated for each numeric size field and cross-tabulated against associated
categories of the endoscopy size descriptor field, as shown in the table below.
Endoscopy size descriptor
category (mm)
Endoscopy size (mm)
Derived value
size (mm) Rationale for derived value sizeMedian (IQR) n
Tiny 3 (2–3) 660 3 Used the median
Small 3 (3–5) 1574 5 Used the larger value of 5 mm to draw
a distinction between Small and Tiny
< 5 3 (2–3) 35 3 Used the median
5–9 n/a 0 7 No examples so took the halfway point
< 10 8 (8–8) 3 8 Used the median of available examples
≥ 10 15 (13–15) 79 15 Used the median
Large 20 (12–30) 2701 20 Used the median
n/a, not applicable.
At analysis, this field had to be assigned quantitative values to enable the classification of each patient’s
baseline risk. Analyses were performed to compare the actual sizes recorded in ‘endo size’ and ‘path size’
with the values recorded in ‘endo size other’, wherever possible. After lengthy discussion, specific sizes
were assigned to each ‘endo size other’ value based on this, and on rationality, as shown above.
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Rule 2: derived procedure type
The study database contained two types of examination reports: those that originated from endoscopy
databases at study hospitals and those that were manually generated from histology reports (taken from
pathology databases) using any clinical and procedural information available. The latter, which were
termed pathology-based procedure reports, did not exist on endoscopy databases, whereas a histology
report was extracted, no corresponding endoscopy report was identified. Both of these types of
examination report had a range of procedure types, such as proctoscopy, sigmoidoscopy, colonoscopy and
surgery. In some cases, however, there was no procedure type described in the report, so the procedure
was deemed an ‘unknown’ procedure. There were also examinations which were vaguely described as
being an endoscopy.
The second rule applied to the data was to relabel certain procedure types and create a ‘derived procedure
type’, where appropriate, with particular focus on those examinations with an unknown procedure type or
examinations which appeared to have an incorrect procedure type given the segment of the colon that
was visualised. (Colonoscopy is abbreviated to ‘col’, flexible sigmoidoscopy to ‘flexi-sig’ and rigid
sigmoidoscopy to ‘rigid sig’ for the purpose of this rule.)
First, all pathology based procedure reports were relabelled with the group term ‘col, flexi-sig or rigid sig’.
Comparatively, all ‘true’ endoscopies (i.e. ones taken from the endoscopy database) were relabelled with
the term ‘col or flexi-sig’. Next, all proctoscopies were relabelled as ‘rigid sig’ because both procedures
reach a similar segment of the bowel and proctoscopies are extremely rare. Then, any sigmoidoscopies
that were obtained from endoscopy databases were relabelled as ‘flexi-sig’, and sigmoidoscopies that were
pathology based procedure reports were called ‘flexi-sig or rigid sig’.
Unknown procedures obtained directly from an endoscopy database were relabelled as ‘col or flexi-sig’.
Unknown procedures that were pathology based procedure reports were relabelled in this way only if they
had bowel preparation/segment reached/distance reached fields completed, as such information clearly
indicated that the procedure must have been endoscopic in nature. In addition, unknown procedures that
were pathology-based procedure reports and did not have certain notable features (pathology blank/
pathology truncated/pathology unclear specimen origin) were relabelled as ‘col, flexi-sig or rigid sig’, as
although the possibility of a rigid sigmoidoscopy could not be ruled out, a surgical procedure could be. It
was possible to identify a pathology report that was obtained from a surgical procedure, as long as the
report was complete.
No procedures taken from endoscopy databases were relabelled as rigid sigmoidoscopies because this type
of procedure was rare and is unlikely to have been recorded on the endoscopy database, as it would most
likely have taken place in outpatient clinic rather than at an endoscopy clinic.
Any procedures that were consequently labelled as ‘col, flexi-sig or rigid sig’ as a result of the above rules
were then relabelled as ‘col or flexi-sig’ if a large lesion (≥ 10 mm) or three or more adenomas were
removed at that procedure, if polyps were seen in the sigmoid colon or beyond or if the procedure
reached the sigmoid colon or more beyond (determined from the ‘segment reached’ field), as these
features ruled out the possibility of a rigid sigmoidoscopy. Additionally, if the above criteria were satisfied,
all procedures labelled as ‘flexi-sig or rigid sig’ were subsequently relabelled as ‘flexi-sig’.
Finally, all procedures labelled as ‘flexi-sig’, ‘rigid sig’, ‘flexi-sig or rigid sig’, ‘col or flexi-sig’ or ‘col, flexi-sig
or rigid sig’, or endoscopies which reached the transverse colon or beyond, or had polyps found in this
region of the bowel, were relabelled as colonoscopies, as it is unlikely that a sigmoidoscopy of any type
would have reached so far into the bowel.
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Create “derived_procedure_type” which is used from here onwards when referring to procedure types.
Note: “phantoms” are examinations that were not on the endoscopy database – a phantom endoscopy
examination was created for the pathology we have.
1. Endoscopy examinations that are phantoms are relabelled as “col, flexi-sig or rigid sig”
2. Endoscopy examinations that are not phantoms are relabelled as “col or flexi-sig”
3. Procotoscopies are relabelled as “rigid sig”
4. Sigmoidoscopies that are not phantoms are relabelled as “flexi-sig”
5. Sigmoidoscopies that are phantoms are relabelled as “flexi-sig or rigid sig”
6. Procedures labelled as unknown that are not phantoms are relabelled as “col or flexi-sig”
7. Procedures labelled as unknown that are phantoms are relabelled as “col or flexi-sig” if they have bowel
preparation/segment reached/distance reached fields completed
8. Procedures labelled as unknown that are phantoms are relabelled as “col, flexi-sig or rigid sig” if they do
not have any of the following notable features – pathology blank/pathology truncated/pathology unclear
specimen origin
9. Procedures labelled as “col, flexi-sig or rigid sig” or can be relabelled as “col or flexi-sig” if ≥ 10 mm lesion
removed or 3+ adenomas removed or polyps in SC or more proximal or segment reached is SC or
more proximal
10. Procedures labelled as “flexi-sig or rigid sig” can be relabelled as “flexi-sig” if ≥ 10mm lesion removed or
3+ adenomas removed or polyps in SC or more proximal or segment reached is SC or more proximal
11. Procedures labelled as “flexi-sig”, “rigid-sig”, “flexi-sig or rigid sig”, “col or flexi-sig”, “col, flexi-sig or rigid
sig” that reach/have polyps found in TC or more proximal are relabelled as “colonoscopy”
Note: phantom endoscopies were later renamed pathology-based procedure reports.
Rule 3: derived pathology/histology
In some cases, coders assigned assumed histology if it appeared that the actual histology was inaccurate or
incorrect in some way. This generally occurred during cleaning incidents to prepare the data for analysis.
In particular, assumed histology was assigned when reviewing groups of polyps, as these were sometimes
vaguely described by the endoscopist and/or pathologist, making it difficult to assign histology to specific
polyps. Rules were used to resolve such cases, which are described below (see rule 14).
In terms of analysis, the histology field was always overridden with the assumed histology, if it was
present, which was used to create a field called derived_path_histology. In addition, if histology was coded
as an adenoma or cancer, and assumed histology was also present, the adenoma type (villousness) and
dysplasia were set to blank. As the polyp was assumed to be something other than an adenoma or cancer,
it would no longer be appropriate for it to be associated with the other histological features that it was
previously thought to possess.
Replace histology (“path_histology”) with assumed histology assigned by coders (“assume_path_histology”) if
assumed histology is completed, to create a field called “derived_path_histology”.
Replace the adenoma type (“path_adenoma_type”) and dysplasia (“path_dysplasia”) as blank if histology
(“path_histology”) is adenoma or cancer (codes 69, 55, 59, 58, 51, 50, 52, 65, 62, 53, 3, 1, 56) and assumed
histology (“assume_path_histology”) is not adenoma or cancer. This is to correct cases where the adenoma
type and dysplasia is no longer applicable (e.g. adenoma→ inflammation).
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Rule 4: relabel as adenomas based on villousness/dysplasia
Owing to missing or incomplete data in pathology reports, some polyps did not have any value coded in
their histology field. In such cases, if the polyp had an adenoma type (villousness) and/or dysplasia
type coded, it was assumed that the polyp was an adenoma and the histology was relabelled as
‘assume_adenoma’. This was a fair assumption, as villousness and dysplasia are both typical histological
features of a classical adenoma.
Based on this, polyps with a histology value of ‘not possible to diagnose’ that had an adenoma type
(villousness) and/or dysplasia type coded were also assumed to be adenomas as were relabelled
as ‘assume_adenoma’.
This rule was applied regardless of whether or not the polyp had histology at another sighting or if the
patient had an adenoma at any time. The histology was not relabelled for any matched polyps (only done
to polyps that fitted the criteria above).
Relabel as “assume adenoma”, any polyps without histology or with histology “not possible to diagnose”
(“derived_path_histology”), and which have villousness (“path_adenoma_type”) and/or dysplasia
(“path_dysplasia”) completed (any value), regardless of whether that polyp has histology at another time or
whether patient has an adenoma at any time. Only the polyp sightings with these criteria are relabelled and
not all matched polyps.
Create variable called “path_hist_incl_assume_adenoma” where “assumed adenomas” are assigned value 97.
Rule 5: choose patients with one or more adenomas found
For inclusion in the IA cohort, patients had to have at least one adenoma present, with a pathology report
confirming that the polyp was indeed adenomatous in nature. This was essential, as the study’s aim was to
examine surveillance intervals in individuals with IR adenomas.
Patients must have at least one adenoma found: pathology for adenoma, serrated adenoma, mixed adenoma/
hyperplastic, unicryptal adenoma or assumed adenoma (‘path_hist_incl_assume_adenoma’ = 1, 3, 53, 56, 97).
Rule 6: exclude any patients with missing examination dates
There were a number of examinations without a date, which coders reviewed when doing examination
numbering. A large proportion of outstanding cases occurred at a single hospital (St Mark’s Hospital) so an
attempt was made to find the examination date by visiting the hospital again to examine the Patient
Administration System. Despite this, it was not possible to classify examinations without a date that had
remained unnumbered following the examination numbering review. It was therefore necessary to exclude
patients with an examination that was missing procedure data, as it was not possible to group such
examinations into visits, which was essential to classify surveillance intervals accurately.
Remove any patients where 1 + endoscopy is missing its date.
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Rule 7: relabel any ≥ 10-mm polyps without histology as assume adenoma
Another rule, similar to rule 4, was used to assign histology to polyps that were missing this information.
Any polyps that were ≥ 10 mm in size with no histology or histology of ‘unable to diagnose’ were
assumed to be adenomas, so the histology was relabelled as ‘assume_adenoma’. A size of ≥ 10 mm was
assessed using the derived size fields (derived_endo_size, derived_endo_size_other and derived_path_size).
This rule was applied to only those patients with at least one actual adenoma. Relabelling of an individual
polyp’s histology was done only if the polyp in question had no histology other than ‘not possible to
diagnose’ or was missing histology at all of its sightings. The histology was relabelled for only the polyp
that fitted the above criteria, not for any matched polyps.
Any ≥ 10-mm polyps without histology or histology recorded as “specimen not seen” or “not able to diagnose”
will be relabelled as “assume adenoma” (use “path_hist_incl_assume_adenoma”). Relabelling occurs only for
polyps which have no histology or “specimen not seen” or “not able to diagnose” at all of their sightings
(use “derived_polyp_number” and “path_hist_incl_assume_adenoma”). Only the polyp sightings with these
criteria are relabelled and not all matched polyps. Use derived sizes (“derived_endo_size”, “derived_path_size”
or “derived_endo_size_other”) to determine size (i.e. if any of these ≥ 10 mm).
Note: this rule is only applied to patients who have at least one adenoma already.
Rule 8: apply baseline rules: define prior, baseline, follow-up
Pre-baseline checks
First, before baseline was defined, checks were carried out to ensure that all patients fulfilled the required
criteria. Namely, a check was done to make sure that there were no polyps with both group1 and group 2
histology, or polyps with more than one type of group 2 histology (see rule 14). Any such histology
combinations were had to be checked by coders and corrected; however, the following exceptions
were allowed:
l Polyps with group 2 histology of only one type and group 1 histology of ‘normal mucosa’, ‘granulation
tissue’, ‘previous polypectomy site’, ‘not possible to diagnose’ or ‘specimen not seen’. In these cases
the group 1 histology was removed.
l Polyps with group 1 and group 2 histology (not of the combinations above) that was caused by
multiplication out of multiple rows (see rule 1). In these cases the group 2 histology was removed.
l Polyp with histology of ‘anal wart’ and ‘squamous cell carcinoma’ (both are group 2) at different
sightings. Such cases were acceptable as long as these different histology types did not both occur
within baseline or within follow-up (time between the occurrence of each one was estimated).
l Polyps with histology of ‘inflammation’ and ‘oedema’ at different sightings (both group 2). In these
cases inflammation took precedence over oedema.
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(a) Checks to do for polyps seen at more than one sighting:
Before apply baseline check that a polyp across all its sightings does not have both group 1 and group 2
histology (see lists below) or if polyp only has group 2 histology it does not have more than one type of group 2
histology (use “path_hist_incl_assume_adenoma”).
Exceptions to this rule are:
if a polyp has reported both group 2 histology (any but only one type) and group 1 histology from normal
mucosa, granulation tissue, previous polypectomy site, not possible to diagnose or specimen not seen
(codes 6, 34, 39, 90, 91)→ remove group 1 histology from “path_hist_incl_assume_adenoma”
if a polyp has group 1 and group 2 histology (not of the combinations above) which is caused by multiplication
out of multiple rows→ remove group 2 histology from “path_hist_incl_assume_adenoma”
if a polyp is reported as anal wart (code 72) and SCC (code 61) at different sightings (both group 2)→ ok as
long as not both within baseline or both within follow-up (estimate time apart)
if a polyp is reported as inflammation (code 15) and oedema (code 22) at different sightings (both group 2)
→ inflammation takes precedence.
Any further combinations across sightings that are not listed as exceptions are checked by the coders
and corrected.
Defining prior, baseline and follow-up visits
The baseline period had to be carefully defined, as the lesions found during this time frame were used to
classify each patient’s baseline risk of CRC and stratify them into risk groups (i.e. low, intermediate or
high). Prior and follow-up visits were then defined around the baseline period, with the length of time
between baseline and follow-up visits being used to determine surveillance intervals. Specifically, prior
examinations were defined as any examinations that occurred before the baseline visit, and follow-up
examinations were defined as any examinations that occurred after the baseline visit.
The baseline visit was defined as a period of time starting from the earliest examination at which an
adenoma or ‘assume adenoma’ was present. Sometimes polyps were seen but not diagnosed as adenomas
until a later examination. Using polyp matching to identify such cases, baseline was shifted back to the
first sighting of the adenoma if the prior matched polyp had histology of hyperplastic polyp, previous
polypectomy site, granulation tissue, normal mucosa, was not possible to diagnose or specimen not seen
or had no histology. Thus the first sighting was used to define the start of baseline rather than the first
diagnosis of adenoma. This rule was applied as long as the matched lesions occurred within 3 years of one
another. A relatively simple rule was then applied whereby all examinations within 11 months following the
first adenoma were included within baseline. Using ‘within 1 year’ as a time frame may have resulted in
surveillance examinations for high-risk individuals being included within baseline (as these are given 1 year
after the initial examination), so 11 months was deemed to be the most appropriate time frame. Thus,
baseline was defined as the first examination with an adenoma and any examinations within the subsequent
11 months.
Using this definition, the baseline period was then extended backwards from the first occurrence of an
adenoma based on the time between prior examinations and the first baseline examination. In addition,
the baseline period was also extended forwards using certain criteria (see rule 9).
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(b) Consideration for setting start of baseline in cases where adenomas seen at more than one sighting:
There are situations where a polyp is sighted at more than one examination. The polyp may not been assigned
histology of an adenoma until a later sighting, for example, if at earlier sightings the polyp was not biopsied/
excised and sent to pathology. We set baseline at the time of the first adenoma. Therefore, we apply adenoma
histology backwards in certain situations as explained below to assure we set baseline at the time of
first adenoma.
Polyps which are seen across multiple examinations and assigned adenoma histology
(“path_hist_incl_assume_adenoma” = 1, 3, 53, 56, 97) at some time are identified. If at prior sightings to
adenoma histology being assigned, the polyp has histology assigned from hyperplastic, previous polypectomy
site, granulation tissue, normal mucosa, not possible to diagnose or specimen not seen histology
(“path_hist_incl_assume_adenoma” = 2, 6, 34, 39, 90, 91) or the histology is unknown then adenoma histology
is applied backwards. Adenoma histology is only applied back over 3 years at the most. If the histology at any of
the prior sightings includes any other histology types than those listed above, the adenoma histology is not
applied backwards (this avoids overwriting histology higher in the precedence list than an adenoma, e.g. cancer,
sessile serrated lesion).
(c) Assigning baseline, prior and follow-up:
Baseline starts at the earliest histology for an adenoma/assume adenoma (“path_hist_incl_assume_adenoma”= 1,
3, 53, 56, 97) for the patient. Baseline then extends 11 months (335 days) from this point.
Prior examinations are any examinations before detection of first adenoma.
Follow-up examinations are any examinations after 11 months after first adenoma.
Flags have been created to indicate prior, baseline and follow-up for each examination for patients who have
one or more adenomas detected.
Rule 9: extend baseline
Extending baseline backwards
Once baseline was defined, it was then extended backwards to include prior examinations that satisfied
certain criteria.
First, if a prior colonoscopy occurred within 11 months of the first baseline examination then it was
included in the baseline visit. This rule was implemented because it is unusual to perform a surveillance
examination at ≤ 1 year after a previous colonoscopy, so it seemed more likely that both procedures were
related and thus part of the same ‘visit’. Baseline was extended backwards regardless of whether or not
the patient had a colonoscopy in his/her original baseline, and any other examinations that occurred
between the prior colonoscopy within 11 months and the examination with the first adenoma also
became part of the baseline visit. This rule was not applied to prior colonoscopies with a clinical indication
of a family history of cancer, as more frequent surveillance or screening would be feasible for such
patients. The baseline visit was extended backwards only once, i.e. inclusion of prior examinations in
relation to the extended baseline examinations was not considered.
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Extending baseline backwards:
l Extend baseline backwards if patient has a prior colonoscopy within 11 months of the first
baseline examination.
l Only extend backwards to colonoscopies that do not have indication of family history of cancer or CRC
(‘indication’ = 15 35).
l Baseline should be extended regardless of whether or not the patient has a colonoscopy in their
current baseline.
l Any other examinations that occur between the prior colonoscopy within 11 months and the first baseline
examination will also become part of baseline clearance.
l Extension of baseline only occurs once.
Extending baseline forwards
There were a number of scenarios for which it was necessary to extend the baseline visit forwards.
This was done using a combination of timing, examination findings and characteristics, including features of
the last baseline examination such as large polyps, an incomplete procedure and poor bowel preparation.
Additionally, if a polyp found at the last baseline examination was matched to a polyp found shortly after
baseline or if there was a surgical procedure shortly after then baseline was extended.
Some patients had examinations that occurred within 1 year of the last baseline examination. As
endoscopic procedures can be delayed for logistical and medical reasons, any examinations that occurred
within 9 months were likely to be part of the baseline visit because surveillance procedures should not
have been carried out this soon. On the other hand, examinations that occurred within 9–11 months after
the last baseline examination could potentially have been high risk surveillance examinations. Bearing this
in mind, baseline was first extended to include all examinations which occurred within 6 months of the
final baseline examination.
Additional criteria were then used to determine whether examinations that occurred 6–9 months after the
final examination in the baseline period should be included in baseline or left as follow-up. Baseline was
extended to include such examinations if:
l the last baseline examination is incomplete
l the last baseline examination has poor bowel preparation
l a large polyp (≥ 15 mm) is seen at the last baseline examination
l the same polyp is seen at the last baseline examination and examination occurring within 6–9 months
l the first examination after the last baseline examination is surgical.
In terms of patients with a surgical examination 6–9 months after the final baseline examination, it was
probable that the surgery was performed based on findings of the earlier examinations, so it was logical
to extend baseline so that it included the surgery. In cases when a polyp found at the last baseline
examination was large or was seen again at an examination within 6–9 months (i.e. matched polyps), the
latter examination was likely to have been done to assess the polyp excision site or perform additional
polyp removal. Finally, if the final baseline examination was low quality (incomplete or poor preparation)
then it was feasible for another examination to have been performed to ensure that the bowel was
properly examined, and this would still be part of the baseline visit.
After applying the rules for the extension of baseline backwards and forwards, the length of baseline was
assessed and only a small proportion of patients had an unusually long baseline, whereas the majority
were no more than 11 months in length. As with the backwards extension of baseline to include prior
examinations, baseline was also extended forwards on only one occasion.
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Extending baseline forwards:
l Any examinations within 6 months of last baseline examination* will be included in baseline.
l Include all examinations which occur 6–9 months after last baseline examination* if:
¢ the patient’s last baseline examination* is incomplete (diagnosis = 14)
¢ the patient’s last baseline examination* has poor preparation (bowel_prep = 1)
¢ the patient’s last baseline examination* finds a polyp ≥ 15mm (if derived_endo_size, derived_path_size
or derived_endo_size_other are ≥ 15mm)
¢ the patient has the same polyp seen at their last baseline examination* as an examination occurring
within 6–9 months
¢ the patient’s first examination after last baseline examination* is surgical and it occurs at 6–9 months
after last baseline examination*
l Extension of baseline only occurs once.
*last baseline examination refers to last examination in baseline where baseline is as originally defined to
include any examinations within 11 months from first adenoma.
Further extension forward of baseline to account for large polyps being removed over many examinations:
l Define date of last examination in baseline.
l Define whether or not lesions ≥ 15mm (distal/proximal/any) found during baseline as it currently is assigned.
l Include any colonoscopy procedures into baseline if they occur within 6 months of last examination in
baseline and a lesion ≥ 15mm more proximal than SC is reported during baseline. ∼
l Redefine date of last examination in baseline. ∼
l Include any FS/sigmoidoscopy/rigid sigmoidoscopy/unknown/endoscopy procedures into baseline if they
occur within 9 months of last examination in baseline and a lesion ≥ 15mm in SC or more distal is reported
during baseline. ∼
l Redefine date of last examination in baseline. ∼
l Include any surgery procedures into baseline if they occur within 9 months of last examination in baseline
and a lesion ≥ 15 mm is reported during baseline. ∼
l Redefine date of last examination in baseline. ∼
l Repeat the steps indicated with a ∼ until no further examinations are included into baseline.
Now baseline has been extended, we assume that the next examination a patient attends after baseline is
follow-up surveillance (or symptomatic).
Rule 10: redefine baseline for patients without baseline colonoscopy
In order to accurately stratify patients into risk groups based on findings at baseline, it was necessary for
patients to have a colonoscopy at baseline. Patients without a ‘definite’ colonoscopy at baseline were
therefore reviewed. First, the procedure types of such patients were refined further. Any procedures that
occurred during baseline that had been relabelled as ‘col or flexi-sig’ or ‘col, flexi-sig or rigid sig’ as a result
of Rule 2 were deemed to be a colonoscopy, and relabelled as such, if the patient had significant
adenomas during baseline (≥ 3, ≥ 10 mm, tubulovillous or villous histology, or HGD). Such procedures
were most likely to be a colonoscopy rather than a sigmoidoscopy if any of these criteria was fulfilled.
Of the remaining patients without a ‘certain’ colonoscopy at baseline, for those who had a colonoscopy at
their FUV1 it was decided that the follow-up visit should become the baseline visit and the original baseline
should become a prior visit. In order to do this, the FUV1 had to be defined beforehand (see rule 21, below).
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No changes were made for patients with no ‘certain’ colonoscopy during baseline or at their FUV1, and
those with a colonoscopy at baseline.
To ensure that risk was not underestimated as a result of shifting the baseline to follow-up, any adenomas
found at prior examinations were used to determine risk as well as those found during the baseline visit.
For patients without a certain baseline “colonoscopy” (derived_procedure_type=1):
(a) If patient has “colonoscopy or flexi-sig” or “colonoscopy, flexi-sig or rigid-sig” examinations during baseline
and significant adenomas during baseline (3 + adenomas, adenoma ≥ 10mm, tubulovillous/villous histology
or HGD), it is likely that this patient would have had a colonoscopy during baseline. Relabel first of either
“colonoscopy or flexi-sig” or “colonoscopy, flexi-sig or rigid-sig” examination at baseline as colonoscopy.
(b) Define follow-up visit 1 (see rule 21). If patient still does not have certain “colonoscopy” during baseline
but has a “colonoscopy” during follow-up visit 1, follow-up visit 1 is relabelled as baseline and baseline is
relabelled as prior.
Note: when baseline risk is defined, it will now need to count adenomas found at prior or baseline.
From the rules above we now have examinations divided into three time periods:
l BASELINE
l PRIOR (examinations prior to BASELINE)
l FOLLOWUP (examinations after BASELINE).
Rule 11: cancer matching rules
Cancer data were obtained from a number of sources. First, information on cancers present in endoscopy
and pathology reports was recorded on the study database. Then additional cancer data were obtained
from external sources (HSCIC and NSS). These data had to be added into the study database, taking into
account the patient and cancer data that were already present to ensure that there was no duplicated or
missing data. This process was termed ‘cancer matching’.
In some cases, cancers in the hospital data were ‘missed’ by external sources (i.e. polyp rows with cancer
histology on the study database could not be matched to a HSCIC cancer). These cases were queried
with HSCIC and NSS; however, it was decided that for all outstanding cases the hospital pathology data
should be accepted as conclusive evidence of cancer unless the histology was ‘cancer in dispute’ or ‘cancer
query’. In the latter case, the evidence had to be deemed inconclusive and the lesion was regarded as an
assumed adenoma with HGD.
Alternatively, sometimes there was no pathology to confirm cancer HSCIC/NSS did not report a cancer;
however there was reason to believe that the patient had either a previous cancer or a cancer at an
endoscopy. Such information was recorded in the notable features (unsolved queries), indications and
diagnosis fields. It was decided that, without confirmation from external sources, any notable feature,
diagnosis or indication of cancer should not be counted as a cancer.
Cancer outcomes
For the purposes of the study, the only cancer outcome of interest was adenocarcinoma of the colorectum.
For the hospital data, it was fairly straightforward to identify such cases: cancer outcomes were defined using
specific cancer histology codes (codes 50, 51, 55, 58, 59, 69). However, in order to determine which cancers
from external sources were outcomes of interest, they all had to be grouped based on their morphology
(Derived Morph Grouping derived from morphology codes) and site (Derived Site Grouping derived from site
codes). Cancers were first selected using site codes and then further refined by morphology codes.
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For cancers from external sources, Derived Morph Group related to morphology codes of lesions that
were seen in the colorectum, although they may not have originated from there. It consisted of the
following categories:
1. adenocarcinomas
2. non-adenocarcinoma cancers
3. cancers of unknown morphology
4. benign lesions
5. no morphology.
Derived Site Group related to site codes and consisted of the following three categories:
1. colon/rectum/anus
2. ill defined/unspecified site
3. other sites (non-colorectal).
As site codes contained morphological information, and some external cancers did not have appropriate
information on morphology, the Derived Site Group was made up of 12 subgroups in total, with groups
1–3 being split into malignant, in situ, benign and unknown/unspecified.
Derived Site Grouping
(only malignant)
Derived Morphology Grouping
1 2 3a 4 5
1 Potential outcome
(known
adenocarcinoma)
Not an
outcome
Potential outcome
(assume
adenocarcinoma)
Not an
outcome
Potential outcome
(assume
adenocarcinoma)
a There is morphology but we did not know into which group the morphology falls.
Only cancers from external sources that fell into in the first site group (malignant lesions of the colon/rectum)
were selected for the study. Of these, any cancers with relevant morphology codes were considered to be
outcomes and were thus added to the ‘cancer outcomes’ file (these are highlighted in the table above). More
specifically, adenocarcinomas (group 1) in the colorectum were counted as outcomes. Cancers with unknown
morphology (group 3) located between the rectum and caecum were assumed to be adenocarcinomas and
thus counted as cancer outcomes. Cancers without morphology (group 5) were also deemed to be potential
outcomes (assumed adenocarcinomas) based on site. If such cancers were located at sites relating to the anus
then they were not included as cancer outcomes. This is because it was assumed that cancers in such sites
were likely to be squamous cell carcinomas unless they were mapped to a rectal lesion without histology,
in which cases they may have been adenocarcinomas and were included as cancer outcomes.
All cancers in the ‘cancer outcomes’ file were either automatically or manually mapped to examinations
and/or polyps in the study database, wherever possible. In some cases, it was possible to map the cancer
to more than one polyp row if, for example, the cancer was seen at more than one examination. The final
polyp that the external cancer was mapped to was based on a hierarchy involving examination date, polyp
numbering and the time between the external cancer date and the hospital procedure dates.
The true cancer date and site were also chosen using hierarchies. In terms of date, if the external cancer
date preceded the mapped endoscopy date then the external date was used; if the mapped endoscopy
date predated the external date then the date nearest to the external cancer event date was used. In terms
of site, the site given in the external cancer data were used if no site was given in the mapped endoscopy
(or site was non-specific) or if there were > 15 days between the dates of each data source. The site from
the mapped endoscopy was used if it was available and the endoscopy contained the earliest polyp or
nearest polyp to the cancer, or if the site given by the external cancer source was non-specific.
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Cancer exclusions
With regards to cancer exclusions, all patients with a CRC were excluded from the study if the true cancer
date occurred before the first examination on the study database, at prior examinations or within the
baseline period.
Cancers from death data
Malignant CRCs reported in cause of death data from external sources were considered outcomes and
added to the ‘cancer outcomes’ file if the patient did not have a cancer outcome reported already by
externally sourced cancer registry information and did not have a cancer outcome reported from hospital
data in the study database.
(a) Chosen malignant colorectal cancers from external sources to add to our data
The “cancer outcomes” file contains cancers from the “allcancers” file which we consider outcomes (malignant
colorectal cancers to be used for exclusions and endpoints) for the IA cohort (the patients remaining after rule 6
applied).
Cancers considered outcomes from external sources and added to the “cancer outcomes” file are highlighted
in the table below:
Derived Site
Grouping
(only malignant) Derived Morphology Grouping
1 – Adenocarcinomas 2 – Non-
adenocarcinoma
cancers
3 – Cancers of
unknown
morphologya
4 – Benign
lesions
5 – No
Group 1 –
malignant
neoplasm – colonb
Potential outcome
(known
adenocarcinoma)
Not an outcome Potential outcome
(assume
adenocarcinoma)
Not an
outcome
Potential outcome
(assume
adenocarcinoma)
a There is morphology but we do not know which group the morphology falls into.
b The site codes included in this group are shown in Appendix 1, Systematized Nomenclature of Medicine codes
version 2, Codes for lesion site.
The histology codes we consider to be evidence of a cancer outcome in our data are shown in Appendix 2,
Reference data table in the appendix (using field “path_hist_incl_assume_adenoma”).
Malignant colorectal cancers reported in cause of death from external sources were considered outcomes and
added to the “cancer outcomes” file if the patient did not have a cancer outcome reported already external
sourced cancer registry information and did not have a cancer outcome reported in our database.
The “cancer outcomes” file does not include cancers marked as “not CRC”, “no indication of cancer” or
“duplicate cancer” by the coders. The “cancer outcomes” file does not include cancers which are not cancer
outcomes in the external data but are mapped to something that is a cancer outcome in our data. This is
because if either the external data or our data reports a cancer outcome this takes precedence even if the other
source reports it is not a cancer outcome. All the cancers in our database have been double checked by coders
so we can be confident of our report of cancer even if no report of cancer was given by external sources or if
there is discrepancy between our report of cancer and the report of cancer by external sources (i.e. we report a
cancer and they report an in situ lesion).
Also removed are cancers situated in the anus or appendix which are not adenocarcinomas (i.e. they are not
morphology group 1).
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
457
morphology
All cancers in the “cancer outcomes” have been attempted to be mapped to examinations and/or polyps in
our database.
(b) Assigning final mapped polyp, true date and true site (and sources)
Following this, the final mapped polyp, true date, true site and true morphology were assigned as explained
below. The final polyp that the external cancer is mapped to in our database (if applicable) is chosen by
hierarchy and the source is assigned:
1. Find the earliest polyp with the same derived polyp number as polyp originally mapped to which has
histology for cancer (codes 50, 51, 55, 58, 59, 69) and occurs earlier or on the same date as the
external cancer
2. Source = “earliest polyp”
3. Find the polyp (any histology) with the same derived polyp number as the polyp originally mapped to, which
occurs nearest to the external cancer (within 15 days)
4. Source = “nearest polyp to cancer”
5. Find the polyp (any histology) with the same derived polyp number as polyp originally mapped to which
occurs nearest to the external cancer (more than 15 days from the external cancer)
Source = “nearest polyp to cancer but difference greater than 15 days”
The true date for the cancer is chosen by hierarchy:
1. Choose the date of the final mapped polyp from our data if the source of the final polyp ID is “earliest
polyp” or “nearest polyp to cancer”. This means that the date of the final mapped polyp is chosen in
these scenarios:
l If the final mapped polyp has cancer histology(codes 50, 51, 55, 58, 59, 69) and occurs earlier than or
on the same date as the external cancer.
l If the final mapped polyp has cancer histology(codes 50, 51, 55, 58, 59, 69) and occurs up to 15 days
later than the external cancer.
l If the final mapped polyp does not have cancer histology but occurs within 15 days (either side) of the
external cancer.
2. Choose the date of the external cancer if the source of the final polyp ID is “nearest polyp to cancer but
difference greater than 15 days” or there is no final mapped polyp. This means that the date of the external
cancer is chosen in the following scenarios:
l If the final mapped polyp in our data has cancer histology (codes 50, 51, 55, 58, 59, 69) but occurs
more than 15 days later than the external cancer date.
l If the final mapped polyp does not have cancer histology and occurs more than 15 days before or after
the external cancer date.
l If there is no polyp mapped.
The true site for the cancer is chosen by hierarchy:
1. Choose the site of the mapped polyp from our data if the site of the final mapped polyp is not missing and
the source of the final mapped polyp is “earliest polyp” or “nearest polyp to cancer”.
2. Choose the site of the external record if site of external cancer is not missing and source of the final
mapped polyp is “nearest polyp to cancer but difference greater than 15 days” or if no polyp is mapped.
3. Choose site of external record if site is missing.
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4. Overwrite with site from external record if site from our data is a range of segments and site from external
record is a site code for a malignant cancer of colon and is specific [i.e. not C189 (ICD10), C188 (ICD10),
1538 (ICD9), 1539 (ICD9), 1538 (ICD8)].
5. Overwrite with site from our data if site from external source is not specific [i.e. one of C189 (ICD10), C188
(ICD10), 1538 (ICD9), 1539 (ICD9), 1538 (ICD8)] and our site is not missing.
(c) Further considerations
Cases where external cancer is mapped to an endoscopy in our database but it is not mapped to a polyp
(currently from above rules for true date and site the source of date and site for all these records is external
source as no mapped polyp):
l if mapped endoscopy is within 15 days of external date of cancer and mapped endoscopy is during
BASELINE or PRIOR then mark cancer to exclude patient
l if mapped endoscopy is within 15 days of external date of cancer and mapped endoscopy is during
FOLLOWUP then mark to create a new polyp at that examination for the cancer
l if mapped endoscopy is outside 15 days of external date of cancer then true cancer date and timings (determined
by external sources) will be used and cancer will either be excluded or a new examination created for it.
If the true site of the cancer is denoted as ILEUM from our data but in the external data it is recorded as
CAECUM, replace as CAECUM (and replace source of site accordingly).
If the true site of the cancer is denoted as ANUS from our data but in the external data it is recorded as
RECTUM or RM/ANUS OVERLAPPING LESION, replace as RECTUM if the morphology of the cancer is
adenocarcinoma (group 1 morphology) (and replace source of site accordingly).
Note: adding the cancer records to our data (section e) creates new examinations which may fall in PRIOR,
BASELINE or FOLLOW-UP (i.e. within the range of examinations we have for the patient) but may also fall
BEFORE FIRST EXAM ON OUR DATABASE or AFTER LAST EXAM ON OUR DATABASE (i.e. outside the range of
examinations we have for the patient).
Check in “allcancers” file→ The “allcancers” file contains all cancers received from external sources. Check
in “allcancers” file for any cases where two or more cancers are mapped to the same polyp ID – any cases like
this need to be resolved.
(d) Adding external cancer outcomes to our data and identifying extra cancer outcomes in our data.
The cancer outcomes were added to our data as follows:
Group 1: identify patients to exclude
(a) Mark patient to be excluded (MERGE TO EXISTING POLYP) if:
i. true date of cancer occurs during “PRIOR”, “BASELINE” or “Before first endoscopy on our database”
OR
ii. external cancer is mapped to an endoscopy but not to a polyp in our and the mapped endoscopy is
within 15 days of external date of cancer and mapped endoscopy is during BASELINE or PRIOR.
(b) If cancer histology codes (50, 51, 55, 58, 59, 69) on our database during “PRIOR” or “BASELINE” and patient
not already marked to exclude from part (a) then mark patient to be excluded (IDENTIFY IN OUR DATA).
(c) If new examination created falls within definition of baseline (see rules 8, 9 and 10) and patient not
already marked to exclude from parts (a) or (b) (IDENTIFY IN OUR DATA).
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Group 2: cancers from external sources that can be merged directly to a polyp in
our database
If true date occurs during “FOLLOWUP” or “After last endoscopy on our database” and true date source is
“OURPOLYP” then use mapped polyp_id to map exactly to data (MERGE TO EXISTING POLYP).
Group 3: cancers from external sources that can be merged directly to a polyp in
our database – create a new polyp at an existing examination
If external cancer is mapped to an endoscopy in our database but it is not mapped to a polyp and the mapped
endoscopy is within 15 days of external date of cancer and mapped endoscopy is during FOLLOWUP then
create a new polyp at that examination for the cancer (APPEND – CREATE NEW POLYP).
Group 4: cancers from external sources that cannot be merged directly to a polyp
in our database – create a new examination
If true date occurs during “FOLLOWUP” or “After last endoscopy on our database” and true date source is
“EXTCANCER” then create new examination (APPEND – CREATE NEW EXAM).
Group 5: cancers identified in our database during follow-up but not identified
from external sources
Identify any cancers in our database (codes 50, 51, 55, 58, 59, 69) occurring during follow-up and not reported
from external source (use polyp numbering of any mapped polyps) (IDENTIFY IN OUR DATA).
Rule 12: apply exclusions for conditions
For inclusion in the analysis, patients had to have at least one adenoma found, whereas exclusion criteria
were based on conditions that would either result in increased risk of CRC or abnormal surveillance.
Once conditions of importance were identified, the time period during which they occurred was then
considered. In some cases it was necessary to censor patients only after the occurrence of the condition or
exclude them only if the condition occurred during prior or baseline examinations. For others it was more
appropriate to exclude the patient regardless of when the condition was identified, for example HNPCC is
a genetic condition that confers an increased risk of cancer throughout an individual’s lifetime.
The presence of an ‘exclusion condition’ was identified using different fields within the database including
patient condition, diagnosis, indication, pathology and procedure type. During manual coding, patients
were marked as excluded by coders; however, this information was transferred to a patient condition field
and the original exclusion field was removed so that the final exclusion criteria could be applied in a more
accurate and systematic way. The patient conditions, diagnosis and indications fields were also cleaned to
prevent duplication of data and also to make it possible to determine the timing of exclusion conditions,
thus simplifying the application of the exclusions criteria.
Patients with any of the following conditions were excluded from the analysis:
l Colitis at prior or baseline examinations Diagnosis/indication of colitis, pathology for colitis.
l IBD/Crohn’s disease at prior or baseline examinations Diagnosis/indication of Crohn’s disease or IBD,
pathology for Crohn’s disease.
l Polyposis (mixture of at any time and at prior or baseline examinations) Diagnosis/indication of
polyposis (see Appendix 5, Polyposis subtypes and exclusion criteria), 100-plus adenomas at any
time (FAP).
l Family history of FAP at any time Indication of family history of FAP.
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l HNPCC at any time Indication of HNPCC.
l Cowden syndrome at any time Indication of Cowden syndrome.
l Volvulus at prior or baseline examinations Diagnosis/indication of volvulus.
l Resection/anastomosis at prior or baseline examinations Surgical procedure type, patient condition of
resection at first examination, diagnosis of anastomosis.
l Juvenile polyps or hamartomatous polyps at any time Pathology for juvenile or hamartomatous polyps.
l Radiation plus proctitis at prior or baseline examinations Diagnosis/indication of radiation plus proctitis
l Derived radiation colitis at prior or baseline examinations (ulcers plus radiation) Diagnosis/indication of
radiation plus ulcers.
l More than 40 examinations recorded.
l Diagnosis of CRC (adenocarcinoma) during or prior to baseline visit.
The exclusion criteria for cancer were more complex, as they had to take into account the cancer
morphology as well as any cancers reported by HSCIC. In some cases it was not possible to be certain
whether or not a patient had cancer. Problematic histology values were ‘cancer in dispute’, ‘cancer query’
and ‘unknown primary’. Cancer values coded in the study database within the diagnosis, indication and
patient condition fields had to be cross-checked cancer with HSCIC cancers, and certain field over-riding
others. Cancers were grouped based on their site and morphology, which were determined using
endoscopic and histological data coded in the study database as well as ICD codes associated with HSCIC
cancers (see section 11, above).
Other complex exclusion criteria were required for patients with polyposis and colitis. There were many
different subtypes of both conditions in the database, and while some cases were confirmed by pathology
or endoscopy reports, others had an uncertain diagnosis in terms of both presence and type. As a result,
each combination of subtype and level of certainty was dealt with individually (see Appendix 5), to ensure
that patients were not excluded unnecessarily, since some subtypes were mild or temporary and therefore
did not require exclusion. In some cases, if polyposis or colitis was proposed but never confirmed, it was
not deemed necessary to exclude such cases.
Patient must not have
l colitis at prior or baseline examinations
¢ diagnosis/indication of colitis (diagnosis = 4/indication = 4 + subtypes list) – see below for rules
¢ pathology for colitis (path_hist_incl_assume_adenoma = 30).
l IBD/Crohn’s at prior or baseline examinations
¢ diagnosis of crohn’s or IBD (diagnosis = 6, 16)
¢ indication of crohn’s or IBD (indication = 7, 36)
¢ pathology for crohn’s (path_hist_incl_assume_adenoma = 28).
l polyposis – mixture of at any time and at prior or baseline examinations
¢ diagnosis/indication of polyposis (diagnosis = 22/indication = 18 + subtypes list) – see below for rules
¢ presence of more than 100 adenomatous polyps of the colon and rectum at any time (FAP)
(path_hist_incl_assume_adenoma = 1, 3, 53, 56 or assume adenoma).
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l family history of FAP at any time
¢ indication of family history of FAP (indication = 41).
l HNPCC at any time
¢ indication of HNPCC (indication = 16).
l Cowden syndrome at any time
¢ indication of Cowden syndrome (indication = 42).
l volvulus at prior or baseline examinations
¢ diagnosis of volvulus (diagnosis = 11)
¢ indication of volvulus (indication = 30).
l resection/anastomosis at prior or baseline examinations
¢ operation type (operation_type = 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 40, 41, 43, 44, 45, 46, 48, 49, 50, 51, 52,
53, 54)
¢ patient condition of resection at first examination (patient_condition = 9)
¢ diagnosis of anastomosis (diagnosis = 9).
l juvenile polyps or hamartomatous polyps at any time
¢ pathology for juvenile or hamartomatous polyps (path_hist_incl_assume_adenoma = 10, 24).
l radiation + proctitis at prior or baseline examinations
¢ diagnosis of radiation + proctitis (diagnosis = 43)
¢ indication of radiation + proctitis (indication = 43).
l ulcers + radiation = derived radiation colitis at prior or baseline examinations
¢ diagnosis of radiation + ulcers (diagnosis = 44)
¢ indication of radiation + ulcers (indication = 44).
l > 40 examinations recorded.
l diagnosis of cancer during or prior to baseline visit.
Rule 13: add in situ cancers and recoding histology in relation to cancer,
in situ cancer and ‘cancer in dispute’
In situ cancers (lesions with HGD) were dealt with in a similar way to cancers (see rule 11).
Adenocarcinoma in situ lesions obtained from external sources were relevant to the study (advanced
adenomas were outcomes of interest) and thus had to be mapped to hospital data in the study database,
wherever possible. The in situ cancers of interest, for the purposes of the study, are highlighted in the
table below.
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Derived Site Grouping
Derived Morphology Grouping
1 – Adenocarcinomas
2 – Non-
adenocarcinoma
cancers
3 – Cancers
of unknown
morphology
4 – Benign
lesions
5 – No
morphology
Group 1 – in situ
neoplasm – colona
Include in situ Do not include in
situ
Include in situ Include in situ Include in situ
a Site codes included: ICD9 codes – 2303 (colon, in situ), 2304 (rectum, in situ), 2305 (anal canal, in situ), 2306 (anus, in
situ); ICD10 codes – D010 (colon, in situ), D011 (rectosigmoid junction, in situ), D012 (rectum, in situ), D013 (anus and
anal canal, in situ).
In situ lesions located in the anus, which were not adenocarcinoma in situ and were not mapped to an
adenoma or cancer in the hospital data, were not considered an outcome of interest, as they were likely to
be squamous cell carcinoma in situ. In situ lesions in site group 1 (in situ neoplasm of the colon) with
non-adenocarcinoma morphology (morphology group 2) were not counted as outcomes either, or were in
situ lesions of unspecified intestinal site or those with uncertain/unspecified behaviour.
The final polyp that the external in situ lesion was mapped to and the true date and site were determined
as before (see rule 11) using hierarchies.
The histology for cancers, in situ cancers and ‘cancer in disputes’ from hospital data were recoded if an in
situ cancer from external sources had been mapped to it. All polyps mapped to an in situ from external
sources were recoded to ‘assume adenoma’ with HGD, in line with the most recent nomenclature for such
lesions, if they were not already coded as such. Dysplasia was recoded to HGD only if it was not already
listed as HGD, severe dysplasia, ‘intra-mucosal cancer in dispute’ or intra-mucosal cancer. Additionally,
polyps in the database with a histology of ‘cancer in dispute’ were recoded to ‘assume adenoma’ with
HGD if they were not mapped to a cancer from external sources (assumed not to be cancer). Any polyps
coded as ‘cancer query’ or ‘unknown primary’ were resolved, where possible, by looking for information to
update their histology in the ‘allcancers’ file (i.e. non outcomes may be mapped to them).
Finally, all records of malignant CRC indicated from an external source, if not already assigned a cancer
code in our data, were assigned code 50 (cancer). The dysplasia field not changed in such cases and was
ignored for use with cancer histology (it can denote the dysplasia of adenoma sections of the cancer for
other work).
(a) Chosen in situ cancers from external sources to add to our data:
In situs to be added to our data from external sources in the “allcancers” file are highlighted in the table below
(selected for patients remaining in cohort after rule 12):
Derived Site
Grouping Derived Morphology Grouping
1 – Adenocarcinomas 2 – Non-
adenocarcinoma
cancers
3 – Cancers
of unknown
morphology
4 – Benign
lesions
5 – No
Group 1 – in situ
neoplasm – colona
Include in situ Do not include in situ Include in
situ
Include in
situ
Include in situ
a Site codes included: ICD9 codes -> 2303 (colon, in situ), 2304 (RM, in situ), 2305 (anal canal, in situ), 2306
(anus, in situ) and ICD10 codes -> D010 (colon, in situ), D011 (RSJ, in situ), D012 (RM, in situ), D013 (anus and
anal canal, in situ).
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morphology
In situ lesions to be removed from those selected in the table above:
l In situ lesions which are mapped to cancers in our database (“path_hist_incl_assume_adenoma“ = 50, 51,
55, 58, 59, 69) as the diagnosis of cancer in our database will take precedence.
l In situ lesions of the anus which are not adenocarcinoma in situ and are not mapped to an adenoma or
cancer in our data.
l In situ lesions which are marked to exclude by the coder.
Note
In situ lesions not included to be added to our data:
l In situ lesions in site “group 1 – in-situ neoplasm of the colon” where morphology is non-adenocarcinoma.
l In situ lesions (denoted by site code) of unspecified intestinal site.
l In situ lesions (denoted by morphology code) of colon with uncertain/unspecified behaviour.
l All in situs to be added have been attempted to be mapped to examinations and/or polyps in our database.
(b) Assigning final mapped polyp, true date and true site (and sources)
Following this, the final mapped polyp, true date and true site were assigned as explained below.
The final polyp that the external in situ is mapped to in our database (if applicable) is chosen by hierarchy and
the source is assigned (this is calculated by Study programmer):
1. Find the earliest polyp with the same derived polyp number as polyp originally mapped to which has histology for
cancer or in situ* and occurs earlier or on the same date as the external record. Source = “in-situ earliest polyp”
i. *“path_hist_incl_assume_adenoma“== 50, 51, 55, 58, 59, 69 (cancers)
ii. OR “path_hist_incl_assume_adenoma“== 52 (cancer in dispute)
iii. OR “path_hist_incl_assume_adenoma“== 1, 3, 53, 56 (adenoma) and path_dysplasia=4, 5, 6, 7 (HGD,
severe dysplasia, IM cancer in dispute or IM cancer)
iv. OR “path_hist_incl_assume_adenoma“==missing or 90 (not possible to diagnose) and path_dysplasia =4,
5, 6, 7 (HGD, severe dysplasia, IM cancer in dispute or IM cancer) (this is to allow for those polyps with
HGD which are recoded as assume adenoma once in my data).
2. Find the polyp (any histology) with the same derived polyp number as the polyp originally mapped to, which
occurs nearest to the external record (within 15 days). Source = “in-situ nearest polyp to cancer”.
3. Find the polyp (any histology) with the same derived polyp number as polyp originally mapped to which
occurs nearest to the external record (more than 15 days from the external record). Source=”in-situ nearest
polyp to cancer but difference greater than 15 days”.
The true date for the in situ is chosen by hierarchy:
1. Choose the date of the final mapped polyp from our data if the source of the final polyp ID is “in-situ
earliest polyp” or “in-situ nearest polyp to cancer”.
This means that the date of the final mapped polyp is chosen in these scenarios:
l If the final mapped polyp has cancer or in situ histology and occurs earlier than or on the same date as
the external record.
l If the final mapped polyp has cancer or in situ histology and occurs up to 15 days later than the
external record.
l If the final mapped polyp does not have cancer histology but occurs within 15 days (either side) of the
external record.
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2. Choose the date of the external record if the source of the final polyp ID is “in-situ nearest polyp to cancer
but difference greater than 15 days” or there is no final mapped polyp.
This means that the date of the external cancer is chosen in the following scenarios:
l If the final mapped polyp in our data has cancer or in situ but occurs more than 15 days later than the date
of the external record.
l If the final mapped polyp does not have cancer or in situ histology and occurs more than 15 days before or
after the date of the external record.
l If there is no polyp mapped.
The true site for the in situ is chosen by hierarchy:
l Choose the site of the mapped polyp from our data if the site of the final mapped polyp is not missing and
the source of the final mapped polyp is “in-situ earliest polyp” or “in-situ nearest polyp to cancer”.
l Choose the site of the external record if site of external record is not missing and source of the final
mapped polyp is “in-situ nearest polyp to cancer but difference greater than 15 days” or if no polyp
is mapped.
l Choose site of external record if site is missing.
l Overwrite with site from external source if site from our data is a range of segments and site from external
record is specific [i.e. not D010 (ICD10)].
l Overwrite with site from our data if site from external record is not specific [i.e. D010 (ICD10)] and our site
is not missing.
(c) Further considerations
Check if any of the newly added examinations for in situ lesions occurs during the definition of baseline. If so
these examinations should be relabelled as baseline.
(d) Adding external cancer outcomes to our data and identifying extra cancer outcomes in our data
The cancer outcomes were added to our data as follows:
Group 1: In situ lesions from external sources that can be merged directly to a
polyp in our database
If true date source is “OURPOLYP” then use mapped polyp_id to map exactly to data (MERGE TO
EXISTING POLYP)
Group 2: In situ lesions from external sources that cannot be merged directly to a
polyp in our database
If true date source is “EXTCANCER” then create new examination (APPEND – CREATE NEW EXAM)
(e) Recoding histology in relation to cancers, in situs and cancer in disputes
1. Recode all polyps which are marked as an in situ from external data, to adenoma+HGD, if not already
recorded as adenoma+HGD in database. Also at this time recode polyp segment in our database as
true segment of in situ.
2. Recode “cancer in dispute” to “assume adenoma” with HGD if not marked as cancer from external
data (only change dysplasia if not already HGD etc.).
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3. Resolve any “cancer query” and “unknown primary” polyps in our database by looking for information
to update their histology in the “allcancers” file (i.e. non outcomes may be mapped to them). Mark
these polyps so we know information has been updated.
4. All records of malignant colorectal cancer (either indicated from external source or codes 50, 51, 55,
58, 59, 69 in our data), if not already assigned a cancer code should be assigned code 50 (cancer). The
dysplasia field will be left as it is and ignored for use with cancer histology (it can denote the dysplasia
of adenoma sections of the cancer for other work). Also at this time recode polyp segment in our
database as true segment of in situ.
Rule 14: True values for polyps found during and prior to baseline
True polyp values had to be determined for a number of polyp characteristics including size, histology,
villousness, dysplasia, segment and shape, as a unique polyp was sometimes seen on a number of
occasions, with different data recorded at each sighting. True polyp values for size, dysplasia, histology
and villousness were applied across prior and baseline examinations, whereas true polyp values for these
characteristics at follow-up visits were applied separate to prior and baseline examinations in order to see
how lesions changed over time. Conversely, segment and shape were applied across all sightings, as these
features were expected to remain constant over time (these are described in rule 15).
A. True size
Assigning size for polyps with multiple sightings across baseline and follow-up visits
In the simplest circumstance, a polyp was seen only once; however, sometimes there were multiple
sightings of a single polyp within and/or across visits. True size was assigned separately for baseline and
each follow-up visit, as polyps may have grown over time.
Once size discrepancies had been resolved and the three derived size fields had been assigned to each
polyp sighting, the true polyp size could be determined. There was debate surrounding whether or not
endoscopy size (derived_endo_size) was likely to be the most reliable derived size field, or if pathology size
(derived_path_size) would be more accurate. Sometimes only a biopsy was sent to pathology, which would
therefore not be representative of the true size of the lesion resulting in the lesion being classified as lower
risk that it really was, whereas some endoscopy sizes (max, min, other) were only approximate values.
It was decided that the largest of the derived sizes should be used, as there were advantages and
disadvantages of both. Once the three derived size fields were defined for each polyp, there were eight
possible combinations. Based on these, true polyp size was assigned as follows:
l Group A Derived pathology size only – use.
l Group B Derived endoscopy size other only – use.
l Group C Derived endoscopy size only – use.
l Group D Derived endoscopy size other and path size – use largest.
l Group E Derived endoscopy size and path size – use largest.
l Group F Derived endoscopy size and endoscopy size other – use derived endoscopy size.
l Group G All three derived sizes – use largest of derived endoscopy and path size (ignore derived
endoscopy size other).
l Group H* No sizes – apply derived unknown range size where available.
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Polyps with an unknown size assigned had no size at any sighting (Group H*). If there was no other size
available, polyps were given a size (derived unknown range) using min/max values where appropriate.
The derived unknown range was assigned once other sightings were accounted for, using the rules below:
(a) no endoscopy size min, endoscopy size max of 6–9 mm, give assume endoscopy size other ‘small’.
(b) min and max, both ≤ 9 mm, give average of min and max in terms of rule b: it was deemed more
accurate to assign an average as (max – 1 +min)/2 as opposed to simply taking an average of the
maximum and minimum values given in the range, in order to avoid making an overestimation of size
(c) min and max, difference ≤ 2 mm, give average of min and max.
(d) min = 40 and max = 50, give average.
(e) min = 20 and max = 30, give average.
(f) min = 10 and max = 12–20, give average.
Use values for true size from baseline sightings of polyp and prior to baseline sightings of polyp.
To define true size use:
l largest endoscopy size = largest “derived_endo_size_numeric”
l largest other endoscopy size = largest “derived_endo_size_other_numeric”
¢ largest pathology size = largest “derived_path_size”.
These fields are derived by calculating largest of each of these derived sizes over baseline sightings of polyp and
prior to baseline sightings of polyp.
Combinations of derived sizes for each unique polyp during baseline:
Group
“largest
endoscopy size”
“largest endoscopy
size other”
“largest
pathology size” How to derive true polyps size
A 0 0 1 Use “largest pathology size”
B 0 1 0 Use “largest endoscopy size other”
C 1 0 0 Use “largest endoscopy size”
D 0 1 1 Use largest of “largest endoscopy size
other” and “largest pathology size”
E 1 0 1 Use largest of “largest endoscopy
size” and “largest pathology size”
F 1 1 0 Use “largest endoscopy size”
G 1 1 1 Use largest of “largest endoscopy
size” and “largest pathology size”
H 0 0 0 “Largest endoscopy size”, “largest
endoscopy other size” and “largest
pathology size” are missing – use
rules belowa
a Group H – “largest endoscopy size”, “largest endoscopy other size” and “largest pathology size” are missing.
Over baseline sightings of polyp and prior sightings of polyp (if within 3 years of start of baseline) – define
“largest endoscopy size minimum” and “largest endoscopy size maximum”.
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Note: Maximum/minimum endoscopy size(s) have already been applied to polyp(s) in the group to which the
maximum/minimum endoscopy size(s) apply to:
(a) “Largest endoscopy size minimum” is missing, “largest endoscopy size maximum” > 5 mm and < 10mm,
assign true size as “small” (which currently = 5 mm)
(b) “Largest endoscopy size minimum” and “largest endoscopy size maximum” both < 10mm, assign true
size as average of “largest endoscopy size minimum” and (“largest endoscopy size maximum” – 1 mm)
(c) Difference between “largest endoscopy size minimum” and “largest endoscopy size maximum” ≤ 2 mm,
assign true size as average of “largest endoscopy size minimum” and “largest endoscopy size maximum”
(d) “Largest endoscopy size minimum” and “largest endoscopy size maximum” both ≥ 20mm and difference
≤ 10, assign true size as average of “largest endoscopy size minimum” and “largest endoscopy size maximum”
(e) “Largest endoscopy size minimum” and “largest endoscopy size maximum” both ≥ 10mm and < 20mm,
assign true size as average of “largest endoscopy size minimum” and “largest endoscopy size maximum”.
B. True histology
It was decided that an order of precedence should be used to define true histology, going from most to
least severe. The order in which unique polyps with different histology types across examinations were
seen did not affect how the true histology was assigned, i.e. hierarchy was applied in the same way for
cases, with the worst histology taking precedence.
All histology types were split into two groups. Group 1 was composed of all ‘relevant’ histology that one would
expect to be matched (i.e. adenoma and adenocarcinoma). Group 2 was made up of all ‘irrelevant’ histology
that one would not expect to be matched to a group 1 histology (i.e. inflammatory polyp). Group 1 histology
types were then put into an order of severity/importance. Polyps with unusual combinations of groups 1 and 2
histology types were reviewed, for example polyp is an adenoma at one sighting but a lipoma at another
sighting. The order of precedence for group 1 was determined as follows, from most to least severe:
POLYPTYPE_ID POLYP_TYPE
69 CANCER + SESSILE SERRATED LESION
55 CANCER +MIXED/SERRATED ADENO
59 CANCER +MIXED ADENOMA
58 CANCER + SERRATED ADENOMA
51 CANCER + ADENOMA
50 CANCER
52 CANCER IN DISPUTE
65 UNKNOWN PRIMARY
62 CANCER QUERY
68 SESSILE SERRATED LESION
53 MIXED ADEN/META
3 SERRATED ADENOMA
1 ADENOMA
97 ASSUME ADENOMA
56 UNICRYPTAL ADENOMA
2 METAPLASTIC/HYPERPLASTIC
39 PREVIOUS POLYPECTOMY SITE
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POLYPTYPE_ID POLYP_TYPE
34 GRANULATION TISSUE
6 NORMAL MUCOSA
90 Not Possible To Diagnose
91 Specimen Not Seen
There was some debate about how to treat sessile serrated lesions (SSL), since if SSLs took precedence
over all types of adenoma, this may have affected the number of patients in the IA cohort. SSLs took
precedence over all types of adenoma. Investigations were carried out to determine the number of patients
who would be lost from the IA cohort as a result of this rule and consequently it was decided that the
order of precedence should be left as such, since only a small number of patients were affected.
Group 2 histology is shown below:
POLYPTYPE_ID POLYP_TYPE
8 CARCINOID/NEUROENDOCRINE TUMOUR
67 BASALOID/CLOACOGENIC CANCER
66 ANAPLASTIC/UNDIFFERENTIATED CARCINOMA
70 GRANULAR CELL TUMOUR
60 METS/TUMOUR – INFILTRATING
61 SQUAMOUS CELL CARCINOMA
63 GASTROINTESTINAL STROMAL TUMOUR
4 LEIOMYOMA
64 SARCOMA
26 NON-HODGKINS LYMPHOMA
71 MELANOMA
57 METASTASES – ANOTHER SITE
24 HAMARTOMATOUS POLYP
10 JUVENILE POLYP
5 INFLAMMATORY
36 CAP POLYP
23 REGENERATIVE POLYP
37 LYMPHOID POLYP
27 FIBROEPITHLIAL POLYP
17 SUBMUCOSAL HAEMATOMA
31 LIPOMA
25 HAEMANGIOMA
21 XANTHOMA
22 OEDEMA
41 AMYLOID
29 NEUROFIBROMATOSIS
40 GANGLIONEUROMATOSIS
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POLYPTYPE_ID POLYP_TYPE
32 PSEUDOLIPOMATUS
33 SPIROCHAETOSIS
19 ANGIODYSPLASIA
44 LYMPHANGIECTASIA
20 ISCHAEMIA
28 CROHN’S DISEASE
30 COLITIS
45 PROCTITIS
15 INFLAMMATION
14 ULCER
11 MUCOSAL PROLAPSE
35 GASTRIC HETEROTOPIA
16 MELANOSIS COLI
43 CONGESTION
Matched polyps with two or more histology types from group 2 and no histology from group 1 did not
have a true histology assigned, as these were not of interest in terms of the study. Meanwhile, matched
polyps with histology types from both groups 1 and 2 were reviewed in order to determine the correct
histology type. An ‘assume histology’ field was used to do the review, so it was clear which type was
considered correct based on the report details.
There were a number of polyps with no histology at any sighting. For polyps with no histology at baseline,
if available, the worst prior histology was matched to such polyps if the prior examination was within
3 years of the baseline polyp.
Unique polyps should not have both group 1 and group 2 histology or more than one type of group 2
histology (use “path_hist_incl_assume_adenoma”).
Exceptions to this rule are:
l if a polyp has reported both group 2 histology (any but only one type) and group 1 histology from normal
mucosa, granulation tissue, previous polypectomy site, not possible to diagnose or specimen not seen
(codes 6,34,39,90,91)→ remove group 1 histology from “path_hist_incl_assume_adenoma”
l if a polyp has group 1 and group 2 histology (not of the combinations above) which is caused by
multiplication out of multiple rows→ remove group 2 histology from “path_hist_incl_assume_adenoma”
l if a polyp is reported as anal wart (code 72) and SCC (code 61) at different sightings (both group 2)→ ok
as long as not both within baseline or both within follow-up (estimate time apart)
l if a polyp is reported as inflammation (code 15) and oedema (code 22) at different sightings (both group 2)
→ remove oedema from “path_hist_incl_assume_adenoma”.
If group 1 histology is reported for a unique polyp during or prior to baseline, this is assigned as the true
histology according to the table of precedence below for group 1 histology.
If group 2 histology is reported for a polyp during or prior to baseline, this histology is then assigned as the true
histology for baseline.
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C. True villousness
Again, it was decided that an order of precedence should be used to define true villousness, going from
most to least severe, as follows:
1. villous
2. tubulovillous
3. tubular.
True villousness values were applied across polyps at prior and baseline examinations (and then separately
for polyps at each follow-up visit). There were a small number of cases with non-adenomatous histology
that had villousness coded, which were reviewed as appropriate, for example a case with amyloid histology
and villousness was reviewed as it was likely that the coder had meant to code an adenoma.
Villousness recorded as tubular, tubulovillous or villous in database.
True villousness is derived by calculating worst villousness over all sightings of the polyp during and prior
to baseline.
D. True dysplasia
As was the case for villousness and histology, true dysplasia was also assigned based an order of
precedence from most to least severe, as follows:
1. intramucosal cancer
2. intramucosal cancer in dispute
3. high grade/severe
4. moderate
5. low grade
6. mild.
The following values were grouped into either high or low grade:
l high grade high grade, severe
l low grade moderate, low grade, mild.
True dysplasia values were also applied across polyps at prior and baseline examinations, and separately for
polyps at follow-up visits.
Dysplasia recorded as low grade, mild, moderate, high grade, severe, intramucosal cancer in dispute and
IM cancer.
True dysplasia is derived by calculating worst dysplasia over all sightings of the polyp during and prior
to baseline.
Mild and moderate are classified as low grade and severe is classified as high grade.
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Rule 15: True values to be applied across all sightings of polyps
True polyp segment and shape were applied across all sightings of a polyp as these features were expected
to remain constant over time.
A. True segment
The following rules were determined to define true polyp segment:
1. Surgical segment (i.e. polyp segment given at a surgical procedure) took precedence, as this was likely
to be the most precise way to identify a polyp’s location.
2. If there was no surgical procedure then the most frequently described segment was assigned as the
true segment.
3. If no segment was given more frequently than another, the most distal segment was assigned as the
true segment.
4. In cases when a segment range was used:
¢ if matched to a polyp with a single segment, assigned that segment
¢ if not, assigned a range (provisional, need to investigate these cases).
When the true segment range was within a segment group, i.e. ascending colon (distal) to ascending colon
(proximal) then true polyp segment was used instead, based on segment group (i.e. ascending colon).
In addition, for a polyp with multiple segment ranges at different sightings but no actual segment,
the smallest of all the ranges was used. Segments were then defined as follows: rectum to sigmoid
colon = distal; descending colon to hepatic flexure =mid; and ascending colon to terminal ileum = proximal.
True segment values were applied across all examinations, as the location of a polyp should remain
constant over time.
B. True shape
It was unclear whether true polyp shape would be best assigned based on an order of precedence as with
other characteristics or if the first recording of shape might be a more accurate method, as shape may have
looked different once a polyp was biopsied or if complete excision was attempted. Shape values were flat,
sessile, pedunculated, subpedunculated and pseudo. If an order of precedence were to be used, there was
some discussion over whether or not pedunculated or sessile shape should take precedence when a lesion was
described as being both shapes at different sightings. Analyses were undertaken to compare both methods
and it was decided that it was more appropriate to assign the first recorded shape of a lesion as the true
shape. In addition, any polyps with shape ‘subpedunculated’ were changed to ‘pedunculated’.
True polyp segment and shape to be applied across all sightings of polyp (not just in baseline).
Group segment information ignoring distal/mid/proximal information within segment.
If no ranges of segments are given for the polyp at any sighting, the order of precedence for assigning true
segment is:
1. Surgical segment (if available).
2. Most frequently used segment (if any segments repeated 2 + times and repeated more than any
other segment).
3. Most distal segment (maximum from ordered segment list).
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If range of segments is given for the polyp at one or more sightings the order of precedence for assigning true
segment is:
1. Use actual segment, if given at any time (use precedence rules above to decide which actual segment –
surgical, frequent, distal).
2. No actual segments given and only one range – assign that range.
3. No actual segments given and several ranges of segments – assign the smallest of the segment ranges as
long as “polyp segment from (ordered)” OR “polyp segment to (ordered)” of each of the ranges are ≤ 2
segments different.
Ordered segment list (proximal to distal):
1 Ileum
2 Caecum
3 Ascending colon
4 Hepatic flexure
5 Transverse colon
6 Splenic flexure
7 Descending colon
8 Sigmoid colon
9 Rectosigmoid
10 Rectum
11 Anus
Where true segment range is within a segment group e.g. ascending colon distal to ascending colon proximal
are both ascending colon, “true polyp segment” will be changed to ascending colon and “true polyp segment
to” will be set as missing.
Note: do not override true polyp segments with true segments for cancer/in situ. Use true cancer segments in
rules above to define true polyp segments. After this, do not use true cancer/in situ segments for site of cancer,
instead refer to true polyp segments (i.e. true cancer segment will not be same as true polyp segment in
some cases).
Any records recorded as sub-pedunculated changed to pedunculated.
If pathology shape is recorded and no endoscopy shape, replace endoscopy shape with pathology shape.
Use first recording of shape as true shape.
True shape to be applied across all sightings of polyp.
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Rule 16: baseline risk groups
The baseline risk groups were defined using the criteria for stratification of patients as low, intermediate
and high risk as described in the current EU Guidelines for Quality Assurance in Colorectal Cancer
Screening and Diagnosis. These definitions were applied using all adenomas found at prior and baseline
examinations, and are as follows:
l Low risk One or two small adenomas (no large adenomas or adenomas without size).
l Intermediate risk Three or four small adenomas (no large adenomas or adenomas without size) or one
or two adenomas of which at least one is large.
l High risk Five or more adenomas (any or unknown size) or three or more adenomas of which at least
one is large.
l Low/intermediate risk One adenoma of unknown size or two adenomas of which none is large but
one or more has unknown size.
l Intermediate/high risk Three or four adenomas of which none is large but one or more has
unknown size.
Small adenomas were those of < 10 mm in size, whereas large adenomas were those of ≥ 10 mm.
Baseline risk groups count adenomas recorded at baseline or prior to baseline or before first examination
on database.
Define true histology and true size for unique polyps using values from PRIOR and BASELINE and BEFORE FIRST
EXAM ON DATABASE together (to account for adenomas that occur or are seen prior to baseline).
These risk groups are defined at this point to be used for rule 18 (relabeling procedure types of baseline
endoscopies) and so still include patients who currently do not have baseline colonoscopy.
Risk group definitions:
l Low risk – 1 or 2 small adenomas (no large adenomas or adenomas without size)
l Intermediate risk – 3 or 4 small adenomas (no large adenomas or adenomas without size) OR 1 or 2
adenomas of which at least 1 is large
l High risk – 5 or more adenomas (any or unknown size) OR 3 or more adenomas of which at least 1 is large
l Low/intermediate risk – 1 adenoma of unknown size OR 2 adenomas of which none is large but 1 or more
has unknown size
l Intermediate/high risk – 3 or 4 adenomas of which none is large but 1 or more has unknown size.
*small adenomas < 10mm, large adenomas ≥ 10mm.
*adenomas histology codes used “path_hist_incl_assume_adenoma”= 1, 3, 53, 56, 97.
Note: sessile serrated lesion not included in baseline risk groups.
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Rule 17: relabelling unclassified endoscopies during baseline
To enable accurate classification of an individual’s baseline risk of CRC, it was preferable that a complete
colonoscopy was performed during the baseline period. In some cases, there were baseline examinations
with no procedure type given. In other cases, examinations were vaguely referred to as endoscopies. Such
procedures were reclassified into more specific procedure types (derived procedure type) in rules 1 and 10.
Patients with no certain colonoscopy at baseline, who instead had the non-specific procedure type of
‘colonoscopy or flexi-sig’, were reviewed with the aim of identifying those in whom such a procedure
could be assumed to be a colonoscopy based on certain criteria. These patients had many different
combinations of specific examinations (i.e. flexi-sig) and non-specific derived procedure types, as well as
having only non-specific derived procedure types during baseline.
Procedures were reclassified based on CRC risk and type of follow-up examination. If high-risk adenomas
were found then one could assume that the patient was likely to have had a colonoscopy at some point
during baseline. If a patient had at least one follow-up colonoscopy or ‘colonoscopy or flexi-sig’ examination,
it was also deemed likely that they had had a colonoscopy at baseline, whereas for those with no follow-up
colonoscopy or ‘colonoscopy or flexi-sig’, it was possible that the non-specific baseline procedure could have
been a FS or a colonoscopy. If a patient had a follow-up examination within 7 years and the patient had
low-risk baseline lesions, one can assume that the follow-up examination was a surveillance examination.
The follow-up examination should be within 7 years for this to be feasible because 5 years is specified as the
low-risk surveillance interval in the guidelines and patients may delay their appointment for a number of
reasons, thus 7 years ought to include all surveillance examinations. If a patient had low-risk polyps and no
follow-up colonoscopy, one cannot assume that the ‘colonoscopy or flexi-sig’ is a colonoscopy.
Specifically, patients were first split into two groups: those with one ‘colonoscopy or flexi-sig’ at baseline
only (no other examinations at baseline) and those with two or more ‘colonoscopy or flexi-sig’
examinations at baseline or other examination types. In both groups, a baseline ‘colonoscopy or flexi-sig’
examination was assumed to be a colonoscopy and relabelled as such if the patient was intermediate, high
or intermediate/high risk. Additionally, patients who were low or low/intermediate risk, who had at least
one follow-up colonoscopy or ‘colonoscopy or flexi-sig’ examination within 7 years of their last baseline
examination, also had their baseline ‘colonoscopy or flexi-sig’ examination relabelled as a colonoscopy.
This is because such patients were likely to be under some sort of colonoscopic surveillance. In cases when
there were two or more ‘colonoscopy or flexi-sig’ examinations during baseline and the patient met the
criteria to have a ‘colonoscopy or flexi-sig’ examination relabelled (as described above), only the first
‘colonoscopy or flexi-sig’ examination during baseline was relabelled as a colonoscopy.
Analyses into examinations sequences showed that colonoscopy tended to follow sigmoidoscopy, except
where a large lesion was detected and the subsequent examination was undertaken to check the
completeness of polypectomy. These analyses also demonstrated that flexi-sig followed by flexi-sig was
fairly uncommon compared with colonoscopy followed by colonoscopy. Consequently, in those with two
examinations at baseline, one of which was a form of sigmoidoscopy, it was assumed that the
‘colonoscopy or flexi-sig’ examination was a colonoscopy if it occurred after the sigmoidoscopy.
Relabelling for patients with no baseline colonoscopies
(a) One ‘colonoscopy or flexi-sig’ examination only at baseline (no other examinations)
Relabel baseline ‘colonoscopy or flexi-sig’ examination as a colonoscopy if:
l patient is intermediate, high or intermediate/high risk, regardless of follow-up
l patient is low or low/intermediate risk and at least one follow-up examination is a colonoscopy within
7 years of last baseline examination
l patient is low or low/intermediate risk and at least one follow-up examination is ‘colonoscopy or
flexi-sig’ examination within 7 years of last baseline examination.
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(b) Two or more ‘colonoscopy or flexi-sig’ examinations at baseline OR one or more ‘colonoscopy or flexi-sig’
examination with other examinations at baseline
Relabel baseline ‘colonoscopy or flexi-sig’ examination as a colonoscopy if:
l patient is intermediate, high or intermediate/high risk, regardless of follow-up
l patient is low or low/intermediate risk and at least one follow-up examination is a colonoscopy within
7 years of last baseline examination
l patient is low or low/intermediate risk and at least one follow-up examination is ‘colonoscopy or
flexi-sig’ within 7 years of last baseline examination.
Note: in cases where there are 2 + ‘colonoscopy or flexi-sig’ examinations during baseline and patient meets
criteria to have a ‘colonoscopy or flexi-sig’ examination relabelled (as above), only the first ‘colonoscopy or
flexi-sig’ examination during baseline will be relabelled as colonoscopy.
l With any remaining patients in this group, relabel ‘colonoscopy or flexi-sig’ examination as a colonoscopy if
two examinations at baseline only, where first is ‘flexi-sig’ or ‘flexi-sig or rigid-sig’ examination and second
is a ‘colonoscopy or flexi-sig’ examination.
Rule 18: indicate which patients do not have baseline colonoscopy
Patients without a colonoscopy during their baseline visit were problematic because their true risk could
not be accurately assessed without an initial examination of the whole colon. It was decided that any such
patients should be marked so that separate analyses can be performed with the exclusion or inclusion of
such patients. This also enabled stratification by procedure type at baseline in order to assess whether
there is an association between risk and examination type. Thus, the most complete full colon examination
available at baseline was defined using a hierarchy based on procedure type, segment reached, polyp site
and whether or not the procedure was marked as incomplete or not.
Indicate which patients do not have a colonoscopy during baseline. We cannot accurately assess their baseline
risk group without the entire colon being seen so they will be excluded from the some analyses.
Defined for each follow-up visit the ‘most complete full colon examination available’ at baseline using the
following hierarchy:
1. complete ‘colonoscopy’
2. (define complete as reaching/recording polyps in CM or IL (segment_reached/true_segment/
true_segment_to = 9, 34,10) and not marked as incomplete (diagnosis = 14) in diagnosis fields)
3. ‘colonoscopy’ that is not complete or unknown whether complete
4. (does not reach/no polyps recorded in CM/IL, no info. on segment reached or marked as incomplete)
5. ‘colonoscopy or flexi-sig’
6. ‘flexi-sig’
7. ‘colonoscopy, flexi-sig or rigid-sig’
8. ‘flexi-sig or rigid-sig’
9. ‘rigid-sig’
10. ‘surgery’
11. ‘unknown’.
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Rule 19: follow-up visit numbering
The rules used to define baseline were also applied to follow-up visits, regardless of the type of follow-up
procedures at each visit. The first examination after baseline or after the previous visit and any examinations
within 11 month of that first examination were defined as the next follow-up visit. The final examination in a
visit was identified and the visit was then extended forwards using the same criteria as those used for the
extension of the baseline period. This procedure was repeated until all of the examinations had been grouped
into visits.
The same rules are used for defining follow-up visits as used at baseline, regardless of types of follow-up
procedures. These rules are as follows (written for defining follow-up visit 1 but they are the same for defining
each follow-up visit):
(a) Define the first examination after the end of baseline, as follow-up visit 1.
Include any examinations within 11 months of this examination in follow-up visit 1.
Define the last examination in follow-up visit 1 so far to use for parts (b) and (c)*.
(b) Any examinations within 6 months of last examination in follow-up visit 1*will be included in follow-up
visit 1.
This rule is only applied once.
(c) Extension of the follow-up visit to account for various scenarios where further examinations may be
performed as part of the same visit e.g. incomplete examinations, poor bowel preparation, large polyps,
surgery to remove lesions.
Include all examinations which occur 6–9 months after last examination in follow-up visit 1* if:
l the last examination in follow-up visit 1* is incomplete
l the last examination in follow-up visit 1* has poor preparation
l the last examination in follow-up visit 1* finds a ≥ 15-mm polyp (use derived_endo_size, derived_path_size
or derived_endo_size_other)
l the same polyp is seen at the last examination in follow-up visit 1* as an examination occurring within
6–9 months after the end of FU visit 1
l the first examination after follow-up visit 1 is surgical and it occurs at 6-9 months after the end of
follow-up visit 1*
These rules are only applied once.
(d) Further extension of the follow-up visit to account for large polyps being removed over many examinations.
l Define date of last examination in follow-up visit 1.
l Define whether ≥ 15 mm lesions (distal/proximal/any) found anytime during follow-up visit 1
(as follow-up visit 1 is currently assigned).
l Include any colonoscopy procedures into follow-up visit 1 if they occur within 6 months of last
examination in follow-up visit 1 and a ≥ 15 mm lesion more proximal than SC is reported during
follow-up visit 1.∼
l Redefine date of last examination in follow-up visit 1. ∼
l Include any FS/sigmoidoscopy/rigid sigmoidoscopy/unknown/endoscopy procedures into follow-up visit
1 if they occur within 9 months of last examination in follow-up visit 1 and a ≥ 15mm lesion in SC or
more distal is reported during follow-up visit 1. ∼
l Redefine date of last examination in follow-up visit 1. ∼
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l Include any surgery procedures into follow-up visit 1 if they occur within 9 months of last examination
in follow-up visit 1 and a ≥ 15 mm lesion is reported during follow-up visit 1. ∼
l Redefine date of last examination in follow-up visit 1. ∼
l Repeat the steps indicated with ∼ until no further examinations are included into follow-up visit 1.
Rule 20: true values for polyps found during follow-up visits
The same rules were applied as those used at prior and baseline examinations (see rule 14), but they were
applied across polyps only within each follow-up visit, so any changes in polyp characteristics over time
could be identified.
A. True size: same rules as above for baseline but only applied across polyps within each follow-up visit.
B. True histology: same rules as above for baseline but only applied across polyps within each follow-up visit.
C. True villousness: same rules as above for baseline but only applied across polyps within each follow-up visit.
D. True dysplasia: same rules as above for baseline but only applied across polyps within each follow-up visit.
Rule 21: start/end date of endoscopy records at each centre
The start and end dates of endoscopy records for each hospital were determined data, based on number
of endoscopies extracted over time. The number of endoscopy examinations on the study database was
plotted by month for each hospital. The plots produced were assessed, and the first and last month in
which the number of endoscopies became steady were identified. The chosen start and end dates were
based on the earliest/latest examination in the chosen months. It was assumed that, for each patient,
all endoscopies that occurred between these dates were present in the study database.
The start and end dates of endoscopy records we will have for each hospital was decided by:
l Plotting by month the number of examinations from the endoscopy database (i.e. not pathology-based
procedure reports) and choosing the month at which the number of examinations was steady (near the
start of collection not many records may have been entered onto the electronic database or near the end
of collection completed examinations may have been waiting to be entered onto the database).
l The chosen start and end dates of examinations we have for each hospital was set to the start/end of the
chosen months the earliest/latest examination was midway through a month.
Therefore, we assume that between the chosen start/end dates we have all the endoscopy exams that occurred
at that hospital between those dates.
Hospital Dates of exams Chosen start/end dates
St Mark’s (SMH) 03/01/1972 – 20/07/2010 01/01/1985 – 31/07/2007
Leicester (LGH) 26/05/1988 – 08/04/2008 01/04/1998 – 31/03/2008
Brighton (BRI) 03/05/2001 – 23/04/2008 03/05/2001 – 23/04/2008
Torbay (TDG) 18/05/1993 – 24/11/2009 01/11/2000 – 31/08/2007
Yeovil (YDH) 16/10/1989 – 06/06/2008 01/02/1997 – 31/05/2008
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Hospital Dates of exams Chosen start/end dates
North Tees (NT) 06/06/1986 – 12/03/2010 06/06/1986 – 31/12/2006
Queen Elizabeth (QEW) 31/01/1990 – 27/06/2009 01/03/1999 – 31/05/2006
Cumberland (CI) 05/05/1994 – 28/01/2010 01/08/1998 – 30/09/2009
Shrewsbury (SH) 06/02/1995 – 30/09/2009 01/01/2002 – 30/09/2009
Liverpool (RLUH) 17/08/1999 – 21/10/2009 01/01/2000 – 21/10/2009
Glasgow (GRI) 01/04/1996 – 08/09/2009 01/05/1996 – 31/08/2009
St Georges (SGH) 15/04/1987 – 29/05/2010 01/02/1992 – 31/07/2009
Sidcup (QMH) 06/01/1988 – 14/07/2009 01/10/1998 – 14/07/2009
New Cross (NC) 04/01/1993 – 23/11/2007 04/01/1993 – 23/11/2007
Surrey (SCH) 25/07/1985 – 29/05/2010 01/09/1997 – 29/05/2010
St Mary’s (ICM) 06/04/1980 – 07/08/2010 01/12/1984 – 31/07/2010
Charing Cross & Hammersmith (CX or HH) 09/06/1994 – 27/11/2007 01/10/1997 – 27/11/2007
Rule 22: cancer and advanced adenoma end points
For the purposes of analysis, records with end points of interest (CRC and advanced adenomas) were
flagged. Advanced adenomas were defined as adenomas of ≥ 10 mm or with HGD or villous/tubulovillous
histology. The earliest record of each unique cancer or advanced adenomas was then identified and
assigned timing in relation to other examinations.
(a) Cancers
l Indicate earliest record of each unique cancer now that true values have been defined.
l Note: this may not be the same as the original polyp recorded as cancer in our data or from external
data due to true values applied across each follow-up visit.
l Define which patients report cancer and which visits report these first records of unique cancer.
l Assign timing of cancers relative to other follow-up exams and collection dates of records at each
hospital. To decide which to use as end points in analyses.
(b) AAs
l Define advanced adenomas as adenomas ≥ 10mm or HGD (or more severe) or tubulovillous/villous.
l Indicate earliest record of each unique advanced adenoma now that true values have been defined.
l NB this may not be the same as the original polyp recorded as AA in our data or from external data
due to true values applied across each follow-up visit.
l Define which patients report AA(s) and which visits report these first records of unique AA.
l Assign timing of AAs relative to other follow-up exams and collection dates of records at each
hospital. To decide which to use as end points in analyses.
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Rule 23: procedure types at follow-up visits
It was decided that no follow-up examinations would have their procedure types relabelled, unlike those at
prior and baseline examinations. Instead, for each follow-up visit the ‘most complete full colon exam’
available was defined using a hierarchy from complete colonoscopy to unknown procedure type. The
completeness of a colonoscopy was defined based on the segment reached, most proximal polyp site and
whether or not the examination was marked as incomplete or not.
Decided not to relabel any follow-up procedure types.
Defined for each follow-up visit the “most complete full colon exam available” using hierarchy:
1. complete colonoscopy (define complete as reaching CM or IL (codes 9, 34,10) and not marked as
incomplete (diagnosis = 14) in diagnosis fields)
2. colonoscopy that is not complete or unknown whether complete (does not reach CM/IL, no information on
segment reached or marked as incomplete)
3. endoscopy
4. FS
5. sigmoidoscopy
6. rigid sig
7. surgery
8. unknown.
Rule 24: visit date and visit intervals
A visit date was defined as the earliest examination date in each visit; this was defined only for baseline
and follow-up visits, not those prior to baseline. Then visit intervals were timed from the last, most
complete examination of one visit to the first examination of the next visit.
Visit intervals:
Create visit date as earliest examination date of each visit.
Note: visit date is defined for baseline visits and visits after baseline (not those prior to baseline).
Visit intervals are timed from the last most complete examination of one visit to the first examination of the
next visit.
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Rule 25: censoring of visits after patient diagnosed with certain conditions
It was decided that visits following a diagnosis of CRC, volvulus and resection/anastomosis should be
censored. Contrastingly, any visits that occur after a diagnosis of colitis, IBD/Crohn’s disease, polyposis,
radiation and proctitis, and ulcers and radiation are not censored.
Censor visits after:
l malignant colorectal cancer diagnosis
l resection/anastomosis
l volvulus.
Note: censor the visits after the visit at which any of these occur during.
No censoring for colitis, IBD/Crohn’s, polyposis, radiation+ proctitis or ulcers+ radiation if they occur after baseline.
Rule 26: deaths
Any cases for which there was more than one date of death for a patient were resolved, and the date of
death for patients who were traced and had died was added to the study database.
Rule 27: tracing
Patients were traced using data from external sources – including HSCIC, NHSCR and NSS – to obtain
follow-up data on cancers and deaths, verify patient information such date of birth and gender,
and identify duplicate patients on the study database.
Use tracing file from Study programmer→ “DERIVED_MR1201_TRACING_DATA”.
(a) One record per patient: There is more than one record for some patients. Study programmer has marked in this
dataset which records to remove so that we only have one record per patient. A patient may have more than one
record because they have been traced by more than one source (traced by NSS and HSCIC – choose NSS record if GRI
patient and HSCIC record if not GRI patient) or because several patients have been merged together (so the duplicate
patients need to be removed). These records are removed and we are left with a file that is one record per patient.
(b) Date of birth and gender: True date of birth and true gender calculated by Study programmer. These fields
are derived in HSCIC and NSS fields separately before the files are merged together. Study programmer uses
hierarchy to decide true values. In HSCIC file – hierarchy 1) MMP 2) HSCIC 3) hospital data 4) patient table.
In NSS file – hierarchy 1) NSS 2) hospital data 3) patient table (NB NSS does not have MMP data, MMP data is
from HSCIC – it is latest info for ENG/WALES cases). Check the true date of birth is not after the exams we
have for that patient and check that any occurring after 1990 or before 1900 look valid.
(c) Embarkation, cancelled cipher, registered in Northern Ireland, registered in Scotland:
Patients are listed as “registered in Scotland” means that the patient has moved to Scotland and we have the date to
show when they moved. In these cases we have all the England/Wales cancers and deaths up to the point they
moved to Scotland and we also have cancers and death from NHSCR after they moved to Scotland. Therefore, for all
“registered in Scotland” patients as long as they are subsequently “flagged in Scotland” we will know about all their
cancers and deaths. In our data all patients indicated as “registered in Scotland” are also “flagged in Scotland”.
Patients are listed as “registered in Northern Ireland” meaning that the patient has moved to Northern Ireland
and we have the date to show when they moved. In these cases we have all the England/Wales cancers and
deaths up to the point they moved to Northern but not after that, unless they re-enter the NHS.
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Patients are listed as “embarked” which is when a patient moves abroad and notifies their GP and we have the
date they moved. In these cases we have all the England/Wales cancers and deaths up to the point they moved
but not after that, unless they re-enter the NHS. A death may become available if it is registered with the
consulate in the country, however, this would only be fact of death, no cause would be available.
Patients are listed as “cancelled cipher” which is when a patient has exited the NHS but the reason is unknown
(may have moved abroad or moved into private care without informing their GP) and we have the date they
moved. In these cases we have all the England/Wales cancers and deaths up to the point they moved but not
after that, unless they re-enter the NHS.
Check that all patients registered in Scotland are also flagged in Scotland. Check that each patient does not
have more than one of four variables above.
(d) Checking dates
Compare the following dates to check they are valid:
l date of cancelled cipher
l date of embarkation
l date of registration in Northern Ireland
l date of death
l date of cancer
l date of exams on our database.
Create “embarkation censor” that censors exams that occur after embarkation/cancelled cipher/registration in NI.
(e) Cancers and deaths after the cut off time for ascertainment.
For each patient we define a cut-off date for ascertainment of cancers and a cut-off date for ascertainment of
deaths (i.e. a date for that source that we know ascertainment of cancers or deaths is complete until by that
source). The cut off dates we use are shown in the table below.
Dataset Completeness
Date we received
the last dataset
from the source
Completeness date
we have used
HSCIC Cancers 6–12 months behind 09/07/2013 30/06/2012
HSCIC Deaths 3 weeks behind 09/07/2013 18/06/2013
NSS Cancers Completion date for 2011 incidence is
31st December 2012 in accordance with
UKACR guidelines. 85–100% complete for
end of 2011 by November 2012
07/11/2012 31/12/2011
NSS Deaths They currently get a weekly update of data
which are considered provisional. In August of
each year we get an update for the previous
year after which the data are considered
complete so 2011 deaths data will be
complete by the end of August 2012
07/11/2012 31/12/2011
NHSCR Cancers ISD can take up to 2 years to compile a
Scottish cancer registration. Their database is
from 1958. NHSCR receive these monthly
12/09/2013 31/12/2011
NHSCR Deaths Scottish deaths are usually registered within
3 weeks of the event. NHSCR obtain coded
death copies each week, within a few weeks
(no more than 9) of registration
12/09/2013 22/08/2013
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As a patient may have been traced by multiple sources we use a hierarchy to obtain the most recent cut-off
date for cancer ascertainment and for death ascertainment for the patient.
For cancer ascertainment date:
1. if any sources are HSCIC, use 30/06/2012
2. if any sources are NHSCR, use 31/12/2011
3. if any sources are NSS, use 31/12/2011.
For death ascertainment date:
1. if any sources are NHSCR, use 22/08/2013
2. if any sources are HSCIC, use 18/06/2013
3. if any sources are NSS, use 31/12/2011.
Any cancers and deaths after the appropriate cut off point are then marked to be censored in the dataset
(“trace censor cancer” and “trace censor death”).
(f) True date of birth and gender: Replace date of birth and gender in our dataset using true values.
(g) Follow-up date for cancer and death for each patient. Create date patient is followed until for cancer:
l Earliest of cancer diagnosis, death, embarkation, cancelled cipher and registration in NI, if any of these
occurred and if they occurred before the cancer ascertainment date.
l If none of these events occurred and the patient was traced, the cancer ascertainment date was used.
l If none of these events occurred and the patient was not traced, the last examination date from our
database was used.
Create date patient is followed until for deaths:
l Earliest of death, embarkation, cancelled cipher and registration in NI, if any of these occurred and if they
occurred before the death ascertainment date.
l If none of these events occurred and the patient was traced, the death ascertainment date was used .
l If none of these events occurred and the patient was not traced, the last examination date from our
database was used.
Check these are correct for groups corrected in section (d).
Calculate follow-up time for cancer and follow-up time for death for each patient.
Rule 28: map previously seen cancers from external sources
When external cancers were initially mapped to polyps on the study database, the criteria used for
matching ensured that only polyps with cancer-related pathology were matched. Any unmapped cancers
were treated as new cancers that had not been seen previously.
Some of the cancers were not mapped to previously seen lesions, as they did not have evidence of
cancerous histology. In June 2014, it was decided that some of the large adenomas probably developed
into the cancer that was reported by the HSCIC. The statistician, study researchers and principal
investigator came up with new rules that could be applied to identify these cases and link the external
cancer to a polyp on the POLYP table on the database.
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The following rule (rule 1) was applied to all patients in the IA cohort (those who are IR patients with a
baseline colonoscopy).
l There must be a polyp record that matches the external cancer when the following criteria are applied:
¢ external cancer and polyp segments must have close proximity (i.e. not more than two-tenths of
the colon away)
¢ polyp must be ≥ 15 mm in size:
¢ DERIVED_ENDO_SIZE ≥ 15 OR
¢ DERIVED_PATH_SIZE ≥ 15 OR
¢ DERIVED_ENDO_SIZE_OTHER is > 10 mm (i.e. 15 mm) or large (i.e. 20 mm)
¢ STAT_TRUE_SIZE ≥ 15 (this is the true size derived by statistician and recorded on the
POLYP table)
l the pathology of the polyp must be adenoma related, i.e. codes (1, 3, 51, 56, 58, 59).
POLYPTYPE_ID POLYP_TYPE
1 ADENOMA
3 SERRATED ADENOMA
51 CA+ ADENOMA
56 UNICRYPTAL ADENOMA
58 CA+ SERRATED
ADENOMA
59 CA+MIXED ADENOMA
CA, cancer.
In either of these fields on the POLYP table: PATH_HISTOLOGY, ASSUME_PATH_HISTOLOGY or
STAT_TRUE_HIST (true histology derived by statistician and recorded on the polyp table):
l The polyp must have occurred within the baseline dates.
l The difference in days between the external cancer and the polyp must be within 5 years (i.e. 1826 days).
l There must be at least one other occurrence of the polyp (i.e. same derived polyp number) within
5 years from the external cancer date (i.e. 1826 days at baseline or follow up).
A random sample of rule 1 records were reviewed so that we could be confident that the criteria used
were successful in identifying previously seen lesions that were likely to have developed into the cancer
from external sources.
Some other rules were also tested (rules 2 and 3), and records found from rule 2 and rule 3 matching
were manually reviewed but there was not enough evidence to show that the cancer matched a previously
seen lesion. Therefore, it was decided that only rule 1 would be applied for matching cancers.
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Appendix 8 Deriving sizes for individual polyps
Polyp sizes
During the manual coding phase the following size fields were recorded on the POLYP table in order to
accommodate the different types of information relating to polyp size that were supplied in endoscopy
and pathology reports.
1. ENDO_SIZE An actual size in mm of the polyp or group of polyps as described on the endoscopy report.
In some cases the ENDO_SIZE was either provided or an exact size was not provided, as it was described
as part of a group of polyps (described later) or looked inaccurate (e.g. transcribing error). The study
researchers reviewed the endoscopy report, pathology report and the occurrence of the polyp across
examinations in order to provide the best guess of the endoscopy size for an individual polyp that was
recorded in the field. ASSUME_ENDO_SIZE. ASSUME_ENDO_SIZE took precedence over ENDO_SIZE.
2. ENDO_SIZE_MAX The maximum size in mm of the polyp or group of polyps as described on the
endoscopy report.
3. ENDO_SIZE_MIN The minimum size in mm of the polyp or group of polyps as described on the
endoscopy report.
4. ENDO_SIZE_OTHER The category for the size of the polyp or group of polyps as described on the
endoscopy report, for example tiny, > 10 mm, < 5 mm, and so on. In some cases the ENDO_SIZE_OTHER
was not provided or was provided but was inaccurate. If no other sizes were available, the study
researcher reviewed the endoscopy report, pathology report and the occurrence of the polyp across
examinations in order to provide the best guess of the ENDO_SIZE_OTHER for an individual polyp and
recorded this in the ASSUME_ENDO_SIZE_OTHER field, which took precedence over ENDO_SIZE_OTHER.
5. MAX_BIOPSY_SIZE The maximum size in millimetres of a given biopsy described by the pathologist on
the pathology report.
6. PATH_SIZE An actual biopsy size in millimetres of a given biopsy described by the pathologist on the
pathology report. On rare occasions, if the PATH_SIZE was not provided or looked inaccurate, the study
researcher reviewed the endoscopy report, pathology report and the occurrence of the polyp across
examinations in order to provide the best guess of the pathology size for an individual polyp which was
recorded in a field called ASSUME_PATH_SIZE and took precedence over PATH_SIZE.
Polyp set
Some polyp sizes were recorded as polyp sets and made up of:
l Collection of polyps, each with the same ENDO_SIZE_MIN and ENDO_SIZE_MAX range
l One individual polyp seen on the same date whose ENDO_SIZE or ASSUME_ENDO_SIZE matched the
ENDO_SIZE_MAX or ENDO_SIZE_MIN of the collection of polyps. The polyp may or may not have an
ENDO_SIZE_MIN and ENDO_SIZE_MAX range. OR Two individual polyps seen on the same date where
the ENDO_SIZE or ASSUME_ENDO_SIZE of one polyp matched the ENDO_SIZE_MAX of the collection
of polyps and the ENDO_SIZE or ASSUME_ENDO_SIZE of the other polyp matched the ENDO_SIZE_MIN
of the collection of polyps. The polyps may or may not have an ENDO_SIZE_MIN and ENDO_SIZE_MAX
range, or
l There were no individual polyps with an ENDO_SIZE or ASSUME_ENDO_SIZE recorded.
The screenshot below shows an example of a polyp set with two individual polyps.
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FIGURE 33 Screenshot showing polyp sets.
Derived polyp sizes
There following size fields were derived:
l DERIVED_ENDO_SIZE Derived from the fields ASSUME_ENDO_SIZE, ENDO_SIZE, ENDO_SIZE_MIN,
ENDO_SIZE_MAX and DERIVED_ENDO_RANGE (ASSUME_ENDO_SIZE took precedence over ENDO_SIZE).
l DERIVED_ENDO_SIZE_SOURCE Shows the field from which the DERIVED_ENDO_SIZE was derived.
l DERIVED_ENDO_SIZE_OTHER Derived from the fields ASSUME_ENDO_SIZE_OTHER and
ENDO_SIZE_OTHER (ASSUME_ENDO_SIZE_OTHER took precedence).
l DERIVED_ENDOSIZE_OTHER_SOURCE Shows the field from which the DERIVED_ENDO_SIZE_OTHER
was derived.
l DERIVED_PATH_SIZE Derived from the fields ASSUME_PATH_SIZE and PATH_SIZE
(ASSUME_PATH_SIZE took precedence).
l DERIVED_PATH_SIZE_SOURCE Shows the field from which the DERIVED_PATH_SIZE was derived.
Deriving endoscopy sizes for individual polyp rows
It was necessary to derive one endoscopy size called DERIVED_ENDO_SIZE where a size value was available
from ENDO_SIZE, ENDO_SIZE_MIN and ENDO_SIZE_MAX but on initial analysis of the data the following
limitations were identified and decisions were made to overcome them.
Only ENDO_SIZE_MAX was recorded
For some polyp rows only ENDO_SIZE_MAX was recorded. It was known that when an endoscopist used
ENDO_SIZE_MAX, it was often to describe the maximum size within a collection of polyps. If the size was large
and used for all the polyps in the collection to get the DERIVED_ENDO_SIZE, it could have led to such polyps
being classified as higher risk. The following decisions were made to allocate the DERIVED_ENDO_SIZE based
on different scenarios:
l If the ENDO_SIZE_MAX was only allocated to one polyp as opposed to a collection of polyps, then the
ENDO_SIZE_MAX was assumed to be its correct size.
l If the ENDO_SIZE_MAX ≤ 5 mm for a collection of polyps, then it was assumed to be the correct size as
it was small so DERIVED_ENDO_SIZE would be set to ENDO_SIZE_MAX.
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
486
l If the ENDO_SIZE_MAX > 5 mm for a collection of polyps and it matched the ENDO_SIZE or
ASSUME_ENDO_SIZE of an individual polyp in the set and all the segments in the polyp set matched
(ENDO_SEGMENT and ENDO_SEGMENT_TO), then the DERIVED_ENDO_SIZE of the individual polyp
was set to ENDO_SIZE_MAX and the DERIVED_ENDO_SIZE of the remaining polyps in the polyp set
were set to ‘UNKNOWN’.
l If the ENDO_SIZE_MAX > 5 mm for a collection of polyps and none of the polyps in the polyp set had
an ENDO_SIZE or ASSUME_ENDO_SIZE recorded, then the polyps set was reviewed by the study
researchers and they allocated an ASSUME_ENDO_SIZE where possible. The DERIVED_ENDO_SIZE was
then taken from ASSUME_ENDO_SIZE where available and the DERIVED_ENDO_SIZE of the remaining
polyps were set to ‘UNKNOWN’.
ENDO_SIZE_MIN and ENDO_SIZE_MAX only recorded
For some polyp rows only ENDO_SIZE_MIN and ENDO_SIZE_MAX were recorded. It would not have been
appropriate to assign a DERIVED_ENDO_SIZE by calculating an average of the two sizes, particularly in
cases where the ENDO_SIZE_MIN and ENDO_SIZE_MAX differed considerably.
The ENDO_SIZE_MIN and ENDO_SIZE_MAX were recorded in 2 different scenarios:
l Scenario A – Some endoscopy reports had specific size and site details for individual polyps. However,
ENDO_SIZE_MIN and ENDO_SIZE_MAX were used by study researchers so that pathology could be
assigned to a polyp, as the pathology report did not give sufficient detail to determine which polyp the
histology belonged to.
l Scenario B – Some endoscopy reports only gave broad details of size (and site) for a collection of
polyps, so ENDO_SIZE_MIN and ENDO_SIZE_MAX had to be used because no individual polyp details
were given e.g. 10 polyps between 5–25 mm.
The following decisions were made to allocate the DERIVED_ENDO_SIZE based on different scenarios:
l For both scenarios, if the ENDO_SIZE or ASSUMED_ENDO_SIZE of two individual polyps in the set
matched the ENDO_SIZE_MIN and ENDO_SIZE_MAX of the polyp set, respectively, and all the
segments in the polyp set matched (ENDO_SEGMENT and ENDO_SEGMENT_TO), then the
DERIVED_ENDO_SIZE of the individual polyp(s) was set to the ENDO_SIZE or ASSUME_ENDO_SIZE and
the DERIVED_ENDO_SIZE of the remaining polyps in the polyp set were set to ‘UNKNOWN’.
l The study researcher created an ENDO_PATH_MAPPING field on the POLYP table, which was used to
record the rule used for matching pathology to the polyp. For scenario A and B, if the DERIVED_ENDO_SIZE
had not been allocated, the study researchers used the rules for ‘endo path mapping’ (described later) to
recode the pathology of the polyps and the ENDO_SIZE when available. The ENDO_SIZE_MIN and
ENDO_SIZE_MAX were set to blank if the ENDO_SIZE was recorded.
l For scenario B, the study researchers tried to assign a value to ASSUME_ENDO_SIZE. They tried to assign
one lesion the ENDO_SIZE_MIN and one lesion the ENDO_SIZE_MAX when possible. They also tried to
assign a size to the other polyps if possible. If the ASSUME_ENDO_SIZE was not assigned then the
DERIVED_ENDO_SIZE was deemed ‘UNKNOWN’, otherwise it was assigned to the DERIVED_ENDO_SIZE.
l An average was assigned to DERIVED_ENDO_SIZE for any cases with just one polyp with
ENDO_SIZE_MIN and ENDO_SIZE_MAX.
l For cases that were not reviewed, an average was assigned to DERIVED_ENDO_SIZE for all polyps for
which ENDO_SIZE_MIN and ENDO_SIZE_MAX did not differ considerably.
l For cases which were reviewed, ‘UNKNOWN’ was assigned to DERIVED_ENDO_SIZE for all polyps in the
review that were not assigned an ASSUME_ENDO_SIZE. Otherwise the ASSUME_ENDO_SIZE was
assigned to DERIVED_ENDO_SIZE.
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Deriving endoscopy size for a collection of polyps based on
pathology information (‘endo path mapping’)
These rules were applied where the ENDO_SIZE_MIN and ENDO_SIZE_MAX were recorded for a collection
of polyps and in some cases the actual size and pathology information was available. Majority of these
records were ‘Scenario A’ type records described earlier. It was decided that such recorded needed to be
recoded and specifically the following records were reviewed:
l ENDO_SIZE_MIN is < 10 mm, ENDO_SIZE_MAX is ≥ 10 mm AND sizes differ by ≥ 3 mm
l ENDO_SIZE_MIN is ≥ 10 mm, ENDO_SIZE_MAX is ≥ 15 mm AND sizes differ by ≥ 5 mm
l ENDO_SIZE_MIN is ≤ 5 mm, ENDO_SIZE_MAX is 6–9 mm AND sizes differ by ≥ 2 mm
l ENDO_SIZE_MIN is > 5 mm, ENDO_SIZE_MAX is ≤ 9 mm AND sizes differ by ≥ 3 mm
The following rules were applied when recoding these cases:
l The study researcher put the specific size and segment details back into the ENDO_SIZE and
ENDO_SEGMENT fields, removing size ranges and ‘SEGMENT_TO’ as appropriate.
l Other pathology was recoded where specific information was available.
l The histology rules were applied and the ENDO_PATH_MAPPING was used to record the rule applied:
¢ Rule 1 – Histology size – Assign histology most likely to be associated with a large polyp to the
largest lesions. Specifically, largest polyp will be a) villous, b) severely dysplastic, c) tubulovillous,
d) mild/moderately dysplastic. These are in order of histological features most predictive of
largest size.
¢ Rule 2 – Hyperplastic Distal ≤ 5mm – Hyperplastic polyp pathology should be assigned to the
most distal lesion but ONLY if this lesion is ≤ 5 mm.
¢ Rule 3 – Excision Method – Excision extent – assume that polyps which were snared are larger
than those that were hot biopsied.
¢ Rule 4 – Specimen Labels – Specimen labels i.e. 1–10/A-E, go from the most proximal to most
distal site.
¢ Rule 5 – Other Sighting – Where a polyp is seen at a prior or subsequent sighting which has
pathology. Polyp numbering is considered for this.
l The polyp numbering was checked to ensure it was still correct after the polyp information had
been amended.
Automatic deriving of ENDO_SIZE for a polyp set
The study programmer used a number of rules to automatically assign an endoscopy size to all the polyps
in the set (the collection and the individual polyps) and this size was recorded on the DERIVED_ENDO_
RANGE field. The method used to derive this size was recorded on the DERIVED_ENDO_RANGE_GROUP.
It was only possible to do this automatically where the segment of the collection of polyps matched the
segment of the individual polyp. This was done before the study researchers manually reviewed any
records for size including the records where the ‘endo path mapping’ rules were applied.
The following rules were used to assign the size to the DERIVED_ENDO_RANGE field.
1. Group A1: Polyp with an ENDO_SIZE_MAX ≤ 5 mm and no ENDO_SIZE_MIN. The
DERIVED_ENDO_RANGE was set to ENDO_SIZE_MAX.
2. Group A2: Polyp with an ENDO_SIZE_MIN ≤ 5 mm and no ENDO_SIZE_MAX. The
DERIVED_ENDO_RANGE was set to ENDO_SIZE_MIN.
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3. Group X1: Polyp with an ENDO_SIZE_MIN and ENDO_SIZE_MAX that both matched the
ASSUME_ENDO_SIZE or ENDO_SIZE of collection of polyps in the polyp set and all the segments of
the polyp set were the same. Such polyps were allocated their ASSUME_ENDO_SIZE or ENDO_SIZE
and the other polyps with that range were allocated ‘UNKNOWN’ size as the DERIVED_ENDO_RANGE.
4. Group Y1: Collection of polyps with an ENDO_SIZE_MAX that matched the ASSUME_ENDO_SIZE
or ENDO_SIZE of an individual polyp in the polyp set, but the segments did not match. The record was
reviewed manually by the study researchers. The DERIVED_ENDO_RANGE was set to ASSUME_ENDO_SIZE
or ENDO_SIZE for the polyp that had this information (after study researchers had populated this
information) and ‘UNKNOWN’ for the other polyps in the polyp set.
5. Groups B, C and D set the DERIVED_ENDO_RANGE to ENDO_SIZE for the individual polyp in the polyp
set and ‘UNKNOWN’ for the rest of the polyp collection where there was only ENDO_SIZE_MAX and it
matched the ENDO_SIZE of the individual polyp in the group.
¢ B was applied for polyp sets where just ENDO_SEGMENT was recorded for all polyps in the set
¢ C was applied for groups where ENDO_SEGMENT and ENDO_SEGMENT_TO were recorded for all
polyps in the set
¢ D was applied for groups where neither ENDO_SEGMENT and ENDO_SEGMENT_TO were recorded
for all polyps in the set
6. Groups E, F and G set the DERIVED_ENDO_RANGE to ENDO_SIZE for the individual polyp in the set
and ‘UNKNOWN’ for the rest of the polyp collection where there was only ENDO_SIZE_MIN and it
matched the ENDO_SIZE of the individual polyp in the polyp set.
¢ E was applied for groups where just ENDO_SEGMENT was recorded
¢ F was applied for groups where ENDO_SEGMENT and ENDO_SEGMENT _TO were recorded
¢ G was applied for groups where neither ENDO_SEGMENT and ENDO_SEGMENT _TO
were recorded
7. Groups H, I and J set the DERIVED_ENDO_RANGE to ASSUME_ENDO_SIZE for the individual polyp and
‘UNKNOWN’ for the rest of the polyp collection where there was only ENDO_SIZE_MAX and it matched
the ASSUME_ENDO_SIZE of the individual polyp in the polyp set.
¢ H was applied for groups where just ENDO_SEGMENT was recorded
¢ I was applied for groups where ENDO_SEGMENT and ENDO_SEGMENT _TO were recorded
¢ J is applied for groups where neither ENDO_SEGMENT and ENDO_SEGMENT _TO were recorded
8. Groups K, L and M set the DERIVED_ENDO_RANGE to ASSUME_ENDO_SIZE for the individual polyp
and ‘UNKNOWN’ for the rest of the polyp collection where there was only ENDO_SIZE_MIN and it
matched the ASSUME_ENDO_SIZE of the of the individual polyp in the polyp set.
¢ K was applied for groups where just ENDO_SEGMENT was recorded
¢ L was applied for groups where ENDO_SEGMENT and ENDO_SEGMENT _TO were recorded
¢ M was applied for groups where neither ENDO_SEGMENT and ENDO_SEGMENT _TO
were recorded
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Deriving endoscopy size for endo quantity rows and
multilinked polyps
For ‘endo quantity rows’ and multilinked polyps, the following rules were applied later to derive the
DERIVED_ENDO_RANGE. The DERIVED_ENDO_RANGE_GROUP and DERIVED_ENDO_RANGE was set to
blank for these type of polyps and the following rules are used to re-derive them. A MP_SET (multiple
polyp set) was defined as a group of polyps at the same examination which was made up of a polyp with
an ‘endo quantity row’ (i.e. ENDO_QUANTITY_OTHER has a value) and another group of polyps that were
multilinked to it (i.e. PATH_MULTI_ENDO_LINK of these polyps is equal to the POLYP_ID of the ‘endo
quantity row’.)
1. Group A1 – sets the DERIVED_ENDO_RANGE to ENDO_SIZE_MAX where the ENDO_SIZE_MAX
≤ 5 mm and no ENDO_SIZE_MIN.
2. Group A2 – sets the DERIVED_ENDO_RANGE to ENDO_SIZE_MIN where the ENDO_SIZE_MIN ≤ 5 mm
and no ENDO_SIZE_MAX.
3. Group Q1 – set the DERIVED_ENDO_RANGE to UNKNOWN for remaining polyps in the MP_SET if
both the ENDO_SIZE_MIN and ENDO_SIZE_MAX of the ‘endo quantity row’ had been allocated to
other multilinked polyps in the MP_SET.
4. Group Q2 – set the DERIVED_ENDO_RANGE to UNKNOWN for remaining polyps if the
ENDO_SIZE_MAX of the ‘endo quantity row’ was null and ENDO_SIZE_MIN of the ‘endo quantity row’
has been allocated to a multilinked polyp in the MP_SET.
5. Group Q3 – set the DERIVED_ENDO_RANGE to UNKNOWN for remaining polyps if the
ENDO_SIZE_MIN of the ‘endo quantity row’ is null and ENDO_SIZE_MAX of the ‘endo quantity row’
had been allocated to a multilinked polyp in the MP_SET.
6. Group Q4a – if the ENDO_SIZE_MIN of the ‘endo quantity row’ was null and ENDO_SIZE_MAX of the
‘endo quantity row’ > 5 mm had not been allocated to a multilinked polyp in the MP_SET, a
programme was used to identify the polyp that the size could be allocated to and the
DERIVED_ENDO_SIZE was allocated to that polyp.
7. Group Q4b – set the DERIVED_ENDO_RANGE to UNKNOWN for all the remaining polyps left in the
MP_SET after the ENDO_SIZE_MAX has been assigned in Group4a.
8. Group 5a – where the ENDO_SIZE_MAX of the ‘endo quantity row’ was null and ENDO_SIZE_MIN of
the ‘endo quantity row’ > 5 mm had not been allocated to a multilinked polyp in the MP_SET, a
programme was used to identify the polyp and the DERIVED_ENDO_SIZE was allocated to that polyp.
9. Group 5b – set the DERIVED_ENDO_RANGE to UNKNOWN for all the remaining polyps left in the
MP_SET after the ENDO_SIZE_MIN had been assigned in Group5a.
10. Group Q6a – where the ENDO_SIZE_MAX and ENDO_SIZE_MIN of the ‘endo quantity row’ was not
null. If the ENDO_SIZE_MAX has not been allocated to a multilinked polyp in the MP_SET, a
programme was used to identify the polyp and the DERIVED_ENDO_SIZE was allocated to that polyp.
11. Group Q7a – if the ENDO_SIZE_MAX and ENDO_SIZE_MIN of the ‘endo quantity row’ was not null
and if the ENDO_SIZE_MIN has not been allocated to a multilinked polyp in the MP_SET, a programme
was used to identify the polyp and the DERIVED_ENDO_SIZE was allocated to that polyp.
12. Group Q6b and Q7b – set the DERIVED_ENDO_RANGE to UNKNOWN For all the remaining polyps
left in the MP_SET after the ENDO_SIZE_MIN and ENDO_SIZE_MAX had been assigned in Groups 6a
and 7a above.
Manual review of size
After the DERIVED_ENDO_RANGE had been automatically assigned, the study researchers manually
reviewed the some of the polyp rows where a size could not be automatically assigned. This manual
review of records has already been discussed earlier under this section on ‘Deriving endoscopy sizes’.
Where possible a size was assigned to ENDO_SIZE and ASSUME_ENDO_SIZE. In very few cases where
(about 22 patients), the ASSUME_ENDO_SIZE_OTHER was sometimes recorded.
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In addition to this, polyp records with other size discrepancies were also manually reviewed by the study
researcher. Although most discrepancies seemed to be due to different measuring techniques used by
endoscopists and pathologists, some reports had a coding, transcription or typographical errors and the sizes
were corrected in such cases. In some cases the study researchers were able to decide what the correct size
must be and recorded it in the ASSUME_ENDO_SIZE or ASSUME_PATH_SIZE fields as appropriate.
Additionally, for certain centres it seemed that endoscopy size was always recorded using ENDO_SIZE_MAX
so these cases were identified and reviewed in order for the size to be correctly assigned to the ENDO_SIZE
field instead. For these reviews, particular attention was paid to the excision method i.e. was the method most
viable for the removal of a large polyp or a small polyp, and the follow-up and patient’s history in general.
¢ Size discrepancy at the same examination – As 10 mm was an important cut-off point where a polyp
becomes classified as high risk, for discrepancies at the same examination there was a manual review
of cases where:
¢ ENDO_SIZE10–20 mm and PATH_SIZE ≥ 40 mm
¢ ENDO_SIZE< 10 mm & PATH_SIZE ≥ 20 mm
¢ Endo_size_other = tiny, small, < 5 mm, 5–9 mm, ≤ 10 mm and pathology size ≥ 20 mm
¢ Size discrepancy across examinations – If the polyp was seen across other examinations (i.e. had
the same POLYP_NUMBER and the MATCH_PROBABILITY ≥ 70%) then there was a manual review of
cases where:
¢ ENDO_SIZE< 10mm at ANY examination and PATH_SIZE ≥ 30 mm at ANY SUBSEQUENT examination
¢ ENDO_SIZE< 10mm at ANY examination and endo_size ≥ 30mm at ANY SUBSEQUENT examination
¢ ENDO_SIZE was 10–20 mm at ANY examination and PATH_SIZE≥ 40 mm at ANY SUBSEQUENT
examination
¢ ENDO_SIZE was 10–20 mm at ANY examination and ENDO_SIZE ≥ 40 mm at ANY SUBSEQUENT
examination
DERIVED_ENDO_SIZE for patients without multiple polyp rows
Once the DERIVED_ENDO_RANGE was generated and size discrepancies were reviewed and corrected
where necessary, the study programmer used a programme and applied further rules to derive the field
DERIVED_ENDO_SIZE. The first set of rules were applied to any polyps that were not an ‘endo quantity
row’ (i.e. ENDO_QUANTITY_ OTHER has a value) or a multilinked polyp (i.e. PATH_MULTI_ENDO_LINK has
been set). The DERIVED_ENDO_RANGE was set to blank for any polyps that had been manually reviewed
after it was derived. The following rules were applied, the size was recorded on field DERIVED_ENDO_SIZE,
the rule used was recorded on DERIVED_ENDO_SIZE_SOURCE and the field used for the size e.g.
ENDO_SIZE, ASSUME_ENDO_SIZE was copied to DERIVED_ENDO_SIZE_SOURCE_OTHER.
1. Rule 1 – ASSUME_ENDO_SIZE took precedence over all endoscopy sizes, as this was field used to
indicate any corrected sizes that should be used.
2. Rule 2 – ENDO_SIZE took precedence over all endoscopy sizes except ASSUME_ENDO_SIZE, as this
was deemed to be the next most accurate size available.
3. Rule 3 – The automated DERIVED_ENDO_RANGE took precedence over all endoscopy sizes except
ASSUME_ENDO_SIZE and ENDO_SIZE.
4. Rule 4 – If there was only one polyp at an examination with ENDO_SIZE_MAX and no other size, the
DERIVED_ENDO_SIZE was set to ENDO_SIZE_MAX.
5. Rule 5 – If there was only one polyp at an examination with ENDO_SIZE_MIN and no other size, the
DERIVED_ENDO_SIZE was set to ENDO_SIZE_MIN.
6. Rule 6 – If there was only one polyp at an examination with just ENDO_SIZE_MIN and
ENDO_SIZE_MAX then the average of ENDO_SIZE_MIN and ENDO_SIZE_MAX was used.
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7. Rule 7 – An average of ENDO_SIZE_MIN and ENDO_SIZE_MIN was used for DERIVED_ENDO_SIZE if
the polyp was not. Polyps were not reviewed when the size discrepancies were quite small so applying
an average was deemed to be acceptable in this scenario.
8. Rule 8 – If the polyp was reviewed and did not have ENDO_SIZE and ASSUME_ENDO_SIZE then the
DERIVED_ENDO_SIZE was set as ‘UNKNOWN’.
9. Rule 9 – If the polyp was reviewed and did not yet have DERIVED_ENDO_SIZE or ENDO_SIZE_MIN and
ENDO_SIZE_MAX ≤ 5, the DERIVED_ENDO_SIZE was set to the ENDO_SIZE_MAX.
10. Rule 10 – If the polyp was reviewed and did not yet have DERIVED_ENDO_SIZE or ENDO_SIZE_MAX
and ENDO_SIZE_MIN ≤ 5, the DERIVED_ENDO_SIZE was set to the ENDO_SIZE_MIN.
DERIVED_ENDO_SIZE for patients with multiple polyp rows
Slightly different rules were applied to multiple polyp patients.
Rules applied to polyps that were not an ‘endo quantity row’ or a
multilinked polyp
The normal rules 1 to 11 described above were applied to the all polyps which were not an ‘endo quantity
row’ or a multilinked polyp. The following additional rules were also applied to this group.
1. Rule 12 – If the polyp was not an ‘endo quantity row’ or a multilinked polyp, the DERIVED_ENDO_SIZE
was blank, the ENDO_SIZE_MAX was blank, the ENDO_SIZE_MIN did not match any ENDO_SIZE,
ASSUME_ENDO_SIZE or ENDO_SIZE_MIN of another polyp at the same endoscopy, then the
DERIVED_ENDO_SIZE was set to ENDO_SIZE_MIN.
2. Rule 13 – If the polyp was not an ‘endo quantity row’ or a multilinked polyp, the DERIVED_ENDO_SIZE
was blank, the ENDO_SIZE_MIN was blank, the ENDO_SIZE_MAX did not match any ENDO_SIZE,
ASSUME_ENDO_SIZE or ENDO_SIZE_MAX of another polyp at the same endoscopy, then the
DERIVED_ENDO_SIZE was set to ENDO_SIZE_MAX.
3. Rule 14 – If the polyp was not an ‘endo quantity row’ or a multilinked polyp, the DERIVED_ENDO_SIZE
was blank and there were no other polyps at the same endoscopy, the DERIVED_ENDO_SIZE was set to
the average of ENDO_SIZE_MIN and ENDO_SIZE_MAX.
4. Rule 15 – If the polyp was not an ‘endo quantity row’ or a multilinked polyp, the DERIVED_ENDO_SIZE
was blank and the polyp sizes were ≤ 5, the DERIVED_ENDO_SIZE was set to the average of
ENDO_SIZE_MIN and ENDO_SIZE_MAX unless the ENDO_SIZE or ASSUME_ENDO_SIZE have a value.
Records with unknown size were overwritten where this applied (DERIVED_ENDO_RANGE remained as
UNKNOWN so it is clear when this was done).
5. Rule 16 – DERIVED_ENDO_SIZE was set to ENDO_SIZE_MIN where there was only ENDO_SIZE_MIN and it
was ≤ 5. This size was allocated to all polyps in the group unless they already had a DERIVED_ENDO_SIZE.
Records with unknown size were overwritten where this applied (DERIVED_ENDO_RANGE remained as
UNKNOWN so it is clear when this was done).
6. Rule 17 – DERIVED_ENDO_SIZE was set to ENDO_SIZE_MAX where there was only ENDO_SIZE_MAX
and it was ≤ 5. This size was allocated to all polyps in the group unless they already had a
DERIVED_ENDO_SIZE. Records with unknown size were overwritten where this applied
(DERIVED_ENDO_RANGE remained as UNKNOWN so it is clear when this was done).
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Rules applied to ‘endo quantity rows’ or multilinked polyps
The DERIVED_ENDO_SIZE, DERIVED_ENDO_SIZE_SOURCE and DERIVED_ENDO_SIZE_SOURCE_OTHER
were reset to blank for ‘endo quantity rows’ and multilinked polyps. Rules 1–6 above were re-applied and
then rules 15–17 were applied. Finally rule 18 below was applied.
1. Rule 18 – An average of ENDO_SIZE_MIN and ENDO_SIZE_MAX was allocated to all remaining polyps
without a DERIVED_ENDO_SIZE, irrespective of the magnitude of these sizes except for any polyps
that already had a ENDO_SIZE or ASSUME_ENDO_SIZE allocated. It did not overwrite records
with UNKNOWN.
Derived endoscopy size other
In some instances, the endoscopist gave a vague description of endoscopic size using terms such as ‘large’
and ‘small’. As such, the field ENDO_SIZE_OTHER was created so these data could be coded. At analysis,
this field had to be assigned quantitative values to enable the classification of each patient’s baseline risk.
Analyses were performed to compare the actual sizes recorded in ENDO_SIZE and PATH_SIZE with the
values recorded in ENDO_SIZE_OTHER, wherever possible. After lengthy discussion, specific sizes were
assigned to each ENDO_SIZE_OTHER value based on this as shown above.
TABLE 110 Assigned values for ENDO_SIZE_OTHER and related fields
ENDO_SIZE_OTHER/ASSUME_ENDO_SIZE_OTHER/
DERIVED_ENDO_SIZE_OTHER Description Assigned value for analysis
1 Tiny 3 mm
2 Small 5 mm
3 < 5 mm 3mm
4 5–9mm 7mm
5 > 10mm 15mm
6 Large 20mm
7 < 10mm 8mm
DERIVED_ENDO_SIZE_OTHER was derived from the fields ASSUME_ENDO_SIZE_OTHER and
ENDO_SIZE_OTHER with ASSUME_ENDO_SIZE_OTHER always taking precedence over ENDO_SIZE_OTHER,
as this field was used to code corrected ‘ASSUMED’ sizes.
Derived pathology size for individual polyp rows
DERIVED_PATH_SIZE was derived from the fields ASSUME_PATH_SIZE and PATH_SIZE with
ASSUME_PATH_SIZE always taking precedence over PATH_SIZE, as this field was used to code corrected
‘assumed’ sizes. DERIVED_PATH_SIZE_SOURCE showed the field from which the size was taken.
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Effect of interval on new advanced neoplasia at the second
follow-up visit
Five models were fitted, adjusting for different covariates:
l Model A Adjusted for FUV1 risk factors.
l Model B Adjusted for baseline risk factors.
l Model C Adjusted for baseline and FUV1 risk factors.
l Model D Adjusted for cumulative baseline and FUV1 risk factors.
l model E Adjusted for baseline, FUV1 and cumulative risk factors.
Model E had the best fit to the data and is presented in Chapter 3, Second follow-up visit, Effect of
interval on new findings at second follow-up of the IA Study monograph. All other models are
shown below.
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
502
TA
B
LE
11
3
C
ru
d
e
an
d
in
d
ep
en
d
en
t
ef
fe
ct
s
o
f
in
te
rv
al
o
n
n
ew
A
N
d
et
ec
ti
o
n
at
th
e
se
co
n
d
fo
llo
w
-u
p
,
w
it
h
in
te
rv
al
as
a
ca
te
g
o
ri
ca
l
an
d
co
n
ti
n
u
o
u
s
va
ri
ab
le
,a
d
ju
st
in
g
fo
r
FU
V
1
ri
sk
fa
ct
o
rs
(m
o
d
el
a)
FU
V
1
ri
sk
fa
ct
o
rs
U
n
iv
ar
ia
te
an
al
ys
is
:
n
ew
A
N
M
u
lt
iv
ar
ia
te
an
al
ys
es
:
n
ew
A
N
M
o
d
el
1
–
in
te
rv
al
as
ca
te
g
o
ri
ca
l(
n
=
16
35
)
M
o
d
el
2
–
in
te
rv
al
as
co
n
ti
n
u
o
u
s
(n
=
16
35
)
U
n
ad
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
In
te
rv
al
FU
V
1
to
FU
V
2
<
18
m
on
th
s
1.
00
0.
23
13
1.
00
0.
01
68
n/
a
2
ye
ar
sa
1.
3
(0
.7
8
to
2.
18
)
1.
7
(0
.9
8
to
2.
93
)
3
ye
ar
sa
1.
42
(0
.8
8
to
2.
28
)
2.
01
(1
.1
9
to
3.
39
)
4
ye
ar
sa
1.
39
(0
.7
2
to
2.
67
)
2.
38
(1
.1
8
to
4.
81
)
5
ye
ar
sa
1.
16
(0
.5
6
to
2.
4)
1.
87
(0
.8
5
to
4.
09
)
6
ye
ar
sa
1.
88
(0
.6
2
to
5.
74
)
2.
7
(0
.8
3
to
8.
76
)
≥
6.
5
ye
ar
s
3.
86
(1
.5
3
to
9.
76
)
5.
89
(2
.1
8
to
15
.9
2)
In
te
rv
al
(p
er
ye
ar
in
cr
ea
se
)
1.
11
(1
to
1.
24
)
0.
05
01
n/
a
1.
2
(1
.0
8
to
1.
34
)
0.
00
14
La
rg
es
t
ad
en
om
a
at
FU
V
1
(m
m
)
N
o
ad
en
om
as
1.
00
0.
00
28
1.
00
0.
00
38
1.
00
0.
00
61
<
20
1.
35
(0
.9
4
to
1.
94
)
1.
21
(0
.7
1
to
2.
05
)
1.
16
(0
.6
9
to
1.
97
)
≥
20
2.
95
(1
.6
to
5.
43
)
3.
73
(1
.7
2
to
8.
1)
3.
44
(1
.6
1
to
7.
38
)
U
nk
no
w
n
3.
1
(1
.1
3
to
8.
53
)
3.
41
(1
.0
9
to
10
.6
3)
3.
18
(1
.0
2
to
9.
86
)
Pr
ox
im
al
po
ly
ps
at
FU
V
1
N
o
po
ly
ps
1.
00
0.
00
05
1.
00
0.
00
62
1.
00
0.
00
66
N
o
1.
18
(0
.7
6
to
1.
83
)
0.
73
(0
.4
to
1.
34
)
0.
75
(0
.4
1
to
1.
36
)
Y
es
2.
12
(1
.4
3
to
3.
15
)
1.
53
(0
.8
1
to
2.
9)
1.
55
(0
.8
2
to
2.
93
)
N
um
be
r
of
po
ly
ps
w
ith
un
kn
ow
n
hi
st
ol
og
y
at
FU
V
1
0
1.
00
0.
00
01
1.
00
0.
00
06
1.
00
0.
00
08
1–
4
1.
52
(1
.0
1
to
2.
29
)
1.
47
(0
.8
8
to
2.
44
)
1.
41
(0
.8
5
to
2.
33
)
5+
7.
13
(3
.0
2
to
16
.8
5)
7.
37
(2
.7
9
to
19
.4
3)
7.
09
(2
.7
2
to
18
.4
3)
n/
a,
no
t
ap
pl
ic
ab
le
.
a
In
te
rv
al
±
6
m
on
th
s.
Re
su
lts
fo
r
ho
sp
ita
la
tt
en
de
d
no
t
pr
es
en
te
d
(m
od
el
1,
p
=
0.
00
06
;
m
od
el
2,
p
=
0.
00
05
).
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
503
TA
B
LE
11
4
C
ru
d
e
an
d
in
d
ep
en
d
en
t
ef
fe
ct
s
o
f
in
te
rv
al
o
n
n
ew
A
N
d
et
ec
ti
o
n
at
th
e
se
co
n
d
fo
llo
w
-u
p
,
w
it
h
in
te
rv
al
as
a
ca
te
g
o
ri
ca
l
an
d
co
n
ti
n
u
o
u
s
va
ri
ab
le
,a
d
ju
st
in
g
fo
r
b
as
el
in
e
ri
sk
fa
ct
o
rs
(m
o
d
el
b
)
B
as
el
in
e
ri
sk
fa
ct
o
rs
U
n
iv
ar
ia
te
an
al
ys
is
:
n
ew
A
N
M
u
lt
iv
ar
ia
te
an
al
ys
es
:
n
ew
A
N
M
o
d
el
1
–
in
te
rv
al
as
ca
te
g
o
ri
ca
l(
n
=
16
35
)
M
o
d
el
2
–
in
te
rv
al
as
co
n
ti
n
u
o
u
s
(n
=
16
35
)
U
n
ad
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
In
te
rv
al
FU
V
1
to
FU
V
2
<
18
m
on
th
s
1
0.
23
13
1.
00
0.
20
82
n/
a
2
ye
ar
sa
1.
3
(0
.7
8
to
2.
18
)
1.
34
(0
.7
9
to
2.
27
)
3
ye
ar
sa
1.
42
(0
.8
8
to
2.
28
)
1.
46
(0
.9
to
2.
38
)
4
ye
ar
sa
1.
39
(0
.7
2
to
2.
67
)
1.
73
(0
.8
8
to
3.
41
)
5
ye
ar
sa
1.
16
(0
.5
6
to
2.
4)
1.
44
(0
.6
8
to
3.
06
)
6
ye
ar
sa
1.
88
(0
.6
2
to
5.
74
)
1.
81
(0
.5
7
to
5.
76
)
≥
6.
5
ye
ar
s
3.
86
(1
.5
3
to
9.
76
)
4.
1
(1
.5
2
to
11
.0
8)
In
te
rv
al
(p
er
ye
ar
in
cr
ea
se
)
1.
11
(1
to
1.
24
)
0.
05
01
n/
a
1.
14
(1
.0
2
to
1.
27
)
0.
02
1
N
um
be
r
of
po
ly
ps
w
ith
un
kn
ow
n
hi
st
ol
og
y
at
ba
se
lin
e
0
1
0.
01
24
1.
00
0.
00
28
1.
00
0.
00
32
1+
1.
63
(1
.1
2
to
2.
37
)
1.
9
(1
.2
6
to
2.
88
)
1.
89
(1
.2
5
to
2.
85
)
M
os
t
co
m
pl
et
e
ba
se
lin
e
co
lo
no
sc
op
y
C
om
pl
et
e
1.
00
0.
00
65
1.
00
0.
01
97
1.
00
0.
01
55
U
nk
no
w
n
co
m
pl
et
en
es
s
1.
11
(0
.7
6
to
1.
61
)
1.
08
(0
.6
7
to
1.
72
)
1.
07
(0
.6
7
to
1.
72
)
In
co
m
pl
et
e
2.
24
(1
.3
9
to
3.
59
)
2.
11
(1
.2
7
to
3.
51
)
2.
15
(1
.3
to
3.
57
)
n/
a,
no
t
ap
pl
ic
ab
le
.
a
In
te
rv
al
±
6
m
on
th
s.
Re
su
lts
fo
r
ho
sp
ita
la
tt
en
de
d
no
t
pr
es
en
te
d
(m
od
el
1,
p
=
0.
00
04
;
m
od
el
2,
p
=
0.
00
03
).
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
504
TA
B
LE
11
5
C
ru
d
e
an
d
in
d
ep
en
d
en
t
ef
fe
ct
s
o
f
in
te
rv
al
o
n
n
ew
A
N
d
et
ec
ti
o
n
at
th
e
se
co
n
d
fo
llo
w
-u
p
,
w
it
h
in
te
rv
al
as
a
ca
te
g
o
ri
ca
l
an
d
co
n
ti
n
u
o
u
s
va
ri
ab
le
,a
d
ju
st
in
g
fo
r
b
as
el
in
e
an
d
FU
V
1
ri
sk
fa
ct
o
rs
(m
o
d
el
c)
B
as
el
in
e
an
d
FU
V
1
ri
sk
fa
ct
o
rs
U
n
iv
ar
ia
te
an
al
ys
is
:
n
ew
A
N
M
u
lt
iv
ar
ia
te
an
al
ys
es
:
n
ew
A
N
M
o
d
el
1
–
in
te
rv
al
as
ca
te
g
o
ri
ca
l(
n
=
16
35
)
M
o
d
el
2
–
in
te
rv
al
as
co
n
ti
n
u
o
u
s
(n
=
16
35
)
U
n
ad
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
In
te
rv
al
FU
V
1
to
FU
V
2
<
18
m
on
th
s
1
0.
23
13
1.
00
0.
01
52
n/
a
2
ye
ar
sa
1.
3
(0
.7
8
to
2.
18
)
1.
66
(0
.9
6
to
2.
88
)
3
ye
ar
sa
1.
42
(0
.8
8
to
2.
28
)
2.
04
(1
.2
to
3.
46
)
4
ye
ar
sa
1.
39
(0
.7
2
to
2.
67
)
2.
5
(1
.2
3
to
5.
11
)
5
ye
ar
sa
1.
16
(0
.5
6
to
2.
4)
2.
06
(0
.9
3
to
4.
53
)
6
ye
ar
sa
1.
88
(0
.6
2
to
5.
74
)
2.
78
(0
.8
5
to
9.
1)
≥
6.
5
ye
ar
s
3.
86
(1
.5
3
to
9.
76
)
5.
93
(2
.1
4
to
16
.4
5)
In
te
rv
al
(p
er
ye
ar
in
cr
ea
se
)
1.
11
(1
to
1.
24
)
0.
05
01
n/
a
1.
21
(1
.0
9
to
1.
36
)
0.
00
1
N
um
be
r
of
po
ly
ps
w
ith
un
kn
ow
n
hi
st
ol
og
y
at
ba
se
lin
e
0
1
0.
01
24
1.
00
0.
00
02
1.
00
0.
01
89
1+
1.
63
(1
.1
2
to
2.
37
)
1.
71
(1
.1
1
to
2.
63
)
1.
69
(1
.1
to
2.
6)
M
os
t
co
m
pl
et
e
co
lo
no
sc
op
y
at
ba
se
lin
e
C
om
pl
et
e
1.
00
0.
00
65
1.
00
0.
01
39
1.
00
0.
01
14
U
nk
no
w
n
co
m
pl
et
en
es
s
1.
11
(0
.7
6
to
1.
61
)
1.
01
(0
.6
2
to
1.
65
)
1.
01
(0
.6
2
to
1.
64
)
In
co
m
pl
et
e
2.
24
(1
.3
9
to
3.
59
)
2.
23
(1
.3
1
to
3.
78
)
2.
25
(1
.3
3
to
3.
81
)
La
rg
es
t
ad
en
om
a
at
FU
V
1
(m
m
)
N
o
ad
en
om
as
1.
00
0.
00
28
1.
00
0.
00
54
1.
00
0.
00
9
<
20
1.
35
(0
.9
4
to
1.
94
)
1.
32
(0
.7
7
to
2.
26
)
1.
26
(0
.7
4
to
2.
15
)
≥
20
2.
95
(1
.6
to
5.
43
)
3.
94
(1
.7
9
to
8.
69
)
3.
6
(1
.6
6
to
7.
83
)
U
nk
no
w
n
3.
1
(1
.1
3
to
8.
53
)
3.
03
(0
.9
6
to
9.
6)
2.
82
(0
.9
to
8.
86
)
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
505
TA
B
LE
11
5
C
ru
d
e
an
d
in
d
ep
en
d
en
t
ef
fe
ct
s
o
f
in
te
rv
al
o
n
n
ew
A
N
d
et
ec
ti
o
n
at
th
e
se
co
n
d
fo
llo
w
-u
p
,
w
it
h
in
te
rv
al
as
a
ca
te
g
o
ri
ca
l
an
d
co
n
ti
n
u
o
u
s
va
ri
ab
le
,a
d
ju
st
in
g
fo
r
b
as
el
in
e
an
d
FU
V
1
ri
sk
fa
ct
o
rs
(m
o
d
el
c)
(c
o
n
ti
n
u
ed
)
B
as
el
in
e
an
d
FU
V
1
ri
sk
fa
ct
o
rs
U
n
iv
ar
ia
te
an
al
ys
is
:
n
ew
A
N
M
u
lt
iv
ar
ia
te
an
al
ys
es
:
n
ew
A
N
M
o
d
el
1
–
in
te
rv
al
as
ca
te
g
o
ri
ca
l(
n
=
16
35
)
M
o
d
el
2
–
in
te
rv
al
as
co
n
ti
n
u
o
u
s
(n
=
16
35
)
U
n
ad
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
Pr
ox
im
al
po
ly
ps
at
FU
V
1
N
o
po
ly
ps
1.
00
0.
00
05
1.
00
0.
01
34
1.
00
0.
01
32
N
o
1.
18
(0
.7
6
to
1.
83
)
0.
74
(0
.4
to
1.
35
)
0.
75
(0
.4
1
to
1.
38
)
Y
es
2.
12
(1
.4
3
to
3.
15
)
1.
47
(0
.7
7
to
2.
81
)
1.
49
(0
.7
8
to
2.
84
)
N
um
be
r
of
po
ly
ps
w
ith
un
kn
ow
n
hi
st
ol
og
y
at
FU
V
1
0
1.
00
0.
00
01
1.
00
0.
00
08
1.
00
0.
00
1
1–
4
1.
52
(1
.0
1
to
2.
29
)
1.
39
(0
.8
3
to
2.
32
)
1.
33
(0
.8
to
2.
22
)
5+
7.
13
(3
.0
2
to
16
.8
5)
7.
31
(2
.7
5
to
19
.4
)
7.
06
(2
.6
9
to
18
.5
1)
n/
a,
no
t
ap
pl
ic
ab
le
.
a
In
te
rv
al
±
6
m
on
th
s.
Re
su
lts
fo
r
ho
sp
ita
la
tt
en
de
d
no
t
pr
es
en
te
d
(m
od
el
1,
p
=
0.
00
04
;
m
od
el
2,
p
=
0.
00
03
).
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
506
TA
B
LE
11
6
C
ru
d
e
an
d
in
d
ep
en
d
en
t
ef
fe
ct
s
o
f
in
te
rv
al
o
n
n
ew
A
N
d
et
ec
ti
o
n
at
th
e
se
co
n
d
fo
llo
w
-u
p
,
w
it
h
in
te
rv
al
as
a
ca
te
g
o
ri
ca
l
an
d
co
n
ti
n
u
o
u
s
va
ri
ab
le
,a
d
ju
st
in
g
fo
r
cu
m
u
la
ti
ve
b
as
el
in
e
an
d
FU
V
1
ri
sk
fa
ct
o
rs
(m
o
d
el
d
)
C
u
m
u
la
ti
ve
b
as
el
in
e
an
d
FU
V
1
ri
sk
fa
ct
o
rs
U
n
iv
ar
ia
te
an
al
ys
is
:
n
ew
A
N
M
u
lt
iv
ar
ia
te
an
al
ys
es
:
n
ew
A
N
M
o
d
el
1
–
in
te
rv
al
as
ca
te
g
o
ri
ca
l(
n
=
16
35
)
M
o
d
el
2
–
in
te
rv
al
as
co
n
ti
n
u
o
u
s
(n
=
16
35
)
U
n
ad
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
A
d
ju
st
ed
O
R
(9
5%
C
I)
p
-v
al
u
e
(L
R
T)
In
te
rv
al
FU
V
1
to
FU
V
2
<
18
m
on
th
s
1
0.
23
13
1.
00
0.
04
13
n/
a
2
ye
ar
sa
1.
3
(0
.7
8
to
2.
18
)
1.
51
(0
.8
9
to
2.
57
)
3
ye
ar
sa
1.
42
(0
.8
8
to
2.
28
)
1.
77
(1
.0
7
to
2.
91
)
4
ye
ar
sa
1.
39
(0
.7
2
to
2.
67
)
2.
04
(1
.0
3
to
4.
05
)
5
ye
ar
sa
1.
16
(0
.5
6
to
2.
4)
1.
66
(0
.7
7
to
3.
56
)
6
ye
ar
sa
1.
88
(0
.6
2
to
5.
74
)
2.
26
(0
.7
to
7.
29
)
≥
6.
5
ye
ar
s
3.
86
(1
.5
3
to
9.
76
)
5.
42
(2
.0
1
to
14
.5
8)
In
te
rv
al
(p
er
ye
ar
in
cr
ea
se
)
1.
11
(1
to
1.
24
)
0.
05
01
n/
a
1.
19
(1
.0
6
to
1.
32
)
0.
00
28
N
um
be
r
of
ad
en
om
as
at
ba
se
lin
e
an
d
FU
V
1
1
1.
00
0.
00
03
1.
00
0.
00
05
1.
00
0.
00
05
2+
1.
85
(1
.3
1
to
2.
6)
1.
88
(1
.3
1
to
2.
69
)
1.
86
(1
.3
to
2.
66
)
N
um
be
r
of
po
ly
ps
w
ith
un
kn
ow
n
hi
st
ol
og
y
at
ba
se
lin
e
an
d
FU
V
1
0
1.
00
0.
00
09
1.
00
0.
00
04
1.
00
0.
00
05
1–
4
1.
46
(1
.0
1
to
2.
11
)
1.
54
(1
.0
4
to
2.
26
)
1.
51
(1
.0
3
to
2.
22
)
5+
3.
13
(1
.7
3
to
5.
66
)
3.
65
(1
.9
2
to
6.
93
)
3.
58
(1
.8
9
to
6.
76
)
n/
a,
no
t
ap
pl
ic
ab
le
.
Re
su
lts
fo
r
ho
sp
ita
la
tt
en
de
d
no
t
pr
es
en
te
d
(m
od
el
1:
p
=
0.
00
03
,
m
od
el
2:
p
=
0.
00
03
).
a
In
te
rv
al
±
6
m
on
th
s.
DOI: 10.3310/hta21250 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 25
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
507
Measures of fit (advanced neoplasia at follow-up visit 2:
logistic regression models)
Five models:
l Model A Adjusted for FUV1 risk factors.
l Model B Adjusted for baseline risk factors.
l Model C Adjusted for baseline and FUV1 risk factors.
l Model D Adjusted for cumulative baseline and FUV1 risk factors.
l Model E Adjusted for individual and cumulative baseline and FUV1 risk factors.
Logistic regression model for effect
of interval on new AN at second
follow-up (adjusted for)
Measure of goodness of fit
Interval as a categorical variable Interval as a continuous variable
AIC BIC AIC BIC
A (FUV1 factors) 980.70 1142.68 975.91 1110.90
B (baseline factors) 1001.49 1141.87 994.59 1107.98
C (baseline and FUV1 factors) 971.71 1149.89 966.60 1117.79
D (cumulative baseline and FUV1 factors) 988.93 1129.31 983.10 1096.49
E (individual and cumulative baseline and
FUV1 factors)
968.15 1151.73 962.84 1119.42
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Appendix 10 Visual logic code for
health-economic model
VL SECTION: No adenomas Work Complete Logic
‘This workcentre determines which of the following competing events will occur first: (1) other-cause
mortality (2) progression to adenomas (3) attend surveillance colonoscopy
‘Determine next event
IF TimeToOCM_lbl < TimeToProgression_lbl
IF TimeToOCM_lbl < TimeToNextCOL_lbl
IF TimeToOCM_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 1
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToProgression_lbl < TimeToNextCOL_lbl
IF TimeToProgression_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 2
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
‘Set next TTNE
IF NextEvent_lbl = 1
SET TTNE_lbl = TimeToOCM_lbl
ELSE IF NextEvent_lbl = 2
SET TTNE_lbl = TimeToProgression_lbl
ELSE IF NextEvent_lbl = 3
SET TTNE_lbl = TimeToNextCOL_lbl
ELSE IF NextEvent_lbl = 4
SET TTNE_lbl = TimeToCancerDeath_lbl
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VL SECTION: Adenoma Work Complete Logic
‘Competing events: (1) other-cause mortality (2) progression to adenomas (3) attend surveillance
colonoscopy
‘Determine next event
IF TimeToOCM_lbl < TimeToProgression_lbl
IF TimeToOCM_lbl < TimeToNextCOL_lbl
IF TimeToOCM_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 1
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToProgression_lbl < TimeToNextCOL_lbl
IF TimeToProgression_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 2
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
‘Set next TTNE
IF NextEvent_lbl = 1
SET TTNE_lbl = TimeToOCM_lbl
ELSE IF NextEvent_lbl = 2
SET TTNE_lbl = TimeToProgression_lbl
ELSE IF NextEvent_lbl = 3
SET TTNE_lbl = TimeToNextCOL_lbl
ELSE IF NextEvent_lbl = 4
SET TTNE_lbl = TimeToCancerDeath_lbl
VL SECTION: Preclinical CRC Work Complete Logic
‘Competing events: (1) other-cause mortality (2) progression to adenomas (3) attend surveillance
colonoscopy
‘Determine next event
IF TimeToOCM_lbl < TimeToProgression_lbl
IF TimeToOCM_lbl < TimeToNextCOL_lbl
IF TimeToOCM_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 1
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
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ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToProgression_lbl < TimeToNextCOL_lbl
IF TimeToProgression_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 2
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
‘Set next TTNE
IF NextEvent_lbl = 1
SET TTNE_lbl = TimeToOCM_lbl
ELSE IF NextEvent_lbl = 2
SET TTNE_lbl = TimeToProgression_lbl
ELSE IF NextEvent_lbl = 3
SET TTNE_lbl = TimeToNextCOL_lbl
ELSE IF NextEvent_lbl = 4
SET TTNE_lbl = TimeToCancerDeath_lbl
VL SECTION: Reset Logic
‘Obeyed just after all simulation objects are initialized at time zero
VL SECTION: Clinical CRC Work Complete Logic
‘Competing events: (1) other-cause mortality (2) progression to adenomas (3) attend surveillance
colonoscopy
‘Determine next event
IF TimeToOCM_lbl < TimeToProgression_lbl
IF TimeToOCM_lbl < TimeToNextCOL_lbl
IF TimeToOCM_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 1
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
ELSE
IF TimeToProgression_lbl < TimeToNextCOL_lbl
IF TimeToProgression_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 2
ELSE
SET NextEvent_lbl = 4
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ELSE
IF TimeToNextCOL_lbl < TimeToCancerDeath_lbl
SET NextEvent_lbl = 3
ELSE
SET NextEvent_lbl = 4
‘Set next TTNE
IF NextEvent_lbl = 1
SET TTNE_lbl = TimeToOCM_lbl
ELSE IF NextEvent_lbl = 2
SET TTNE_lbl = TimeToProgression_lbl
ELSE IF NextEvent_lbl = 3
SET TTNE_lbl = TimeToNextCOL_lbl
ELSE IF NextEvent_lbl = 4
SET TTNE_lbl = TimeToCancerDeath_lbl
VL SECTION: End Run Logic
‘Obeyed when the simulation reaches end of "Results Collection Period"
SET Model entry.Interarrival Time = 0.00001
IF SOUR_nbr < MaxSOUR_nbr
SET SOUR_nbr = SOUR_nbr+1
Reset before next run
RunModel 10000
VL SECTION: Dead Work Complete Logic
‘This workcentre records all health gains and stores model results
‘Record patient life years gained
SET UndiscountedLYGs_lbl = TimeStampDeath_lbl-TimeStampModelEntry_lbl
SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDeath_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampModelEntry_lbl]
SET DiscountedLYGs_lbl = DiscountedLYGs_lbl+[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
‘Record patient QALY gains
IF histology_lbl <= 2
‘Calculate undiscounted QALY gains (never develop cancer)
SET temp1_lbl = TimeStampDeath_lbl-TimeStampModelEntry_lbl
SET UndiscountedQALYs_lbl = temp1_lbl*Params_ss[15,SSrowoffset_nbr+SOUR_nbr]
‘Calculate discounted QALY gains
SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDeath_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampModelEntry_lbl]
SET DiscountedQALYs_lbl = DiscountedQALYs_lbl+[[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
*Params_ss[15,SSrowoffset_nbr+SOUR_nbr]]
ELSE IF histology_lbl = 3
‘Calculate undiscounted QALY gains (develop preclinical cancer only)
SET temp1_lbl = TimeStampDevelopCancer_lbl-TimeStampModelEntry_lbl
SET temp2_lbl = TimeStampDeath_lbl-TimeStampDevelopCancer_lbl
SET UndiscountedQALYs_lbl = UndiscountedQALYs_lbl+[temp1_lbl*Params_
ss[15,SSrowoffset_nbr+SOUR_nbr]]
SET UndiscountedQALYs_lbl = UndiscountedQALYs_lbl+[temp2_lbl*Params_
ss[16,SSrowoffset_nbr+SOUR_nbr]]
‘Calculate discounted QALY gains
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SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDevelopCancer_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampModelEntry_lbl]
SET DiscountedQALYs_lbl = DiscountedQALYs_lbl+[[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
*Params_ss[15,SSrowoffset_nbr+SOUR_nbr]]
SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDeath_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampDevelopCancer_lbl]
SET DiscountedQALYs_lbl = DiscountedQALYs_lbl+[[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
*Params_ss[16,SSrowoffset_nbr+SOUR_nbr]]
ELSE IF histology_lbl = 4
‘Calculate undiscounted QALY gains (develop clinical cancer)
SET temp1_lbl = TimeStampDevelopCancer_lbl-TimeStampModelEntry_lbl
SET temp2_lbl = TimeStampDiagnosedCancer_lbl-TimeStampDevelopCancer_lbl
SET temp3_lbl = TimeStampDeath_lbl-TimeStampDiagnosedCancer_lbl
SET UndiscountedQALYs_lbl = UndiscountedQALYs_lbl+[temp1_lbl*Params_
ss[15,SSrowoffset_nbr+SOUR_nbr]]
SET UndiscountedQALYs_lbl = UndiscountedQALYs_lbl+[temp2_lbl*Params_
ss[16,SSrowoffset_nbr+SOUR_nbr]]
SET UndiscountedQALYs_lbl = UndiscountedQALYs_lbl+[temp3_lbl*Params_
ss[17,SSrowoffset_nbr+SOUR_nbr]]
‘Calculate discounted QALY gains
SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDevelopCancer_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampModelEntry_lbl]
SET DiscountedQALYs_lbl = DiscountedQALYs_lbl+[[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
*Params_ss[15,SSrowoffset_nbr+SOUR_nbr]]
SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDiagnosedCancer_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampDevelopCancer_lbl]
SET DiscountedQALYs_lbl = DiscountedQALYs_lbl+[[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
*Params_ss[16,SSrowoffset_nbr+SOUR_nbr]]
SET DiscTemp1_lbl = EXP[DRi_QALYs_nbr*TimeStampDeath_lbl]
SET DiscTemp2_lbl = EXP[DRi_QALYs_nbr*TimeStampDiagnosedCancer_lbl]
SET DiscountedQALYs_lbl = DiscountedQALYs_lbl+[[[1/DRi_QALYs_nbr]*[DiscTemp1_lbl-DiscTemp2_lbl]]
*Params_ss[17,SSrowoffset_nbr+SOUR_nbr]]
‘Store patient costs and QALYs in aggregate worksheet
SET ModelResults_ss[2,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[2,SSrowoffset_nbr
+SOUR_nbr]+UndiscountedLYGs_lbl
SET ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[3,SSrowoffset_nbr
+SOUR_nbr]+DiscountedLYGs_lbl
SET ModelResults_ss[4,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[4,SSrowoffset_nbr
+SOUR_nbr]+UndiscountedQALYs_lbl
SET ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[5,SSrowoffset_nbr
+SOUR_nbr]+DiscountedQALYs_lbl
SET ModelResults_ss[6,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[6,SSrowoffset_nbr
+SOUR_nbr]+UndiscountedCost_lbl
SET ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[7,SSrowoffset_nbr
+SOUR_nbr]+DiscountedCost_lbl
‘Store patient diary (if selected)
IF StorePatientDiary_nbr = 1
SET PatientDiary_ss[13+[15+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = UndiscountedLYGs_lbl
SET PatientDiary_ss[13+[16+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = UndiscountedQALYs_lbl
SET PatientDiary_ss[13+[17+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = UndiscountedCost_lbl
SET PatientDiary_ss[13+[18+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = DiscountedLYGs_lbl
SET PatientDiary_ss[13+[19+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = DiscountedQALYs_lbl
SET PatientDiary_ss[13+[20+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = DiscountedCost_lbl
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‘Store intermediate outcomes (if selected)
IF StoreIntermediateOutcomes_nbr = 1
SET ModelResults_ss[9,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[9,SSrowoffset_nbr
+SOUR_nbr]+COLindex_lbl
IF histology_lbl <= 2
SET ModelResults_ss[10,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[10,SSrowoffset_nbr
+SOUR_nbr]+1
ELSE IF histology_lbl = 3
SET ModelResults_ss[11,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[11,SSrowoffset_nbr
+SOUR_nbr]+1
ELSE
SET ModelResults_ss[12,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[12,SSrowoffset_nbr
+SOUR_nbr]+1
IF CoD_lbl = 1
SET ModelResults_ss[13,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[13,SSrowoffset_nbr
+SOUR_nbr]+1
ELSE IF CoD_lbl = 2
SET ModelResults_ss[14,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[14,SSrowoffset_nbr
+SOUR_nbr]+1
ELSE IF CoD_lbl = 3
SET ModelResults_ss[15,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[15,SSrowoffset_nbr
+SOUR_nbr]+1
IF AdenomaHistory_lbl = 1
SET ModelResults_ss[16,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[16,SSrowoffset_nbr
+SOUR_nbr]+1
IF Cancerhistory_lbl = 2
SET ModelResults_ss[17,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[17,SSrowoffset_nbr
+SOUR_nbr]+1
ELSE IF Cancerhistory_lbl = 1
SET ModelResults_ss[18,SSrowoffset_nbr+SOUR_nbr] = ModelResults_ss[18,SSrowoffset_nbr
+SOUR_nbr]+1
‘Check stability
IF StoreStabilityTest_nbr = 1
IF StabilityTemp_nbr = StabilityTest_ss[2,3]
SET StabilityTest_ss[3,3] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,3] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,3] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,4]
SET StabilityTest_ss[3,4] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,4] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,4] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,5]
SET StabilityTest_ss[3,5] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,5] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,5] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,6]
SET StabilityTest_ss[3,6] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,6] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,6] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,7]
SET StabilityTest_ss[3,7] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,7] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,7] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
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ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,8]
SET StabilityTest_ss[3,8] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,8] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,8] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,9]
SET StabilityTest_ss[3,9] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,9] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,9] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,10]
SET StabilityTest_ss[3,10] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,10] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,10] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,11]
SET StabilityTest_ss[3,11] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,11] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,11] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,12]
SET StabilityTest_ss[3,12] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,12] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,12] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,13]
SET StabilityTest_ss[3,13] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,13] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,13] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,14]
SET StabilityTest_ss[3,14] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,14] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,14] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,15]
SET StabilityTest_ss[3,15] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,15] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,15] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,16]
SET StabilityTest_ss[3,16] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,16] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,16] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,17]
SET StabilityTest_ss[3,17] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,17] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,17] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,18]
SET StabilityTest_ss[3,18] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,18] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,18] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,19]
SET StabilityTest_ss[3,19] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,19] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,19] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,20]
SET StabilityTest_ss[3,20] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,20] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,20] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
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ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,21]
SET StabilityTest_ss[3,21] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,21] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,21] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,22]
SET StabilityTest_ss[3,22] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,22] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,22] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,23]
SET StabilityTest_ss[3,23] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,23] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,23] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,24]
SET StabilityTest_ss[3,24] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,24] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,24] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,25]
SET StabilityTest_ss[3,25] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,25] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,25] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,26]
SET StabilityTest_ss[3,26] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,26] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,26] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
ELSE IF StabilityTemp_nbr = StabilityTest_ss[2,27]
SET StabilityTest_ss[3,27] = ModelResults_ss[3,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[4,27] = ModelResults_ss[5,SSrowoffset_nbr+SOUR_nbr]
SET StabilityTest_ss[5,27] = ModelResults_ss[7,SSrowoffset_nbr+SOUR_nbr]
‘Track simulation progress
SET PercentRunComplete = [UniqId_lbl/PatientsPerRun_nbr]*100
SET PercentPSAComplete = [SOUR_nbr/MaxSOUR_nbr]*100
Setup Progress Bar SOUR_nbr , MaxSOUR_nbr
Set Progress Bar SOUR_nbr
VL SECTION: Reset model On OK Dialog
‘Determine selected surveillance option timings
SET COLInterval1_nbr = SurveillanceOptions_ss[4,2+SelectedSurveillanceOption_nbr]
SET COLInterval2_nbr = SurveillanceOptions_ss[5,2+SelectedSurveillanceOption_nbr]
SET MaxCOLage_nbr = SurveillanceOptions_ss[6,2+SelectedSurveillanceOption_nbr]
‘Reset model
SET SOUR_nbr = 1
Clear Sheet Area PatientDiary_ss[1,2] , 1000 , 100000
Clear Sheet Area ModelResults_ss[2,8] , 1000 , 100000
Clear Sheet Area StabilityTest_ss[3,3] , 100 , 100
Reset before next run
Reset Clock 1
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VL SECTION: Surveillance COL (plus event router) Work
Complete Logic
‘This workcentre deals with events in the simulation (death, progression, surveillance COL and
related complications)
‘Set random numbers
SET rand1_nbr = RANDOM[0]
SET rand2_nbr = RANDOM[0]
SET rand3_nbr = RANDOM[0]
SET rand4_nbr = RANDOM[0]
SET rand5_nbr = RANDOM[0]
‘Update patient age (age at previous event + TTNE interval)
SET PatientAge_lbl = PatientAge_lbl+TTNE_lbl
‘Event 1 - patient dies of other causes (timestamp death, record cause of death, route to dead workcentre)
IF NextEvent_lbl = 1
SET TimeStampDeath_lbl = PatientAge_lbl-PatientStartAge_lbl
SET CoD_lbl = 1
SET Router_lbl = 1
‘Event 2 - patient progresses (increase histology by 1, route to next state and update next event times)
ELSE IF NextEvent_lbl = 2
SET histology_lbl = histology_lbl+1
IF histology_lbl = 2
SET Router_lbl = 3
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TPAdenomaToPreclinicalCRC_dst
IF TimeToNextCOL_lbl = LargeN_nbr
SET TimeToNextCOL_lbl = LargeN_nbr
ELSE
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl-TTNE_lbl
SET TimeToCancerDeath_lbl = LargeN_nbr
ELSE IF histology_lbl = 3
SET TimeStampDevelopCancer_lbl = PatientAge_lbl-PatientStartAge_lbl
SET Router_lbl = 4
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TPPreclinicalCRCToClinicalCRC_dst
IF TimeToNextCOL_lbl = LargeN_nbr
SET TimeToNextCOL_lbl = LargeN_nbr
ELSE
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl-TTNE_lbl
SET TimeToCancerDeath_lbl = CancerDeathTemp2_lbl
ELSE IF histology_lbl = 4
SET TimeStampDiagnosedCancer_lbl = PatientAge_lbl-PatientStartAge_lbl
SET Cancerhistory_lbl = 1
SET Router_lbl = 5
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = LargeN_nbr
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = CancerDeathTemp1_lbl
‘Event 3 - patient undergoes surveillance COL (update next COL interval, determine COL findings, route
conditional on findings, update histology, update event times)
ELSE IF NextEvent_lbl = 3
SET COLindex_lbl = COLindex_lbl+1
IF histology_lbl = 1
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IF rand1_nbr > Params_ss[8,SSrowoffset_nbr+SOUR_nbr]
SET Surveillancefindings_lbl = 1
SET histology_lbl = histology_lbl
SET Router_lbl = 2
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TimeToProgression_lbl-TTNE_lbl
SET TimeToNextCOL_lbl = COLInterval2_nbr
IF PatientAge_lbl+TimeToNextCOL_lbl < MaxCOLage_nbr
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl
ELSE
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = LargeN_nbr
ELSE
SET Surveillancefindings_lbl = 2
SET histology_lbl = histology_lbl
SET Router_lbl = 2
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TimeToProgression_lbl-TTNE_lbl
SET TimeToNextCOL_lbl = COLInterval2_nbr
IF PatientAge_lbl+TimeToNextCOL_lbl < MaxCOLage_nbr
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl
ELSE
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = LargeN_nbr
ELSE IF histology_lbl = 2
IF rand1_nbr < Params_ss[9,SSrowoffset_nbr+SOUR_nbr]
SET Surveillancefindings_lbl = 3
SET AdenomaHistory_lbl = 1
SET histology_lbl = 1
SET Router_lbl = 2
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TPNoAdenomaToAdenoma_dst
SET TimeToNextCOL_lbl = COLInterval2_nbr
IF PatientAge_lbl+TimeToNextCOL_lbl < MaxCOLage_nbr
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl
ELSE
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = LargeN_nbr
ELSE
SET Surveillancefindings_lbl = 4
SET histology_lbl = histology_lbl
SET Router_lbl = 3
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TimeToProgression_lbl-TTNE_lbl
SET TimeToNextCOL_lbl = COLInterval2_nbr
IF PatientAge_lbl+TimeToNextCOL_lbl < MaxCOLage_nbr
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl
ELSE
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = LargeN_nbr
ELSE IF histology_lbl = 3
IF rand1_nbr < Params_ss[10,SSrowoffset_nbr+SOUR_nbr]
SET Surveillancefindings_lbl = 5
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SET TimeStampDiagnosedCancer_lbl = PatientAge_lbl-PatientStartAge_lbl
SET Cancerhistory_lbl = 2
SET histology_lbl = 4
SET Router_lbl = 5
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = LargeN_nbr
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = CancerDeathTemp1_lbl
ELSE
SET Surveillancefindings_lbl = 6
SET histology_lbl = histology_lbl
SET Router_lbl = 4
SET TimeToOCM_lbl = TimeToOCM_lbl-TTNE_lbl
SET TimeToProgression_lbl = TimeToProgression_lbl-TTNE_lbl
SET TimeToNextCOL_lbl = COLInterval2_nbr
IF PatientAge_lbl+TimeToNextCOL_lbl < MaxCOLage_nbr
SET TimeToNextCOL_lbl = TimeToNextCOL_lbl
ELSE
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = TimeToCancerDeath_lbl-TTNE_lbl
‘Determine whether patient has complications (perforation or bleed), risk of death and associated costs
IF rand2_nbr < Params_ss[11,SSrowoffset_nbr+SOUR_nbr]
IF rand3_nbr < Params_ss[12,SSrowoffset_nbr+SOUR_nbr]
IF rand4_nbr < Params_ss[13,SSrowoffset_nbr+SOUR_nbr]
SET TimeStampDeath_lbl = PatientAge_lbl-PatientStartAge_lbl
SET CoD_lbl = 3
SET Router_lbl = 1
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[20,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[20,SSrowoffset_nbr+SOUR_nbr]/
[1+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
ELSE
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[20,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[20,SSrowoffset_nbr+SOUR_nbr]/
[1+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
ELSE
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[21,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[21,SSrowoffset_nbr+SOUR_nbr]/
[1+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
‘Patient dies as a consequence of their colorectal cancer (timestamp death)
ELSE IF NextEvent_lbl = 4
SET TimeStampDeath_lbl = PatientAge_lbl-PatientStartAge_lbl
SET CoD_lbl = 2
SET Router_lbl = 1
‘Add undiscounted and discounted costs (surveillance COL and lifetime cancer costs)
IF NextEvent_lbl = 3
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[18,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[18,SSrowoffset_nbr+SOUR_nbr]/
[1+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
IF histology_lbl = 4
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[19,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[19,SSrowoffset_nbr+SOUR_nbr]/
[1+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
IF NextEvent_lbl = 2
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IF histology_lbl = 4
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[19,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[19,SSrowoffset_nbr+SOUR_nbr]/
[1+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
‘Store patient diary (if selected)
IF StorePatientDiary_nbr = 1
SET EventCount_lbl = EventCount_lbl+1
SET PatientDiary_ss[13+[1+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = PatientAge_lbl
SET PatientDiary_ss[13+[2+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = NextEvent_lbl
SET PatientDiary_ss[13+[3+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TTNE_lbl
SET PatientDiary_ss[13+[4+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeStampDevelopCancer_lbl
SET PatientDiary_ss[13+[5+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeStampDiagnosedCancer_lbl
SET PatientDiary_ss[13+[6+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeStampDeath_lbl
SET PatientDiary_ss[13+[7+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = CoD_lbl
SET PatientDiary_ss[13+[8+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = histology_lbl
SET PatientDiary_ss[13+[9+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = Surveillancefindings_lbl
SET PatientDiary_ss[13+[10+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = COLindex_lbl
SET PatientDiary_ss[13+[11+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeToOCM_lbl
SET PatientDiary_ss[13+[12+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeToProgression_lbl
SET PatientDiary_ss[13+[13+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeToNextCOL_lbl
SET PatientDiary_ss[13+[14+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = TimeToCancerDeath_lbl
SET PatientDiary_ss[13+[15+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = UndiscountedLYGs_lbl
SET PatientDiary_ss[13+[16+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = UndiscountedQALYs_lbl
SET PatientDiary_ss[13+[17+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = UndiscountedCost_lbl
SET PatientDiary_ss[13+[18+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = DiscountedLYGs_lbl
SET PatientDiary_ss[13+[19+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = DiscountedQALYs_lbl
SET PatientDiary_ss[13+[20+[[EventCount_lbl-1]*20]],1+UniqId_lbl] = DiscountedCost_lbl
‘ResetSurveillanceFindings
SET Surveillancefindings_lbl = 0
VL SECTION: Model entry Entry Logic
‘PATIENT ENTRY - this workcentre sets the intial characteristics of the patient cohort
‘Set random numbers
SET rand1_nbr = RANDOM[0]
‘Determine simulation running conditions
IF Model entry.Arrived Count = PatientsPerRun_nbr
SET Model entry.Interarrival Time = LargeN_nbr
ELSE
SET Model entry.Interarrival Time = Model entry.Interarrival Time
‘Timestamp model entry
SET TimeStampModelEntry_lbl = 0
‘Set patient characteristics (start age, current age, histology, time to next COL, life expectancy)
SET PatientStartAge_lbl = PatientAge_dst
SET PatientAge_lbl = PatientStartAge_lbl
SET Sex_lbl = Sex_dst
SET histology_lbl = 1
IF Sex_lbl = 2
IF PatientStartAge_lbl = 0
SET LifeExpectancy_lbl = GenPopDeathFemales0_dst
ELSE IF PatientStartAge_lbl = 1
SET LifeExpectancy_lbl = GenPopDeathFemales1_dst
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ELSE IF PatientStartAge_lbl = 2
SET LifeExpectancy_lbl = GenPopDeathFemales2_dst
ELSE IF PatientStartAge_lbl = 3
SET LifeExpectancy_lbl = GenPopDeathFemales3_dst
ELSE IF PatientStartAge_lbl = 4
SET LifeExpectancy_lbl = GenPopDeathFemales4_dst
ELSE IF PatientStartAge_lbl = 5
SET LifeExpectancy_lbl = GenPopDeathFemales5_dst
ELSE IF PatientStartAge_lbl = 6
SET LifeExpectancy_lbl = GenPopDeathFemales6_dst
ELSE IF PatientStartAge_lbl = 7
SET LifeExpectancy_lbl = GenPopDeathFemales7_dst
ELSE IF PatientStartAge_lbl = 8
SET LifeExpectancy_lbl = GenPopDeathFemales8_dst
ELSE IF PatientStartAge_lbl = 9
SET LifeExpectancy_lbl = GenPopDeathFemales9_dst
ELSE IF PatientStartAge_lbl = 10
SET LifeExpectancy_lbl = GenPopDeathFemales10_dst
ELSE IF PatientStartAge_lbl = 11
SET LifeExpectancy_lbl = GenPopDeathFemales11_dst
ELSE IF PatientStartAge_lbl = 12
SET LifeExpectancy_lbl = GenPopDeathFemales12_dst
ELSE IF PatientStartAge_lbl = 13
SET LifeExpectancy_lbl = GenPopDeathFemales13_dst
ELSE IF PatientStartAge_lbl = 14
SET LifeExpectancy_lbl = GenPopDeathFemales14_dst
ELSE IF PatientStartAge_lbl = 15
SET LifeExpectancy_lbl = GenPopDeathFemales15_dst
ELSE IF PatientStartAge_lbl = 16
SET LifeExpectancy_lbl = GenPopDeathFemales16_dst
ELSE IF PatientStartAge_lbl = 17
SET LifeExpectancy_lbl = GenPopDeathFemales17_dst
ELSE IF PatientStartAge_lbl = 18
SET LifeExpectancy_lbl = GenPopDeathFemales18_dst
ELSE IF PatientStartAge_lbl = 19
SET LifeExpectancy_lbl = GenPopDeathFemales19_dst
ELSE IF PatientStartAge_lbl = 20
SET LifeExpectancy_lbl = GenPopDeathFemales20_dst
ELSE IF PatientStartAge_lbl = 21
SET LifeExpectancy_lbl = GenPopDeathFemales21_dst
ELSE IF PatientStartAge_lbl = 22
SET LifeExpectancy_lbl = GenPopDeathFemales22_dst
ELSE IF PatientStartAge_lbl = 23
SET LifeExpectancy_lbl = GenPopDeathFemales23_dst
ELSE IF PatientStartAge_lbl = 24
SET LifeExpectancy_lbl = GenPopDeathFemales24_dst
ELSE IF PatientStartAge_lbl = 25
SET LifeExpectancy_lbl = GenPopDeathFemales25_dst
ELSE IF PatientStartAge_lbl = 26
SET LifeExpectancy_lbl = GenPopDeathFemales26_dst
ELSE IF PatientStartAge_lbl = 27
SET LifeExpectancy_lbl = GenPopDeathFemales27_dst
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ELSE IF PatientStartAge_lbl = 28
SET LifeExpectancy_lbl = GenPopDeathFemales28_dst
ELSE IF PatientStartAge_lbl = 29
SET LifeExpectancy_lbl = GenPopDeathFemales29_dst
ELSE IF PatientStartAge_lbl = 30
SET LifeExpectancy_lbl = GenPopDeathFemales30_dst
ELSE IF PatientStartAge_lbl = 31
SET LifeExpectancy_lbl = GenPopDeathFemales31_dst
ELSE IF PatientStartAge_lbl = 32
SET LifeExpectancy_lbl = GenPopDeathFemales32_dst
ELSE IF PatientStartAge_lbl = 33
SET LifeExpectancy_lbl = GenPopDeathFemales33_dst
ELSE IF PatientStartAge_lbl = 34
SET LifeExpectancy_lbl = GenPopDeathFemales34_dst
ELSE IF PatientStartAge_lbl = 35
SET LifeExpectancy_lbl = GenPopDeathFemales35_dst
ELSE IF PatientStartAge_lbl = 36
SET LifeExpectancy_lbl = GenPopDeathFemales36_dst
ELSE IF PatientStartAge_lbl = 37
SET LifeExpectancy_lbl = GenPopDeathFemales37_dst
ELSE IF PatientStartAge_lbl = 38
SET LifeExpectancy_lbl = GenPopDeathFemales38_dst
ELSE IF PatientStartAge_lbl = 39
SET LifeExpectancy_lbl = GenPopDeathFemales39_dst
ELSE IF PatientStartAge_lbl = 40
SET LifeExpectancy_lbl = GenPopDeathFemales40_dst
ELSE IF PatientStartAge_lbl = 41
SET LifeExpectancy_lbl = GenPopDeathFemales41_dst
ELSE IF PatientStartAge_lbl = 42
SET LifeExpectancy_lbl = GenPopDeathFemales42_dst
ELSE IF PatientStartAge_lbl = 43
SET LifeExpectancy_lbl = GenPopDeathFemales43_dst
ELSE IF PatientStartAge_lbl = 44
SET LifeExpectancy_lbl = GenPopDeathFemales44_dst
ELSE IF PatientStartAge_lbl = 45
SET LifeExpectancy_lbl = GenPopDeathFemales45_dst
ELSE IF PatientStartAge_lbl = 46
SET LifeExpectancy_lbl = GenPopDeathFemales46_dst
ELSE IF PatientStartAge_lbl = 47
SET LifeExpectancy_lbl = GenPopDeathFemales47_dst
ELSE IF PatientStartAge_lbl = 48
SET LifeExpectancy_lbl = GenPopDeathFemales48_dst
ELSE IF PatientStartAge_lbl = 49
SET LifeExpectancy_lbl = GenPopDeathFemales49_dst
ELSE IF PatientStartAge_lbl = 50
SET LifeExpectancy_lbl = GenPopDeathFemales50_dst
ELSE IF PatientStartAge_lbl = 51
SET LifeExpectancy_lbl = GenPopDeathFemales51_dst
ELSE IF PatientStartAge_lbl = 52
SET LifeExpectancy_lbl = GenPopDeathFemales52_dst
ELSE IF PatientStartAge_lbl = 53
SET LifeExpectancy_lbl = GenPopDeathFemales53_dst
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ELSE IF PatientStartAge_lbl = 54
SET LifeExpectancy_lbl = GenPopDeathFemales54_dst
ELSE IF PatientStartAge_lbl = 55
SET LifeExpectancy_lbl = GenPopDeathFemales55_dst
ELSE IF PatientStartAge_lbl = 56
SET LifeExpectancy_lbl = GenPopDeathFemales56_dst
ELSE IF PatientStartAge_lbl = 57
SET LifeExpectancy_lbl = GenPopDeathFemales57_dst
ELSE IF PatientStartAge_lbl = 58
SET LifeExpectancy_lbl = GenPopDeathFemales58_dst
ELSE IF PatientStartAge_lbl = 59
SET LifeExpectancy_lbl = GenPopDeathFemales59_dst
ELSE IF PatientStartAge_lbl = 60
SET LifeExpectancy_lbl = GenPopDeathFemales60_dst
ELSE IF PatientStartAge_lbl = 61
SET LifeExpectancy_lbl = GenPopDeathFemales61_dst
ELSE IF PatientStartAge_lbl = 62
SET LifeExpectancy_lbl = GenPopDeathFemales62_dst
ELSE IF PatientStartAge_lbl = 63
SET LifeExpectancy_lbl = GenPopDeathFemales63_dst
ELSE IF PatientStartAge_lbl = 64
SET LifeExpectancy_lbl = GenPopDeathFemales64_dst
ELSE IF PatientStartAge_lbl = 65
SET LifeExpectancy_lbl = GenPopDeathFemales65_dst
ELSE IF PatientStartAge_lbl = 66
SET LifeExpectancy_lbl = GenPopDeathFemales66_dst
ELSE IF PatientStartAge_lbl = 67
SET LifeExpectancy_lbl = GenPopDeathFemales67_dst
ELSE IF PatientStartAge_lbl = 68
SET LifeExpectancy_lbl = GenPopDeathFemales68_dst
ELSE IF PatientStartAge_lbl = 69
SET LifeExpectancy_lbl = GenPopDeathFemales69_dst
ELSE IF PatientStartAge_lbl = 70
SET LifeExpectancy_lbl = GenPopDeathFemales70_dst
ELSE IF PatientStartAge_lbl = 71
SET LifeExpectancy_lbl = GenPopDeathFemales71_dst
ELSE IF PatientStartAge_lbl = 72
SET LifeExpectancy_lbl = GenPopDeathFemales72_dst
ELSE IF PatientStartAge_lbl = 73
SET LifeExpectancy_lbl = GenPopDeathFemales73_dst
ELSE IF PatientStartAge_lbl = 74
SET LifeExpectancy_lbl = GenPopDeathFemales74_dst
ELSE IF PatientStartAge_lbl = 75
SET LifeExpectancy_lbl = GenPopDeathFemales75_dst
ELSE IF PatientStartAge_lbl = 76
SET LifeExpectancy_lbl = GenPopDeathFemales76_dst
ELSE IF PatientStartAge_lbl = 77
SET LifeExpectancy_lbl = GenPopDeathFemales77_dst
ELSE IF PatientStartAge_lbl = 78
SET LifeExpectancy_lbl = GenPopDeathFemales78_dst
ELSE IF PatientStartAge_lbl = 79
SET LifeExpectancy_lbl = GenPopDeathFemales79_dst
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ELSE IF PatientStartAge_lbl = 80
SET LifeExpectancy_lbl = GenPopDeathFemales80_dst
ELSE IF PatientStartAge_lbl = 81
SET LifeExpectancy_lbl = GenPopDeathFemales81_dst
ELSE IF PatientStartAge_lbl = 82
SET LifeExpectancy_lbl = GenPopDeathFemales82_dst
ELSE IF PatientStartAge_lbl = 83
SET LifeExpectancy_lbl = GenPopDeathFemales83_dst
ELSE IF PatientStartAge_lbl = 84
SET LifeExpectancy_lbl = GenPopDeathFemales84_dst
ELSE IF PatientStartAge_lbl = 85
SET LifeExpectancy_lbl = GenPopDeathFemales85_dst
ELSE IF PatientStartAge_lbl = 86
SET LifeExpectancy_lbl = GenPopDeathFemales86_dst
ELSE IF PatientStartAge_lbl = 87
SET LifeExpectancy_lbl = GenPopDeathFemales87_dst
ELSE IF PatientStartAge_lbl = 88
SET LifeExpectancy_lbl = GenPopDeathFemales88_dst
ELSE IF PatientStartAge_lbl = 89
SET LifeExpectancy_lbl = GenPopDeathFemales89_dst
ELSE IF PatientStartAge_lbl = 90
SET LifeExpectancy_lbl = GenPopDeathFemales90_dst
ELSE IF PatientStartAge_lbl = 91
SET LifeExpectancy_lbl = GenPopDeathFemales91_dst
ELSE IF PatientStartAge_lbl = 92
SET LifeExpectancy_lbl = GenPopDeathFemales92_dst
ELSE IF PatientStartAge_lbl = 93
SET LifeExpectancy_lbl = GenPopDeathFemales93_dst
ELSE IF PatientStartAge_lbl = 94
SET LifeExpectancy_lbl = GenPopDeathFemales94_dst
ELSE IF PatientStartAge_lbl = 95
SET LifeExpectancy_lbl = GenPopDeathFemales95_dst
ELSE IF PatientStartAge_lbl = 96
SET LifeExpectancy_lbl = GenPopDeathFemales96_dst
ELSE IF PatientStartAge_lbl = 97
SET LifeExpectancy_lbl = GenPopDeathFemales97_dst
ELSE IF PatientStartAge_lbl = 98
SET LifeExpectancy_lbl = GenPopDeathFemales98_dst
ELSE IF PatientStartAge_lbl = 99
SET LifeExpectancy_lbl = GenPopDeathFemales99_dst
ELSE IF PatientStartAge_lbl = 100
SET LifeExpectancy_lbl = GenPopDeathFemales100_dst
ELSE
IF PatientStartAge_lbl = 0
SET LifeExpectancy_lbl = GenPopDeathMales0_dst
ELSE IF PatientStartAge_lbl = 1
SET LifeExpectancy_lbl = GenPopDeathMales1_dst
ELSE IF PatientStartAge_lbl = 2
SET LifeExpectancy_lbl = GenPopDeathMales2_dst
ELSE IF PatientStartAge_lbl = 3
SET LifeExpectancy_lbl = GenPopDeathMales3_dst
ELSE IF PatientStartAge_lbl = 4
SET LifeExpectancy_lbl = GenPopDeathMales4_dst
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ELSE IF PatientStartAge_lbl = 5
SET LifeExpectancy_lbl = GenPopDeathMales5_dst
ELSE IF PatientStartAge_lbl = 6
SET LifeExpectancy_lbl = GenPopDeathMales6_dst
ELSE IF PatientStartAge_lbl = 7
SET LifeExpectancy_lbl = GenPopDeathMales7_dst
ELSE IF PatientStartAge_lbl = 8
SET LifeExpectancy_lbl = GenPopDeathMales8_dst
ELSE IF PatientStartAge_lbl = 9
SET LifeExpectancy_lbl = GenPopDeathMales9_dst
ELSE IF PatientStartAge_lbl = 10
SET LifeExpectancy_lbl = GenPopDeathMales10_dst
ELSE IF PatientStartAge_lbl = 11
SET LifeExpectancy_lbl = GenPopDeathMales11_dst
ELSE IF PatientStartAge_lbl = 12
SET LifeExpectancy_lbl = GenPopDeathMales12_dst
ELSE IF PatientStartAge_lbl = 13
SET LifeExpectancy_lbl = GenPopDeathMales13_dst
ELSE IF PatientStartAge_lbl = 14
SET LifeExpectancy_lbl = GenPopDeathMales14_dst
ELSE IF PatientStartAge_lbl = 15
SET LifeExpectancy_lbl = GenPopDeathMales15_dst
ELSE IF PatientStartAge_lbl = 16
SET LifeExpectancy_lbl = GenPopDeathMales16_dst
ELSE IF PatientStartAge_lbl = 17
SET LifeExpectancy_lbl = GenPopDeathMales17_dst
ELSE IF PatientStartAge_lbl = 18
SET LifeExpectancy_lbl = GenPopDeathMales18_dst
ELSE IF PatientStartAge_lbl = 19
SET LifeExpectancy_lbl = GenPopDeathMales19_dst
ELSE IF PatientStartAge_lbl = 20
SET LifeExpectancy_lbl = GenPopDeathMales20_dst
ELSE IF PatientStartAge_lbl = 21
SET LifeExpectancy_lbl = GenPopDeathMales21_dst
ELSE IF PatientStartAge_lbl = 22
SET LifeExpectancy_lbl = GenPopDeathMales22_dst
ELSE IF PatientStartAge_lbl = 23
SET LifeExpectancy_lbl = GenPopDeathMales23_dst
ELSE IF PatientStartAge_lbl = 24
SET LifeExpectancy_lbl = GenPopDeathMales24_dst
ELSE IF PatientStartAge_lbl = 25
SET LifeExpectancy_lbl = GenPopDeathMales25_dst
ELSE IF PatientStartAge_lbl = 26
SET LifeExpectancy_lbl = GenPopDeathMales26_dst
ELSE IF PatientStartAge_lbl = 27
SET LifeExpectancy_lbl = GenPopDeathMales27_dst
ELSE IF PatientStartAge_lbl = 28
SET LifeExpectancy_lbl = GenPopDeathMales28_dst
ELSE IF PatientStartAge_lbl = 29
SET LifeExpectancy_lbl = GenPopDeathMales29_dst
ELSE IF PatientStartAge_lbl = 30
SET LifeExpectancy_lbl = GenPopDeathMales30_dst
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ELSE IF PatientStartAge_lbl = 31
SET LifeExpectancy_lbl = GenPopDeathMales31_dst
ELSE IF PatientStartAge_lbl = 32
SET LifeExpectancy_lbl = GenPopDeathMales32_dst
ELSE IF PatientStartAge_lbl = 33
SET LifeExpectancy_lbl = GenPopDeathMales33_dst
ELSE IF PatientStartAge_lbl = 34
SET LifeExpectancy_lbl = GenPopDeathMales34_dst
ELSE IF PatientStartAge_lbl = 35
SET LifeExpectancy_lbl = GenPopDeathMales35_dst
ELSE IF PatientStartAge_lbl = 36
SET LifeExpectancy_lbl = GenPopDeathMales36_dst
ELSE IF PatientStartAge_lbl = 37
SET LifeExpectancy_lbl = GenPopDeathMales37_dst
ELSE IF PatientStartAge_lbl = 38
SET LifeExpectancy_lbl = GenPopDeathMales38_dst
ELSE IF PatientStartAge_lbl = 39
SET LifeExpectancy_lbl = GenPopDeathMales39_dst
ELSE IF PatientStartAge_lbl = 40
SET LifeExpectancy_lbl = GenPopDeathMales40_dst
ELSE IF PatientStartAge_lbl = 41
SET LifeExpectancy_lbl = GenPopDeathMales41_dst
ELSE IF PatientStartAge_lbl = 42
SET LifeExpectancy_lbl = GenPopDeathMales42_dst
ELSE IF PatientStartAge_lbl = 43
SET LifeExpectancy_lbl = GenPopDeathMales43_dst
ELSE IF PatientStartAge_lbl = 44
SET LifeExpectancy_lbl = GenPopDeathMales44_dst
ELSE IF PatientStartAge_lbl = 45
SET LifeExpectancy_lbl = GenPopDeathMales45_dst
ELSE IF PatientStartAge_lbl = 46
SET LifeExpectancy_lbl = GenPopDeathMales46_dst
ELSE IF PatientStartAge_lbl = 47
SET LifeExpectancy_lbl = GenPopDeathMales47_dst
ELSE IF PatientStartAge_lbl = 48
SET LifeExpectancy_lbl = GenPopDeathMales48_dst
ELSE IF PatientStartAge_lbl = 49
SET LifeExpectancy_lbl = GenPopDeathMales49_dst
ELSE IF PatientStartAge_lbl = 50
SET LifeExpectancy_lbl = GenPopDeathMales50_dst
ELSE IF PatientStartAge_lbl = 51
SET LifeExpectancy_lbl = GenPopDeathMales51_dst
ELSE IF PatientStartAge_lbl = 52
SET LifeExpectancy_lbl = GenPopDeathMales52_dst
ELSE IF PatientStartAge_lbl = 53
SET LifeExpectancy_lbl = GenPopDeathMales53_dst
ELSE IF PatientStartAge_lbl = 54
SET LifeExpectancy_lbl = GenPopDeathMales54_dst
ELSE IF PatientStartAge_lbl = 55
SET LifeExpectancy_lbl = GenPopDeathMales55_dst
ELSE IF PatientStartAge_lbl = 56
SET LifeExpectancy_lbl = GenPopDeathMales56_dst
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ELSE IF PatientStartAge_lbl = 57
SET LifeExpectancy_lbl = GenPopDeathMales57_dst
ELSE IF PatientStartAge_lbl = 58
SET LifeExpectancy_lbl = GenPopDeathMales58_dst
ELSE IF PatientStartAge_lbl = 59
SET LifeExpectancy_lbl = GenPopDeathMales59_dst
ELSE IF PatientStartAge_lbl = 60
SET LifeExpectancy_lbl = GenPopDeathMales60_dst
ELSE IF PatientStartAge_lbl = 61
SET LifeExpectancy_lbl = GenPopDeathMales61_dst
ELSE IF PatientStartAge_lbl = 62
SET LifeExpectancy_lbl = GenPopDeathMales62_dst
ELSE IF PatientStartAge_lbl = 63
SET LifeExpectancy_lbl = GenPopDeathMales63_dst
ELSE IF PatientStartAge_lbl = 64
SET LifeExpectancy_lbl = GenPopDeathMales64_dst
ELSE IF PatientStartAge_lbl = 65
SET LifeExpectancy_lbl = GenPopDeathMales65_dst
ELSE IF PatientStartAge_lbl = 66
SET LifeExpectancy_lbl = GenPopDeathMales66_dst
ELSE IF PatientStartAge_lbl = 67
SET LifeExpectancy_lbl = GenPopDeathMales67_dst
ELSE IF PatientStartAge_lbl = 68
SET LifeExpectancy_lbl = GenPopDeathMales68_dst
ELSE IF PatientStartAge_lbl = 69
SET LifeExpectancy_lbl = GenPopDeathMales69_dst
ELSE IF PatientStartAge_lbl = 70
SET LifeExpectancy_lbl = GenPopDeathMales70_dst
ELSE IF PatientStartAge_lbl = 71
SET LifeExpectancy_lbl = GenPopDeathMales71_dst
ELSE IF PatientStartAge_lbl = 72
SET LifeExpectancy_lbl = GenPopDeathMales72_dst
ELSE IF PatientStartAge_lbl = 73
SET LifeExpectancy_lbl = GenPopDeathMales73_dst
ELSE IF PatientStartAge_lbl = 74
SET LifeExpectancy_lbl = GenPopDeathMales74_dst
ELSE IF PatientStartAge_lbl = 75
SET LifeExpectancy_lbl = GenPopDeathMales75_dst
ELSE IF PatientStartAge_lbl = 76
SET LifeExpectancy_lbl = GenPopDeathMales76_dst
ELSE IF PatientStartAge_lbl = 77
SET LifeExpectancy_lbl = GenPopDeathMales77_dst
ELSE IF PatientStartAge_lbl = 78
SET LifeExpectancy_lbl = GenPopDeathMales78_dst
ELSE IF PatientStartAge_lbl = 79
SET LifeExpectancy_lbl = GenPopDeathMales79_dst
ELSE IF PatientStartAge_lbl = 80
SET LifeExpectancy_lbl = GenPopDeathMales80_dst
ELSE IF PatientStartAge_lbl = 81
SET LifeExpectancy_lbl = GenPopDeathMales81_dst
ELSE IF PatientStartAge_lbl = 82
SET LifeExpectancy_lbl = GenPopDeathMales82_dst
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ELSE IF PatientStartAge_lbl = 83
SET LifeExpectancy_lbl = GenPopDeathMales83_dst
ELSE IF PatientStartAge_lbl = 84
SET LifeExpectancy_lbl = GenPopDeathMales84_dst
ELSE IF PatientStartAge_lbl = 85
SET LifeExpectancy_lbl = GenPopDeathMales85_dst
ELSE IF PatientStartAge_lbl = 86
SET LifeExpectancy_lbl = GenPopDeathMales86_dst
ELSE IF PatientStartAge_lbl = 87
SET LifeExpectancy_lbl = GenPopDeathMales87_dst
ELSE IF PatientStartAge_lbl = 88
SET LifeExpectancy_lbl = GenPopDeathMales88_dst
ELSE IF PatientStartAge_lbl = 89
SET LifeExpectancy_lbl = GenPopDeathMales89_dst
ELSE IF PatientStartAge_lbl = 90
SET LifeExpectancy_lbl = GenPopDeathMales90_dst
ELSE IF PatientStartAge_lbl = 91
SET LifeExpectancy_lbl = GenPopDeathMales91_dst
ELSE IF PatientStartAge_lbl = 92
SET LifeExpectancy_lbl = GenPopDeathMales92_dst
ELSE IF PatientStartAge_lbl = 93
SET LifeExpectancy_lbl = GenPopDeathMales93_dst
ELSE IF PatientStartAge_lbl = 94
SET LifeExpectancy_lbl = GenPopDeathMales94_dst
ELSE IF PatientStartAge_lbl = 95
SET LifeExpectancy_lbl = GenPopDeathMales95_dst
ELSE IF PatientStartAge_lbl = 96
SET LifeExpectancy_lbl = GenPopDeathMales96_dst
ELSE IF PatientStartAge_lbl = 97
SET LifeExpectancy_lbl = GenPopDeathMales97_dst
ELSE IF PatientStartAge_lbl = 98
SET LifeExpectancy_lbl = GenPopDeathMales98_dst
ELSE IF PatientStartAge_lbl = 99
SET LifeExpectancy_lbl = GenPopDeathMales99_dst
ELSE IF PatientStartAge_lbl = 100
SET LifeExpectancy_lbl = GenPopDeathMales100_dst
‘Set time to first events (note time to preclinical and cancer death are sampled with a multiplier here to
ensure monotonically correct ordering)
SET TimeToOCM_lbl = LifeExpectancy_lbl-PatientAge_lbl
SET TimeToProgression_lbl = TPNoAdenomaToAdenoma_dst
IF PatientAge_lbl < MaxCOLage_nbr
SET TimeToNextCOL_lbl = COLInterval1_nbr
ELSE
SET TimeToNextCOL_lbl = LargeN_nbr
SET TimeToCancerDeath_lbl = LargeN_nbr
SET CancerDeathTemp1_lbl = ClinicalCRCSurvival_dst
SET CancerDeathTemp2_lbl = CancerDeathTemp1_lbl*Params_ss[5,SOUR_nbr+SSrowoffset_nbr]
‘Include costs of initial colonoscopy
SET UndiscountedCost_lbl = UndiscountedCost_lbl+Params_ss[18,SSrowoffset_nbr+SOUR_nbr]
SET DiscountedCost_lbl = DiscountedCost_lbl+[Params_ss[18,SSrowoffset_nbr+SOUR_nbr]/[1
+DRp_costs_nbr]^[PatientAge_lbl-PatientStartAge_lbl]]
‘Store patient diary (if selected)
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IF StorePatientDiary_nbr = 1
SET PatientDiary_ss[1,1+UniqId_lbl] = UniqId_lbl
SET PatientDiary_ss[2,1+UniqId_lbl] = TimeStampModelEntry_lbl
SET PatientDiary_ss[3,1+UniqId_lbl] = PatientStartAge_lbl
SET PatientDiary_ss[4,1+UniqId_lbl] = PatientAge_lbl
SET PatientDiary_ss[5,1+UniqId_lbl] = Sex_lbl
SET PatientDiary_ss[6,1+UniqId_lbl] = histology_lbl
SET PatientDiary_ss[7,1+UniqId_lbl] = LifeExpectancy_lbl
SET PatientDiary_ss[8,1+UniqId_lbl] = TimeToOCM_lbl
SET PatientDiary_ss[9,1+UniqId_lbl] = TimeToProgression_lbl
SET PatientDiary_ss[10,1+UniqId_lbl] = TimeToNextCOL_lbl
SET PatientDiary_ss[11,1+UniqId_lbl] = TimeToCancerDeath_lbl
SET PatientDiary_ss[12,1+UniqId_lbl] = CancerDeathTemp1_lbl
SET PatientDiary_ss[13,1+UniqId_lbl] = CancerDeathTemp2_lbl
‘Set patient run tracker for stability testing
SET StabilityTemp_nbr = UniqId_lbl
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Appendix 11 Search strategy for health-utility
studies
MEDLINE search strategy
Please note, the MEDLINE search strategies provided were adapted according to each of the
databases searched.
1. exp Colorectal Neoplasms/
2. Neoplasms/
3. Carcinoma/
4. Adenocarcinoma/
5. or/2-4
6. Colonic Diseases/
7. Rectal Diseases/
8. exp Colon/
9. exp Rectum/
10. or/6-9
11. 5 and 10
12. (carcinoma adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
13. (neoplasia adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
14. (neoplasm$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
15. (adenocarcinoma adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
16. (cancer$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
17. (tumor$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
18. (tumour$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
19. (malignan$ adj3 (colorectal or colon$ or rect$ or intestin$ or bowel)).tw.
20. or/12-19
21. 1 or 11 or 20
22. health related quality of life.tw.
23. hrql.tw.
24. hrqol.tw.
25. hql.tw.
26. sf 36.tw.
27. sf thirtysix.tw.
28. sf thirty six.tw.
29. short form 36.tw.
30. short form thirty six.tw.
31. short form thirtysix.tw.
32. shortform 36.tw.
33. shortform thirty six.tw.
34. shortform thirty six.tw.
35. sf36.tw.
36. medical outcomes survey.tw.
37. mos.tw.
38. euroqol.tw.
39. eq 5d.tw.
40. eq5d.tw.
41. qaly$.tw.
42. quality adjusted life years/
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43. quality adjusted life year$.tw.
44. hye$.tw.
45. health$ year$ equivalent$.tw.
46. psychological general well being index.tw.
47. psychological general wellbeing index.tw.
48. pgwb$.tw.
49. health utilit$.tw.
50. hui.tw.
51. quality of wellbeing$.tw.
52. quality of well being.tw.
53. qwb$.tw.
54. rosser.tw.
55. trade off$.tw.
56. standard gamble.tw.
57. tto.tw.
58. “Quality of Life”/
59. “Outcome Assessment (Health Care)”/
60. (preference$ or utilit$).tw. and (58 or 59)
61. ((preference$ or utilit$) and quality of life).tw.
62. (preference$ adj2 (elicit$ or patient$ or population$ or measure$ or based or cost$)).tw.
63. (utilit$ adj2 (elicit$ or patient$ or population$ or measure$ or based or cost$)).tw.
64. or/22-57,60-63
65. 21 and 64
66. limit 65 to yr=“2005-Current”
Databases
The following databases and grey literature sources were searched from inception to present.
1. MEDLINE and MEDLINE in Process & Other Non-Indexed citations (Ovid)
2. EMBASE (Ovid)
3. Cumulative Index to Nursing and Allied Health Literature (EBSCO)
4. BIOSIS previews (WoK)
5. Science Citation Index (Web of Science)
6. Cochrane Database of Systematic Reviews (Cochrane)
7. Cochrane Central Register of Controlled Trials (Cochrane)
8. Database of Abstracts of Reviews of Effects (Cochrane)
9. NHS Health Economic Evaluation Database (Cochrane)
10. Health Technology Assessment database (Cochrane)
11. EconLit (Ovid)
12. Web of Science (WoK)
13. Conference Proceedings index (Web of Science via WoK)
14. ProQuest Dissertations and Theses (ProQuest)
15. Tufts (Cost Effectiveness Analysis Registry).
Limits applied
Results were limited to 2005–current.
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Appendix 12 STROBE statement: checklist of
items that should be included in reports of
cohort studies
The following STROBE table pertains to our workstream, the hospital data set. The screening data setand psychological study involved different, pre-existing study samples.
Item no. Recommendation
Reported in
chapter/section/page no.
Title and abstract 1 (a) Indicate the study’s design with a commonly
used term in the title or the abstract
p. vii
(b) Provide in the abstract an informative and
balanced summary of what was done and what
was found
p. vii, viii
Introduction
Background/
rationale
2 Explain the scientific background and rationale for
the investigation being reported
Chapter 1
Objectives 3 State specific objectives, including any prespecified
hypotheses
Chapter 1, Aims and objectives
Methods
Study design 4 Present key elements of study design early in the
paper
Chapter 1, Study design and
setting
Setting 5 Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure,
follow-up and data collection
Chapter 2
Participants 6 (a) Give the eligibility criteria, and the sources and
methods of selection of participants. Describe
methods of follow-up
Chapter 2: Patient eligibility
(b) For matched studies, give matching criteria and
number of exposed and unexposed
n/a
Variables 7 Clearly define all outcomes, exposures, predictors,
potential confounders and effect modifiers. Give
diagnostic criteria, if applicable
Chapter 2, Variables
Data sources/
measurement
8a For each variable of interest, give sources of
data and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one
group
Chapter 2:
Manual data coding
Creating summary values for
polyp characteristics
Procedure information
Defining baseline and
surveillance visits
Bias 9 Describe any efforts to address potential sources
of bias
Chapter 2:
Patient follow-up (selection
bias)
Defining baseline and
surveillance visits
Variables (information bias)
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Item no. Recommendation
Reported in
chapter/section/page no.
Study size 10 Explain how the study size was arrived at Chapter 2, Study size
Quantitative
variables
11 Explain how quantitative variables were handled
in the analyses. If applicable, describe which
groupings were chosen and why
Chapter 2, Variables
Statistical methods 12 (a) Describe all statistical methods, including those
used to control for confounding
Chapter 2, Statistical methods
(b) Describe any methods used to examine
subgroups and interactions
Chapter 2, Statistical methods
(c) Explain how missing data were addressed Chapter 2:
Creating summary values for
polyp characteristics
Data collection from hospitals
(d) If applicable, explain how loss to follow-up was
addressed
n/a
(e) Describe any sensitivity analyses Chapter 2, Statistical methods;
Chapter 3, Sensitivity analyses
and internal validation
Results
Participants 13a (a) Report numbers of individuals at each stage of
study, e.g. numbers potentially eligible, examined
for eligibility, confirmed eligible, included in the
study, completing follow-up, and analysed
Chapter 3
(b) Give reasons for non-participation at each
stage
n/a
(c) Consider use of a flow diagram Chapter 3, Figure 2
Descriptive data 14a (a) Give characteristics of study participants (e.g.
demographic, clinical, social) and information on
exposures and potential confounders
Chapter 3, Baseline
characteristics of all
intermediate-risk patients and
those with follow-up
(b) Indicate number of participants with missing
data for each variable of interest
Chapter 3
(c) Summarise follow-up time (e.g., average and
total amount)
Chapter 3, Colorectal cancer
risk after baseline
Outcome data 15a Report numbers of outcome events or summary
measures over time
Chapter 3
Main results 16 (a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision
(e.g. 95% CI). Make clear which confounders
were adjusted for and why they were included
Chapter 3
(b) Report category boundaries when continuous
variables were categorised
n/a
(c) If relevant, consider translating estimates of
relative risk into absolute risk for a meaningful
time period
Chapter 3, Long-term cancer
risk; Lower- and higher-
intermediate-risk groups
Other analyses 17 Report other analyses done, e.g. analyses of
subgroups and interactions, and sensitivity analyses
Chapter 3, Lower- and
intermediate-risk subgroups;
Sensitivity
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Item no. Recommendation
Reported in
chapter/section/page no.
Discussion
Key results 18 Summarise key results with reference to study
objectives
Chapter 7, Hospital and
screening data sets; Main
findings
Limitations 19 Discuss limitations of the study, taking into
account sources of potential bias or imprecision.
Discuss both direction and magnitude of any
potential bias
Chapter 7, Strengths and
limitations
Interpretation 20 Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other
relevant evidence
Chapter 8
Generalisability 21 Discuss the generalisability (external validity) of the
study results
Chapter 7, Strengths and
limitations
Chapter 8
Other information
Funding 22 Give the source of funding and the role of the
funders for the present study and, if applicable, for
the original study on which the present article is
based
n/a, not applicable.
a Give information separately for exposed and unexposed groups in cohort and cross-sectional studies.
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